Inclusion NCT03923946 0 9 O
Criteria NCT03923946 10 18 O
: NCT03923946 19 20 O

- NCT03923946 24 25 O
Eligible NCT03923946 27 35 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03923946 36 39 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03923946 40 43 O
early NCT03923946 44 49 B-Modifier
supported NCT03923946 50 59 I-Modifier
discharge NCT03923946 60 69 B-Encounter
pathway NCT03923946 70 77 O
this NCT03923946 78 82 O
includes NCT03923946 83 91 O
: NCT03923946 92 93 O

- NCT03923946 102 103 O
Confirmed NCT03923946 105 114 O
diagnosis NCT03923946 115 124 O
of NCT03923946 125 127 O
a NCT03923946 128 129 O
new NCT03923946 130 133 B-Eq-Comparison
stroke NCT03923946 134 140 B-Condition
. NCT03923946 140 141 O

- NCT03923946 150 151 O
Over NCT03923946 153 157 B-Eq-Comparison
18 NCT03923946 158 160 I-Eq-Comparison
Years NCT03923946 161 166 I-Eq-Comparison
old NCT03923946 167 170 B-Age
. NCT03923946 170 171 O

- NCT03923946 180 181 O
Able NCT03923946 183 187 O
to NCT03923946 188 190 O
consent NCT03923946 191 198 O
to NCT03923946 199 201 O
being NCT03923946 202 207 O
in NCT03923946 208 210 O
the NCT03923946 211 214 O
study NCT03923946 215 220 B-Study
. NCT03923946 220 221 O

- NCT03923946 230 231 O
The NCT03923946 233 236 O
patient NCT03923946 237 244 B-Family-Member___Family-Member-Type:patient
and NCT03923946 245 248 B-And
their NCT03923946 249 254 O
family NCT03923946 255 261 B-Family-Member
/ NCT03923946 262 263 O
carer NCT03923946 264 269 O
agree NCT03923946 270 275 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03923946 276 278 I-Assertion___Assertion-Type-Value:hypothetical
rehabilitation NCT03923946 279 293 B-Procedure
process NCT03923946 294 301 O
continuing NCT03923946 302 312 O
at NCT03923946 313 315 O
home NCT03923946 316 320 O
. NCT03923946 320 321 O

- NCT03923946 330 331 O
The NCT03923946 333 336 O
home NCT03923946 337 341 O
environment NCT03923946 342 353 O
is NCT03923946 354 356 O
conducive NCT03923946 357 366 O
to NCT03923946 367 369 O
the NCT03923946 370 373 O
community NCT03923946 374 383 O
- NCT03923946 384 385 O
based NCT03923946 386 391 O
rehabilitation NCT03923946 392 406 O
. NCT03923946 406 407 O

- NCT03923946 416 417 O
Achievable NCT03923946 419 429 O
rehabilitation NCT03923946 430 444 B-Procedure
goals NCT03923946 445 450 O
can NCT03923946 451 454 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03923946 455 457 I-Assertion___Assertion-Type-Value:hypothetical
identified NCT03923946 458 468 O
. NCT03923946 468 469 O

- NCT03923946 478 479 O
Document NCT03923946 481 489 O
acknowledgement NCT03923946 490 505 O
that NCT03923946 506 510 O
the NCT03923946 511 514 O
patient NCT03923946 515 522 O
is NCT03923946 523 525 O
sufficiently NCT03923946 526 538 O
well NCT03923946 539 543 O
enough NCT03923946 544 550 O
from NCT03923946 551 555 O
a NCT03923946 556 557 O
medical NCT03923946 558 565 O
perspective NCT03923946 566 577 O
to NCT03923946 578 580 O
be NCT03923946 581 583 O
managed NCT03923946 584 591 O
in NCT03923946 592 594 O
the NCT03923946 595 598 O
community NCT03923946 599 608 O
. NCT03923946 608 609 O

- NCT03923946 618 619 O
The NCT03923946 621 624 O
patient NCT03923946 625 632 O
's NCT03923946 632 634 O
language NCT03923946 635 643 O
and NCT03923946 644 647 O
/ NCT03923946 648 649 O
or NCT03923946 650 652 O
cognitive NCT03923946 653 662 O
skills NCT03923946 663 669 O
are NCT03923946 670 673 O
at NCT03923946 674 676 O
a NCT03923946 677 678 O
level NCT03923946 679 684 O
for NCT03923946 685 688 O
them NCT03923946 689 693 O
to NCT03923946 694 696 O
manage NCT03923946 697 703 O
on NCT03923946 704 706 O
their NCT03923946 707 712 O
own NCT03923946 713 716 O
for NCT03923946 717 720 O
periods NCT03923946 721 728 O
as NCT03923946 729 731 O
is NCT03923946 732 734 O
necessary NCT03923946 735 744 O
. NCT03923946 744 745 O

In NCT03923946 747 749 O
addition NCT03923946 750 758 O
to NCT03923946 759 761 O
ESSD NCT03923946 762 766 B-Condition
criteria NCT03923946 767 775 O
participants NCT03923946 776 788 O
must NCT03923946 789 793 O
; NCT03923946 793 794 O

- NCT03923946 797 798 O
Have NCT03923946 800 804 O
a NCT03923946 805 806 O
good NCT03923946 807 811 O
grasp NCT03923946 812 817 O
of NCT03923946 818 820 O
the NCT03923946 821 824 O
English NCT03923946 825 832 O
language NCT03923946 833 841 O

- NCT03923946 844 845 O
Have NCT03923946 847 851 O
been NCT03923946 852 856 B-Eq-Comparison
discharged NCT03923946 857 867 B-Encounter
from NCT03923946 868 872 O
the NCT03923946 873 876 O
ESSD NCT03923946 877 881 B-Condition
pathway NCT03923946 882 889 O

Exclusion NCT03923946 890 899 O
Criteria NCT03923946 900 908 O
: NCT03923946 909 910 O

- NCT03923946 914 915 O
Participants NCT03923946 917 929 O
will NCT03923946 930 934 O
be NCT03923946 935 937 O
excluded NCT03923946 938 946 O
if NCT03923946 947 949 O
they NCT03923946 950 954 O
: NCT03923946 955 956 O

- NCT03923946 965 966 O
Have NCT03923946 968 972 O
any NCT03923946 973 976 O
communication NCT03923946 977 990 B-Condition
difficulties NCT03923946 991 1003 I-Condition
that NCT03923946 1004 1008 O
would NCT03923946 1009 1014 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03923946 1015 1022 B-Negation
them NCT03923946 1023 1027 O
from NCT03923946 1028 1032 O
engaging NCT03923946 1033 1041 O
in NCT03923946 1042 1044 B-Procedure
the NCT03923946 1045 1048 O
intervention NCT03923946 1049 1061 O
( NCT03923946 1062 1063 O
including NCT03923946 1064 1073 O
hearing NCT03923946 1074 1081 B-Condition
impairments NCT03923946 1082 1093 I-Condition|Condition
, NCT03923946 1094 1095 O
visual NCT03923946 1096 1102 B-Condition
impairments NCT03923946 1103 1114 O
, NCT03923946 1115 1116 O
inability NCT03923946 1117 1126 B-Negation
to NCT03923946 1127 1129 O
understand NCT03923946 1130 1140 O
English NCT03923946 1141 1148 O
) NCT03923946 1149 1150 O
. NCT03923946 1151 1152 O
These NCT03923946 1154 1159 O
will NCT03923946 1160 1164 O
be NCT03923946 1165 1167 O
assessed NCT03923946 1168 1176 O
at NCT03923946 1177 1179 O
researcher NCT03923946 1180 1190 O
's NCT03923946 1190 1192 O
discretion NCT03923946 1193 1203 O
during NCT03923946 1204 1210 O
baseline NCT03923946 1211 1219 O
assessments NCT03923946 1220 1231 O
. NCT03923946 1231 1232 O

- NCT03923946 1241 1242 O
Had NCT03923946 1244 1247 O
a NCT03923946 1248 1249 O
diagnosis NCT03923946 1250 1259 O
of NCT03923946 1260 1262 O
dementia NCT03923946 1263 1271 B-Condition
prior NCT03923946 1272 1277 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923946 1278 1280 O
the NCT03923946 1281 1284 O
stroke NCT03923946 1285 1291 B-Condition
. NCT03923946 1291 1292 O

- NCT03923946 1301 1302 O
Are NCT03923946 1304 1307 O
deemed NCT03923946 1308 1314 O
to NCT03923946 1315 1317 O
lack NCT03923946 1318 1322 O
capacity NCT03923946 1323 1331 O
to NCT03923946 1332 1334 O
give NCT03923946 1335 1339 O
informed NCT03923946 1340 1348 O
consent NCT03923946 1349 1356 O
. NCT03923946 1356 1357 O
This NCT03923946 1359 1363 O
will NCT03923946 1364 1368 O
be NCT03923946 1369 1371 O
judged NCT03923946 1372 1378 O
via NCT03923946 1379 1382 O
a NCT03923946 1383 1384 O
qualified NCT03923946 1385 1394 O
clinician NCT03923946 1395 1404 O
. NCT03923946 1404 1405 O

- NCT03923946 1414 1415 O
Have NCT03923946 1417 1421 O
had NCT03923946 1422 1425 O
previous NCT03923946 1426 1434 B-Eq-Comparison
experience NCT03923946 1435 1445 O
of NCT03923946 1446 1448 O
CFT NCT03923946 1449 1452 B-Procedure

- NCT03923946 1460 1461 O
Were NCT03923946 1463 1467 B-Eq-Comparison
receiving NCT03923946 1468 1477 I-Eq-Comparison
medical NCT03923946 1478 1485 B-Modifier
or NCT03923946 1486 1488 B-Or
psychological NCT03923946 1489 1502 B-Modifier
treatment NCT03923946 1503 1512 B-Procedure
for NCT03923946 1513 1516 O
a NCT03923946 1517 1518 O
mental NCT03923946 1519 1525 B-Condition
illness NCT03923946 1526 1533 I-Condition
at NCT03923946 1534 1536 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923946 1537 1540 O
time NCT03923946 1541 1545 O
of NCT03923946 1546 1548 O
their NCT03923946 1549 1554 O
stroke NCT03923946 1555 1561 B-Condition
. NCT03923946 1561 1562 O

Inclusion NCT03923985 0 9 O
Criteria NCT03923985 10 18 O
: NCT03923985 19 20 O

- NCT03923985 24 25 O
Healthy NCT03923985 27 34 B-Condition
women NCT03923985 35 40 O
between NCT03923985 41 48 B-Eq-Comparison
18 NCT03923985 49 51 I-Eq-Comparison
and NCT03923985 52 55 I-Eq-Comparison
45 NCT03923985 56 58 I-Eq-Comparison
years NCT03923985 59 64 I-Eq-Comparison
old NCT03923985 65 68 B-Age

- NCT03923985 71 72 O
Women NCT03923985 74 79 O
without NCT03923985 80 87 B-Negation
current NCT03923985 88 95 B-Eq-Comparison
symptoms NCT03923985 96 104 B-Assertion___Assertion-Type-Value:possible
of NCT03923985 105 107 O
vaginal NCT03923985 108 115 B-Condition
infection NCT03923985 116 125 I-Condition

- NCT03923985 128 129 O
Negative NCT03923985 131 139 O
bacteriological NCT03923985 140 155 B-Modifier
and NCT03923985 156 159 B-And
clinical NCT03923985 160 168 B-Modifier
examination NCT03923985 169 180 B-Procedure

Exclusion NCT03923985 181 190 O
Criteria NCT03923985 191 199 O
: NCT03923985 200 201 O

- NCT03923985 205 206 O
Women NCT03923985 208 213 O
with NCT03923985 214 218 B-And
vaginal NCT03923985 219 226 B-Condition
infection NCT03923985 227 236 I-Condition

- NCT03923985 239 240 O
Women NCT03923985 242 247 O
with NCT03923985 248 252 B-And
undiagnosed NCT03923985 253 264 O
vaginal NCT03923985 265 272 B-Condition
bleeding NCT03923985 273 281 I-Condition

- NCT03923985 284 285 O
Patients NCT03923985 287 295 O
with NCT03923985 296 300 O
endometrial NCT03923985 301 312 B-Condition
hyperplasia NCT03923985 313 324 I-Condition

- NCT03923985 327 328 O
Suspicion NCT03923985 330 339 B-Assertion___Assertion-Type-Value:possible
of NCT03923985 340 342 O
neoplasia NCT03923985 343 352 B-Condition
or NCT03923985 353 355 B-Or
active NCT03923985 356 362 B-Eq-Comparison
neoplasia NCT03923985 363 372 B-Condition

- NCT03923985 375 376 O
Women NCT03923985 378 383 O
with NCT03923985 384 388 B-And
intolerance NCT03923985 389 400 B-Condition
, NCT03923985 401 402 O
allergy NCT03923985 403 410 B-Allergy
or NCT03923985 411 413 B-Or
hypersensitivity NCT03923985 414 430 B-Condition
to NCT03923985 431 433 O
the NCT03923985 434 437 O
components NCT03923985 438 448 O
of NCT03923985 449 451 O
the NCT03923985 452 455 O
probiotic NCT03923985 456 465 B-Drug

- NCT03923985 468 469 O
Women NCT03923985 471 476 O
with NCT03923985 477 481 B-And
immunosuppressive NCT03923985 482 499 B-Condition
disorders NCT03923985 500 509 I-Condition
or NCT03923985 510 512 B-Or
with NCT03923985 513 517 O
HIV NCT03923985 518 521 B-Condition

- NCT03923985 524 525 O
Women NCT03923985 527 532 O
who NCT03923985 533 536 B-And
are NCT03923985 537 540 O
currently NCT03923985 541 550 B-Eq-Comparison
using NCT03923985 551 556 I-Eq-Comparison
probiotics NCT03923985 557 567 B-Drug
by NCT03923985 568 570 O
any NCT03923985 571 574 O
route NCT03923985 575 580 O
of NCT03923985 581 583 O
administration NCT03923985 584 598 O

- NCT03923985 601 602 O
Women NCT03923985 604 609 O
who NCT03923985 610 613 B-And
are NCT03923985 614 617 O
using NCT03923985 618 623 B-Eq-Comparison
some NCT03923985 624 628 O
treatment NCT03923985 629 638 B-Procedure
for NCT03923985 639 642 O
vaginal NCT03923985 643 650 B-Modifier
sepsis NCT03923985 651 657 B-Condition

- NCT03923985 660 661 O
Chronic NCT03923985 663 670 B-Modifier
decompensated NCT03923985 671 684 B-Modifier
noncommunicable NCT03923985 685 700 B-Condition
diseases NCT03923985 701 709 I-Condition
( NCT03923985 710 711 O
diabetes NCT03923985 712 720 B-Condition
mellitus NCT03923985 721 729 I-Condition
, NCT03923985 730 731 O
heart NCT03923985 732 737 B-Condition
disease NCT03923985 738 745 I-Condition
. NCT03923985 746 747 O
. NCT03923985 748 749 O
. NCT03923985 750 751 O
) NCT03923985 752 753 O

- NCT03923985 757 758 O
Pregnant NCT03923985 760 768 B-Condition
women NCT03923985 769 774 O
or NCT03923985 775 777 B-Or
those NCT03923985 778 783 O
with NCT03923985 784 788 O
precocious NCT03923985 789 799 B-Condition
menopause NCT03923985 800 809 I-Condition

Inclusion NCT03926143 0 9 O
Criteria NCT03926143 10 18 O
: NCT03926143 19 20 O

- NCT03926143 24 25 O
Participants NCT03926143 27 39 O
ongoing NCT03926143 40 47 O
in NCT03926143 48 50 O
an NCT03926143 51 53 O
applicable NCT03926143 54 64 O
Bayer NCT03926143 65 70 O
- NCT03926143 71 72 O
sponsored NCT03926143 73 82 O
anetumab NCT03926143 83 91 B-Drug
ravtansine NCT03926143 92 102 I-Drug
parent NCT03926143 103 109 O
study NCT03926143 110 115 B-Study
at NCT03926143 116 118 O
the NCT03926143 119 122 O
time NCT03926143 123 127 O
of NCT03926143 128 130 O
its NCT03926143 131 134 O
planned NCT03926143 135 142 O
study NCT03926143 143 148 O
closure NCT03926143 149 156 O
. NCT03926143 156 157 O

- NCT03926143 161 162 O
For NCT03926143 164 167 O
on NCT03926143 168 170 B-Eq-Comparison
- NCT03926143 171 172 O
treatment NCT03926143 173 182 B-Procedure
participants NCT03926143 183 195 O
: NCT03926143 196 197 O
participant NCT03926143 198 209 O
is NCT03926143 210 212 O
eligible NCT03926143 213 221 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926143 222 224 O
receive NCT03926143 225 232 O
the NCT03926143 233 236 O
next NCT03926143 237 241 O
dose NCT03926143 242 246 O
of NCT03926143 247 249 O
study NCT03926143 250 255 B-Study
intervention NCT03926143 256 268 B-Drug
per NCT03926143 269 272 O
the NCT03926143 273 276 O
parent NCT03926143 277 283 O
study NCT03926143 284 289 O
protocol NCT03926143 290 298 O
. NCT03926143 298 299 O

Exclusion NCT03926143 301 310 O
Criteria NCT03926143 311 319 O
: NCT03926143 320 321 O

- NCT03926143 325 326 O
For NCT03926143 328 331 O
on NCT03926143 332 334 B-Eq-Comparison
- NCT03926143 335 336 O
treatment NCT03926143 337 346 B-Procedure
participants NCT03926143 347 359 O
: NCT03926143 360 361 O
a NCT03926143 362 363 O
positive NCT03926143 364 372 O
serum NCT03926143 373 378 B-Observation
pregnancy NCT03926143 379 388 I-Observation
test NCT03926143 389 393 I-Observation
. NCT03926143 393 394 O

- NCT03926143 398 399 O
For NCT03926143 401 404 O
on NCT03926143 405 407 B-Eq-Comparison
- NCT03926143 408 409 O
treatment NCT03926143 410 419 B-Procedure
participants NCT03926143 420 432 O
: NCT03926143 433 434 O
use NCT03926143 435 438 O
of NCT03926143 439 441 O
one NCT03926143 442 445 B-Eq-Comparison
or NCT03926143 446 448 I-Eq-Comparison
more NCT03926143 449 453 I-Eq-Comparison
of NCT03926143 454 456 O
the NCT03926143 457 460 O
prohibited NCT03926143 461 471 O
medications NCT03926143 472 483 B-Drug
listed NCT03926143 484 490 O
in NCT03926143 491 493 O
the NCT03926143 494 497 O
respective NCT03926143 498 508 O
parent NCT03926143 509 515 O
study NCT03926143 516 521 O
protocol NCT03926143 522 530 O
. NCT03926143 530 531 O

- NCT03926143 535 536 O
Participants NCT03926143 538 550 O
who NCT03926143 551 554 O
are NCT03926143 555 558 O
receiving NCT03926143 559 568 B-Eq-Comparison
standard NCT03926143 569 577 O
- NCT03926143 578 579 O
of NCT03926143 580 582 O
- NCT03926143 583 584 O
care NCT03926143 585 589 O
agent NCT03926143 590 595 B-Drug
( NCT03926143 596 597 O
s NCT03926143 598 599 O
) NCT03926143 600 601 O
but NCT03926143 602 605 B-And
not NCT03926143 606 609 B-Negation
anetumab NCT03926143 610 618 B-Drug
ravtansine NCT03926143 619 629 I-Drug
in NCT03926143 630 632 O
the NCT03926143 633 636 O
parent NCT03926143 637 643 O
study NCT03926143 644 649 O
, NCT03926143 650 651 O
and NCT03926143 652 655 B-And
are NCT03926143 656 659 O
able NCT03926143 660 664 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926143 665 667 I-Assertion___Assertion-Type-Value:hypothetical
receive NCT03926143 668 675 O
standard NCT03926143 676 684 O
- NCT03926143 685 686 O
of NCT03926143 687 689 O
- NCT03926143 690 691 O
care NCT03926143 692 696 O
agent NCT03926143 697 702 B-Drug
outside NCT03926143 703 710 B-Other
of NCT03926143 711 713 O
the NCT03926143 714 717 O
clinical NCT03926143 718 726 O
study NCT03926143 727 732 B-Study
. NCT03926143 732 733 O

Inclusion NCT03926962 0 9 O
Criteria NCT03926962 10 18 O
: NCT03926962 19 20 O

- NCT03926962 24 25 O
BMI NCT03926962 27 30 B-Observation
: NCT03926962 31 32 O
18 NCT03926962 33 35 B-Eq-Comparison
- NCT03926962 36 37 I-Eq-Comparison
30 NCT03926962 38 40 I-Eq-Comparison
kg NCT03926962 41 43 I-Eq-Comparison
/ NCT03926962 44 45 I-Eq-Comparison
m2 NCT03926962 46 48 I-Eq-Comparison
( NCT03926962 49 50 O
Body NCT03926962 51 55 B-Observation
Mass NCT03926962 56 60 I-Observation
Index NCT03926962 61 66 I-Observation
[ NCT03926962 67 68 O
BMI NCT03926962 69 72 B-Observation
] NCT03926962 73 74 O
[ NCT03926962 75 76 O
kg NCT03926962 77 79 O
/ NCT03926962 80 81 O
m2 NCT03926962 82 84 O
] NCT03926962 85 86 O
= NCT03926962 87 88 O
Body NCT03926962 89 93 O
weight NCT03926962 94 100 O
[ NCT03926962 101 102 O
kg NCT03926962 103 105 O
] NCT03926962 106 107 O
Height2 NCT03926962 108 115 O
[ NCT03926962 116 117 O
m2 NCT03926962 118 120 O
] NCT03926962 121 122 O
) NCT03926962 124 125 O

- NCT03926962 129 130 O
Ability NCT03926962 132 139 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03926962 140 143 B-And
willingness NCT03926962 144 155 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926962 156 158 I-Assertion___Assertion-Type-Value:hypothetical
abstain NCT03926962 159 166 B-Negation
from NCT03926962 167 171 O
alcohol NCT03926962 172 179 B-Drug
, NCT03926962 180 181 O
methylxanthine NCT03926962 182 196 B-Drug
- NCT03926962 197 198 O
containing NCT03926962 199 209 O
beverages NCT03926962 210 219 O
or NCT03926962 220 222 O
food NCT03926962 223 227 O
( NCT03926962 228 229 O
coffee NCT03926962 230 236 O
, NCT03926962 237 238 O
tea NCT03926962 239 242 O
, NCT03926962 243 244 O
cola NCT03926962 245 249 O
, NCT03926962 250 251 O
chocolate NCT03926962 252 261 O
, NCT03926962 262 263 O
" NCT03926962 264 265 O
powerdrinks NCT03926962 265 276 O
" NCT03926962 276 277 O
) NCT03926962 278 279 O
, NCT03926962 281 282 O
grapefruit NCT03926962 283 293 O
( NCT03926962 294 295 O
juice NCT03926962 296 301 O
) NCT03926962 302 303 O
from NCT03926962 304 308 O
48 NCT03926962 309 311 B-Eq-Comparison
h NCT03926962 312 313 I-Eq-Comparison
prior NCT03926962 314 319 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926962 320 322 I-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03926962 323 328 B-Study
in NCT03926962 329 331 O
the NCT03926962 332 335 O
clinical NCT03926962 336 344 O
research NCT03926962 345 353 O
center NCT03926962 354 360 O
until NCT03926962 361 366 B-Temporal-Connection___Temporal-Connection-Type-Value:before
discharge NCT03926962 367 376 B-Encounter

- NCT03926962 379 380 O
Medical NCT03926962 382 389 O
history NCT03926962 390 397 B-Eq-Comparison
without NCT03926962 398 405 B-Negation
major NCT03926962 406 411 B-Modifier
pathology NCT03926962 412 421 B-Condition

Exclusion NCT03926962 422 431 O
Criteria NCT03926962 432 440 O
: NCT03926962 441 442 O

- NCT03926962 446 447 O
Evidence NCT03926962 449 457 O
of NCT03926962 458 460 O
clinically NCT03926962 461 471 O
relevant NCT03926962 472 480 B-Modifier
pathology NCT03926962 481 490 B-Condition

- NCT03926962 493 494 O
Mental NCT03926962 496 502 B-Condition
handicap NCT03926962 503 511 I-Condition

- NCT03926962 514 515 O
History NCT03926962 517 524 B-Eq-Comparison
of NCT03926962 525 527 O
relevant NCT03926962 528 536 O
drug NCT03926962 537 541 O
and NCT03926962 542 545 B-Or
/ NCT03926962 546 547 I-Or
or NCT03926962 548 550 I-Or
food NCT03926962 551 555 O
allergies NCT03926962 556 565 B-Allergy

- NCT03926962 568 569 O
Regular NCT03926962 571 578 O
/ NCT03926962 579 580 O
routine NCT03926962 581 588 B-Eq-Comparison
treatment NCT03926962 589 598 B-Procedure
with NCT03926962 599 603 B-Eq-Comparison
non NCT03926962 604 607 B-Negation
- NCT03926962 608 609 O
topical NCT03926962 610 617 B-Drug|Temporal-Connection___Temporal-Connection-Type-Value:before
medications NCT03926962 618 629 I-Drug
within NCT03926962 630 636 O
30 NCT03926962 637 639 I-Eq-Comparison
days NCT03926962 640 644 I-Eq-Comparison
prior NCT03926962 645 650 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926962 651 653 O
entry NCT03926962 654 659 B-Study
into NCT03926962 660 664 O
the NCT03926962 665 668 O
clinical NCT03926962 669 677 O
research NCT03926962 678 686 O
center NCT03926962 687 693 O

- NCT03926962 696 697 O
Smoking NCT03926962 699 706 B-Condition
within NCT03926962 707 713 B-Eq-Comparison
60 NCT03926962 714 716 I-Eq-Comparison
days NCT03926962 717 721 I-Eq-Comparison
prior NCT03926962 722 727 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926962 728 730 I-Temporal-Connection___Temporal-Connection-Type-Value:before
drug NCT03926962 731 735 B-Procedure
administration NCT03926962 736 750 I-Procedure
and NCT03926962 751 754 B-And
through NCT03926962 755 762 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926962 763 766 O
follow NCT03926962 767 773 B-Encounter
- NCT03926962 774 775 I-Encounter
up NCT03926962 776 778 I-Encounter
visit NCT03926962 779 784 I-Encounter

- NCT03926962 787 788 O
History NCT03926962 790 797 B-Eq-Comparison
of NCT03926962 798 800 O
alcohol NCT03926962 801 808 B-Condition
abuse NCT03926962 809 814 I-Condition
or NCT03926962 815 817 B-Or
drug NCT03926962 818 822 B-Condition|Condition
addiction NCT03926962 823 832 I-Condition
( NCT03926962 833 834 O
including NCT03926962 835 844 O
soft NCT03926962 845 849 B-Condition
drugs NCT03926962 850 855 O
like NCT03926962 856 860 O
cannabis NCT03926962 861 869 B-Condition
products NCT03926962 870 878 O
) NCT03926962 879 880 O

Inclusion NCT03922906 0 9 O
Criteria NCT03922906 10 18 O
: NCT03922906 19 20 O

1 NCT03922906 24 25 O
. NCT03922906 25 26 O
Subjects NCT03922906 28 36 O
with NCT03922906 37 41 O
history NCT03922906 42 49 B-Eq-Comparison
of NCT03922906 50 52 O
inadequate NCT03922906 53 63 B-Condition
bowel NCT03922906 64 69 I-Condition
preparation NCT03922906 70 81 I-Condition
. NCT03922906 81 82 O

2 NCT03922906 86 87 O
. NCT03922906 87 88 O
Subjects NCT03922906 90 98 O
in NCT03922906 99 101 O
the NCT03922906 102 105 O
age NCT03922906 106 109 B-Age
range NCT03922906 110 115 O
of NCT03922906 116 118 O
22 NCT03922906 119 121 B-Eq-Comparison
- NCT03922906 122 123 I-Eq-Comparison
75 NCT03922906 124 126 I-Eq-Comparison
years NCT03922906 127 132 I-Eq-Comparison
inclusive NCT03922906 133 142 O

3 NCT03922906 145 146 O
. NCT03922906 146 147 O
Subjects NCT03922906 149 157 O
with NCT03922906 158 162 O
BodyMass NCT03922906 163 171 B-Observation
Index NCT03922906 172 177 I-Observation
( NCT03922906 178 179 O
BMI NCT03922906 180 183 B-Observation
) NCT03922906 184 185 O
within NCT03922906 186 192 O
the NCT03922906 193 196 O
range NCT03922906 197 202 O
of NCT03922906 203 205 O
18.5 NCT03922906 206 210 B-Eq-Comparison
- NCT03922906 211 212 I-Eq-Comparison
35 NCT03922906 213 215 I-Eq-Comparison
inclusive NCT03922906 216 225 O

4 NCT03922906 228 229 O
. NCT03922906 229 230 O
Subject NCT03922906 232 239 O
has NCT03922906 240 243 O
signed NCT03922906 244 250 O
the NCT03922906 251 254 O
informed NCT03922906 255 263 O
consent NCT03922906 264 271 O

Exclusion NCT03922906 272 281 O
Criteria NCT03922906 282 290 O
: NCT03922906 291 292 O

1 NCT03922906 296 297 O
. NCT03922906 297 298 O
Patients NCT03922906 300 308 O
with NCT03922906 309 313 O
active NCT03922906 314 320 B-Eq-Comparison
Inflammatory NCT03922906 321 333 B-Condition
Bowel NCT03922906 334 339 I-Condition
Disease NCT03922906 340 347 I-Condition

2 NCT03922906 350 351 O
. NCT03922906 351 352 O
Patients NCT03922906 354 362 O
with NCT03922906 363 367 O
previous NCT03922906 368 376 B-Eq-Comparison
history NCT03922906 377 384 I-Eq-Comparison
of NCT03922906 385 387 O
acute NCT03922906 388 393 O
diverticulitis NCT03922906 394 408 B-Condition
disease NCT03922906 409 416 I-Condition
or NCT03922906 417 419 B-Or
with NCT03922906 420 424 O
prior NCT03922906 425 430 B-Eq-Comparison
incomplete NCT03922906 431 441 B-Modifier
colonoscopy NCT03922906 442 453 B-Procedure
due NCT03922906 454 457 O
to NCT03922906 458 460 O
diverticular NCT03922906 461 473 B-Condition
disease NCT03922906 474 481 I-Condition

3 NCT03922906 484 485 O
. NCT03922906 485 486 O
Patients NCT03922906 488 496 O
with NCT03922906 497 501 O
known NCT03922906 502 507 O
bowel NCT03922906 508 513 B-Condition
obstruction NCT03922906 514 525 I-Condition
/ NCT03922906 526 527 B-Or
strictures NCT03922906 528 538 B-Condition

4 NCT03922906 541 542 O
. NCT03922906 542 543 O
History NCT03922906 545 552 B-Eq-Comparison
of NCT03922906 553 555 I-Eq-Comparison
prior NCT03922906 556 561 I-Eq-Comparison
surgery NCT03922906 562 569 B-Procedure
to NCT03922906 570 572 O
colon NCT03922906 573 578 B-Modifier
and NCT03922906 579 582 B-Or
/ NCT03922906 583 584 I-Or
or NCT03922906 585 587 I-Or
rectum NCT03922906 588 594 B-Modifier

5 NCT03922906 597 598 O
. NCT03922906 598 599 O
ASA NCT03922906 601 604 B-Condition
≥ NCT03922906 605 606 B-Eq-Comparison
III NCT03922906 607 610 I-Eq-Comparison

6 NCT03922906 613 614 O
. NCT03922906 614 615 O
Renal NCT03922906 617 622 B-Condition
insufficiency NCT03922906 623 636 I-Condition
( NCT03922906 637 638 O
Creatinine NCT03922906 639 649 B-Observation
≥ NCT03922906 650 651 B-Eq-Comparison
1.5 NCT03922906 652 655 I-Eq-Comparison
mg NCT03922906 656 658 O
/ NCT03922906 659 660 I-Eq-Comparison
dL NCT03922906 661 663 I-Eq-Comparison
) NCT03922906 664 665 O
( NCT03922906 666 667 O
based NCT03922906 668 673 O
on NCT03922906 674 676 O
medical NCT03922906 677 684 O
history NCT03922906 685 692 O
) NCT03922906 693 694 O

7 NCT03922906 698 699 O
. NCT03922906 699 700 O
Abnormal NCT03922906 702 710 O
Liver NCT03922906 711 716 B-Condition
enzymes NCT03922906 717 724 I-Condition
( NCT03922906 725 726 O
ALT NCT03922906 727 730 B-Observation
/ NCT03922906 731 732 B-Or
AST NCT03922906 733 736 B-Observation
≥ NCT03922906 737 738 B-Eq-Comparison
2 NCT03922906 739 740 I-Eq-Comparison
times NCT03922906 741 746 I-Eq-Comparison
upper NCT03922906 747 752 I-Eq-Comparison
limits NCT03922906 753 759 I-Eq-Comparison
of NCT03922906 760 762 I-Eq-Comparison
normal NCT03922906 763 769 I-Eq-Comparison
) NCT03922906 770 771 O
( NCT03922906 772 773 O
based NCT03922906 774 779 O
on NCT03922906 780 782 O
medical NCT03922906 783 790 O
history NCT03922906 791 798 O
) NCT03922906 799 800 O

8 NCT03922906 804 805 O
. NCT03922906 805 806 O
Patients NCT03922906 808 816 O
taking NCT03922906 817 823 B-Eq-Comparison
anticoagulants NCT03922906 824 838 B-Drug
drugs NCT03922906 839 844 I-Drug
( NCT03922906 845 846 O
excluding NCT03922906 847 856 B-Exception
aspirin NCT03922906 857 864 B-Drug
) NCT03922906 865 866 O
or NCT03922906 867 869 B-Or
dual NCT03922906 870 874 B-Modifier
antiplatelet NCT03922906 875 887 B-Procedure
therapy NCT03922906 888 895 I-Procedure

9 NCT03922906 898 899 O
. NCT03922906 899 900 O
Patients NCT03922906 902 910 O
with NCT03922906 911 915 O
known NCT03922906 916 921 O
coagulation NCT03922906 922 933 B-Condition
disorder NCT03922906 934 942 I-Condition
( NCT03922906 943 944 O
INR NCT03922906 945 948 B-Observation
> NCT03922906 949 950 B-Eq-Comparison
1.5 NCT03922906 951 954 I-Eq-Comparison
) NCT03922906 955 956 O
. NCT03922906 957 958 O

10 NCT03922906 961 963 O
. NCT03922906 963 964 O
Patients NCT03922906 966 974 O
at NCT03922906 975 977 O
risk NCT03922906 978 982 B-Risk
of NCT03922906 983 985 O
hypokalemia NCT03922906 986 997 B-Condition
or NCT03922906 998 1000 B-Or
hyponatremia NCT03922906 1001 1013 B-Condition

11 NCT03922906 1015 1017 O
. NCT03922906 1017 1018 O
Patients NCT03922906 1020 1028 O
with NCT03922906 1029 1033 O
congestive NCT03922906 1034 1044 B-Condition
cardiac NCT03922906 1045 1052 I-Condition
failure NCT03922906 1053 1060 I-Condition

12 NCT03922906 1062 1064 O
. NCT03922906 1064 1065 O
Pregnancy NCT03922906 1067 1076 B-Condition
( NCT03922906 1077 1078 O
as NCT03922906 1079 1081 O
stated NCT03922906 1082 1088 O
by NCT03922906 1089 1091 O
patient NCT03922906 1092 1099 O
) NCT03922906 1100 1101 O
or NCT03922906 1102 1104 B-Or
breast NCT03922906 1105 1111 B-Condition
feeding NCT03922906 1112 1119 I-Condition

13 NCT03922906 1121 1123 O
. NCT03922906 1123 1124 O
Patients NCT03922906 1126 1134 O
with NCT03922906 1135 1139 O
altered NCT03922906 1140 1147 B-Condition
mental NCT03922906 1148 1154 I-Condition
status NCT03922906 1155 1161 I-Condition
/ NCT03922906 1162 1163 O
inability NCT03922906 1164 1173 O
to NCT03922906 1174 1176 O
provide NCT03922906 1177 1184 O
informed NCT03922906 1185 1193 O
consent NCT03922906 1194 1201 O

14 NCT03922906 1203 1205 O
. NCT03922906 1205 1206 O
Patients NCT03922906 1208 1216 O
who NCT03922906 1217 1220 O
have NCT03922906 1221 1225 O
participated NCT03922906 1226 1238 O
in NCT03922906 1239 1241 O
another NCT03922906 1242 1249 B-Other
interventional NCT03922906 1250 1264 O
clinical NCT03922906 1265 1273 O
study NCT03922906 1274 1279 B-Study
in NCT03922906 1280 1282 O
the NCT03922906 1283 1286 O
last NCT03922906 1287 1291 B-Eq-Comparison
2 NCT03922906 1292 1293 I-Eq-Comparison
months NCT03922906 1294 1300 I-Eq-Comparison

Inclusion NCT03925714 0 9 O
Criteria NCT03925714 10 18 O
: NCT03925714 19 20 O

- NCT03925714 24 25 O
Prediabetic NCT03925714 27 38 B-Condition
subjects NCT03925714 39 47 O
. NCT03925714 47 48 O

Exclusion NCT03925714 50 59 O
Criteria NCT03925714 60 68 O
: NCT03925714 69 70 O

- NCT03925714 74 75 O
Confirmed NCT03925714 77 86 O
diabetes NCT03925714 87 95 B-Condition
. NCT03925714 95 96 O

- NCT03925714 100 101 O
Hepatic NCT03925714 103 110 B-Modifier
or NCT03925714 111 113 B-Or
renal NCT03925714 114 119 B-Modifier
impairment NCT03925714 120 130 B-Condition
. NCT03925714 130 131 O

Inclusion NCT03926221 0 9 O
Criteria NCT03926221 10 18 O
: NCT03926221 19 20 O

1 NCT03926221 24 25 O
. NCT03926221 25 26 O
Age NCT03926221 28 31 B-Age
between NCT03926221 32 39 B-Eq-Comparison
10 NCT03926221 40 42 I-Eq-Comparison
and NCT03926221 43 46 I-Eq-Comparison
18 NCT03926221 47 49 I-Eq-Comparison
and NCT03926221 50 53 O
living NCT03926221 54 60 O
with NCT03926221 61 65 O
a NCT03926221 66 67 O
parent NCT03926221 68 74 B-Family-Member___Family-Member-Type:parent
or NCT03926221 75 77 O
guardian NCT03926221 78 86 O

2 NCT03926221 89 90 O
. NCT03926221 90 91 O
Lowest NCT03926221 93 99 O
quartile NCT03926221 100 108 O
of NCT03926221 109 111 O
the NCT03926221 112 115 O
widely NCT03926221 116 122 O
used NCT03926221 123 127 O
and NCT03926221 128 131 O
well NCT03926221 132 136 O
- NCT03926221 137 138 O
validated NCT03926221 139 148 O
Children NCT03926221 149 157 B-Observation
's NCT03926221 157 159 O
Morningness NCT03926221 160 171 I-Observation
- NCT03926221 172 173 I-Observation
Eveningness NCT03926221 174 185 I-Observation
Preferences NCT03926221 186 197 I-Observation
Scale NCT03926221 198 203 I-Observation
( NCT03926221 204 205 O
CMEP NCT03926221 206 210 B-Observation
; NCT03926221 210 211 O
27 NCT03926221 212 214 B-Eq-Comparison
or NCT03926221 215 217 I-Eq-Comparison
lower NCT03926221 218 223 I-Eq-Comparison
) NCT03926221 224 225 O
and NCT03926221 226 229 O

3 NCT03926221 232 233 O
. NCT03926221 233 234 O
Youth NCT03926221 236 241 O
self NCT03926221 242 246 O
- NCT03926221 247 248 O
reported NCT03926221 249 257 O
weekday NCT03926221 258 265 O
sleep NCT03926221 266 271 B-Observation
onset NCT03926221 272 277 I-Observation
time NCT03926221 278 282 I-Observation
for NCT03926221 283 286 O
the NCT03926221 287 290 O
past NCT03926221 291 295 B-Eq-Comparison
month NCT03926221 296 301 I-Eq-Comparison
later NCT03926221 302 307 B-Eq-Comparison
than NCT03926221 308 312 I-Eq-Comparison
10 NCT03926221 313 315 I-Eq-Comparison|Eq-Comparison
: NCT03926221 316 317 O
40 NCT03926221 318 320 O
pm NCT03926221 321 323 I-Eq-Comparison
for NCT03926221 324 327 O
10 NCT03926221 328 330 O
- NCT03926221 331 332 I-Eq-Comparison
to NCT03926221 333 335 I-Eq-Comparison
13 NCT03926221 336 338 I-Eq-Comparison
- NCT03926221 339 340 O
year NCT03926221 341 345 I-Eq-Comparison
- NCT03926221 346 347 O
olds NCT03926221 348 352 B-Age
; NCT03926221 352 353 O
11 NCT03926221 354 356 B-Eq-Comparison
: NCT03926221 357 358 O
00 NCT03926221 359 361 O
pm NCT03926221 362 364 O
for NCT03926221 365 368 O
14 NCT03926221 369 371 B-Eq-Comparison
- NCT03926221 372 373 I-Eq-Comparison
16 NCT03926221 374 376 I-Eq-Comparison
year NCT03926221 377 381 I-Eq-Comparison
olds NCT03926221 382 386 B-Age
, NCT03926221 387 388 O
and NCT03926221 389 392 B-Or
later NCT03926221 393 398 B-Eq-Comparison
than NCT03926221 399 403 I-Eq-Comparison
11 NCT03926221 404 406 I-Eq-Comparison
: NCT03926221 407 408 O
20 NCT03926221 409 411 O
for NCT03926221 412 415 O
17 NCT03926221 416 418 B-Eq-Comparison
- NCT03926221 419 420 I-Eq-Comparison
18 NCT03926221 421 423 I-Eq-Comparison
year NCT03926221 424 428 I-Eq-Comparison
olds NCT03926221 429 433 B-Age
at NCT03926221 434 436 B-Eq-Comparison
least NCT03926221 437 442 I-Eq-Comparison
3 NCT03926221 443 444 I-Eq-Comparison
nights NCT03926221 445 451 I-Eq-Comparison
per NCT03926221 452 455 I-Eq-Comparison
week NCT03926221 456 460 I-Eq-Comparison
; NCT03926221 460 461 O

4 NCT03926221 464 465 O
. NCT03926221 465 466 O
English NCT03926221 468 475 O
language NCT03926221 476 484 O
fluency NCT03926221 485 492 O
; NCT03926221 492 493 O

5 NCT03926221 496 497 O
. NCT03926221 497 498 O
able NCT03926221 500 504 O
and NCT03926221 505 508 O
willing NCT03926221 509 516 O
to NCT03926221 517 519 O
give NCT03926221 520 524 O
informed NCT03926221 525 533 O
assent NCT03926221 534 540 O
; NCT03926221 540 541 O

6 NCT03926221 544 545 O
. NCT03926221 545 546 O
at NCT03926221 548 550 B-Eq-Comparison
least NCT03926221 551 556 I-Eq-Comparison
one NCT03926221 557 560 I-Eq-Comparison
parent NCT03926221 561 567 B-Family-Member___Family-Member-Type:parent
/ NCT03926221 568 569 O
primary NCT03926221 570 577 O
caregiver NCT03926221 578 587 O
who NCT03926221 588 591 O
lives NCT03926221 592 597 O
in NCT03926221 598 600 O
the NCT03926221 601 604 O
same NCT03926221 605 609 O
household NCT03926221 610 619 O
as NCT03926221 620 622 O
the NCT03926221 623 626 I-Eq-Comparison
teen NCT03926221 627 631 O
for NCT03926221 632 635 O
at NCT03926221 636 638 B-Eq-Comparison
least NCT03926221 639 644 I-Eq-Comparison
50 NCT03926221 645 647 I-Eq-Comparison
% NCT03926221 648 649 O
of NCT03926221 650 652 I-Eq-Comparison
the NCT03926221 653 656 O
week NCT03926221 657 661 I-Eq-Comparison
must NCT03926221 662 666 O
participate NCT03926221 667 678 O
in NCT03926221 679 681 O
all NCT03926221 682 685 O
study NCT03926221 686 691 O
sessions NCT03926221 692 700 O
. NCT03926221 700 701 O

Exclusion NCT03926221 703 712 O
Criteria NCT03926221 713 721 O
: NCT03926221 722 723 O

1 NCT03926221 727 728 O
. NCT03926221 728 729 O
An NCT03926221 731 733 O
active NCT03926221 734 740 B-Eq-Comparison
, NCT03926221 741 742 O
progressive NCT03926221 743 754 B-Modifier
physical NCT03926221 755 763 B-Condition
illness NCT03926221 764 771 I-Condition
directly NCT03926221 772 780 O
related NCT03926221 781 788 O
to NCT03926221 789 791 O
the NCT03926221 792 795 O
onset NCT03926221 796 801 B-Eq-Comparison
and NCT03926221 802 805 O
course NCT03926221 806 812 O
of NCT03926221 813 815 O
the NCT03926221 816 819 O
sleep NCT03926221 820 825 B-Condition|Condition
disturbance NCT03926221 826 837 I-Condition
; NCT03926221 837 838 O

2 NCT03926221 841 842 O
. NCT03926221 842 843 O
evidence NCT03926221 845 853 O
of NCT03926221 854 856 O
sleep NCT03926221 857 862 O
apnea NCT03926221 863 868 I-Condition
, NCT03926221 869 870 O
restless NCT03926221 871 879 B-Condition
legs NCT03926221 880 884 I-Condition
or NCT03926221 885 887 B-Or
periodic NCT03926221 888 896 B-Modifier
limb NCT03926221 897 901 B-Condition
movements NCT03926221 902 911 I-Condition
; NCT03926221 911 912 O

3 NCT03926221 915 916 O
. NCT03926221 916 917 O
significantly NCT03926221 919 932 O
impairing NCT03926221 933 942 O
pervasive NCT03926221 943 952 B-Modifier
developmental NCT03926221 953 966 B-Condition
disorder NCT03926221 967 975 I-Condition
; NCT03926221 975 976 O

4 NCT03926221 979 980 O
. NCT03926221 980 981 O
history NCT03926221 983 990 B-Eq-Comparison
of NCT03926221 991 993 O
substance NCT03926221 994 1003 B-Condition
dependence NCT03926221 1004 1014 I-Condition
in NCT03926221 1015 1017 O
the NCT03926221 1018 1021 O
past NCT03926221 1022 1026 B-Eq-Comparison
six NCT03926221 1027 1030 I-Eq-Comparison
months NCT03926221 1031 1037 I-Eq-Comparison
; NCT03926221 1037 1038 O

5 NCT03926221 1041 1042 O
. NCT03926221 1042 1043 O
suicide NCT03926221 1045 1052 B-Condition
risk NCT03926221 1053 1057 B-Risk
; NCT03926221 1057 1058 O
bipolar NCT03926221 1059 1066 B-Condition
disorder NCT03926221 1067 1075 I-Condition
or NCT03926221 1076 1078 B-Or
schizophrenia NCT03926221 1079 1092 B-Condition
or NCT03926221 1093 1095 O
another NCT03926221 1096 1103 B-Other
current NCT03926221 1104 1111 B-Eq-Comparison
Axis NCT03926221 1112 1116 B-Eq-Comparison
I NCT03926221 1117 1118 I-Eq-Comparison
disorder NCT03926221 1119 1127 B-Condition
if NCT03926221 1128 1130 O
there NCT03926221 1131 1136 O
is NCT03926221 1137 1139 O
a NCT03926221 1140 1141 O
significant NCT03926221 1142 1153 O
risk NCT03926221 1154 1158 B-Risk
of NCT03926221 1159 1161 O
harm NCT03926221 1162 1166 B-Condition
and NCT03926221 1167 1170 B-Or
/ NCT03926221 1171 1172 I-Or
or NCT03926221 1173 1175 I-Or
decompensation NCT03926221 1176 1190 B-Condition
if NCT03926221 1191 1193 O
treatment NCT03926221 1194 1203 B-Procedure
of NCT03926221 1204 1206 O
that NCT03926221 1207 1211 B-Condition|Coreference
comorbid NCT03926221 1212 1220 I-Condition|Coreference
condition NCT03926221 1221 1230 I-Condition|Coreference
is NCT03926221 1231 1233 O
delayed NCT03926221 1234 1241 O
as NCT03926221 1242 1244 O
a NCT03926221 1245 1246 O
function NCT03926221 1247 1255 O
of NCT03926221 1256 1258 O
participating NCT03926221 1259 1272 O
in NCT03926221 1273 1275 O
any NCT03926221 1276 1279 O
stage NCT03926221 1280 1285 O
of NCT03926221 1286 1288 O
this NCT03926221 1289 1293 O
study NCT03926221 1294 1299 B-Study
; NCT03926221 1299 1300 O

6 NCT03926221 1303 1304 O
. NCT03926221 1304 1305 O
Participants NCT03926221 1307 1319 O
will NCT03926221 1320 1324 O
not NCT03926221 1325 1328 B-Negation
be NCT03926221 1329 1331 O
excluded NCT03926221 1332 1340 B-Negation
if NCT03926221 1341 1343 O
medications NCT03926221 1344 1355 B-Drug
are NCT03926221 1356 1359 O
stable NCT03926221 1360 1366 O
( NCT03926221 1367 1368 O
> NCT03926221 1370 1371 B-Eq-Comparison
4 NCT03926221 1372 1373 I-Eq-Comparison
weeks NCT03926221 1374 1379 I-Eq-Comparison
) NCT03926221 1380 1381 O
. NCT03926221 1382 1383 O

Inclusion NCT03924999 0 9 O
Criteria NCT03924999 10 18 O
: NCT03924999 19 20 O

- NCT03924999 24 25 O
Subject NCT03924999 27 34 O
diagnosed NCT03924999 35 44 O
with NCT03924999 45 49 O
lipedema NCT03924999 50 58 B-Condition
according NCT03924999 59 68 O
to NCT03924999 69 71 O
the NCT03924999 72 75 O
criteria NCT03924999 76 84 O
of NCT03924999 85 87 O
revised NCT03924999 88 95 O
Wold NCT03924999 96 100 O
. NCT03924999 100 101 O

- NCT03924999 105 106 O
Subject NCT03924999 108 115 O
did NCT03924999 116 119 O
not NCT03924999 120 123 B-Negation
participate NCT03924999 124 135 O
in NCT03924999 136 138 O
any NCT03924999 139 142 O
exercise NCT03924999 143 151 B-Procedure
program NCT03924999 152 159 I-Procedure
within NCT03924999 160 166 B-Eq-Comparison
the NCT03924999 167 170 I-Eq-Comparison
last NCT03924999 171 175 I-Eq-Comparison
three NCT03924999 176 181 I-Eq-Comparison
months NCT03924999 182 188 I-Eq-Comparison
. NCT03924999 188 189 O

- NCT03924999 193 194 O
No NCT03924999 196 198 B-Negation
pregnancy NCT03924999 199 208 B-Condition
/ NCT03924999 209 210 B-Or
breastfeeding NCT03924999 211 224 B-Condition

Exclusion NCT03924999 225 234 O
Criteria NCT03924999 235 243 O
: NCT03924999 244 245 O

- NCT03924999 249 250 O
History NCT03924999 252 259 B-Eq-Comparison
of NCT03924999 260 262 O
acute NCT03924999 263 268 O
infection NCT03924999 269 278 B-Condition
, NCT03924999 279 280 O
cancer NCT03924999 281 287 B-Condition
, NCT03924999 288 289 O
inflammatory NCT03924999 290 302 B-Modifier
rheumatic NCT03924999 303 312 I-Modifier
/ NCT03924999 313 314 B-Or
connective NCT03924999 315 325 B-Modifier
tissue NCT03924999 326 332 I-Modifier
diseases NCT03924999 333 341 B-Condition

- NCT03924999 344 345 O
History NCT03924999 347 354 B-Eq-Comparison
of NCT03924999 355 357 O
cardiovascular NCT03924999 358 372 B-Modifier
or NCT03924999 373 375 B-Or
musculoskeletal NCT03924999 376 391 B-Modifier
problems NCT03924999 392 400 B-Condition
that NCT03924999 401 405 O
may NCT03924999 406 409 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03924999 410 417 B-Negation
them NCT03924999 418 422 O
from NCT03924999 423 427 O
participating NCT03924999 428 441 O
in NCT03924999 442 444 O
the NCT03924999 445 448 O
exercise NCT03924999 449 457 B-Procedure
program NCT03924999 458 465 I-Procedure

Inclusion NCT03926156 0 9 O
Criteria NCT03926156 10 18 O
: NCT03926156 19 20 O

1 NCT03926156 24 25 O
. NCT03926156 25 26 O
Provision NCT03926156 28 37 O
of NCT03926156 38 40 O
signed NCT03926156 41 47 O
and NCT03926156 48 51 O
dated NCT03926156 52 57 O
informed NCT03926156 58 66 O
consent NCT03926156 67 74 O
form NCT03926156 75 79 O

2 NCT03926156 82 83 O
. NCT03926156 83 84 O
Stated NCT03926156 86 92 O
willingness NCT03926156 93 104 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926156 105 107 O
comply NCT03926156 108 114 O
with NCT03926156 115 119 O
all NCT03926156 120 123 O
study NCT03926156 124 129 B-Study
procedures NCT03926156 130 140 B-Procedure
and NCT03926156 141 144 O
availability NCT03926156 145 157 O
for NCT03926156 158 161 O
the NCT03926156 162 165 O
duration NCT03926156 166 174 O
of NCT03926156 175 177 O
the NCT03926156 178 181 O
study NCT03926156 182 187 O

3 NCT03926156 190 191 O
. NCT03926156 191 192 O
Men NCT03926156 194 197 O
and NCT03926156 198 201 B-Or
women NCT03926156 202 207 O
≥ NCT03926156 208 209 B-Eq-Comparison
18 NCT03926156 210 212 I-Eq-Comparison
year NCT03926156 213 217 I-Eq-Comparison
- NCT03926156 218 219 I-Eq-Comparison
old NCT03926156 220 223 I-Age|Eq-Comparison

4 NCT03926156 226 227 O
. NCT03926156 227 228 O
Diagnosed NCT03926156 230 239 O
with NCT03926156 240 244 O
moderate NCT03926156 245 253 B-Eq-Comparison
to NCT03926156 254 256 I-Eq-Comparison
severe NCT03926156 257 263 I-Eq-Comparison
mitral NCT03926156 264 270 B-Condition
stenosis NCT03926156 271 279 I-Condition
who NCT03926156 280 283 B-And
have NCT03926156 284 288 O
a NCT03926156 289 290 O
history NCT03926156 291 298 B-Eq-Comparison
of NCT03926156 299 301 O
AF NCT03926156 302 304 B-Condition
of NCT03926156 305 307 O
any NCT03926156 308 311 O
duration NCT03926156 312 320 O
documented NCT03926156 321 331 O
by NCT03926156 332 334 O
any NCT03926156 335 338 O
electrical NCT03926156 339 349 B-Procedure
tracing NCT03926156 350 357 I-Procedure
within NCT03926156 358 364 O
the NCT03926156 365 368 O
prior NCT03926156 369 374 B-Eq-Comparison
12 NCT03926156 375 377 I-Eq-Comparison
months NCT03926156 378 384 I-Eq-Comparison
and NCT03926156 385 388 B-And
for NCT03926156 389 392 O
which NCT03926156 393 398 O
anticoagulation NCT03926156 399 414 B-Procedure
is NCT03926156 415 417 O
indicated NCT03926156 418 427 B-Indication
and NCT03926156 428 431 O
planned NCT03926156 432 439 B-Eq-Comparison
for NCT03926156 440 443 I-Eq-Comparison
the NCT03926156 444 447 O
duration NCT03926156 448 456 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03926156 457 459 O
the NCT03926156 460 463 O
study NCT03926156 464 469 B-Study
. NCT03926156 469 470 O

5 NCT03926156 474 475 O
. NCT03926156 475 476 O
Ability NCT03926156 478 485 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926156 486 488 I-Assertion___Assertion-Type-Value:hypothetical
take NCT03926156 489 493 O
oral NCT03926156 494 498 B-Procedure
medication NCT03926156 499 509 I-Procedure
and NCT03926156 510 513 B-And
be NCT03926156 514 516 O
willing NCT03926156 517 524 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926156 525 527 I-Assertion___Assertion-Type-Value:hypothetical
adhere NCT03926156 528 534 O
to NCT03926156 535 537 O
the NCT03926156 538 541 O
rivaroxaban NCT03926156 542 553 B-Drug
regimen NCT03926156 554 561 O

Exclusion NCT03926156 562 571 O
Criteria NCT03926156 572 580 O
: NCT03926156 581 582 O

1 NCT03926156 586 587 O
. NCT03926156 587 588 O
Left NCT03926156 590 594 B-Modifier
atrial NCT03926156 595 601 I-Modifier
clot NCT03926156 602 606 B-Condition

2 NCT03926156 609 610 O
. NCT03926156 610 611 O
Severe NCT03926156 613 619 O
renal NCT03926156 620 625 B-Condition
dysfunction NCT03926156 626 637 I-Condition
( NCT03926156 638 639 O
creatinine NCT03926156 640 650 B-Observation
clearance NCT03926156 651 660 I-Observation
[ NCT03926156 661 662 O
CrCl NCT03926156 663 667 B-Observation
] NCT03926156 668 669 O
< NCT03926156 670 671 B-Eq-Comparison
15 NCT03926156 672 674 I-Eq-Comparison
mL NCT03926156 675 677 I-Eq-Comparison
/ NCT03926156 678 679 I-Eq-Comparison
min NCT03926156 680 683 I-Eq-Comparison
) NCT03926156 684 685 O
, NCT03926156 687 688 O
subjects NCT03926156 689 697 O
with NCT03926156 698 702 O

3 NCT03926156 705 706 O
. NCT03926156 706 707 O
A NCT03926156 709 710 O
condition NCT03926156 711 720 B-Condition
associated NCT03926156 721 731 O
with NCT03926156 732 736 O
a NCT03926156 737 738 O
high NCT03926156 739 743 O
risk NCT03926156 744 748 B-Risk
of NCT03926156 749 751 O
bleeding NCT03926156 752 760 B-Condition

4 NCT03926156 763 764 O
. NCT03926156 764 765 O
Allergic NCT03926156 767 775 B-Allergy
to NCT03926156 776 778 O
rivaroxabn NCT03926156 779 789 B-Drug
/ NCT03926156 790 791 B-Or
warfarin NCT03926156 792 800 B-Drug

Inclusion NCT03920527 0 9 O
Criteria NCT03920527 10 18 O
: NCT03920527 19 20 O
includes NCT03920527 21 29 O
presence NCT03920527 30 38 O
of NCT03920527 39 41 O
all NCT03920527 42 45 O
the NCT03920527 46 49 O
following NCT03920527 50 59 O
: NCT03920527 60 61 O

- NCT03920527 65 66 O
one NCT03920527 68 71 B-Eq-Comparison
or NCT03920527 72 74 I-Eq-Comparison
more NCT03920527 75 79 I-Eq-Comparison
clinical NCT03920527 80 88 B-Condition
symptoms NCT03920527 89 97 I-Condition
( NCT03920527 98 99 O
persistent NCT03920527 100 110 B-Modifier
cough NCT03920527 111 116 B-Condition
, NCT03920527 117 118 O
recurrent NCT03920527 119 128 B-Modifier
hemoptysis NCT03920527 129 139 B-Condition
, NCT03920527 140 141 O
weight NCT03920527 142 148 B-Condition
loss NCT03920527 149 153 I-Condition
, NCT03920527 154 155 O
malaise NCT03920527 156 163 B-Condition
, NCT03920527 164 165 O
fever NCT03920527 166 171 B-Condition
and NCT03920527 172 175 B-Or
dyspnea NCT03920527 176 183 B-Condition
) NCT03920527 184 185 O
for NCT03920527 186 189 O
≥ NCT03920527 190 191 B-Eq-Comparison
3 NCT03920527 192 193 I-Eq-Comparison
months NCT03920527 194 200 I-Eq-Comparison

- NCT03920527 203 204 O
slowly NCT03920527 206 212 B-Modifier
progressive NCT03920527 213 224 I-Modifier
or NCT03920527 225 227 B-Or
persistent NCT03920527 228 238 B-Modifier
radiological NCT03920527 239 251 B-Procedure
findings NCT03920527 252 260 B-Condition
( NCT03920527 261 262 O
one NCT03920527 263 266 B-Eq-Comparison
or NCT03920527 267 269 I-Eq-Comparison
more NCT03920527 270 274 I-Eq-Comparison
cavities NCT03920527 275 283 B-Condition
and NCT03920527 284 287 B-Or
surrounding NCT03920527 288 299 B-Modifier
fibrosis NCT03920527 300 308 B-Condition
, NCT03920527 309 310 O
infiltrates NCT03920527 311 322 B-Condition
, NCT03920527 323 324 O
consolidation NCT03920527 325 338 B-Condition
, NCT03920527 339 340 O
with NCT03920527 341 345 O
or NCT03920527 346 348 O
without NCT03920527 349 356 O
fungal NCT03920527 357 363 B-Condition
ball NCT03920527 364 368 I-Condition
or NCT03920527 369 371 B-Or
progressive NCT03920527 372 383 B-Modifier
pleural NCT03920527 384 391 B-Condition
thickening NCT03920527 392 402 I-Condition
) NCT03920527 403 404 O
on NCT03920527 405 407 O
computed NCT03920527 408 416 B-Procedure
tomography NCT03920527 417 427 I-Procedure
( NCT03920527 428 429 O
CT NCT03920527 430 432 B-Procedure
) NCT03920527 433 434 O
of NCT03920527 435 437 O
the NCT03920527 438 441 O
thorax NCT03920527 442 448 B-Modifier

- NCT03920527 451 452 O
immunological NCT03920527 454 467 B-Modifier
( NCT03920527 468 469 O
A. NCT03920527 470 472 B-Organism
fumigatus NCT03920527 473 482 O
- NCT03920527 483 484 O
specific NCT03920527 485 493 O
IgG NCT03920527 494 497 B-Observation
> NCT03920527 498 499 B-Eq-Comparison
27 NCT03920527 500 502 I-Eq-Comparison
mgA NCT03920527 503 506 I-Eq-Comparison
/ NCT03920527 507 508 I-Eq-Comparison
L NCT03920527 509 510 I-Eq-Comparison
or NCT03920527 511 513 B-Or
positive NCT03920527 514 522 O
Aspergillus NCT03920527 523 534 B-Organism
precipitins NCT03920527 535 546 I-Organism
) NCT03920527 547 548 O
or NCT03920527 549 551 O
microbiological NCT03920527 552 567 B-Observation
evidence NCT03920527 568 576 O
of NCT03920527 577 579 O
Aspergillus NCT03920527 580 591 B-Modifier
infection NCT03920527 592 601 B-Condition
( NCT03920527 602 603 O
growth NCT03920527 604 610 O
of NCT03920527 611 613 O
Aspergillus NCT03920527 614 625 B-Organism
in NCT03920527 626 628 O
respiratory NCT03920527 629 640 B-Observation
secretions NCT03920527 641 651 I-Observation
or NCT03920527 652 654 B-Or
serum NCT03920527 655 660 B-Observation
galactomannan NCT03920527 661 674 I-Observation
index NCT03920527 675 680 I-Observation
> NCT03920527 681 682 B-Eq-Comparison
0.5 NCT03920527 683 686 I-Eq-Comparison
or NCT03920527 687 689 B-Or
BALF NCT03920527 690 694 B-Observation
galactomannan NCT03920527 695 708 I-Observation
index NCT03920527 709 714 I-Observation
> NCT03920527 715 716 B-Eq-Comparison
1 NCT03920527 717 718 I-Eq-Comparison
) NCT03920527 719 720 O
and NCT03920527 721 724 B-And
, NCT03920527 725 726 O

- NCT03920527 730 731 O
exclusion NCT03920527 733 742 B-Negation
of NCT03920527 743 745 O
other NCT03920527 746 751 B-Other
pulmonary NCT03920527 752 761 B-Modifier
disorders NCT03920527 762 771 B-Condition
with NCT03920527 772 776 O
similar NCT03920527 777 784 O
presentation NCT03920527 785 797 O
. NCT03920527 797 798 O

Exclusion NCT03920527 800 809 O
Criteria NCT03920527 810 818 O
: NCT03920527 819 820 O

- NCT03920527 824 825 O
failure NCT03920527 827 834 O
to NCT03920527 835 837 O
provide NCT03920527 838 845 O
informed NCT03920527 846 854 O
consent NCT03920527 855 862 O

- NCT03920527 865 866 O
patients NCT03920527 868 876 O
on NCT03920527 877 879 B-Eq-Comparison
immunosuppressive NCT03920527 880 897 B-Drug
drugs NCT03920527 898 903 I-Drug
, NCT03920527 904 905 O
intake NCT03920527 906 912 O
of NCT03920527 913 915 O
prednisolone NCT03920527 916 928 B-Drug
( NCT03920527 929 930 O
or NCT03920527 931 933 O
equivalent NCT03920527 934 944 O
) NCT03920527 945 946 O
> NCT03920527 947 948 B-Eq-Comparison
10 NCT03920527 949 951 I-Eq-Comparison
mg NCT03920527 952 954 I-Eq-Comparison
for NCT03920527 955 958 O
at NCT03920527 959 961 B-Eq-Comparison
least NCT03920527 962 967 I-Eq-Comparison
3 NCT03920527 968 969 I-Eq-Comparison
weeks NCT03920527 970 975 I-Eq-Comparison
or NCT03920527 976 978 B-Or
a NCT03920527 979 980 O
diagnosis NCT03920527 981 990 O
of NCT03920527 991 993 O
human NCT03920527 994 999 B-Condition
immunodeficiency NCT03920527 1000 1016 I-Condition
virus NCT03920527 1017 1022 I-Condition
syndrome NCT03920527 1023 1031 I-Condition

- NCT03920527 1034 1035 O
intake NCT03920527 1037 1043 O
antifungal NCT03920527 1044 1054 B-Drug
azoles NCT03920527 1055 1061 I-Drug
for NCT03920527 1062 1065 O
> NCT03920527 1066 1067 B-Eq-Comparison
3 NCT03920527 1068 1069 I-Eq-Comparison
weeks NCT03920527 1070 1075 I-Eq-Comparison
in NCT03920527 1076 1078 O
the NCT03920527 1079 1082 O
preceding NCT03920527 1083 1092 B-Eq-Comparison
six NCT03920527 1093 1096 I-Eq-Comparison
months NCT03920527 1097 1103 I-Eq-Comparison

- NCT03920527 1106 1107 O
subjects NCT03920527 1109 1117 O
with NCT03920527 1118 1122 O
active NCT03920527 1123 1129 B-Eq-Comparison
pulmonary NCT03920527 1130 1139 B-Modifier
infection NCT03920527 1140 1149 B-Condition
due NCT03920527 1150 1153 O
to NCT03920527 1154 1156 O
mycobacterium NCT03920527 1157 1170 B-Organism
tuberculosis NCT03920527 1171 1183 I-Organism
or NCT03920527 1184 1186 B-Or
mycobacteria NCT03920527 1187 1199 B-Organism
other NCT03920527 1200 1205 B-Exception
than NCT03920527 1206 1210 I-Exception
tuberculosis NCT03920527 1211 1223 B-Condition
( NCT03920527 1224 1225 O
MOTT NCT03920527 1226 1230 B-Condition
) NCT03920527 1231 1232 O

- NCT03920527 1236 1237 O
subjects NCT03920527 1239 1247 O
with NCT03920527 1248 1252 O
others NCT03920527 1253 1259 B-Other
forms NCT03920527 1260 1265 O
of NCT03920527 1266 1268 O
pulmonary NCT03920527 1269 1278 B-Modifier
aspergillosis NCT03920527 1279 1292 B-Condition|Condition
( NCT03920527 1293 1294 O
allergic NCT03920527 1295 1303 B-Modifier
bronchopulmonary NCT03920527 1304 1320 I-Modifier
aspergillosis NCT03920527 1321 1334 B-Condition
, NCT03920527 1335 1336 O
chronic NCT03920527 1337 1344 B-Modifier
necrotizing NCT03920527 1345 1356 I-Modifier
aspergillosis NCT03920527 1357 1370 B-Condition
and NCT03920527 1371 1374 B-Or
angio NCT03920527 1375 1380 B-Modifier
- NCT03920527 1381 1382 I-Modifier
invasive NCT03920527 1383 1391 I-Modifier
aspergillosis NCT03920527 1392 1405 O
) NCT03920527 1406 1407 O

- NCT03920527 1411 1412 O
pregnancy NCT03920527 1414 1423 B-Condition

Inclusion NCT03920241 0 9 O
Criteria NCT03920241 10 18 O
: NCT03920241 19 20 O

- NCT03920241 24 25 O
18 NCT03920241 27 29 B-Eq-Comparison
years NCT03920241 30 35 I-Eq-Comparison
of NCT03920241 36 38 I-Eq-Comparison
age NCT03920241 39 42 I-Eq-Comparison
or NCT03920241 43 45 I-Eq-Comparison
more NCT03920241 46 50 I-Eq-Comparison

- NCT03920241 53 54 O
Fluency NCT03920241 56 63 O
in NCT03920241 64 66 O
oral NCT03920241 67 71 O
and NCT03920241 72 75 O
written NCT03920241 76 83 O
Spanish NCT03920241 84 91 O

Exclusion NCT03920241 92 101 O
Criteria NCT03920241 102 110 O
: NCT03920241 111 112 O

- NCT03920241 116 117 O
Having NCT03920241 119 125 O
any NCT03920241 126 129 O
current NCT03920241 130 137 B-Eq-Comparison
of NCT03920241 138 140 O
serious NCT03920241 141 148 O
psychological NCT03920241 149 162 B-Condition
disorder NCT03920241 163 171 I-Condition
or NCT03920241 172 174 B-Or
substance NCT03920241 175 184 B-Condition
abuse NCT03920241 185 190 B-Modifier
/ NCT03920241 191 192 B-Or
dependence NCT03920241 193 203 B-Modifier
. NCT03920241 203 204 O

- NCT03920241 208 209 O
Being NCT03920241 211 216 O
currently NCT03920241 217 226 B-Eq-Comparison
enrolled NCT03920241 227 235 O
in NCT03920241 236 238 O
another NCT03920241 239 246 O
standardized NCT03920241 247 259 O
meditation NCT03920241 260 270 B-Procedure
program NCT03920241 271 278 I-Procedure

Inclusion NCT03927274 0 9 O
Criteria NCT03927274 10 18 O
: NCT03927274 19 20 O

- NCT03927274 24 25 O
Histologically NCT03927274 27 41 B-Procedure
confirmed NCT03927274 42 51 O
diagnosis NCT03927274 52 61 O
of NCT03927274 62 64 O
supratentorial NCT03927274 65 79 B-Modifier
WHO NCT03927274 80 83 O
Grade NCT03927274 84 89 B-Eq-Comparison
III NCT03927274 90 93 I-Eq-Comparison
or NCT03927274 94 96 I-Eq-Comparison
IV NCT03927274 97 99 I-Eq-Comparison
Glioma NCT03927274 100 106 B-Condition
( NCT03927274 107 108 O
High NCT03927274 109 113 B-Modifier
Grade NCT03927274 114 119 I-Modifier
Glioma NCT03927274 120 126 B-Condition
) NCT03927274 127 128 O
that NCT03927274 129 133 O
has NCT03927274 134 137 B-And
undergone NCT03927274 138 147 B-Eq-Comparison
surgical NCT03927274 148 156 B-Procedure
biopsy NCT03927274 157 163 I-Procedure
or NCT03927274 164 166 B-Or
resection NCT03927274 167 176 B-Procedure
followed NCT03927274 177 185 B-Temporal-Connection___Temporal-Connection-Type-Value:before
by NCT03927274 186 188 I-Temporal-Connection___Temporal-Connection-Type-Value:before
adjuvant NCT03927274 189 197 B-Procedure
chemoradiotherapy NCT03927274 198 215 I-Procedure
, NCT03927274 216 217 O
that NCT03927274 218 222 O
has NCT03927274 223 226 B-And
evidence NCT03927274 227 235 O
of NCT03927274 236 238 O
recurrence NCT03927274 239 249 B-Coreference
or NCT03927274 250 252 B-Or
progression NCT03927274 253 264 B-Coreference
based NCT03927274 265 270 O
on NCT03927274 271 273 O
imaging NCT03927274 274 281 B-Procedure
studies NCT03927274 282 289 O
and NCT03927274 290 293 B-And
a NCT03927274 294 295 O
stereotactic NCT03927274 296 308 B-Modifier
biopsy NCT03927274 309 315 B-Procedure
is NCT03927274 316 318 O
indicated NCT03927274 319 328 B-Indication
for NCT03927274 329 332 O
confirmation NCT03927274 333 345 O
of NCT03927274 346 348 O
recurrence NCT03927274 349 359 B-Coreference
/ NCT03927274 360 361 B-Or
progression NCT03927274 362 373 B-Coreference
. NCT03927274 373 374 O

- NCT03927274 378 379 O
18 NCT03927274 381 383 B-Eq-Comparison
years NCT03927274 384 389 I-Eq-Comparison
of NCT03927274 390 392 I-Eq-Comparison
age NCT03927274 393 396 I-Eq-Comparison
or NCT03927274 397 399 I-Eq-Comparison
older NCT03927274 400 405 I-Eq-Comparison

- NCT03927274 408 409 O
Karnofsky NCT03927274 411 420 B-Observation
Performance NCT03927274 421 432 I-Observation
Status NCT03927274 433 439 I-Observation
70 NCT03927274 440 442 B-Eq-Comparison
- NCT03927274 443 444 I-Eq-Comparison
100 NCT03927274 445 448 O
; NCT03927274 449 450 O

- NCT03927274 453 454 O
MRI NCT03927274 456 459 B-Procedure
demonstration NCT03927274 460 473 O
of NCT03927274 474 476 O
a NCT03927274 477 478 O
stereotactically NCT03927274 479 495 B-Modifier
accessible NCT03927274 496 506 I-Modifier
enhancing NCT03927274 507 516 I-Modifier
or NCT03927274 517 519 B-Or
predominantly NCT03927274 520 533 B-Modifier
non NCT03927274 534 537 I-Modifier
- NCT03927274 538 539 I-Modifier
enhancing NCT03927274 540 549 I-Modifier
mass NCT03927274 550 554 B-Condition
that NCT03927274 555 559 B-And
does NCT03927274 560 564 O
not NCT03927274 565 568 B-Negation
require NCT03927274 569 576 B-Assertion___Assertion-Type-Value:hypothetical
resection NCT03927274 577 586 B-Procedure
to NCT03927274 587 589 O
relieve NCT03927274 590 597 O
clinically NCT03927274 598 608 O
significant NCT03927274 609 620 O
mass NCT03927274 621 625 B-Condition
effect NCT03927274 626 632 I-Condition
; NCT03927274 632 633 O

- NCT03927274 636 637 O
Participant NCT03927274 639 650 O
understands NCT03927274 651 662 O
the NCT03927274 663 666 O
procedures NCT03927274 667 677 O
and NCT03927274 678 681 O
agrees NCT03927274 682 688 O
to NCT03927274 689 691 O
comply NCT03927274 692 698 O
with NCT03927274 699 703 O
the NCT03927274 704 707 O
study NCT03927274 708 713 O
requirements NCT03927274 714 726 O
by NCT03927274 727 729 O
providing NCT03927274 730 739 O
written NCT03927274 740 747 O
informed NCT03927274 748 756 O
consent NCT03927274 757 764 O

- NCT03927274 767 768 O
Adequate NCT03927274 770 778 O
organ NCT03927274 779 784 B-Condition
function NCT03927274 785 793 I-Condition
as NCT03927274 794 796 O
indicated NCT03927274 797 806 O
in NCT03927274 807 809 O
protocol NCT03927274 810 818 O

Exclusion NCT03927274 819 828 O
Criteria NCT03927274 829 837 O
: NCT03927274 838 839 O

- NCT03927274 843 844 O
Participant NCT03927274 846 857 O
is NCT03927274 858 860 O
mentally NCT03927274 861 869 B-Modifier
or NCT03927274 870 872 B-Or
legally NCT03927274 873 880 B-Modifier
incapacitated NCT03927274 881 894 B-Condition
at NCT03927274 895 897 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927274 898 901 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03927274 902 906 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03927274 907 909 O
the NCT03927274 910 913 O
study NCT03927274 914 919 B-Study
; NCT03927274 919 920 O

- NCT03927274 923 924 O
Known NCT03927274 926 931 O
HIV NCT03927274 932 935 B-Condition
( NCT03927274 936 937 O
+ NCT03927274 939 940 O
) NCT03927274 942 943 O
or NCT03927274 944 946 B-Or
has NCT03927274 947 950 O
been NCT03927274 951 955 O
diagnosed NCT03927274 956 965 O
with NCT03927274 966 970 O
AIDS NCT03927274 971 975 B-Condition

- NCT03927274 978 979 O
Participation NCT03927274 981 994 O
in NCT03927274 995 997 O
another NCT03927274 998 1005 B-Other
investigational NCT03927274 1006 1021 O
drug NCT03927274 1022 1026 B-Drug
study NCT03927274 1027 1032 B-Study
in NCT03927274 1033 1035 O
the NCT03927274 1036 1039 O
prior NCT03927274 1040 1045 B-Eq-Comparison
4 NCT03927274 1046 1047 I-Eq-Comparison
weeks NCT03927274 1048 1053 I-Eq-Comparison

- NCT03927274 1056 1057 O
Positive NCT03927274 1059 1067 O
pregnancy NCT03927274 1068 1077 B-Observation
test NCT03927274 1078 1082 I-Observation
in NCT03927274 1083 1085 O
a NCT03927274 1086 1087 O
female NCT03927274 1088 1094 O

- NCT03927274 1097 1098 O
Patient NCT03927274 1100 1107 O
, NCT03927274 1108 1109 O
in NCT03927274 1110 1112 O
the NCT03927274 1113 1116 O
opinion NCT03927274 1117 1124 O
of NCT03927274 1125 1127 O
the NCT03927274 1128 1131 O
investigator NCT03927274 1132 1144 O
, NCT03927274 1145 1146 O
is NCT03927274 1147 1149 O
likely NCT03927274 1150 1156 O
to NCT03927274 1157 1159 O
be NCT03927274 1160 1162 O
poorly NCT03927274 1163 1169 O
compliant NCT03927274 1170 1179 O
. NCT03927274 1179 1180 O

- NCT03927274 1184 1185 O
Diffuse NCT03927274 1187 1194 B-Condition
subependymal NCT03927274 1195 1207 I-Condition
or NCT03927274 1208 1210 B-Or
Cerebral NCT03927274 1211 1219 B-Modifier
Spinal NCT03927274 1220 1226 I-Modifier
Fluid NCT03927274 1227 1232 I-Modifier
( NCT03927274 1233 1234 O
CSF NCT03927274 1235 1238 B-Condition
) NCT03927274 1239 1240 O
disease NCT03927274 1241 1248 B-Condition

- NCT03927274 1251 1252 O
Tumors NCT03927274 1254 1260 B-Condition
involving NCT03927274 1261 1270 O
the NCT03927274 1271 1274 O
cerebellum NCT03927274 1275 1285 B-Modifier

- NCT03927274 1288 1289 O
Tumor NCT03927274 1291 1296 B-Condition
enhancement NCT03927274 1297 1308 B-Modifier
involving NCT03927274 1309 1318 I-Modifier
both NCT03927274 1319 1323 I-Modifier
hemispheres NCT03927274 1324 1335 I-Modifier

- NCT03927274 1338 1339 O
Active NCT03927274 1341 1347 B-Eq-Comparison
infection NCT03927274 1348 1357 B-Condition
requiring NCT03927274 1358 1367 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03927274 1368 1377 B-Procedure

- NCT03927274 1380 1381 O
Unexplained NCT03927274 1383 1394 B-Modifier
febrile NCT03927274 1395 1402 B-Condition
illness NCT03927274 1403 1410 I-Condition

- NCT03927274 1413 1414 O
Radiation NCT03927274 1416 1425 B-Procedure
or NCT03927274 1426 1428 B-Or
chemotherapy NCT03927274 1429 1441 B-Procedure
within NCT03927274 1442 1448 B-Eq-Comparison
4 NCT03927274 1449 1450 I-Eq-Comparison
weeks NCT03927274 1451 1456 I-Eq-Comparison
of NCT03927274 1457 1459 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03927274 1460 1470 B-Study

- NCT03927274 1473 1474 O
Systemic NCT03927274 1476 1484 B-Modifier
diseases NCT03927274 1485 1493 B-Condition
associated NCT03927274 1494 1504 O
with NCT03927274 1505 1509 O
unacceptable NCT03927274 1510 1522 O
anesthesia NCT03927274 1523 1533 B-Procedure
or NCT03927274 1534 1536 B-Or
operative NCT03927274 1537 1546 B-Procedure
risk NCT03927274 1547 1551 B-Risk

- NCT03927274 1554 1555 O
Inability NCT03927274 1557 1566 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03927274 1567 1569 O
undergo NCT03927274 1570 1577 O
magnetic NCT03927274 1578 1586 B-Procedure
resonance NCT03927274 1587 1596 I-Procedure
imaging NCT03927274 1597 1604 I-Procedure
( NCT03927274 1605 1606 O
MRI NCT03927274 1607 1610 B-Procedure
) NCT03927274 1611 1612 O

Inclusion NCT03921177 0 9 O
Criteria NCT03921177 10 18 O
: NCT03921177 19 20 O

- NCT03921177 24 25 O
Resident NCT03921177 27 35 O
of NCT03921177 36 38 O
566 NCT03921177 39 42 O
rural NCT03921177 43 48 O
sectors NCT03921177 49 56 O
( NCT03921177 57 58 O
clusters NCT03921177 59 67 O
) NCT03921177 68 69 O
in NCT03921177 70 72 O
Gaibandha NCT03921177 73 82 O
district NCT03921177 83 91 O

- NCT03921177 94 95 O
Recently NCT03921177 97 105 B-Eq-Comparison
- NCT03921177 106 107 O
married NCT03921177 108 115 B-Condition
woman NCT03921177 116 121 O

- NCT03921177 124 125 O
Nulligravid NCT03921177 127 138 B-Condition

Exclusion NCT03921177 139 148 O
Criteria NCT03921177 149 157 O
: NCT03921177 158 159 O

- NCT03921177 163 164 O
Women NCT03921177 166 171 O
with NCT03921177 172 176 B-And
a NCT03921177 177 178 O
history NCT03921177 179 186 B-Eq-Comparison
of NCT03921177 187 189 I-Eq-Comparison
previous NCT03921177 190 198 I-Eq-Comparison
pregnancy NCT03921177 199 208 B-Condition

- NCT03921177 211 212 O
Women NCT03921177 214 219 O
who NCT03921177 220 223 O
refuse NCT03921177 224 230 O
consent NCT03921177 231 238 O
for NCT03921177 239 242 O
participation NCT03921177 243 256 O

Inclusion NCT03925311 0 9 O
Criteria NCT03925311 10 18 O
: NCT03925311 19 20 O

Age NCT03925311 22 25 B-Age
20 NCT03925311 26 28 B-Eq-Comparison
- NCT03925311 29 30 I-Eq-Comparison
40 NCT03925311 31 33 I-Eq-Comparison
years NCT03925311 34 39 I-Eq-Comparison
. NCT03925311 39 40 O

Exclusion NCT03925311 42 51 O
Criteria NCT03925311 52 60 O
: NCT03925311 61 62 O

- NCT03925311 66 67 O
Uncorrected NCT03925311 69 80 B-Modifier
uterine NCT03925311 81 88 I-Modifier
anomalies NCT03925311 89 98 B-Condition
, NCT03925311 99 100 O
such NCT03925311 101 105 O
as NCT03925311 106 108 O
septate NCT03925311 109 116 B-Modifier
or NCT03925311 117 119 B-Or
bicornuate NCT03925311 120 130 B-Modifier
uterus NCT03925311 131 137 B-Condition
, NCT03925311 138 139 O
fibroids NCT03925311 140 148 B-Condition
( NCT03925311 149 150 O
submucous NCT03925311 151 160 B-Modifier
/ NCT03925311 161 162 B-Or
intramural NCT03925311 163 173 B-Modifier
) NCT03925311 174 175 O
. NCT03925311 176 177 O

- NCT03925311 181 182 O
Intrauterine NCT03925311 184 196 B-Condition
adhesions NCT03925311 197 206 I-Condition
. NCT03925311 206 207 O

- NCT03925311 211 212 O
Adenomyosis NCT03925311 214 225 B-Condition
. NCT03925311 225 226 O

Key NCT03926195 0 3 O
Inclusion NCT03926195 4 13 O
Criteria NCT03926195 14 22 O
: NCT03926195 23 24 O

- NCT03926195 28 29 O
Male NCT03926195 31 35 O
participants NCT03926195 36 48 O
who NCT03926195 49 52 B-And
are NCT03926195 53 56 O
between NCT03926195 57 64 B-Eq-Comparison
the NCT03926195 65 68 I-Eq-Comparison
ages NCT03926195 69 73 I-Age|Eq-Comparison
of NCT03926195 74 76 I-Eq-Comparison
21 NCT03926195 77 79 I-Eq-Comparison
and NCT03926195 80 83 I-Eq-Comparison
65 NCT03926195 84 86 I-Eq-Comparison
years NCT03926195 87 92 I-Eq-Comparison
( NCT03926195 93 94 O
inclusive NCT03926195 95 104 O
) NCT03926195 105 106 O
on NCT03926195 107 109 O
the NCT03926195 110 113 O
day NCT03926195 114 117 O
of NCT03926195 118 120 O
signing NCT03926195 121 128 O
informed NCT03926195 129 137 O
consent NCT03926195 138 145 O

- NCT03926195 148 149 O
Diagnosis NCT03926195 151 160 O
of NCT03926195 161 163 O
active NCT03926195 164 170 B-Eq-Comparison
rheumatoid NCT03926195 171 181 B-Condition
arthritis NCT03926195 182 191 I-Condition
, NCT03926195 192 193 O
psoriatic NCT03926195 194 203 B-Condition
arthritis NCT03926195 204 213 I-Condition
, NCT03926195 214 215 O
ankylosing NCT03926195 216 226 B-Condition
spondylitis NCT03926195 227 238 I-Condition
or NCT03926195 239 241 B-Or
, NCT03926195 242 243 O
non NCT03926195 244 247 B-Modifier
- NCT03926195 248 249 I-Modifier
radiographic NCT03926195 250 262 I-Modifier
axial NCT03926195 263 268 B-Condition
spondyloarthritis NCT03926195 269 286 I-Condition
for NCT03926195 287 290 O
at NCT03926195 291 293 B-Eq-Comparison
least NCT03926195 294 299 I-Eq-Comparison
12 NCT03926195 300 302 I-Eq-Comparison
weeks NCT03926195 303 308 I-Eq-Comparison
prior NCT03926195 309 314 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926195 315 317 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03926195 318 327 B-Study
, NCT03926195 328 329 O
meeting NCT03926195 330 337 O
the NCT03926195 338 341 O
corresponding NCT03926195 342 355 O
specific NCT03926195 356 364 O
disease NCT03926195 365 372 O
classification NCT03926195 373 387 O
criteria NCT03926195 388 396 O
as NCT03926195 397 399 O
specified NCT03926195 400 409 O
in NCT03926195 410 412 O
the NCT03926195 413 416 O
protocol NCT03926195 417 425 O

Key NCT03926195 426 429 O
Exclusion NCT03926195 430 439 O
Criteria NCT03926195 440 448 O
: NCT03926195 449 450 O

- NCT03926195 454 455 O
Previously NCT03926195 457 467 B-Eq-Comparison
documented NCT03926195 468 478 O
problems NCT03926195 479 487 B-Condition
with NCT03926195 488 492 I-Condition
male NCT03926195 493 497 I-Condition
reproductive NCT03926195 498 510 I-Condition
health NCT03926195 511 517 I-Condition

- NCT03926195 520 521 O
Prior NCT03926195 523 528 B-Eq-Comparison
diagnosis NCT03926195 529 538 O
of NCT03926195 539 541 O
male NCT03926195 542 546 B-Condition
infertility NCT03926195 547 558 I-Condition

- NCT03926195 561 562 O
Use NCT03926195 564 567 B-Eq-Comparison
of NCT03926195 568 570 O
any NCT03926195 571 574 O
prohibited NCT03926195 575 585 B-Modifier
concomitant NCT03926195 586 597 I-Modifier
medication NCT03926195 598 608 B-Drug
as NCT03926195 609 611 O
outlined NCT03926195 612 620 O
by NCT03926195 621 623 O
protocol NCT03926195 624 632 O

Note NCT03926195 633 637 O
: NCT03926195 638 639 O
Other NCT03926195 640 645 O
protocol NCT03926195 646 654 O
- NCT03926195 655 656 O
defined NCT03926195 657 664 O
Inclusion NCT03926195 665 674 O
/ NCT03926195 675 676 O
Exclusion NCT03926195 677 686 O
criteria NCT03926195 687 695 O
may NCT03926195 696 699 O
apply NCT03926195 700 705 O
. NCT03926195 705 706 O

Inclusion NCT03928379 0 9 O
Criteria NCT03928379 10 18 O
: NCT03928379 19 20 O

- NCT03928379 24 25 O
Have NCT03928379 27 31 O
Type NCT03928379 32 36 B-Condition
II NCT03928379 37 39 I-Condition
diabetes NCT03928379 40 48 I-Condition

- NCT03928379 51 52 O
Body NCT03928379 54 58 B-Observation
mass NCT03928379 59 63 I-Observation
index NCT03928379 64 69 I-Observation
( NCT03928379 70 71 O
BMI NCT03928379 72 75 B-Observation
) NCT03928379 76 77 O
of NCT03928379 78 80 O
25 NCT03928379 81 83 B-Eq-Comparison
- NCT03928379 84 85 I-Eq-Comparison
40 NCT03928379 86 88 I-Eq-Comparison
kilograms NCT03928379 89 98 I-Eq-Comparison
per NCT03928379 99 102 I-Eq-Comparison
square NCT03928379 103 109 I-Eq-Comparison
meter NCT03928379 110 115 I-Eq-Comparison
( NCT03928379 116 117 O
kg NCT03928379 118 120 O
/ NCT03928379 121 122 O
m² NCT03928379 123 125 O
) NCT03928379 126 127 O
, NCT03928379 129 130 O
inclusive NCT03928379 131 140 O

- NCT03928379 143 144 O
Have NCT03928379 146 150 O
a NCT03928379 151 152 O
body NCT03928379 153 157 B-Observation
weight NCT03928379 158 164 I-Observation
of NCT03928379 165 167 O
< NCT03928379 168 169 B-Eq-Comparison
150 NCT03928379 170 173 I-Eq-Comparison
kilograms NCT03928379 174 183 I-Eq-Comparison
( NCT03928379 184 185 O
kg NCT03928379 186 188 O
) NCT03928379 189 190 O

- NCT03928379 194 195 O
Have NCT03928379 197 201 O
clinical NCT03928379 202 210 O
lab NCT03928379 211 214 B-Observation
test NCT03928379 215 219 I-Observation
results NCT03928379 220 227 O
within NCT03928379 228 234 B-Eq-Comparison
normal NCT03928379 235 241 I-Eq-Comparison
reference NCT03928379 242 251 I-Eq-Comparison
range NCT03928379 252 257 I-Eq-Comparison
for NCT03928379 258 261 O
the NCT03928379 262 265 O
population NCT03928379 266 276 O
or NCT03928379 277 279 O
investigator NCT03928379 280 292 O
site NCT03928379 293 297 O
, NCT03928379 298 299 O
or NCT03928379 300 302 O
results NCT03928379 303 310 O
with NCT03928379 311 315 O
acceptable NCT03928379 316 326 O
deviations NCT03928379 327 337 O
that NCT03928379 338 342 O
are NCT03928379 343 346 O
judged NCT03928379 347 353 O
to NCT03928379 354 356 O
be NCT03928379 357 359 O
not NCT03928379 360 363 O
clinically NCT03928379 364 374 O
significant NCT03928379 375 386 O
by NCT03928379 387 389 O
the NCT03928379 390 393 O
investigator NCT03928379 394 406 O
; NCT03928379 406 407 O
however NCT03928379 408 415 O
, NCT03928379 416 417 O
should NCT03928379 418 424 O
have NCT03928379 425 429 O
serum NCT03928379 430 435 B-Observation
magnesium NCT03928379 436 445 I-Observation
and NCT03928379 446 449 B-And
potassium NCT03928379 450 459 B-Observation
levels NCT03928379 460 466 I-Observation
, NCT03928379 467 468 O
along NCT03928379 469 474 B-And
with NCT03928379 475 479 I-And
lactate NCT03928379 480 487 B-Observation
dehydrogenase NCT03928379 488 501 I-Observation
, NCT03928379 502 503 O
CK NCT03928379 504 506 B-Observation
values NCT03928379 507 513 O
within NCT03928379 514 520 B-Eq-Comparison
the NCT03928379 521 524 I-Eq-Comparison
normal NCT03928379 525 531 I-Eq-Comparison
range NCT03928379 532 537 I-Eq-Comparison
at NCT03928379 538 540 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03928379 541 550 B-Study
and NCT03928379 551 554 B-And
Day NCT03928379 555 558 B-Study
- NCT03928379 559 560 O
2 NCT03928379 561 562 O
. NCT03928379 562 563 O

Exclusion NCT03928379 565 574 O
Criteria NCT03928379 575 583 O
: NCT03928379 584 585 O

- NCT03928379 589 590 O
Have NCT03928379 592 596 O
Type NCT03928379 597 601 B-Condition
1 NCT03928379 602 603 I-Condition
diabetes NCT03928379 604 612 I-Condition
or NCT03928379 613 615 B-Or
latent NCT03928379 616 622 B-Modifier
autoimmune NCT03928379 623 633 I-Modifier
diabetes NCT03928379 634 642 B-Condition
in NCT03928379 643 645 B-Modifier
adults NCT03928379 646 652 I-Modifier

- NCT03928379 655 656 O
Have NCT03928379 658 662 O
uncontrolled NCT03928379 663 675 B-Modifier
diabetes NCT03928379 676 684 B-Condition
defined NCT03928379 685 692 O
as NCT03928379 693 695 O
an NCT03928379 696 698 O
episode NCT03928379 699 706 O
of NCT03928379 707 709 O
ketoacidosis NCT03928379 710 722 B-Condition
or NCT03928379 723 725 B-Or
hyperosmolar NCT03928379 726 738 B-Condition
state NCT03928379 739 744 I-Condition
requiring NCT03928379 745 754 O
hospitalization NCT03928379 755 770 B-Encounter
for NCT03928379 771 774 O
6 NCT03928379 775 776 B-Eq-Comparison
months NCT03928379 777 783 I-Eq-Comparison
prior NCT03928379 784 789 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928379 790 792 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928379 793 802 B-Study

- NCT03928379 805 806 O
Have NCT03928379 808 812 O
had NCT03928379 813 816 O
an NCT03928379 817 819 O
episode NCT03928379 820 827 O
of NCT03928379 828 830 O
severe NCT03928379 831 837 O
hypoglycemia NCT03928379 838 850 B-Condition
, NCT03928379 851 852 O
defined NCT03928379 853 860 O
by NCT03928379 861 863 O
the NCT03928379 864 867 O
occurrence NCT03928379 868 878 O
of NCT03928379 879 881 O
neuroglycopenic NCT03928379 882 897 B-Condition
symptoms NCT03928379 898 906 B-Assertion___Assertion-Type-Value:possible
requiring NCT03928379 907 916 O
the NCT03928379 917 920 O
assistance NCT03928379 921 931 B-Observation
of NCT03928379 932 934 I-Observation
another NCT03928379 935 942 I-Observation
person NCT03928379 943 949 I-Observation
for NCT03928379 950 953 O
recovery NCT03928379 954 962 O
, NCT03928379 963 964 O
within NCT03928379 965 971 B-Eq-Comparison
6 NCT03928379 972 973 I-Eq-Comparison
months NCT03928379 974 980 I-Eq-Comparison
prior NCT03928379 981 986 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928379 987 989 O
Visit NCT03928379 990 995 B-Study
1 NCT03928379 996 997 O

- NCT03928379 1001 1002 I-Procedure
Have NCT03928379 1004 1008 O
an NCT03928379 1009 1011 O
abnormal NCT03928379 1012 1020 O
12 NCT03928379 1021 1023 B-Procedure
- NCT03928379 1024 1025 O
lead NCT03928379 1026 1030 I-Procedure
electrocardiogram NCT03928379 1031 1048 I-Procedure
( NCT03928379 1049 1050 O
ECG NCT03928379 1051 1054 B-Procedure
) NCT03928379 1055 1056 O
at NCT03928379 1057 1059 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03928379 1060 1069 B-Study
and NCT03928379 1070 1073 B-Or
/ NCT03928379 1074 1075 I-Or
or NCT03928379 1076 1078 I-Or
Day NCT03928379 1079 1082 B-Study
- NCT03928379 1083 1084 O
2 NCT03928379 1085 1086 O
that NCT03928379 1087 1091 O
, NCT03928379 1092 1093 O
in NCT03928379 1094 1096 O
the NCT03928379 1097 1100 O
opinion NCT03928379 1101 1108 O
of NCT03928379 1109 1111 O
the NCT03928379 1112 1115 O
investigator NCT03928379 1116 1128 O
, NCT03928379 1129 1130 O
increases NCT03928379 1131 1140 O
the NCT03928379 1141 1144 O
risks NCT03928379 1145 1150 B-Risk
associated NCT03928379 1151 1161 O
with NCT03928379 1162 1166 O
participating NCT03928379 1167 1180 O
in NCT03928379 1181 1183 O
the NCT03928379 1184 1187 O
study NCT03928379 1188 1193 B-Study
or NCT03928379 1194 1196 O
may NCT03928379 1197 1200 O
confound NCT03928379 1201 1209 O
ECG NCT03928379 1210 1213 O
data NCT03928379 1214 1218 O
analysis NCT03928379 1219 1227 O

- NCT03928379 1230 1231 O
Have NCT03928379 1233 1237 O
poorly NCT03928379 1238 1244 B-Modifier
controlled NCT03928379 1245 1255 I-Modifier
hypertension NCT03928379 1256 1268 B-Condition
at NCT03928379 1269 1271 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03928379 1272 1281 B-Study
; NCT03928379 1281 1282 O
or NCT03928379 1283 1285 B-Or
a NCT03928379 1286 1287 O
change NCT03928379 1288 1294 O
in NCT03928379 1295 1297 O
antihypertensive NCT03928379 1298 1314 B-Drug
medication NCT03928379 1315 1325 I-Drug
within NCT03928379 1326 1332 B-Eq-Comparison
30 NCT03928379 1333 1335 I-Eq-Comparison
days NCT03928379 1336 1340 I-Eq-Comparison
of NCT03928379 1341 1343 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928379 1344 1353 B-Study

- NCT03928379 1356 1357 O
Have NCT03928379 1359 1363 O
an NCT03928379 1364 1366 O
estimated NCT03928379 1367 1376 B-Observation
glomerular NCT03928379 1377 1387 I-Observation
filtration NCT03928379 1388 1398 I-Observation
rate NCT03928379 1399 1403 I-Observation
< NCT03928379 1404 1405 B-Eq-Comparison
45 NCT03928379 1406 1408 I-Eq-Comparison
milliliters NCT03928379 1409 1420 I-Eq-Comparison
per NCT03928379 1421 1424 I-Eq-Comparison
minute NCT03928379 1425 1431 I-Eq-Comparison
per NCT03928379 1432 1435 O
1.73 NCT03928379 1436 1440 I-Eq-Comparison
meters NCT03928379 1441 1447 I-Eq-Comparison
squared NCT03928379 1448 1455 I-Eq-Comparison
of NCT03928379 1456 1458 O
body NCT03928379 1459 1463 O
surface NCT03928379 1464 1471 O
area NCT03928379 1472 1476 O
( NCT03928379 1477 1478 O
mL NCT03928379 1479 1481 O
/ NCT03928379 1482 1483 O
min NCT03928379 1484 1487 O
/ NCT03928379 1488 1489 O
1.73 NCT03928379 1490 1494 O
m² NCT03928379 1495 1497 O
) NCT03928379 1498 1499 O

Inclusion NCT03925649 0 9 O
Criteria NCT03925649 10 18 O
: NCT03925649 19 20 O

- NCT03925649 24 25 O
Cognitively NCT03925649 27 38 O
intact NCT03925649 39 45 O
, NCT03925649 46 47 O
capable NCT03925649 48 55 O
of NCT03925649 56 58 O
giving NCT03925649 59 65 O
informed NCT03925649 66 74 O
consent NCT03925649 75 82 O

- NCT03925649 85 86 O
Clinical NCT03925649 88 96 O
diagnosis NCT03925649 97 106 O
of NCT03925649 107 109 O
a NCT03925649 110 111 O
non NCT03925649 112 115 B-Modifier
- NCT03925649 116 117 I-Modifier
penetrating NCT03925649 118 129 I-Modifier
traumatic NCT03925649 130 139 I-Modifier
SCI NCT03925649 140 143 B-Condition

- NCT03925649 146 147 O
Asia NCT03925649 149 153 B-Condition
Impairment NCT03925649 154 164 I-Condition
Scale NCT03925649 165 170 I-Condition
grade NCT03925649 171 176 B-Eq-Comparison
of NCT03925649 177 179 I-Eq-Comparison
A NCT03925649 180 181 I-Eq-Comparison
, NCT03925649 182 183 O
B NCT03925649 184 185 I-Eq-Comparison
, NCT03925649 186 187 O
or NCT03925649 188 190 I-Eq-Comparison
C NCT03925649 191 192 I-Eq-Comparison

Exclusion NCT03925649 193 202 O
Criteria NCT03925649 203 211 O
: NCT03925649 212 213 O

1 NCT03925649 217 218 O
. NCT03925649 218 219 O
Prior NCT03925649 221 226 B-Eq-Comparison
history NCT03925649 227 234 O
of NCT03925649 235 237 O
: NCT03925649 238 239 O

- NCT03925649 248 249 O
Brain NCT03925649 251 256 B-Modifier
injury NCT03925649 257 263 B-Condition

- NCT03925649 271 272 O
Recent NCT03925649 274 280 B-Eq-Comparison
or NCT03925649 281 283 B-Or
ongoing NCT03925649 284 291 B-Eq-Comparison
infection NCT03925649 292 301 B-Condition

- NCT03925649 309 310 O
Clinically NCT03925649 312 322 O
significant NCT03925649 323 334 O
cardiovascular NCT03925649 335 349 B-Modifier
, NCT03925649 350 351 O
lung NCT03925649 352 356 B-Modifier
, NCT03925649 357 358 O
renal NCT03925649 359 364 B-Modifier
, NCT03925649 365 366 O
hepatic NCT03925649 367 374 B-Modifier
or NCT03925649 375 377 B-Or
endocrine NCT03925649 378 387 B-Modifier
disease NCT03925649 388 395 B-Condition
, NCT03925649 396 397 O

- NCT03925649 406 407 O
Neurodegenerative NCT03925649 409 426 B-Condition
disorders NCT03925649 427 436 I-Condition

- NCT03925649 444 445 O
Cancer NCT03925649 447 453 B-Condition

- NCT03925649 461 462 O
Immunosuppression NCT03925649 464 481 B-Condition
as NCT03925649 482 484 O
defined NCT03925649 485 492 O
by NCT03925649 493 495 O
WBC NCT03925649 496 499 B-Observation
< NCT03925649 500 501 B-Eq-Comparison
3 NCT03925649 502 503 I-Eq-Comparison
, NCT03925649 504 505 O
000 NCT03925649 506 509 O
cells NCT03925649 510 515 I-Eq-Comparison
/ NCT03925649 516 517 I-Eq-Comparison
ml NCT03925649 518 520 I-Eq-Comparison
at NCT03925649 521 523 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03925649 524 532 B-Study
screening NCT03925649 533 542 O
, NCT03925649 543 544 O

- NCT03925649 553 554 O
HIV NCT03925649 556 559 B-Condition
+ NCT03925649 560 561 O

- NCT03925649 570 571 O
Chemical NCT03925649 573 581 B-Modifier
or NCT03925649 582 584 B-Or
ETOH NCT03925649 585 589 B-Modifier
dependency NCT03925649 590 600 B-Condition

2 NCT03925649 603 604 O
. NCT03925649 604 605 O
Having NCT03925649 607 613 O
a NCT03925649 614 615 O
contraindication NCT03925649 616 632 B-Contraindication
to NCT03925649 633 635 O
MRI NCT03925649 636 639 B-Procedure
scans NCT03925649 640 645 O

3 NCT03925649 648 649 O
. NCT03925649 649 650 O
Other NCT03925649 652 657 O
acute NCT03925649 658 663 O
or NCT03925649 664 666 B-Or
chronic NCT03925649 667 674 B-Modifier
medical NCT03925649 675 682 B-Condition
conditions NCT03925649 683 693 I-Condition
that NCT03925649 694 698 O
, NCT03925649 699 700 O
in NCT03925649 701 703 O
the NCT03925649 704 707 O
opinion NCT03925649 708 715 O
of NCT03925649 716 718 O
the NCT03925649 719 722 O
investigator NCT03925649 723 735 O
, NCT03925649 736 737 O
may NCT03925649 738 741 B-Assertion___Assertion-Type-Value:hypothetical
increase NCT03925649 742 750 O
the NCT03925649 751 754 O
risks NCT03925649 755 760 B-Risk
associated NCT03925649 761 771 O
with NCT03925649 772 776 O
study NCT03925649 777 782 B-Study
participation NCT03925649 783 796 O
or NCT03925649 797 799 B-Or
HB NCT03925649 800 802 B-Drug
- NCT03925649 803 804 I-Drug
adMSC NCT03925649 805 810 I-Drug
administration NCT03925649 811 825 O

4 NCT03925649 828 829 O
. NCT03925649 829 830 O
Participation NCT03925649 832 845 O
in NCT03925649 846 848 O
other NCT03925649 849 854 B-Other
interventional NCT03925649 855 869 O
research NCT03925649 870 878 O
studies NCT03925649 879 886 B-Study

5 NCT03925649 889 890 O
. NCT03925649 890 891 O
Unwillingness NCT03925649 893 906 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03925649 907 909 O
return NCT03925649 910 916 O
for NCT03925649 917 920 O
follow NCT03925649 921 927 B-Encounter
- NCT03925649 928 929 I-Encounter
up NCT03925649 930 932 I-Encounter
visits NCT03925649 933 939 I-Encounter

Inclusion NCT03922126 0 9 O
Criteria NCT03922126 10 18 O
: NCT03922126 19 20 O

- NCT03922126 24 25 O
male NCT03922126 27 31 O
sex NCT03922126 32 35 O
( NCT03922126 36 37 O
at NCT03922126 38 40 B-Temporal-Connection___Temporal-Connection-Type-Value:during
birth NCT03922126 41 46 B-Birth
) NCT03922126 47 48 O

- NCT03922126 52 53 O
adult NCT03922126 55 60 O
aged NCT03922126 61 65 B-Age
18 NCT03922126 66 68 B-Eq-Comparison
and NCT03922126 69 72 I-Eq-Comparison
older NCT03922126 73 78 I-Eq-Comparison

- NCT03922126 81 82 O
immigrant NCT03922126 84 93 B-Observation
( NCT03922126 94 95 O
not NCT03922126 96 99 B-Negation
born NCT03922126 100 104 B-Birth
in NCT03922126 105 107 O
continental NCT03922126 108 119 O
U. NCT03922126 120 122 O
S. NCT03922126 123 125 O
) NCT03922126 126 127 O

- NCT03922126 131 132 O
Latino NCT03922126 134 140 O
( NCT03922126 141 142 O
identifies NCT03922126 143 153 O
as NCT03922126 154 156 O
either NCT03922126 157 163 O
Latinx NCT03922126 164 170 O
or NCT03922126 171 173 B-Or
Hispanic NCT03922126 174 182 O

- NCT03922126 185 186 O
reports NCT03922126 188 195 O
sex NCT03922126 196 199 B-Observation
with NCT03922126 200 204 O
men NCT03922126 205 208 O
in NCT03922126 209 211 O
past NCT03922126 212 216 B-Eq-Comparison
12 NCT03922126 217 219 O
months NCT03922126 220 226 O

- NCT03922126 229 230 O
reports NCT03922126 232 239 O
not NCT03922126 240 243 B-Negation
knowing NCT03922126 244 251 B-Assertion___Assertion-Type-Value:hypothetical
their NCT03922126 252 257 O
HIV NCT03922126 258 261 B-Condition
status NCT03922126 262 268 O
or NCT03922126 269 271 B-Or
being NCT03922126 272 277 O
HIV NCT03922126 278 281 B-Condition
negative NCT03922126 282 290 O

Exclusion NCT03922126 291 300 O
Criteria NCT03922126 301 309 O
: NCT03922126 310 311 O

- NCT03922126 315 316 O
Does NCT03922126 318 322 O
not NCT03922126 323 326 B-Negation
identify NCT03922126 327 335 O
as NCT03922126 336 338 O
Latino NCT03922126 339 345 O
/ NCT03922126 346 347 B-Or
Hispanic NCT03922126 348 356 O

- NCT03922126 359 360 O
Born NCT03922126 362 366 B-Birth
in NCT03922126 367 369 O
the NCT03922126 370 373 O
continental NCT03922126 374 385 O
U. NCT03922126 386 388 O
S. NCT03922126 389 391 O

- NCT03922126 395 396 O
Female NCT03922126 398 404 O
sex NCT03922126 405 408 O
( NCT03922126 409 410 O
at NCT03922126 411 413 O
birth NCT03922126 414 419 O
) NCT03922126 420 421 O

- NCT03922126 425 426 O
Does NCT03922126 428 432 O
not NCT03922126 433 436 B-Negation
report NCT03922126 437 443 O
sex NCT03922126 444 447 B-Condition
with NCT03922126 448 452 I-Condition
men NCT03922126 453 456 I-Condition
in NCT03922126 457 459 O
the NCT03922126 460 463 O
last NCT03922126 464 468 B-Eq-Comparison
12 NCT03922126 469 471 I-Eq-Comparison
months NCT03922126 472 478 I-Eq-Comparison

- NCT03922126 481 482 O
Reports NCT03922126 484 491 O
being NCT03922126 492 497 O
HIV NCT03922126 498 501 B-Condition
positive NCT03922126 502 510 O

- NCT03922126 513 514 O
Younger NCT03922126 516 523 B-Eq-Comparison
than NCT03922126 524 528 I-Eq-Comparison
18 NCT03922126 529 531 I-Eq-Comparison
years NCT03922126 532 537 I-Eq-Comparison
old NCT03922126 538 541 B-Age

Inclusion NCT03924557 0 9 O
Criteria NCT03924557 10 18 O
: NCT03924557 19 20 O

- NCT03924557 24 25 O
Must NCT03924557 27 31 O
have NCT03924557 32 36 O
a NCT03924557 37 38 O
clinical NCT03924557 39 47 O
diagnosis NCT03924557 48 57 O
of NCT03924557 58 60 O
solid NCT03924557 61 66 B-Modifier
tumor NCT03924557 67 72 I-Modifier
cancer NCT03924557 73 79 B-Condition
and NCT03924557 80 83 O
be NCT03924557 84 86 O
seeking NCT03924557 87 94 B-Assertion___Assertion-Type-Value:intention
treatment NCT03924557 95 104 B-Procedure
and NCT03924557 105 108 B-And
supportive NCT03924557 109 119 B-Procedure
care NCT03924557 120 124 I-Procedure
at NCT03924557 125 127 O
the NCT03924557 128 131 O
UF NCT03924557 132 134 O
Health NCT03924557 135 141 O
Cancer NCT03924557 142 148 O
Center NCT03924557 149 155 O
( NCT03924557 156 157 O
Medical NCT03924557 158 165 O
Plaza NCT03924557 166 171 O
) NCT03924557 172 173 O

- NCT03924557 177 178 O
Patients NCT03924557 180 188 O
must NCT03924557 189 193 O
plan NCT03924557 194 198 B-Eq-Comparison
to NCT03924557 199 201 O
receive NCT03924557 202 209 O
chemotherapy NCT03924557 210 222 B-Procedure
known NCT03924557 223 228 O
to NCT03924557 229 231 O
be NCT03924557 232 234 O
associated NCT03924557 235 245 O
with NCT03924557 246 250 O
the NCT03924557 251 254 O
need NCT03924557 255 259 O
for NCT03924557 260 263 O
supportive NCT03924557 264 274 O
care NCT03924557 275 279 O
within NCT03924557 280 286 B-Eq-Comparison
30 NCT03924557 287 289 I-Eq-Comparison
days NCT03924557 290 294 I-Eq-Comparison
of NCT03924557 295 297 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03924557 298 308 B-Study

- NCT03924557 311 312 O
Life NCT03924557 314 318 B-Observation
expectancy NCT03924557 319 329 I-Observation
must NCT03924557 330 334 O
be NCT03924557 335 337 O
greater NCT03924557 338 345 B-Eq-Comparison
than NCT03924557 346 350 I-Eq-Comparison
6 NCT03924557 351 352 I-Eq-Comparison
months NCT03924557 353 359 I-Eq-Comparison

- NCT03924557 362 363 O
Must NCT03924557 365 369 O
have NCT03924557 370 374 O
Eastern NCT03924557 375 382 B-Observation
Cooperative NCT03924557 383 394 I-Observation
Oncology NCT03924557 395 403 I-Observation
Group NCT03924557 404 409 I-Observation
( NCT03924557 410 411 O
ECOG NCT03924557 412 416 B-Observation
) NCT03924557 417 418 O
performance NCT03924557 419 430 O
status NCT03924557 431 437 O
of NCT03924557 438 440 O
0 NCT03924557 441 442 B-Eq-Comparison
- NCT03924557 443 444 I-Eq-Comparison
2 NCT03924557 445 446 O

- NCT03924557 450 451 O
Written NCT03924557 453 460 O
informed NCT03924557 461 469 O
consent NCT03924557 470 477 O
obtained NCT03924557 478 486 O
from NCT03924557 487 491 O
the NCT03924557 492 495 O
patient NCT03924557 496 503 O

- NCT03924557 506 507 O
The NCT03924557 509 512 O
ability NCT03924557 513 520 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924557 521 524 O
the NCT03924557 525 528 O
patient NCT03924557 529 536 O
to NCT03924557 537 539 O
comply NCT03924557 540 546 O
with NCT03924557 547 551 O
all NCT03924557 552 555 O
the NCT03924557 556 559 O
study NCT03924557 560 565 B-Study
- NCT03924557 566 567 O
related NCT03924557 568 575 O
procedures NCT03924557 576 586 B-Procedure
. NCT03924557 586 587 O

Exclusion NCT03924557 589 598 O
Criteria NCT03924557 599 607 O
: NCT03924557 608 609 O

- NCT03924557 613 614 O
Patients NCT03924557 616 624 O
unwilling NCT03924557 625 634 O
or NCT03924557 635 637 O
unable NCT03924557 638 644 O
to NCT03924557 645 647 O
provide NCT03924557 648 655 O
voluntary NCT03924557 656 665 O
informed NCT03924557 666 674 O
consent NCT03924557 675 682 O

- NCT03924557 685 686 O
Patients NCT03924557 688 696 O
who NCT03924557 697 700 O
are NCT03924557 701 704 O
unwilling NCT03924557 705 714 O
or NCT03924557 715 717 O
unable NCT03924557 718 724 O
to NCT03924557 725 727 O
comply NCT03924557 728 734 O
with NCT03924557 735 739 O
protocol NCT03924557 740 748 O
requirement NCT03924557 749 760 O
and NCT03924557 761 764 O
/ NCT03924557 765 766 O
or NCT03924557 767 769 O
follow NCT03924557 770 776 O
- NCT03924557 777 778 O
up NCT03924557 779 781 O
procedures NCT03924557 782 792 O

- NCT03924557 795 796 O
Patients NCT03924557 798 806 O
planned NCT03924557 807 814 B-Eq-Comparison
to NCT03924557 815 817 I-Eq-Comparison
undergo NCT03924557 818 825 I-Eq-Comparison
cancer NCT03924557 826 832 B-Condition
therapy NCT03924557 833 840 B-Procedure
other NCT03924557 841 846 B-Exception
than NCT03924557 847 851 I-Exception
chemotherapy NCT03924557 852 864 B-Procedure
( NCT03924557 865 866 O
i. NCT03924557 867 869 O
e. NCT03924557 870 872 O
, NCT03924557 873 874 O
radiation NCT03924557 875 884 B-Procedure
, NCT03924557 885 886 O
surgery NCT03924557 887 894 B-Procedure
or NCT03924557 895 897 B-Or
hormonal NCT03924557 898 906 B-Procedure
treatment NCT03924557 907 916 I-Procedure
alone NCT03924557 917 922 O
) NCT03924557 923 924 O

- NCT03924557 928 929 O
Prisoners NCT03924557 931 940 B-Observation
or NCT03924557 941 943 B-Or
patients NCT03924557 944 952 O
who NCT03924557 953 956 O
are NCT03924557 957 960 O
involuntarily NCT03924557 961 974 B-Observation
incarcerated NCT03924557 975 987 I-Observation
. NCT03924557 987 988 O
Patients NCT03924557 990 998 O
who NCT03924557 999 1002 O
are NCT03924557 1003 1006 O
compulsorily NCT03924557 1007 1019 O
detained NCT03924557 1020 1028 O
for NCT03924557 1029 1032 O
treatment NCT03924557 1033 1042 B-Procedure
of NCT03924557 1043 1045 O
either NCT03924557 1046 1052 O
a NCT03924557 1053 1054 O
psychiatric NCT03924557 1055 1066 B-Modifier
or NCT03924557 1067 1069 B-Or
physical NCT03924557 1070 1078 B-Modifier
illness NCT03924557 1079 1086 B-Condition
. NCT03924557 1086 1087 O

Inclusion NCT03927937 0 9 O
Criteria NCT03927937 10 18 O
: NCT03927937 19 20 O

- NCT03927937 24 25 O
Tooth NCT03927937 27 32 O
with NCT03927937 33 37 O
imposible NCT03927937 38 47 O
prognosis NCT03927937 48 57 O

- NCT03927937 60 61 O
Plaque NCT03927937 63 69 B-Observation
index NCT03927937 70 75 I-Observation
score NCT03927937 76 81 I-Observation
less NCT03927937 82 86 B-Eq-Comparison
than NCT03927937 87 91 I-Eq-Comparison
30 NCT03927937 92 94 I-Eq-Comparison
% NCT03927937 95 96 O

- NCT03927937 99 100 O
No NCT03927937 102 104 B-Negation
relevant NCT03927937 105 113 O
systemic NCT03927937 114 122 B-Modifier
disease NCT03927937 123 130 B-Condition

- NCT03927937 133 134 O
Smokers NCT03927937 136 143 B-Observation
( NCT03927937 144 145 O
Less NCT03927937 146 150 B-Eq-Comparison
than NCT03927937 151 155 I-Eq-Comparison
20 NCT03927937 156 158 I-Eq-Comparison
cigars NCT03927937 159 165 I-Eq-Comparison
/ NCT03927937 166 167 I-Eq-Comparison
day NCT03927937 168 171 I-Eq-Comparison
) NCT03927937 172 173 O

Exclusion NCT03927937 175 184 O
Criteria NCT03927937 185 193 O
: NCT03927937 194 195 O

- NCT03927937 199 200 O
Pregnancy NCT03927937 202 211 B-Condition
- NCT03927937 212 213 B-Or
Lactation NCT03927937 214 223 B-Condition

- NCT03927937 226 227 O
Relevant NCT03927937 229 237 O
systemic NCT03927937 238 246 B-Modifier
disease NCT03927937 247 254 B-Condition

Inclusion NCT03929926 0 9 O
Criteria NCT03929926 10 18 O
: NCT03929926 19 20 O

- NCT03929926 24 25 O
Had NCT03929926 27 30 O
a NCT03929926 31 32 O
recent NCT03929926 33 39 B-Eq-Comparison
office NCT03929926 40 46 B-Encounter
visit NCT03929926 47 52 I-Encounter
with NCT03929926 53 57 O
a NCT03929926 58 59 O
primary NCT03929926 60 67 B-Provider
care NCT03929926 68 72 I-Provider
physician NCT03929926 73 82 I-Provider
in NCT03929926 83 85 O
one NCT03929926 86 89 O
of NCT03929926 90 92 O
the NCT03929926 93 96 O
study NCT03929926 97 102 O
practices NCT03929926 103 112 O
. NCT03929926 112 113 O

- NCT03929926 117 118 O
History NCT03929926 120 127 B-Eq-Comparison
of NCT03929926 128 130 O
smoking NCT03929926 131 138 B-Condition
( NCT03929926 139 140 O
current NCT03929926 141 148 B-Eq-Comparison
or NCT03929926 149 151 B-Or
former NCT03929926 152 158 B-Eq-Comparison
) NCT03929926 159 160 O
in NCT03929926 161 163 O
the NCT03929926 164 167 O
electronic NCT03929926 168 178 O
health NCT03929926 179 185 O
record NCT03929926 186 192 O
( NCT03929926 193 194 O
EHR NCT03929926 195 198 O
) NCT03929926 199 200 O
. NCT03929926 201 202 O

Exclusion NCT03929926 204 213 O
Criteria NCT03929926 214 222 O
: NCT03929926 223 224 O

- NCT03929926 228 229 O
LDCT NCT03929926 231 235 B-Procedure
performed NCT03929926 236 245 O
in NCT03929926 246 248 O
the NCT03929926 249 252 O
12 NCT03929926 253 255 B-Eq-Comparison
months NCT03929926 256 262 I-Eq-Comparison
prior NCT03929926 263 268 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929926 269 271 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03929926 272 277 B-Study
initiation NCT03929926 278 288 O
according NCT03929926 289 298 O
to NCT03929926 299 301 O
EHR NCT03929926 302 305 O
. NCT03929926 305 306 O

- NCT03929926 310 311 O
Diagnosis NCT03929926 313 322 O
of NCT03929926 323 325 O
lung NCT03929926 326 330 B-Modifier
cancer NCT03929926 331 337 B-Condition
indicated NCT03929926 338 347 O
in NCT03929926 348 350 O
problem NCT03929926 351 358 O
list NCT03929926 359 363 O
in NCT03929926 364 366 O
the NCT03929926 367 370 O
EHR NCT03929926 371 374 O
. NCT03929926 374 375 O

Inclusion NCT03928392 0 9 O
Criteria NCT03928392 10 18 O
: NCT03928392 19 20 O

- NCT03928392 24 25 O
18 NCT03928392 27 29 B-Eq-Comparison
to NCT03928392 30 32 I-Eq-Comparison
95 NCT03928392 33 35 I-Eq-Comparison
years NCT03928392 36 41 I-Eq-Comparison
of NCT03928392 42 44 O
age NCT03928392 45 48 B-Age

- NCT03928392 51 52 O
Participation NCT03928392 54 67 O
in NCT03928392 68 70 O
WAVES NCT03928392 71 76 O
Project NCT03928392 77 84 O
for NCT03928392 85 88 O
at NCT03928392 89 91 B-Eq-Comparison
least NCT03928392 92 97 I-Eq-Comparison
3 NCT03928392 98 99 I-Eq-Comparison
months NCT03928392 100 106 I-Eq-Comparison

- NCT03928392 109 110 O
Completion NCT03928392 112 122 O
of NCT03928392 123 125 O
3 NCT03928392 126 127 B-Eq-Comparison
open NCT03928392 128 132 B-Observation
water NCT03928392 133 138 I-Observation
dives NCT03928392 139 144 I-Observation

- NCT03928392 147 148 O
Proficient NCT03928392 150 160 O
in NCT03928392 161 163 O
written NCT03928392 164 171 O
and NCT03928392 172 175 O
verbal NCT03928392 176 182 O
English NCT03928392 183 190 O

Exclusion NCT03928392 191 200 O
Criteria NCT03928392 201 209 O
: NCT03928392 210 211 O

- NCT03928392 215 216 O
Younger NCT03928392 218 225 B-Eq-Comparison
than NCT03928392 226 230 I-Eq-Comparison
18 NCT03928392 231 233 I-Eq-Comparison
years NCT03928392 234 239 I-Eq-Comparison
of NCT03928392 240 242 O
age NCT03928392 243 246 B-Age
or NCT03928392 247 249 B-Or
older NCT03928392 250 255 B-Eq-Comparison
than NCT03928392 256 260 I-Eq-Comparison
95 NCT03928392 261 263 I-Eq-Comparison
years NCT03928392 264 269 I-Eq-Comparison
of NCT03928392 270 272 O
age NCT03928392 273 276 B-Age

- NCT03928392 279 280 O
Not NCT03928392 282 285 B-Negation
a NCT03928392 286 287 O
member NCT03928392 288 294 O
of NCT03928392 295 297 O
WAVES NCT03928392 298 303 O
Project NCT03928392 304 311 O
within NCT03928392 312 318 B-Eq-Comparison
3 NCT03928392 319 320 I-Eq-Comparison
months NCT03928392 321 327 I-Eq-Comparison
of NCT03928392 328 330 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928392 331 336 B-Study
recruitment NCT03928392 337 348 O

- NCT03928392 351 352 O
Has NCT03928392 354 357 O
not NCT03928392 358 361 B-Negation
completed NCT03928392 362 371 O
3 NCT03928392 372 373 B-Eq-Comparison
open NCT03928392 374 378 B-Observation
water NCT03928392 379 384 I-Observation
dives NCT03928392 385 390 I-Observation

- NCT03928392 393 394 O
Not NCT03928392 396 399 B-Negation
proficient NCT03928392 400 410 O
in NCT03928392 411 413 O
written NCT03928392 414 421 O
and NCT03928392 422 425 O
verbal NCT03928392 426 432 O
English NCT03928392 433 440 O

Inclusion NCT03922867 0 9 O
Criteria NCT03922867 10 18 O
: NCT03922867 19 20 O

- NCT03922867 24 25 O
Meets NCT03922867 27 32 O
diagnostic NCT03922867 33 43 O
criteria NCT03922867 44 52 O
for NCT03922867 53 56 O
fibromyalgia NCT03922867 57 69 B-Condition

- NCT03922867 72 73 O
Has NCT03922867 75 78 O
insomnia NCT03922867 79 87 B-Condition

- NCT03922867 90 91 O
Have NCT03922867 93 97 O
internet NCT03922867 98 106 O
access NCT03922867 107 113 O
and NCT03922867 114 117 O
a NCT03922867 118 119 O
device NCT03922867 120 126 O
that NCT03922867 127 131 O
can NCT03922867 132 135 O
access NCT03922867 136 142 O
the NCT03922867 143 146 O
web NCT03922867 147 150 O
- NCT03922867 151 152 O
based NCT03922867 153 158 O
program NCT03922867 159 166 O
. NCT03922867 166 167 O

Exclusion NCT03922867 169 178 O
Criteria NCT03922867 179 187 O
: NCT03922867 188 189 O

- NCT03922867 193 194 O
Active NCT03922867 196 202 B-Eq-Comparison
sleep NCT03922867 203 208 B-Condition
disorder NCT03922867 209 217 I-Condition
which NCT03922867 218 223 O
is NCT03922867 224 226 O
not NCT03922867 227 230 B-Negation
treated NCT03922867 231 238 B-Procedure
( NCT03922867 239 240 O
obstructive NCT03922867 241 252 B-Condition
sleep NCT03922867 253 258 I-Condition
apnea NCT03922867 259 264 I-Condition
, NCT03922867 265 266 O
obesity NCT03922867 267 274 B-Condition
hypoventilation NCT03922867 275 290 I-Condition
syndrome NCT03922867 291 299 I-Condition
) NCT03922867 300 301 O

- NCT03922867 305 306 O
Active NCT03922867 308 314 B-Eq-Comparison
psychiatric NCT03922867 315 326 B-Condition
disorder NCT03922867 327 335 I-Condition
( NCT03922867 336 337 O
Bipolar NCT03922867 338 345 B-Condition
affective NCT03922867 346 355 I-Condition
disorder NCT03922867 356 364 I-Condition
, NCT03922867 365 366 O
anxiety NCT03922867 367 374 B-Condition
, NCT03922867 375 376 O
depression NCT03922867 377 387 B-Condition
, NCT03922867 388 389 O
schizophrenia NCT03922867 390 403 B-Condition
) NCT03922867 404 405 O
which NCT03922867 406 411 O
is NCT03922867 412 414 O
not NCT03922867 415 418 O
optimally NCT03922867 419 428 O
managed NCT03922867 429 436 O
. NCT03922867 436 437 O

- NCT03922867 441 442 O
Chronic NCT03922867 444 451 B-Modifier
fatigue NCT03922867 452 459 B-Condition
syndrome NCT03922867 460 468 I-Condition

- NCT03922867 471 472 O
Morbid NCT03922867 474 480 B-Condition
obesity NCT03922867 481 488 I-Condition

Inclusion NCT03920891 0 9 O
Criteria NCT03920891 10 18 O
: NCT03920891 19 20 O

- NCT03920891 24 25 O
1 NCT03920891 27 28 O
. NCT03920891 28 29 O
Patient NCT03920891 31 38 O
with NCT03920891 39 43 O
hemodynamic NCT03920891 44 55 B-Modifier
corrected NCT03920891 56 65 I-Modifier
valvular NCT03920891 66 74 I-Modifier
atrial NCT03920891 75 81 B-Condition
fibrillation NCT03920891 82 94 I-Condition
who NCT03920891 95 98 B-And
is NCT03920891 99 101 O
scheduled NCT03920891 102 111 B-Eq-Comparison
for NCT03920891 112 115 O
ablation NCT03920891 116 124 B-Procedure
procedure NCT03920891 125 134 I-Procedure
and NCT03920891 135 138 B-And
≥ NCT03920891 139 140 B-Eq-Comparison
20 NCT03920891 141 143 I-Eq-Comparison
and NCT03920891 144 147 B-And
≤ NCT03920891 148 149 B-Eq-Comparison
80 NCT03920891 150 152 I-Eq-Comparison
years NCT03920891 153 158 I-Eq-Comparison
of NCT03920891 159 161 O
age NCT03920891 162 165 B-Age

- NCT03920891 168 169 O
2 NCT03920891 171 172 O
. NCT03920891 172 173 O
Left NCT03920891 175 179 B-Observation
atrium NCT03920891 180 186 I-Observation
size NCT03920891 187 191 I-Observation
< NCT03920891 192 193 B-Eq-Comparison
50 NCT03920891 194 196 I-Eq-Comparison
mm NCT03920891 197 199 O

- NCT03920891 202 203 O
3 NCT03920891 205 206 O
. NCT03920891 206 207 O
paroxysmal NCT03920891 209 219 B-Modifier
atrial NCT03920891 220 226 B-Condition
fibrillation NCT03920891 227 239 I-Condition
that NCT03920891 240 244 O
is NCT03920891 245 247 O
recurrence NCT03920891 248 258 O
during NCT03920891 259 265 B-Temporal-Connection___Temporal-Connection-Type-Value:during
antiarrhythmic NCT03920891 266 280 B-Drug
drug NCT03920891 281 285 I-Drug
treatment NCT03920891 286 295 B-Procedure
or NCT03920891 296 298 B-Or
is NCT03920891 299 301 O
not NCT03920891 302 305 B-Negation
able NCT03920891 306 310 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920891 311 313 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03920891 314 317 O
an NCT03920891 318 320 B-Drug
antiarrhythmic NCT03920891 321 335 O
drug NCT03920891 336 340 I-Drug
. NCT03920891 340 341 O

- NCT03920891 345 346 O
4 NCT03920891 348 349 O
. NCT03920891 349 350 O
Patient NCT03920891 352 359 O
who NCT03920891 360 363 O
is NCT03920891 364 366 O
indicated NCT03920891 367 376 B-Indication
for NCT03920891 377 380 O
anticoagulation NCT03920891 381 396 B-Procedure
therapy NCT03920891 397 404 I-Procedure
( NCT03920891 405 406 O
for NCT03920891 407 410 O
prevention NCT03920891 411 421 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920891 422 424 I-Assertion___Assertion-Type-Value:hypothetical
cerebral NCT03920891 425 433 B-Condition
infarction NCT03920891 434 444 I-Condition
) NCT03920891 445 446 O

Exclusion NCT03920891 448 457 O
Criteria NCT03920891 458 466 O
: NCT03920891 467 468 O

- NCT03920891 472 473 O
1 NCT03920891 475 476 O
. NCT03920891 476 477 O
Patients NCT03920891 479 487 O
with NCT03920891 488 492 O
permanent NCT03920891 493 502 B-Modifier
atrial NCT03920891 503 509 B-Condition
fibrillation NCT03920891 510 522 I-Condition

- NCT03920891 525 526 O
2 NCT03920891 528 529 O
. NCT03920891 529 530 O
Atrial NCT03920891 532 538 B-Condition
fibrillation NCT03920891 539 551 I-Condition
associated NCT03920891 552 562 O
with NCT03920891 563 567 O
severe NCT03920891 568 574 O
cardiac NCT03920891 575 582 B-Condition
malformation NCT03920891 583 595 I-Condition
or NCT03920891 596 598 B-Or
a NCT03920891 599 600 O
structural NCT03920891 601 611 B-Modifier
heart NCT03920891 612 617 B-Condition
disease NCT03920891 618 625 I-Condition
that NCT03920891 626 630 O
is NCT03920891 631 633 O
hemodynamically NCT03920891 634 649 B-Modifier
affected NCT03920891 650 658 O

- NCT03920891 661 662 O
3 NCT03920891 664 665 O
. NCT03920891 665 666 O
Patients NCT03920891 668 676 O
with NCT03920891 677 681 O
severe NCT03920891 682 688 O
renal NCT03920891 689 694 B-Modifier
impairment NCT03920891 695 705 B-Condition
or NCT03920891 706 708 B-Or
CT NCT03920891 709 711 B-Procedure
imaging NCT03920891 712 719 I-Procedure
difficulty NCT03920891 720 730 B-Assertion___Assertion-Type-Value:hypothetical|Negation
using NCT03920891 731 736 O
contrast NCT03920891 737 745 B-Procedure
media NCT03920891 746 751 I-Procedure

- NCT03920891 754 755 O
4 NCT03920891 757 758 O
. NCT03920891 758 759 O
Patients NCT03920891 761 769 O
with NCT03920891 770 774 O
a NCT03920891 775 776 O
past NCT03920891 777 781 B-Eq-Comparison
history NCT03920891 782 789 I-Eq-Comparison
of NCT03920891 790 792 O
radiofrequency NCT03920891 793 807 B-Procedure
ablation NCT03920891 808 816 I-Procedure
for NCT03920891 817 820 O
atrial NCT03920891 821 827 B-Condition
fibrillation NCT03920891 828 840 I-Condition
or NCT03920891 841 843 B-Or
other NCT03920891 844 849 B-Other
cardiac NCT03920891 850 857 B-Modifier
surgery NCT03920891 858 865 B-Procedure

- NCT03920891 868 869 O
5 NCT03920891 871 872 O
. NCT03920891 872 873 O
Patients NCT03920891 875 883 O
with NCT03920891 884 888 O
active NCT03920891 889 895 B-Eq-Comparison
internal NCT03920891 896 904 B-Modifier
bleeding NCT03920891 905 913 B-Condition

- NCT03920891 916 917 O
6 NCT03920891 919 920 O
. NCT03920891 920 921 O
Patients NCT03920891 923 931 O
with NCT03920891 932 936 O
contraindications NCT03920891 937 954 B-Contraindication
for NCT03920891 955 958 O
anticoagulation NCT03920891 959 974 B-Procedure
therapy NCT03920891 975 982 I-Procedure
( NCT03920891 983 984 O
for NCT03920891 985 988 O
prevention NCT03920891 989 999 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920891 1000 1002 I-Assertion___Assertion-Type-Value:hypothetical
cerebral NCT03920891 1003 1011 B-Condition
infarction NCT03920891 1012 1022 I-Condition
) NCT03920891 1023 1024 O
and NCT03920891 1025 1028 B-Or
antiarrhythmic NCT03920891 1029 1043 B-Drug
drugs NCT03920891 1044 1049 I-Drug

- NCT03920891 1052 1053 I-Modifier
7 NCT03920891 1055 1056 O
. NCT03920891 1056 1057 O
Patients NCT03920891 1059 1067 O
with NCT03920891 1068 1072 O
non NCT03920891 1073 1076 B-Modifier
- NCT03920891 1077 1078 O
valvular NCT03920891 1079 1087 I-Modifier
atrial NCT03920891 1088 1094 B-Condition
fibrillation NCT03920891 1095 1107 I-Condition

- NCT03920891 1110 1111 O
8 NCT03920891 1113 1114 O
. NCT03920891 1114 1115 O
Patients NCT03920891 1117 1125 O
with NCT03920891 1126 1130 O
a NCT03920891 1131 1132 O
severe NCT03920891 1133 1139 O
comorbid NCT03920891 1140 1148 B-Condition
disease NCT03920891 1149 1156 I-Condition

- NCT03920891 1159 1160 O
9 NCT03920891 1162 1163 O
. NCT03920891 1163 1164 O
Expected NCT03920891 1166 1174 B-Observation
survival NCT03920891 1175 1183 I-Observation
< NCT03920891 1184 1185 B-Eq-Comparison
1 NCT03920891 1186 1187 I-Eq-Comparison
year NCT03920891 1188 1192 I-Eq-Comparison

- NCT03920891 1195 1196 O
10 NCT03920891 1198 1200 O
. NCT03920891 1200 1201 O
Drug NCT03920891 1203 1207 B-Condition
addicts NCT03920891 1208 1215 I-Condition
or NCT03920891 1216 1218 B-Or
alcoholics NCT03920891 1219 1229 B-Condition

- NCT03920891 1232 1233 O
11 NCT03920891 1235 1237 O
. NCT03920891 1237 1238 O
Patients NCT03920891 1240 1248 O
who NCT03920891 1249 1252 O
can NCT03920891 1253 1256 O
not NCT03920891 1256 1259 O
read NCT03920891 1260 1264 O
the NCT03920891 1265 1268 O
consent NCT03920891 1269 1276 O
form NCT03920891 1277 1281 O
( NCT03920891 1282 1283 O
illiterates NCT03920891 1284 1295 B-Condition
, NCT03920891 1296 1297 O
foreigners NCT03920891 1298 1308 O
, NCT03920891 1309 1310 O
etc NCT03920891 1311 1314 O
. NCT03920891 1314 1315 O
) NCT03920891 1316 1317 O

- NCT03920891 1321 1322 O
12 NCT03920891 1324 1326 O
. NCT03920891 1326 1327 O
Other NCT03920891 1329 1334 O
patients NCT03920891 1335 1343 O
who NCT03920891 1344 1347 O
are NCT03920891 1348 1351 O
judged NCT03920891 1352 1358 O
by NCT03920891 1359 1361 O
the NCT03920891 1362 1365 O
principal NCT03920891 1366 1375 O
or NCT03920891 1376 1378 O
sub NCT03920891 1379 1382 O
- NCT03920891 1383 1384 O
investigator NCT03920891 1385 1397 O
to NCT03920891 1398 1400 O
be NCT03920891 1401 1403 O
ineligible NCT03920891 1404 1414 O
for NCT03920891 1415 1418 O
participation NCT03920891 1419 1432 O
in NCT03920891 1433 1435 O
this NCT03920891 1436 1440 O
clinical NCT03920891 1441 1449 O
study NCT03920891 1450 1455 O

Inclusion NCT03924349 0 9 O
Criteria NCT03924349 10 18 O
: NCT03924349 19 20 O

- NCT03924349 24 25 O
Cases NCT03924349 27 32 O
which NCT03924349 33 38 O
are NCT03924349 39 42 O
deemed NCT03924349 43 49 O
necessary NCT03924349 50 59 O
to NCT03924349 60 62 O
mark NCT03924349 63 67 O
the NCT03924349 68 71 O
location NCT03924349 72 80 O
of NCT03924349 81 83 O
the NCT03924349 84 87 O
colon NCT03924349 88 93 B-Modifier
lesion NCT03924349 94 100 B-Condition
before NCT03924349 101 107 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03924349 108 115 B-Procedure

Exclusion NCT03924349 116 125 O
Criteria NCT03924349 126 134 O
: NCT03924349 135 136 O

- NCT03924349 140 141 O
Pre NCT03924349 143 146 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03924349 147 148 O
- NCT03924349 150 151 O
operative NCT03924349 152 161 B-Procedure
colonoscopy NCT03924349 162 173 B-Procedure
is NCT03924349 174 176 O
not NCT03924349 177 180 B-Negation
possible NCT03924349 181 189 B-Assertion___Assertion-Type-Value:hypothetical
due NCT03924349 190 193 O
to NCT03924349 194 196 O
intestinal NCT03924349 197 207 B-Condition
obstruction NCT03924349 208 219 I-Condition

- NCT03924349 222 223 O
If NCT03924349 225 227 O
the NCT03924349 228 231 O
lesion NCT03924349 232 238 B-Condition
is NCT03924349 239 241 O
located NCT03924349 242 249 O
in NCT03924349 250 252 O
the NCT03924349 253 256 O
rectal NCT03924349 257 263 B-Modifier
area NCT03924349 264 268 I-Modifier
and NCT03924349 269 272 B-And
the NCT03924349 273 276 O
lesion NCT03924349 277 283 B-Condition
can NCT03924349 284 287 O
be NCT03924349 288 290 O
confirmed NCT03924349 291 300 O
by NCT03924349 301 303 O
digital NCT03924349 304 311 B-Modifier
rectal NCT03924349 312 318 B-Procedure
exam NCT03924349 319 323 I-Procedure

- NCT03924349 326 327 O
disagreement NCT03924349 329 341 O
with NCT03924349 342 346 O
the NCT03924349 347 350 O
study NCT03924349 351 356 B-Study

Inclusion NCT03923426 0 9 O
Criteria NCT03923426 10 18 O
: NCT03923426 19 20 O

1 NCT03923426 24 25 O
. NCT03923426 25 26 O
Hospitalized NCT03923426 28 40 B-Encounter
patient NCT03923426 41 48 O
≥ NCT03923426 49 50 B-Eq-Comparison
18 NCT03923426 51 53 I-Eq-Comparison
years NCT03923426 54 59 I-Eq-Comparison
old NCT03923426 60 63 B-Age
or NCT03923426 64 66 B-Or
considered NCT03923426 67 77 O
an NCT03923426 78 80 O
adult NCT03923426 81 86 O
in NCT03923426 87 89 O
accordance NCT03923426 90 100 O
with NCT03923426 101 105 O
the NCT03923426 106 109 O
age NCT03923426 110 113 O
of NCT03923426 114 116 O
majority NCT03923426 117 125 O
in NCT03923426 126 128 O
the NCT03923426 129 132 O
participant NCT03923426 133 144 O
's NCT03923426 144 146 O
country NCT03923426 147 154 O
of NCT03923426 155 157 O
residence NCT03923426 158 167 O
at NCT03923426 168 170 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923426 171 174 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03923426 175 179 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03923426 180 182 O
treatment NCT03923426 183 192 B-Procedure
with NCT03923426 193 197 O
ceftazidime NCT03923426 198 209 B-Drug
- NCT03923426 210 211 I-Drug
avibactam NCT03923426 212 221 I-Drug
. NCT03923426 221 222 O

2 NCT03923426 226 227 O
. NCT03923426 227 228 O
Patient NCT03923426 230 237 O
received NCT03923426 238 246 B-Eq-Comparison
≥ NCT03923426 247 248 B-Eq-Comparison
1 NCT03923426 249 250 I-Eq-Comparison
dose NCT03923426 251 255 O
of NCT03923426 256 258 O
ceftazidime NCT03923426 259 270 B-Drug
- NCT03923426 271 272 I-Drug
avibactam NCT03923426 273 282 I-Drug
in NCT03923426 283 285 O
routine NCT03923426 286 293 O
practice NCT03923426 294 302 O
at NCT03923426 303 305 O
participating NCT03923426 306 319 O
site NCT03923426 320 324 O
since NCT03923426 325 330 B-Eq-Comparison
01 NCT03923426 331 333 I-Eq-Comparison
January NCT03923426 334 341 I-Eq-Comparison
, NCT03923426 342 343 O
2018 NCT03923426 344 348 I-Eq-Comparison
onwards NCT03923426 349 356 O
or NCT03923426 357 359 B-Or
since NCT03923426 360 365 O
the NCT03923426 366 369 O
date NCT03923426 370 374 O
of NCT03923426 375 377 O
launch NCT03923426 378 384 O
in NCT03923426 385 387 O
the NCT03923426 388 391 O
country NCT03923426 392 399 O
if NCT03923426 400 402 O
it NCT03923426 403 405 O
is NCT03923426 406 408 O
after NCT03923426 409 414 B-Temporal-Connection___Temporal-Connection-Type-Value:after
01 NCT03923426 415 417 B-Eq-Comparison
January NCT03923426 418 425 I-Eq-Comparison
, NCT03923426 426 427 O
2018 NCT03923426 428 432 I-Eq-Comparison
. NCT03923426 432 433 O

3 NCT03923426 437 438 O
. NCT03923426 438 439 O
Patient NCT03923426 441 448 O
underwent NCT03923426 449 458 B-Eq-Comparison
microbiologic NCT03923426 459 472 B-Observation
sampling NCT03923426 473 481 I-Observation
≤ NCT03923426 482 483 B-Eq-Comparison
5 NCT03923426 484 485 I-Eq-Comparison
days NCT03923426 486 490 I-Eq-Comparison
before NCT03923426 491 497 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923426 498 501 O
initiation NCT03923426 502 512 B-Eq-Comparison
of NCT03923426 513 515 O
ceftazidime NCT03923426 516 527 B-Drug
- NCT03923426 528 529 I-Drug
avibactam NCT03923426 530 539 I-Drug
( NCT03923426 540 541 O
irrespective NCT03923426 542 554 O
of NCT03923426 555 557 O
results NCT03923426 558 565 O
and NCT03923426 566 569 O
actual NCT03923426 570 576 O
bacteriological NCT03923426 577 592 O
identification NCT03923426 593 607 O
) NCT03923426 608 609 O
. NCT03923426 610 611 O

4 NCT03923426 615 616 O
. NCT03923426 616 617 O
Patient NCT03923426 619 626 O
has NCT03923426 627 630 O
all NCT03923426 631 634 O
required NCT03923426 635 643 O
essential NCT03923426 644 653 O
data NCT03923426 654 658 O
elements NCT03923426 659 667 O
which NCT03923426 668 673 O
include NCT03923426 674 681 O
: NCT03923426 682 683 O

1 NCT03923426 692 693 O
. NCT03923426 693 694 O
Start NCT03923426 696 701 O
and NCT03923426 702 705 O
stop NCT03923426 706 710 O
dates NCT03923426 711 716 O
of NCT03923426 717 719 O
ceftazidime NCT03923426 720 731 B-Drug
- NCT03923426 732 733 I-Drug
avibactam NCT03923426 734 743 I-Drug
, NCT03923426 744 745 O

2 NCT03923426 754 755 O
. NCT03923426 755 756 O
Start NCT03923426 758 763 O
and NCT03923426 764 767 O
stop NCT03923426 768 772 O
dates NCT03923426 773 778 O
of NCT03923426 779 781 O
prior NCT03923426 782 787 B-Eq-Comparison
antibiotic NCT03923426 788 798 B-Procedure
therapy NCT03923426 799 806 I-Procedure
used NCT03923426 807 811 O
for NCT03923426 812 815 O
the NCT03923426 816 819 O
index NCT03923426 820 825 O
infection NCT03923426 826 835 B-Condition
, NCT03923426 836 837 O

3 NCT03923426 846 847 O
. NCT03923426 847 848 O
Type NCT03923426 850 854 O
of NCT03923426 855 857 O
combined NCT03923426 858 866 O
antibiotic NCT03923426 867 877 B-Procedure
therapy NCT03923426 878 885 I-Procedure
( NCT03923426 886 887 O
if NCT03923426 888 890 O
applicable NCT03923426 891 901 O
) NCT03923426 902 903 O
and NCT03923426 904 907 B-And
start NCT03923426 908 913 O
and NCT03923426 914 917 O
stop NCT03923426 918 922 O
dates NCT03923426 923 928 O
of NCT03923426 929 931 O
any NCT03923426 932 935 O
antibiotic NCT03923426 936 946 B-Drug
combined NCT03923426 947 955 B-And
with NCT03923426 956 960 I-And
ceftazidime NCT03923426 961 972 B-Drug
- NCT03923426 973 974 I-Drug
avibactam NCT03923426 975 984 I-Drug
. NCT03923426 984 985 O

5 NCT03923426 989 990 O
. NCT03923426 990 991 O
Evidence NCT03923426 993 1001 O
of NCT03923426 1002 1004 O
a NCT03923426 1005 1006 O
personally NCT03923426 1007 1017 O
signed NCT03923426 1018 1024 O
and NCT03923426 1025 1028 O
dated NCT03923426 1029 1034 O
informed NCT03923426 1035 1043 O
consent NCT03923426 1044 1051 O
document NCT03923426 1052 1060 O
indicating NCT03923426 1061 1071 O
that NCT03923426 1072 1076 O
the NCT03923426 1077 1080 O
patient NCT03923426 1081 1088 O
( NCT03923426 1089 1090 O
or NCT03923426 1091 1093 O
a NCT03923426 1094 1095 O
legally NCT03923426 1096 1103 O
acceptable NCT03923426 1104 1114 O
representative NCT03923426 1115 1129 O
) NCT03923426 1130 1131 O
has NCT03923426 1132 1135 O
been NCT03923426 1136 1140 O
informed NCT03923426 1141 1149 O
of NCT03923426 1150 1152 O
all NCT03923426 1153 1156 O
pertinent NCT03923426 1157 1166 O
aspects NCT03923426 1167 1174 O
of NCT03923426 1175 1177 O
the NCT03923426 1178 1181 O
study NCT03923426 1182 1187 O
where NCT03923426 1188 1193 O
required NCT03923426 1194 1202 O
by NCT03923426 1203 1205 O
local NCT03923426 1206 1211 O
regulations NCT03923426 1212 1223 O
. NCT03923426 1223 1224 O

Exclusion NCT03923426 1226 1235 O
Criteria NCT03923426 1236 1244 O
: NCT03923426 1245 1246 O

Patients NCT03923426 1248 1256 O
must NCT03923426 1257 1261 O
not NCT03923426 1262 1265 O
meet NCT03923426 1266 1270 O
any NCT03923426 1271 1274 O
of NCT03923426 1275 1277 O
the NCT03923426 1278 1281 O
following NCT03923426 1282 1291 O
exclusion NCT03923426 1292 1301 O
criteria NCT03923426 1302 1310 O
to NCT03923426 1311 1313 O
be NCT03923426 1314 1316 O
eligible NCT03923426 1317 1325 O
: NCT03923426 1326 1327 O

1 NCT03923426 1331 1332 O
. NCT03923426 1332 1333 O
The NCT03923426 1335 1338 O
patient NCT03923426 1339 1346 O
is NCT03923426 1347 1349 O
enrolled NCT03923426 1350 1358 O
in NCT03923426 1359 1361 B-Drug
any NCT03923426 1362 1365 B-Other
clinical NCT03923426 1366 1374 B-Study
trial NCT03923426 1375 1380 I-Study
of NCT03923426 1381 1383 O
an NCT03923426 1384 1386 O
investigational NCT03923426 1387 1402 O
product NCT03923426 1403 1410 I-Drug
. NCT03923426 1410 1411 O
Patients NCT03923426 1413 1421 O
who NCT03923426 1422 1425 O
are NCT03923426 1426 1429 O
enrolled NCT03923426 1430 1438 O
in NCT03923426 1439 1441 O
non NCT03923426 1442 1445 O
- NCT03923426 1446 1447 O
interventional NCT03923426 1448 1462 O
studies NCT03923426 1463 1470 O
( NCT03923426 1471 1472 O
NISs NCT03923426 1473 1477 O
) NCT03923426 1478 1479 O
( NCT03923426 1480 1481 O
e. NCT03923426 1482 1484 O
g. NCT03923426 1485 1487 O
registries NCT03923426 1489 1499 O
) NCT03923426 1500 1501 O
are NCT03923426 1502 1505 O
eligible NCT03923426 1506 1514 O
for NCT03923426 1515 1518 O
inclusion NCT03923426 1519 1528 O
. NCT03923426 1528 1529 O

2 NCT03923426 1533 1534 O
. NCT03923426 1534 1535 O
The NCT03923426 1537 1540 O
patient NCT03923426 1541 1548 O
has NCT03923426 1549 1552 O
received NCT03923426 1553 1561 B-Eq-Comparison
ceftazidime NCT03923426 1562 1573 B-Drug
- NCT03923426 1574 1575 I-Drug
avibactam NCT03923426 1576 1585 I-Drug
in NCT03923426 1586 1588 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03923426 1589 1590 O
compassionate NCT03923426 1591 1604 B-Procedure
care NCT03923426 1605 1609 I-Procedure
program NCT03923426 1610 1617 I-Procedure
setting NCT03923426 1618 1625 O
. NCT03923426 1625 1626 O

3 NCT03923426 1630 1631 O
. NCT03923426 1631 1632 O
The NCT03923426 1634 1637 O
patient NCT03923426 1638 1645 O
was NCT03923426 1646 1649 O
exposed NCT03923426 1650 1657 B-Eq-Comparison
to NCT03923426 1658 1660 O
ceftazidime NCT03923426 1661 1672 B-Drug
- NCT03923426 1673 1674 I-Drug
avibactam NCT03923426 1675 1684 I-Drug
before NCT03923426 1685 1691 B-Temporal-Connection___Temporal-Connection-Type-Value:before
use NCT03923426 1692 1695 O
for NCT03923426 1696 1699 O
the NCT03923426 1700 1703 O
index NCT03923426 1704 1709 O
infection NCT03923426 1710 1719 B-Condition
. NCT03923426 1719 1720 O

Inclusion NCT03929679 0 9 O
Criteria NCT03929679 10 18 O
: NCT03929679 19 20 O

- NCT03929679 24 25 O
Signed NCT03929679 27 33 O
informed NCT03929679 34 42 O
consent NCT03929679 43 50 O
obtained NCT03929679 51 59 O
before NCT03929679 60 66 O
any NCT03929679 67 70 O
study NCT03929679 71 76 O
- NCT03929679 77 78 O
related NCT03929679 79 86 O
activities NCT03929679 87 97 O
( NCT03929679 98 99 O
study NCT03929679 100 105 O
- NCT03929679 106 107 O
related NCT03929679 108 115 O
activities NCT03929679 116 126 O
are NCT03929679 127 130 O
any NCT03929679 131 134 O
procedures NCT03929679 135 145 O
related NCT03929679 146 153 O
to NCT03929679 154 156 O
recording NCT03929679 157 166 O
of NCT03929679 167 169 O
data NCT03929679 170 174 O
according NCT03929679 175 184 O
to NCT03929679 185 187 O
protocol NCT03929679 188 196 O
) NCT03929679 197 198 O

- NCT03929679 202 203 O
The NCT03929679 205 208 O
decision NCT03929679 209 217 O
to NCT03929679 218 220 O
initiate NCT03929679 221 229 O
treatment NCT03929679 230 239 O
with NCT03929679 240 244 O
commercially NCT03929679 245 257 O
available NCT03929679 258 267 O
semaglutide NCT03929679 268 279 O
has NCT03929679 280 283 O
been NCT03929679 284 288 O
made NCT03929679 289 293 O
by NCT03929679 294 296 O
the NCT03929679 297 300 O
patient NCT03929679 301 308 O
/ NCT03929679 309 310 O
Legally NCT03929679 311 318 O
Acceptable NCT03929679 319 329 O
Representative NCT03929679 330 344 O
and NCT03929679 345 348 O
the NCT03929679 349 352 O
treating NCT03929679 353 361 O
physician NCT03929679 362 371 O
before NCT03929679 372 378 O
and NCT03929679 379 382 O
independently NCT03929679 383 396 O
from NCT03929679 397 401 O
the NCT03929679 402 405 O
decision NCT03929679 406 414 O
to NCT03929679 415 417 O
include NCT03929679 418 425 O
the NCT03929679 426 429 O
patient NCT03929679 430 437 O
in NCT03929679 438 440 O
this NCT03929679 441 445 O
study NCT03929679 446 451 O

- NCT03929679 454 455 O
Male NCT03929679 457 461 O
or NCT03929679 462 464 B-Or
female NCT03929679 465 471 O
, NCT03929679 472 473 O
age NCT03929679 474 477 B-Age
greater NCT03929679 478 485 B-Eq-Comparison
than NCT03929679 486 490 I-Eq-Comparison
or NCT03929679 491 493 I-Eq-Comparison
equal NCT03929679 494 499 I-Eq-Comparison
to NCT03929679 500 502 I-Eq-Comparison
18 NCT03929679 503 505 I-Eq-Comparison
years NCT03929679 506 511 I-Eq-Comparison
at NCT03929679 512 514 O
the NCT03929679 515 518 O
time NCT03929679 519 523 O
of NCT03929679 524 526 O
signing NCT03929679 527 534 O
informed NCT03929679 535 543 O
consent NCT03929679 544 551 O

- NCT03929679 554 555 O
Diagnosed NCT03929679 557 566 O
with NCT03929679 567 571 O
type NCT03929679 572 576 B-Condition
2 NCT03929679 577 578 I-Condition
diabetes NCT03929679 579 587 I-Condition
at NCT03929679 588 590 B-Eq-Comparison
least NCT03929679 591 596 I-Eq-Comparison
12 NCT03929679 597 599 I-Eq-Comparison
weeks NCT03929679 600 605 I-Eq-Comparison
prior NCT03929679 606 611 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929679 612 614 I-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03929679 615 624 B-Study

- NCT03929679 627 628 O
Available NCT03929679 630 639 O
and NCT03929679 640 643 O
documented NCT03929679 644 654 O
haemoglobin NCT03929679 655 666 B-Observation
A1c NCT03929679 667 670 I-Observation
( NCT03929679 671 672 O
HbA1c NCT03929679 673 678 B-Observation
) NCT03929679 679 680 O
value NCT03929679 681 686 O
less NCT03929679 687 691 B-Eq-Comparison
than NCT03929679 692 696 I-Eq-Comparison
or NCT03929679 697 699 I-Eq-Comparison
equal NCT03929679 700 705 I-Eq-Comparison
to NCT03929679 706 708 I-Eq-Comparison
12 NCT03929679 709 711 I-Eq-Comparison
weeks NCT03929679 712 717 I-Eq-Comparison
prior NCT03929679 718 723 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929679 724 726 I-Temporal-Connection___Temporal-Connection-Type-Value:before
initiation NCT03929679 727 737 B-Eq-Comparison
of NCT03929679 738 740 O
semaglutide NCT03929679 741 752 B-Drug
treatment NCT03929679 753 762 B-Procedure

Exclusion NCT03929679 763 772 O
Criteria NCT03929679 773 781 O
: NCT03929679 782 783 O

- NCT03929679 787 788 O
Previous NCT03929679 790 798 B-Eq-Comparison
participation NCT03929679 799 812 O
in NCT03929679 813 815 O
this NCT03929679 816 820 O
study NCT03929679 821 826 B-Study
. NCT03929679 826 827 O
Participation NCT03929679 829 842 O
is NCT03929679 843 845 O
defined NCT03929679 846 853 O
as NCT03929679 854 856 O
having NCT03929679 857 863 O
given NCT03929679 864 869 O
informed NCT03929679 870 878 O
consent NCT03929679 879 886 O
in NCT03929679 887 889 O
this NCT03929679 890 894 O
study NCT03929679 895 900 O

- NCT03929679 903 904 O
Mental NCT03929679 906 912 B-Condition
incapacity NCT03929679 913 923 I-Condition
, NCT03929679 924 925 O
unwillingness NCT03929679 926 939 O
or NCT03929679 940 942 B-Or
language NCT03929679 943 951 B-Condition
barriers NCT03929679 952 960 I-Condition
precluding NCT03929679 961 971 O
adequate NCT03929679 972 980 O
understanding NCT03929679 981 994 O
or NCT03929679 995 997 O
cooperation NCT03929679 998 1009 O

- NCT03929679 1012 1013 O
Treatment NCT03929679 1015 1024 B-Procedure
with NCT03929679 1025 1029 O
any NCT03929679 1030 1033 O
investigational NCT03929679 1034 1049 B-Study
drug NCT03929679 1050 1054 B-Drug
within NCT03929679 1055 1061 B-Eq-Comparison
90 NCT03929679 1062 1064 I-Eq-Comparison
days NCT03929679 1065 1069 I-Eq-Comparison
prior NCT03929679 1070 1075 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929679 1076 1078 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03929679 1079 1088 O
into NCT03929679 1089 1093 O
the NCT03929679 1094 1097 O
study NCT03929679 1098 1103 B-Study

- NCT03929679 1106 1107 O
Hypersensitivity NCT03929679 1109 1125 B-Condition
to NCT03929679 1126 1128 O
semaglutide NCT03929679 1129 1140 B-Drug
or NCT03929679 1141 1143 O
to NCT03929679 1144 1146 O
any NCT03929679 1147 1150 O
of NCT03929679 1151 1153 O
the NCT03929679 1154 1157 O
excipients NCT03929679 1158 1168 O

Inclusion NCT03924375 0 9 O
Criteria NCT03924375 10 18 O
: NCT03924375 19 20 O

- NCT03924375 24 25 O
Gastroscopy NCT03924375 27 38 B-Procedure
can NCT03924375 39 42 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03924375 43 45 I-Assertion___Assertion-Type-Value:hypothetical
performed NCT03924375 46 55 O

- NCT03924375 58 59 O
Serologic NCT03924375 61 70 B-Observation
markers NCT03924375 71 78 I-Observation
including NCT03924375 79 88 O
serum NCT03924375 89 94 B-Observation
pepsinogen NCT03924375 95 105 I-Observation
can NCT03924375 106 109 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03924375 110 112 I-Assertion___Assertion-Type-Value:hypothetical
measured NCT03924375 113 121 O

Exclusion NCT03924375 122 131 O
Criteria NCT03924375 132 140 O
: NCT03924375 141 142 O

- NCT03924375 146 147 O
Age NCT03924375 149 152 B-Age
< NCT03924375 153 154 B-Eq-Comparison
20 NCT03924375 155 157 I-Eq-Comparison
or NCT03924375 158 160 B-Or
> NCT03924375 161 162 B-Eq-Comparison
70 NCT03924375 163 165 I-Eq-Comparison
years NCT03924375 166 171 I-Eq-Comparison

- NCT03924375 174 175 O
Anemia NCT03924375 177 183 B-Condition
( NCT03924375 184 185 O
serum NCT03924375 186 191 B-Observation
hemoglobin NCT03924375 192 202 I-Observation
level NCT03924375 203 208 I-Observation
< NCT03924375 209 210 B-Eq-Comparison
10 NCT03924375 211 213 I-Eq-Comparison
g NCT03924375 214 215 I-Eq-Comparison
/ NCT03924375 216 217 I-Eq-Comparison
dL NCT03924375 218 220 I-Eq-Comparison
) NCT03924375 221 222 O

- NCT03924375 226 227 O
Severe NCT03924375 229 235 O
systemic NCT03924375 236 244 B-Modifier
disease NCT03924375 245 252 B-Condition

- NCT03924375 255 256 O
Advanced NCT03924375 258 266 O
chronic NCT03924375 267 274 B-Modifier
liver NCT03924375 275 280 B-Condition
disease NCT03924375 281 288 I-Condition

- NCT03924375 291 292 O
Use NCT03924375 294 297 B-Eq-Comparison
of NCT03924375 298 300 O
certain NCT03924375 301 308 O
medications NCT03924375 309 320 B-Drug
, NCT03924375 321 322 O
including NCT03924375 323 332 O
proton NCT03924375 333 339 B-Drug
pump NCT03924375 340 344 I-Drug
inhibitors NCT03924375 345 355 I-Drug
, NCT03924375 356 357 O
H2 NCT03924375 358 360 B-Drug
- NCT03924375 361 362 I-Drug
receptor NCT03924375 363 371 I-Drug
antagonists NCT03924375 372 383 I-Drug
, NCT03924375 384 385 O
or NCT03924375 386 388 B-Or
antibiotics NCT03924375 389 400 B-Drug

- NCT03924375 403 404 O
History NCT03924375 406 413 B-Eq-Comparison
of NCT03924375 414 416 O
H. NCT03924375 417 419 B-Organism
pylori NCT03924375 421 427 I-Organism
eradication NCT03924375 428 439 B-Condition

- NCT03924375 442 443 O
History NCT03924375 445 452 B-Eq-Comparison
of NCT03924375 453 455 O
gastric NCT03924375 456 463 B-Procedure
surgery NCT03924375 464 471 I-Procedure

- NCT03924375 474 475 O
Recent NCT03924375 477 483 O
history NCT03924375 484 491 B-Eq-Comparison
of NCT03924375 492 494 O
upper NCT03924375 495 500 B-Modifier
gastrointestinal NCT03924375 501 517 I-Modifier
bleeding NCT03924375 518 526 B-Condition

Inclusion NCT03921580 0 9 O
Criteria NCT03921580 10 18 O
: NCT03921580 19 20 O

- NCT03921580 24 25 O
Men NCT03921580 27 30 O
and NCT03921580 31 34 B-Or
women NCT03921580 35 40 O
from NCT03921580 41 45 O
18 NCT03921580 46 48 B-Eq-Comparison
to NCT03921580 49 51 I-Eq-Comparison
65 NCT03921580 52 54 I-Eq-Comparison
years NCT03921580 55 60 I-Eq-Comparison
old NCT03921580 61 64 B-Age
. NCT03921580 64 65 O

- NCT03921580 69 70 O
Body NCT03921580 72 76 B-Observation
Mass NCT03921580 77 81 I-Observation
Index NCT03921580 82 87 I-Observation
( NCT03921580 88 89 O
BMI NCT03921580 90 93 B-Observation
) NCT03921580 94 95 O
≥ NCT03921580 96 97 B-Eq-Comparison
25 NCT03921580 98 100 I-Eq-Comparison
and NCT03921580 101 104 B-And
< NCT03921580 105 106 B-Eq-Comparison
30 NCT03921580 107 109 I-Eq-Comparison
kg NCT03921580 110 112 I-Eq-Comparison
/ NCT03921580 113 114 I-Eq-Comparison
m2 NCT03921580 115 117 I-Eq-Comparison
. NCT03921580 117 118 O

- NCT03921580 122 123 O
Adequate NCT03921580 125 133 O
cultural NCT03921580 134 142 O
level NCT03921580 143 148 O
and NCT03921580 149 152 O
understanding NCT03921580 153 166 O
for NCT03921580 167 170 O
the NCT03921580 171 174 O
clinical NCT03921580 175 183 O
trial NCT03921580 184 189 O
. NCT03921580 189 190 O

- NCT03921580 194 195 O
Signed NCT03921580 197 203 O
informed NCT03921580 204 212 O
consent NCT03921580 213 220 O

Exclusion NCT03921580 221 230 O
Criteria NCT03921580 231 239 O
: NCT03921580 240 241 O

- NCT03921580 245 246 O
Subjects NCT03921580 248 256 O
with NCT03921580 257 261 O
BMI NCT03921580 262 265 B-Observation
≥ NCT03921580 266 267 B-Eq-Comparison
30 NCT03921580 268 270 I-Eq-Comparison
or NCT03921580 271 273 B-Or
< NCT03921580 274 275 B-Eq-Comparison
25 NCT03921580 276 278 I-Eq-Comparison
kg NCT03921580 279 281 I-Eq-Comparison
/ NCT03921580 282 283 I-Eq-Comparison
m2 NCT03921580 284 286 I-Eq-Comparison

- NCT03921580 289 290 O
Subjects NCT03921580 292 300 O
diagnosed NCT03921580 301 310 O
with NCT03921580 311 315 O
Diabetes NCT03921580 316 324 B-Condition
Mellitus NCT03921580 325 333 I-Condition
. NCT03921580 333 334 O

- NCT03921580 338 339 O
Subjects NCT03921580 341 349 O
with NCT03921580 350 354 O
dyslipidemia NCT03921580 355 367 B-Condition
on NCT03921580 368 370 B-Eq-Comparison
pharmacological NCT03921580 371 386 B-Procedure
treatment NCT03921580 387 396 I-Procedure

- NCT03921580 399 400 O
Subjects NCT03921580 402 410 O
with NCT03921580 411 415 O
hypertension NCT03921580 416 428 B-Condition
on NCT03921580 429 431 B-Eq-Comparison
pharmacological NCT03921580 432 447 B-Procedure
treatment NCT03921580 448 457 I-Procedure

- NCT03921580 460 461 O
Subjects NCT03921580 463 471 O
with NCT03921580 472 476 O
established NCT03921580 477 488 O
diagnosis NCT03921580 489 498 O
of NCT03921580 499 501 O
eating NCT03921580 502 508 B-Condition
disorder NCT03921580 509 517 I-Condition

- NCT03921580 520 521 O
Smokers NCT03921580 523 530 O
or NCT03921580 531 533 O
those NCT03921580 534 539 O
subjects NCT03921580 540 548 O
with NCT03921580 549 553 O
high NCT03921580 554 558 O
alcohol NCT03921580 559 566 B-Observation
consumption NCT03921580 567 578 I-Observation
( NCT03921580 579 580 O
> NCT03921580 582 583 B-Eq-Comparison
2 NCT03921580 584 585 I-Eq-Comparison
- NCT03921580 586 587 I-Eq-Comparison
3 NCT03921580 588 589 I-Eq-Comparison
servings NCT03921580 590 598 I-Eq-Comparison
/ NCT03921580 599 600 I-Eq-Comparison
day NCT03921580 601 604 I-Eq-Comparison
in NCT03921580 605 607 O
men NCT03921580 608 611 O
and NCT03921580 612 615 B-Or
> NCT03921580 616 617 B-Eq-Comparison
1 NCT03921580 618 619 I-Eq-Comparison
serving NCT03921580 620 627 I-Eq-Comparison
/ NCT03921580 628 629 I-Eq-Comparison
day NCT03921580 630 633 I-Eq-Comparison
in NCT03921580 634 636 O
women NCT03921580 637 642 O
( NCT03921580 643 644 O
1 NCT03921580 645 646 O
serving NCT03921580 647 654 O
= NCT03921580 655 656 O
1 NCT03921580 657 658 O
glass NCT03921580 659 664 O
of NCT03921580 665 667 O
wine NCT03921580 668 672 O
or NCT03921580 673 675 O
1 NCT03921580 676 677 O
bottle NCT03921580 678 684 O
of NCT03921580 685 687 O
beer NCT03921580 688 692 O
) NCT03921580 693 694 O

- NCT03921580 698 699 O
Subjects NCT03921580 701 709 O
under NCT03921580 710 715 O
pharmacological NCT03921580 716 731 B-Procedure
treatment NCT03921580 732 741 I-Procedure
( NCT03921580 742 743 O
except NCT03921580 744 750 B-Exception
oral NCT03921580 751 755 B-Drug
contraceptives NCT03921580 756 770 I-Drug
) NCT03921580 771 772 O

- NCT03921580 776 777 O
Subjects NCT03921580 779 787 O
with NCT03921580 788 792 O
large NCT03921580 793 798 O
weight NCT03921580 799 805 B-Observation
fluctuations NCT03921580 806 818 O
of NCT03921580 819 821 O
more NCT03921580 822 826 B-Eq-Comparison
than NCT03921580 827 831 I-Eq-Comparison
4 NCT03921580 832 833 I-Eq-Comparison
kg NCT03921580 834 836 I-Eq-Comparison
or NCT03921580 837 839 B-Or
who NCT03921580 840 843 O
have NCT03921580 844 848 O
undergone NCT03921580 849 858 B-Eq-Comparison
in NCT03921580 859 861 O
six NCT03921580 862 865 B-Eq-Comparison
months NCT03921580 866 872 I-Eq-Comparison
a NCT03921580 873 874 O
weight NCT03921580 875 881 B-Procedure
loss NCT03921580 882 886 I-Procedure
diet NCT03921580 887 891 I-Procedure

- NCT03921580 894 895 O
Subjects NCT03921580 897 905 O
with NCT03921580 906 910 O
sensory NCT03921580 911 918 O
problems NCT03921580 919 927 O

- NCT03921580 930 931 O
Subjects NCT03921580 933 941 O
with NCT03921580 942 946 O
gastrointestinal NCT03921580 947 963 B-Condition
diseases NCT03921580 964 972 I-Condition
that NCT03921580 973 977 O
affect NCT03921580 978 984 O
the NCT03921580 985 988 O
digestion NCT03921580 989 998 B-Condition
or NCT03921580 999 1001 B-Or
absorption NCT03921580 1002 1012 B-Condition
of NCT03921580 1013 1015 I-Condition
nutrients NCT03921580 1016 1025 I-Condition

- NCT03921580 1028 1029 O
Pregnant NCT03921580 1031 1039 B-Condition
or NCT03921580 1040 1042 B-Or
breastfeeding NCT03921580 1043 1056 B-Condition
women NCT03921580 1057 1062 O

- NCT03921580 1065 1066 O
Women NCT03921580 1068 1073 O
with NCT03921580 1074 1078 B-And
menstrual NCT03921580 1079 1088 B-Condition
irregularities NCT03921580 1089 1103 I-Condition
( NCT03921580 1104 1105 O
absence NCT03921580 1106 1113 B-Condition
of NCT03921580 1114 1116 I-Condition
menstrual NCT03921580 1117 1126 I-Condition
cycle NCT03921580 1127 1132 I-Condition
at NCT03921580 1133 1135 B-Eq-Comparison
least NCT03921580 1136 1141 I-Eq-Comparison
2 NCT03921580 1142 1143 I-Eq-Comparison
months NCT03921580 1144 1150 I-Eq-Comparison
) NCT03921580 1151 1152 O

- NCT03921580 1156 1157 O
Subjects NCT03921580 1159 1167 O
with NCT03921580 1168 1172 O
intense NCT03921580 1173 1180 O
physical NCT03921580 1181 1189 B-Observation
activity NCT03921580 1190 1198 I-Observation
. NCT03921580 1198 1199 O

- NCT03921580 1203 1204 O
Subjects NCT03921580 1206 1214 O
with NCT03921580 1215 1219 O
food NCT03921580 1220 1224 O
allergies NCT03921580 1225 1234 B-Allergy
to NCT03921580 1235 1237 O
meals NCT03921580 1238 1243 O
included NCT03921580 1244 1252 O
in NCT03921580 1253 1255 O
breakfast NCT03921580 1256 1265 O
, NCT03921580 1266 1267 O
study NCT03921580 1268 1273 B-Study
product NCT03921580 1274 1281 B-Drug
or NCT03921580 1282 1284 O
lunch NCT03921580 1285 1290 O
or NCT03921580 1291 1293 O
that NCT03921580 1294 1298 O
reject NCT03921580 1299 1305 O
their NCT03921580 1306 1311 O
consumption NCT03921580 1312 1323 O

- NCT03921580 1326 1327 O
Subjects NCT03921580 1329 1337 O
with NCT03921580 1338 1342 O
a NCT03921580 1343 1344 O
diagnosis NCT03921580 1345 1354 O
of NCT03921580 1355 1357 O
celiac NCT03921580 1358 1364 B-Condition
disease NCT03921580 1365 1372 I-Condition
or NCT03921580 1373 1375 B-Or
a NCT03921580 1376 1377 O
gluten NCT03921580 1378 1384 B-Condition
intolerance NCT03921580 1385 1396 I-Condition

Inclusion NCT03929692 0 9 O
Criteria NCT03929692 10 18 O
: NCT03929692 19 20 O

- NCT03929692 24 25 O
Intervention NCT03929692 27 39 O
group NCT03929692 40 45 O
: NCT03929692 46 47 O
Participants NCT03929692 48 60 O
must NCT03929692 61 65 O
be NCT03929692 66 68 O
in NCT03929692 69 71 O
10 NCT03929692 72 74 O
th NCT03929692 75 77 O
school NCT03929692 78 84 O
grade NCT03929692 85 90 O
or NCT03929692 91 93 O
aged NCT03929692 94 98 B-Age
15 NCT03929692 99 101 B-Eq-Comparison
to NCT03929692 102 104 I-Eq-Comparison
16 NCT03929692 105 107 I-Eq-Comparison
years NCT03929692 108 113 I-Eq-Comparison
when NCT03929692 114 118 O
recruited NCT03929692 119 128 O
in NCT03929692 129 131 O
training NCT03929692 132 140 O
companies NCT03929692 141 150 O
. NCT03929692 150 151 O

- NCT03929692 155 156 O
Control NCT03929692 158 165 O
Group NCT03929692 166 171 O
: NCT03929692 172 173 O
Participants NCT03929692 174 186 O
must NCT03929692 187 191 O
be NCT03929692 192 194 O
in NCT03929692 195 197 O
12 NCT03929692 198 200 O
th NCT03929692 201 203 O
school NCT03929692 204 210 O
grade NCT03929692 211 216 O
or NCT03929692 217 219 O
aged NCT03929692 220 224 B-Age
17 NCT03929692 225 227 B-Eq-Comparison
to NCT03929692 228 230 I-Eq-Comparison
18 NCT03929692 231 233 I-Eq-Comparison
years NCT03929692 234 239 I-Eq-Comparison
when NCT03929692 240 244 O
recruited NCT03929692 245 254 O
in NCT03929692 255 257 O
training NCT03929692 258 266 O
companies NCT03929692 267 276 O
. NCT03929692 276 277 O

Exclusion NCT03929692 279 288 O
Criteria NCT03929692 289 297 O
: NCT03929692 298 299 O

- NCT03929692 302 303 O
none NCT03929692 304 308 O

Inclusion NCT03927456 0 9 O
Criteria NCT03927456 10 18 O
: NCT03927456 19 20 O

1 NCT03927456 24 25 O
. NCT03927456 25 26 O
Has NCT03927456 28 31 O
the NCT03927456 32 35 O
pathologically NCT03927456 36 50 O
- NCT03927456 51 52 O
confirmed NCT03927456 53 62 O
diagnosis NCT03927456 63 72 O
of NCT03927456 73 75 O
locally NCT03927456 76 83 B-Modifier
recurrent NCT03927456 84 93 I-Modifier
or NCT03927456 94 96 B-Or
metastatic NCT03927456 97 107 B-Modifier
, NCT03927456 108 109 O
hormone NCT03927456 110 117 B-Modifier
- NCT03927456 118 119 I-Modifier
receptor NCT03927456 120 128 I-Modifier
positive NCT03927456 129 137 I-Modifier
, NCT03927456 138 139 O
HER2 NCT03927456 140 144 B-Modifier
negative NCT03927456 145 153 I-Modifier
Breast NCT03927456 154 160 I-Modifier
Cancer NCT03927456 161 167 B-Condition
. NCT03927456 167 168 O

2 NCT03927456 172 173 O
. NCT03927456 173 174 O
Age NCT03927456 176 179 B-Age
: NCT03927456 180 181 O
18 NCT03927456 182 184 B-Eq-Comparison
- NCT03927456 185 186 I-Eq-Comparison
75 NCT03927456 187 189 I-Eq-Comparison
years NCT03927456 190 195 I-Eq-Comparison
old NCT03927456 196 199 O
, NCT03927456 200 201 O
postmenopausal NCT03927456 202 216 B-Condition
women NCT03927456 217 222 O
or NCT03927456 223 225 B-Or
prepostmenopausal NCT03927456 226 243 B-Condition
women NCT03927456 244 249 O

3 NCT03927456 252 253 O
. NCT03927456 253 254 O
Received NCT03927456 256 264 B-Eq-Comparison
prior NCT03927456 265 270 I-Eq-Comparison
endocrine NCT03927456 271 280 B-Procedure
therapy NCT03927456 281 288 I-Procedure

4 NCT03927456 291 292 O
. NCT03927456 292 293 O
One NCT03927456 295 298 B-Eq-Comparison
previous NCT03927456 299 307 B-Eq-Comparison
line NCT03927456 308 312 O
of NCT03927456 313 315 O
chemotherapy NCT03927456 316 328 B-Procedure
for NCT03927456 329 332 O
advanced NCT03927456 333 341 B-Modifier
/ NCT03927456 342 343 B-Or
metastatic NCT03927456 344 354 B-Modifier
disease NCT03927456 355 362 B-Condition
is NCT03927456 363 365 O
allowed NCT03927456 366 373 O
in NCT03927456 374 376 B-And
addition NCT03927456 377 385 I-And
to NCT03927456 386 388 O
endocrine NCT03927456 389 398 B-Procedure
therapy NCT03927456 399 406 I-Procedure
. NCT03927456 406 407 O

5 NCT03927456 411 412 O
. NCT03927456 412 413 O
Eastern NCT03927456 415 422 B-Condition
Cooperative NCT03927456 423 434 I-Condition
Oncology NCT03927456 435 443 I-Condition
Group NCT03927456 444 449 I-Condition
[ NCT03927456 450 451 O
ECOG NCT03927456 452 456 B-Condition
] NCT03927456 457 458 O
0 NCT03927456 459 460 B-Eq-Comparison
- NCT03927456 461 462 I-Eq-Comparison
1 NCT03927456 463 464 O

Exclusion NCT03927456 466 475 O
Criteria NCT03927456 476 484 O
: NCT03927456 485 486 O

1 NCT03927456 490 491 O
. NCT03927456 491 492 O
Patients NCT03927456 494 502 O
who NCT03927456 503 506 O
received NCT03927456 507 515 B-Eq-Comparison
prior NCT03927456 516 521 I-Eq-Comparison
treatment NCT03927456 522 531 B-Procedure
with NCT03927456 532 536 O
any NCT03927456 537 540 O
CDK4 NCT03927456 541 545 B-Drug
/ NCT03927456 546 547 I-Drug
6 NCT03927456 548 549 I-Drug
inhibitor NCT03927456 550 559 I-Drug
, NCT03927456 560 561 O
everolimus NCT03927456 562 572 B-Drug
or NCT03927456 573 575 B-Or
fulvestant NCT03927456 576 586 B-Drug
. NCT03927456 586 587 O

2 NCT03927456 591 592 O
. NCT03927456 592 593 O
Clinically NCT03927456 595 605 O
significant NCT03927456 606 617 O
cardiovascular NCT03927456 618 632 B-Modifier
and NCT03927456 633 636 B-Or
cerebrovascular NCT03927456 637 652 B-Modifier
diseases NCT03927456 653 661 B-Condition
, NCT03927456 662 663 O
including NCT03927456 664 673 O
but NCT03927456 674 677 O
not NCT03927456 678 681 O
limited NCT03927456 682 689 O
to NCT03927456 690 692 O
severe NCT03927456 693 699 O
acute NCT03927456 700 705 B-Condition
myocardial NCT03927456 706 716 I-Condition
infarction NCT03927456 717 727 I-Condition
within NCT03927456 728 734 B-Eq-Comparison
6 NCT03927456 735 736 I-Eq-Comparison
months NCT03927456 737 743 I-Eq-Comparison
before NCT03927456 744 750 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03927456 751 761 B-Study
, NCT03927456 762 763 O
unstable NCT03927456 764 772 B-Modifier
or NCT03927456 773 775 B-Or
severe NCT03927456 776 782 O
angina NCT03927456 783 789 B-Condition
, NCT03927456 790 791 O
Congestive NCT03927456 792 802 B-Condition
heart NCT03927456 803 808 I-Condition|Condition
failure NCT03927456 809 816 I-Condition
( NCT03927456 817 818 O
New NCT03927456 819 822 B-Condition
York NCT03927456 823 827 I-Condition
heart NCT03927456 828 833 O
association NCT03927456 834 845 I-Condition
( NCT03927456 846 847 O
NYHA NCT03927456 848 852 B-Condition
) NCT03927456 853 854 O
class NCT03927456 855 860 B-Eq-Comparison
> NCT03927456 861 862 I-Eq-Comparison
2 NCT03927456 863 864 I-Eq-Comparison
) NCT03927456 865 866 O
, NCT03927456 868 869 O
or NCT03927456 870 872 B-Or
ventricular NCT03927456 873 884 B-Condition
arrhythmia NCT03927456 885 895 I-Condition
which NCT03927456 896 901 O
need NCT03927456 902 906 B-Assertion___Assertion-Type-Value:hypothetical
medical NCT03927456 907 914 O
intervention NCT03927456 915 927 B-Procedure
. NCT03927456 927 928 O

Inclusion NCT03920488 0 9 O
Criteria NCT03920488 10 18 O
: NCT03920488 19 20 O

1 NCT03920488 24 25 O
. NCT03920488 25 26 O
age NCT03920488 28 31 B-Age
between NCT03920488 32 39 B-Eq-Comparison
18 NCT03920488 40 42 I-Eq-Comparison
and NCT03920488 43 46 I-Eq-Comparison
60 NCT03920488 47 49 I-Eq-Comparison
years NCT03920488 50 55 I-Eq-Comparison

2 NCT03920488 58 59 O
. NCT03920488 59 60 O
has NCT03920488 62 65 O
signed NCT03920488 66 72 O
informed NCT03920488 73 81 O
consent NCT03920488 82 89 O

3 NCT03920488 92 93 O
. NCT03920488 93 94 O
histologically NCT03920488 96 110 B-Procedure
confirmed NCT03920488 111 120 O
triple NCT03920488 121 127 B-Modifier
negative NCT03920488 128 136 O
breast NCT03920488 137 143 B-Modifier
cancer NCT03920488 144 150 B-Condition
( NCT03920488 151 152 O
ER NCT03920488 153 155 B-Observation
( NCT03920488 156 157 O
Estrogen NCT03920488 158 166 B-Observation
Receptors NCT03920488 167 176 I-Observation
) NCT03920488 177 178 O
< NCT03920488 179 180 B-Eq-Comparison
1 NCT03920488 181 182 I-Eq-Comparison
% NCT03920488 183 184 O
, NCT03920488 185 186 O
PgR NCT03920488 187 190 B-Observation
( NCT03920488 191 192 O
Progesterone NCT03920488 193 205 B-Observation
Receptors NCT03920488 206 215 I-Observation
) NCT03920488 216 217 O
< NCT03920488 218 219 B-Eq-Comparison
1 NCT03920488 220 221 I-Eq-Comparison
% NCT03920488 222 223 O
, NCT03920488 224 225 O
HER2 NCT03920488 226 230 B-Condition
/ NCT03920488 231 232 B-Or
neu NCT03920488 233 236 B-Condition
negative NCT03920488 237 245 O
( NCT03920488 246 247 O
IHC NCT03920488 248 251 B-Observation
0 NCT03920488 252 253 B-Eq-Comparison
, NCT03920488 254 255 O
1 NCT03920488 256 257 I-Eq-Comparison
+ NCT03920488 258 259 O
or NCT03920488 260 262 I-Eq-Comparison
2 NCT03920488 263 264 I-Eq-Comparison
+ NCT03920488 265 266 O
FISH NCT03920488 267 271 B-Condition
negative NCT03920488 272 280 O
) NCT03920488 281 282 O
. NCT03920488 283 284 O

4 NCT03920488 288 289 O
. NCT03920488 289 290 O
Stage NCT03920488 292 297 B-Eq-Comparison
I NCT03920488 298 299 I-Eq-Comparison
- NCT03920488 300 301 I-Eq-Comparison
III NCT03920488 302 305 I-Eq-Comparison

5 NCT03920488 308 309 O
. NCT03920488 309 310 O
Able NCT03920488 312 316 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920488 317 319 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03920488 320 327 O
surgery NCT03920488 328 335 B-Procedure
( NCT03920488 336 337 O
primary NCT03920488 338 345 B-Modifier
or NCT03920488 346 348 B-Or
post NCT03920488 349 353 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03920488 354 355 O
neoadjuvant NCT03920488 356 367 B-Procedure
) NCT03920488 368 369 O

6 NCT03920488 373 374 O
. NCT03920488 374 375 O
Availability NCT03920488 377 389 O
of NCT03920488 390 392 O
surgical NCT03920488 393 401 B-Modifier
/ NCT03920488 402 403 B-Or
bioptic NCT03920488 404 411 B-Modifier
material NCT03920488 412 420 B-Observation
within NCT03920488 421 427 B-Eq-Comparison
6 NCT03920488 428 429 I-Eq-Comparison
months NCT03920488 430 436 I-Eq-Comparison
from NCT03920488 437 441 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrolment NCT03920488 442 451 B-Study

Exclusion NCT03920488 452 461 O
Criteria NCT03920488 462 470 O
: NCT03920488 471 472 O

- NCT03920488 476 477 O
unable NCT03920488 479 485 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03920488 486 488 B-Or
unwilling NCT03920488 489 498 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03920488 499 501 O
receive NCT03920488 502 509 O
genetic NCT03920488 510 517 B-Procedure
counselling NCT03920488 518 529 I-Procedure

Inclusion NCT03923803 0 9 O
Criteria NCT03923803 10 18 O
: NCT03923803 19 20 O

- NCT03923803 23 24 O
Patients NCT03923803 25 33 O
admitted NCT03923803 34 42 B-Encounter
to NCT03923803 43 45 O
the NCT03923803 46 49 O
hospital NCT03923803 50 58 O

Exclusion NCT03923803 59 68 O
Criteria NCT03923803 69 77 O
: NCT03923803 78 79 O

- NCT03923803 83 84 O
patients NCT03923803 86 94 O
with NCT03923803 95 99 O
malignancies NCT03923803 100 112 B-Condition

- NCT03923803 115 116 O
patients NCT03923803 118 126 O
with NCT03923803 127 131 O
other NCT03923803 132 137 B-Other
systemic NCT03923803 138 146 B-Modifier
infection NCT03923803 147 156 B-Condition

- NCT03928639 1 2 O
INCLUSION NCT03928639 4 13 O
CRITERIA NCT03928639 14 22 O
: NCT03928639 23 24 O

- NCT03928639 28 29 O
Adults NCT03928639 31 37 O
age NCT03928639 38 41 B-Age
greater NCT03928639 42 49 B-Eq-Comparison
than NCT03928639 50 54 I-Eq-Comparison
or NCT03928639 55 57 I-Eq-Comparison
equal NCT03928639 58 63 I-Eq-Comparison
to NCT03928639 64 66 I-Eq-Comparison
18 NCT03928639 67 69 I-Eq-Comparison
years NCT03928639 70 75 I-Eq-Comparison
. NCT03928639 75 76 O

- NCT03928639 80 81 O
Receiving NCT03928639 83 92 B-Eq-Comparison
care NCT03928639 93 97 B-Procedure
from NCT03928639 98 102 O
the NCT03928639 103 106 O
structural NCT03928639 107 117 O
heart NCT03928639 118 123 O
and NCT03928639 124 127 O
valve NCT03928639 128 133 O
program NCT03928639 134 141 O
at NCT03928639 142 144 O
the NCT03928639 145 148 O
participating NCT03928639 149 162 O
NHLBI NCT03928639 163 168 O
structural NCT03928639 169 179 O
heart NCT03928639 180 185 O
disease NCT03928639 186 193 O
network NCT03928639 194 201 O
site NCT03928639 202 206 O
. NCT03928639 206 207 O

- NCT03928639 211 212 O
Consent NCT03928639 214 221 O
to NCT03928639 222 224 O
participate NCT03928639 225 236 O
in NCT03928639 237 239 O
the NCT03928639 240 243 O
protocol NCT03928639 244 252 O
, NCT03928639 253 254 O
directly NCT03928639 255 263 O
, NCT03928639 264 265 O
or NCT03928639 266 268 O
through NCT03928639 269 276 O
legally NCT03928639 277 284 O
authorized NCT03928639 285 295 O
representatives NCT03928639 296 311 O
( NCT03928639 312 313 O
LAR NCT03928639 314 317 O
) NCT03928639 318 319 O
. NCT03928639 320 321 O

EXCLUSION NCT03928639 323 332 O
CRITERIA NCT03928639 333 341 O
: NCT03928639 342 343 O

- NCT03928639 346 347 O
Does NCT03928639 348 352 O
not NCT03928639 353 356 O
consent NCT03928639 357 364 O
to NCT03928639 365 367 O
participate NCT03928639 368 379 O
in NCT03928639 380 382 O
this NCT03928639 383 387 O
protocol NCT03928639 388 396 O
. NCT03928639 396 397 O

Inclusion NCT03927287 0 9 O
Criteria NCT03927287 10 18 O
: NCT03927287 19 20 O

For NCT03927287 22 25 O
the NCT03927287 26 29 O
two NCT03927287 30 33 O
retrospective NCT03927287 34 47 O
cohorts NCT03927287 48 55 O
: NCT03927287 56 57 O

1 NCT03927287 61 62 O
. NCT03927287 62 63 O
All NCT03927287 65 68 O
patients NCT03927287 69 77 O
that NCT03927287 78 82 O
older NCT03927287 83 88 I-Eq-Comparison
than NCT03927287 89 93 I-Eq-Comparison
18 NCT03927287 94 96 I-Eq-Comparison
treated NCT03927287 97 104 B-Procedure
for NCT03927287 105 108 O
localized NCT03927287 109 118 B-Modifier
adenocarcinoma NCT03927287 119 133 B-Condition
of NCT03927287 134 136 O
the NCT03927287 137 140 O
prostate NCT03927287 141 149 B-Modifier
between NCT03927287 150 157 B-Eq-Comparison
2000 NCT03927287 158 162 I-Eq-Comparison
and NCT03927287 163 166 I-Eq-Comparison
2017 NCT03927287 167 171 I-Eq-Comparison
with NCT03927287 172 176 O
either NCT03927287 177 183 O
radical NCT03927287 184 191 B-Procedure
prostatectomy NCT03927287 192 205 I-Procedure
or NCT03927287 206 208 B-Or
radiotherapy NCT03927287 209 221 B-Procedure

2 NCT03927287 224 225 O
. NCT03927287 225 226 O
All NCT03927287 228 231 O
treated NCT03927287 232 239 O
patients NCT03927287 240 248 O
had NCT03927287 249 252 O
a NCT03927287 253 254 O
rising NCT03927287 255 261 O
post NCT03927287 262 266 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03927287 267 268 O
treatment NCT03927287 269 278 B-Procedure
PSA NCT03927287 279 282 B-Observation
, NCT03927287 283 284 O
with NCT03927287 285 289 B-And
at NCT03927287 290 292 B-Eq-Comparison
least NCT03927287 293 298 I-Eq-Comparison
one NCT03927287 299 302 I-Eq-Comparison
post NCT03927287 303 307 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03927287 308 309 O
treatment NCT03927287 310 319 B-Procedure
free NCT03927287 320 324 O
PSA NCT03927287 325 328 B-Observation
blood NCT03927287 329 334 I-Observation
test NCT03927287 335 339 I-Observation
. NCT03927287 339 340 O

For NCT03927287 342 345 O
the NCT03927287 346 349 O
biobank NCT03927287 350 357 O
validation NCT03927287 358 368 O
cohort NCT03927287 369 375 O
: NCT03927287 376 377 O

1 NCT03927287 379 380 O
. NCT03927287 380 381 O
All NCT03927287 383 386 O
patients NCT03927287 387 395 O
treated NCT03927287 396 403 O
with NCT03927287 404 408 O
radical NCT03927287 409 416 B-Procedure
prostatectomy NCT03927287 417 430 I-Procedure
for NCT03927287 431 434 O
localized NCT03927287 435 444 B-Modifier
prostate NCT03927287 445 453 I-Modifier
cancer NCT03927287 454 460 B-Condition
between NCT03927287 461 468 B-Eq-Comparison
2000 NCT03927287 469 473 I-Eq-Comparison
and NCT03927287 474 477 I-Eq-Comparison
2017 NCT03927287 478 482 I-Eq-Comparison
who NCT03927287 483 486 B-And
had NCT03927287 487 490 O
biobank NCT03927287 491 498 B-Observation
samples NCT03927287 499 506 I-Observation
taken NCT03927287 507 512 B-Eq-Comparison
when NCT03927287 513 517 B-Temporal-Connection___Temporal-Connection-Type-Value:during
developing NCT03927287 518 528 O
biochemical NCT03927287 529 540 B-Condition
recurrence NCT03927287 541 551 I-Condition
. NCT03927287 551 552 O

Exclusion NCT03927287 554 563 O
Criteria NCT03927287 564 572 O
: NCT03927287 573 574 O

1 NCT03927287 578 579 O
. NCT03927287 579 580 O
Patients NCT03927287 582 590 O
that NCT03927287 591 595 O
were NCT03927287 596 600 O
younger NCT03927287 601 608 I-Eq-Comparison
than NCT03927287 609 613 I-Eq-Comparison
18 NCT03927287 614 616 I-Eq-Comparison
, NCT03927287 617 618 O

2 NCT03927287 623 624 O
. NCT03927287 624 625 O
Patients NCT03927287 627 635 O
with NCT03927287 636 640 O
prostate NCT03927287 641 649 B-Modifier
cancer NCT03927287 650 656 B-Condition
other NCT03927287 657 662 B-Exception
than NCT03927287 663 667 I-Exception
adenocarcinoma NCT03927287 668 682 B-Condition
, NCT03927287 683 684 O
such NCT03927287 685 689 O
as NCT03927287 690 692 O
small NCT03927287 693 698 B-Modifier
cell NCT03927287 699 703 I-Modifier
and NCT03927287 704 707 B-Or
neuroendocrine NCT03927287 708 722 B-Modifier
cancer NCT03927287 723 729 B-Condition

3 NCT03927287 732 733 O
. NCT03927287 733 734 O
Patients NCT03927287 736 744 O
with NCT03927287 745 749 O
prostate NCT03927287 750 758 B-Modifier
adenocarcinoma NCT03927287 759 773 B-Condition
that NCT03927287 774 778 B-And
did NCT03927287 779 782 O
not NCT03927287 783 786 B-Negation
develop NCT03927287 787 794 O
biochemical NCT03927287 795 806 B-Condition
recurrence NCT03927287 807 817 I-Condition
. NCT03927287 817 818 O

4 NCT03927287 822 823 O
. NCT03927287 823 824 O
In NCT03927287 826 828 O
the NCT03927287 829 832 O
retrospective NCT03927287 833 846 O
cohorts NCT03927287 847 854 O
- NCT03927287 855 856 O
patients NCT03927287 857 865 O
that NCT03927287 866 870 O
did NCT03927287 871 874 O
not NCT03927287 875 878 B-Negation
have NCT03927287 879 883 O
at NCT03927287 884 886 B-Eq-Comparison
least NCT03927287 887 892 I-Eq-Comparison
one NCT03927287 893 896 I-Eq-Comparison
post NCT03927287 897 901 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03927287 902 903 O
treatment NCT03927287 904 913 B-Procedure
free NCT03927287 914 918 O
PSA NCT03927287 919 922 B-Observation
blood NCT03927287 923 928 I-Observation
test NCT03927287 929 933 I-Observation
. NCT03927287 933 934 O

Inclusion NCT03921190 0 9 O
Criteria NCT03921190 10 18 O
: NCT03921190 19 20 O

- NCT03921190 24 25 O
Adult NCT03921190 27 32 O
patients NCT03921190 33 41 O
( NCT03921190 42 43 O
16 NCT03921190 44 46 B-Eq-Comparison
years NCT03921190 47 52 I-Eq-Comparison
old NCT03921190 53 56 I-Eq-Comparison
and NCT03921190 57 60 I-Eq-Comparison
older NCT03921190 61 66 I-Eq-Comparison
) NCT03921190 67 68 O

- NCT03921190 72 73 O
Healthy NCT03921190 75 82 B-Condition
( NCT03921190 83 84 O
American NCT03921190 85 93 B-Condition
Society NCT03921190 94 101 I-Condition
of NCT03921190 102 104 I-Condition
Anaesthesiologists NCT03921190 105 123 I-Condition
( NCT03921190 124 125 O
ASA NCT03921190 126 129 B-Condition
) NCT03921190 130 131 O
category NCT03921190 132 140 B-Eq-Comparison
I NCT03921190 141 142 I-Eq-Comparison
or NCT03921190 143 145 I-Eq-Comparison
II NCT03921190 146 148 I-Eq-Comparison
) NCT03921190 149 150 O

- NCT03921190 154 155 O
A NCT03921190 157 158 O
maxillary NCT03921190 159 168 B-Modifier
posterior NCT03921190 169 178 I-Modifier
tooth NCT03921190 179 184 I-Modifier
( NCT03921190 185 186 O
excluding NCT03921190 187 196 B-Exception
third NCT03921190 197 202 B-Modifier
molars NCT03921190 203 209 I-Modifier
) NCT03921190 210 211 O
referred NCT03921190 212 220 O
for NCT03921190 221 224 O
root NCT03921190 225 229 B-Procedure
canal NCT03921190 230 235 I-Procedure
treatment NCT03921190 236 245 I-Procedure
and NCT03921190 246 249 B-And
diagnosed NCT03921190 250 259 O
with NCT03921190 260 264 O
irreversible NCT03921190 265 277 B-Condition
pulpitis NCT03921190 278 286 I-Condition
and NCT03921190 287 290 B-And
normal NCT03921190 291 297 O
apical NCT03921190 298 304 B-Condition
tissues NCT03921190 305 312 I-Condition

Exclusion NCT03921190 313 322 O
Criteria NCT03921190 323 331 O
: NCT03921190 332 333 O

- NCT03921190 337 338 O
Psychological NCT03921190 340 353 B-Condition
disorders NCT03921190 354 363 I-Condition

- NCT03921190 366 367 O
Intraoral NCT03921190 369 378 B-Modifier
soft NCT03921190 379 383 B-Condition
tissue NCT03921190 384 390 I-Condition
abnormalities NCT03921190 391 404 I-Condition

- NCT03921190 407 408 O
necrotic NCT03921190 410 418 B-Condition
pulp NCT03921190 419 423 I-Condition
with NCT03921190 424 428 O
/ NCT03921190 429 430 O
without NCT03921190 431 438 O
apical NCT03921190 439 445 B-Condition
pathology NCT03921190 446 455 I-Condition

- NCT03921190 458 459 O
tenderness NCT03921190 461 471 B-Condition
to NCT03921190 472 474 O
palpation NCT03921190 475 484 B-Procedure
and NCT03921190 485 488 B-Or
/ NCT03921190 489 490 I-Or
or NCT03921190 491 493 I-Or
percussion NCT03921190 494 504 B-Procedure

- NCT03921190 507 508 O
The NCT03921190 510 513 O
use NCT03921190 514 517 O
of NCT03921190 518 520 O
analgesics NCT03921190 521 531 B-Drug
in NCT03921190 532 534 O
the NCT03921190 535 538 O
preceding NCT03921190 539 548 B-Eq-Comparison
12 NCT03921190 549 551 I-Eq-Comparison
hours NCT03921190 552 557 I-Eq-Comparison
before NCT03921190 558 564 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03921190 565 568 O
appointment NCT03921190 569 580 B-Encounter
. NCT03921190 580 581 O

Inclusion NCT03921437 0 9 O
conditions NCT03921437 10 20 O
: NCT03921437 21 22 O

1 NCT03921437 26 27 O
. NCT03921437 27 28 O
The NCT03921437 30 33 O
fifth NCT03921437 34 39 B-Eq-Comparison
stage NCT03921437 40 45 I-Eq-Comparison
of NCT03921437 46 48 O
chronic NCT03921437 49 56 B-Modifier
renal NCT03921437 57 62 B-Condition
failure NCT03921437 63 70 I-Condition
diagnosed NCT03921437 71 80 O
by NCT03921437 81 83 O
a NCT03921437 84 85 O
physician NCT03921437 86 95 O
. NCT03921437 95 96 O

2 NCT03921437 100 101 O
. NCT03921437 101 102 O
The NCT03921437 104 107 O
physician NCT03921437 108 117 O
advises NCT03921437 118 125 O
and NCT03921437 126 129 O
informs NCT03921437 130 137 O
the NCT03921437 138 141 O
patient NCT03921437 142 149 O
who NCT03921437 150 153 O
has NCT03921437 154 157 O
to NCT03921437 158 160 O
undergo NCT03921437 161 168 B-Eq-Comparison
renal NCT03921437 169 174 B-Procedure
replacement NCT03921437 175 186 I-Procedure
therapy NCT03921437 187 194 I-Procedure
but NCT03921437 195 198 B-And
has NCT03921437 199 202 O
not NCT03921437 203 206 B-Negation
yet NCT03921437 207 210 O
decided NCT03921437 211 218 O
what NCT03921437 219 223 O
treatment NCT03921437 224 233 B-Procedure
to NCT03921437 234 236 O
take NCT03921437 237 241 O
. NCT03921437 241 242 O

3 NCT03921437 246 247 O
. NCT03921437 247 248 O
Being NCT03921437 250 255 O
able NCT03921437 256 260 O
to NCT03921437 261 263 O
communicate NCT03921437 264 275 O
in NCT03921437 276 278 O
Mandarin NCT03921437 279 287 O
and NCT03921437 288 291 B-And
Taiwan NCT03921437 292 298 O
. NCT03921437 298 299 O

4 NCT03921437 303 304 O
. NCT03921437 304 305 O
Ages NCT03921437 307 311 B-Age
over NCT03921437 312 316 O
20 NCT03921437 317 319 B-Eq-Comparison
years NCT03921437 320 325 I-Eq-Comparison
old NCT03921437 326 329 O
. NCT03921437 329 330 O

Exclusion NCT03921437 332 341 O
conditions NCT03921437 342 352 O
: NCT03921437 353 354 O

1 NCT03921437 358 359 O
. NCT03921437 359 360 O
Cognitive NCT03921437 362 371 B-Condition
impairment NCT03921437 372 382 I-Condition
: NCT03921437 383 384 O
The NCT03921437 385 388 O
MMSE NCT03921437 389 393 B-Observation
of NCT03921437 394 396 O
the NCT03921437 397 400 O
above NCT03921437 401 406 O
- NCT03921437 407 408 O
mentioned NCT03921437 409 418 O
educators NCT03921437 419 428 O
was NCT03921437 429 432 O
26 NCT03921437 433 435 B-Eq-Comparison
points NCT03921437 436 442 I-Eq-Comparison
, NCT03921437 443 444 O
and NCT03921437 445 448 B-And
the NCT03921437 449 452 O
national NCT03921437 453 461 B-Observation
minimum NCT03921437 462 469 I-Observation
was NCT03921437 470 473 O
< NCT03921437 474 475 B-Eq-Comparison
21 NCT03921437 476 478 I-Eq-Comparison
points NCT03921437 479 485 I-Eq-Comparison
, NCT03921437 486 487 O
those NCT03921437 488 493 O
who NCT03921437 494 497 O
are NCT03921437 498 501 O
not NCT03921437 502 505 B-Negation
educated NCT03921437 506 514 B-Condition
are NCT03921437 515 518 O
< NCT03921437 519 520 B-Eq-Comparison
16 NCT03921437 521 523 I-Eq-Comparison
points NCT03921437 524 530 I-Eq-Comparison
, NCT03921437 531 532 O
and NCT03921437 533 536 O
the NCT03921437 537 540 O
case NCT03921437 541 545 O
is NCT03921437 546 548 O
excluded NCT03921437 549 557 O
. NCT03921437 557 558 O

2 NCT03921437 562 563 O
. NCT03921437 563 564 O
Patients NCT03921437 566 574 O
who NCT03921437 575 578 O
have NCT03921437 579 583 O
received NCT03921437 584 592 B-Eq-Comparison
non NCT03921437 593 596 B-Negation
- NCT03921437 597 598 O
emergency NCT03921437 599 608 B-Modifier
dialysis NCT03921437 609 617 B-Procedure
treatment NCT03921437 618 627 I-Procedure
. NCT03921437 627 628 O

3 NCT03921437 632 633 O
. NCT03921437 633 634 O
Patients NCT03921437 636 644 O
with NCT03921437 645 649 O
severe NCT03921437 650 656 O
cardiopulmonary NCT03921437 657 672 B-Modifier
dysfunction NCT03921437 673 684 B-Condition
, NCT03921437 685 686 O
severe NCT03921437 687 693 O
shock NCT03921437 694 699 B-Condition
, NCT03921437 700 701 O
low NCT03921437 702 705 B-Condition
blood NCT03921437 706 711 I-Condition
pressure NCT03921437 712 720 I-Condition
, NCT03921437 721 722 O
and NCT03921437 723 726 O
large NCT03921437 727 732 O
bleeding NCT03921437 733 741 B-Condition
are NCT03921437 742 745 O
not NCT03921437 746 749 O
controlled NCT03921437 750 760 O
. NCT03921437 760 761 O

4 NCT03921437 765 766 O
. NCT03921437 766 767 O
Patients NCT03921437 769 777 O
with NCT03921437 778 782 O
chronic NCT03921437 783 790 B-Modifier
active NCT03921437 791 797 B-Eq-Comparison
hepatitis NCT03921437 798 807 B-Condition
, NCT03921437 808 809 O
cirrhosis NCT03921437 810 819 B-Condition
or NCT03921437 820 822 B-Or
liver NCT03921437 823 828 B-Condition
failure NCT03921437 829 836 I-Condition
. NCT03921437 836 837 O

5 NCT03921437 841 842 O
. NCT03921437 842 843 O
A NCT03921437 845 846 O
history NCT03921437 847 854 B-Eq-Comparison
of NCT03921437 855 857 O
cancer NCT03921437 858 864 B-Condition
that NCT03921437 865 869 O
may NCT03921437 870 873 O
be NCT03921437 874 876 O
transferred NCT03921437 877 888 O
. NCT03921437 888 889 O

6 NCT03921437 893 894 O
. NCT03921437 894 895 O
Severe NCT03921437 897 903 O
bleeding NCT03921437 904 912 B-Condition
tendency NCT03921437 913 921 O
. NCT03921437 921 922 O

7 NCT03921437 926 927 O
. NCT03921437 927 928 O
Loss NCT03921437 930 934 O
of NCT03921437 935 937 O
peritoneal NCT03921437 938 948 B-Condition|Condition
function NCT03921437 949 957 I-Condition
or NCT03921437 958 960 B-Or
extensive NCT03921437 961 970 O
peritoneal NCT03921437 971 981 B-Procedure
adhesion NCT03921437 982 990 I-Condition
, NCT03921437 991 992 O
unable NCT03921437 993 999 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03921437 1000 1002 O
use NCT03921437 1003 1006 O
peritoneal NCT03921437 1007 1017 O
dialysis NCT03921437 1018 1026 I-Procedure
. NCT03921437 1026 1027 O

8 NCT03921437 1031 1032 O
. NCT03921437 1032 1033 O
Unable NCT03921437 1035 1041 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03921437 1042 1044 O
correct NCT03921437 1045 1052 B-Procedure
physiological NCT03921437 1053 1066 B-Condition
defects NCT03921437 1067 1074 I-Condition
, NCT03921437 1075 1076 O
may NCT03921437 1077 1080 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03921437 1081 1090 O
with NCT03921437 1091 1095 O
peritoneal NCT03921437 1096 1106 B-Procedure
dialysis NCT03921437 1107 1115 I-Procedure
, NCT03921437 1116 1117 O
or NCT03921437 1118 1120 B-Or
increase NCT03921437 1121 1129 O
the NCT03921437 1130 1133 O
chance NCT03921437 1134 1140 B-Risk
of NCT03921437 1141 1143 I-Risk
infection NCT03921437 1144 1153 B-Condition
, NCT03921437 1154 1155 O
such NCT03921437 1156 1160 O
as NCT03921437 1161 1163 O
umbilical NCT03921437 1164 1173 B-Condition
hernia NCT03921437 1174 1180 I-Condition
. NCT03921437 1180 1181 O

9 NCT03921437 1185 1186 O
. NCT03921437 1186 1187 O
The NCT03921437 1189 1192 O
patient NCT03921437 1193 1200 O
is NCT03921437 1201 1203 O
unable NCT03921437 1204 1210 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03921437 1211 1213 O
operate NCT03921437 1214 1221 O
the NCT03921437 1222 1225 O
fluid NCT03921437 1226 1231 B-Procedure
change NCT03921437 1232 1238 I-Procedure
, NCT03921437 1239 1240 O
hand NCT03921437 1241 1245 O
shake NCT03921437 1246 1251 O
, NCT03921437 1252 1253 O
and NCT03921437 1254 1257 O
no NCT03921437 1258 1260 B-Negation
family NCT03921437 1261 1267 B-Family-Member
members NCT03921437 1268 1275 I-Family-Member
can NCT03921437 1276 1279 O
assist NCT03921437 1280 1286 O
. NCT03921437 1286 1287 O

10 NCT03921437 1290 1292 O
. NCT03921437 1292 1293 O
Patients NCT03921437 1295 1303 O
who NCT03921437 1304 1307 O
are NCT03921437 1308 1311 O
blind NCT03921437 1312 1317 B-Condition
, NCT03921437 1318 1319 O
have NCT03921437 1320 1324 O
poor NCT03921437 1325 1329 B-Condition
eyesight NCT03921437 1330 1338 I-Condition
, NCT03921437 1339 1340 O
and NCT03921437 1341 1344 B-Or
have NCT03921437 1345 1349 O
difficulty NCT03921437 1350 1360 B-Condition
operating NCT03921437 1361 1370 I-Condition
. NCT03921437 1370 1371 O

Inclusion NCT03929731 0 9 O
Criteria NCT03929731 10 18 O
: NCT03929731 19 20 O

- NCT03929731 24 25 O
Participants NCT03929731 27 39 O
will NCT03929731 40 44 O
have NCT03929731 45 49 O
completed NCT03929731 50 59 O
the NCT03929731 60 63 O
previous NCT03929731 64 72 B-Eq-Comparison
PCV NCT03929731 73 76 B-Procedure
RCTs NCT03929731 77 81 O
: NCT03929731 82 83 O
EVEREST NCT03929731 84 91 O
II NCT03929731 92 94 O
, NCT03929731 95 96 O
PLANET NCT03929731 97 103 O
and NCT03929731 104 107 O
PCV NCT03929731 108 111 B-Procedure
T&amp;E NCT03929731 112 119 O
studies NCT03929731 120 127 O

- NCT03929731 130 131 O
Are NCT03929731 133 136 O
able NCT03929731 137 141 O
to NCT03929731 142 144 O
give NCT03929731 145 149 O
consent NCT03929731 150 157 O
for NCT03929731 158 161 O
this NCT03929731 162 166 O
follow NCT03929731 167 173 O
up NCT03929731 174 176 O
study NCT03929731 177 182 O

Exclusion NCT03929731 183 192 O
Criteria NCT03929731 193 201 O
: NCT03929731 202 203 O

- NCT03929731 207 208 O
No NCT03929731 210 212 O
exclusion NCT03929731 213 222 O
criteria NCT03929731 223 231 O
unless NCT03929731 232 238 O
they NCT03929731 239 243 O
do NCT03929731 244 246 O
not NCT03929731 247 250 O
meet NCT03929731 251 255 O
the NCT03929731 256 259 O
inclusion NCT03929731 260 269 O
criteria NCT03929731 270 278 O

Inclusion NCT03920098 0 9 O
Criteria NCT03920098 10 18 O
: NCT03920098 19 20 O

- NCT03920098 24 25 O
Primipara NCT03920098 27 36 B-Condition
( NCT03920098 37 38 O
no NCT03920098 39 41 B-Negation
previous NCT03920098 42 50 B-Eq-Comparison
pregnancies NCT03920098 51 62 B-Condition
) NCT03920098 63 64 O

- NCT03920098 68 69 O
18 NCT03920098 71 73 B-Eq-Comparison
to NCT03920098 74 76 I-Eq-Comparison
25 NCT03920098 77 79 I-Eq-Comparison
years NCT03920098 80 85 I-Eq-Comparison
of NCT03920098 86 88 O
age NCT03920098 89 92 B-Age

- NCT03920098 95 96 O
Gestation NCT03920098 98 107 B-Observation
< NCT03920098 108 109 B-Eq-Comparison
15 NCT03920098 110 112 I-Eq-Comparison
weeks NCT03920098 113 118 I-Eq-Comparison
at NCT03920098 119 121 B-Temporal-Connection___Temporal-Connection-Type-Value:during
first NCT03920098 122 127 B-Eq-Comparison
prenatal NCT03920098 128 136 B-Condition
visit NCT03920098 137 142 B-Encounter

- NCT03920098 145 146 O
No NCT03920098 148 150 B-Negation
intention NCT03920098 151 160 B-Assertion___Assertion-Type-Value:intention
to NCT03920098 161 163 O
move NCT03920098 164 168 B-Observation
outside NCT03920098 169 176 O
the NCT03920098 177 180 O
city NCT03920098 181 185 O
of NCT03920098 186 188 O
Santiago NCT03920098 189 197 O
in NCT03920098 198 200 O
the NCT03920098 201 204 O
next NCT03920098 205 209 B-Eq-Comparison
to NCT03920098 210 212 I-Eq-Comparison
years NCT03920098 213 218 I-Eq-Comparison

Exclusion NCT03920098 219 228 O
Criteria NCT03920098 229 237 O
: NCT03920098 238 239 O

- NCT03920098 243 244 O
Multipara NCT03920098 246 255 B-Condition

- NCT03920098 258 259 I-Eq-Comparison
Pre NCT03920098 261 264 B-Eq-Comparison
- NCT03920098 265 266 O
existing NCT03920098 267 275 I-Eq-Comparison
cancer NCT03920098 276 282 B-Condition
( NCT03920098 283 284 O
except NCT03920098 285 291 B-Exception
non NCT03920098 292 295 B-Modifier
- NCT03920098 296 297 I-Modifier
melanoma NCT03920098 298 306 I-Modifier
skin NCT03920098 307 311 B-Modifier
cancer NCT03920098 312 318 B-Condition
) NCT03920098 319 320 O

- NCT03920098 324 325 O
Family NCT03920098 327 333 B-Family-Member
history NCT03920098 334 341 I-Family-Member
of NCT03920098 342 344 O
breast NCT03920098 345 351 B-Modifier
cancer NCT03920098 352 358 B-Condition
( NCT03920098 359 360 O
one NCT03920098 361 364 B-Eq-Comparison
first NCT03920098 365 370 B-Modifier
- NCT03920098 371 372 I-Modifier
degree NCT03920098 373 379 I-Modifier
female NCT03920098 380 386 B-Family-Member
relative NCT03920098 387 395 I-Family-Member
diagnosed NCT03920098 396 405 O
with NCT03920098 406 410 O
breast NCT03920098 411 417 B-Modifier
cancer NCT03920098 418 424 B-Condition
) NCT03920098 425 426 O

- NCT03920098 430 431 I-Modifier
High NCT03920098 433 437 B-Modifier
- NCT03920098 438 439 O
risk NCT03920098 440 444 I-Modifier
pregnancy NCT03920098 445 454 B-Condition
according NCT03920098 455 464 O
to NCT03920098 465 467 O
national NCT03920098 468 476 O
guidelines NCT03920098 477 487 O

- NCT03920098 490 491 I-Encounter
During NCT03920098 493 499 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03920098 500 503 O
follow NCT03920098 504 510 B-Encounter
- NCT03920098 511 512 O
up NCT03920098 513 515 I-Encounter
, NCT03920098 516 517 O
pregnant NCT03920098 518 526 B-Condition
women NCT03920098 527 532 O
under NCT03920098 533 538 O
any NCT03920098 539 542 O
treatment NCT03920098 543 552 B-Procedure
that NCT03920098 553 557 O
may NCT03920098 558 561 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920098 562 568 O
the NCT03920098 569 572 O
levels NCT03920098 573 579 O
of NCT03920098 580 582 O
metabolic NCT03920098 583 592 B-Observation
markers NCT03920098 593 600 I-Observation
will NCT03920098 601 605 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03920098 606 608 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03920098 609 617 B-Negation
from NCT03920098 618 622 O
the NCT03920098 623 626 O
analysis NCT03920098 627 635 B-Study

- NCT03920098 638 639 O
Pregnant NCT03920098 641 649 B-Condition
women NCT03920098 650 655 O
with NCT03920098 656 660 B-And
pre NCT03920098 661 664 B-Condition|Condition
- NCT03920098 665 666 I-Condition
eclampsia NCT03920098 667 676 I-Condition
or NCT03920098 677 679 B-Or
with NCT03920098 680 684 O
preterm NCT03920098 685 692 O
birth NCT03920098 693 698 I-Condition
( NCT03920098 699 700 O
less NCT03920098 701 705 B-Eq-Comparison
than NCT03920098 706 710 I-Eq-Comparison
37 NCT03920098 711 713 I-Eq-Comparison
weeks NCT03920098 714 719 I-Eq-Comparison
of NCT03920098 720 722 O
gestational NCT03920098 723 734 B-Observation
age NCT03920098 735 738 I-Observation
) NCT03920098 739 740 O
will NCT03920098 741 745 O
be NCT03920098 746 748 O
also NCT03920098 749 753 O
excluded NCT03920098 754 762 B-Negation

Inclusion NCT03926403 0 9 O
Criteria NCT03926403 10 18 O
: NCT03926403 19 20 O

- NCT03926403 24 25 O
Patient NCT03926403 27 34 O
treated NCT03926403 35 42 B-Eq-Comparison
under NCT03926403 43 48 O
local NCT03926403 49 54 B-Procedure
anaesthesia NCT03926403 55 66 I-Procedure
in NCT03926403 67 69 O
the NCT03926403 70 73 O
Maxillo NCT03926403 74 81 O
Facial NCT03926403 82 88 O
Surgery NCT03926403 89 96 O
department NCT03926403 97 107 O
with NCT03926403 108 112 O
ultra NCT03926403 113 118 B-Procedure
- NCT03926403 119 120 I-Procedure
short NCT03926403 121 126 I-Procedure
circuit NCT03926403 127 134 I-Procedure

- NCT03926403 137 138 O
Patient NCT03926403 140 147 O
undergoing NCT03926403 148 158 B-Eq-Comparison
face NCT03926403 159 163 B-Modifier
surgery NCT03926403 164 171 B-Procedure

- NCT03926403 174 175 O
Patient NCT03926403 177 184 O
who NCT03926403 185 188 O
has NCT03926403 189 192 O
received NCT03926403 193 201 B-Eq-Comparison
appropriate NCT03926403 202 213 O
information NCT03926403 214 225 O
and NCT03926403 226 229 O
has NCT03926403 230 233 O
provided NCT03926403 234 242 O
informed NCT03926403 243 251 O
consent NCT03926403 252 259 O

- NCT03926403 262 263 O
Adult NCT03926403 265 270 O
patient NCT03926403 271 278 O
≥ NCT03926403 279 280 B-Eq-Comparison
18 NCT03926403 281 283 I-Eq-Comparison
years NCT03926403 284 289 I-Eq-Comparison
old NCT03926403 290 293 B-Age

- NCT03926403 296 297 O
Patient NCT03926403 299 306 O
with NCT03926403 307 311 O
a NCT03926403 312 313 O
score NCT03926403 314 319 O
of NCT03926403 320 322 O
≥ NCT03926403 323 324 B-Eq-Comparison
46 NCT03926403 325 327 I-Eq-Comparison
on NCT03926403 328 330 O
the NCT03926403 331 334 O
initial NCT03926403 335 342 B-Eq-Comparison
anxiety NCT03926403 343 350 B-Observation
self NCT03926403 351 355 I-Observation
- NCT03926403 356 357 I-Observation
assessment NCT03926403 358 368 I-Observation
questionnaire NCT03926403 369 382 I-Observation

Exclusion NCT03926403 383 392 O
Criteria NCT03926403 393 401 O
: NCT03926403 402 403 O

- NCT03926403 407 408 O
Patient NCT03926403 410 417 O
under NCT03926403 418 423 O
general NCT03926403 424 431 B-Procedure
anaesthesia NCT03926403 432 443 I-Procedure

- NCT03926403 446 447 O
Patients NCT03926403 449 457 O
treated NCT03926403 458 465 B-Eq-Comparison
in NCT03926403 466 468 O
conventional NCT03926403 469 481 O
inpatient NCT03926403 482 491 B-Encounter
care NCT03926403 492 496 I-Encounter
or NCT03926403 497 499 B-Or
in NCT03926403 500 502 O
the NCT03926403 503 506 O
traditional NCT03926403 507 518 O
ambulatory NCT03926403 519 529 B-Encounter
circuit NCT03926403 530 537 I-Encounter

- NCT03926403 540 541 O
Patient NCT03926403 543 550 O
under NCT03926403 551 556 B-Observation
guardianship NCT03926403 557 569 I-Observation
or NCT03926403 570 572 B-Or
trusteeship NCT03926403 573 584 B-Observation

- NCT03926403 587 588 O
Minor NCT03926403 590 595 O
patient NCT03926403 596 603 O
< NCT03926403 604 605 B-Eq-Comparison
18 NCT03926403 606 608 I-Eq-Comparison
years NCT03926403 609 614 I-Eq-Comparison
of NCT03926403 615 617 O
age NCT03926403 618 621 B-Age

- NCT03926403 624 625 O
Patient NCT03926403 627 634 O
who NCT03926403 635 638 O
has NCT03926403 639 642 O
not NCT03926403 643 646 O
provided NCT03926403 647 655 O
informed NCT03926403 656 664 O
consent NCT03926403 665 672 O
or NCT03926403 673 675 O
who NCT03926403 676 679 O
can NCT03926403 680 683 O
not NCT03926403 683 686 O
submit NCT03926403 687 693 O
to NCT03926403 694 696 O
the NCT03926403 697 700 O
study NCT03926403 701 706 O
protocol NCT03926403 707 715 O

- NCT03926403 718 719 O
Patient NCT03926403 721 728 O
suffering NCT03926403 729 738 O
from NCT03926403 739 743 O
cognitive NCT03926403 744 753 B-Condition
disorders NCT03926403 754 763 I-Condition
( NCT03926403 764 765 O
ex NCT03926403 766 768 O
: NCT03926403 769 770 O
Alzheimer NCT03926403 771 780 B-Condition
's NCT03926403 780 782 O
disease NCT03926403 783 790 I-Condition
) NCT03926403 791 792 O

- NCT03926403 796 797 O
Patients NCT03926403 799 807 O
who NCT03926403 808 811 O
are NCT03926403 812 815 O
deaf NCT03926403 816 820 B-Condition
or NCT03926403 821 823 B-Or
hearing NCT03926403 824 831 B-Condition
- NCT03926403 832 833 I-Condition
impaired NCT03926403 834 842 I-Condition

Inclusion NCT03922659 0 9 O
Criteria NCT03922659 10 18 O
: NCT03922659 19 20 O

- NCT03922659 24 25 O
Diagnosis NCT03922659 27 36 O
as NCT03922659 37 39 O
heroin NCT03922659 40 46 B-Condition
dependence NCT03922659 47 57 I-Condition
according NCT03922659 58 67 O
to NCT03922659 68 70 O
DSM NCT03922659 71 74 O
- NCT03922659 75 76 O
IV NCT03922659 77 79 O
criteria NCT03922659 80 88 O

- NCT03922659 91 92 O
No NCT03922659 94 96 O
definite NCT03922659 97 105 O
history NCT03922659 106 113 B-Eq-Comparison
of NCT03922659 114 116 O
neurological NCT03922659 117 129 B-Condition
diseases NCT03922659 130 138 I-Condition
and NCT03922659 139 142 B-Or
psychological NCT03922659 143 156 B-Condition
problems NCT03922659 157 165 I-Condition

- NCT03922659 168 169 O
Volunteer NCT03922659 171 180 O
to NCT03922659 181 183 O
participate NCT03922659 184 195 O
the NCT03922659 196 199 O
study NCT03922659 200 205 O
, NCT03922659 206 207 O
cooperate NCT03922659 208 217 O
to NCT03922659 218 220 O
be NCT03922659 221 223 O
followed NCT03922659 224 232 O
up NCT03922659 233 235 O

Exclusion NCT03922659 236 245 O
Criteria NCT03922659 246 254 O
: NCT03922659 255 256 O

- NCT03922659 260 261 O
Acute NCT03922659 263 268 O
withdrawal NCT03922659 269 279 B-Condition
state NCT03922659 280 285 I-Condition
and NCT03922659 286 289 O
CIWA NCT03922659 290 294 B-Observation
score NCT03922659 295 300 O
> NCT03922659 301 302 B-Eq-Comparison
9 NCT03922659 303 304 I-Eq-Comparison

- NCT03922659 308 309 O
With NCT03922659 311 315 O
other NCT03922659 316 321 B-Other
neurological NCT03922659 322 334 B-Condition
diseases NCT03922659 335 343 I-Condition
and NCT03922659 344 347 B-Or
psychological NCT03922659 348 361 B-Condition
problems NCT03922659 362 370 I-Condition

- NCT03922659 373 374 O
With NCT03922659 376 380 O
ever NCT03922659 381 385 B-Eq-Comparison
brain NCT03922659 386 391 B-Modifier
trauma NCT03922659 392 398 B-Condition
and NCT03922659 399 402 B-Or
damage NCT03922659 403 409 B-Condition

- NCT03922659 412 413 O
With NCT03922659 415 419 O
other NCT03922659 420 425 B-Other
psychological NCT03922659 426 439 B-Drug
medications NCT03922659 440 451 I-Drug
or NCT03922659 452 454 B-Or
other NCT03922659 455 460 B-Other
substance NCT03922659 461 470 B-Condition
dependence NCT03922659 471 481 I-Condition

- NCT03922659 484 485 O
With NCT03922659 487 491 O
other NCT03922659 492 497 B-Other
contraindications NCT03922659 498 515 B-Contraindication
to NCT03922659 516 518 O
have NCT03922659 519 523 O
transcranial NCT03922659 524 536 B-Procedure
magnetic NCT03922659 537 545 I-Procedure
stimulation NCT03922659 546 557 I-Procedure

Inclusion NCT03929718 0 9 O
Criteria NCT03929718 10 18 O
: NCT03929718 19 20 O

- NCT03929718 24 25 O
diagnosis NCT03929718 27 36 O
of NCT03929718 37 39 O
typical NCT03929718 40 47 B-Modifier
AFL NCT03929718 48 51 B-Condition
confirmed NCT03929718 52 61 O
by NCT03929718 62 64 O
12 NCT03929718 65 67 B-Procedure
- NCT03929718 68 69 I-Procedure
lead NCT03929718 70 74 I-Procedure
ECG NCT03929718 75 78 I-Procedure

- NCT03929718 81 82 O
no NCT03929718 84 86 B-Negation
documented NCT03929718 87 97 O
AF NCT03929718 98 100 B-Condition
on NCT03929718 101 103 O
ECG NCT03929718 104 107 B-Procedure
, NCT03929718 108 109 O
ambulatory NCT03929718 110 120 B-Procedure
monitor NCT03929718 121 128 I-Procedure
, NCT03929718 129 130 O
pacemaker NCT03929718 131 140 B-Procedure
or NCT03929718 141 143 B-Or
ICD NCT03929718 144 147 B-Procedure
at NCT03929718 148 150 O
any NCT03929718 151 154 B-Eq-Comparison
time NCT03929718 155 159 I-Eq-Comparison

- NCT03929718 162 163 O
scheduled NCT03929718 165 174 B-Eq-Comparison
to NCT03929718 175 177 O
undergo NCT03929718 178 185 O
catheter NCT03929718 186 194 B-Procedure
ablation NCT03929718 195 203 I-Procedure
of NCT03929718 204 206 O
the NCT03929718 207 210 O
CTI NCT03929718 211 214 B-Modifier
for NCT03929718 215 218 O
treatment NCT03929718 219 228 B-Procedure
of NCT03929718 229 231 O
AFL NCT03929718 232 235 B-Condition

- NCT03929718 238 239 O
history NCT03929718 241 248 B-Eq-Comparison
of NCT03929718 249 251 O
hypertension NCT03929718 252 264 B-Condition
( NCT03929718 265 266 O
HTN NCT03929718 267 270 B-Condition
) NCT03929718 271 272 O
or NCT03929718 273 275 B-Or
heart NCT03929718 276 281 B-Condition
failure NCT03929718 282 289 I-Condition
( NCT03929718 290 291 O
HF NCT03929718 292 294 B-Condition
) NCT03929718 295 296 O
( NCT03929718 297 298 O
reduced NCT03929718 299 306 B-Modifier
or NCT03929718 307 309 B-Or
preserved NCT03929718 310 319 B-Modifier
systolic NCT03929718 320 328 B-Condition
function NCT03929718 329 337 I-Condition
) NCT03929718 338 339 O

Exclusion NCT03929718 341 350 O
Criteria NCT03929718 351 359 O
: NCT03929718 360 361 O

- NCT03929718 365 366 O
history NCT03929718 368 375 B-Eq-Comparison
of NCT03929718 376 378 O
known NCT03929718 379 384 O
AF NCT03929718 385 387 B-Condition
episodes NCT03929718 388 396 O

- NCT03929718 399 400 O
previous NCT03929718 402 410 B-Eq-Comparison
CTI NCT03929718 411 414 B-Modifier
or NCT03929718 415 417 B-Or
PVI NCT03929718 418 421 B-Modifier
ablation NCT03929718 422 430 B-Procedure
procedure NCT03929718 431 440 I-Procedure

- NCT03929718 443 444 O
other NCT03929718 446 451 B-Other
SVT NCT03929718 452 455 B-Condition
mechanisms NCT03929718 456 466 I-Condition
demonstrated NCT03929718 467 479 O
( NCT03929718 480 481 O
AVNRT NCT03929718 482 487 B-Condition
, NCT03929718 488 489 O
AVRT NCT03929718 490 494 B-Condition
or NCT03929718 495 497 B-Or
accessory NCT03929718 498 507 B-Condition
pathways NCT03929718 508 516 I-Condition
) NCT03929718 517 518 O

- NCT03929718 522 523 O
amiodarone NCT03929718 525 535 B-Drug
usage NCT03929718 536 541 O
within NCT03929718 542 548 B-Eq-Comparison
the NCT03929718 549 552 I-Eq-Comparison
past NCT03929718 553 557 I-Eq-Comparison
3 NCT03929718 558 559 I-Eq-Comparison
months NCT03929718 560 566 I-Eq-Comparison
, NCT03929718 567 568 O

- NCT03929718 572 573 O
unwillingness NCT03929718 575 588 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03929718 589 591 O
participate NCT03929718 592 603 O
or NCT03929718 604 606 O
undergo NCT03929718 607 614 O
insertable NCT03929718 615 625 B-Procedure
monitor NCT03929718 626 633 I-Procedure
implantation NCT03929718 634 646 I-Procedure

- NCT03929718 649 650 O
hyperkalemia NCT03929718 652 664 B-Condition
( NCT03929718 665 666 O
potassium NCT03929718 667 676 B-Observation
> NCT03929718 677 678 B-Eq-Comparison
5.0 NCT03929718 679 682 I-Eq-Comparison
mEq NCT03929718 683 686 I-Eq-Comparison
/ NCT03929718 687 688 I-Eq-Comparison
L NCT03929718 689 690 I-Eq-Comparison
) NCT03929718 691 692 O

- NCT03929718 696 697 O
severe NCT03929718 699 705 O
renal NCT03929718 706 711 B-Condition
disease NCT03929718 712 719 I-Condition
( NCT03929718 720 721 O
Cr NCT03929718 722 724 B-Observation
> NCT03929718 725 726 B-Eq-Comparison|Eq-Comparison
2.5 NCT03929718 727 730 I-Eq-Comparison
mg NCT03929718 731 733 I-Eq-Comparison|Eq-Comparison
/ NCT03929718 734 735 I-Eq-Comparison|Eq-Comparison
dL NCT03929718 736 738 I-Eq-Comparison|Eq-Comparison
[ NCT03929718 739 740 O
men NCT03929718 741 744 O
] NCT03929718 745 746 O
, NCT03929718 748 749 O
> NCT03929718 750 751 O
2.0 NCT03929718 752 755 I-Eq-Comparison
mg NCT03929718 756 758 O
/ NCT03929718 759 760 I-Eq-Comparison
dL NCT03929718 761 763 O
[ NCT03929718 764 765 O
women NCT03929718 766 771 O
, NCT03929718 772 773 O
GFR NCT03929718 774 777 B-Observation
< NCT03929718 778 779 B-Eq-Comparison
30 NCT03929718 780 782 I-Eq-Comparison
mL NCT03929718 783 785 I-Eq-Comparison
/ NCT03929718 786 787 O
min NCT03929718 788 791 I-Eq-Comparison
/ NCT03929718 792 793 O
1.73 NCT03929718 794 798 I-Eq-Comparison
m2 NCT03929718 799 801 I-Eq-Comparison
) NCT03929718 802 803 O

- NCT03929718 807 808 O
life NCT03929718 810 814 B-Observation
expectancy NCT03929718 815 825 I-Observation
< NCT03929718 826 827 B-Eq-Comparison
18 NCT03929718 828 830 I-Eq-Comparison
months NCT03929718 831 837 I-Eq-Comparison

- NCT03929718 840 841 O
prior NCT03929718 843 848 B-Eq-Comparison
intolerance NCT03929718 849 860 B-Condition
to NCT03929718 861 863 O
treatment NCT03929718 864 873 B-Procedure
with NCT03929718 874 878 O
an NCT03929718 879 881 I-Drug
aldosterone NCT03929718 882 893 B-Drug
antagonist NCT03929718 894 904 O

- NCT03929718 907 908 O
current NCT03929718 910 917 B-Eq-Comparison
treatment NCT03929718 918 927 B-Procedure
with NCT03929718 928 932 O
an NCT03929718 933 935 I-Drug
aldosterone NCT03929718 936 947 B-Drug
antagonist NCT03929718 948 958 O

- NCT03929718 961 962 O
need NCT03929718 964 968 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929718 969 972 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03929718 973 982 B-Procedure
with NCT03929718 983 987 O
a NCT03929718 988 989 O
class NCT03929718 990 995 B-Eq-Comparison
I NCT03929718 996 997 I-Eq-Comparison
or NCT03929718 998 1000 I-Eq-Comparison
III NCT03929718 1001 1004 I-Eq-Comparison
AAD NCT03929718 1005 1008 B-Drug
for NCT03929718 1009 1012 O
another NCT03929718 1013 1020 B-Other
indication NCT03929718 1021 1031 B-Indication

- NCT03929718 1034 1035 O
operative NCT03929718 1037 1046 B-Modifier
AFL NCT03929718 1047 1050 B-Condition
( NCT03929718 1051 1052 O
occurring NCT03929718 1053 1062 O
within NCT03929718 1063 1069 B-Eq-Comparison
30 NCT03929718 1070 1072 I-Eq-Comparison
days NCT03929718 1073 1077 I-Eq-Comparison
of NCT03929718 1078 1080 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03929718 1081 1088 B-Procedure
) NCT03929718 1089 1090 O
that NCT03929718 1091 1095 O
is NCT03929718 1096 1098 O
expected NCT03929718 1099 1107 O
to NCT03929718 1108 1110 O
resolve NCT03929718 1111 1118 O

- NCT03929718 1121 1122 O
presence NCT03929718 1124 1132 O
of NCT03929718 1133 1135 O
a NCT03929718 1136 1137 O
cardiac NCT03929718 1138 1145 B-Procedure
rhythm NCT03929718 1146 1152 I-Procedure
device NCT03929718 1153 1159 I-Procedure
( NCT03929718 1160 1161 O
pacemaker NCT03929718 1162 1171 B-Procedure
or NCT03929718 1172 1174 B-Or
ICD NCT03929718 1175 1178 B-Procedure
) NCT03929718 1179 1180 O
capable NCT03929718 1181 1188 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03929718 1189 1191 O
AF NCT03929718 1192 1194 B-Procedure
monitoring NCT03929718 1195 1205 I-Procedure

- NCT03929718 1208 1209 O
currently NCT03929718 1211 1220 B-Eq-Comparison
pregnant NCT03929718 1221 1229 B-Condition
or NCT03929718 1230 1232 B-Or
nursing NCT03929718 1233 1240 B-Condition
a NCT03929718 1241 1242 I-Condition
child NCT03929718 1243 1248 I-Condition

- NCT03929718 1251 1252 O
unwilling NCT03929718 1254 1263 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03929718 1264 1267 B-Negation
to NCT03929718 1268 1270 O
become NCT03929718 1271 1277 O
pregnant NCT03929718 1278 1286 B-Condition
and NCT03929718 1287 1290 B-And
to NCT03929718 1291 1293 O
use NCT03929718 1294 1297 O
birth NCT03929718 1298 1303 B-Procedure
control NCT03929718 1304 1311 I-Procedure
while NCT03929718 1312 1317 B-Temporal-Connection___Temporal-Connection-Type-Value:during
taking NCT03929718 1318 1324 B-Eq-Comparison
spironolactone NCT03929718 1325 1339 B-Drug

Inclusion NCT03926832 0 9 O
Criteria NCT03926832 10 18 O
: NCT03926832 19 20 O

- NCT03926832 24 25 O
Subjects NCT03926832 27 35 O
with NCT03926832 36 40 O
a NCT03926832 41 42 O
definite NCT03926832 43 51 O
diagnosis NCT03926832 52 61 O
of NCT03926832 62 64 O
sarcoidosis NCT03926832 65 76 B-Condition
according NCT03926832 77 86 O
to NCT03926832 87 89 O
international NCT03926832 90 103 O
ATS NCT03926832 104 107 O
and NCT03926832 108 111 O
WASOG NCT03926832 112 117 O
guideline NCT03926832 118 127 O

Exclusion NCT03926832 128 137 O
Criteria NCT03926832 138 146 O
: NCT03926832 147 148 O

- NCT03926832 152 153 O
Ongoing NCT03926832 155 162 B-Eq-Comparison
CPAP NCT03926832 163 167 B-Procedure
treatment NCT03926832 168 177 I-Procedure

- NCT03926832 180 181 O
Psychiatric NCT03926832 183 194 B-Condition
disorders NCT03926832 195 204 I-Condition

Inclusion NCT03923023 0 9 O
Criteria NCT03923023 10 18 O
: NCT03923023 19 20 O

- NCT03923023 24 25 O
Pregnant NCT03923023 27 35 B-Condition
women NCT03923023 36 41 O
who NCT03923023 42 45 B-And
seek NCT03923023 46 50 B-Assertion___Assertion-Type-Value:intention
Antenatal NCT03923023 51 60 B-Provider
care NCT03923023 61 65 I-Provider
services NCT03923023 66 74 I-Provider
and NCT03923023 75 78 B-And
plan NCT03923023 79 83 B-Assertion___Assertion-Type-Value:intention
to NCT03923023 84 86 I-Assertion___Assertion-Type-Value:intention
deliver NCT03923023 87 94 B-Procedure
in NCT03923023 95 97 O
the NCT03923023 98 101 O
selected NCT03923023 102 110 O
health NCT03923023 111 117 O
facilities NCT03923023 118 128 O

- NCT03923023 131 132 O
Women NCT03923023 134 139 O
who NCT03923023 140 143 O
reside NCT03923023 144 150 O
within NCT03923023 151 157 O
the NCT03923023 158 161 O
larger NCT03923023 162 168 O
catchment NCT03923023 169 178 O
area NCT03923023 179 183 O
of NCT03923023 184 186 O
the NCT03923023 187 190 O
selected NCT03923023 191 199 O
3 NCT03923023 200 201 B-Eq-Comparison
health NCT03923023 202 208 O
facilities NCT03923023 209 219 O

Exclusion NCT03923023 220 229 O
Criteria NCT03923023 230 238 O
: NCT03923023 239 240 O

- NCT03923023 244 245 O
Women NCT03923023 247 252 O
who NCT03923023 253 256 O
reside NCT03923023 257 263 O
outside NCT03923023 264 271 B-Other
the NCT03923023 272 275 O
larger NCT03923023 276 282 O
catchment NCT03923023 283 292 O
area NCT03923023 293 297 O
of NCT03923023 298 300 O
the NCT03923023 301 304 O
health NCT03923023 305 311 O
facilities NCT03923023 312 322 O

- NCT03923023 325 326 O
Women NCT03923023 328 333 O
who NCT03923023 334 337 B-And
have NCT03923023 338 342 O
not NCT03923023 343 346 B-Negation
sought NCT03923023 347 353 B-Assertion___Assertion-Type-Value:intention
antenatal NCT03923023 354 363 B-Provider
care NCT03923023 364 368 I-Provider
services NCT03923023 369 377 I-Provider
in NCT03923023 378 380 O
the NCT03923023 381 384 O
3 NCT03923023 385 386 B-Eq-Comparison
health NCT03923023 387 393 O
facilities NCT03923023 394 404 O
and NCT03923023 405 408 O
have NCT03923023 409 413 O
come NCT03923023 414 418 O
to NCT03923023 419 421 O
only NCT03923023 422 426 O
deliver NCT03923023 427 434 O
there NCT03923023 435 440 O

Inclusion NCT03923751 0 9 O
Criteria NCT03923751 10 18 O
: NCT03923751 19 20 O

- NCT03923751 24 25 O
All NCT03923751 27 30 O
Polish NCT03923751 31 37 O
hospitals NCT03923751 38 47 O
practising NCT03923751 48 58 O
anesthesiology NCT03923751 59 73 O
and NCT03923751 74 77 O
intensive NCT03923751 78 87 O
care NCT03923751 88 92 O
in NCT03923751 93 95 O
the NCT03923751 96 99 O
national NCT03923751 100 108 O
register NCT03923751 109 117 O
of NCT03923751 118 120 O
medical NCT03923751 121 128 O
practices NCT03923751 129 138 O
( NCT03923751 139 140 O
www NCT03923751 141 144 O
. NCT03923751 144 145 O
rpwdl NCT03923751 146 151 O
. NCT03923751 151 152 O
csioz NCT03923751 153 158 O
. NCT03923751 158 159 O
gov NCT03923751 160 163 O
. NCT03923751 163 164 O
pl NCT03923751 165 167 O
) NCT03923751 168 169 O

Exclusion NCT03923751 171 180 O
Criteria NCT03923751 181 189 O
: NCT03923751 190 191 O

- NCT03923751 195 196 O
Hospitals NCT03923751 198 207 O
and NCT03923751 208 211 O
medical NCT03923751 212 219 O
practices NCT03923751 220 229 O
not NCT03923751 230 233 O
practising NCT03923751 234 244 O
anesthesiology NCT03923751 245 259 O
or NCT03923751 260 262 O
intensive NCT03923751 263 272 O
care NCT03923751 273 277 O

Inclusion NCT03923816 0 9 O
Criteria NCT03923816 10 18 O
: NCT03923816 19 20 O

- NCT03923816 24 25 O
patients NCT03923816 27 35 O
> NCT03923816 36 37 B-Eq-Comparison
18 NCT03923816 38 40 I-Eq-Comparison
years NCT03923816 41 46 I-Eq-Comparison
old NCT03923816 47 50 B-Age
, NCT03923816 51 52 O
undergoing NCT03923816 53 63 B-Eq-Comparison
elective NCT03923816 64 72 O
hepatobiliary NCT03923816 73 86 B-Procedure
surgery NCT03923816 87 94 I-Procedure
under NCT03923816 95 100 O
general NCT03923816 101 108 B-Procedure
anesthesia NCT03923816 109 119 I-Procedure
and NCT03923816 120 123 B-And
American NCT03923816 124 132 B-Condition
Society NCT03923816 133 140 I-Condition
of NCT03923816 141 143 I-Condition
Anesthesiologists NCT03923816 144 161 I-Condition
grade NCT03923816 162 167 B-Eq-Comparison
II NCT03923816 168 170 I-Eq-Comparison
. NCT03923816 170 171 O

Exclusion NCT03923816 173 182 O
Criteria NCT03923816 183 191 O
: NCT03923816 192 193 O

- NCT03923816 197 198 O
1 NCT03923816 200 201 O
- NCT03923816 202 203 O
patient NCT03923816 204 211 O
refusal NCT03923816 212 219 O
. NCT03923816 219 220 O
2 NCT03923816 222 223 O
- NCT03923816 224 225 O
psychiatric NCT03923816 226 237 B-Condition
disorders NCT03923816 238 247 I-Condition
. NCT03923816 247 248 O
3 NCT03923816 250 251 O
- NCT03923816 252 253 O
pregnancy NCT03923816 254 263 B-Condition
and NCT03923816 264 267 B-And
lactation NCT03923816 268 277 B-Condition
. NCT03923816 277 278 O
4 NCT03923816 280 281 O
- NCT03923816 282 283 O
preexisting NCT03923816 284 295 B-Eq-Comparison
neurological NCT03923816 296 308 B-Condition
dysfunction NCT03923816 309 320 I-Condition
( NCT03923816 321 322 O
history NCT03923816 323 330 B-Eq-Comparison
of NCT03923816 331 333 O
cerebrovascular NCT03923816 334 349 B-Condition
stroke NCT03923816 350 356 I-Condition
CVS NCT03923816 357 360 B-Condition
) NCT03923816 361 362 O
5 NCT03923816 363 364 O
- NCT03923816 365 366 O
metastatic NCT03923816 367 377 B-Modifier
cancer NCT03923816 378 384 B-Condition
. NCT03923816 384 385 O

6 NCT03923816 392 393 O
- NCT03923816 394 395 O
Inflammatory NCT03923816 396 408 B-Condition
bowel NCT03923816 409 414 I-Condition
disease NCT03923816 415 422 I-Condition
. NCT03923816 422 423 O
7 NCT03923816 425 426 O
- NCT03923816 427 428 O
Diabetes NCT03923816 429 437 B-Condition
mellitus NCT03923816 438 446 I-Condition
. NCT03923816 446 447 O
8 NCT03923816 449 450 O
- NCT03923816 451 452 O
Renal NCT03923816 453 458 B-Condition
insufficiency NCT03923816 459 472 I-Condition
( NCT03923816 473 474 O
serum NCT03923816 475 480 B-Observation
creatinine NCT03923816 481 491 I-Observation
level NCT03923816 492 497 I-Eq-Comparison|Observation
more NCT03923816 498 502 B-Eq-Comparison
than NCT03923816 503 507 I-Eq-Comparison
180 NCT03923816 508 511 I-Eq-Comparison
μmol NCT03923816 512 516 I-Eq-Comparison
/ NCT03923816 517 518 I-Eq-Comparison
l NCT03923816 519 520 O
) NCT03923816 521 522 O
. NCT03923816 523 524 O
9 NCT03923816 526 527 O
- NCT03923816 528 529 O
unexpected NCT03923816 530 540 B-Assertion___Assertion-Type-Value:hypothetical
intraoperative NCT03923816 541 555 B-Condition
findings NCT03923816 556 564 I-Condition
( NCT03923816 565 566 O
inoperable NCT03923816 567 577 O
) NCT03923816 578 579 O
. NCT03923816 580 581 O
10 NCT03923816 583 585 O
- NCT03923816 586 587 O
accidental NCT03923816 588 598 B-Modifier
massive NCT03923816 599 606 I-Modifier
intraoperative NCT03923816 607 621 B-Condition
hemorrhage NCT03923816 622 632 I-Condition
. NCT03923816 632 633 O

Inclusion NCT03926013 0 9 O
Criteria NCT03926013 10 18 O
: NCT03926013 19 20 O

- NCT03926013 24 25 O
Histology NCT03926013 27 36 O
: NCT03926013 37 38 O
Part NCT03926013 39 43 O
1 NCT03926013 44 45 O
: NCT03926013 46 47 O
Metastatic NCT03926013 48 58 B-Modifier
castration NCT03926013 59 69 I-Modifier
- NCT03926013 70 71 I-Modifier
resistant NCT03926013 72 81 I-Modifier
prostate NCT03926013 82 90 I-Modifier
cancer NCT03926013 91 97 B-Condition
( NCT03926013 98 99 O
mCRPC NCT03926013 100 105 B-Condition
) NCT03926013 106 107 O
with NCT03926013 108 112 B-And
histologic NCT03926013 113 123 B-Procedure
confirmation NCT03926013 124 136 O
of NCT03926013 137 139 O
adenocarcinoma NCT03926013 140 154 B-Condition
. NCT03926013 154 155 O
Adenocarcinoma NCT03926013 157 171 B-Condition
with NCT03926013 172 176 O
small NCT03926013 177 182 B-Modifier
- NCT03926013 183 184 I-Modifier
cell NCT03926013 185 189 I-Modifier
or NCT03926013 190 192 B-Or
neuroendocrine NCT03926013 193 207 B-Modifier
features NCT03926013 208 216 O
is NCT03926013 217 219 O
allowed NCT03926013 220 227 O
. NCT03926013 227 228 O
mCRPC NCT03926013 230 235 B-Condition
is NCT03926013 236 238 O
defined NCT03926013 239 246 O
by NCT03926013 247 249 O
prostate NCT03926013 250 258 O
Cancer NCT03926013 259 265 O
Working NCT03926013 266 273 O
Group NCT03926013 274 279 O
( NCT03926013 280 281 O
PCWG NCT03926013 282 286 O
) NCT03926013 287 288 O
3 NCT03926013 289 290 O
criteria NCT03926013 291 299 O
. NCT03926013 299 300 O
Part NCT03926013 302 306 O
2 NCT03926013 307 308 O
: NCT03926013 309 310 O
mCRPC NCT03926013 311 316 B-Condition
as NCT03926013 317 319 O
defined NCT03926013 320 327 O
above NCT03926013 328 333 O
or NCT03926013 334 336 B-Or
pathologically NCT03926013 337 351 B-Procedure
confirmed NCT03926013 352 361 O
metastatic NCT03926013 362 372 B-Modifier
renal NCT03926013 373 378 I-Modifier
cell NCT03926013 379 383 I-Modifier
carcinoma NCT03926013 384 393 B-Condition
( NCT03926013 394 395 O
RCC NCT03926013 396 399 B-Condition
) NCT03926013 400 401 O
as NCT03926013 402 404 O
defined NCT03926013 405 412 O
by NCT03926013 413 415 O
world NCT03926013 416 421 O
health NCT03926013 422 428 O
organization NCT03926013 429 441 O
( NCT03926013 442 443 O
WHO NCT03926013 444 447 O
) NCT03926013 448 449 O

2016 NCT03926013 456 460 O
Classifications NCT03926013 461 476 O

- NCT03926013 479 480 O
Measurable NCT03926013 482 492 B-Modifier
or NCT03926013 493 495 B-Or
evaluable NCT03926013 496 505 B-Modifier
disease NCT03926013 506 513 B-Condition
: NCT03926013 514 515 O
Part NCT03926013 516 520 O
1 NCT03926013 521 522 O
: NCT03926013 523 524 O
Either NCT03926013 525 531 O
measurable NCT03926013 532 542 B-Modifier
or NCT03926013 543 545 B-Or
evaluable NCT03926013 546 555 B-Modifier
disease NCT03926013 556 563 B-Condition
for NCT03926013 564 567 O
prostate NCT03926013 568 576 B-Modifier
cancer NCT03926013 577 583 B-Condition
. NCT03926013 583 584 O
Part NCT03926013 586 590 O
2 NCT03926013 591 592 O
: NCT03926013 593 594 O
At NCT03926013 595 597 B-Eq-Comparison
least NCT03926013 598 603 I-Eq-Comparison
one NCT03926013 604 607 I-Eq-Comparison
measurable NCT03926013 608 618 O
lesion NCT03926013 619 625 B-Condition
as NCT03926013 626 628 O
per NCT03926013 629 632 O
RECIST NCT03926013 633 639 O
v1.1 NCT03926013 640 644 O
. NCT03926013 644 645 O

- NCT03926013 649 650 O
Evidence NCT03926013 652 660 O
of NCT03926013 661 663 O
disease NCT03926013 664 671 B-Condition
progression NCT03926013 672 683 I-Condition
on NCT03926013 684 686 O
prior NCT03926013 687 692 B-Eq-Comparison
therapy NCT03926013 693 700 B-Procedure
that NCT03926013 701 705 O
requires NCT03926013 706 714 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03926013 715 716 O
new NCT03926013 717 720 O
line NCT03926013 721 725 O
of NCT03926013 726 728 O
treatment NCT03926013 729 738 B-Procedure

- NCT03926013 741 742 O
Participants NCT03926013 744 756 O
with NCT03926013 757 761 O
accessible NCT03926013 762 772 O
lesions NCT03926013 773 780 B-Condition
enrolled NCT03926013 781 789 O
in NCT03926013 790 792 O
selected NCT03926013 793 801 O
pharmacokinetic NCT03926013 802 817 O
( NCT03926013 818 819 O
PK NCT03926013 820 822 O
) NCT03926013 823 824 O
/ NCT03926013 826 827 O
pharmacodynamics NCT03926013 828 844 O
( NCT03926013 845 846 O
PD NCT03926013 847 849 O
) NCT03926013 850 851 O
cohorts NCT03926013 852 859 O
and NCT03926013 860 863 O
in NCT03926013 864 866 O
Part NCT03926013 867 871 O
2 NCT03926013 872 873 O
must NCT03926013 874 878 O
agree NCT03926013 879 884 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926013 885 887 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03926013 888 895 O
the NCT03926013 896 899 O
mandatory NCT03926013 900 909 O
fresh NCT03926013 910 915 B-Modifier
tumor NCT03926013 916 921 I-Modifier
biopsies NCT03926013 922 930 B-Procedure
, NCT03926013 931 932 O
unless NCT03926013 933 939 B-Exception
collection NCT03926013 940 950 O
of NCT03926013 951 953 O
the NCT03926013 954 957 O
biopsy NCT03926013 958 964 B-Procedure
presents NCT03926013 965 973 O
a NCT03926013 974 975 O
safety NCT03926013 976 982 O
risk NCT03926013 983 987 B-Risk

Exclusion NCT03926013 988 997 O
Criteria NCT03926013 998 1006 O
: NCT03926013 1007 1008 O

- NCT03926013 1012 1013 O
At NCT03926013 1015 1017 B-Eq-Comparison
least NCT03926013 1018 1023 I-Eq-Comparison
2 NCT03926013 1024 1025 I-Eq-Comparison
weeks NCT03926013 1026 1031 I-Eq-Comparison
between NCT03926013 1032 1039 B-Temporal-Connection___Temporal-Connection-Type-Value:after
prior NCT03926013 1040 1045 B-Eq-Comparison
anticancer NCT03926013 1046 1056 B-Procedure
treatment NCT03926013 1057 1066 I-Procedure
( NCT03926013 1067 1068 O
including NCT03926013 1069 1078 O
radiotherapy NCT03926013 1079 1091 B-Procedure
) NCT03926013 1092 1093 O
discontinuation NCT03926013 1094 1109 O
and NCT03926013 1110 1113 O
the NCT03926013 1114 1117 O
first NCT03926013 1118 1123 B-Eq-Comparison
dose NCT03926013 1124 1128 O
of NCT03926013 1129 1131 O
study NCT03926013 1132 1137 B-Study
drug NCT03926013 1138 1142 B-Drug
, NCT03926013 1143 1144 O
and NCT03926013 1145 1148 O
toxicities NCT03926013 1149 1159 B-Observation
have NCT03926013 1160 1164 O
returned NCT03926013 1165 1173 O
to NCT03926013 1174 1176 I-Eq-Comparison
Grade NCT03926013 1177 1182 B-Eq-Comparison
less NCT03926013 1183 1187 I-Eq-Comparison
than NCT03926013 1188 1192 I-Eq-Comparison
or NCT03926013 1193 1195 I-Eq-Comparison|Or
equal NCT03926013 1196 1201 I-Eq-Comparison
to NCT03926013 1202 1204 O
( NCT03926013 1205 1206 I-Eq-Comparison
< NCT03926013 1208 1209 I-Eq-Comparison
= NCT03926013 1211 1212 I-Eq-Comparison
) NCT03926013 1214 1215 I-Eq-Comparison
1 NCT03926013 1216 1217 I-Eq-Comparison
or NCT03926013 1218 1220 O
baseline NCT03926013 1221 1229 B-Study

- NCT03926013 1232 1233 I-Drug
Prior NCT03926013 1235 1240 B-Eq-Comparison
treatment NCT03926013 1241 1250 B-Procedure
with NCT03926013 1251 1255 O
prostate NCT03926013 1256 1264 B-Drug
- NCT03926013 1265 1266 O
specific NCT03926013 1267 1275 I-Drug
membrane NCT03926013 1276 1284 I-Drug
antigen NCT03926013 1285 1292 I-Drug
( NCT03926013 1293 1294 O
PSMA NCT03926013 1295 1299 B-Drug|Immunization
) NCT03926013 1300 1301 O
- NCT03926013 1303 1304 I-Immunization
targeted NCT03926013 1305 1313 I-Immunization
therapy NCT03926013 1314 1321 O
except NCT03926013 1322 1328 B-Exception
for NCT03926013 1329 1332 O
PSMA NCT03926013 1333 1337 O
- NCT03926013 1338 1339 O
targeted NCT03926013 1340 1348 O
vaccine NCT03926013 1349 1356 I-Immunization
is NCT03926013 1357 1359 O
permitted NCT03926013 1360 1369 O

- NCT03926013 1372 1373 O
Solid NCT03926013 1375 1380 B-Modifier
organ NCT03926013 1381 1386 I-Modifier|Or|Or
or NCT03926013 1387 1389 O
bone NCT03926013 1390 1394 B-Modifier
marrow NCT03926013 1395 1401 I-Modifier
transplantation NCT03926013 1402 1417 B-Procedure

- NCT03926013 1420 1421 O
Seizure NCT03926013 1423 1430 B-Condition
or NCT03926013 1431 1433 B-Or
known NCT03926013 1434 1439 O
condition NCT03926013 1440 1449 B-Condition
that NCT03926013 1450 1454 O
may NCT03926013 1455 1458 B-Assertion___Assertion-Type-Value:hypothetical
predispose NCT03926013 1459 1469 O
to NCT03926013 1470 1472 O
seizure NCT03926013 1473 1480 B-Condition
or NCT03926013 1481 1483 O
intracranial NCT03926013 1484 1496 B-Condition
masses NCT03926013 1497 1503 I-Condition

- NCT03926013 1506 1507 O
Other NCT03926013 1509 1514 B-Other
active NCT03926013 1515 1521 B-Eq-Comparison
malignancy NCT03926013 1522 1532 B-Condition
requiring NCT03926013 1533 1542 B-Assertion___Assertion-Type-Value:hypothetical
systemic NCT03926013 1543 1551 B-Modifier
treatment NCT03926013 1552 1561 B-Procedure
< NCT03926013 1562 1563 B-Eq-Comparison
= NCT03926013 1565 1566 I-Eq-Comparison
12 NCT03926013 1567 1569 I-Eq-Comparison
months NCT03926013 1570 1576 I-Eq-Comparison
prior NCT03926013 1577 1582 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926013 1583 1585 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03926013 1586 1596 B-Study

Inclusion NCT03920462 0 9 O
Criteria NCT03920462 10 18 O
: NCT03920462 19 20 O

- NCT03920462 24 25 O
Capacity NCT03920462 27 35 O
to NCT03920462 36 38 O
ride NCT03920462 39 43 O
a NCT03920462 44 45 O
bike NCT03920462 46 50 O

- NCT03920462 53 54 O
Volunteer NCT03920462 56 65 O
without NCT03920462 66 73 B-Negation
a NCT03920462 74 75 O
contraindication NCT03920462 76 92 B-Contraindication
to NCT03920462 93 95 O
moderate NCT03920462 96 104 O
physical NCT03920462 105 113 B-Observation
activity NCT03920462 114 122 I-Observation
or NCT03920462 123 125 B-Or
cycling NCT03920462 126 133 B-Observation
( NCT03920462 134 135 O
acute NCT03920462 136 141 O
coronary NCT03920462 142 150 B-Condition
artery NCT03920462 151 157 I-Condition
disease NCT03920462 158 165 I-Condition
less NCT03920462 166 170 B-Eq-Comparison
than NCT03920462 171 175 I-Eq-Comparison
2 NCT03920462 176 177 I-Eq-Comparison
years NCT03920462 178 183 I-Eq-Comparison
old NCT03920462 184 187 O
, NCT03920462 188 189 O
musculoskeletal NCT03920462 190 205 B-Modifier
problem NCT03920462 206 213 B-Condition
of NCT03920462 214 216 O
the NCT03920462 217 220 O
spine NCT03920462 221 226 B-Modifier
or NCT03920462 227 229 B-Or
lower NCT03920462 230 235 B-Modifier
limbs NCT03920462 236 241 I-Modifier
incompatible NCT03920462 242 254 B-Negation
with NCT03920462 255 259 O
cycling NCT03920462 260 267 B-Observation
) NCT03920462 268 269 O
. NCT03920462 270 271 O

- NCT03920462 275 276 O
weight NCT03920462 278 284 B-Observation
< NCT03920462 285 286 B-Eq-Comparison
125 NCT03920462 287 290 I-Eq-Comparison
kg NCT03920462 291 293 I-Eq-Comparison

- NCT03920462 296 297 O
volunteer NCT03920462 299 308 O
available NCT03920462 309 318 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920462 319 322 I-Assertion___Assertion-Type-Value:hypothetical
an NCT03920462 323 325 O
intervention NCT03920462 326 338 B-Procedure
of NCT03920462 339 341 O
2 NCT03920462 342 343 B-Eq-Comparison
- NCT03920462 344 345 I-Eq-Comparison
3 NCT03920462 346 347 I-Eq-Comparison
hours NCT03920462 348 353 I-Eq-Comparison
twice NCT03920462 354 359 I-Eq-Comparison
a NCT03920462 360 361 I-Eq-Comparison
week NCT03920462 362 366 I-Eq-Comparison
during NCT03920462 367 373 B-Temporal-Connection___Temporal-Connection-Type-Value:during
1 NCT03920462 374 375 B-Eq-Comparison
month NCT03920462 376 381 I-Eq-Comparison
. NCT03920462 381 382 O

Exclusion NCT03920462 384 393 O
Criteria NCT03920462 394 402 O
: NCT03920462 403 404 O

- NCT03920462 408 409 O
Person NCT03920462 411 417 O
deprived NCT03920462 418 426 B-Observation
of NCT03920462 427 429 I-Observation
liberty NCT03920462 430 437 I-Observation
or NCT03920462 438 440 B-Or
legal NCT03920462 441 446 B-Observation
protection NCT03920462 447 457 I-Observation
measure NCT03920462 458 465 O

Inclusion NCT03928002 0 9 O
Criteria NCT03928002 10 18 O
: NCT03928002 19 20 O

- NCT03928002 24 25 O
Patient NCT03928002 27 34 O
≥ NCT03928002 35 36 B-Eq-Comparison
7 NCT03928002 37 38 I-Eq-Comparison
years NCT03928002 39 44 I-Eq-Comparison
old NCT03928002 45 48 B-Age

- NCT03928002 51 52 O
Patient NCT03928002 54 61 O
affiliated NCT03928002 62 72 O
to NCT03928002 73 75 O
a NCT03928002 76 77 O
social NCT03928002 78 84 O
security NCT03928002 85 93 O
system NCT03928002 94 100 O

- NCT03928002 103 104 O
Giving NCT03928002 106 112 O
their NCT03928002 113 118 O
informed NCT03928002 119 127 O
consent NCT03928002 128 135 O
for NCT03928002 136 139 O
the NCT03928002 140 143 O
study NCT03928002 144 149 O
( NCT03928002 150 151 O
adults NCT03928002 152 158 O
, NCT03928002 159 160 O
parents NCT03928002 161 168 O
of NCT03928002 169 171 O
minors NCT03928002 172 178 O
) NCT03928002 179 180 O

- NCT03928002 184 185 O
Patients NCT03928002 187 195 O
with NCT03928002 196 200 O
PAH NCT03928002 201 204 B-Condition
associated NCT03928002 205 215 O
with NCT03928002 216 220 O
congenital NCT03928002 221 231 B-Condition
heart NCT03928002 232 237 I-Condition
disease NCT03928002 238 245 I-Condition
requiring NCT03928002 246 255 B-Assertion___Assertion-Type-Value:hypothetical
cardiac NCT03928002 256 263 B-Procedure
catheterization NCT03928002 264 279 I-Procedure
and NCT03928002 280 283 B-And
2 NCT03928002 284 285 B-Modifier
D NCT03928002 286 287 O
MRI NCT03928002 288 291 B-Procedure
for NCT03928002 292 295 O
the NCT03928002 296 299 O
diagnosis NCT03928002 300 309 O
or NCT03928002 310 312 O
follow NCT03928002 313 319 O
- NCT03928002 320 321 O
up NCT03928002 322 324 O
of NCT03928002 325 327 O
PAH NCT03928002 328 331 B-Condition
associated NCT03928002 332 342 O
with NCT03928002 343 347 O
congenital NCT03928002 348 358 B-Condition
heart NCT03928002 359 364 I-Condition
disease NCT03928002 365 372 I-Condition

Exclusion NCT03928002 373 382 O
Criteria NCT03928002 383 391 O
: NCT03928002 392 393 O

- NCT03928002 397 398 O
➢ NCT03928002 400 401 O
Patient NCT03928002 402 409 O
< NCT03928002 410 411 B-Eq-Comparison
7 NCT03928002 412 413 I-Eq-Comparison
years NCT03928002 414 419 I-Eq-Comparison
old NCT03928002 420 423 B-Age

- NCT03928002 431 432 O
Pregnant NCT03928002 434 442 B-Condition
woman NCT03928002 443 448 O

- NCT03928002 456 457 O
Contraindications NCT03928002 459 476 B-Contraindication
to NCT03928002 477 479 O
MRI NCT03928002 480 483 B-Procedure
( NCT03928002 484 485 O
claustrophobia NCT03928002 486 500 B-Condition
, NCT03928002 501 502 O
intraocular NCT03928002 503 514 B-Modifier
metal NCT03928002 515 520 B-Condition
foreign NCT03928002 521 528 I-Condition
bodies NCT03928002 529 535 I-Condition
, NCT03928002 536 537 O
pacemaker NCT03928002 538 547 B-Procedure
, NCT03928002 548 549 O
neurostimulator NCT03928002 550 565 B-Procedure
, NCT03928002 566 567 O
cochlear NCT03928002 568 576 B-Procedure
implants NCT03928002 577 585 I-Procedure
, NCT03928002 586 587 O
old NCT03928002 588 591 B-Modifier
heart NCT03928002 592 597 B-Procedure
valves NCT03928002 598 604 I-Procedure
) NCT03928002 605 606 O

- NCT03928002 615 616 O
Contraindication NCT03928002 618 634 B-Contraindication
to NCT03928002 635 637 O
gadolinium NCT03928002 638 648 B-Drug
injection NCT03928002 649 658 B-Procedure
( NCT03928002 659 660 O
allergy NCT03928002 661 668 B-Allergy
, NCT03928002 669 670 O
renal NCT03928002 671 676 B-Condition
failure NCT03928002 677 684 I-Condition
with NCT03928002 685 689 B-And
DFG NCT03928002 690 693 B-Observation
< NCT03928002 694 695 B-Eq-Comparison
30 NCT03928002 696 698 I-Eq-Comparison
ml NCT03928002 699 701 I-Eq-Comparison
/ NCT03928002 702 703 I-Eq-Comparison
min NCT03928002 704 707 I-Eq-Comparison
/ NCT03928002 708 709 O
1.73 NCT03928002 710 714 I-Eq-Comparison
m² NCT03928002 715 717 O
) NCT03928002 718 719 O

- NCT03928002 728 729 O
Hemodynamically NCT03928002 731 746 O
unstable NCT03928002 747 755 O
patients NCT03928002 756 764 O

- NCT03928002 772 773 O
Refusal NCT03928002 775 782 O
to NCT03928002 783 785 O
participate NCT03928002 786 797 O

Inclusion NCT03927872 0 9 O
criteria NCT03927872 10 18 O
: NCT03927872 19 20 O

- NCT03927872 24 25 O
CES NCT03927872 27 30 B-Condition
and NCT03927872 31 34 B-Or
non NCT03927872 35 38 B-Negation
- NCT03927872 39 40 O
CES NCT03927872 41 44 B-Condition
diagnosis NCT03927872 45 54 O
was NCT03927872 55 58 O
according NCT03927872 59 68 O
to NCT03927872 69 71 O
Trial NCT03927872 72 77 O
of NCT03927872 78 80 O
Org NCT03927872 81 84 O
10172 NCT03927872 85 90 O
in NCT03927872 91 93 O
Acute NCT03927872 94 99 B-Procedure
Stroke NCT03927872 100 106 I-Procedure
Treatment NCT03927872 107 116 I-Procedure
﴾ NCT03927872 117 118 O
TOAST NCT03927872 119 124 B-Procedure
﴿ NCT03927872 125 126 O
classification NCT03927872 127 141 O
criteria NCT03927872 142 150 O
. NCT03927872 150 151 O

- NCT03927872 155 156 O
non NCT03927872 158 161 B-Negation
- NCT03927872 162 163 O
CES NCT03927872 164 167 B-Condition
were NCT03927872 168 172 O
selected NCT03927872 173 181 O
to NCT03927872 182 184 O
match NCT03927872 185 190 O
patients NCT03927872 191 199 O
with NCT03927872 200 204 O
CES NCT03927872 205 208 B-Condition
regarding NCT03927872 209 218 O
age NCT03927872 219 222 O
and NCT03927872 223 226 O
vascular NCT03927872 227 235 O
risk NCT03927872 236 240 O
factors NCT03927872 241 248 O
as NCT03927872 249 251 O
a NCT03927872 252 253 O
control NCT03927872 254 261 O
group NCT03927872 262 267 O
. NCT03927872 267 268 O

- NCT03927872 272 273 O
Patients NCT03927872 275 283 O
with NCT03927872 284 288 O
National NCT03927872 289 297 B-Condition
Institutes NCT03927872 298 308 I-Condition
of NCT03927872 309 311 I-Condition
Health NCT03927872 312 318 I-Condition
Stroke NCT03927872 319 325 I-Condition
Scale NCT03927872 326 331 I-Condition
﴾ NCT03927872 332 333 O
NIHSS NCT03927872 334 339 B-Condition
﴿ NCT03927872 340 341 O
score NCT03927872 342 347 O
more NCT03927872 348 352 B-Eq-Comparison
than NCT03927872 353 357 I-Eq-Comparison
5 NCT03927872 358 359 I-Eq-Comparison
. NCT03927872 359 360 O

- NCT03927872 364 365 O
Adult NCT03927872 367 372 O
patients NCT03927872 373 381 O
with NCT03927872 382 386 B-And
their NCT03927872 387 392 O
ages NCT03927872 393 397 B-Age
more NCT03927872 398 402 B-Eq-Comparison
than NCT03927872 403 407 I-Eq-Comparison
18 NCT03927872 408 410 I-Eq-Comparison
year NCT03927872 411 415 I-Eq-Comparison
. NCT03927872 415 416 O

Exclusion NCT03927872 418 427 O
criteria NCT03927872 428 436 O
: NCT03927872 437 438 O

- NCT03927872 442 443 O
Lacunar NCT03927872 445 452 B-Modifier
stroke NCT03927872 453 459 B-Condition
and NCT03927872 460 463 O
transient NCT03927872 464 473 B-Condition
ischemic NCT03927872 474 482 I-Condition
attacks NCT03927872 483 490 I-Condition
( NCT03927872 491 492 O
TIAs NCT03927872 493 497 B-Condition
) NCT03927872 498 499 O

- NCT03927872 503 504 O
Haemorrhagic NCT03927872 506 518 B-Modifier
stroke NCT03927872 519 525 B-Condition
. NCT03927872 525 526 O

- NCT03927872 530 531 O
Neurological NCT03927872 533 545 B-Condition
causes NCT03927872 546 552 I-Condition
of NCT03927872 553 555 O
acute NCT03927872 556 561 O
focal NCT03927872 562 567 B-Modifier
cerebral NCT03927872 568 576 B-Condition
dysfunction NCT03927872 577 588 I-Condition
such NCT03927872 589 593 O
as NCT03927872 594 596 O
cerebral NCT03927872 597 605 B-Condition
venous NCT03927872 606 612 I-Condition
sinus NCT03927872 613 618 I-Condition
thrombosis NCT03927872 619 629 I-Condition
, NCT03927872 630 631 O
head NCT03927872 632 636 B-Modifier
trauma NCT03927872 637 643 B-Condition
, NCT03927872 644 645 O
infection NCT03927872 646 655 B-Condition
, NCT03927872 656 657 O
and NCT03927872 658 661 B-Or
auto NCT03927872 662 666 B-Condition
immune NCT03927872 667 673 I-Condition
disorders NCT03927872 674 683 I-Condition

- NCT03927872 686 687 O
Heart NCT03927872 689 694 B-Condition
failure NCT03927872 695 702 I-Condition|Condition

- NCT03927872 705 706 O
Liver NCT03927872 708 713 B-Condition
failure NCT03927872 714 721 O

- NCT03927872 724 725 O
Chronic NCT03927872 727 734 B-Condition
renal NCT03927872 735 740 I-Condition
disease NCT03927872 741 748 I-Condition
. NCT03927872 748 749 O

Inclusion NCT03929900 0 9 O
Criteria NCT03929900 10 18 O
: NCT03929900 19 20 O

- NCT03929900 24 25 O
Age NCT03929900 27 30 B-Age
45 NCT03929900 31 33 B-Eq-Comparison
- NCT03929900 34 35 I-Eq-Comparison
79 NCT03929900 36 38 I-Eq-Comparison
years NCT03929900 39 44 I-Eq-Comparison

- NCT03929900 47 48 O
Estimated NCT03929900 50 59 B-Observation
glomerular NCT03929900 60 70 I-Observation
filtration NCT03929900 71 81 I-Observation
rate NCT03929900 82 86 I-Observation
20 NCT03929900 87 89 B-Eq-Comparison
- NCT03929900 90 91 I-Eq-Comparison
60 NCT03929900 92 94 I-Eq-Comparison
mL NCT03929900 95 97 O
/ NCT03929900 98 99 I-Eq-Comparison
min NCT03929900 100 103 I-Eq-Comparison
/ NCT03929900 104 105 O
1.73 NCT03929900 106 110 I-Eq-Comparison
m2 NCT03929900 111 113 O
based NCT03929900 114 119 O
on NCT03929900 120 122 O
CKD NCT03929900 123 126 O
- NCT03929900 127 128 O
EPI NCT03929900 129 132 O
( NCT03929900 133 134 O
Cr NCT03929900 135 137 O
) NCT03929900 138 139 O
equation NCT03929900 140 148 O

- NCT03929900 151 152 I-Condition
Non NCT03929900 154 157 B-Condition
- NCT03929900 158 159 O
dialysis NCT03929900 160 168 I-Condition
dependent NCT03929900 169 178 I-Condition
( NCT03929900 179 180 O
NDD NCT03929900 181 184 B-Condition
) NCT03929900 185 186 O

Exclusion NCT03929900 188 197 O
Criteria NCT03929900 198 206 O
: NCT03929900 207 208 O

- NCT03929900 212 213 O
Autosomal NCT03929900 215 224 B-Condition
dominant NCT03929900 225 233 I-Condition
polycystic NCT03929900 234 244 I-Condition
kidney NCT03929900 245 251 I-Condition
disease NCT03929900 252 259 I-Condition

- NCT03929900 262 263 O
Unable NCT03929900 265 271 O
or NCT03929900 272 274 O
unwilling NCT03929900 275 284 O
to NCT03929900 285 287 O
give NCT03929900 288 292 O
consent NCT03929900 293 300 O

- NCT03929900 303 304 O
Previously NCT03929900 306 316 B-Eq-Comparison
received NCT03929900 317 325 I-Eq-Comparison
chronic NCT03929900 326 333 B-Modifier
dialysis NCT03929900 334 342 B-Procedure

- NCT03929900 345 346 O
Previous NCT03929900 348 356 B-Eq-Comparison
any NCT03929900 357 360 O
organ NCT03929900 361 366 B-Procedure
transplant NCT03929900 367 377 I-Procedure

- NCT03929900 380 381 O
Patients NCT03929900 383 391 O
who NCT03929900 392 395 O
diagnosed NCT03929900 396 405 O
heart NCT03929900 406 411 B-Condition
failure NCT03929900 412 419 I-Condition
with NCT03929900 420 424 B-And
NYHA NCT03929900 425 429 B-Condition
class NCT03929900 430 435 B-Eq-Comparison
3 NCT03929900 436 437 I-Eq-Comparison
or NCT03929900 438 440 I-Eq-Comparison
4 NCT03929900 441 442 I-Eq-Comparison

- NCT03929900 446 447 O
Known NCT03929900 449 454 O
liver NCT03929900 455 460 B-Condition
cirrhosis NCT03929900 461 470 I-Condition
( NCT03929900 471 472 O
Child NCT03929900 473 478 B-Condition
- NCT03929900 479 480 I-Condition
pugh NCT03929900 481 485 I-Condition
class NCT03929900 486 491 B-Eq-Comparison
2 NCT03929900 492 493 I-Eq-Comparison
or NCT03929900 494 496 I-Eq-Comparison
3 NCT03929900 497 498 I-Eq-Comparison
) NCT03929900 499 500 O

- NCT03929900 504 505 O
Pregnant NCT03929900 507 515 B-Condition
women NCT03929900 516 521 O

- NCT03929900 524 525 O
Single NCT03929900 527 533 B-Condition
kidney NCT03929900 534 540 I-Condition
due NCT03929900 541 544 O
to NCT03929900 545 547 O
trauma NCT03929900 548 554 B-Condition
or NCT03929900 555 557 B-Or
donation NCT03929900 558 566 B-Condition

- NCT03929900 569 570 O
Patients NCT03929900 572 580 O
who NCT03929900 581 584 O
received NCT03929900 585 593 B-Eq-Comparison
immunosuppressive NCT03929900 594 611 B-Drug
agent NCT03929900 612 617 I-Drug
within NCT03929900 618 624 B-Eq-Comparison
the NCT03929900 625 628 I-Eq-Comparison
past NCT03929900 629 633 I-Eq-Comparison
1 NCT03929900 634 635 I-Eq-Comparison
year NCT03929900 636 640 I-Eq-Comparison

- NCT03929900 643 644 O
Patients NCT03929900 646 654 O
who NCT03929900 655 658 O
diagnosed NCT03929900 659 668 O
with NCT03929900 669 673 O
glomerulonephritis NCT03929900 674 692 B-Condition
through NCT03929900 693 700 O
kidney NCT03929900 701 707 B-Modifier
biopsy NCT03929900 708 714 B-Procedure

Inclusion NCT03928834 0 9 O
Criteria NCT03928834 10 18 O
: NCT03928834 19 20 O

1 NCT03928834 24 25 O
. NCT03928834 25 26 O
HIV NCT03928834 28 31 B-Condition
- NCT03928834 32 33 O
positive NCT03928834 34 42 O
adolescents NCT03928834 43 54 O
aged NCT03928834 55 59 B-Age
10 NCT03928834 60 62 B-Eq-Comparison
- NCT03928834 63 64 I-Eq-Comparison
19 NCT03928834 65 67 I-Eq-Comparison
years NCT03928834 68 73 I-Eq-Comparison
who NCT03928834 74 77 O
know NCT03928834 78 82 O
their NCT03928834 83 88 O
status NCT03928834 89 95 O

2 NCT03928834 98 99 O
. NCT03928834 99 100 O
On NCT03928834 102 104 B-Eq-Comparison
ART NCT03928834 105 108 B-Procedure
for NCT03928834 109 112 O
at NCT03928834 113 115 B-Eq-Comparison
least NCT03928834 116 121 I-Eq-Comparison
6 NCT03928834 122 123 I-Eq-Comparison
months NCT03928834 124 130 I-Eq-Comparison
as NCT03928834 131 133 O
per NCT03928834 134 137 O
clinic NCT03928834 138 144 O
records NCT03928834 145 152 O
: NCT03928834 153 154 O
the NCT03928834 155 158 O
patient NCT03928834 159 166 O
will NCT03928834 167 171 O
have NCT03928834 172 176 O
attended NCT03928834 177 185 B-Encounter
the NCT03928834 186 189 O
clinic NCT03928834 190 196 O
as NCT03928834 197 199 O
shown NCT03928834 200 205 O
in NCT03928834 206 208 O
clinic NCT03928834 209 215 O
records NCT03928834 216 223 O
at NCT03928834 224 226 B-Eq-Comparison
least NCT03928834 227 232 I-Eq-Comparison
once NCT03928834 233 237 I-Eq-Comparison
since NCT03928834 238 243 B-Temporal-Connection___Temporal-Connection-Type-Value:after
initiation NCT03928834 244 254 B-Eq-Comparison
AND NCT03928834 255 258 B-And
will NCT03928834 259 263 O
have NCT03928834 264 268 O
re NCT03928834 269 271 O
- NCT03928834 272 273 O
filled NCT03928834 274 280 O
their NCT03928834 281 286 O
ART NCT03928834 287 290 B-Procedure
at NCT03928834 291 293 B-Eq-Comparison
least NCT03928834 294 299 I-Eq-Comparison
once NCT03928834 300 304 I-Eq-Comparison
since NCT03928834 305 310 O
initiation NCT03928834 311 321 O
as NCT03928834 322 324 O
shown NCT03928834 325 330 O
in NCT03928834 331 333 O
clinic NCT03928834 334 340 O
records NCT03928834 341 348 O
. NCT03928834 348 349 O
. NCT03928834 350 351 O

3 NCT03928834 355 356 O
. NCT03928834 356 357 O
Planning NCT03928834 359 367 B-Assertion___Assertion-Type-Value:intention
to NCT03928834 368 370 O
stay NCT03928834 371 375 O
in NCT03928834 376 378 O
care NCT03928834 379 383 B-Encounter
at NCT03928834 384 386 O
that NCT03928834 387 391 O
facility NCT03928834 392 400 O
for NCT03928834 401 404 O
at NCT03928834 405 407 B-Eq-Comparison
least NCT03928834 408 413 I-Eq-Comparison
12 NCT03928834 414 416 I-Eq-Comparison
months NCT03928834 417 423 I-Eq-Comparison

Exclusion NCT03928834 424 433 O
Criteria NCT03928834 434 442 O
: NCT03928834 443 444 O

1 NCT03928834 448 449 O
. NCT03928834 449 450 O
Participant NCT03928834 452 463 O
and NCT03928834 464 467 O
/ NCT03928834 468 469 O
or NCT03928834 470 472 O
caregiver NCT03928834 473 482 O
unable NCT03928834 483 489 O
to NCT03928834 490 492 O
give NCT03928834 493 497 O
consent NCT03928834 498 505 O
and NCT03928834 506 509 O
assent NCT03928834 510 516 O

2 NCT03928834 519 520 O
. NCT03928834 520 521 O
Those NCT03928834 523 528 O
participants NCT03928834 529 541 O
who NCT03928834 542 545 O
the NCT03928834 546 549 O
healthcare NCT03928834 550 560 O
worker NCT03928834 561 567 O
considers NCT03928834 568 577 O
to NCT03928834 578 580 O
be NCT03928834 581 583 O
too NCT03928834 584 587 O
ill NCT03928834 588 591 O
to NCT03928834 592 594 O
participate NCT03928834 595 606 O

For NCT03920267 0 3 O
more NCT03920267 4 8 O
information NCT03920267 9 20 O
regarding NCT03920267 21 30 O
Bristol NCT03920267 31 38 O
- NCT03920267 39 40 O
Myers NCT03920267 41 46 O
Squibb NCT03920267 47 53 O
Clinical NCT03920267 54 62 O
Trial NCT03920267 63 68 O
participation NCT03920267 69 82 O
, NCT03920267 83 84 O
please NCT03920267 85 91 O

visit NCT03920267 92 97 O
www NCT03920267 98 101 O
. NCT03920267 101 102 O
BMSStudyConnect NCT03920267 103 118 O
. NCT03920267 118 119 O
com NCT03920267 120 123 O

Inclusion NCT03920267 124 133 O
Criteria NCT03920267 134 142 O
: NCT03920267 143 144 O

- NCT03920267 148 149 O
Completion NCT03920267 151 161 O
of NCT03920267 162 164 O
SLE NCT03920267 165 168 O
Study NCT03920267 169 174 O
( NCT03920267 175 176 O
NCT03252587 NCT03920267 177 188 O
) NCT03920267 189 190 O
through NCT03920267 191 198 O
the NCT03920267 199 202 O
protocol NCT03920267 203 211 O
- NCT03920267 212 213 O
required NCT03920267 214 222 O
treatment NCT03920267 223 232 O
period NCT03920267 233 239 O
, NCT03920267 240 241 O
and NCT03920267 242 245 O
currently NCT03920267 246 255 B-Eq-Comparison
receiving NCT03920267 256 265 I-Eq-Comparison
blinded NCT03920267 266 273 O
study NCT03920267 274 279 B-Study
drug NCT03920267 280 284 B-Drug

- NCT03920267 287 288 O
Women NCT03920267 290 295 O
of NCT03920267 296 298 B-And
childbearing NCT03920267 299 311 B-Condition
potential NCT03920267 312 321 I-Condition
( NCT03920267 322 323 O
WOCBP NCT03920267 324 329 B-Condition
) NCT03920267 330 331 O
must NCT03920267 332 336 O
have NCT03920267 337 341 O
a NCT03920267 342 343 O
negative NCT03920267 344 352 O
urine NCT03920267 353 358 B-Observation
pregnancy NCT03920267 359 368 I-Observation
test NCT03920267 369 373 I-Observation
and NCT03920267 374 377 B-And
must NCT03920267 378 382 O
agree NCT03920267 383 388 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920267 389 391 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03920267 392 395 O
correctly NCT03920267 396 405 O
a NCT03920267 406 407 O
highly NCT03920267 408 414 O
effective NCT03920267 415 424 O
method NCT03920267 425 431 O
( NCT03920267 432 433 O
s NCT03920267 434 435 O
) NCT03920267 436 437 O
of NCT03920267 438 440 O
contraception NCT03920267 441 454 B-Procedure
for NCT03920267 455 458 O
the NCT03920267 459 462 O
duration NCT03920267 463 471 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03920267 472 474 O
treatment NCT03920267 475 484 B-Procedure
with NCT03920267 485 489 O
study NCT03920267 490 495 B-Study
drug NCT03920267 496 500 B-Drug

Exclusion NCT03920267 501 510 O
Criteria NCT03920267 511 519 O
: NCT03920267 520 521 O

- NCT03920267 525 526 O
Any NCT03920267 528 531 O
disease NCT03920267 532 539 B-Condition
or NCT03920267 540 542 B-Or
medical NCT03920267 543 550 B-Condition
condition NCT03920267 551 560 I-Condition
that NCT03920267 561 565 O
, NCT03920267 566 567 O
in NCT03920267 568 570 O
the NCT03920267 571 574 O
opinion NCT03920267 575 582 O
of NCT03920267 583 585 O
the NCT03920267 586 589 O
investigator NCT03920267 590 602 O
, NCT03920267 603 604 O
would NCT03920267 605 610 B-Assertion___Assertion-Type-Value:hypothetical
make NCT03920267 611 615 O
the NCT03920267 616 619 O
subject NCT03920267 620 627 O
unsuitable NCT03920267 628 638 B-Negation
for NCT03920267 639 642 O
this NCT03920267 643 647 O
study NCT03920267 648 653 B-Study
, NCT03920267 654 655 O
would NCT03920267 656 661 O
interfere NCT03920267 662 671 O
with NCT03920267 672 676 O
the NCT03920267 677 680 O
interpretation NCT03920267 681 695 O
of NCT03920267 696 698 O
subject NCT03920267 699 706 O
safety NCT03920267 707 713 O
or NCT03920267 714 716 O
study NCT03920267 717 722 O
results NCT03920267 723 730 O
, NCT03920267 731 732 O
or NCT03920267 733 735 O
considered NCT03920267 736 746 O
unsuitable NCT03920267 747 757 O
by NCT03920267 758 760 O
the NCT03920267 761 764 O
investigator NCT03920267 765 777 O
for NCT03920267 778 781 O
any NCT03920267 782 785 O
other NCT03920267 786 791 O
reason NCT03920267 792 798 O

- NCT03920267 801 802 O
Evidence NCT03920267 804 812 O
of NCT03920267 813 815 O
active NCT03920267 816 822 B-Eq-Comparison
tuberculosis NCT03920267 823 835 B-Condition
( NCT03920267 836 837 O
TB NCT03920267 838 840 B-Condition
) NCT03920267 841 842 O

Other NCT03920267 844 849 O
protocol NCT03920267 850 858 O
defined NCT03920267 859 866 O
inclusion NCT03920267 867 876 O
/ NCT03920267 877 878 O
exclusion NCT03920267 879 888 O
criteria NCT03920267 889 897 O
could NCT03920267 898 903 O
apply NCT03920267 904 909 O

Inclusion NCT03927534 0 9 O
Criteria NCT03927534 10 18 O
: NCT03927534 19 20 O

- NCT03927534 24 25 O
Age NCT03927534 27 30 B-Age
between NCT03927534 31 38 B-Eq-Comparison
45 NCT03927534 39 41 I-Eq-Comparison
- NCT03927534 42 43 I-Eq-Comparison
75 NCT03927534 44 46 I-Eq-Comparison
years NCT03927534 47 52 I-Eq-Comparison

- NCT03927534 55 56 O
Have NCT03927534 58 62 O
overweight NCT03927534 63 73 B-Condition
or NCT03927534 74 76 B-Or
obesity NCT03927534 77 84 B-Condition
condition NCT03927534 85 94 O
based NCT03927534 95 100 O
in NCT03927534 101 103 O
BMI NCT03927534 104 107 B-Observation
( NCT03927534 108 109 O
Body NCT03927534 110 114 B-Observation
Mass NCT03927534 115 119 I-Observation
Index NCT03927534 120 125 I-Observation
) NCT03927534 126 127 O
. NCT03927534 128 129 O
Individuals NCT03927534 131 142 O
with NCT03927534 143 147 O
BMI NCT03927534 148 151 B-Observation
of NCT03927534 152 154 O
25 NCT03927534 155 157 B-Eq-Comparison
or NCT03927534 158 160 I-Eq-Comparison
more NCT03927534 161 165 I-Eq-Comparison
. NCT03927534 165 166 O

- NCT03927534 170 171 O
Have NCT03927534 173 177 O
two NCT03927534 178 181 B-Eq-Comparison
of NCT03927534 182 184 B-Criteria-Count
these NCT03927534 185 190 I-Criteria-Count
three NCT03927534 191 196 B-Eq-Comparison
risk NCT03927534 197 201 B-Risk
: NCT03927534 202 203 O
sedentary NCT03927534 204 213 B-Condition
lifestyle NCT03927534 214 223 I-Condition
, NCT03927534 224 225 O
poor NCT03927534 226 230 B-Condition
diet NCT03927534 231 235 I-Condition
and NCT03927534 236 239 B-Or
binge NCT03927534 240 245 B-Condition
episodes NCT03927534 246 254 I-Condition
. NCT03927534 254 255 O

- NCT03927534 259 260 O
Ability NCT03927534 262 269 O
to NCT03927534 270 272 O
understand NCT03927534 273 283 O
oral NCT03927534 284 288 O
and NCT03927534 289 292 O
written NCT03927534 293 300 O
Spanish NCT03927534 301 308 O
. NCT03927534 308 309 O

- NCT03927534 313 314 O
Willingness NCT03927534 316 327 O
to NCT03927534 328 330 O
participate NCT03927534 331 342 O
in NCT03927534 343 345 O
the NCT03927534 346 349 O
study NCT03927534 350 355 O
and NCT03927534 356 359 O
signing NCT03927534 360 367 O
informed NCT03927534 368 376 O
consent NCT03927534 377 384 O
. NCT03927534 384 385 O

Exclusion NCT03927534 387 396 O
Criteria NCT03927534 397 405 O
: NCT03927534 406 407 O

- NCT03927534 411 412 O
Any NCT03927534 414 417 O
diagnosis NCT03927534 418 427 O
of NCT03927534 428 430 O
a NCT03927534 431 432 O
disease NCT03927534 433 440 B-Condition
that NCT03927534 441 445 O
may NCT03927534 446 449 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03927534 450 456 O
the NCT03927534 457 460 O
central NCT03927534 461 468 B-Condition
nervous NCT03927534 469 476 I-Condition
system NCT03927534 477 483 I-Condition
( NCT03927534 484 485 O
brain NCT03927534 486 491 B-Modifier
condition NCT03927534 492 501 B-Condition
, NCT03927534 502 503 O
traumatic NCT03927534 504 513 B-Condition
brain NCT03927534 514 519 I-Condition
injury NCT03927534 520 526 I-Condition
, NCT03927534 527 528 O
dementia NCT03927534 529 537 B-Condition
, NCT03927534 538 539 O
etc NCT03927534 540 543 O
) NCT03927534 544 545 O
. NCT03927534 546 547 O

- NCT03927534 551 552 O
Other NCT03927534 554 559 O
psychiatric NCT03927534 560 571 B-Condition
diagnoses NCT03927534 572 581 I-Condition
or NCT03927534 582 584 B-Or
acute NCT03927534 585 590 O
psychiatric NCT03927534 591 602 B-Condition
illness NCT03927534 603 610 I-Condition
( NCT03927534 611 612 O
substance NCT03927534 613 622 B-Condition
dependence NCT03927534 623 633 B-Modifier
or NCT03927534 634 636 B-Or
abuse NCT03927534 637 642 B-Modifier
, NCT03927534 643 644 O
history NCT03927534 645 652 B-Eq-Comparison
of NCT03927534 653 655 O
schizophrenia NCT03927534 656 669 B-Condition
or NCT03927534 670 672 O
other NCT03927534 673 678 B-Other
psychotic NCT03927534 679 688 B-Condition
disorders NCT03927534 689 698 I-Condition
, NCT03927534 699 700 O
etc NCT03927534 701 704 O
. NCT03927534 704 705 O
) NCT03927534 706 707 O
, NCT03927534 709 710 O
except NCT03927534 711 717 B-Exception
for NCT03927534 718 721 I-Exception
anxiety NCT03927534 722 729 B-Condition
disorder NCT03927534 730 738 I-Condition|Condition
or NCT03927534 739 741 B-Or
personality NCT03927534 742 753 B-Condition
disorders NCT03927534 754 763 O
. NCT03927534 763 764 O

- NCT03927534 768 769 O
Presence NCT03927534 771 779 O
of NCT03927534 780 782 O
delusional NCT03927534 783 793 B-Condition
ideas NCT03927534 794 799 I-Condition
or NCT03927534 800 802 B-Or
hallucinations NCT03927534 803 817 B-Condition
whether NCT03927534 818 825 O
consistent NCT03927534 826 836 O
or NCT03927534 837 839 O
not NCT03927534 840 843 O
with NCT03927534 844 848 O
mood NCT03927534 849 853 O
. NCT03927534 853 854 O

- NCT03927534 858 859 O
Suicide NCT03927534 861 868 B-Condition
risk NCT03927534 869 873 B-Risk
. NCT03927534 873 874 O

Inclusion NCT03928613 0 9 O
Criteria NCT03928613 10 18 O
: NCT03928613 19 20 O

- NCT03928613 24 25 O
Aged NCT03928613 27 31 B-Age
above NCT03928613 32 37 B-Eq-Comparison
60 NCT03928613 38 40 I-Eq-Comparison

- NCT03928613 44 45 O
Confirmed NCT03928613 47 56 O
literacy NCT03928613 57 65 B-Condition
o NCT03928613 66 67 O
Diagnosed NCT03928613 68 77 O
with NCT03928613 78 82 O
mild NCT03928613 83 87 O
cognitive NCT03928613 88 97 B-Condition
impairment NCT03928613 98 108 I-Condition
by NCT03928613 109 111 O
International NCT03928613 112 125 O
Working NCT03928613 126 133 O
Group NCT03928613 134 139 O
on NCT03928613 140 142 O
Mild NCT03928613 143 147 O
Cognitive NCT03928613 148 157 O
Impairment NCT03928613 158 168 O
and NCT03928613 169 172 B-And
Clinical NCT03928613 173 181 B-Observation
Dementia NCT03928613 182 190 I-Observation
Rating NCT03928613 191 197 I-Observation
( NCT03928613 198 199 O
CDR NCT03928613 200 203 B-Observation
) NCT03928613 204 205 O
of NCT03928613 206 208 O
0 NCT03928613 209 210 B-Eq-Comparison
or NCT03928613 211 213 I-Eq-Comparison
0.5 NCT03928613 214 217 I-Eq-Comparison
. NCT03928613 217 218 O

Exclusion NCT03928613 220 229 O
Criteria NCT03928613 230 238 O
: NCT03928613 239 240 O

- NCT03928613 244 245 O
Evidence NCT03928613 247 255 O
of NCT03928613 256 258 O
delirium NCT03928613 259 267 B-Condition
, NCT03928613 268 269 O
confusion NCT03928613 270 279 B-Condition

- NCT03928613 282 283 O
Any NCT03928613 285 288 O
neurological NCT03928613 289 301 B-Condition
conditions NCT03928613 302 312 I-Condition
causing NCT03928613 313 320 O
cognitive NCT03928613 321 330 B-Condition
decline NCT03928613 331 338 I-Condition
such NCT03928613 339 343 O
as NCT03928613 344 346 O
Parkinson NCT03928613 347 356 B-Condition
's NCT03928613 356 358 O
disease NCT03928613 359 366 I-Condition
, NCT03928613 367 368 O
brain NCT03928613 369 374 B-Modifier
hemorrhage NCT03928613 375 385 B-Condition
, NCT03928613 386 387 O
brain NCT03928613 388 393 B-Modifier
tumor NCT03928613 394 399 B-Condition
, NCT03928613 400 401 O
normal NCT03928613 402 408 B-Condition
pressure NCT03928613 409 417 I-Condition
hydrocephalus NCT03928613 418 431 I-Condition

- NCT03928613 434 435 O
Evidence NCT03928613 437 445 O
of NCT03928613 446 448 O
severe NCT03928613 449 455 O
cerebrovascular NCT03928613 456 471 B-Condition
pathology NCT03928613 472 481 I-Condition

- NCT03928613 484 485 O
Presence NCT03928613 487 495 O
of NCT03928613 496 498 O
depressive NCT03928613 499 509 B-Condition
symptoms NCT03928613 510 518 B-Assertion___Assertion-Type-Value:possible
that NCT03928613 519 523 O
could NCT03928613 524 529 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03928613 530 539 O
cognitive NCT03928613 540 549 B-Condition
function NCT03928613 550 558 I-Condition

- NCT03928613 561 562 O
Presence NCT03928613 564 572 O
of NCT03928613 573 575 O
medical NCT03928613 576 583 B-Condition
comorbidities NCT03928613 584 597 I-Condition
that NCT03928613 598 602 O
could NCT03928613 603 608 B-Assertion___Assertion-Type-Value:hypothetical
result NCT03928613 609 615 O
in NCT03928613 616 618 O
any NCT03928613 619 622 O
difficulties NCT03928613 623 635 B-Negation
in NCT03928613 636 638 O
study NCT03928613 639 644 B-Study
participation NCT03928613 645 658 O

Inclusion NCT03925337 0 9 O
Criteria NCT03925337 10 18 O
: NCT03925337 19 20 O

- NCT03925337 24 25 O
Patients NCT03925337 27 35 O
age NCT03925337 36 39 B-Age
: NCT03925337 40 41 O
≥ NCT03925337 42 43 B-Eq-Comparison
22 NCT03925337 44 46 I-Eq-Comparison
years NCT03925337 47 52 I-Eq-Comparison

- NCT03925337 55 56 O
Patients NCT03925337 58 66 O
presenting NCT03925337 67 77 B-Eq-Comparison
for NCT03925337 78 81 O
routine NCT03925337 82 89 B-Modifier
colonoscopy NCT03925337 90 101 B-Procedure
for NCT03925337 102 105 O
screening NCT03925337 106 115 B-Procedure
and NCT03925337 116 119 B-Or
/ NCT03925337 120 121 I-Or
or NCT03925337 122 124 I-Or
surveillance NCT03925337 125 137 B-Procedure
purposes NCT03925337 138 146 O
. NCT03925337 146 147 O

- NCT03925337 151 152 O
Willingness NCT03925337 154 165 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925337 166 168 O
undergo NCT03925337 169 176 O
two NCT03925337 177 180 B-Eq-Comparison
withdrawals NCT03925337 181 192 B-Condition
with NCT03925337 193 197 O
and NCT03925337 198 201 O
without NCT03925337 202 209 O
the NCT03925337 210 213 O
use NCT03925337 214 217 O
of NCT03925337 218 220 O
computer NCT03925337 221 229 O
- NCT03925337 230 231 O
aided NCT03925337 232 237 O
software NCT03925337 238 246 O
while NCT03925337 247 252 B-Temporal-Connection___Temporal-Connection-Type-Value:during
undergoing NCT03925337 253 263 O
conventional NCT03925337 264 276 B-Modifier
colonoscopy NCT03925337 277 288 B-Procedure
with NCT03925337 289 293 O
sedation NCT03925337 294 302 B-Procedure

- NCT03925337 305 306 O
Ability NCT03925337 308 315 O
to NCT03925337 316 318 O
provide NCT03925337 319 326 O
written NCT03925337 327 334 O
, NCT03925337 335 336 O
informed NCT03925337 337 345 O
consent NCT03925337 346 353 O
and NCT03925337 354 357 O
understand NCT03925337 358 368 O
the NCT03925337 369 372 O
responsibilities NCT03925337 373 389 O
of NCT03925337 390 392 O
trial NCT03925337 393 398 O
participation NCT03925337 399 412 O

Exclusion NCT03925337 413 422 O
Criteria NCT03925337 423 431 O
: NCT03925337 432 433 O

- NCT03925337 437 438 O
Minors NCT03925337 440 446 O
aged NCT03925337 447 451 B-Age
< NCT03925337 452 453 B-Eq-Comparison
22 NCT03925337 454 456 I-Eq-Comparison
years NCT03925337 457 462 I-Eq-Comparison
. NCT03925337 462 463 O

- NCT03925337 467 468 O
People NCT03925337 470 476 O
with NCT03925337 477 481 O
diminished NCT03925337 482 492 B-Condition
cognitive NCT03925337 493 502 I-Condition
capacity NCT03925337 503 511 I-Condition

- NCT03925337 514 515 O
Patients NCT03925337 517 525 O
undergoing NCT03925337 526 536 B-Eq-Comparison
diagnostic NCT03925337 537 547 B-Modifier
colonoscopy NCT03925337 548 559 B-Procedure
( NCT03925337 560 561 O
e. NCT03925337 562 564 O
g. NCT03925337 565 567 O
as NCT03925337 569 571 O
an NCT03925337 572 574 O
evaluation NCT03925337 575 585 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03925337 586 589 I-Assertion___Assertion-Type-Value:hypothetical
active NCT03925337 590 596 B-Eq-Comparison
gastrointestinal NCT03925337 597 613 B-Modifier
bleed NCT03925337 614 619 B-Condition
, NCT03925337 620 621 O
referring NCT03925337 622 631 O
collectively NCT03925337 632 644 O
to NCT03925337 645 647 O
the NCT03925337 648 651 O
stomach NCT03925337 652 659 B-Modifier
and NCT03925337 660 663 B-Or|Or
the NCT03925337 664 667 O
small NCT03925337 668 673 B-Modifier
and NCT03925337 674 677 O
large NCT03925337 678 683 B-Modifier
intestine NCT03925337 684 693 I-Modifier
) NCT03925337 694 695 O
. NCT03925337 696 697 O

- NCT03925337 701 702 O
Patients NCT03925337 704 712 O
with NCT03925337 713 717 O
incomplete NCT03925337 718 728 B-Modifier
colonoscopies NCT03925337 729 742 B-Procedure
( NCT03925337 743 744 O
those NCT03925337 745 750 O
where NCT03925337 751 756 O
endoscopists NCT03925337 757 769 O
did NCT03925337 770 773 O
not NCT03925337 774 777 B-Negation
successfully NCT03925337 778 790 O
intubate NCT03925337 791 799 B-Procedure
the NCT03925337 800 803 O
cecum NCT03925337 804 809 B-Modifier
due NCT03925337 810 813 O
to NCT03925337 814 816 O
technical NCT03925337 817 826 O
difficulties NCT03925337 827 839 O
or NCT03925337 840 842 B-Or
poor NCT03925337 843 847 B-Modifier
bowel NCT03925337 848 853 B-Procedure
preparation NCT03925337 854 865 I-Procedure
) NCT03925337 866 867 O

- NCT03925337 871 872 O
Patients NCT03925337 874 882 O
that NCT03925337 883 887 O
have NCT03925337 888 892 O
standard NCT03925337 893 901 O
contraindications NCT03925337 902 919 B-Contraindication
to NCT03925337 920 922 O
colonoscopy NCT03925337 923 934 B-Procedure
in NCT03925337 935 937 O
general NCT03925337 938 945 O
( NCT03925337 946 947 O
e. NCT03925337 948 950 O
g. NCT03925337 951 953 O
documented NCT03925337 955 965 O
acute NCT03925337 966 971 O
diverticulitis NCT03925337 972 986 B-Condition
, NCT03925337 987 988 O
fulminant NCT03925337 989 998 B-Condition
colitis NCT03925337 999 1006 I-Condition
and NCT03925337 1007 1010 O
known NCT03925337 1011 1016 O
or NCT03925337 1017 1019 O
suspected NCT03925337 1020 1029 B-Assertion___Assertion-Type-Value:possible
perforation NCT03925337 1030 1041 B-Condition
) NCT03925337 1042 1043 O
. NCT03925337 1044 1045 O

- NCT03925337 1049 1050 O
Patients NCT03925337 1052 1060 O
with NCT03925337 1061 1065 O
inflammatory NCT03925337 1066 1078 B-Condition
bowel NCT03925337 1079 1084 I-Condition
disease NCT03925337 1085 1092 I-Condition

- NCT03925337 1095 1096 O
Patients NCT03925337 1098 1106 O
with NCT03925337 1107 1111 O
any NCT03925337 1112 1115 O
polypoid NCT03925337 1116 1124 B-Modifier
/ NCT03925337 1125 1126 B-Or
ulcerated NCT03925337 1127 1136 B-Modifier
lesion NCT03925337 1137 1143 B-Observation
> NCT03925337 1144 1145 B-Eq-Comparison
2 NCT03925337 1146 1147 I-Eq-Comparison
cm NCT03925337 1148 1150 I-Eq-Comparison
concerning NCT03925337 1151 1161 O
for NCT03925337 1162 1165 O
invasive NCT03925337 1166 1174 B-Modifier
cancer NCT03925337 1175 1181 B-Condition
on NCT03925337 1182 1184 O
endoscopy NCT03925337 1185 1194 B-Procedure

- NCT03925337 1197 1198 O
Patients NCT03925337 1200 1208 O
referred NCT03925337 1209 1217 B-Encounter
for NCT03925337 1218 1221 O
endoscopic NCT03925337 1222 1232 B-Procedure
mucosal NCT03925337 1233 1240 I-Procedure
resection NCT03925337 1241 1250 I-Procedure
( NCT03925337 1251 1252 O
EMR NCT03925337 1253 1256 B-Procedure
) NCT03925337 1257 1258 O
, NCT03925337 1260 1261 O
which NCT03925337 1262 1267 O
is NCT03925337 1268 1270 O
a NCT03925337 1271 1272 O
procedure NCT03925337 1273 1282 O
to NCT03925337 1283 1285 O
remove NCT03925337 1286 1292 O
early NCT03925337 1293 1298 O
- NCT03925337 1299 1300 O
stage NCT03925337 1301 1306 O
cancer NCT03925337 1307 1313 O
and NCT03925337 1314 1317 O
precancerous NCT03925337 1318 1330 O
growths NCT03925337 1331 1338 O
from NCT03925337 1339 1343 O
the NCT03925337 1344 1347 O
lining NCT03925337 1348 1354 O
of NCT03925337 1355 1357 O
the NCT03925337 1358 1361 O
digestive NCT03925337 1362 1371 O
tract NCT03925337 1372 1377 O
. NCT03925337 1377 1378 O

Inclusion NCT03924362 0 9 O
Criteria NCT03924362 10 18 O
: NCT03924362 19 20 O

All NCT03924362 22 25 O
subjects NCT03924362 26 34 O
with NCT03924362 35 39 O
a NCT03924362 40 41 O
clinical NCT03924362 42 50 O
diagnosis NCT03924362 51 60 O
of NCT03924362 61 63 O
struvite NCT03924362 64 72 B-Condition
calculi NCT03924362 73 80 I-Condition
will NCT03924362 81 85 O
potentially NCT03924362 86 97 O
be NCT03924362 98 100 O
included NCT03924362 101 109 O
. NCT03924362 109 110 O

Specific NCT03924362 112 120 O
inclusion NCT03924362 121 130 O
criteria NCT03924362 131 139 O
include NCT03924362 140 147 O
the NCT03924362 148 151 O
following NCT03924362 152 161 O
: NCT03924362 162 163 O

1 NCT03924362 167 168 O
. NCT03924362 168 169 O
Age NCT03924362 171 174 B-Age
> NCT03924362 175 176 B-Eq-Comparison
18 NCT03924362 177 179 I-Eq-Comparison
years NCT03924362 180 185 I-Eq-Comparison

2 NCT03924362 188 189 O
. NCT03924362 189 190 O
Any NCT03924362 192 195 O
patient NCT03924362 196 203 O
with NCT03924362 204 208 O
bilateral NCT03924362 209 218 B-Condition
stone NCT03924362 219 224 I-Condition
burden NCT03924362 225 231 I-Condition
eligible NCT03924362 232 240 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03924362 241 244 B-And
appropriate NCT03924362 245 256 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924362 257 260 O
PCNL NCT03924362 261 265 B-Procedure
procedure NCT03924362 266 275 I-Procedure

3 NCT03924362 278 279 O
. NCT03924362 279 280 O
Medically NCT03924362 282 291 O
fit NCT03924362 292 295 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924362 296 299 I-Assertion___Assertion-Type-Value:hypothetical
definitive NCT03924362 300 310 O
surgical NCT03924362 311 319 B-Procedure
management NCT03924362 320 330 I-Procedure
of NCT03924362 331 333 O
stone NCT03924362 334 339 B-Condition
. NCT03924362 339 340 O

Exclusion NCT03924362 342 351 O
Criteria NCT03924362 352 360 O
: NCT03924362 361 362 O

Patients NCT03924362 364 372 O
with NCT03924362 373 377 O
any NCT03924362 378 381 O
of NCT03924362 382 384 O
the NCT03924362 385 388 O
following NCT03924362 389 398 O
characteristics NCT03924362 399 414 O
will NCT03924362 415 419 O
not NCT03924362 420 423 B-Negation
be NCT03924362 424 426 O
eligible NCT03924362 427 435 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924362 436 439 O
the NCT03924362 440 443 O
present NCT03924362 444 451 O

study NCT03924362 452 457 B-Study
: NCT03924362 458 459 O

1 NCT03924362 463 464 O
. NCT03924362 464 465 O
Those NCT03924362 467 472 O
with NCT03924362 473 477 O
medical NCT03924362 478 485 B-Condition
comorbidities NCT03924362 486 499 I-Condition
preventing NCT03924362 500 510 B-Assertion___Assertion-Type-Value:hypothetical|Negation
them NCT03924362 511 515 O
from NCT03924362 516 520 O
safely NCT03924362 521 527 O
undergoing NCT03924362 528 538 O
definitive NCT03924362 539 549 O
surgical NCT03924362 550 558 B-Procedure
therapy NCT03924362 559 566 I-Procedure
. NCT03924362 566 567 O

2 NCT03924362 571 572 O
. NCT03924362 572 573 O
Patients NCT03924362 575 583 O
who NCT03924362 584 587 O
are NCT03924362 588 591 O
unable NCT03924362 592 598 O
to NCT03924362 599 601 O
provide NCT03924362 602 609 O
informed NCT03924362 610 618 O
consent NCT03924362 619 626 O
. NCT03924362 626 627 O

3 NCT03924362 631 632 O
. NCT03924362 632 633 O
Patients NCT03924362 635 643 O
who NCT03924362 644 647 O
are NCT03924362 648 651 O
planned NCT03924362 652 659 B-Eq-Comparison
for NCT03924362 660 663 O
alternative NCT03924362 664 675 B-Other
procedures NCT03924362 676 686 B-Procedure
( NCT03924362 687 688 O
ureteroscopy NCT03924362 689 701 B-Procedure
, NCT03924362 702 703 O
extracorporeal NCT03924362 704 718 B-Procedure
shock NCT03924362 719 724 I-Procedure
wave NCT03924362 725 729 I-Procedure
lithotripsy NCT03924362 730 741 I-Procedure
) NCT03924362 742 743 O

4 NCT03924362 747 748 O
. NCT03924362 748 749 O
Anyone NCT03924362 751 757 O
who NCT03924362 758 761 O
is NCT03924362 762 764 O
unable NCT03924362 765 771 O
to NCT03924362 772 774 O
give NCT03924362 775 779 O
their NCT03924362 780 785 O
informed NCT03924362 786 794 O
consent NCT03924362 795 802 O

5 NCT03924362 805 806 O
. NCT03924362 806 807 O
Anyone NCT03924362 809 815 O
under NCT03924362 816 821 B-Eq-Comparison
the NCT03924362 822 825 I-Eq-Comparison
age NCT03924362 826 829 I-Eq-Comparison
of NCT03924362 830 832 I-Eq-Comparison
19 NCT03924362 833 835 I-Eq-Comparison

6 NCT03924362 839 840 O
. NCT03924362 840 841 O
Anyone NCT03924362 843 849 O
who NCT03924362 850 853 O
, NCT03924362 854 855 O
in NCT03924362 856 858 O
the NCT03924362 859 862 O
opinion NCT03924362 863 870 O
of NCT03924362 871 873 O
the NCT03924362 874 877 O
PI NCT03924362 878 880 O
, NCT03924362 881 882 O
is NCT03924362 883 885 O
unfit NCT03924362 886 891 O
or NCT03924362 892 894 O
unsuitable NCT03924362 895 905 O
to NCT03924362 906 908 O
participate NCT03924362 909 920 O
in NCT03924362 921 923 O
the NCT03924362 924 927 O
study NCT03924362 928 933 B-Study

Inclusion NCT03926039 0 9 O
Criteria NCT03926039 10 18 O
: NCT03926039 19 20 O

1 NCT03926039 24 25 O
. NCT03926039 25 26 O
Primary NCT03926039 28 35 B-Modifier
liver NCT03926039 36 41 I-Modifier
cancer NCT03926039 42 48 B-Condition
patients NCT03926039 49 57 O
( NCT03926039 58 59 O
ICD NCT03926039 60 63 O
10 NCT03926039 64 66 O
is NCT03926039 67 69 O
C22.0 NCT03926039 70 75 O
) NCT03926039 76 77 O
and NCT03926039 78 81 B-And
Barcelona NCT03926039 82 91 B-Condition
stage NCT03926039 92 97 I-Condition
( NCT03926039 98 99 O
BCLC NCT03926039 100 104 B-Condition
stage NCT03926039 105 110 I-Condition
) NCT03926039 111 112 O
0 NCT03926039 113 114 B-Eq-Comparison
- NCT03926039 115 116 I-Eq-Comparison
A. NCT03926039 117 119 I-Eq-Comparison

2 NCT03926039 123 124 O
. NCT03926039 124 125 O
At NCT03926039 127 129 B-Eq-Comparison
least NCT03926039 130 135 I-Eq-Comparison
20 NCT03926039 136 138 I-Eq-Comparison
years NCT03926039 139 144 I-Eq-Comparison
of NCT03926039 145 147 O
age NCT03926039 148 151 B-Age
. NCT03926039 151 152 O

3 NCT03926039 156 157 O
. NCT03926039 157 158 O
No NCT03926039 160 162 B-Negation
mental NCT03926039 163 169 B-Condition
illness NCT03926039 170 177 I-Condition
. NCT03926039 177 178 O

4 NCT03926039 182 183 O
. NCT03926039 183 184 O
Patients NCT03926039 186 194 O
who NCT03926039 195 198 O
can NCT03926039 199 202 O
communicate NCT03926039 203 214 O
in NCT03926039 215 217 O
Mandarin NCT03926039 218 226 O
or NCT03926039 227 229 B-Or
Taiwanese NCT03926039 230 239 O
. NCT03926039 239 240 O

Exclusion NCT03926039 242 251 O
Criteria NCT03926039 252 260 O
: NCT03926039 261 262 O

1 NCT03926039 266 267 O
. NCT03926039 267 268 O
Do NCT03926039 270 272 O
n't NCT03926039 272 275 O
know NCT03926039 276 280 O
himself NCT03926039 281 288 O
condition NCT03926039 289 298 B-Condition
. NCT03926039 298 299 O

2 NCT03926039 303 304 O
. NCT03926039 304 305 O
Unconscious NCT03926039 307 318 B-Condition
patients NCT03926039 319 327 O
. NCT03926039 327 328 O

3 NCT03926039 332 333 O
. NCT03926039 333 334 O
Patients NCT03926039 336 344 O
with NCT03926039 345 349 O
liver NCT03926039 350 355 B-Modifier
cancer NCT03926039 356 362 B-Procedure
resection NCT03926039 363 372 I-Procedure
or NCT03926039 373 375 B-Or
partial NCT03926039 376 383 B-Modifier
liver NCT03926039 384 389 I-Modifier
resection NCT03926039 390 399 B-Procedure
were NCT03926039 400 404 O
performed NCT03926039 405 414 B-Eq-Comparison
within NCT03926039 415 421 B-Eq-Comparison
3 NCT03926039 422 423 I-Eq-Comparison
months NCT03926039 424 430 I-Eq-Comparison
. NCT03926039 430 431 O


Inclusion NCT03927469 0 9 O
Criteria NCT03927469 10 18 O
: NCT03927469 19 20 O

- NCT03927469 24 25 O
Being NCT03927469 27 32 O
hospitalized NCT03927469 33 45 B-Encounter
in NCT03927469 46 48 O
the NCT03927469 49 52 O
hospital NCT03927469 53 61 O
between NCT03927469 62 69 B-Eq-Comparison
January NCT03927469 70 77 I-Eq-Comparison
2015 NCT03927469 78 82 I-Eq-Comparison
and NCT03927469 83 86 I-Eq-Comparison
July NCT03927469 87 91 I-Eq-Comparison
2018 NCT03927469 92 96 I-Eq-Comparison
, NCT03927469 97 98 O
according NCT03927469 99 108 O
to NCT03927469 109 111 O
ICD NCT03927469 112 115 O
10 NCT03927469 116 118 O
code NCT03927469 119 123 O
; NCT03927469 123 124 O
hemiplegia NCT03927469 125 135 B-Condition
( NCT03927469 136 137 O
G81 NCT03927469 138 141 O
) NCT03927469 142 143 O
, NCT03927469 145 146 O
flaccid NCT03927469 147 154 B-Condition
hemiplegia NCT03927469 155 165 I-Condition
( NCT03927469 166 167 O
G81.0 NCT03927469 168 173 O
) NCT03927469 174 175 O
, NCT03927469 177 178 O
hemiplegia NCT03927469 179 189 B-Condition
, NCT03927469 190 191 O
unspecified NCT03927469 192 203 I-Condition
( NCT03927469 204 205 O
G81.9 NCT03927469 206 211 O
) NCT03927469 212 213 O
, NCT03927469 215 216 O
Spastic NCT03927469 217 224 B-Condition
hemiplegia NCT03927469 225 235 I-Condition
( NCT03927469 236 237 O
G81.1 NCT03927469 238 243 O
) NCT03927469 244 245 O

- NCT03927469 249 250 O
Being NCT03927469 252 257 O
ischemic NCT03927469 258 266 B-Modifier
or NCT03927469 267 269 B-Or
hemorrhagic NCT03927469 270 281 B-Modifier
stroke NCT03927469 282 288 B-Condition

Exclusion NCT03927469 289 298 O
Criteria NCT03927469 299 307 O
: NCT03927469 308 309 O

- NCT03927469 313 314 O
Being NCT03927469 316 321 O
hemiplegic NCT03927469 322 332 B-Condition
due NCT03927469 333 336 O
to NCT03927469 337 339 O
trauma NCT03927469 340 346 B-Condition
, NCT03927469 347 348 O
cancer NCT03927469 349 355 B-Condition
and NCT03927469 356 359 B-Or
intracranial NCT03927469 360 372 B-Procedure
operation NCT03927469 373 382 I-Procedure

Inclusion NCT03920306 0 9 O
Criteria NCT03920306 10 18 O
: NCT03920306 19 20 O

- NCT03920306 24 25 O
Eligible NCT03920306 27 35 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920306 36 39 I-Assertion___Assertion-Type-Value:hypothetical
gastrostomy NCT03920306 40 51 B-Procedure
tube NCT03920306 52 56 I-Procedure
removal NCT03920306 57 64 I-Procedure

Exclusion NCT03920306 65 74 O
Criteria NCT03920306 75 83 O
: NCT03920306 84 85 O

- NCT03920306 89 90 O
Recurrent NCT03920306 92 101 O
gastrocutaneous NCT03920306 102 117 B-Condition
fistula NCT03920306 118 125 I-Condition

- NCT03920306 128 129 O
Non NCT03920306 131 134 O
- NCT03920306 135 136 O
consenting NCT03920306 137 147 O

- NCT03920306 150 151 O
Unable NCT03920306 153 159 O
to NCT03920306 160 162 O
comply NCT03920306 163 169 O
with NCT03920306 170 174 O
follow NCT03920306 175 181 O
up NCT03920306 182 184 O
assessments NCT03920306 185 196 O

- NCT03920306 199 200 O
Known NCT03920306 202 207 O
allergic NCT03920306 208 216 B-Allergy
reaction NCT03920306 217 225 O
to NCT03920306 226 228 O
study NCT03920306 229 234 B-Study
products NCT03920306 235 243 B-Drug

Inclusion NCT03928028 0 9 O
Criteria NCT03928028 10 18 O
: NCT03928028 19 20 O
Adolescents NCT03928028 21 32 O

1 NCT03928028 35 36 O
. NCT03928028 36 37 O
Age NCT03928028 39 42 B-Age
12 NCT03928028 43 45 B-Eq-Comparison
- NCT03928028 46 47 I-Eq-Comparison
18 NCT03928028 48 50 O

2 NCT03928028 54 55 O
. NCT03928028 55 56 O
Currently NCT03928028 58 67 B-Eq-Comparison
meets NCT03928028 68 73 O
Diagnostic NCT03928028 74 84 O
and NCT03928028 85 88 O
Statistical NCT03928028 89 100 O
Manual NCT03928028 101 107 O
- NCT03928028 108 109 O
5 NCT03928028 110 111 O
criteria NCT03928028 112 120 O
for NCT03928028 121 124 O
Anorexia NCT03928028 125 133 B-Condition
Nervosa NCT03928028 134 141 I-Condition

3 NCT03928028 144 145 O
. NCT03928028 145 146 O
Medically NCT03928028 148 157 O
stable NCT03928028 158 164 B-Condition
for NCT03928028 165 168 B-Assertion___Assertion-Type-Value:hypothetical
outpatient NCT03928028 169 179 B-Encounter
treatment NCT03928028 180 189 B-Procedure

4 NCT03928028 192 193 O
. NCT03928028 193 194 O
Fluent NCT03928028 196 202 O
in NCT03928028 203 205 O
English NCT03928028 206 213 O

5 NCT03928028 216 217 O
. NCT03928028 217 218 O
No NCT03928028 220 222 B-Negation
co NCT03928028 223 225 B-Condition
- NCT03928028 226 227 I-Condition
morbid NCT03928028 228 234 I-Condition
condition NCT03928028 235 244 O
that NCT03928028 245 249 O
would NCT03928028 250 255 O
exclude NCT03928028 256 263 O
participation NCT03928028 264 277 O

6 NCT03928028 280 281 O
. NCT03928028 281 282 O
Medical NCT03928028 284 291 O
clearance NCT03928028 292 301 O
from NCT03928028 302 306 O
primary NCT03928028 307 314 O
care NCT03928028 315 319 O
physician NCT03928028 320 329 O
and NCT03928028 330 333 O
permission NCT03928028 334 344 O
to NCT03928028 345 347 O
speak NCT03928028 348 353 O
to NCT03928028 354 356 O
Primary NCT03928028 357 364 O
Care NCT03928028 365 369 O
Physician NCT03928028 370 379 O
about NCT03928028 380 385 O
clinical NCT03928028 386 394 O
issues NCT03928028 395 401 O

7 NCT03928028 404 405 O
. NCT03928028 405 406 O
Biological NCT03928028 408 418 O
parent NCT03928028 419 425 B-Family-Member___Family-Member-Type:parent
or NCT03928028 426 428 O
primary NCT03928028 429 436 O
caregiver NCT03928028 437 446 O
willing NCT03928028 447 454 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928028 455 457 I-Assertion___Assertion-Type-Value:hypothetical
engage NCT03928028 458 464 O
in NCT03928028 465 467 O
treatment NCT03928028 468 477 B-Procedure
and NCT03928028 478 481 O
who NCT03928028 482 485 O
live NCT03928028 486 490 O
with NCT03928028 491 495 O
the NCT03928028 496 499 O
adolescent NCT03928028 500 510 O

Inclusion NCT03928028 511 520 O
Criteria NCT03928028 521 529 O
: NCT03928028 530 531 O
Parents NCT03928028 532 539 B-Family-Member___Family-Member-Type:parent

1 NCT03928028 542 543 O
. NCT03928028 543 544 O
Age NCT03928028 546 549 B-Age
> NCT03928028 550 551 B-Eq-Comparison
18 NCT03928028 552 554 I-Eq-Comparison

2 NCT03928028 558 559 O
. NCT03928028 559 560 O
Child NCT03928028 562 567 O
with NCT03928028 568 572 B-And
a NCT03928028 573 574 O
diagnoses NCT03928028 575 584 O
of NCT03928028 585 587 O
AN NCT03928028 588 590 B-Condition

3 NCT03928028 593 594 O
. NCT03928028 594 595 O
Both NCT03928028 597 601 O
parents NCT03928028 602 609 O
willing NCT03928028 610 617 O
to NCT03928028 618 620 O
participate NCT03928028 621 632 O

4 NCT03928028 635 636 O
. NCT03928028 636 637 O
Fluent NCT03928028 639 645 O
in NCT03928028 646 648 O
English NCT03928028 649 656 O

5 NCT03928028 659 660 O
. NCT03928028 660 661 O
No NCT03928028 663 665 B-Negation
co NCT03928028 666 668 B-Condition
- NCT03928028 669 670 I-Condition
morbid NCT03928028 671 677 I-Condition
condition NCT03928028 678 687 O
that NCT03928028 688 692 O
would NCT03928028 693 698 O
exclude NCT03928028 699 706 O
participation NCT03928028 707 720 O

Exclusion NCT03928028 721 730 O
Criteria NCT03928028 731 739 O
: NCT03928028 740 741 O
Adolescent NCT03928028 742 752 O

1 NCT03928028 755 756 O
. NCT03928028 756 757 O
Adolescent NCT03928028 759 769 O
outside NCT03928028 770 777 B-Negation
age NCT03928028 778 781 B-Age
range NCT03928028 782 787 B-Eq-Comparison

2 NCT03928028 790 791 O
. NCT03928028 791 792 O
Adolescent NCT03928028 794 804 O
adopted NCT03928028 805 812 B-Condition

3 NCT03928028 815 816 O
. NCT03928028 816 817 O
Pregnant NCT03928028 819 827 B-Condition
adolescent NCT03928028 828 838 O

4 NCT03928028 841 842 O
. NCT03928028 842 843 O
Presence NCT03928028 845 853 O
of NCT03928028 854 856 O
: NCT03928028 857 858 O
pervasive NCT03928028 859 868 O
developmental NCT03928028 869 882 B-Condition
disability NCT03928028 883 893 I-Condition
, NCT03928028 894 895 O
psychosis NCT03928028 896 905 B-Condition
, NCT03928028 906 907 O
bipolar NCT03928028 908 915 B-Condition
disorder NCT03928028 916 924 I-Condition
, NCT03928028 925 926 O
substance NCT03928028 927 936 B-Condition
abuse NCT03928028 937 942 I-Condition
, NCT03928028 943 944 O
autism NCT03928028 945 951 B-Condition
spectrum NCT03928028 952 960 I-Condition
disorder NCT03928028 961 969 I-Condition
, NCT03928028 970 971 O
or NCT03928028 972 974 B-Or
intellectual NCT03928028 975 987 B-Condition
disability NCT03928028 988 998 I-Condition

5 NCT03928028 1001 1002 O
. NCT03928028 1002 1003 O
Presence NCT03928028 1005 1013 O
of NCT03928028 1014 1016 O
: NCT03928028 1017 1018 O
a NCT03928028 1019 1020 O
brain NCT03928028 1021 1026 B-Modifier
disorder NCT03928028 1027 1035 B-Condition
or NCT03928028 1036 1038 B-Or
injury NCT03928028 1039 1045 B-Condition
( NCT03928028 1046 1047 O
such NCT03928028 1048 1052 O
as NCT03928028 1053 1055 O
TBI NCT03928028 1056 1059 B-Condition
) NCT03928028 1060 1061 O
that NCT03928028 1062 1066 O
could NCT03928028 1067 1072 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03928028 1073 1079 O
the NCT03928028 1080 1083 O
ability NCT03928028 1084 1091 O
to NCT03928028 1092 1094 O
engage NCT03928028 1095 1101 O
in NCT03928028 1102 1104 O
treatment NCT03928028 1105 1114 B-Procedure

6 NCT03928028 1117 1118 O
. NCT03928028 1118 1119 O
Use NCT03928028 1121 1124 B-Eq-Comparison
of NCT03928028 1125 1127 O
anti NCT03928028 1128 1132 B-Drug
- NCT03928028 1133 1134 I-Drug
psychotic NCT03928028 1135 1144 I-Drug
medication NCT03928028 1145 1155 I-Drug

7 NCT03928028 1158 1159 O
. NCT03928028 1159 1160 O
Concurrent NCT03928028 1162 1172 B-Eq-Comparison
psychosocial NCT03928028 1173 1185 B-Procedure
therapy NCT03928028 1186 1193 I-Procedure

Exclusion NCT03928028 1194 1203 O
Criteria NCT03928028 1204 1212 O
: NCT03928028 1213 1214 O
Parents NCT03928028 1215 1222 B-Family-Member___Family-Member-Type:parent

1 NCT03928028 1225 1226 O
. NCT03928028 1226 1227 O
Presence NCT03928028 1229 1237 O
of NCT03928028 1238 1240 O
: NCT03928028 1241 1242 O
pervasive NCT03928028 1243 1252 O
developmental NCT03928028 1253 1266 B-Condition
disability NCT03928028 1267 1277 I-Condition
, NCT03928028 1278 1279 O
psychosis NCT03928028 1280 1289 B-Condition
, NCT03928028 1290 1291 O
bipolar NCT03928028 1292 1299 B-Condition
disorder NCT03928028 1300 1308 I-Condition|Condition
, NCT03928028 1309 1310 O
substance NCT03928028 1311 1320 B-Condition
abuse NCT03928028 1321 1326 I-Condition
, NCT03928028 1327 1328 O
autism NCT03928028 1329 1335 B-Condition
spectrum NCT03928028 1336 1344 I-Condition
disorder NCT03928028 1345 1353 O
, NCT03928028 1354 1355 O
or NCT03928028 1356 1358 B-Or
intellectual NCT03928028 1359 1371 B-Condition
disability NCT03928028 1372 1382 I-Condition
. NCT03928028 1382 1383 O

2 NCT03928028 1387 1388 O
. NCT03928028 1388 1389 O
Presence NCT03928028 1391 1399 O
of NCT03928028 1400 1402 O
: NCT03928028 1403 1404 O
a NCT03928028 1405 1406 O
brain NCT03928028 1407 1412 B-Modifier
disorder NCT03928028 1413 1421 B-Condition
or NCT03928028 1422 1424 B-Or
injury NCT03928028 1425 1431 B-Condition
( NCT03928028 1432 1433 O
such NCT03928028 1434 1438 O
as NCT03928028 1439 1441 O
TBI NCT03928028 1442 1445 B-Condition
) NCT03928028 1446 1447 O
that NCT03928028 1448 1452 O
could NCT03928028 1453 1458 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03928028 1459 1465 O
the NCT03928028 1466 1469 O
ability NCT03928028 1470 1477 O
to NCT03928028 1478 1480 O
engage NCT03928028 1481 1487 O
in NCT03928028 1488 1490 O
treatment NCT03928028 1491 1500 B-Procedure

3 NCT03928028 1503 1504 O
. NCT03928028 1504 1505 O
Use NCT03928028 1507 1510 B-Eq-Comparison
of NCT03928028 1511 1513 O
anti NCT03928028 1514 1518 B-Drug
- NCT03928028 1519 1520 I-Drug
psychotic NCT03928028 1521 1530 I-Drug
medication NCT03928028 1531 1541 I-Drug

Inclusion NCT03927482 0 9 O
Criteria NCT03927482 10 18 O
: NCT03927482 19 20 O

- NCT03927482 24 25 O
Currently NCT03927482 27 36 B-Eq-Comparison
enrolled NCT03927482 37 45 O
community NCT03927482 46 55 O
college NCT03927482 56 63 O
student NCT03927482 64 71 O

- NCT03927482 74 75 O
At NCT03927482 77 79 B-Eq-Comparison
least NCT03927482 80 85 I-Eq-Comparison
2 NCT03927482 86 87 I-Eq-Comparison
heavy NCT03927482 88 93 B-Condition
drinking NCT03927482 94 102 I-Condition
episodes NCT03927482 103 111 O
in NCT03927482 112 114 O
past NCT03927482 115 119 B-Eq-Comparison
2 NCT03927482 120 121 I-Eq-Comparison
weeks NCT03927482 122 127 I-Eq-Comparison
at NCT03927482 128 130 B-Temporal-Connection___Temporal-Connection-Type-Value:during
recruitment NCT03927482 131 142 B-Study

- NCT03927482 145 146 O
Own NCT03927482 148 151 O
smart NCT03927482 152 157 O
phone NCT03927482 158 163 O

Exclusion NCT03927482 164 173 O
Criteria NCT03927482 174 182 O
: NCT03927482 183 184 O

- NCT03927482 188 189 O
Alcohol NCT03927482 191 198 B-Condition
abuse NCT03927482 199 204 I-Condition
disorder NCT03927482 205 213 I-Condition
or NCT03927482 214 216 B-Or
currently NCT03927482 217 226 B-Eq-Comparison
in NCT03927482 227 229 O
treatment NCT03927482 230 239 B-Procedure
for NCT03927482 240 243 O
alcohol NCT03927482 244 251 B-Condition
- NCT03927482 252 253 I-Condition
related NCT03927482 254 261 I-Condition
problems NCT03927482 262 270 I-Condition

Inclusion NCT03920514 0 9 O
Criteria NCT03920514 10 18 O
: NCT03920514 19 20 O

- NCT03920514 24 25 O
Mild NCT03920514 27 31 O
male NCT03920514 32 36 B-Condition
infertility NCT03920514 37 48 I-Condition
or NCT03920514 49 51 B-Or
unexplained NCT03920514 52 63 B-Modifier
infertility NCT03920514 64 75 B-Condition

Exclusion NCT03920514 76 85 O
Criteria NCT03920514 86 94 O
: NCT03920514 95 96 O

- NCT03920514 100 101 O
Adanced NCT03920514 103 110 O
male NCT03920514 111 115 B-Modifier
factor NCT03920514 116 122 I-Modifier
endometriosis NCT03920514 123 136 B-Condition
uterine NCT03920514 137 144 B-Condition
abnormality NCT03920514 145 156 I-Condition
sever NCT03920514 157 162 O
semen NCT03920514 163 168 B-Condition
parameters NCT03920514 169 179 I-Condition
i NCT03920514 180 181 O
impairment NCT03920514 182 192 O
according NCT03920514 193 202 O
to NCT03920514 203 205 O
WHO NCT03920514 206 209 O
2010 NCT03920514 210 214 O
non NCT03920514 215 218 B-Condition
ovulatory NCT03920514 219 228 I-Condition
cycles NCT03920514 229 235 I-Condition
bilatral NCT03920514 236 244 B-Modifier
tubal NCT03920514 245 250 B-Condition
block NCT03920514 251 256 I-Condition

Inclusion NCT03923790 0 9 O
Criteria NCT03923790 10 18 O
: NCT03923790 19 20 O

- NCT03923790 24 25 O
Ischemic NCT03923790 27 35 B-Modifier
and NCT03923790 36 39 B-Or
hemorrhagic NCT03923790 40 51 B-Modifier
stroke NCT03923790 52 58 B-Condition
patients NCT03923790 59 67 O

- NCT03923790 70 71 O
Presence NCT03923790 73 81 O
of NCT03923790 82 84 O
at NCT03923790 85 87 B-Eq-Comparison
least NCT03923790 88 93 I-Eq-Comparison
one NCT03923790 94 97 I-Eq-Comparison
of NCT03923790 98 100 O
the NCT03923790 101 104 B-Criteria-Count
following NCT03923790 105 114 I-Criteria-Count
high NCT03923790 115 119 O
risk NCT03923790 120 124 B-Risk
criteria NCT03923790 125 133 O
: NCT03923790 134 135 O
uninsured NCT03923790 136 145 B-Negation
, NCT03923790 146 147 O
Medicaid NCT03923790 148 156 O
payer NCT03923790 157 162 O
status NCT03923790 163 169 O
, NCT03923790 170 171 O
small NCT03923790 172 177 B-Modifier
vessel NCT03923790 178 184 I-Modifier
ischemic NCT03923790 185 193 B-Condition
stroke NCT03923790 194 200 I-Condition
, NCT03923790 201 202 O
hypertensive NCT03923790 203 215 B-Modifier
ICH NCT03923790 216 219 B-Condition
) NCT03923790 220 221 O

- NCT03923790 225 226 O
Age NCT03923790 228 231 B-Age
≥ NCT03923790 232 233 B-Eq-Comparison
18 NCT03923790 234 236 I-Eq-Comparison
; NCT03923790 237 238 O
presence NCT03923790 239 247 O
of NCT03923790 248 250 O
hypertension NCT03923790 251 263 B-Condition
( NCT03923790 264 265 O
by NCT03923790 266 268 O
clinical NCT03923790 269 277 B-Observation
history NCT03923790 278 285 I-Observation
or NCT03923790 286 288 B-Or
hospital NCT03923790 289 297 O
BP NCT03923790 298 300 B-Observation
≥ NCT03923790 301 302 B-Eq-Comparison
140 NCT03923790 303 306 I-Eq-Comparison
/ NCT03923790 307 308 O
90 NCT03923790 309 311 O
on NCT03923790 312 314 O
two NCT03923790 315 318 B-Eq-Comparison
occasions NCT03923790 319 328 O
) NCT03923790 329 330 O

- NCT03923790 334 335 O
Plan NCT03923790 337 341 B-Eq-Comparison
to NCT03923790 342 344 O
discharge NCT03923790 345 354 B-Encounter
home NCT03923790 355 359 O
after NCT03923790 360 365 B-Temporal-Connection___Temporal-Connection-Type-Value:after
stroke NCT03923790 366 372 B-Condition

- NCT03923790 375 376 O
Ability NCT03923790 378 385 O
to NCT03923790 386 388 O
provide NCT03923790 389 396 O
consent NCT03923790 397 404 O
( NCT03923790 405 406 O
patient NCT03923790 407 414 O
or NCT03923790 415 417 O
caregiver NCT03923790 418 427 O
) NCT03923790 428 429 O

- NCT03923790 433 434 O
Ability NCT03923790 436 443 O
to NCT03923790 444 446 O
communicate NCT03923790 447 458 O
in NCT03923790 459 461 O
English NCT03923790 462 469 O

Exclusion NCT03923790 470 479 O
Criteria NCT03923790 480 488 O
: NCT03923790 489 490 O

- NCT03923790 494 495 O
modified NCT03923790 497 505 B-Observation
Rankin NCT03923790 506 512 I-Observation
scale NCT03923790 513 518 I-Observation
> NCT03923790 519 520 B-Eq-Comparison
4 NCT03923790 521 522 I-Eq-Comparison
at NCT03923790 523 525 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923790 526 529 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03923790 530 534 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03923790 535 537 O
enrollment NCT03923790 538 548 B-Study
( NCT03923790 549 550 O
severe NCT03923790 551 557 O
disability NCT03923790 558 568 B-Condition
) NCT03923790 569 570 O

- NCT03923790 574 575 O
life NCT03923790 577 581 B-Observation
expectancy NCT03923790 582 592 I-Observation
< NCT03923790 593 594 B-Eq-Comparison
1 NCT03923790 595 596 I-Eq-Comparison
year NCT03923790 597 601 I-Eq-Comparison
or NCT03923790 602 604 B-Or
terminal NCT03923790 605 613 B-Condition
illness NCT03923790 614 621 I-Condition
, NCT03923790 622 623 O

- NCT03923790 627 628 O
eGFR NCT03923790 630 634 B-Observation
< NCT03923790 635 636 B-Eq-Comparison
30 NCT03923790 637 639 I-Eq-Comparison
at NCT03923790 640 642 B-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03923790 643 647 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03923790 648 650 I-Temporal-Connection___Temporal-Connection-Type-Value:during
discharge NCT03923790 651 660 B-Encounter

- NCT03923790 663 664 O
pregnancy NCT03923790 666 675 B-Condition

- NCT03923790 678 679 O
symptomatic NCT03923790 681 692 B-Condition
flow NCT03923790 693 697 I-Condition
limiting NCT03923790 698 706 O
carotid NCT03923790 707 714 B-Condition
stenosis NCT03923790 715 723 I-Condition
without NCT03923790 724 731 B-Negation
plan NCT03923790 732 736 B-Assertion___Assertion-Type-Value:intention
for NCT03923790 737 740 O
intervention NCT03923790 741 753 B-Procedure

- NCT03923790 756 757 O
urine NCT03923790 759 764 B-Observation
toxicology NCT03923790 765 775 I-Observation
positive NCT03923790 776 784 O
for NCT03923790 785 788 O
cocaine NCT03923790 789 796 B-Drug
or NCT03923790 797 799 B-Or|Or
methamphetamine NCT03923790 800 815 B-Drug
or NCT03923790 816 818 O
recent NCT03923790 819 825 B-Eq-Comparison
use NCT03923790 826 829 B-Coreference

- NCT03923790 832 833 I-Modifier
long NCT03923790 835 839 B-Modifier
- NCT03923790 840 841 O
term NCT03923790 842 846 I-Modifier
BP NCT03923790 847 849 B-Observation
goal NCT03923790 850 854 B-Assertion___Assertion-Type-Value:hypothetical
≥ NCT03923790 855 856 B-Eq-Comparison
130 NCT03923790 857 860 I-Eq-Comparison
/ NCT03923790 861 862 I-Eq-Comparison
80 NCT03923790 863 865 I-Eq-Comparison
mmHg NCT03923790 866 870 I-Eq-Comparison
according NCT03923790 871 880 O
to NCT03923790 881 883 O
clinical NCT03923790 884 892 O
team NCT03923790 893 897 O

Inclusion NCT03929068 0 9 O
Criteria NCT03929068 10 18 O
: NCT03929068 19 20 O

- NCT03929068 24 25 O
Diagnosis NCT03929068 27 36 O
of NCT03929068 37 39 O
ALS NCT03929068 40 43 B-Condition
or NCT03929068 44 46 B-Or
PLS NCT03929068 47 50 B-Condition

- NCT03929068 53 54 O
Age NCT03929068 56 59 B-Age
greater NCT03929068 60 67 B-Eq-Comparison
than NCT03929068 68 72 I-Eq-Comparison
18 NCT03929068 73 75 I-Eq-Comparison
years NCT03929068 76 81 I-Eq-Comparison

- NCT03929068 84 85 O
Clinically NCT03929068 87 97 O
significant NCT03929068 98 109 O
spasticity NCT03929068 110 120 B-Condition
. NCT03929068 120 121 O

Exclusion NCT03929068 123 132 O
Criteria NCT03929068 133 141 O
: NCT03929068 142 143 O

- NCT03929068 147 148 O
Individuals NCT03929068 150 161 O
currently NCT03929068 162 171 B-Eq-Comparison
taking NCT03929068 172 178 I-Eq-Comparison
carbidopa NCT03929068 179 188 B-Drug
- NCT03929068 189 190 I-Drug
levodopa NCT03929068 191 199 I-Drug
or NCT03929068 200 202 B-Or
with NCT03929068 203 207 O
known NCT03929068 208 213 O
hypersensitivity NCT03929068 214 230 B-Condition
of NCT03929068 231 233 O
any NCT03929068 234 237 O
component NCT03929068 238 247 O
of NCT03929068 248 250 O
carbidopa NCT03929068 251 260 B-Drug
- NCT03929068 261 262 I-Drug
levodopa NCT03929068 263 271 I-Drug

- NCT03929068 274 275 I-Condition
Narrow NCT03929068 277 283 B-Condition
- NCT03929068 284 285 O
angle NCT03929068 286 291 I-Condition
glaucoma NCT03929068 292 300 I-Condition

- NCT03929068 303 304 O
Current NCT03929068 306 313 B-Eq-Comparison
use NCT03929068 314 317 I-Eq-Comparison
of NCT03929068 318 320 O
a NCT03929068 321 322 O
non NCT03929068 323 326 B-Drug
- NCT03929068 327 328 I-Drug
selective NCT03929068 329 338 I-Drug
monoamine NCT03929068 339 348 I-Drug
oxidase NCT03929068 349 356 I-Drug
inhibitor NCT03929068 357 366 I-Drug
( NCT03929068 367 368 O
MAOI NCT03929068 369 373 B-Drug
) NCT03929068 374 375 O

- NCT03929068 379 380 O
History NCT03929068 382 389 B-Eq-Comparison
of NCT03929068 390 392 O
malignant NCT03929068 393 402 B-Condition
melanoma NCT03929068 403 411 I-Condition
or NCT03929068 412 414 B-Or
suspicious NCT03929068 415 425 O
skin NCT03929068 426 430 B-Condition
lesions NCT03929068 431 438 I-Condition

- NCT03929068 441 442 O
History NCT03929068 444 451 B-Eq-Comparison
of NCT03929068 452 454 O
depression NCT03929068 455 465 B-Condition
, NCT03929068 466 467 O
suicidal NCT03929068 468 476 B-Condition
ideation NCT03929068 477 485 I-Condition
, NCT03929068 486 487 O
or NCT03929068 488 490 B-Or
psychosis NCT03929068 491 500 B-Condition

- NCT03929068 503 504 O
History NCT03929068 506 513 B-Eq-Comparison
of NCT03929068 514 516 O
myocardial NCT03929068 517 527 B-Condition
infarction NCT03929068 528 538 I-Condition
, NCT03929068 539 540 O
ventricular NCT03929068 541 552 B-Condition
arrhythmia NCT03929068 553 563 I-Condition
, NCT03929068 564 565 O
or NCT03929068 566 568 B-Or
severe NCT03929068 569 575 O
cardiopulmonary NCT03929068 576 591 B-Condition
disease NCT03929068 592 599 I-Condition

- NCT03929068 602 603 O
Uncontrolled NCT03929068 605 617 B-Modifier
hypertension NCT03929068 618 630 B-Condition

- NCT03929068 633 634 O
Asthma NCT03929068 636 642 B-Condition

- NCT03929068 645 646 O
Renal NCT03929068 648 653 B-Condition
disease NCT03929068 654 661 I-Condition|Condition

- NCT03929068 664 665 O
Hepatic NCT03929068 667 674 B-Condition
disease NCT03929068 675 682 O

- NCT03929068 685 686 O
Endocrine NCT03929068 688 697 B-Condition
disease NCT03929068 698 705 I-Condition

- NCT03929068 708 709 O
History NCT03929068 711 718 B-Eq-Comparison
of NCT03929068 719 721 O
peptic NCT03929068 722 728 B-Condition
ulcer NCT03929068 729 734 I-Condition

- NCT03929068 737 738 O
Pregnant NCT03929068 740 748 O
and NCT03929068 749 752 O
/ NCT03929068 753 754 O
or NCT03929068 755 757 O
breastfeeding NCT03929068 758 771 O

- NCT03929068 774 775 O
Current NCT03929068 777 784 B-Eq-Comparison
participation NCT03929068 785 798 O
in NCT03929068 799 801 O
another NCT03929068 802 809 B-Other
interventional NCT03929068 810 824 O
study NCT03929068 825 830 B-Study

Inclusion NCT03926429 0 9 O
Criteria NCT03926429 10 18 O
: NCT03926429 19 20 O

- NCT03926429 24 25 O
reactive NCT03926429 27 35 B-Condition
arthritis NCT03926429 36 45 I-Condition
diagnosed NCT03926429 46 55 O
in NCT03926429 56 58 O
one NCT03926429 59 62 O
of NCT03926429 63 65 O
the NCT03926429 66 69 O
two NCT03926429 70 73 O
rheumatology NCT03926429 74 86 O
departments NCT03926429 87 98 O
from NCT03926429 99 103 O
Centre NCT03926429 104 110 O
Hospitalier NCT03926429 111 122 O
Lyon NCT03926429 123 127 O
Sud NCT03926429 128 131 O
or NCT03926429 132 134 B-Or
Besançon NCT03926429 135 143 O

Exclusion NCT03926429 144 153 O
Criteria NCT03926429 154 162 O
: NCT03926429 163 164 O

- NCT03926429 168 169 O
presence NCT03926429 171 179 O
of NCT03926429 180 182 O
other NCT03926429 183 188 B-Other
known NCT03926429 189 194 O
causes NCT03926429 195 201 B-Condition
of NCT03926429 202 204 O
arthritis NCT03926429 205 214 B-Condition
, NCT03926429 215 216 O
such NCT03926429 217 221 O
as NCT03926429 222 224 O
other NCT03926429 225 230 B-Other
defined NCT03926429 231 238 O
spondyloarthritides NCT03926429 239 258 B-Condition
, NCT03926429 259 260 O
septic NCT03926429 261 267 B-Modifier
arthritis NCT03926429 268 277 B-Condition
, NCT03926429 278 279 O
Lyme NCT03926429 280 284 B-Condition
disease NCT03926429 285 292 I-Condition
, NCT03926429 293 294 O
microcrystalline NCT03926429 295 311 B-Modifier
arthritis NCT03926429 312 321 B-Condition
or NCT03926429 322 324 B-Or
rheumatoid NCT03926429 325 335 B-Modifier
arthritis NCT03926429 336 345 B-Condition

Inclusion NCT03927079 0 9 O
Criteria NCT03927079 10 18 O
: NCT03927079 19 20 O

- NCT03927079 24 25 O
patients NCT03927079 27 35 O
who NCT03927079 36 39 O
undergo NCT03927079 40 47 O
a NCT03927079 48 49 O
flexible NCT03927079 50 58 O
bronchoscopic NCT03927079 59 72 B-Procedure
lavage NCT03927079 73 79 I-Procedure
and NCT03927079 80 83 B-And
with NCT03927079 84 88 O
a NCT03927079 89 90 O
beta NCT03927079 91 95 B-Drug
lactamines NCT03927079 96 106 I-Drug
treatment NCT03927079 107 116 B-Procedure
as NCT03927079 117 119 O
cephalosporin NCT03927079 120 133 B-Drug
of NCT03927079 134 136 O
3 NCT03927079 137 138 B-Modifier
rd NCT03927079 139 141 O
generation NCT03927079 142 152 I-Modifier
( NCT03927079 153 154 O
CEFTRIAXONE NCT03927079 155 166 B-Drug
/ NCT03927079 167 168 B-Or
CEFOTAXIME NCT03927079 169 179 B-Drug
, NCT03927079 180 181 O
CEFTAZIDIME NCT03927079 182 193 B-Drug
) NCT03927079 194 195 O
, NCT03927079 197 198 O
of NCT03927079 199 201 O
4 NCT03927079 202 203 B-Modifier
th NCT03927079 204 206 O
generation NCT03927079 207 217 I-Modifier
( NCT03927079 218 219 O
CEFEPIM NCT03927079 220 227 B-Drug
) NCT03927079 228 229 O
, NCT03927079 231 232 O
or NCT03927079 233 235 B-Or
AMOXICILLIN NCT03927079 236 247 B-Drug
- NCT03927079 248 249 I-Drug
CLAVULANIC NCT03927079 250 260 I-Drug
ACID NCT03927079 261 265 I-Drug
, NCT03927079 266 267 O
or NCT03927079 268 270 B-Or
PIPERACILLIN NCT03927079 271 283 B-Drug
- NCT03927079 284 285 I-Drug
TAZOBACTAM NCT03927079 286 296 I-Drug

- NCT03927079 299 300 O
patient NCT03927079 302 309 O
major NCT03927079 310 315 O

- NCT03927079 318 319 O
informed NCT03927079 321 329 O
and NCT03927079 330 333 O
signed NCT03927079 334 340 O
consent NCT03927079 341 348 O
form NCT03927079 349 353 O

Exclusion NCT03927079 354 363 O
Criteria NCT03927079 364 372 O
: NCT03927079 373 374 O

- NCT03927079 378 379 O
patient NCT03927079 381 388 O
under NCT03927079 389 394 B-Eq-Comparison
chronic NCT03927079 395 402 B-Modifier
dialysis NCT03927079 403 411 B-Procedure

- NCT03927079 414 415 O
patient NCT03927079 417 424 O
placed NCT03927079 425 431 O
under NCT03927079 432 437 O
judicial NCT03927079 438 446 B-Observation
protection NCT03927079 447 457 I-Observation

Inclusion NCT03922698 0 9 O
Criteria NCT03922698 10 18 O
: NCT03922698 19 20 O

- NCT03922698 24 25 O
age NCT03922698 27 30 B-Age
≥ NCT03922698 31 32 B-Eq-Comparison
45 NCT03922698 33 35 I-Eq-Comparison
and NCT03922698 36 39 B-And
≤ NCT03922698 40 41 B-Eq-Comparison
90 NCT03922698 42 44 I-Eq-Comparison
years NCT03922698 45 50 I-Eq-Comparison
; NCT03922698 50 51 O

- NCT03922698 54 55 O
patients NCT03922698 57 65 O
with NCT03922698 66 70 O
severe NCT03922698 71 77 O
( NCT03922698 78 79 O
70 NCT03922698 80 82 B-Eq-Comparison
- NCT03922698 83 84 I-Eq-Comparison
99 NCT03922698 85 87 I-Eq-Comparison
% NCT03922698 88 89 O
) NCT03922698 90 91 O
carotid NCT03922698 92 99 B-Observation
stenosis NCT03922698 100 108 I-Observation
, NCT03922698 109 110 O
diagnosed NCT03922698 111 120 O
with NCT03922698 121 125 O
color NCT03922698 126 131 B-Procedure
doppler NCT03922698 132 139 I-Procedure
echography NCT03922698 140 150 I-Procedure
or NCT03922698 151 153 B-Or
angio NCT03922698 154 159 B-Modifier
- NCT03922698 160 161 O
MRI NCT03922698 162 165 B-Procedure
or NCT03922698 166 168 B-Or
angiography NCT03922698 169 180 B-Procedure
; NCT03922698 180 181 O

- NCT03922698 184 185 O
written NCT03922698 187 194 O
informed NCT03922698 195 203 O
consent NCT03922698 204 211 O
. NCT03922698 211 212 O

Exclusion NCT03922698 214 223 O
Criteria NCT03922698 224 232 O
: NCT03922698 233 234 O

- NCT03922698 238 239 O
carotid NCT03922698 241 248 B-Observation
stenosis NCT03922698 249 257 I-Observation
< NCT03922698 258 259 B-Eq-Comparison
70 NCT03922698 260 262 I-Eq-Comparison
% NCT03922698 263 264 O
at NCT03922698 265 267 O
carotid NCT03922698 268 275 B-Modifier
bifurcation NCT03922698 276 287 I-Modifier
or NCT03922698 288 290 B-Or
diagnosed NCT03922698 291 300 O
with NCT03922698 301 305 O
color NCT03922698 306 311 B-Procedure
doppler NCT03922698 312 319 I-Procedure
echography NCT03922698 320 330 I-Procedure
or NCT03922698 331 333 B-Or|Or
angio NCT03922698 334 339 B-Modifier|Procedure
- NCT03922698 340 341 O
MRI NCT03922698 342 345 B-Procedure
or NCT03922698 346 348 O
angiography NCT03922698 349 360 O
; NCT03922698 360 361 O

- NCT03922698 364 365 O
severe NCT03922698 367 373 O
neoplasia NCT03922698 374 383 B-Condition
; NCT03922698 383 384 O

- NCT03922698 387 388 O
participation NCT03922698 390 403 O
to NCT03922698 404 406 O
other NCT03922698 407 412 B-Other
clinical NCT03922698 413 421 B-Study
trial NCT03922698 422 427 I-Study
, NCT03922698 428 429 O
ongoing NCT03922698 430 437 B-Eq-Comparison
or NCT03922698 438 440 B-Or
terminated NCT03922698 441 451 O
less NCT03922698 452 456 B-Eq-Comparison
than NCT03922698 457 461 I-Eq-Comparison
one NCT03922698 462 465 I-Eq-Comparison
month NCT03922698 466 471 I-Eq-Comparison
before NCT03922698 472 478 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03922698 479 488 O
in NCT03922698 489 491 O
this NCT03922698 492 496 O
study NCT03922698 497 502 B-Study
. NCT03922698 502 503 O

Inclusion NCT03927092 0 9 O
Criteria NCT03927092 10 18 O
: NCT03927092 19 20 O

- NCT03927092 24 25 O
Diagnosed NCT03927092 27 36 O
as NCT03927092 37 39 O
having NCT03927092 40 46 O
Multiple NCT03927092 47 55 B-Condition
Sclerosis NCT03927092 56 65 I-Condition

- NCT03927092 68 69 O
Attends NCT03927092 71 78 O
the NCT03927092 79 82 O
annual NCT03927092 83 89 O
patient NCT03927092 90 97 O
education NCT03927092 98 107 O
seminar NCT03927092 108 115 O
at NCT03927092 116 118 O
the NCT03927092 119 122 O
investigators NCT03927092 123 136 O
' NCT03927092 136 137 O
university NCT03927092 138 148 O
hospital NCT03927092 149 157 O

- NCT03927092 160 161 O
Older NCT03927092 163 168 B-Eq-Comparison
than NCT03927092 169 173 I-Eq-Comparison
18 NCT03927092 174 176 I-Eq-Comparison
years NCT03927092 177 182 I-Eq-Comparison
of NCT03927092 183 185 O
age NCT03927092 186 189 B-Age

- NCT03927092 192 193 O
Can NCT03927092 195 198 O
read NCT03927092 199 203 O
and NCT03927092 204 207 O
write NCT03927092 208 213 O

Exclusion NCT03927092 214 223 O
Criteria NCT03927092 224 232 O
: NCT03927092 233 234 O

- NCT03927092 238 239 O
Does NCT03927092 241 245 O
not NCT03927092 246 249 B-Negation
accept NCT03927092 250 256 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03927092 257 259 O
answer NCT03927092 260 266 O
the NCT03927092 267 270 O
questionnaire NCT03927092 271 284 B-Observation

- NCT03927092 287 288 O
Unable NCT03927092 290 296 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03927092 297 299 O
answer NCT03927092 300 306 O
the NCT03927092 307 310 O
questions NCT03927092 311 320 B-Procedure
due NCT03927092 321 324 O
to NCT03927092 325 327 O
a NCT03927092 328 329 O
cognitive NCT03927092 330 339 B-Condition
impairment NCT03927092 340 350 I-Condition

Inclusion NCT03920930 0 9 O
Criteria NCT03920930 10 18 O
: NCT03920930 19 20 O

• NCT03920930 22 23 O
patients NCT03920930 24 32 O
undergoing NCT03920930 33 43 B-Eq-Comparison
elective NCT03920930 44 52 O
, NCT03920930 53 54 O
primary NCT03920930 55 62 B-Modifier
knee NCT03920930 63 67 B-Procedure
joint NCT03920930 68 73 I-Procedure
replacement NCT03920930 74 85 I-Procedure
in NCT03920930 86 88 O
combined NCT03920930 89 97 O
general NCT03920930 98 105 B-Procedure
anaesthesia NCT03920930 106 117 I-Procedure

Exclusion NCT03920930 118 127 O
Criteria NCT03920930 128 136 O
: NCT03920930 137 138 O

- NCT03920930 142 143 O
heart NCT03920930 145 150 B-Condition
insufficiency NCT03920930 151 164 I-Condition
NYHA NCT03920930 165 169 B-Condition
> NCT03920930 170 171 B-Eq-Comparison
2 NCT03920930 172 173 I-Eq-Comparison

- NCT03920930 177 178 O
liver NCT03920930 180 185 B-Condition
insufficiency NCT03920930 186 199 I-Condition
> NCT03920930 200 201 O
CHILD NCT03920930 202 207 O
B NCT03920930 208 209 O

- NCT03920930 212 213 O
evidence NCT03920930 215 223 O
of NCT03920930 224 226 O
diabetic NCT03920930 227 235 B-Condition
polyneuropathy NCT03920930 236 250 I-Condition

- NCT03920930 253 254 O
severe NCT03920930 256 262 O
adipositas NCT03920930 263 273 B-Condition
BMI NCT03920930 274 277 B-Observation
> NCT03920930 278 279 B-Eq-Comparison
40 NCT03920930 280 282 I-Eq-Comparison

- NCT03920930 286 287 O
patients NCT03920930 289 297 O
< NCT03920930 298 299 B-Eq-Comparison
18 NCT03920930 300 302 I-Eq-Comparison
years NCT03920930 303 308 I-Age|Eq-Comparison

- NCT03920930 311 312 O
pregnancy NCT03920930 314 323 B-Condition

- NCT03920930 326 327 O
in NCT03920930 329 331 O
case NCT03920930 332 336 O
of NCT03920930 337 339 O
police NCT03920930 340 346 B-Observation
custody NCT03920930 347 354 I-Observation

- NCT03920930 357 358 O
participation NCT03920930 360 373 O
in NCT03920930 374 376 O
a NCT03920930 377 378 O
paralleled NCT03920930 379 389 B-Other
interventional NCT03920930 390 404 O
RCT NCT03920930 405 408 B-Study
in NCT03920930 409 411 O
a NCT03920930 412 413 O
time NCT03920930 414 418 O
frame NCT03920930 419 424 O
of NCT03920930 425 427 O
30 NCT03920930 428 430 B-Eq-Comparison
days NCT03920930 431 435 I-Eq-Comparison

- NCT03920930 438 439 O
chronic NCT03920930 441 448 B-Modifier
opioid NCT03920930 449 455 B-Procedure
therapy NCT03920930 456 463 I-Procedure
> NCT03920930 464 465 B-Eq-Comparison
3 NCT03920930 466 467 I-Eq-Comparison
months NCT03920930 468 474 I-Eq-Comparison
before NCT03920930 475 481 B-Temporal-Connection___Temporal-Connection-Type-Value:before
scheduled NCT03920930 482 491 B-Eq-Comparison
surgery NCT03920930 492 499 B-Procedure

- NCT03920930 502 503 O
allergy NCT03920930 505 512 B-Allergy
against NCT03920930 513 520 O
medication NCT03920930 521 531 B-Drug
required NCT03920930 532 540 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920930 541 544 I-Assertion___Assertion-Type-Value:hypothetical
surgery NCT03920930 545 552 B-Procedure
or NCT03920930 553 555 B-Or
anaesthesia NCT03920930 556 567 B-Procedure


Inclusion NCT03922841 0 9 O
Criteria NCT03922841 10 18 O
: NCT03922841 19 20 O

- NCT03922841 24 25 O
The NCT03922841 27 30 O
subject NCT03922841 31 38 O
must NCT03922841 39 43 O
meet NCT03922841 44 48 O
all NCT03922841 49 52 O
of NCT03922841 53 55 O
the NCT03922841 56 59 O
following NCT03922841 60 69 O
inclusion NCT03922841 70 79 O
criteria NCT03922841 80 88 O
to NCT03922841 89 91 O
participate NCT03922841 92 103 O
in NCT03922841 104 106 O
this NCT03922841 107 111 O
study NCT03922841 112 117 O
. NCT03922841 117 118 O

1 NCT03922841 127 128 O
. NCT03922841 128 129 O
Evidence NCT03922841 131 139 O
of NCT03922841 140 142 O
pleural NCT03922841 143 150 B-Condition
disease NCT03922841 151 158 I-Condition
on NCT03922841 159 161 O
chest NCT03922841 162 167 B-Procedure
radiograph NCT03922841 168 178 I-Procedure
or NCT03922841 179 181 B-Or
bedside NCT03922841 182 189 B-Procedure
ultrasound NCT03922841 190 200 I-Procedure
or NCT03922841 201 203 B-Or
Computed NCT03922841 204 212 B-Procedure
Tomography NCT03922841 213 223 I-Procedure
regardless NCT03922841 224 234 O
of NCT03922841 235 237 O
underlying NCT03922841 238 248 O
aetiology NCT03922841 249 258 O

2 NCT03922841 266 267 O
. NCT03922841 267 268 O
No NCT03922841 270 272 B-Negation
age NCT03922841 273 276 B-Age
or NCT03922841 277 279 B-Or
gender NCT03922841 280 286 O
restrictions NCT03922841 287 299 O

3 NCT03922841 307 308 O
. NCT03922841 308 309 O
Ability NCT03922841 311 318 O
to NCT03922841 319 321 O
provide NCT03922841 322 329 O
informed NCT03922841 330 338 O
consent NCT03922841 339 346 O

Exclusion NCT03922841 347 356 O
Criteria NCT03922841 357 365 O
: NCT03922841 366 367 O

- NCT03922841 371 372 O
Subjects NCT03922841 374 382 O
who NCT03922841 383 386 O
no NCT03922841 387 389 B-Negation
radiographic NCT03922841 390 402 B-Procedure
evidence NCT03922841 403 411 O
of NCT03922841 412 414 O
pleural NCT03922841 415 422 B-Condition
disease NCT03922841 423 430 I-Condition
or NCT03922841 431 433 O
who NCT03922841 434 437 O
are NCT03922841 438 441 O
unwilling NCT03922841 442 451 O
/ NCT03922841 452 453 O
unable NCT03922841 454 460 O
to NCT03922841 461 463 O
provide NCT03922841 464 471 O
informed NCT03922841 472 480 O
consent NCT03922841 481 488 O

Inclusion NCT03922672 0 9 O
Criteria NCT03922672 10 18 O
: NCT03922672 19 20 O

- NCT03922672 24 25 O
Caregiver NCT03922672 27 36 O
: NCT03922672 37 38 O

- NCT03922672 47 48 O
Are NCT03922672 50 53 O
currently NCT03922672 54 63 B-Eq-Comparison
a NCT03922672 64 65 O
primary NCT03922672 66 73 B-Observation
caregiver NCT03922672 74 83 I-Observation
to NCT03922672 84 86 O
an NCT03922672 87 89 O
adult NCT03922672 90 95 O
with NCT03922672 96 100 B-And
PD NCT03922672 101 103 B-Condition

- NCT03922672 111 112 O
Are NCT03922672 114 117 O
between NCT03922672 118 125 O
the NCT03922672 126 129 O
age NCT03922672 130 133 B-Age
of NCT03922672 134 136 O
40 NCT03922672 137 139 B-Eq-Comparison
- NCT03922672 140 141 I-Eq-Comparison
80 NCT03922672 142 144 I-Eq-Comparison
years NCT03922672 145 150 I-Eq-Comparison

- NCT03922672 158 159 O
Have NCT03922672 161 165 O
less NCT03922672 166 170 B-Eq-Comparison
than NCT03922672 171 175 I-Eq-Comparison
5 NCT03922672 176 177 I-Eq-Comparison
years NCT03922672 178 183 I-Eq-Comparison
of NCT03922672 184 186 O
music NCT03922672 187 192 B-Observation
training NCT03922672 193 201 I-Observation

- NCT03922672 209 210 O
Speak NCT03922672 212 217 O
and NCT03922672 218 221 O
read NCT03922672 222 226 O
English NCT03922672 227 234 O
fluently NCT03922672 235 243 O

Adult NCT03922672 244 249 O
with NCT03922672 250 254 B-And
PD NCT03922672 255 257 B-Condition
: NCT03922672 258 259 O

- NCT03922672 263 264 O
Stage NCT03922672 266 271 B-Eq-Comparison
1 NCT03922672 272 273 I-Eq-Comparison
- NCT03922672 274 275 I-Eq-Comparison
3 NCT03922672 276 277 I-Eq-Comparison
Parkinson NCT03922672 278 287 B-Condition
's NCT03922672 287 289 O
disease NCT03922672 290 297 I-Condition

- NCT03922672 300 301 O
Are NCT03922672 303 306 O
between NCT03922672 307 314 O
the NCT03922672 315 318 O
age NCT03922672 319 322 B-Age
of NCT03922672 323 325 O
40 NCT03922672 326 328 B-Eq-Comparison
- NCT03922672 329 330 I-Eq-Comparison
80 NCT03922672 331 333 O

- NCT03922672 337 338 O
Have NCT03922672 340 344 O
less NCT03922672 345 349 B-Eq-Comparison
than NCT03922672 350 354 I-Eq-Comparison
5 NCT03922672 355 356 I-Eq-Comparison
years NCT03922672 357 362 I-Eq-Comparison
of NCT03922672 363 365 O
music NCT03922672 366 371 B-Observation
training NCT03922672 372 380 I-Observation

- NCT03922672 383 384 O
Speak NCT03922672 386 391 O
and NCT03922672 392 395 O
read NCT03922672 396 400 O
English NCT03922672 401 408 O
fluently NCT03922672 409 417 O

Exclusion NCT03922672 418 427 O
Criteria NCT03922672 428 436 O
: NCT03922672 437 438 O

- NCT03922672 442 443 O
Does NCT03922672 445 449 O
n't NCT03922672 449 452 O
meet NCT03922672 453 457 O
all NCT03922672 458 461 O
the NCT03922672 462 465 O
inclusion NCT03922672 466 475 O
criteria NCT03922672 476 484 O

Inclusion NCT03929055 0 9 O
Criteria NCT03929055 10 18 O
: NCT03929055 19 20 O

- NCT03929055 24 25 O
patient NCT03929055 27 34 O
with NCT03929055 35 39 O
acute NCT03929055 40 45 B-Condition
respiratory NCT03929055 46 57 I-Condition
failure NCT03929055 58 65 I-Condition
, NCT03929055 66 67 O
not NCT03929055 68 71 B-Negation
intubated NCT03929055 72 81 B-Procedure
, NCT03929055 82 83 O
who NCT03929055 84 87 B-And
require NCT03929055 88 95 B-Assertion___Assertion-Type-Value:hypothetical
non NCT03929055 96 99 B-Modifier
invasive NCT03929055 100 108 I-Modifier
mechanical NCT03929055 109 119 B-Procedure
ventilation NCT03929055 120 131 I-Procedure

Exclusion NCT03929055 132 141 O
Criteria NCT03929055 142 150 O
: NCT03929055 151 152 O

- NCT03929055 156 157 O
patients NCT03929055 159 167 O
in NCT03929055 168 170 O
which NCT03929055 171 176 O
it NCT03929055 177 179 O
is NCT03929055 180 182 O
not NCT03929055 183 186 B-Negation
possible NCT03929055 187 195 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929055 196 198 O
place NCT03929055 199 204 O
the NCT03929055 205 208 O
esophageal NCT03929055 209 219 B-Modifier
catheter NCT03929055 220 228 B-Procedure
or NCT03929055 229 231 B-Or
it NCT03929055 232 234 O
is NCT03929055 235 237 O
not NCT03929055 238 241 B-Negation
possible NCT03929055 242 250 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929055 251 253 O
detect NCT03929055 254 260 O
the NCT03929055 261 264 O
diaphragm NCT03929055 265 274 B-Condition
by NCT03929055 275 277 O
ultrasound NCT03929055 278 288 B-Procedure
or NCT03929055 289 291 B-Or
it NCT03929055 292 294 O
is NCT03929055 295 297 O
not NCT03929055 298 301 B-Negation
possible NCT03929055 302 310 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929055 311 313 O
apply NCT03929055 314 319 O
the NCT03929055 320 323 O
nasal NCT03929055 324 329 B-Procedure
cannula NCT03929055 330 337 I-Procedure
device NCT03929055 338 344 I-Procedure

Inclusion NCT03928405 0 9 O
Criteria NCT03928405 10 18 O
: NCT03928405 19 20 O

- NCT03928405 24 25 O
Having NCT03928405 27 33 O
mild NCT03928405 34 38 O
or NCT03928405 39 41 B-Or
moderate NCT03928405 42 50 O
severity NCT03928405 51 59 O
of NCT03928405 60 62 O
AD NCT03928405 63 65 B-Condition

- NCT03928405 68 69 O
Lack NCT03928405 71 75 B-Negation
of NCT03928405 76 78 O
communication NCT03928405 79 92 B-Condition
difficulties NCT03928405 93 105 B-Modifier
or NCT03928405 106 108 B-Or
problems NCT03928405 109 117 B-Modifier

- NCT03928405 120 121 O
Volunteering NCT03928405 123 135 O
to NCT03928405 136 138 O
participate NCT03928405 139 150 O
in NCT03928405 151 153 O
the NCT03928405 154 157 O
study NCT03928405 158 163 B-Study

- NCT03928405 166 167 O
Cerebrovascular NCT03928405 169 184 B-Condition
event NCT03928405 185 190 I-Condition
, NCT03928405 191 192 O

- NCT03928405 196 197 O
Having NCT03928405 199 205 O
disturbing NCT03928405 206 216 O
the NCT03928405 217 220 O
balance NCT03928405 221 228 B-Condition
and NCT03928405 229 232 B-Or
coordination NCT03928405 233 245 B-Condition
of NCT03928405 246 248 O
neurological NCT03928405 249 261 B-Condition
disease NCT03928405 262 269 I-Condition
such NCT03928405 270 274 O
as NCT03928405 275 277 O
Parkinson NCT03928405 278 287 B-Condition
, NCT03928405 288 289 O
MS NCT03928405 290 292 B-Condition
, NCT03928405 293 294 O

- NCT03928405 298 299 O
Mini NCT03928405 301 305 B-Observation
Mental NCT03928405 306 312 I-Observation
Test NCT03928405 313 317 I-Observation
Score NCT03928405 318 323 I-Observation
, NCT03928405 324 325 O
18 NCT03928405 326 328 B-Eq-Comparison
to NCT03928405 329 331 I-Eq-Comparison
24 NCT03928405 332 334 I-Eq-Comparison
points NCT03928405 335 341 O
from NCT03928405 342 346 O
being NCT03928405 347 352 O
scored NCT03928405 353 359 O

- NCT03928405 362 363 O
being NCT03928405 365 370 O
65 NCT03928405 371 373 B-Eq-Comparison
- NCT03928405 374 375 I-Eq-Comparison
80 NCT03928405 376 378 O
aged NCT03928405 379 383 B-Age
. NCT03928405 383 384 O

Exclusion NCT03928405 386 395 O
Criteria NCT03928405 396 404 O
: NCT03928405 405 406 O

- NCT03928405 410 411 O
Patients NCT03928405 413 421 O
diagnosed NCT03928405 422 431 O
with NCT03928405 432 436 O
dementia NCT03928405 437 445 B-Condition
( NCT03928405 446 447 O
infection NCT03928405 448 457 B-Condition
, NCT03928405 458 459 O
vascular NCT03928405 460 468 B-Condition
, NCT03928405 469 470 O
hematological NCT03928405 471 484 B-Condition
diseases NCT03928405 485 493 I-Condition
) NCT03928405 494 495 O
, NCT03928405 497 498 O
patients NCT03928405 499 507 O
who NCT03928405 508 511 O
could NCT03928405 512 517 O
not NCT03928405 518 521 B-Negation
be NCT03928405 522 524 O
contacted NCT03928405 525 534 B-Observation
during NCT03928405 535 541 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928405 542 545 O
follow NCT03928405 546 552 B-Study
- NCT03928405 553 554 I-Study
up NCT03928405 555 557 I-Study
period NCT03928405 558 564 I-Study
or NCT03928405 565 567 B-Or
who NCT03928405 568 571 O
did NCT03928405 572 575 O
not NCT03928405 576 579 B-Negation
come NCT03928405 580 584 O
to NCT03928405 585 587 O
control NCT03928405 588 595 B-Modifier
, NCT03928405 596 597 O
cardiac NCT03928405 598 605 B-Modifier
and NCT03928405 606 609 B-Or
cerebrovascular NCT03928405 610 625 B-Modifier
event NCT03928405 626 631 B-Condition
, NCT03928405 632 633 O

- NCT03928405 637 638 O
Endocrine NCT03928405 640 649 B-Condition
disorder NCT03928405 650 658 I-Condition
, NCT03928405 659 660 O
fluid NCT03928405 661 666 B-Condition
- NCT03928405 667 668 I-Condition
electrolyte NCT03928405 669 680 I-Condition
imbalance NCT03928405 681 690 I-Condition
and NCT03928405 691 694 B-Or
infection NCT03928405 695 704 B-Condition

- NCT03928405 707 708 O
Patients NCT03928405 710 718 O
with NCT03928405 719 723 O
malignancy NCT03928405 724 734 B-Condition|Condition
and NCT03928405 735 738 B-Or
malignancy NCT03928405 739 749 O
, NCT03928405 750 751 O
chemotherapy NCT03928405 752 764 B-Procedure
and NCT03928405 765 768 B-Or
radiotherapy NCT03928405 769 781 B-Procedure
, NCT03928405 782 783 O

- NCT03928405 787 788 O
Patients NCT03928405 790 798 O
with NCT03928405 799 803 O
delirium NCT03928405 804 812 B-Condition
or NCT03928405 813 815 B-Or
depression NCT03928405 816 826 B-Condition

- NCT03928405 829 830 O
Those NCT03928405 832 837 O
with NCT03928405 838 842 O
protective NCT03928405 843 853 B-Condition
sensation NCT03928405 854 863 I-Condition
loss NCT03928405 864 868 I-Condition
( NCT03928405 869 870 O
those NCT03928405 871 876 O
with NCT03928405 877 881 O
Semmes NCT03928405 882 888 B-Observation
- NCT03928405 889 890 I-Observation
Weinstein NCT03928405 891 900 I-Observation
Monofilament NCT03928405 901 913 I-Observation
Thickness NCT03928405 914 923 I-Observation
4.56 NCT03928405 924 928 B-Eq-Comparison
and NCT03928405 929 932 I-Eq-Comparison
above NCT03928405 933 938 I-Eq-Comparison
) NCT03928405 939 940 O

- NCT03928405 944 945 O
patients NCT03928405 947 955 O
with NCT03928405 956 960 O
lower NCT03928405 961 966 B-Modifier
or NCT03928405 967 969 B-Or
upper NCT03928405 970 975 B-Modifier
extremity NCT03928405 976 985 I-Modifier
amputations NCT03928405 986 997 B-Procedure
at NCT03928405 998 1000 O
any NCT03928405 1001 1004 O
level NCT03928405 1005 1010 O

Inclusion NCT03921970 0 9 O
Criteria NCT03921970 10 18 O
: NCT03921970 19 20 O

- NCT03921970 24 25 O
American NCT03921970 27 35 B-Condition
Society NCT03921970 36 43 I-Condition
of NCT03921970 44 46 I-Condition
Anesthesiologists NCT03921970 47 64 I-Condition
( NCT03921970 65 66 O
ASA NCT03921970 67 70 B-Condition
) NCT03921970 71 72 O
classification NCT03921970 73 87 B-Eq-Comparison
I NCT03921970 88 89 I-Eq-Comparison
- NCT03921970 90 91 I-Eq-Comparison
II NCT03921970 92 94 I-Eq-Comparison

- NCT03921970 97 98 O
Scheduled NCT03921970 100 109 B-Eq-Comparison
for NCT03921970 110 113 O
laparoscopic NCT03921970 114 126 B-Procedure
sleeve NCT03921970 127 133 I-Procedure
gastrectomy NCT03921970 134 145 I-Procedure
under NCT03921970 146 151 O
general NCT03921970 152 159 B-Procedure
anesthesia NCT03921970 160 170 I-Procedure

Exclusion NCT03921970 171 180 O
Criteria NCT03921970 181 189 O
: NCT03921970 190 191 O

- NCT03921970 195 196 O
Bleeding NCT03921970 198 206 B-Condition
diathesis NCT03921970 207 216 I-Condition

- NCT03921970 219 220 O
Receiving NCT03921970 222 231 B-Eq-Comparison
anticoagulant NCT03921970 232 245 B-Drug
treatment NCT03921970 246 255 B-Procedure

- NCT03921970 258 259 O
Known NCT03921970 261 266 O
local NCT03921970 267 272 O
anesthetics NCT03921970 273 284 O
and NCT03921970 285 288 B-Or
opioid NCT03921970 289 295 B-Drug
allergy NCT03921970 296 303 B-Allergy

- NCT03921970 306 307 O
Infection NCT03921970 309 318 B-Condition
of NCT03921970 319 321 O
the NCT03921970 322 325 O
skin NCT03921970 326 330 B-Modifier
at NCT03921970 331 333 I-Modifier
the NCT03921970 334 337 I-Modifier
site NCT03921970 338 342 I-Modifier
of NCT03921970 343 345 I-Modifier
the NCT03921970 346 349 O
needle NCT03921970 350 356 I-Modifier
puncture NCT03921970 357 365 I-Modifier

- NCT03921970 368 369 O
Pregnancy NCT03921970 371 380 B-Condition
or NCT03921970 381 383 B-Or
lactation NCT03921970 384 393 B-Condition

- NCT03921970 396 397 O
Patients NCT03921970 399 407 O
who NCT03921970 408 411 O
do NCT03921970 412 414 O
not NCT03921970 415 418 B-Negation
accept NCT03921970 419 425 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03921970 426 429 O
procedure NCT03921970 430 439 B-Procedure

Inclusion NCT03923829 0 9 O
Criteria NCT03923829 10 18 O
: NCT03923829 19 20 O

- NCT03923829 24 25 O
Controlled NCT03923829 27 37 B-Modifier
Type NCT03923829 38 42 I-Modifier
- NCT03923829 43 44 I-Modifier
2 NCT03923829 45 46 I-Modifier
diabetes NCT03923829 47 55 B-Condition
mellitus NCT03923829 56 64 I-Condition

- NCT03923829 67 68 O
Stage NCT03923829 70 75 B-Eq-Comparison
- NCT03923829 76 77 I-Eq-Comparison
II NCT03923829 78 80 I-Eq-Comparison
& NCT03923829 81 82 I-Eq-Comparison
III NCT03923829 82 85 O
periodontitis NCT03923829 86 99 B-Condition

- NCT03923829 102 103 O
At NCT03923829 105 107 B-Eq-Comparison
least NCT03923829 108 113 I-Eq-Comparison
2 NCT03923829 114 115 I-Eq-Comparison
sites NCT03923829 116 121 I-Eq-Comparison
with NCT03923829 122 126 O
clinical NCT03923829 127 135 O
attachment NCT03923829 136 146 B-Observation
loss NCT03923829 147 151 I-Observation
3 NCT03923829 152 153 B-Eq-Comparison
or NCT03923829 154 156 I-Eq-Comparison
4 NCT03923829 157 158 I-Eq-Comparison
mm NCT03923829 159 161 I-Eq-Comparison
to NCT03923829 162 164 I-Eq-Comparison
≥ NCT03923829 165 166 I-Eq-Comparison
5 NCT03923829 167 168 I-Eq-Comparison
mm NCT03923829 169 171 O
and NCT03923829 172 175 B-And
radiographic NCT03923829 176 188 B-Procedure
bone NCT03923829 189 193 B-Observation
loss NCT03923829 194 198 I-Observation
15 NCT03923829 199 201 B-Eq-Comparison
% NCT03923829 202 203 O
Extending NCT03923829 204 213 B-Modifier
to NCT03923829 214 216 I-Modifier
mid NCT03923829 217 220 I-Modifier
- NCT03923829 221 222 I-Modifier
third NCT03923829 223 228 I-Modifier
of NCT03923829 229 231 I-Modifier
root NCT03923829 232 236 I-Modifier
and NCT03923829 237 240 I-Modifier
beyond NCT03923829 241 247 I-Modifier
. NCT03923829 247 248 O

- NCT03923829 252 253 O
Probing NCT03923829 255 262 B-Observation
depth NCT03923829 263 268 I-Observation
from NCT03923829 269 273 O
≤ NCT03923829 274 275 B-Eq-Comparison
5 NCT03923829 276 277 I-Eq-Comparison
mm NCT03923829 278 280 I-Eq-Comparison
to NCT03923829 281 283 I-Eq-Comparison
≥ NCT03923829 284 285 I-Eq-Comparison
6 NCT03923829 286 287 I-Eq-Comparison
mm NCT03923829 288 290 O

Exclusion NCT03923829 291 300 O
Criteria NCT03923829 301 309 O
: NCT03923829 310 311 O

- NCT03923829 315 316 O
Any NCT03923829 318 321 O
periodontal NCT03923829 322 333 B-Procedure
or NCT03923829 334 336 B-Or
Antibiotic NCT03923829 337 347 B-Drug
treatment NCT03923829 348 357 B-Procedure
during NCT03923829 358 364 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923829 365 368 O
last NCT03923829 369 373 B-Eq-Comparison
six NCT03923829 374 377 I-Eq-Comparison
months NCT03923829 378 384 I-Eq-Comparison
. NCT03923829 384 385 O

- NCT03923829 389 390 O
Receiving NCT03923829 392 401 B-Eq-Comparison
trace NCT03923829 402 407 B-Drug
element NCT03923829 408 415 I-Drug
supplements NCT03923829 416 427 I-Drug
in NCT03923829 428 430 O
the NCT03923829 431 434 O
previous NCT03923829 435 443 B-Eq-Comparison
three NCT03923829 444 449 I-Eq-Comparison
months NCT03923829 450 456 I-Eq-Comparison

- NCT03923829 459 460 O
Pregnant NCT03923829 462 470 B-Condition
or NCT03923829 471 473 B-Or
lactating NCT03923829 474 483 B-Condition
females NCT03923829 484 491 O

- NCT03923829 494 495 O
Gastric NCT03923829 497 504 B-Modifier
or NCT03923829 505 507 B-Or
diuretic NCT03923829 508 516 B-Modifier
treatment NCT03923829 517 526 B-Procedure

- NCT03923829 529 530 O
Acute NCT03923829 532 537 O
renal NCT03923829 538 543 B-Condition
failure NCT03923829 544 551 I-Condition

- NCT03923829 554 555 O
smoking NCT03923829 557 564 B-Condition

Inclusion NCT03920475 0 9 O
Criteria NCT03920475 10 18 O
: NCT03920475 19 20 O

- NCT03920475 24 25 O
Patients NCT03920475 27 35 O
with NCT03920475 36 40 O
uni NCT03920475 41 44 B-Modifier
- NCT03920475 45 46 O
or NCT03920475 47 49 B-Or
bipolar NCT03920475 50 57 B-Modifier
depression NCT03920475 58 68 B-Condition
, NCT03920475 69 70 O
diagnosed NCT03920475 71 80 O
according NCT03920475 81 90 O
to NCT03920475 91 93 O
the NCT03920475 94 97 O
criteria NCT03920475 98 106 O
of NCT03920475 107 109 O
the NCT03920475 110 113 O
DSM NCT03920475 114 117 O
- NCT03920475 118 119 O
IV NCT03920475 120 122 O
via NCT03920475 123 126 O
MINI NCT03920475 127 131 O
6.0 NCT03920475 132 135 O
diagnostic NCT03920475 136 146 O
tool NCT03920475 147 151 O
. NCT03920475 151 152 O

- NCT03920475 156 157 O
At NCT03920475 159 161 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03920475 162 165 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03920475 166 170 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03920475 171 173 O
inclusion NCT03920475 174 183 O
in NCT03920475 184 186 O
the NCT03920475 187 190 O
study NCT03920475 191 196 B-Study
, NCT03920475 197 198 O
the NCT03920475 199 202 O
symptoms NCT03920475 203 211 O
must NCT03920475 212 216 O
meet NCT03920475 217 221 O
at NCT03920475 222 224 O
least NCT03920475 225 230 O
the NCT03920475 231 234 O
requirements NCT03920475 235 247 O
of NCT03920475 248 250 O
a NCT03920475 251 252 O
moderately NCT03920475 253 263 O
severe NCT03920475 264 270 O
depression NCT03920475 271 281 B-Condition
, NCT03920475 282 283 O
defined NCT03920475 284 291 O
by NCT03920475 292 294 O
a NCT03920475 295 296 O
minimum NCT03920475 297 304 O
score NCT03920475 305 310 O
of NCT03920475 311 313 O
≥ NCT03920475 314 315 B-Eq-Comparison
22 NCT03920475 316 318 I-Eq-Comparison
on NCT03920475 319 321 O
the NCT03920475 322 325 O
Montgomery NCT03920475 326 336 B-Observation
- NCT03920475 337 338 I-Observation
Åsberg NCT03920475 339 345 I-Observation
Depression NCT03920475 346 356 I-Observation
Scale NCT03920475 357 362 I-Observation
. NCT03920475 362 363 O

Exclusion NCT03920475 365 374 O
Criteria NCT03920475 375 383 O
: NCT03920475 384 385 O

- NCT03920475 389 390 O
Patients NCT03920475 392 400 O
with NCT03920475 401 405 O
severe NCT03920475 406 412 O
somatic NCT03920475 413 420 B-Modifier
, NCT03920475 421 422 O
rheumatic NCT03920475 423 432 B-Modifier
, NCT03920475 433 434 O
endocrine NCT03920475 435 444 B-Modifier
or NCT03920475 445 447 B-Or
neurological NCT03920475 448 460 B-Modifier
comorbidities NCT03920475 461 474 B-Condition
. NCT03920475 474 475 O
This NCT03920475 477 481 O
includes NCT03920475 482 490 O
in NCT03920475 491 493 O
particular NCT03920475 494 504 O
neurological NCT03920475 505 517 B-Condition
disorders NCT03920475 518 527 I-Condition
associated NCT03920475 528 538 O
with NCT03920475 539 543 O
cognitive NCT03920475 544 553 B-Condition
disorder NCT03920475 554 562 I-Condition
, NCT03920475 563 564 O
severe NCT03920475 565 571 O
liver NCT03920475 572 577 B-Modifier
, NCT03920475 578 579 O
kidney NCT03920475 580 586 B-Modifier
and NCT03920475 587 590 B-Or
cardiac NCT03920475 591 598 B-Modifier
diseases NCT03920475 599 607 B-Condition
. NCT03920475 607 608 O

- NCT03920475 612 613 O
Patients NCT03920475 615 623 O
, NCT03920475 624 625 O
who NCT03920475 626 629 O
are NCT03920475 630 633 O
being NCT03920475 634 639 B-Eq-Comparison
treated NCT03920475 640 647 I-Eq-Comparison
permanently NCT03920475 648 659 O
with NCT03920475 660 664 O
anti NCT03920475 665 669 B-Drug
- NCT03920475 670 671 I-Drug
inflammatory NCT03920475 672 684 I-Drug
or NCT03920475 685 687 B-Or
immunosuppressive NCT03920475 688 705 B-Drug
drugs NCT03920475 706 711 I-Drug
( NCT03920475 712 713 O
e. NCT03920475 714 716 O
g. NCT03920475 717 719 O
corticosteroids NCT03920475 721 736 B-Drug
or NCT03920475 737 739 O
alpha NCT03920475 740 745 B-Modifier
/ NCT03920475 746 747 B-Or
beta NCT03920475 748 752 B-Modifier
- NCT03920475 753 754 O
a NCT03920475 755 756 B-Drug
( NCT03920475 757 758 O
nta NCT03920475 759 762 O
) NCT03920475 763 764 O
gonists NCT03920475 765 772 O
, NCT03920475 773 774 O
immuno NCT03920475 775 781 B-Drug
suppressant NCT03920475 782 793 I-Drug
drugs NCT03920475 794 799 I-Drug
) NCT03920475 800 801 O
. NCT03920475 802 803 O

- NCT03920475 807 808 O
Patients NCT03920475 810 818 O
with NCT03920475 819 823 O
severe NCT03920475 824 830 O
psychiatric NCT03920475 831 842 B-Condition
disorders NCT03920475 843 852 I-Condition
( NCT03920475 853 854 O
Axis NCT03920475 855 859 B-Eq-Comparison
I NCT03920475 860 861 I-Eq-Comparison
) NCT03920475 862 863 O
such NCT03920475 864 868 O
as NCT03920475 869 871 O
schizophrenia NCT03920475 872 885 B-Condition
, NCT03920475 886 887 O
dementia NCT03920475 888 896 B-Condition
, NCT03920475 897 898 O
ADHD NCT03920475 899 903 B-Condition
, NCT03920475 904 905 O
obsessive NCT03920475 906 915 B-Condition
- NCT03920475 916 917 I-Condition
compulsive NCT03920475 918 928 I-Condition
disorder NCT03920475 929 937 I-Condition
, NCT03920475 938 939 O
current NCT03920475 940 947 B-Eq-Comparison
alcohol NCT03920475 948 955 B-Modifier
, NCT03920475 956 957 O
drugs NCT03920475 958 963 B-Modifier|Modifier
or NCT03920475 964 966 B-Or
drug NCT03920475 967 971 O
addiction NCT03920475 972 981 B-Condition
. NCT03920475 981 982 O

- NCT03920475 986 987 O
Patients NCT03920475 989 997 O
who NCT03920475 998 1001 O
have NCT03920475 1002 1006 O
already NCT03920475 1007 1014 B-Eq-Comparison
been NCT03920475 1015 1019 O
treated NCT03920475 1020 1027 B-Procedure
unsuccessfully NCT03920475 1028 1042 O
with NCT03920475 1043 1047 O
sertraline NCT03920475 1048 1058 B-Drug
and NCT03920475 1059 1062 B-Or
all NCT03920475 1063 1066 O
alternate NCT03920475 1067 1076 B-Drug
medications NCT03920475 1077 1088 I-Drug
allowed NCT03920475 1089 1096 O
in NCT03920475 1097 1099 O
the NCT03920475 1100 1103 O
study NCT03920475 1104 1109 B-Study
. NCT03920475 1109 1110 O

- NCT03920475 1114 1115 O
Pregnant NCT03920475 1117 1125 B-Condition
or NCT03920475 1126 1128 B-Or
lactating NCT03920475 1129 1138 B-Condition
( NCT03920475 1139 1140 O
breast NCT03920475 1141 1147 B-Condition
feeding NCT03920475 1148 1155 I-Condition
) NCT03920475 1156 1157 O
women NCT03920475 1158 1163 O
. NCT03920475 1163 1164 O

Inclusion NCT03925519 0 9 O
Criteria NCT03925519 10 18 O
: NCT03925519 19 20 O

- NCT03925519 24 25 O
patients NCT03925519 27 35 O
with NCT03925519 36 40 O
type NCT03925519 41 45 B-Condition
2 NCT03925519 46 47 I-Condition
diabetes NCT03925519 48 56 I-Condition
for NCT03925519 57 60 O
more NCT03925519 61 65 B-Eq-Comparison
than NCT03925519 66 70 I-Eq-Comparison
5 NCT03925519 71 72 I-Eq-Comparison
years NCT03925519 73 78 I-Eq-Comparison
. NCT03925519 78 79 O

- NCT03925519 83 84 O
Patients NCT03925519 86 94 O
who NCT03925519 95 98 O
were NCT03925519 99 103 O
diagnosed NCT03925519 104 113 O
according NCT03925519 114 123 O
to NCT03925519 124 126 O
the NCT03925519 127 130 O
criteria NCT03925519 131 139 O
of NCT03925519 140 142 O
the NCT03925519 143 146 O
American NCT03925519 147 155 O
diabetes NCT03925519 156 164 O
association NCT03925519 165 176 O
. NCT03925519 176 177 O

- NCT03925519 181 182 O
Not NCT03925519 184 187 B-Negation
receiving NCT03925519 188 197 B-Eq-Comparison
any NCT03925519 198 201 O
drugs NCT03925519 202 207 B-Drug
affecting NCT03925519 208 217 O
the NCT03925519 218 221 O
data NCT03925519 222 226 O
obtained NCT03925519 227 235 O

- NCT03925519 238 239 O
had NCT03925519 241 244 O
Normal NCT03925519 245 251 O
daily NCT03925519 252 257 B-Eq-Comparison
diets NCT03925519 258 263 B-Observation

- NCT03925519 266 267 O
Not NCT03925519 269 272 B-Negation
participating NCT03925519 273 286 O
in NCT03925519 287 289 O
any NCT03925519 290 293 O
other NCT03925519 294 299 B-Other
exercise NCT03925519 300 308 B-Procedure
programs NCT03925519 309 317 I-Procedure

- NCT03925519 320 321 O
Without NCT03925519 323 330 B-Negation
any NCT03925519 331 334 O
musculoskeletal NCT03925519 335 350 B-Condition
disorders NCT03925519 351 360 I-Condition
affecting NCT03925519 361 370 O
an NCT03925519 371 373 O
exercise NCT03925519 374 382 B-Procedure
program NCT03925519 383 390 I-Procedure

Exclusion NCT03925519 391 400 O
Criteria NCT03925519 401 409 O
: NCT03925519 410 411 O

- NCT03925519 415 416 O
Exclusion NCT03925519 418 427 O
criteria NCT03925519 428 436 O
included NCT03925519 437 445 O
anemia NCT03925519 446 452 B-Condition
, NCT03925519 453 454 O
overt NCT03925519 455 460 O
complications NCT03925519 461 474 B-Condition
of NCT03925519 475 477 O
diabetes NCT03925519 478 486 B-Condition
like NCT03925519 487 491 O
nephropathy NCT03925519 492 503 B-Condition
, NCT03925519 504 505 O
neuropathy NCT03925519 506 516 B-Condition
, NCT03925519 517 518 O
retinopathy NCT03925519 519 530 B-Condition
, NCT03925519 531 532 O
obvious NCT03925519 533 540 O
ischemic NCT03925519 541 549 B-Condition
heart NCT03925519 550 555 I-Condition
disease NCT03925519 556 563 I-Condition
( NCT03925519 564 565 O
angina NCT03925519 566 572 B-Condition
, NCT03925519 573 574 O
myocardial NCT03925519 575 585 B-Condition
infarction NCT03925519 586 596 I-Condition
, NCT03925519 597 598 O
and NCT03925519 599 602 O
lead NCT03925519 603 607 B-Procedure
electrocardiogram NCT03925519 608 625 I-Procedure
abnormalities NCT03925519 626 639 O
) NCT03925519 640 641 O
, NCT03925519 643 644 O
HCV NCT03925519 645 648 B-Condition
, NCT03925519 649 650 O
HBV NCT03925519 651 654 B-Condition
, NCT03925519 655 656 O
chronic NCT03925519 657 664 B-Modifier
liver NCT03925519 665 670 I-Modifier
and NCT03925519 671 674 B-Or
kidney NCT03925519 675 681 B-Modifier
diseases NCT03925519 682 690 B-Condition
, NCT03925519 691 692 O
hypothyroidism NCT03925519 693 707 B-Condition
, NCT03925519 708 709 O
and NCT03925519 710 713 B-Or
drugs NCT03925519 714 719 B-Drug
( NCT03925519 720 721 O
diuretics NCT03925519 722 731 B-Drug
; NCT03925519 731 732 O
oral NCT03925519 733 737 B-Drug
contraceptives NCT03925519 738 752 I-Drug
) NCT03925519 753 754 O
. NCT03925519 755 756 O

Inclusion NCT03927326 0 9 O
Criteria NCT03927326 10 18 O
: NCT03927326 19 20 O

- NCT03927326 24 25 O
Patients NCT03927326 27 35 O
scheduled NCT03927326 36 45 B-Eq-Comparison
for NCT03927326 46 49 O
elective NCT03927326 50 58 O
laparoscopic NCT03927326 59 71 B-Procedure
colorectal NCT03927326 72 82 I-Procedure
surgery NCT03927326 83 90 I-Procedure
at NCT03927326 91 93 O
UWMC NCT03927326 94 98 O
requiring NCT03927326 99 108 B-Assertion___Assertion-Type-Value:hypothetical
inpatient NCT03927326 109 118 B-Encounter
stay NCT03927326 119 123 I-Encounter

Exclusion NCT03927326 124 133 O
Criteria NCT03927326 134 142 O
: NCT03927326 143 144 O

- NCT03927326 148 149 O
Patients NCT03927326 151 159 O
on NCT03927326 160 162 B-Eq-Comparison
chronic NCT03927326 163 170 B-Modifier
pain NCT03927326 171 175 B-Condition
mediations NCT03927326 176 186 B-Drug
equaling NCT03927326 187 195 B-Eq-Comparison
or NCT03927326 196 198 I-Eq-Comparison
exceeding NCT03927326 199 208 I-Eq-Comparison
> NCT03927326 209 210 I-Eq-Comparison
25 NCT03927326 211 213 I-Eq-Comparison
morphine NCT03927326 214 222 I-Eq-Comparison
daily NCT03927326 223 228 I-Eq-Comparison
equivalents NCT03927326 229 240 I-Eq-Comparison

- NCT03927326 243 244 O
Patients NCT03927326 246 254 O
allergic NCT03927326 255 263 B-Allergy
to NCT03927326 264 266 O
bupivacaine NCT03927326 267 278 B-Drug

- NCT03927326 281 282 O
Patients NCT03927326 284 292 O
with NCT03927326 293 297 O
ASA NCT03927326 298 301 B-Condition
status NCT03927326 302 308 O
IV NCT03927326 309 311 B-Eq-Comparison
, NCT03927326 312 313 O
V NCT03927326 314 315 I-Eq-Comparison
, NCT03927326 316 317 O
or NCT03927326 318 320 I-Eq-Comparison
VI NCT03927326 321 323 I-Eq-Comparison

- NCT03927326 326 327 O
Patients NCT03927326 329 337 O
unable NCT03927326 338 344 O
to NCT03927326 345 347 O
consent NCT03927326 348 355 O

- NCT03927326 358 359 O
Patients NCT03927326 361 369 O
that NCT03927326 370 374 O
are NCT03927326 375 378 O
pregnant NCT03927326 379 387 B-Condition

- NCT03927326 390 391 O
Patients NCT03927326 393 401 O
that NCT03927326 402 406 O
are NCT03927326 407 410 O
incarcerated NCT03927326 411 423 B-Observation

- NCT03927326 426 427 O
Patients NCT03927326 429 437 O
receiving NCT03927326 438 447 B-Eq-Comparison
procedures NCT03927326 448 458 B-Procedure
in NCT03927326 459 461 B-Exception
addition NCT03927326 462 470 I-Exception
to NCT03927326 471 473 I-Exception
laparoscopic NCT03927326 474 486 B-Procedure
colorectal NCT03927326 487 497 I-Procedure
procedure NCT03927326 498 507 I-Procedure

- NCT03927326 510 511 O
Patients NCT03927326 513 521 O
on NCT03927326 522 524 B-Eq-Comparison
systemic NCT03927326 525 533 B-Modifier
anticoagulation NCT03927326 534 549 B-Procedure
precluding NCT03927326 550 560 B-Negation
them NCT03927326 561 565 O
from NCT03927326 566 570 O
regional NCT03927326 571 579 B-Procedure
blocks NCT03927326 580 586 I-Procedure

Inclusion NCT03928015 0 9 O
Criteria NCT03928015 10 18 O
: NCT03928015 19 20 O

1 NCT03928015 24 25 O
. NCT03928015 25 26 O
Male NCT03928015 28 32 O
or NCT03928015 33 35 B-Or
female NCT03928015 36 42 O
, NCT03928015 43 44 O
18 NCT03928015 45 47 B-Eq-Comparison
years NCT03928015 48 53 I-Eq-Comparison
to NCT03928015 54 56 I-Eq-Comparison
65 NCT03928015 57 59 I-Eq-Comparison
years NCT03928015 60 65 I-Eq-Comparison
old NCT03928015 66 69 B-Age
( NCT03928015 70 71 O
inclusive NCT03928015 72 81 O
) NCT03928015 82 83 O

2 NCT03928015 87 88 O
. NCT03928015 88 89 O
Index NCT03928015 91 96 O
admission NCT03928015 97 106 B-Encounter
for NCT03928015 107 110 O
traumatic NCT03928015 111 120 B-Condition
injury NCT03928015 121 127 I-Condition

3 NCT03928015 130 131 O
. NCT03928015 131 132 O
High NCT03928015 134 138 O
initial NCT03928015 139 146 B-Eq-Comparison
morphine NCT03928015 147 155 B-Drug
equivalent NCT03928015 156 166 O
use NCT03928015 167 170 O
≥ NCT03928015 171 172 B-Eq-Comparison
90 NCT03928015 173 175 I-Eq-Comparison
mg NCT03928015 176 178 I-Eq-Comparison
in NCT03928015 179 181 O
the NCT03928015 182 185 O
first NCT03928015 186 191 B-Eq-Comparison
24 NCT03928015 192 194 I-Eq-Comparison
hours NCT03928015 195 200 I-Eq-Comparison
from NCT03928015 201 205 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03928015 206 215 B-Encounter

4 NCT03928015 218 219 O
. NCT03928015 219 220 O
Baseline NCT03928015 222 230 O
pain NCT03928015 231 235 B-Condition
assessed NCT03928015 236 244 O
at NCT03928015 245 247 O
screening NCT03928015 248 257 B-Procedure
of NCT03928015 258 260 O
≥ NCT03928015 261 262 B-Eq-Comparison
5 NCT03928015 263 264 I-Eq-Comparison
on NCT03928015 265 267 O
the NCT03928015 268 271 O
pain NCT03928015 272 276 B-Observation
numeric NCT03928015 277 284 I-Observation
rating NCT03928015 285 291 I-Observation
score NCT03928015 292 297 I-Observation
( NCT03928015 298 299 O
NRS NCT03928015 300 303 B-Observation
) NCT03928015 304 305 O

5 NCT03928015 309 310 O
. NCT03928015 310 311 O
Willing NCT03928015 313 320 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928015 321 323 I-Assertion___Assertion-Type-Value:hypothetical
divulge NCT03928015 324 331 O
habitual NCT03928015 332 340 O
marijuana NCT03928015 341 350 B-Condition
usage NCT03928015 351 356 O
( NCT03928015 357 358 O
yes NCT03928015 359 362 O
or NCT03928015 363 365 O
no NCT03928015 366 368 O
. NCT03928015 368 369 O
Yes NCT03928015 371 374 O
, NCT03928015 375 376 O
habitual NCT03928015 377 385 O
/ NCT03928015 386 387 O
chronic NCT03928015 388 395 O
usage NCT03928015 396 401 O
; NCT03928015 401 402 O
no NCT03928015 403 405 O
, NCT03928015 406 407 O
recreational NCT03928015 408 420 O
, NCT03928015 421 422 O
former NCT03928015 423 429 O
, NCT03928015 430 431 O
or NCT03928015 432 434 O
never NCT03928015 435 440 O
usage NCT03928015 441 446 O
) NCT03928015 447 448 O

Exclusion NCT03928015 454 463 O
Criteria NCT03928015 464 472 O
: NCT03928015 473 474 O

1 NCT03928015 478 479 O
. NCT03928015 479 480 O
Patients NCT03928015 482 490 O
on NCT03928015 491 493 B-Eq-Comparison
a NCT03928015 494 495 O
pain NCT03928015 496 500 B-Procedure
management NCT03928015 501 511 I-Procedure
agreement NCT03928015 512 521 O

2 NCT03928015 524 525 O
. NCT03928015 525 526 O
Patients NCT03928015 528 536 O
who NCT03928015 537 540 O
are NCT03928015 541 544 O
nil NCT03928015 545 548 B-Procedure
per NCT03928015 549 552 I-Procedure
os NCT03928015 553 555 I-Procedure
( NCT03928015 556 557 O
NPO NCT03928015 558 561 B-Procedure
) NCT03928015 562 563 O
at NCT03928015 564 566 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928015 567 570 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03928015 571 575 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03928015 576 578 O
randomization NCT03928015 579 592 B-Study
or NCT03928015 593 595 B-Or
are NCT03928015 596 599 O
expected NCT03928015 600 608 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928015 609 611 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03928015 612 614 O
NPO NCT03928015 615 618 B-Procedure
within NCT03928015 619 625 B-Eq-Comparison
the NCT03928015 626 629 I-Eq-Comparison
next NCT03928015 630 634 I-Eq-Comparison
48 NCT03928015 635 637 I-Eq-Comparison
hours NCT03928015 638 643 I-Eq-Comparison

3 NCT03928015 646 647 O
. NCT03928015 647 648 O
Patients NCT03928015 650 658 O
who NCT03928015 659 662 O
have NCT03928015 663 667 O
received NCT03928015 668 676 B-Eq-Comparison
or NCT03928015 677 679 B-Or
are NCT03928015 680 683 O
expected NCT03928015 684 692 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928015 693 695 I-Assertion___Assertion-Type-Value:hypothetical
receive NCT03928015 696 703 O
neuraxial NCT03928015 704 713 B-Modifier
/ NCT03928015 714 715 B-Or
locoregional NCT03928015 716 728 B-Modifier
blocks NCT03928015 729 735 B-Drug
for NCT03928015 736 739 O
pain NCT03928015 740 744 B-Condition
within NCT03928015 745 751 B-Eq-Comparison
the NCT03928015 752 755 I-Eq-Comparison
next NCT03928015 756 760 I-Eq-Comparison
48 NCT03928015 761 763 I-Eq-Comparison
hours NCT03928015 764 769 I-Eq-Comparison

4 NCT03928015 772 773 O
. NCT03928015 773 774 O
Known NCT03928015 776 781 O
allergy NCT03928015 782 789 B-Allergy
or NCT03928015 790 792 B-Or
previous NCT03928015 793 801 B-Eq-Comparison
hypersensitivity NCT03928015 802 818 B-Condition
reaction NCT03928015 819 827 O
to NCT03928015 828 830 O
dronabinol NCT03928015 831 841 B-Drug
or NCT03928015 842 844 B-Or
sesame NCT03928015 845 851 B-Drug
oil NCT03928015 852 855 I-Drug

5 NCT03928015 858 859 O
. NCT03928015 859 860 O
Patients NCT03928015 862 870 O
prescribed NCT03928015 871 881 B-Eq-Comparison
dronabinol NCT03928015 882 892 B-Drug
between NCT03928015 893 900 B-Temporal-Connection___Temporal-Connection-Type-Value:after
arrival NCT03928015 901 908 B-Encounter
and NCT03928015 909 912 O
prior NCT03928015 913 918 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928015 919 921 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928015 922 931 B-Study
/ NCT03928015 932 933 B-Or
randomization NCT03928015 934 947 B-Study

6 NCT03928015 950 951 O
. NCT03928015 951 952 O
Pregnancy NCT03928015 954 963 B-Condition
or NCT03928015 964 966 B-Or
breast NCT03928015 967 973 B-Condition
feeding NCT03928015 974 981 I-Condition

7 NCT03928015 984 985 O
. NCT03928015 985 986 O
Incarceration NCT03928015 988 1001 B-Observation


Inclusion NCT03920449 0 9 O
Criteria NCT03920449 10 18 O
: NCT03920449 19 20 O

- NCT03920449 24 25 O
Chronic NCT03920449 27 34 B-Modifier
anal NCT03920449 35 39 B-Condition
fissure NCT03920449 40 47 I-Condition
lasting NCT03920449 48 55 O
more NCT03920449 56 60 B-Eq-Comparison
than NCT03920449 61 65 I-Eq-Comparison
6 NCT03920449 66 67 I-Eq-Comparison
weeks NCT03920449 68 73 I-Eq-Comparison

Exclusion NCT03920449 74 83 O
Criteria NCT03920449 84 92 O
: NCT03920449 93 94 O

- NCT03920449 98 99 O
Pregnant NCT03920449 101 109 B-Condition

- NCT03920449 112 113 O
cardiovascular NCT03920449 115 129 B-Condition
disease NCT03920449 130 137 I-Condition
or NCT03920449 138 140 B-Or
heart NCT03920449 141 146 B-Condition
failure NCT03920449 147 154 I-Condition

- NCT03920449 157 158 O
on NCT03920449 160 162 B-Eq-Comparison
antihypertensive NCT03920449 163 179 B-Drug
medications NCT03920449 180 191 I-Drug

- NCT03920449 194 195 O
recurrent NCT03920449 197 206 O
anal NCT03920449 207 211 B-Condition
fissure NCT03920449 212 219 I-Condition
after NCT03920449 220 225 B-Temporal-Connection___Temporal-Connection-Type-Value:after
previous NCT03920449 226 234 B-Eq-Comparison
sphincterotomy NCT03920449 235 249 B-Procedure

- NCT03920449 252 253 O
prior NCT03920449 255 260 B-Eq-Comparison
history NCT03920449 261 268 I-Eq-Comparison
of NCT03920449 269 271 O
anal NCT03920449 272 276 B-Modifier
surgery NCT03920449 277 284 B-Procedure

- NCT03920449 287 288 O
other NCT03920449 290 295 B-Other
benign NCT03920449 296 302 B-Modifier
anorectal NCT03920449 303 312 B-Condition
diseases NCT03920449 313 321 I-Condition

- NCT03920449 324 325 O
with NCT03920449 327 331 O
inflammatory NCT03920449 332 344 B-Condition
bowel NCT03920449 345 350 I-Condition
diseases NCT03920449 351 359 I-Condition

Inclusion NCT03923140 0 9 O
Criteria NCT03923140 10 18 O
: NCT03923140 19 20 O

- NCT03923140 24 25 O
All NCT03923140 27 30 O
patients NCT03923140 31 39 O
must NCT03923140 40 44 O
meet NCT03923140 45 49 O
the NCT03923140 50 53 O
following NCT03923140 54 63 O
diagnostic NCT03923140 64 74 O
criteria NCT03923140 75 83 O
of NCT03923140 84 86 O
CAPS NCT03923140 87 91 B-Condition
and NCT03923140 92 95 B-And
have NCT03923140 96 100 O
pathogenic NCT03923140 101 111 B-Condition
mutation NCT03923140 112 120 I-Condition
( NCT03923140 121 122 O
s NCT03923140 123 124 O
) NCT03923140 125 126 O
in NCT03923140 127 129 O
NLRP3 NCT03923140 130 135 B-Modifier
gene NCT03923140 136 140 I-Modifier
. NCT03923140 140 141 O

1 NCT03923140 150 151 O
. NCT03923140 151 152 O
Raised NCT03923140 154 160 B-Condition
inflammatory NCT03923140 161 173 I-Condition
markers NCT03923140 174 181 I-Condition
( NCT03923140 182 183 O
CRP NCT03923140 184 187 B-Condition
/ NCT03923140 188 189 B-Or
SAA NCT03923140 190 193 B-Condition
) NCT03923140 194 195 O
( NCT03923140 196 197 O
mandatory NCT03923140 198 207 O
criteria NCT03923140 208 216 O
) NCT03923140 217 218 O

2 NCT03923140 227 228 I-Eq-Comparison
. NCT03923140 228 229 O
≥ NCT03923140 231 232 B-Eq-Comparison
2 NCT03923140 233 234 O
of NCT03923140 235 237 O
6 NCT03923140 238 239 O
CAPS NCT03923140 240 244 B-Condition
typical NCT03923140 245 252 O
signs NCT03923140 253 258 O
/ NCT03923140 259 260 O
symptoms NCT03923140 261 269 B-Assertion___Assertion-Type-Value:possible
: NCT03923140 270 271 O

1 NCT03923140 285 286 O
. NCT03923140 286 287 O
Urticaria NCT03923140 289 298 B-Condition
- NCT03923140 299 300 I-Condition
like NCT03923140 301 305 I-Condition
rash NCT03923140 306 310 I-Condition
; NCT03923140 310 311 O

2 NCT03923140 324 325 O
. NCT03923140 325 326 O
Cold NCT03923140 328 332 B-Condition
/ NCT03923140 333 334 B-Or
stress NCT03923140 335 341 B-Condition
triggered NCT03923140 342 351 O
episodes NCT03923140 352 360 O
; NCT03923140 360 361 O

3 NCT03923140 374 375 O
. NCT03923140 375 376 O
Sensorineural NCT03923140 378 391 B-Condition
hearing NCT03923140 392 399 I-Condition
loss NCT03923140 400 404 I-Condition
; NCT03923140 404 405 O

4 NCT03923140 418 419 O
. NCT03923140 419 420 O
Musculoskeletal NCT03923140 422 437 B-Condition
symptoms NCT03923140 438 446 B-Assertion___Assertion-Type-Value:possible
( NCT03923140 447 448 O
arthralgia NCT03923140 449 459 B-Condition
/ NCT03923140 460 461 B-Or|Or
arthritis NCT03923140 462 471 B-Condition
/ NCT03923140 472 473 O
myalgia NCT03923140 474 481 B-Condition
) NCT03923140 482 483 O
; NCT03923140 484 485 O

5 NCT03923140 498 499 O
. NCT03923140 499 500 O
Chronic NCT03923140 502 509 B-Modifier
aseptic NCT03923140 510 517 B-Condition
meningitis NCT03923140 518 528 I-Condition
; NCT03923140 528 529 O

6 NCT03923140 542 543 O
. NCT03923140 543 544 O
Skeletal NCT03923140 546 554 B-Modifier
abnormalities NCT03923140 555 568 B-Condition
( NCT03923140 569 570 O
epiphyseal NCT03923140 571 581 B-Condition
overgrowth NCT03923140 582 592 I-Condition
/ NCT03923140 593 594 B-Or
frontal NCT03923140 595 602 B-Condition
bossing NCT03923140 603 610 I-Condition
) NCT03923140 611 612 O
. NCT03923140 613 614 O

Exclusion NCT03923140 616 625 O
Criteria NCT03923140 626 634 O
: NCT03923140 635 636 O

- NCT03923140 640 641 O
Patients NCT03923140 643 651 O
will NCT03923140 652 656 O
not NCT03923140 657 660 O
be NCT03923140 661 663 O
included NCT03923140 664 672 O
if NCT03923140 673 675 O
meets NCT03923140 676 681 O
any NCT03923140 682 685 O
of NCT03923140 686 688 O
the NCT03923140 689 692 O
following NCT03923140 693 702 O
criteria NCT03923140 703 711 O
: NCT03923140 712 713 O

1 NCT03923140 722 723 I-Drug
. NCT03923140 723 724 O
Being NCT03923140 726 731 B-Eq-Comparison
treated NCT03923140 732 739 B-Procedure
with NCT03923140 740 744 O
IL NCT03923140 745 747 B-Drug
- NCT03923140 748 749 I-Drug
1 NCT03923140 750 751 O
inhibitor NCT03923140 752 761 I-Drug
, NCT03923140 762 763 O
other NCT03923140 764 769 B-Other
biological NCT03923140 770 780 B-Drug
agents NCT03923140 781 787 I-Drug
and NCT03923140 788 791 B-Or|Or
immunosuppressants NCT03923140 792 810 B-Drug

2 NCT03923140 818 819 O
. NCT03923140 819 820 O
Pregnant NCT03923140 822 830 B-Condition
and NCT03923140 831 834 O
lactating NCT03923140 835 844 B-Condition
women NCT03923140 845 850 O

3 NCT03923140 858 859 O
. NCT03923140 859 860 O
Serious NCT03923140 862 869 O
organ NCT03923140 870 875 B-Condition
function NCT03923140 876 884 I-Condition
failure NCT03923140 885 892 I-Condition
, NCT03923140 893 894 O
expected NCT03923140 895 903 B-Observation
life NCT03923140 904 908 I-Observation
time NCT03923140 909 913 I-Observation
less NCT03923140 914 918 B-Eq-Comparison
than NCT03923140 919 923 I-Eq-Comparison
6 NCT03923140 924 925 I-Eq-Comparison
months NCT03923140 926 932 I-Eq-Comparison

Inclusion NCT03929848 0 9 O
Criteria NCT03929848 10 18 O
: NCT03929848 19 20 O

- NCT03929848 24 25 O
patients NCT03929848 27 35 O
who NCT03929848 36 39 O
is NCT03929848 40 42 O
scheduled NCT03929848 43 52 B-Eq-Comparison
for NCT03929848 53 56 O
laryngomicrosurgery NCT03929848 57 76 B-Procedure
due NCT03929848 77 80 O
to NCT03929848 81 83 O
simple NCT03929848 84 90 B-Modifier
vocal NCT03929848 91 96 I-Modifier
cord NCT03929848 97 101 I-Modifier
cyst NCT03929848 102 106 B-Condition
or NCT03929848 107 109 B-Or
nodule NCT03929848 110 116 B-Condition

Exclusion NCT03929848 117 126 O
Criteria NCT03929848 127 135 O
: NCT03929848 136 137 O

- NCT03929848 141 142 O
Who NCT03929848 144 147 O
does NCT03929848 148 152 B-Negation
n't NCT03929848 152 155 O
agree NCT03929848 156 161 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929848 162 164 I-Assertion___Assertion-Type-Value:hypothetical
enroll NCT03929848 165 171 B-Study

- NCT03929848 174 175 O
do NCT03929848 177 179 O
not NCT03929848 180 183 B-Negation
use NCT03929848 184 187 O
a NCT03929848 188 189 O
reinforced NCT03929848 190 200 B-Procedure
tracheal NCT03929848 201 209 I-Procedure
tube NCT03929848 210 214 I-Procedure
of NCT03929848 215 217 O
internal NCT03929848 218 226 B-Observation
diameter NCT03929848 227 235 I-Observation
of NCT03929848 236 238 O
5.5 NCT03929848 239 242 B-Eq-Comparison
mm NCT03929848 243 245 I-Eq-Comparison
for NCT03929848 246 249 O
male NCT03929848 250 254 O
patient NCT03929848 255 262 O

- NCT03929848 265 266 O
do NCT03929848 268 270 O
not NCT03929848 271 274 B-Negation
use NCT03929848 275 278 O
a NCT03929848 279 280 O
reinforced NCT03929848 281 291 B-Procedure
tracheal NCT03929848 292 300 I-Procedure
tube NCT03929848 301 305 I-Procedure
of NCT03929848 306 308 O
internal NCT03929848 309 317 B-Observation
diameter NCT03929848 318 326 I-Observation
of NCT03929848 327 329 O
5.0 NCT03929848 330 333 B-Eq-Comparison
mm NCT03929848 334 336 I-Eq-Comparison
for NCT03929848 337 340 O
female NCT03929848 341 347 O
patient NCT03929848 348 355 O

Inclusion NCT03920878 0 9 O
Criteria NCT03920878 10 18 O
: NCT03920878 19 20 O

- NCT03920878 24 25 O
Adults NCT03920878 27 33 O
over NCT03920878 34 38 B-Eq-Comparison
age NCT03920878 39 42 I-Eq-Comparison
18 NCT03920878 43 45 I-Eq-Comparison
with NCT03920878 46 50 B-And
diabetes NCT03920878 51 59 B-Condition
mellitus NCT03920878 60 68 I-Condition
, NCT03920878 69 70 O
diabetic NCT03920878 71 79 B-Condition
macular NCT03920878 80 87 I-Condition
edema NCT03920878 88 93 I-Condition
and NCT03920878 94 97 B-And
visually NCT03920878 98 106 O
significant NCT03920878 107 118 O
cataracts NCT03920878 119 128 B-Condition
planning NCT03920878 129 137 B-Eq-Comparison
to NCT03920878 138 140 O
undergo NCT03920878 141 148 O
cataract NCT03920878 149 157 B-Procedure
surgery NCT03920878 158 165 I-Procedure

Exclusion NCT03920878 166 175 O
Criteria NCT03920878 176 184 O
: NCT03920878 185 186 O

- NCT03920878 190 191 O
Patients NCT03920878 193 201 O
who NCT03920878 202 205 O
have NCT03920878 206 210 O
undergone NCT03920878 211 220 B-Eq-Comparison
panretinal NCT03920878 221 231 B-Procedure
photocoagulation NCT03920878 232 248 I-Procedure
( NCT03920878 249 250 O
PRP NCT03920878 251 254 B-Procedure
) NCT03920878 255 256 O
in NCT03920878 257 259 O
prior NCT03920878 260 265 B-Eq-Comparison
4 NCT03920878 266 267 I-Eq-Comparison
months NCT03920878 268 274 I-Eq-Comparison
or NCT03920878 275 277 B-Or
an NCT03920878 278 280 O
ocular NCT03920878 281 287 B-Condition
condition NCT03920878 288 297 I-Condition
( NCT03920878 298 299 O
other NCT03920878 300 305 B-Exception
than NCT03920878 306 310 I-Exception
cataract NCT03920878 311 319 B-Condition
and NCT03920878 320 323 B-Or
DME NCT03920878 324 327 B-Condition
) NCT03920878 328 329 O
that NCT03920878 330 334 O
might NCT03920878 335 340 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920878 341 347 O
visual NCT03920878 348 354 B-Condition
acuity NCT03920878 355 361 I-Condition
during NCT03920878 362 368 B-Temporal-Connection___Temporal-Connection-Type-Value:during
course NCT03920878 369 375 O
of NCT03920878 376 378 O
study NCT03920878 379 384 B-Study
. NCT03920878 384 385 O

- NCT03920878 389 390 O
Patients NCT03920878 392 400 O
with NCT03920878 401 405 O
history NCT03920878 406 413 B-Eq-Comparison
of NCT03920878 414 416 O
vitrectomy NCT03920878 417 427 B-Condition
. NCT03920878 427 428 O

- NCT03920878 432 433 O
Patients NCT03920878 435 443 O
with NCT03920878 444 448 O
neovascular NCT03920878 449 460 B-Condition
glaucoma NCT03920878 461 469 I-Condition
. NCT03920878 469 470 O

Inclusion NCT03929874 0 9 O
Criteria NCT03929874 10 18 O
: NCT03929874 19 20 O

- NCT03929874 24 25 O
Patients NCT03929874 27 35 O
under NCT03929874 36 41 B-Eq-Comparison
40 NCT03929874 42 44 I-Eq-Comparison
or NCT03929874 45 47 B-Or
over NCT03929874 48 52 B-Eq-Comparison
60 NCT03929874 53 55 I-Eq-Comparison
years NCT03929874 56 61 I-Eq-Comparison
of NCT03929874 62 64 O
age NCT03929874 65 68 B-Age
who NCT03929874 69 72 B-And
require NCT03929874 73 80 B-Assertion___Assertion-Type-Value:hypothetical
spinal NCT03929874 81 87 B-Procedure
anesthesia NCT03929874 88 98 I-Procedure
for NCT03929874 99 102 O
orthopedic NCT03929874 103 113 B-Procedure
surgery NCT03929874 114 121 I-Procedure
, NCT03929874 122 123 O

- NCT03929874 127 128 O
with NCT03929874 130 134 O
ASA NCT03929874 135 138 B-Condition
physical NCT03929874 139 147 O
status NCT03929874 148 154 O
classification NCT03929874 155 169 O
system NCT03929874 170 176 O
I NCT03929874 177 178 B-Eq-Comparison
, NCT03929874 179 180 O
II NCT03929874 181 183 I-Eq-Comparison
, NCT03929874 184 185 O
III NCT03929874 186 189 I-Eq-Comparison

Exclusion NCT03929874 190 199 O
Criteria NCT03929874 200 208 O
: NCT03929874 209 210 O

- NCT03929874 214 215 O
Patients NCT03929874 217 225 O
with NCT03929874 226 230 O
contraindication NCT03929874 231 247 B-Contraindication
to NCT03929874 248 250 O
spinal NCT03929874 251 257 B-Procedure
anesthesia NCT03929874 258 268 I-Procedure
( NCT03929874 269 270 O
coagulopathy NCT03929874 271 283 B-Condition
, NCT03929874 284 285 O
local NCT03929874 286 291 B-Modifier
infection NCT03929874 292 301 B-Condition
, NCT03929874 302 303 O
allergy NCT03929874 304 311 B-Allergy
to NCT03929874 312 314 O
local NCT03929874 315 320 B-Procedure
anesthetic NCT03929874 321 331 I-Procedure
) NCT03929874 332 333 O

- NCT03929874 337 338 O
Patients NCT03929874 340 348 O
with NCT03929874 349 353 O
communication NCT03929874 354 367 B-Condition
difficulties NCT03929874 368 380 I-Condition

- NCT03929874 383 384 O
Patient NCT03929874 386 393 O
who NCT03929874 394 397 O
can NCT03929874 398 401 O
not NCT03929874 402 405 B-Negation
take NCT03929874 406 410 O
a NCT03929874 411 412 O
sitting NCT03929874 413 420 B-Modifier
or NCT03929874 421 423 B-Or
lateral NCT03929874 424 431 B-Modifier
decubitus NCT03929874 432 441 I-Modifier
position NCT03929874 442 450 B-Condition
( NCT03929874 451 452 O
fracture NCT03929874 453 461 B-Condition
) NCT03929874 462 463 O

- NCT03929874 467 468 O
Patients NCT03929874 470 478 O
with NCT03929874 479 483 O
a NCT03929874 484 485 O
history NCT03929874 486 493 B-Eq-Comparison
of NCT03929874 494 496 O
spinal NCT03929874 497 503 B-Procedure
surgery NCT03929874 504 511 I-Procedure

- NCT03929874 514 515 O
Patient NCT03929874 517 524 O
with NCT03929874 525 529 O
anatomical NCT03929874 530 540 B-Condition
abnormality NCT03929874 541 552 I-Condition
of NCT03929874 553 555 O
the NCT03929874 556 559 O
spine NCT03929874 560 565 B-Modifier

Inclusion NCT03927859 0 9 O
Criteria NCT03927859 10 18 O
: NCT03927859 19 20 O

Only NCT03927859 22 26 O
patients NCT03927859 27 35 O
diagnosed NCT03927859 36 45 O
with NCT03927859 46 50 O
Type NCT03927859 51 55 B-Modifier
I NCT03927859 56 57 I-Modifier
or NCT03927859 58 60 B-Or
Type NCT03927859 61 65 B-Modifier
II NCT03927859 66 68 I-Modifier
Diabetes NCT03927859 69 77 B-Condition
with NCT03927859 78 82 B-And
no NCT03927859 83 85 B-Negation
evidence NCT03927859 86 94 O
in NCT03927859 95 97 O
their NCT03927859 98 103 O
medical NCT03927859 104 111 O
records NCT03927859 112 119 O
of NCT03927859 120 122 O
a NCT03927859 123 124 O
screening NCT03927859 125 134 B-Procedure
within NCT03927859 135 141 B-Eq-Comparison
the NCT03927859 142 145 I-Eq-Comparison
last NCT03927859 146 150 I-Eq-Comparison
2 NCT03927859 151 152 I-Eq-Comparison
years NCT03927859 153 158 I-Eq-Comparison
will NCT03927859 159 163 O
be NCT03927859 164 166 O
included NCT03927859 167 175 O
in NCT03927859 176 178 O
the NCT03927859 179 182 O
study NCT03927859 183 188 B-Study
and NCT03927859 189 192 O
only NCT03927859 193 197 O
individuals NCT03927859 198 209 O
18 NCT03927859 210 212 B-Eq-Comparison
years NCT03927859 213 218 I-Eq-Comparison
of NCT03927859 219 221 I-Eq-Comparison
age NCT03927859 222 225 I-Eq-Comparison
or NCT03927859 226 228 I-Eq-Comparison
older NCT03927859 229 234 I-Eq-Comparison
will NCT03927859 235 239 O
be NCT03927859 240 242 O
included NCT03927859 243 251 O
. NCT03927859 251 252 O

Exclusion NCT03927859 254 263 O
Criteria NCT03927859 264 272 O
: NCT03927859 273 274 O

Patients NCT03927859 276 284 O
screened NCT03927859 285 293 B-Procedure
within NCT03927859 294 300 B-Eq-Comparison
the NCT03927859 301 304 I-Eq-Comparison
last NCT03927859 305 309 I-Eq-Comparison
year NCT03927859 310 314 I-Eq-Comparison
. NCT03927859 314 315 O
In NCT03927859 317 319 O
addition NCT03927859 320 328 O
, NCT03927859 329 330 O
individuals NCT03927859 331 342 O
who NCT03927859 343 346 O
can NCT03927859 347 350 B-Negation
not NCT03927859 350 353 O
speak NCT03927859 354 359 O
English NCT03927859 360 367 O
will NCT03927859 368 372 O
be NCT03927859 373 375 O
excluded NCT03927859 376 384 B-Negation
from NCT03927859 385 389 O
the NCT03927859 390 393 O
study NCT03927859 394 399 B-Study
to NCT03927859 400 402 O
minimize NCT03927859 403 411 O
additional NCT03927859 412 422 O
workload NCT03927859 423 431 O
placed NCT03927859 432 438 O
on NCT03927859 439 441 O
administrative NCT03927859 442 456 O
staff NCT03927859 457 462 O
. NCT03927859 462 463 O


Inclusion NCT03929653 0 9 O
Criteria NCT03929653 10 18 O
: NCT03929653 19 20 O

1 NCT03929653 24 25 O
. NCT03929653 25 26 O
Is NCT03929653 28 30 O
equal NCT03929653 31 36 B-Eq-Comparison
to NCT03929653 37 39 I-Eq-Comparison
or NCT03929653 40 42 I-Eq-Comparison
greater NCT03929653 43 50 I-Eq-Comparison
than NCT03929653 51 55 I-Eq-Comparison
18 NCT03929653 56 58 I-Eq-Comparison
years NCT03929653 59 64 I-Eq-Comparison
of NCT03929653 65 67 O
age NCT03929653 68 71 B-Age
. NCT03929653 71 72 O

2 NCT03929653 76 77 O
. NCT03929653 77 78 O
Histologic NCT03929653 80 90 B-Procedure
or NCT03929653 91 93 B-Or
cytologic NCT03929653 94 103 B-Procedure
confirmation NCT03929653 104 116 O
of NCT03929653 117 119 O
advanced NCT03929653 120 128 B-Modifier
refractory NCT03929653 129 139 I-Modifier
solid NCT03929653 140 145 B-Condition
tumors NCT03929653 146 152 I-Condition
with NCT03929653 153 157 O
no NCT03929653 158 160 B-Negation
standard NCT03929653 161 169 O
treatment NCT03929653 170 179 B-Procedure
options NCT03929653 180 187 B-Assertion___Assertion-Type-Value:hypothetical
, NCT03929653 188 189 O
including NCT03929653 190 199 O
some NCT03929653 200 204 O
patients NCT03929653 205 213 O
with NCT03929653 214 218 O
advanced NCT03929653 219 227 B-Coreference
disease NCT03929653 228 235 I-Coreference
in NCT03929653 236 238 O
reduced NCT03929653 239 246 B-Condition
general NCT03929653 247 254 I-Condition
condition NCT03929653 255 264 I-Condition
( NCT03929653 265 266 O
Eastern NCT03929653 267 274 B-Condition
Cooperative NCT03929653 275 286 I-Condition
Oncology NCT03929653 287 295 I-Condition
Group NCT03929653 296 301 I-Condition
( NCT03929653 302 303 O
ECOG NCT03929653 304 308 B-Condition
) NCT03929653 309 310 O
3 NCT03929653 311 312 B-Eq-Comparison
and NCT03929653 313 316 I-Eq-Comparison
4 NCT03929653 317 318 I-Eq-Comparison
) NCT03929653 319 320 O
. NCT03929653 321 322 O

3 NCT03929653 326 327 O
. NCT03929653 327 328 O
Patients NCT03929653 330 338 O
with NCT03929653 339 343 O
measurable NCT03929653 344 354 B-Modifier
or NCT03929653 355 357 B-Or
evaluable NCT03929653 358 367 B-Modifier
disease NCT03929653 368 375 B-Condition
per NCT03929653 376 379 O
Response NCT03929653 380 388 O
Evaluation NCT03929653 389 399 O
Criteria NCT03929653 400 408 O
In NCT03929653 409 411 O
Solid NCT03929653 412 417 O
Tumors NCT03929653 418 424 O
( NCT03929653 425 426 O
RECIST NCT03929653 427 433 O
) NCT03929653 434 435 O
version NCT03929653 436 443 O
1.1 NCT03929653 444 447 O
. NCT03929653 447 448 O

4 NCT03929653 452 453 O
. NCT03929653 453 454 O
Patients NCT03929653 456 464 O
must NCT03929653 465 469 O
be NCT03929653 470 472 O
able NCT03929653 473 477 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929653 478 480 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03929653 481 488 O
blood NCT03929653 489 494 B-Observation
samples NCT03929653 495 502 I-Observation|Observation
or NCT03929653 503 505 B-Or
tissue NCT03929653 506 512 B-Observation
samples NCT03929653 513 520 O
for NCT03929653 521 524 O
NGS NCT03929653 525 528 B-Procedure
( NCT03929653 529 530 O
Next NCT03929653 531 535 B-Procedure
Generation NCT03929653 536 546 I-Procedure
Sequencing NCT03929653 547 557 I-Procedure
) NCT03929653 558 559 O
testing NCT03929653 560 567 O
. NCT03929653 567 568 O
The NCT03929653 570 573 O
amount NCT03929653 574 580 O
of NCT03929653 581 583 O
blood NCT03929653 584 589 B-Observation
and NCT03929653 590 593 B-Or
tissue NCT03929653 594 600 B-Observation
samples NCT03929653 601 608 I-Observation
should NCT03929653 609 615 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929653 616 618 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03929653 619 623 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03929653 624 626 O
meet NCT03929653 627 631 O
the NCT03929653 632 635 O
requirements NCT03929653 636 648 O
of NCT03929653 649 651 O
DNA NCT03929653 652 655 O
extraction NCT03929653 656 666 O
and NCT03929653 667 670 O
quality NCT03929653 671 678 O
control NCT03929653 679 686 O
. NCT03929653 686 687 O

5 NCT03929653 691 692 O
. NCT03929653 692 693 O
Adequate NCT03929653 695 703 O
baseline NCT03929653 704 712 O
organ NCT03929653 713 718 B-Condition
system NCT03929653 719 725 I-Condition
function NCT03929653 726 734 I-Condition
. NCT03929653 734 735 O

6 NCT03929653 739 740 O
. NCT03929653 740 741 O
Patients NCT03929653 743 751 O
could NCT03929653 752 757 B-Assertion___Assertion-Type-Value:hypothetical
receive NCT03929653 758 765 O
treatment NCT03929653 766 775 B-Procedure
program NCT03929653 776 783 O
from NCT03929653 784 788 O
MTB NCT03929653 789 792 B-Procedure
( NCT03929653 793 794 O
Molecular NCT03929653 795 804 B-Procedure
Tumor NCT03929653 805 810 I-Procedure
Board NCT03929653 811 816 I-Procedure
) NCT03929653 817 818 O
. NCT03929653 819 820 O

7 NCT03929653 824 825 O
. NCT03929653 825 826 O
Ability NCT03929653 828 835 O
to NCT03929653 836 838 O
understand NCT03929653 839 849 O
and NCT03929653 850 853 O
the NCT03929653 854 857 O
willingness NCT03929653 858 869 O
to NCT03929653 870 872 O
provide NCT03929653 873 880 O
a NCT03929653 881 882 O
written NCT03929653 883 890 O
informed NCT03929653 891 899 O
consent NCT03929653 900 907 O
document NCT03929653 908 916 O
. NCT03929653 916 917 O

Exclusion NCT03929653 919 928 O
Criteria NCT03929653 929 937 O
: NCT03929653 938 939 O

1 NCT03929653 941 942 O
. NCT03929653 942 943 O
According NCT03929653 944 953 O
to NCT03929653 954 956 O
the NCT03929653 957 960 O
investigator NCT03929653 961 973 O
' NCT03929653 973 974 O
judgment NCT03929653 975 983 O
, NCT03929653 984 985 O
there NCT03929653 986 991 O
are NCT03929653 992 995 O
serious NCT03929653 996 1003 O
, NCT03929653 1004 1005 O
uncontrollable NCT03929653 1006 1020 B-Modifier
risks NCT03929653 1021 1026 B-Risk
to NCT03929653 1027 1029 O
patients NCT03929653 1030 1038 O
' NCT03929653 1038 1039 O
safety NCT03929653 1040 1046 O
, NCT03929653 1047 1048 O
or NCT03929653 1049 1051 B-Or
associated NCT03929653 1052 1062 O
diseases NCT03929653 1063 1071 B-Condition
( NCT03929653 1072 1073 O
such NCT03929653 1074 1078 O
as NCT03929653 1079 1081 O
severe NCT03929653 1082 1088 O
diabetes NCT03929653 1089 1097 B-Condition
, NCT03929653 1098 1099 O
thyroid NCT03929653 1100 1107 B-Condition
disease NCT03929653 1108 1115 I-Condition
, NCT03929653 1116 1117 O
infection NCT03929653 1118 1127 B-Condition
, NCT03929653 1128 1129 O
spinal NCT03929653 1130 1136 B-Condition
cord NCT03929653 1137 1141 I-Condition
compression NCT03929653 1142 1153 I-Condition
, NCT03929653 1154 1155 O
superior NCT03929653 1156 1164 B-Condition
vena NCT03929653 1165 1169 I-Condition
cava NCT03929653 1170 1174 I-Condition
syndrome NCT03929653 1175 1183 I-Condition
, NCT03929653 1184 1185 O
neurological NCT03929653 1186 1198 B-Modifier
or NCT03929653 1199 1201 B-Or
psychiatric NCT03929653 1202 1213 B-Modifier
disorders NCT03929653 1214 1223 B-Condition
and NCT03929653 1224 1227 O
so NCT03929653 1228 1230 O
on NCT03929653 1231 1233 O
) NCT03929653 1234 1235 O
that NCT03929653 1236 1240 O
affect NCT03929653 1241 1247 O
the NCT03929653 1248 1251 O
patients NCT03929653 1252 1260 O
completion NCT03929653 1261 1271 O
of NCT03929653 1272 1274 O
the NCT03929653 1275 1278 O
study NCT03929653 1279 1284 B-Study
. NCT03929653 1284 1285 O


Inclusion NCT03927118 0 9 O
Criteria NCT03927118 10 18 O

Patients NCT03927118 19 27 O
who NCT03927118 28 31 O
underwent NCT03927118 32 41 B-Eq-Comparison
first NCT03927118 42 47 I-Eq-Comparison
time NCT03927118 48 52 I-Eq-Comparison
intravitreal NCT03927118 53 65 B-Procedure
injection NCT03927118 66 75 I-Procedure

Exclusion NCT03927118 76 85 O
Criteria NCT03927118 86 94 O

Previously NCT03927118 95 105 B-Eq-Comparison
received NCT03927118 106 114 I-Eq-Comparison
any NCT03927118 115 118 O
surgery NCT03927118 119 126 B-Procedure

Proliferative NCT03927118 127 140 B-Condition
diabetic NCT03927118 141 149 I-Condition
retinopathy NCT03927118 150 161 I-Condition

Glaucoma NCT03927118 162 170 B-Condition
or NCT03927118 171 173 B-Or
glaucoma NCT03927118 174 182 B-Condition
suspicion NCT03927118 183 192 B-Assertion___Assertion-Type-Value:possible

Optic NCT03927118 193 198 B-Condition
disc NCT03927118 199 203 I-Condition
fatigue NCT03927118 204 211 I-Condition

Optic NCT03927118 212 217 B-Condition
disc NCT03927118 218 222 I-Condition
edema NCT03927118 223 228 I-Condition

Uveitis NCT03927118 229 236 B-Condition
and NCT03927118 237 240 B-Or
media NCT03927118 241 246 B-Condition
opacity NCT03927118 247 254 I-Condition

Blurred NCT03927118 255 262 B-Condition
of NCT03927118 263 265 I-Condition
image NCT03927118 266 271 I-Condition
clarity NCT03927118 272 279 I-Condition

Inclusion NCT03922074 0 9 O
Criteria NCT03922074 10 18 O
: NCT03922074 19 20 O

Healthy NCT03922074 22 29 B-Condition
patients NCT03922074 30 38 O
- NCT03922074 39 40 O

Exclusion NCT03922074 42 51 O
Criteria NCT03922074 52 60 O
: NCT03922074 61 62 O

Patients NCT03922074 64 72 O
with NCT03922074 73 77 O
familial NCT03922074 78 86 B-Family-Member
colorectal NCT03922074 87 97 B-Modifier
cancer NCT03922074 98 104 B-Condition
history NCT03922074 105 112 B-Eq-Comparison

- NCT03922074 114 115 O

Inclusion NCT03925727 0 9 O
Criteria NCT03925727 10 18 O
: NCT03925727 19 20 O

- NCT03925727 24 25 O
Subject NCT03925727 27 34 O
- NCT03925727 35 36 O
reported NCT03925727 37 45 O
history NCT03925727 46 53 B-Eq-Comparison
of NCT03925727 54 56 O
dry NCT03925727 57 60 B-Condition
eye NCT03925727 61 64 I-Condition
disease NCT03925727 65 72 I-Condition
in NCT03925727 73 75 O
both NCT03925727 76 80 B-Modifier
eyes NCT03925727 81 85 I-Modifier
for NCT03925727 86 89 O
at NCT03925727 90 92 B-Eq-Comparison
least NCT03925727 93 98 I-Eq-Comparison
6 NCT03925727 99 100 I-Eq-Comparison
months NCT03925727 101 107 I-Eq-Comparison
; NCT03925727 107 108 O

- NCT03925727 111 112 O
History NCT03925727 114 121 B-Eq-Comparison
of NCT03925727 122 124 O
use NCT03925727 125 128 O
of NCT03925727 129 131 O
artificial NCT03925727 132 142 B-Procedure
tear NCT03925727 143 147 I-Procedure
eye NCT03925727 148 151 I-Procedure
drops NCT03925727 152 157 I-Procedure
for NCT03925727 158 161 O
dry NCT03925727 162 165 B-Condition
eye NCT03925727 166 169 I-Condition
symptoms NCT03925727 170 178 B-Assertion___Assertion-Type-Value:possible
; NCT03925727 178 179 O

- NCT03925727 182 183 O
Total NCT03925727 185 190 O
score NCT03925727 191 196 O
of NCT03925727 197 199 O
≥ NCT03925727 200 201 B-Eq-Comparison
40 NCT03925727 202 204 I-Eq-Comparison
on NCT03925727 205 207 O
SANDE NCT03925727 208 213 B-Observation
; NCT03925727 213 214 O

- NCT03925727 217 218 O
TFBUT NCT03925727 220 225 B-Observation
; NCT03925727 225 226 O

- NCT03925727 229 230 O
Corneal NCT03925727 232 239 B-Condition
fluorescein NCT03925727 240 251 I-Condition
staining NCT03925727 252 260 I-Condition
; NCT03925727 260 261 O

- NCT03925727 264 265 O
Lissamine NCT03925727 267 276 B-Modifier
green NCT03925727 277 282 I-Modifier
conjunctival NCT03925727 283 295 B-Condition
staining NCT03925727 296 304 I-Condition
; NCT03925727 304 305 O

- NCT03925727 308 309 O
Schirmer NCT03925727 311 319 B-Observation
's NCT03925727 319 321 O
test NCT03925727 322 326 I-Observation
score NCT03925727 327 332 O
. NCT03925727 332 333 O

Exclusion NCT03925727 335 344 O
Criteria NCT03925727 345 353 O
: NCT03925727 354 355 O

- NCT03925727 359 360 O
Have NCT03925727 362 366 O
participated NCT03925727 367 379 O
in NCT03925727 380 382 O
a NCT03925727 383 384 O
previous NCT03925727 385 393 B-Eq-Comparison
tavilermide NCT03925727 394 405 B-Drug
( NCT03925727 406 407 O
MIM NCT03925727 408 411 B-Drug
- NCT03925727 412 413 I-Drug
D3 NCT03925727 414 416 I-Drug
) NCT03925727 417 418 O
study NCT03925727 419 424 B-Study
; NCT03925727 424 425 O

- NCT03925727 428 429 O
Have NCT03925727 431 435 O
clinically NCT03925727 436 446 O
significant NCT03925727 447 458 O
slit NCT03925727 459 463 B-Condition
lamp NCT03925727 464 468 I-Condition
findings NCT03925727 469 477 I-Condition
at NCT03925727 478 480 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Visit NCT03925727 481 486 B-Study
1 NCT03925727 487 488 O
; NCT03925727 489 490 O

- NCT03925727 493 494 O
Have NCT03925727 496 500 O
a NCT03925727 501 502 O
history NCT03925727 503 510 B-Eq-Comparison
of NCT03925727 511 513 O
lacrimal NCT03925727 514 522 B-Condition
duct NCT03925727 523 527 I-Condition
obstruction NCT03925727 528 539 I-Condition
within NCT03925727 540 546 B-Eq-Comparison
12 NCT03925727 547 549 I-Eq-Comparison
months NCT03925727 550 556 I-Eq-Comparison
of NCT03925727 557 559 B-Temporal-Connection___Temporal-Connection-Type-Value:before
Visit NCT03925727 560 565 B-Study
1 NCT03925727 566 567 O
; NCT03925727 568 569 O

- NCT03925727 572 573 O
Have NCT03925727 575 579 O
an NCT03925727 580 582 O
uncontrolled NCT03925727 583 595 B-Modifier
systemic NCT03925727 596 604 B-Condition
disease NCT03925727 605 612 I-Condition
; NCT03925727 612 613 O

- NCT03925727 616 617 O
Be NCT03925727 619 621 O
a NCT03925727 622 623 O
woman NCT03925727 624 629 O
who NCT03925727 630 633 B-And
is NCT03925727 634 636 O
pregnant NCT03925727 637 645 B-Condition
, NCT03925727 646 647 O
nursing NCT03925727 648 655 B-Condition
or NCT03925727 656 658 B-Or
planning NCT03925727 659 667 B-Assertion___Assertion-Type-Value:intention
a NCT03925727 668 669 O
pregnancy NCT03925727 670 679 B-Condition
; NCT03925727 679 680 O

- NCT03925727 683 684 O
Be NCT03925727 686 688 O
a NCT03925727 689 690 O
woman NCT03925727 691 696 O
of NCT03925727 697 699 B-And
childbearing NCT03925727 700 712 B-Condition
potential NCT03925727 713 722 I-Condition
who NCT03925727 723 726 B-And
is NCT03925727 727 729 O
not NCT03925727 730 733 B-Negation
using NCT03925727 734 739 B-Eq-Comparison
an NCT03925727 740 742 O
acceptable NCT03925727 743 753 O
means NCT03925727 754 759 O
of NCT03925727 760 762 O
birth NCT03925727 763 768 B-Procedure
control NCT03925727 769 776 I-Procedure
; NCT03925727 776 777 O

- NCT03925727 780 781 O
Have NCT03925727 783 787 O
a NCT03925727 788 789 O
condition NCT03925727 790 799 B-Condition
or NCT03925727 800 802 O
be NCT03925727 803 805 O
in NCT03925727 806 808 O
a NCT03925727 809 810 O
situation NCT03925727 811 820 O
which NCT03925727 821 826 O
the NCT03925727 827 830 O
investigator NCT03925727 831 843 O
feels NCT03925727 844 849 O
may NCT03925727 850 853 O
put NCT03925727 854 857 O
the NCT03925727 858 861 O
subject NCT03925727 862 869 O
at NCT03925727 870 872 O
significant NCT03925727 873 884 O
risk NCT03925727 885 889 B-Risk
, NCT03925727 890 891 O
may NCT03925727 892 895 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03925727 896 904 O
the NCT03925727 905 908 O
study NCT03925727 909 914 B-Study
results NCT03925727 915 922 O
, NCT03925727 923 924 O
or NCT03925727 925 927 B-Or
may NCT03925727 928 931 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03925727 932 941 O
significantly NCT03925727 942 955 O
with NCT03925727 956 960 O
the NCT03925727 961 964 O
subject NCT03925727 965 972 O
's NCT03925727 972 974 O
participation NCT03925727 975 988 O
in NCT03925727 989 991 O
the NCT03925727 992 995 O
study NCT03925727 996 1001 B-Study
; NCT03925727 1001 1002 O

- NCT03925727 1005 1006 O
Be NCT03925727 1008 1010 O
currently NCT03925727 1011 1020 B-Eq-Comparison
enrolled NCT03925727 1021 1029 O
in NCT03925727 1030 1032 O
an NCT03925727 1033 1035 O
investigational NCT03925727 1036 1051 O
drug NCT03925727 1052 1056 B-Drug
or NCT03925727 1057 1059 B-Or|Or
device NCT03925727 1060 1066 B-Procedure
study NCT03925727 1067 1072 B-Study
or NCT03925727 1073 1075 O
have NCT03925727 1076 1080 O
used NCT03925727 1081 1085 B-Eq-Comparison
an NCT03925727 1086 1088 O
investigational NCT03925727 1089 1104 B-Study
drug NCT03925727 1105 1109 B-Drug
or NCT03925727 1110 1112 B-Or
device NCT03925727 1113 1119 B-Procedure
within NCT03925727 1120 1126 B-Eq-Comparison
45 NCT03925727 1127 1129 I-Eq-Comparison
days NCT03925727 1130 1134 I-Eq-Comparison
prior NCT03925727 1135 1140 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03925727 1141 1143 O
Visit NCT03925727 1144 1149 B-Study
1 NCT03925727 1150 1151 O
. NCT03925727 1151 1152 O

Inclusion NCT03929939 0 9 O
Criteria NCT03929939 10 18 O
: NCT03929939 19 20 O

1 NCT03929939 24 25 O
. NCT03929939 25 26 O
Be NCT03929939 28 30 O
either NCT03929939 31 37 O
a NCT03929939 38 39 O
female NCT03929939 40 46 O
veteran NCT03929939 47 54 B-Observation
with NCT03929939 55 59 B-And
a NCT03929939 60 61 O
current NCT03929939 62 69 B-Eq-Comparison
diagnosis NCT03929939 70 79 O
of NCT03929939 80 82 O
PTSD NCT03929939 83 87 B-Condition
( NCT03929939 88 89 O
for NCT03929939 90 93 O
the NCT03929939 94 97 O
PTSD NCT03929939 98 102 B-Condition
group NCT03929939 103 108 O
) NCT03929939 109 110 O
or NCT03929939 111 113 B-Or
a NCT03929939 114 115 O
female NCT03929939 116 122 O
non NCT03929939 123 126 B-Negation
- NCT03929939 127 128 O
veteran NCT03929939 129 136 B-Observation
without NCT03929939 137 144 B-Negation
a NCT03929939 145 146 O
current NCT03929939 147 154 B-Eq-Comparison
diagnosis NCT03929939 155 164 O
of NCT03929939 165 167 O
PTSD NCT03929939 168 172 B-Condition
( NCT03929939 173 174 O
for NCT03929939 175 178 O
the NCT03929939 179 182 O
non NCT03929939 183 186 B-Negation
- NCT03929939 187 188 O
PTSD NCT03929939 189 193 B-Condition
control NCT03929939 194 201 O
group NCT03929939 202 207 O
) NCT03929939 208 209 O
. NCT03929939 210 211 O

2 NCT03929939 215 216 O
. NCT03929939 216 217 O
Be NCT03929939 219 221 O
between NCT03929939 222 229 O
the NCT03929939 230 233 O
ages NCT03929939 234 238 B-Age
of NCT03929939 239 241 O
18 NCT03929939 242 244 B-Eq-Comparison
- NCT03929939 245 246 I-Eq-Comparison
65 NCT03929939 247 249 I-Eq-Comparison
. NCT03929939 249 250 O

3 NCT03929939 254 255 O
. NCT03929939 255 256 O
Sedentary NCT03929939 258 267 B-Condition
( NCT03929939 268 269 O
exercises NCT03929939 270 279 B-Observation
less NCT03929939 280 284 B-Eq-Comparison
than NCT03929939 285 289 I-Eq-Comparison
three NCT03929939 290 295 I-Eq-Comparison
times NCT03929939 296 301 I-Eq-Comparison
a NCT03929939 302 303 I-Eq-Comparison
week NCT03929939 304 308 I-Eq-Comparison
for NCT03929939 309 312 O
thirty NCT03929939 313 319 B-Eq-Comparison
minutes NCT03929939 320 327 I-Eq-Comparison
or NCT03929939 328 330 I-Eq-Comparison
less NCT03929939 331 335 I-Eq-Comparison
) NCT03929939 336 337 O
. NCT03929939 338 339 O

Exclusion NCT03929939 341 350 O
Criteria NCT03929939 351 359 O
: NCT03929939 360 361 O

1 NCT03929939 365 366 O
. NCT03929939 366 367 O
Any NCT03929939 369 372 O
evidence NCT03929939 373 381 O
of NCT03929939 382 384 O
cardiopulmonary NCT03929939 385 400 B-Modifier
and NCT03929939 401 404 B-Or
neurological NCT03929939 405 417 B-Modifier
diseases NCT03929939 418 426 B-Condition
by NCT03929939 427 429 O
history NCT03929939 430 437 O
or NCT03929939 438 440 O
by NCT03929939 441 443 O
physical NCT03929939 444 452 B-Procedure
examination NCT03929939 453 464 I-Procedure
. NCT03929939 464 465 O

2 NCT03929939 469 470 O
. NCT03929939 470 471 O
Chronic NCT03929939 473 480 B-Modifier
kidney NCT03929939 481 487 B-Condition
disease NCT03929939 488 495 I-Condition
( NCT03929939 496 497 O
serum NCT03929939 498 503 B-Observation
creatinine NCT03929939 504 514 I-Observation
> NCT03929939 515 516 B-Eq-Comparison
1.5 NCT03929939 517 520 I-Eq-Comparison
mg NCT03929939 521 523 I-Eq-Comparison
/ NCT03929939 524 525 I-Eq-Comparison
dL NCT03929939 526 528 I-Eq-Comparison
) NCT03929939 529 530 O
. NCT03929939 531 532 O

3 NCT03929939 536 537 O
. NCT03929939 537 538 O
Peripheral NCT03929939 540 550 B-Condition|Condition
vascular NCT03929939 551 559 I-Condition
disease NCT03929939 560 567 I-Condition
. NCT03929939 567 568 O

4 NCT03929939 572 573 O
. NCT03929939 573 574 O
Peripheral NCT03929939 576 586 O
neuropathy NCT03929939 587 597 I-Condition
. NCT03929939 597 598 O

5 NCT03929939 602 603 O
. NCT03929939 603 604 O
Current NCT03929939 606 613 B-Eq-Comparison
substance NCT03929939 614 623 B-Condition
use NCT03929939 624 627 I-Condition
disorder NCT03929939 628 636 I-Condition
other NCT03929939 637 642 B-Exception
than NCT03929939 643 647 I-Exception
tobacco NCT03929939 648 655 B-Drug
related NCT03929939 656 663 O
. NCT03929939 663 664 O

6 NCT03929939 668 669 O
. NCT03929939 669 670 O
Endurance NCT03929939 672 681 B-Condition
- NCT03929939 682 683 I-Condition
trained NCT03929939 684 691 I-Condition
athletes NCT03929939 692 700 I-Condition
due NCT03929939 701 704 O
to NCT03929939 705 707 O
the NCT03929939 708 711 O
effects NCT03929939 712 719 O
of NCT03929939 720 722 O
exercise NCT03929939 723 731 B-Procedure
training NCT03929939 732 740 I-Procedure
on NCT03929939 741 743 O
sympathetic NCT03929939 744 755 B-Condition
neural NCT03929939 756 762 I-Condition
control NCT03929939 763 770 I-Condition
and NCT03929939 771 774 B-Or
cardiac NCT03929939 775 782 B-Condition
- NCT03929939 783 784 I-Condition
vascular NCT03929939 785 793 I-Condition
function NCT03929939 794 802 I-Condition
. NCT03929939 802 803 O

7 NCT03929939 807 808 O
. NCT03929939 808 809 O
Current NCT03929939 811 818 B-Eq-Comparison
pregnancy NCT03929939 819 828 B-Condition
. NCT03929939 828 829 O

Inclusion NCT03928366 0 9 O
Criteria NCT03928366 10 18 O
: NCT03928366 19 20 O

- NCT03928366 24 25 O
Healthy NCT03928366 27 34 B-Condition
adult NCT03928366 35 40 O
volunteers NCT03928366 41 51 O
( NCT03928366 52 53 O
ASA NCT03928366 54 57 B-Condition
1 NCT03928366 58 59 B-Eq-Comparison
physical NCT03928366 60 68 O
state NCT03928366 69 74 O
) NCT03928366 75 76 O
who NCT03928366 77 80 O
agree NCT03928366 81 86 O
to NCT03928366 87 89 O
participate NCT03928366 90 101 O
voluntarily NCT03928366 102 113 O
in NCT03928366 114 116 O
the NCT03928366 117 120 O
study NCT03928366 121 126 B-Study
, NCT03928366 127 128 O
previous NCT03928366 129 137 B-Eq-Comparison
information NCT03928366 138 149 O
about NCT03928366 150 155 O
it NCT03928366 156 158 O
by NCT03928366 159 161 O
the NCT03928366 162 165 O
Principal NCT03928366 166 175 O
Investigators NCT03928366 176 189 O
( NCT03928366 190 191 O
IP NCT03928366 192 194 O
) NCT03928366 195 196 O
. NCT03928366 197 198 O

Exclusion NCT03928366 200 209 O
Criteria NCT03928366 210 218 O
: NCT03928366 219 220 O

- NCT03928366 224 225 O
Psychological NCT03928366 227 240 B-Modifier
, NCT03928366 241 242 O
psychiatric NCT03928366 243 254 B-Modifier
or NCT03928366 255 257 B-Or
neurological NCT03928366 258 270 B-Modifier
disorders NCT03928366 271 280 B-Condition
. NCT03928366 280 281 O
Consumption NCT03928366 283 294 O
of NCT03928366 295 297 O
drugs NCT03928366 298 303 B-Drug
. NCT03928366 303 304 O
Alterations NCT03928366 306 317 B-Condition
cutaneous NCT03928366 318 327 B-Modifier
or NCT03928366 328 330 B-Or
anatomical NCT03928366 331 341 B-Modifier
cranial NCT03928366 342 349 I-Modifier
. NCT03928366 349 350 O
Idiomatic NCT03928366 352 361 B-Modifier
or NCT03928366 362 364 B-Or
communication NCT03928366 365 378 B-Modifier
barrier NCT03928366 379 386 B-Condition
. NCT03928366 386 387 O
Allergy NCT03928366 389 396 B-Allergy
to NCT03928366 397 399 O
propofol NCT03928366 400 408 B-Drug
, NCT03928366 409 410 O
remifentanil NCT03928366 411 423 B-Drug
or NCT03928366 424 426 O
to NCT03928366 427 429 O
some NCT03928366 430 434 O
of NCT03928366 435 437 O
its NCT03928366 438 441 O
excipients NCT03928366 442 452 O
. NCT03928366 452 453 O
Body NCT03928366 455 459 B-Observation
mass NCT03928366 460 464 I-Observation
index NCT03928366 465 470 I-Observation
( NCT03928366 471 472 O
BMI NCT03928366 473 476 B-Observation
) NCT03928366 477 478 O
< NCT03928366 479 480 B-Eq-Comparison
18 NCT03928366 481 483 I-Eq-Comparison
or NCT03928366 484 486 B-Or
> NCT03928366 487 488 B-Eq-Comparison
30 NCT03928366 489 491 I-Eq-Comparison
kg NCT03928366 492 494 I-Eq-Comparison
/ NCT03928366 495 496 I-Eq-Comparison
m2 NCT03928366 497 499 I-Eq-Comparison
. NCT03928366 499 500 O
Pregnancy NCT03928366 502 511 B-Condition
. NCT03928366 511 512 O
Airway NCT03928366 514 520 B-Modifier
or NCT03928366 521 523 B-Or
ventilation NCT03928366 524 535 B-Modifier
criteria NCT03928366 536 544 O
hard NCT03928366 545 549 B-Condition
. NCT03928366 549 550 O
Absence NCT03928366 552 559 B-Negation
of NCT03928366 560 562 O
accompanying NCT03928366 563 575 O
adult NCT03928366 576 581 B-Family-Member___Family-Member-Type:parent
at NCT03928366 582 584 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928366 585 588 O
end NCT03928366 589 592 O
of NCT03928366 593 595 O
the NCT03928366 596 599 O
study NCT03928366 600 605 B-Study
. NCT03928366 605 606 O

Inclusion NCT03922893 0 9 O
Criteria NCT03922893 10 18 O
: NCT03922893 19 20 O

- NCT03922893 24 25 O
Individuals NCT03922893 27 38 O
who NCT03922893 39 42 O
have NCT03922893 43 47 O
undergone NCT03922893 48 57 O
clinical NCT03922893 58 66 B-Modifier
and NCT03922893 67 70 B-Or
/ NCT03922893 71 72 I-Or
or NCT03922893 73 75 I-Or
research NCT03922893 76 84 B-Modifier
genetic NCT03922893 85 92 B-Procedure
evaluation NCT03922893 93 103 I-Procedure
, NCT03922893 104 105 O
found NCT03922893 106 111 O
to NCT03922893 112 114 O
have NCT03922893 115 119 O
or NCT03922893 120 122 O
not NCT03922893 123 126 O
have NCT03922893 127 131 O
a NCT03922893 132 133 O
germline NCT03922893 134 142 B-Condition
genetic NCT03922893 143 150 I-Condition
variant NCT03922893 151 158 I-Condition
( NCT03922893 159 160 O
pathogenic NCT03922893 161 171 B-Modifier
, NCT03922893 172 173 O
likely NCT03922893 174 180 B-Assertion___Assertion-Type-Value:possible
pathogenic NCT03922893 181 191 B-Modifier
, NCT03922893 192 193 O
variant NCT03922893 194 201 O
of NCT03922893 202 204 O
uncertain NCT03922893 205 214 O
/ NCT03922893 215 216 O
unknown NCT03922893 217 224 O
significance NCT03922893 225 237 O
, NCT03922893 238 239 O
likely NCT03922893 240 246 B-Assertion___Assertion-Type-Value:possible
benign NCT03922893 247 253 B-Modifier
) NCT03922893 254 255 O
. NCT03922893 256 257 O

- NCT03922893 261 262 O
Individuals NCT03922893 264 275 O
with NCT03922893 276 280 O
or NCT03922893 281 283 O
without NCT03922893 284 291 O
a NCT03922893 292 293 O
personal NCT03922893 294 302 O
history NCT03922893 303 310 B-Eq-Comparison
of NCT03922893 311 313 O
malignant NCT03922893 314 323 B-Modifier
or NCT03922893 324 326 B-Or
pre NCT03922893 327 330 B-Modifier
- NCT03922893 331 332 I-Modifier
malignant NCT03922893 333 342 I-Modifier
lesions NCT03922893 343 350 B-Condition
who NCT03922893 351 354 O
demonstrate NCT03922893 355 366 O
: NCT03922893 367 368 O
a NCT03922893 369 370 O
) NCT03922893 371 372 O
clinical NCT03922893 373 381 O
findings NCT03922893 382 390 O
suggestive NCT03922893 391 401 B-Assertion___Assertion-Type-Value:possible
of NCT03922893 402 404 O
a NCT03922893 405 406 O
genetic NCT03922893 407 414 B-Condition
cancer NCT03922893 415 421 I-Condition
susceptibility NCT03922893 422 436 I-Condition
syndrome NCT03922893 437 445 I-Condition
including NCT03922893 446 455 B-And
very NCT03922893 456 460 O
early NCT03922893 461 466 B-Modifier
age NCT03922893 467 470 B-Age
at NCT03922893 471 473 O
onset NCT03922893 474 479 B-Eq-Comparison
, NCT03922893 480 481 O
multiple NCT03922893 482 490 B-Modifier
primary NCT03922893 491 498 I-Modifier
malignancies NCT03922893 499 511 B-Condition
, NCT03922893 512 513 O
or NCT03922893 514 516 B-Or
other NCT03922893 517 522 B-Other
features NCT03922893 523 531 B-Condition
; NCT03922893 531 532 O
and NCT03922893 533 536 B-Or
/ NCT03922893 537 538 I-Or
or NCT03922893 539 541 I-Or
b NCT03922893 542 543 O
) NCT03922893 544 545 O
family NCT03922893 546 552 B-Family-Member
histories NCT03922893 553 562 I-Family-Member
suggestive NCT03922893 563 573 B-Assertion___Assertion-Type-Value:possible
of NCT03922893 574 576 O
a NCT03922893 577 578 O
genetic NCT03922893 579 586 B-Condition
cancer NCT03922893 587 593 I-Condition
susceptibility NCT03922893 594 608 I-Condition
syndrome NCT03922893 609 617 I-Condition
, NCT03922893 618 619 O
or NCT03922893 620 622 O
c NCT03922893 623 624 O
) NCT03922893 625 626 O
other NCT03922893 627 632 B-Other
features NCT03922893 633 641 B-Condition
suggesting NCT03922893 642 652 B-Assertion___Assertion-Type-Value:possible
inherited NCT03922893 653 662 O
etiology NCT03922893 663 671 O
of NCT03922893 672 674 O
malignancy NCT03922893 675 685 B-Condition
as NCT03922893 686 688 O
determined NCT03922893 689 699 O
by NCT03922893 700 702 O
the NCT03922893 703 706 O
PI NCT03922893 707 709 O
. NCT03922893 709 710 O

- NCT03922893 714 715 O
Family NCT03922893 717 723 B-Family-Member
members NCT03922893 724 731 I-Family-Member
of NCT03922893 732 734 O
the NCT03922893 735 738 O
above NCT03922893 739 744 O
participants NCT03922893 745 757 O
. NCT03922893 757 758 O
Both NCT03922893 760 764 O
children NCT03922893 765 773 O
( NCT03922893 774 775 O
with NCT03922893 776 780 O
parental NCT03922893 781 789 O
consent NCT03922893 790 797 O
as NCT03922893 798 800 O
age NCT03922893 801 804 O
appropriate NCT03922893 805 816 O
) NCT03922893 817 818 O
and NCT03922893 819 822 B-Or
adults NCT03922893 823 829 O
are NCT03922893 830 833 O
eligible NCT03922893 834 842 O
to NCT03922893 843 845 O
participation NCT03922893 846 859 O
. NCT03922893 859 860 O

- NCT03922893 864 865 O
Individuals NCT03922893 867 878 O
may NCT03922893 879 882 O
or NCT03922893 883 885 O
may NCT03922893 886 889 O
not NCT03922893 890 893 O
be NCT03922893 894 896 O
enrolled NCT03922893 897 905 O
MSK NCT03922893 906 909 O
patients NCT03922893 910 918 O
; NCT03922893 918 919 O
probands NCT03922893 920 928 O
may NCT03922893 929 932 O
be NCT03922893 933 935 O
referred NCT03922893 936 944 O
to NCT03922893 945 947 O
( NCT03922893 948 949 O
or NCT03922893 950 952 O
self NCT03922893 953 957 O
- NCT03922893 958 959 O
referred NCT03922893 960 968 O
to NCT03922893 969 971 O
) NCT03922893 972 973 O
the NCT03922893 974 977 O
study NCT03922893 978 983 O
and NCT03922893 984 987 O
may NCT03922893 988 991 O
be NCT03922893 992 994 O
enrolled NCT03922893 995 1003 O
at NCT03922893 1004 1006 O
discretion NCT03922893 1007 1017 O
of NCT03922893 1018 1020 O
the NCT03922893 1021 1024 O
PI NCT03922893 1025 1027 O
and NCT03922893 1028 1031 O
if NCT03922893 1032 1034 O
able NCT03922893 1035 1039 O
to NCT03922893 1040 1042 O
provide NCT03922893 1043 1050 O
informed NCT03922893 1051 1059 O
consent NCT03922893 1060 1067 O
. NCT03922893 1067 1068 O

- NCT03922893 1072 1073 O
Biospecimens NCT03922893 1075 1087 O
derived NCT03922893 1088 1095 O
from NCT03922893 1096 1100 O
deceased NCT03922893 1101 1109 B-Death
family NCT03922893 1110 1116 B-Family-Member
members NCT03922893 1117 1124 I-Family-Member
may NCT03922893 1125 1128 O
be NCT03922893 1129 1131 O
used NCT03922893 1132 1136 O
for NCT03922893 1137 1140 O
research NCT03922893 1141 1149 O
in NCT03922893 1150 1152 O
this NCT03922893 1153 1157 O
study NCT03922893 1158 1163 O
if NCT03922893 1164 1166 O
consent NCT03922893 1167 1174 O
if NCT03922893 1175 1177 O
provided NCT03922893 1178 1186 O
by NCT03922893 1187 1189 O
the NCT03922893 1190 1193 O
executor NCT03922893 1194 1202 O
of NCT03922893 1203 1205 O
the NCT03922893 1206 1209 O
estate NCT03922893 1210 1216 O
of NCT03922893 1217 1219 O
that NCT03922893 1220 1224 O
individual NCT03922893 1225 1235 O
. NCT03922893 1235 1236 O

Exclusion NCT03922893 1238 1247 O
Criteria NCT03922893 1248 1256 O
: NCT03922893 1257 1258 O

- NCT03922893 1262 1263 O
Patients NCT03922893 1265 1273 O
will NCT03922893 1274 1278 O
be NCT03922893 1279 1281 O
excluded NCT03922893 1282 1290 B-Negation
from NCT03922893 1291 1295 O
this NCT03922893 1296 1300 O
study NCT03922893 1301 1306 B-Study
if NCT03922893 1307 1309 O
he NCT03922893 1310 1312 O
/ NCT03922893 1313 1314 O
she NCT03922893 1315 1318 O
has NCT03922893 1319 1322 O
physical NCT03922893 1323 1331 B-Modifier
, NCT03922893 1332 1333 O
cognitive NCT03922893 1334 1343 B-Modifier
or NCT03922893 1344 1346 B-Or
psychiatric NCT03922893 1347 1358 B-Modifier
conditions NCT03922893 1359 1369 B-Condition
that NCT03922893 1370 1374 O
interfere NCT03922893 1375 1384 O
with NCT03922893 1385 1389 O
ability NCT03922893 1390 1397 O
to NCT03922893 1398 1400 O
give NCT03922893 1401 1405 O
meaningful NCT03922893 1406 1416 O
informed NCT03922893 1417 1425 O
consent NCT03922893 1426 1433 O
. NCT03922893 1433 1434 O

Inclusion NCT03926377 0 9 O
Criteria NCT03926377 10 18 O
: NCT03926377 19 20 O

- NCT03926377 24 25 O
patients NCT03926377 27 35 O
presenting NCT03926377 36 46 O
a NCT03926377 47 48 O
multi NCT03926377 49 54 B-Modifier
- NCT03926377 55 56 I-Modifier
bullous NCT03926377 57 64 I-Modifier
pemphigoid NCT03926377 65 75 B-Condition
newly NCT03926377 76 81 O
diagnosed NCT03926377 82 91 O
or NCT03926377 92 94 O
relapsed NCT03926377 95 103 O
more NCT03926377 104 108 B-Eq-Comparison
than NCT03926377 109 113 I-Eq-Comparison
3 NCT03926377 114 115 I-Eq-Comparison
months NCT03926377 116 122 I-Eq-Comparison
after NCT03926377 123 128 B-Temporal-Connection___Temporal-Connection-Type-Value:after
stopping NCT03926377 129 137 O
corticosteroids NCT03926377 138 153 B-Drug
and NCT03926377 154 157 B-And
treated NCT03926377 158 165 B-Procedure
according NCT03926377 166 175 O
to NCT03926377 176 178 O
the NCT03926377 179 182 O
national NCT03926377 183 191 O
protocol NCT03926377 192 200 O
for NCT03926377 201 204 O
diagnosis NCT03926377 205 214 O
and NCT03926377 215 218 O
care NCT03926377 219 223 O
issued NCT03926377 224 230 O
by NCT03926377 231 233 O
the NCT03926377 234 237 O
reference NCT03926377 238 247 O
center NCT03926377 248 254 O
for NCT03926377 255 258 O
autoimmune NCT03926377 259 269 O
bullous NCT03926377 270 277 O
diseases NCT03926377 278 286 O
of NCT03926377 287 289 O
April NCT03926377 290 295 O
2016 NCT03926377 296 300 O

- NCT03926377 304 305 O
patients NCT03926377 307 315 O
having NCT03926377 316 322 O
received NCT03926377 323 331 B-Eq-Comparison
written NCT03926377 332 339 O
and NCT03926377 340 343 O
oral NCT03926377 344 348 O
information NCT03926377 349 360 O
and NCT03926377 361 364 O
signed NCT03926377 365 371 O
informed NCT03926377 372 380 O
consent NCT03926377 381 388 O

- NCT03926377 391 392 O
patients NCT03926377 394 402 O
covered NCT03926377 403 410 O
by NCT03926377 411 413 O
national NCT03926377 414 422 O
health NCT03926377 423 429 O
insurance NCT03926377 430 439 O

Exclusion NCT03926377 440 449 O
Criteria NCT03926377 450 458 O
: NCT03926377 459 460 O

- NCT03926377 464 465 O
Patients NCT03926377 467 475 O
under NCT03926377 476 481 O
tutorship NCT03926377 482 491 O
or NCT03926377 492 494 O
curatorship NCT03926377 495 506 O
or NCT03926377 507 509 O
inability NCT03926377 510 519 O
to NCT03926377 520 522 O
give NCT03926377 523 527 O
informed NCT03926377 528 536 O
consent NCT03926377 537 544 O

- NCT03926377 547 548 O
Patients NCT03926377 550 558 O
receiving NCT03926377 559 568 B-Eq-Comparison
an NCT03926377 569 571 B-Drug
anti NCT03926377 572 576 O
- NCT03926377 577 578 I-Drug
osteoporotic NCT03926377 579 591 I-Drug
treatment NCT03926377 592 601 B-Procedure

- NCT03926377 604 605 O
Patients NCT03926377 607 615 O
requiring NCT03926377 616 625 B-Assertion___Assertion-Type-Value:hypothetical
an NCT03926377 626 628 B-Drug
anti NCT03926377 629 633 O
- NCT03926377 634 635 I-Drug
osteoporotic NCT03926377 636 648 I-Drug
baseline NCT03926377 649 657 O
treatment NCT03926377 658 667 B-Procedure
( NCT03926377 668 669 O
T NCT03926377 670 671 B-Observation
- NCT03926377 672 673 I-Eq-Comparison|Observation
score NCT03926377 674 679 I-Observation
⩽ NCT03926377 680 681 B-Eq-Comparison
- NCT03926377 682 683 O
3 NCT03926377 684 685 I-Eq-Comparison
DS NCT03926377 686 688 O
on NCT03926377 689 691 O
at NCT03926377 692 694 B-Eq-Comparison
least NCT03926377 695 700 I-Eq-Comparison
1 NCT03926377 701 702 I-Eq-Comparison
site NCT03926377 703 707 I-Eq-Comparison
or NCT03926377 708 710 B-Or
FRAX NCT03926377 711 715 B-Observation
score NCT03926377 716 721 I-Observation
above NCT03926377 722 727 B-Eq-Comparison
the NCT03926377 728 731 I-Eq-Comparison
therapeutic NCT03926377 732 743 O
intervention NCT03926377 744 756 I-Eq-Comparison
threshold NCT03926377 757 766 I-Eq-Comparison
) NCT03926377 767 768 O

- NCT03926377 776 777 O
Patients NCT03926377 779 787 O
with NCT03926377 788 792 O
one NCT03926377 793 796 B-Eq-Comparison
or NCT03926377 797 799 I-Eq-Comparison
more NCT03926377 800 804 I-Eq-Comparison
major NCT03926377 805 810 O
risk NCT03926377 811 815 B-Risk
factors NCT03926377 816 823 O
for NCT03926377 824 827 O
osteoporosis NCT03926377 828 840 B-Condition

- NCT03926377 843 844 O
Patients NCT03926377 846 854 O
who NCT03926377 855 858 O
have NCT03926377 859 863 O
received NCT03926377 864 872 B-Eq-Comparison
topical NCT03926377 873 880 B-Drug
corticosteroids NCT03926377 881 896 I-Drug
in NCT03926377 897 899 O
less NCT03926377 900 904 B-Eq-Comparison
than NCT03926377 905 909 I-Eq-Comparison
3 NCT03926377 910 911 I-Eq-Comparison
months NCT03926377 912 918 I-Eq-Comparison


Inclusion NCT03923569 0 9 O
Criteria NCT03923569 10 18 O
: NCT03923569 19 20 O

For NCT03923569 22 25 O
all NCT03923569 26 29 O
participants NCT03923569 30 42 O
: NCT03923569 43 44 O

- NCT03923569 48 49 O
age NCT03923569 51 54 B-Age
from NCT03923569 55 59 O
50 NCT03923569 60 62 B-Eq-Comparison
to NCT03923569 63 65 I-Eq-Comparison
75 NCT03923569 66 68 I-Eq-Comparison
years NCT03923569 69 74 I-Eq-Comparison
old NCT03923569 75 78 O

- NCT03923569 81 82 O
affiliated NCT03923569 84 94 O
to NCT03923569 95 97 O
the NCT03923569 98 101 O
French NCT03923569 102 108 O
health NCT03923569 109 115 O
care NCT03923569 116 120 O
system NCT03923569 121 127 O

For NCT03923569 128 131 O
AD NCT03923569 132 134 B-Condition
patients NCT03923569 135 143 O
: NCT03923569 144 145 O

- NCT03923569 149 150 O
meeting NCT03923569 152 159 O
International NCT03923569 160 173 O
Working NCT03923569 174 181 O
Group NCT03923569 182 187 O
( NCT03923569 188 189 O
IWG NCT03923569 190 193 O
) NCT03923569 194 195 O
- NCT03923569 197 198 O
2 NCT03923569 199 200 O
criteria NCT03923569 201 209 O
for NCT03923569 210 213 O
diagnosis NCT03923569 214 223 O

- NCT03923569 226 227 I-Observation
Mini NCT03923569 229 233 B-Observation
- NCT03923569 234 235 O
Mental NCT03923569 236 242 I-Observation
State NCT03923569 243 248 I-Observation
Examination NCT03923569 249 260 I-Observation
( NCT03923569 261 262 O
MMSE NCT03923569 263 267 B-Observation
) NCT03923569 268 269 O
≥ NCT03923569 270 271 B-Eq-Comparison
20 NCT03923569 272 274 I-Eq-Comparison
( NCT03923569 275 276 O
Greco NCT03923569 277 282 O
version NCT03923569 283 290 O
) NCT03923569 291 292 O

For NCT03923569 294 297 O
healthy NCT03923569 298 305 B-Condition
volunteers NCT03923569 306 316 O
: NCT03923569 317 318 O

- NCT03923569 322 323 O
MMSE NCT03923569 325 329 B-Observation
> NCT03923569 330 331 B-Eq-Comparison
25 NCT03923569 332 334 I-Eq-Comparison

- NCT03923569 338 339 O
Dubois NCT03923569 341 347 B-Observation
5 NCT03923569 348 349 I-Observation
words NCT03923569 350 355 I-Observation
test NCT03923569 356 360 I-Observation
≥ NCT03923569 361 362 B-Eq-Comparison
9 NCT03923569 363 364 I-Eq-Comparison

Exclusion NCT03923569 366 375 O
Criteria NCT03923569 376 384 O
: NCT03923569 385 386 O

For NCT03923569 388 391 O
all NCT03923569 392 395 O
participants NCT03923569 396 408 O
: NCT03923569 409 410 O

- NCT03923569 414 415 O
Pregnancy NCT03923569 417 426 B-Condition

- NCT03923569 429 430 O
people NCT03923569 432 438 O
not NCT03923569 439 442 O
able NCT03923569 443 447 O
to NCT03923569 448 450 O
give NCT03923569 451 455 O
consent NCT03923569 456 463 O

- NCT03923569 466 467 O
contraindication NCT03923569 469 485 B-Contraindication
for NCT03923569 486 489 O
MRI NCT03923569 490 493 B-Procedure
( NCT03923569 494 495 O
metallic NCT03923569 496 504 B-Condition
body NCT03923569 505 509 I-Condition
parts NCT03923569 510 515 I-Condition
, NCT03923569 516 517 O
claustrophobia NCT03923569 518 532 B-Condition
) NCT03923569 533 534 O
, NCT03923569 536 537 O

- NCT03923569 541 542 O
aphasia NCT03923569 544 551 B-Condition
, NCT03923569 552 553 O
apraxia NCT03923569 554 561 B-Condition
or NCT03923569 562 564 B-Or
agnosia NCT03923569 565 572 B-Condition

- NCT03923569 575 576 O
neurological NCT03923569 578 590 B-Modifier
( NCT03923569 591 592 O
other NCT03923569 593 598 B-Exception|Other
than NCT03923569 599 603 I-Exception
AD NCT03923569 604 606 B-Condition
) NCT03923569 607 608 O
or NCT03923569 609 611 B-Or
any NCT03923569 612 615 O
other NCT03923569 616 621 O
serious NCT03923569 622 629 O
disease NCT03923569 630 637 I-Condition|Condition
( NCT03923569 638 639 O
cancer NCT03923569 640 646 O
, NCT03923569 647 648 O
addiction NCT03923569 649 658 B-Condition
, NCT03923569 659 660 O
systemic NCT03923569 661 669 B-Condition
disease NCT03923569 670 677 O
) NCT03923569 678 679 O

- NCT03923569 683 684 O
sleep NCT03923569 686 691 O
apnea NCT03923569 692 697 O

- NCT03923569 700 701 O
major NCT03923569 703 708 O
depression NCT03923569 709 719 B-Condition
or NCT03923569 720 722 B-Or
anxiety NCT03923569 723 730 B-Condition
for NCT03923569 731 734 O
more NCT03923569 735 739 B-Eq-Comparison
than NCT03923569 740 744 I-Eq-Comparison
3 NCT03923569 745 746 I-Eq-Comparison
months NCT03923569 747 753 I-Eq-Comparison
( NCT03923569 754 755 O
Beck NCT03923569 756 760 B-Observation
> NCT03923569 761 762 B-Eq-Comparison
10 NCT03923569 763 765 I-Eq-Comparison
) NCT03923569 766 767 O
or NCT03923569 768 770 B-Or
psychiatric NCT03923569 771 782 B-Condition
disease NCT03923569 783 790 I-Condition

- NCT03923569 793 794 O
documented NCT03923569 796 806 O
epilepsy NCT03923569 807 815 B-Condition

- NCT03923569 818 819 O
use NCT03923569 821 824 B-Eq-Comparison
of NCT03923569 825 827 O
neuroleptics NCT03923569 828 840 B-Drug
( NCT03923569 841 842 O
more NCT03923569 843 847 B-Eq-Comparison
than NCT03923569 848 852 I-Eq-Comparison
one NCT03923569 853 856 I-Eq-Comparison
dose NCT03923569 857 861 I-Eq-Comparison
per NCT03923569 862 865 I-Eq-Comparison
day NCT03923569 866 869 I-Eq-Comparison
) NCT03923569 870 871 O

- NCT03923569 875 876 O
use NCT03923569 878 881 B-Eq-Comparison|Eq-Comparison
of NCT03923569 882 884 O
antiepileptics NCT03923569 885 899 B-Drug

- NCT03923569 902 903 O
use NCT03923569 905 908 O
of NCT03923569 909 911 O
benzodiazepines NCT03923569 912 927 B-Drug
at NCT03923569 928 930 O
a NCT03923569 931 932 O
dose NCT03923569 933 937 O
superior NCT03923569 938 946 B-Eq-Comparison
or NCT03923569 947 949 I-Eq-Comparison
equal NCT03923569 950 955 I-Eq-Comparison
to NCT03923569 956 958 I-Eq-Comparison
two NCT03923569 959 962 I-Eq-Comparison
intakes NCT03923569 963 970 I-Eq-Comparison
per NCT03923569 971 974 I-Eq-Comparison
day NCT03923569 975 978 I-Eq-Comparison

- NCT03923569 981 982 O
use NCT03923569 984 987 B-Eq-Comparison
of NCT03923569 988 990 O
antidepressants NCT03923569 991 1006 B-Drug

- NCT03923569 1009 1010 O
restless NCT03923569 1012 1020 B-Condition
leg NCT03923569 1021 1024 I-Condition
syndrome NCT03923569 1025 1033 I-Condition
treated NCT03923569 1034 1041 O
by NCT03923569 1042 1044 O
dopaminergic NCT03923569 1045 1057 B-Drug
agonists NCT03923569 1058 1066 I-Drug
. NCT03923569 1066 1067 O

For NCT03923569 1069 1072 O
AD NCT03923569 1073 1075 B-Condition
patients NCT03923569 1076 1084 O
: NCT03923569 1085 1086 O

- NCT03923569 1090 1091 I-Modifier
other NCT03923569 1093 1098 B-Other
causes NCT03923569 1099 1105 B-Condition
of NCT03923569 1106 1108 O
dementia NCT03923569 1109 1117 B-Condition

- NCT03923569 1120 1121 O
non NCT03923569 1123 1126 B-Modifier
- NCT03923569 1127 1128 O
degenerative NCT03923569 1129 1141 I-Modifier
neurological NCT03923569 1142 1154 I-Modifier
lesions NCT03923569 1155 1162 B-Condition

- NCT03923569 1165 1166 O
white NCT03923569 1168 1173 B-Condition
matter NCT03923569 1174 1180 I-Condition
hypersignals NCT03923569 1181 1193 I-Condition

- NCT03923569 1196 1197 O
acute NCT03923569 1199 1204 O
cognitive NCT03923569 1205 1214 B-Condition
deficits NCT03923569 1215 1223 I-Condition

Inclusion NCT03924206 0 9 O
Criteria NCT03924206 10 18 O
: NCT03924206 19 20 O

- NCT03924206 23 24 O
All NCT03924206 25 28 O
surgical NCT03924206 29 37 B-Procedure
procedures NCT03924206 38 48 I-Procedure
with NCT03924206 49 53 O
a NCT03924206 54 55 O
planned NCT03924206 56 63 B-Eq-Comparison
duration NCT03924206 64 72 O
of NCT03924206 73 75 O
more NCT03924206 76 80 B-Eq-Comparison
than NCT03924206 81 85 I-Eq-Comparison
1 NCT03924206 86 87 I-Eq-Comparison
hour NCT03924206 88 92 I-Eq-Comparison

Exclusion NCT03924206 93 102 O
Criteria NCT03924206 103 111 O
: NCT03924206 112 113 O

- NCT03924206 117 118 O
Patients NCT03924206 120 128 O
with NCT03924206 129 133 O
a NCT03924206 134 135 O
contraindication NCT03924206 136 152 B-Contraindication
for NCT03924206 153 156 O
electrocautery NCT03924206 157 171 B-Procedure
use NCT03924206 172 175 O

- NCT03924206 178 179 O
Patients NCT03924206 181 189 O
with NCT03924206 190 194 O
Pacemaker NCT03924206 195 204 B-Procedure
or NCT03924206 205 207 B-Or
implantable NCT03924206 208 219 B-Procedure
cardioverter NCT03924206 220 232 I-Procedure
- NCT03924206 233 234 I-Procedure
defibrillator NCT03924206 235 248 I-Procedure
( NCT03924206 249 250 O
ICD NCT03924206 251 254 B-Procedure
) NCT03924206 255 256 O

- NCT03924206 260 261 O
Patients NCT03924206 263 271 O
with NCT03924206 272 276 O
an NCT03924206 277 279 O
implanted NCT03924206 280 289 B-Procedure
neurostimulator NCT03924206 290 305 I-Procedure
device NCT03924206 306 312 I-Procedure

Inclusion NCT03925454 0 9 O
Criteria NCT03925454 10 18 O
: NCT03925454 19 20 O

- NCT03925454 24 25 O
Receiving NCT03925454 27 36 B-Eq-Comparison
HHD NCT03925454 37 40 B-Procedure
or NCT03925454 41 43 B-Or
ICHDF NCT03925454 44 49 B-Procedure
for NCT03925454 50 53 O
more NCT03925454 54 58 B-Eq-Comparison
than NCT03925454 59 63 I-Eq-Comparison
3 NCT03925454 64 65 I-Eq-Comparison
months NCT03925454 66 72 I-Eq-Comparison
and NCT03925454 73 76 B-And
less NCT03925454 77 81 B-Eq-Comparison
than NCT03925454 82 86 I-Eq-Comparison
36 NCT03925454 87 89 I-Eq-Comparison
months NCT03925454 90 96 I-Eq-Comparison
. NCT03925454 96 97 O

- NCT03925454 101 102 O
Haemoglobin NCT03925454 104 115 B-Observation
equal NCT03925454 116 121 B-Eq-Comparison
to NCT03925454 122 124 I-Eq-Comparison
or NCT03925454 125 127 I-Eq-Comparison
greater NCT03925454 128 135 I-Eq-Comparison
than100 NCT03925454 136 143 I-Eq-Comparison
g NCT03925454 144 145 I-Eq-Comparison
/ NCT03925454 146 147 I-Eq-Comparison
L NCT03925454 148 149 I-Eq-Comparison
at NCT03925454 150 152 B-Temporal-Connection___Temporal-Connection-Type-Value:during
enrolment NCT03925454 153 162 B-Study
. NCT03925454 162 163 O

- NCT03925454 167 168 O
Willing NCT03925454 170 177 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03925454 178 181 B-And
physically NCT03925454 182 192 O
able NCT03925454 193 197 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925454 198 200 O
undertake NCT03925454 201 210 O
the NCT03925454 211 214 O
study NCT03925454 215 220 B-Study
assessments NCT03925454 221 232 B-Procedure
/ NCT03925454 233 234 B-Or
tests NCT03925454 235 240 B-Procedure

- NCT03925454 243 244 O
Willing NCT03925454 246 253 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925454 254 256 O
provide NCT03925454 257 264 O
blood NCT03925454 265 270 B-Observation
for NCT03925454 271 274 O
storage NCT03925454 275 282 O
and NCT03925454 283 286 O
future NCT03925454 287 293 O
analysis NCT03925454 294 302 O

- NCT03925454 305 306 O
Able NCT03925454 308 312 O
to NCT03925454 313 315 O
give NCT03925454 316 320 O
informed NCT03925454 321 329 O
consent NCT03925454 330 337 O

Exclusion NCT03925454 338 347 O
Criteria NCT03925454 348 356 O
: NCT03925454 357 358 O

- NCT03925454 362 363 O
Living NCT03925454 365 371 B-Procedure
donor NCT03925454 372 377 I-Procedure
transplant NCT03925454 378 388 I-Procedure
or NCT03925454 389 391 B-Or
change NCT03925454 392 398 O
to NCT03925454 399 401 O
peritoneal NCT03925454 402 412 B-Procedure
dialysis NCT03925454 413 421 I-Procedure
planned NCT03925454 422 429 B-Eq-Comparison

- NCT03925454 432 433 O
Physical NCT03925454 435 443 B-Procedure
assessments NCT03925454 444 455 I-Procedure
contraindicated NCT03925454 456 471 B-Contraindication
for NCT03925454 472 475 O
the NCT03925454 476 479 O
following NCT03925454 480 489 O
clinical NCT03925454 490 498 O
reasons NCT03925454 499 506 O

- NCT03925454 514 515 O
Acute NCT03925454 517 522 B-Condition
Coronary NCT03925454 523 531 I-Condition
Syndrome NCT03925454 532 540 I-Condition
( NCT03925454 541 542 O
ACS NCT03925454 543 546 B-Condition
) NCT03925454 547 548 O
within NCT03925454 549 555 B-Eq-Comparison
the NCT03925454 556 559 I-Eq-Comparison
last NCT03925454 560 564 I-Eq-Comparison
3 NCT03925454 565 566 I-Eq-Comparison
months NCT03925454 567 573 I-Eq-Comparison
( NCT03925454 574 575 O
chest NCT03925454 576 581 B-Modifier
pain NCT03925454 582 586 B-Condition
, NCT03925454 587 588 O
ECG NCT03925454 589 592 B-Procedure
changes NCT03925454 593 600 O
or NCT03925454 601 603 B-Or
typical NCT03925454 604 611 O
biomarker NCT03925454 612 621 B-Observation
elevation NCT03925454 622 631 O
) NCT03925454 632 633 O
. NCT03925454 634 635 O

- NCT03925454 644 645 O
Any NCT03925454 647 650 O
current NCT03925454 651 658 B-Eq-Comparison
uncontrolled NCT03925454 659 671 B-Modifier
cardiac NCT03925454 672 679 B-Condition
dysrhythmias NCT03925454 680 692 I-Condition
causing NCT03925454 693 700 O
symptoms NCT03925454 701 709 B-Assertion___Assertion-Type-Value:possible
( NCT03925454 710 711 O
chest NCT03925454 712 717 B-Modifier
pain NCT03925454 718 722 B-Condition
, NCT03925454 723 724 O
palpitations NCT03925454 725 737 B-Condition
, NCT03925454 738 739 O
syncope NCT03925454 740 747 B-Condition
or NCT03925454 748 750 B-Or
dizziness NCT03925454 751 760 B-Condition
) NCT03925454 761 762 O

- NCT03925454 771 772 O
Symptomatic NCT03925454 774 785 B-Condition
aortic NCT03925454 786 792 I-Condition
stenosis NCT03925454 793 801 I-Condition

- NCT03925454 809 810 O
New NCT03925454 812 815 B-Condition
York NCT03925454 816 820 I-Condition
Heart NCT03925454 821 826 I-Condition
Association NCT03925454 827 838 I-Condition
grade NCT03925454 839 844 B-Eq-Comparison
IV NCT03925454 845 847 I-Eq-Comparison
Heart NCT03925454 848 853 B-Condition
failure NCT03925454 854 861 I-Condition

- NCT03925454 869 870 O
Severe NCT03925454 872 878 O
chronic NCT03925454 879 886 B-Modifier
obstructive NCT03925454 887 898 B-Condition
pulmonary NCT03925454 899 908 I-Condition
disease NCT03925454 909 916 I-Condition

- NCT03925454 924 925 O
Acute NCT03925454 927 932 O
pulmonary NCT03925454 933 942 B-Condition|Condition
embolus NCT03925454 943 950 I-Condition
or NCT03925454 951 953 B-Or
pulmonary NCT03925454 954 963 O
infarction NCT03925454 964 974 I-Condition
in NCT03925454 975 977 O
the NCT03925454 978 981 O
last NCT03925454 982 986 B-Eq-Comparison
3 NCT03925454 987 988 I-Eq-Comparison
months NCT03925454 989 995 I-Eq-Comparison

- NCT03925454 1003 1004 O
Current NCT03925454 1006 1013 B-Eq-Comparison
acute NCT03925454 1014 1019 B-Condition
myocarditis NCT03925454 1020 1031 I-Condition
or NCT03925454 1032 1034 B-Or
pericarditis NCT03925454 1035 1047 B-Condition

- NCT03925454 1055 1056 O
Suspected NCT03925454 1058 1067 B-Assertion___Assertion-Type-Value:possible
or NCT03925454 1068 1070 B-Or
known NCT03925454 1071 1076 B-Modifier
dissecting NCT03925454 1077 1087 B-Condition
aneurysm NCT03925454 1088 1096 I-Condition

- NCT03925454 1104 1105 O
Acute NCT03925454 1107 1112 O
systemic NCT03925454 1113 1121 B-Modifier
infection NCT03925454 1122 1131 B-Condition
, NCT03925454 1132 1133 O
accompanied NCT03925454 1134 1145 B-And
by NCT03925454 1146 1148 I-And
fever NCT03925454 1149 1154 B-Condition
, NCT03925454 1155 1156 O
body NCT03925454 1157 1161 B-Condition
aches NCT03925454 1162 1167 I-Condition
or NCT03925454 1168 1170 B-Or
swollen NCT03925454 1171 1178 B-Condition
lymph NCT03925454 1179 1184 I-Condition
glands NCT03925454 1185 1191 I-Condition

- NCT03925454 1194 1195 O
Pregnancy NCT03925454 1197 1206 B-Condition

- NCT03925454 1209 1210 O
Life NCT03925454 1212 1216 B-Observation
expectancy NCT03925454 1217 1227 I-Observation
of NCT03925454 1228 1230 O
less NCT03925454 1231 1235 B-Eq-Comparison
than NCT03925454 1236 1240 I-Eq-Comparison
twelve NCT03925454 1241 1247 I-Eq-Comparison
months NCT03925454 1248 1254 I-Eq-Comparison

Inclusion NCT03921632 0 9 O
Criteria NCT03921632 10 18 O
: NCT03921632 19 20 O

- NCT03921632 24 25 O
Patient NCT03921632 27 34 O
of NCT03921632 35 37 O
the NCT03921632 38 41 O
UNC NCT03921632 42 45 O
Center NCT03921632 46 52 O
for NCT03921632 53 56 O
Excellence NCT03921632 57 67 O
for NCT03921632 68 71 O
Eating NCT03921632 72 78 O
Disorders NCT03921632 79 88 O
inpatient NCT03921632 89 98 O
unit NCT03921632 99 103 O
or NCT03921632 104 106 B-Or
outpatient NCT03921632 107 117 O
clinic NCT03921632 118 124 O
. NCT03921632 124 125 O

- NCT03921632 129 130 O
Diagnosis NCT03921632 132 141 O
of NCT03921632 142 144 O
anorexia NCT03921632 145 153 B-Condition
nervosa NCT03921632 154 161 I-Condition
or NCT03921632 162 164 B-Or
bulimia NCT03921632 165 172 B-Condition
nervosa NCT03921632 173 180 I-Condition

- NCT03921632 183 184 O
Aged NCT03921632 186 190 B-Age
13 NCT03921632 191 193 B-Eq-Comparison
- NCT03921632 194 195 I-Eq-Comparison
50 NCT03921632 196 198 I-Eq-Comparison
years NCT03921632 199 204 I-Eq-Comparison

- NCT03921632 207 208 O
English NCT03921632 210 217 O
- NCT03921632 218 219 O
speaking NCT03921632 220 228 O

Exclusion NCT03921632 229 238 O
Criteria NCT03921632 239 247 O
: NCT03921632 248 249 O

- NCT03921632 253 254 O
Decisionally NCT03921632 256 268 B-Condition
impaired NCT03921632 269 277 I-Condition
( NCT03921632 278 279 O
i. NCT03921632 280 282 O
e. NCT03921632 283 285 O
, NCT03921632 286 287 O
Incapable NCT03921632 288 297 O
of NCT03921632 298 300 O
providing NCT03921632 301 310 O
informed NCT03921632 311 319 O
consent NCT03921632 320 327 O
in NCT03921632 328 330 O
the NCT03921632 331 334 O
opinion NCT03921632 335 342 O
of NCT03921632 343 345 O
the NCT03921632 346 349 O
primary NCT03921632 350 357 O
care NCT03921632 358 362 O
provider NCT03921632 363 371 O
in NCT03921632 372 374 O
UNC NCT03921632 375 378 O
Center NCT03921632 379 385 O
for NCT03921632 386 389 O
Excellence NCT03921632 390 400 O
for NCT03921632 401 404 O
Eating NCT03921632 405 411 O
Disorders NCT03921632 412 421 O
) NCT03921632 422 423 O

- NCT03921632 427 428 O
Involuntarily NCT03921632 430 443 B-Observation
committed NCT03921632 444 453 I-Observation
to NCT03921632 454 456 O
the NCT03921632 457 460 O
inpatient NCT03921632 461 470 O
service NCT03921632 471 478 O
of NCT03921632 479 481 O
the NCT03921632 482 485 O
UNC NCT03921632 486 489 B-Provider
Department NCT03921632 490 500 I-Provider
of NCT03921632 501 503 I-Provider
Psychiatry NCT03921632 504 514 I-Provider

Inclusion NCT03928158 0 9 O
Criteria NCT03928158 10 18 O
: NCT03928158 19 20 O

1 NCT03928158 24 25 O
. NCT03928158 25 26 O
Moderate NCT03928158 28 36 O
/ NCT03928158 37 38 B-Or
severe NCT03928158 39 45 O
hypertensive NCT03928158 46 58 B-Modifier
left NCT03928158 59 63 I-Modifier
ventricular NCT03928158 64 75 I-Modifier
( NCT03928158 76 77 O
LV NCT03928158 78 80 B-Modifier
) NCT03928158 81 82 O
hypertrophy NCT03928158 83 94 B-Condition
( NCT03928158 95 96 O
LVMi NCT03928158 97 101 B-Observation
≥ NCT03928158 102 103 B-Eq-Comparison
109 NCT03928158 104 107 I-Eq-Comparison
g NCT03928158 108 109 I-Eq-Comparison
/ NCT03928158 110 111 I-Eq-Comparison
m² NCT03928158 112 114 I-Eq-Comparison
in NCT03928158 115 117 O
women NCT03928158 118 123 O
and NCT03928158 124 127 B-Or
≥ NCT03928158 128 129 B-Eq-Comparison
132 NCT03928158 130 133 I-Eq-Comparison
g NCT03928158 134 135 I-Eq-Comparison
/ NCT03928158 136 137 I-Eq-Comparison
m² NCT03928158 138 140 I-Eq-Comparison
in NCT03928158 141 143 O
men NCT03928158 144 147 O
) NCT03928158 148 149 O
; NCT03928158 150 151 O

2 NCT03928158 154 155 O
. NCT03928158 155 156 O
New NCT03928158 158 161 B-Condition
York NCT03928158 162 166 I-Condition
Heart NCT03928158 167 172 I-Condition
Association NCT03928158 173 184 I-Condition
( NCT03928158 185 186 O
NYHA NCT03928158 187 191 B-Condition
) NCT03928158 192 193 O
class NCT03928158 194 199 B-Eq-Comparison
II NCT03928158 200 202 I-Eq-Comparison
- NCT03928158 203 204 I-Eq-Comparison
III NCT03928158 205 208 O
heart NCT03928158 209 214 B-Condition
failure NCT03928158 215 222 I-Condition
; NCT03928158 222 223 O

3 NCT03928158 226 227 O
. NCT03928158 227 228 O
Left NCT03928158 230 234 B-Observation
ventricular NCT03928158 235 246 I-Observation
ejection NCT03928158 247 255 I-Observation
fraction NCT03928158 256 264 I-Observation
> NCT03928158 265 266 B-Eq-Comparison
50 NCT03928158 267 269 I-Eq-Comparison
% NCT03928158 270 271 O
; NCT03928158 271 272 O

4 NCT03928158 275 276 O
. NCT03928158 276 277 O
Increased NCT03928158 279 288 O
LV NCT03928158 289 291 B-Observation
filling NCT03928158 292 299 I-Observation
pressures NCT03928158 300 309 I-Observation
assessed NCT03928158 310 318 O
at NCT03928158 319 321 O
rest NCT03928158 322 326 B-Modifier
or NCT03928158 327 329 B-Or
at NCT03928158 330 332 O
peak NCT03928158 333 337 B-Modifier
exercise NCT03928158 338 346 I-Modifier
by NCT03928158 347 349 O
echocardiography NCT03928158 350 366 B-Procedure

5 NCT03928158 369 370 O
. NCT03928158 370 371 O
Body NCT03928158 373 377 B-Observation
mass NCT03928158 378 382 I-Observation
index NCT03928158 383 388 I-Observation
( NCT03928158 389 390 O
BMI NCT03928158 391 394 B-Observation
) NCT03928158 395 396 O
> NCT03928158 397 398 B-Eq-Comparison
30 NCT03928158 399 401 I-Eq-Comparison
kg NCT03928158 402 404 I-Eq-Comparison
/ NCT03928158 405 406 I-Eq-Comparison
m² NCT03928158 407 409 I-Eq-Comparison

6 NCT03928158 412 413 O
. NCT03928158 413 414 O
Signed NCT03928158 416 422 O
and NCT03928158 423 426 O
data NCT03928158 427 431 O
informed NCT03928158 432 440 O
consent NCT03928158 441 448 O

Exclusion NCT03928158 449 458 O
Criteria NCT03928158 459 467 O
: NCT03928158 468 469 O

1 NCT03928158 473 474 O
. NCT03928158 474 475 O
Age NCT03928158 477 480 B-Age
≤ NCT03928158 481 482 B-Eq-Comparison
18 NCT03928158 483 485 O
years NCT03928158 486 491 I-Eq-Comparison
; NCT03928158 491 492 O

2 NCT03928158 495 496 O
. NCT03928158 496 497 O
Evidence NCT03928158 499 507 O
of NCT03928158 508 510 O
myocardial NCT03928158 511 521 B-Condition
ischemia NCT03928158 522 530 I-Condition
during NCT03928158 531 537 O
stress NCT03928158 538 544 B-Procedure
echocardiography NCT03928158 545 561 I-Procedure
; NCT03928158 561 562 O

3 NCT03928158 565 566 O
. NCT03928158 566 567 O
Chronic NCT03928158 569 576 B-Modifier
atrial NCT03928158 577 583 B-Condition|Condition
flutter NCT03928158 584 591 I-Condition
or NCT03928158 592 594 B-Or
atrial NCT03928158 595 601 O
fibrillation NCT03928158 602 614 I-Condition
; NCT03928158 614 615 O

4 NCT03928158 618 619 O
. NCT03928158 619 620 O
Alternative NCT03928158 622 633 B-Other
cause NCT03928158 634 639 B-Condition
of NCT03928158 640 642 O
left NCT03928158 643 647 B-Condition
ventricular NCT03928158 648 659 I-Condition
hypertrophy NCT03928158 660 671 I-Condition
and NCT03928158 672 675 B-Or
impaired NCT03928158 676 684 B-Condition
diastolic NCT03928158 685 694 I-Condition
function NCT03928158 695 703 I-Condition
( NCT03928158 704 705 O
hypertrophic NCT03928158 706 718 B-Modifier
/ NCT03928158 719 720 B-Or
restictive NCT03928158 721 731 B-Modifier
cardiomyopathy NCT03928158 732 746 B-Condition
, NCT03928158 747 748 O
aortic NCT03928158 749 755 B-Condition
stenosis NCT03928158 756 764 I-Condition
, NCT03928158 765 766 O
constrictive NCT03928158 767 779 B-Condition
pericarditis NCT03928158 780 792 I-Condition
and NCT03928158 793 796 O
etc NCT03928158 797 800 O
. NCT03928158 800 801 O
) NCT03928158 802 803 O
; NCT03928158 804 805 O

5 NCT03928158 808 809 O
. NCT03928158 809 810 O
NYHA NCT03928158 812 816 B-Condition
classification NCT03928158 817 831 B-Eq-Comparison
I NCT03928158 832 833 I-Eq-Comparison
or NCT03928158 834 836 B-Or
decompensated NCT03928158 837 850 B-Modifier
heart NCT03928158 851 856 B-Condition
failure NCT03928158 857 864 I-Condition
at NCT03928158 865 867 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03928158 868 877 B-Study
; NCT03928158 877 878 O

6 NCT03928158 881 882 O
. NCT03928158 882 883 O
Systolic NCT03928158 885 893 B-Observation
blood NCT03928158 894 899 I-Observation
pressure NCT03928158 900 908 I-Observation
< NCT03928158 909 910 B-Eq-Comparison
110 NCT03928158 911 914 I-Eq-Comparison
mmHg NCT03928158 915 919 I-Eq-Comparison|Eq-Comparison
or NCT03928158 920 922 B-Or
> NCT03928158 923 924 B-Eq-Comparison
180 NCT03928158 925 928 I-Eq-Comparison|Eq-Comparison
mmHg NCT03928158 929 933 I-Eq-Comparison
; NCT03928158 933 934 O

7 NCT03928158 937 938 O
. NCT03928158 938 939 O
Diastolic NCT03928158 941 950 B-Observation
blood NCT03928158 951 956 I-Observation
pressure NCT03928158 957 965 I-Observation
< NCT03928158 966 967 B-Eq-Comparison|Eq-Comparison
40 NCT03928158 968 970 I-Eq-Comparison
mmHg NCT03928158 971 975 I-Eq-Comparison
or NCT03928158 976 978 B-Or
> NCT03928158 979 980 B-Eq-Comparison
100 NCT03928158 981 984 I-Eq-Comparison|Eq-Comparison
mmHg NCT03928158 985 989 O
; NCT03928158 989 990 O

8 NCT03928158 993 994 O
. NCT03928158 994 995 O
Anemia NCT03928158 997 1003 B-Condition
( NCT03928158 1004 1005 O
Hb NCT03928158 1006 1008 B-Observation
< NCT03928158 1009 1010 O
100 NCT03928158 1011 1014 O
g NCT03928158 1015 1016 I-Eq-Comparison
/ NCT03928158 1017 1018 I-Eq-Comparison
l NCT03928158 1019 1020 I-Eq-Comparison
) NCT03928158 1021 1022 O
; NCT03928158 1023 1024 O

9 NCT03928158 1027 1028 O
. NCT03928158 1028 1029 O
Significant NCT03928158 1031 1042 O
left NCT03928158 1043 1047 B-Modifier
sided NCT03928158 1048 1053 I-Modifier
structural NCT03928158 1054 1064 B-Condition
valve NCT03928158 1065 1070 I-Condition
disease NCT03928158 1071 1078 I-Condition
; NCT03928158 1078 1079 O

10 NCT03928158 1081 1083 O
. NCT03928158 1083 1084 O
Secondary NCT03928158 1086 1095 B-Modifier
hypertension NCT03928158 1096 1108 B-Condition
; NCT03928158 1108 1109 O

11 NCT03928158 1111 1113 O
. NCT03928158 1113 1114 O
Dyspnea NCT03928158 1116 1123 B-Condition
due NCT03928158 1124 1127 O
to NCT03928158 1128 1130 O
non NCT03928158 1131 1134 B-Modifier
- NCT03928158 1135 1136 I-Modifier
cardiac NCT03928158 1137 1144 I-Modifier
causes NCT03928158 1145 1151 B-Condition
such NCT03928158 1152 1156 O
as NCT03928158 1157 1159 O
pulmonary NCT03928158 1160 1169 B-Condition
disease NCT03928158 1170 1177 I-Condition
, NCT03928158 1178 1179 O
anemia NCT03928158 1180 1186 B-Condition
, NCT03928158 1187 1188 O
severe NCT03928158 1189 1195 O
obesity NCT03928158 1196 1203 B-Condition
, NCT03928158 1204 1205 O
primary NCT03928158 1206 1213 B-Condition
valvular NCT03928158 1214 1222 I-Condition
, NCT03928158 1223 1224 O
or NCT03928158 1225 1227 B-Or|Or
myocardial NCT03928158 1228 1238 B-Condition|Procedure
diseases NCT03928158 1239 1247 I-Condition
; NCT03928158 1247 1248 O

12 NCT03928158 1250 1252 O
. NCT03928158 1252 1253 O
Myocardial NCT03928158 1255 1265 B-Condition
infarction NCT03928158 1266 1276 I-Condition
or NCT03928158 1277 1279 O
myocardial NCT03928158 1280 1290 O
revascularization NCT03928158 1291 1308 I-Procedure
within NCT03928158 1309 1315 B-Eq-Comparison|Eq-Comparison
the NCT03928158 1316 1319 I-Eq-Comparison|Eq-Comparison
last NCT03928158 1320 1324 I-Eq-Comparison|Eq-Comparison
3 NCT03928158 1325 1326 I-Eq-Comparison|Eq-Comparison
months NCT03928158 1327 1333 I-Eq-Comparison|Eq-Comparison
of NCT03928158 1334 1336 B-Temporal-Connection___Temporal-Connection-Type-Value:before|Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928158 1337 1346 B-Study|Study
; NCT03928158 1346 1347 O

13 NCT03928158 1349 1351 O
. NCT03928158 1351 1352 O
Stroke NCT03928158 1354 1360 B-Condition
or NCT03928158 1361 1363 B-Or
TIA NCT03928158 1364 1367 B-Condition
within NCT03928158 1368 1374 O
the NCT03928158 1375 1378 O
last NCT03928158 1379 1383 O
3 NCT03928158 1384 1385 O
months NCT03928158 1386 1392 O
of NCT03928158 1393 1395 O
screening NCT03928158 1396 1405 O
; NCT03928158 1405 1406 O

14 NCT03928158 1408 1410 O
. NCT03928158 1410 1411 O
Autoimmunic NCT03928158 1413 1424 B-Modifier
and NCT03928158 1425 1428 B-Or
oncological NCT03928158 1429 1440 B-Modifier
diseases NCT03928158 1441 1449 B-Condition
; NCT03928158 1449 1450 O

15 NCT03928158 1452 1454 O
. NCT03928158 1454 1455 O
Impaired NCT03928158 1457 1465 B-Condition
renal NCT03928158 1466 1471 I-Condition
function NCT03928158 1472 1480 I-Condition|Condition
, NCT03928158 1481 1482 O
defined NCT03928158 1483 1490 O
as NCT03928158 1491 1493 O
eGFR NCT03928158 1494 1498 B-Observation
< NCT03928158 1499 1500 B-Eq-Comparison
30 NCT03928158 1501 1503 I-Eq-Comparison
ml NCT03928158 1504 1506 I-Eq-Comparison
/ NCT03928158 1507 1508 I-Eq-Comparison
min NCT03928158 1509 1512 I-Eq-Comparison
/ NCT03928158 1513 1514 O
1.73 NCT03928158 1515 1519 I-Eq-Comparison
m² NCT03928158 1520 1522 I-Eq-Comparison
; NCT03928158 1522 1523 O

16 NCT03928158 1525 1527 O
. NCT03928158 1527 1528 O
Impaired NCT03928158 1530 1538 B-Condition
liver NCT03928158 1539 1544 I-Condition
function NCT03928158 1545 1553 O
; NCT03928158 1553 1554 O

17 NCT03928158 1556 1558 O
. NCT03928158 1558 1559 O
Potassium NCT03928158 1561 1570 B-Observation
concentration NCT03928158 1571 1584 I-Observation
> NCT03928158 1585 1586 B-Eq-Comparison
5.2 NCT03928158 1587 1590 I-Eq-Comparison
mmol NCT03928158 1591 1595 I-Eq-Comparison
/ NCT03928158 1596 1597 I-Eq-Comparison
L. NCT03928158 1598 1600 I-Eq-Comparison

Inclusion NCT03929497 0 9 O
Criteria NCT03929497 10 18 O
: NCT03929497 19 20 O

- NCT03929497 24 25 O
The NCT03929497 27 30 O
patient NCT03929497 31 38 O
completed NCT03929497 39 48 O
Study NCT03929497 49 54 B-Study
17972 NCT03929497 55 60 O
A. NCT03929497 61 63 O

- NCT03929497 67 68 O
The NCT03929497 70 73 O
patient NCT03929497 74 81 O
and NCT03929497 82 85 O
the NCT03929497 86 89 O
patient NCT03929497 90 97 O
's NCT03929497 97 99 O
caregiver NCT03929497 100 109 O
or NCT03929497 110 112 O
identified NCT03929497 113 123 O
responsible NCT03929497 124 135 O
person NCT03929497 136 142 O
is NCT03929497 143 145 O
able NCT03929497 146 150 O
to NCT03929497 151 153 O
read NCT03929497 154 158 O
and NCT03929497 159 162 O
understand NCT03929497 163 173 O
the NCT03929497 174 177 O
Informed NCT03929497 178 186 O
Consent NCT03929497 187 194 O
Form NCT03929497 195 199 O
. NCT03929497 199 200 O

- NCT03929497 204 205 O
The NCT03929497 207 210 O
patient NCT03929497 211 218 O
has NCT03929497 219 222 O
signed NCT03929497 223 229 O
the NCT03929497 230 233 O
Informed NCT03929497 234 242 O
Consent NCT03929497 243 250 O
Form NCT03929497 251 255 O
specific NCT03929497 256 264 O
for NCT03929497 265 268 O
Study NCT03929497 269 274 B-Study
17972 NCT03929497 275 280 O
B. NCT03929497 281 283 O

- NCT03929497 287 288 O
The NCT03929497 290 293 O
patient NCT03929497 294 301 O
can NCT03929497 302 305 B-Assertion___Assertion-Type-Value:hypothetical
potentially NCT03929497 306 317 I-Assertion___Assertion-Type-Value:hypothetical
benefit NCT03929497 318 325 O
from NCT03929497 326 330 O
24 NCT03929497 331 333 B-Eq-Comparison
weeks NCT03929497 334 339 I-Eq-Comparison
of NCT03929497 340 342 O
treatment NCT03929497 343 352 B-Procedure
with NCT03929497 353 357 O
Lu NCT03929497 358 360 B-Drug
AF11167 NCT03929497 361 368 I-Drug
according NCT03929497 369 378 O
to NCT03929497 379 381 O
the NCT03929497 382 385 O
investigator NCT03929497 386 398 O
's NCT03929497 398 400 O
clinical NCT03929497 401 409 O
judgment NCT03929497 410 418 O
. NCT03929497 418 419 O

Exclusion NCT03929497 421 430 O
Criteria NCT03929497 431 439 O
: NCT03929497 440 441 O

- NCT03929497 445 446 O
The NCT03929497 448 451 O
patient NCT03929497 452 459 O
has NCT03929497 460 463 O
any NCT03929497 464 467 O
current NCT03929497 468 475 B-Eq-Comparison
primary NCT03929497 476 483 B-Modifier
psychiatric NCT03929497 484 495 B-Condition
disorder NCT03929497 496 504 I-Condition
other NCT03929497 505 510 B-Exception
than NCT03929497 511 515 I-Exception
schizophrenia NCT03929497 516 529 B-Condition
diagnosed NCT03929497 530 539 O
during NCT03929497 540 546 B-Temporal-Connection___Temporal-Connection-Type-Value:during
study NCT03929497 547 552 B-Study
17972 NCT03929497 553 558 O
A NCT03929497 559 560 O

- NCT03929497 563 564 O
The NCT03929497 566 569 O
patient NCT03929497 570 577 O
, NCT03929497 578 579 O
in NCT03929497 580 582 O
the NCT03929497 583 586 O
opinion NCT03929497 587 594 O
of NCT03929497 595 597 O
the NCT03929497 598 601 O
investigator NCT03929497 602 614 O
, NCT03929497 615 616 O
is NCT03929497 617 619 O
at NCT03929497 620 622 O
significant NCT03929497 623 634 O
risk NCT03929497 635 639 B-Risk
of NCT03929497 640 642 O
suicide NCT03929497 643 650 B-Condition

Other NCT03929497 651 656 O
in NCT03929497 657 659 O
- NCT03929497 660 661 O
and NCT03929497 662 665 O
exclusion NCT03929497 666 675 O
criteria NCT03929497 676 684 O
may NCT03929497 685 688 O
apply NCT03929497 689 694 O

Inclusion NCT03921593 0 9 O
Criteria NCT03921593 10 18 O
: NCT03921593 19 20 O

- NCT03921593 24 25 O
Willing NCT03921593 27 34 O
and NCT03921593 35 38 O
able NCT03921593 39 43 O
to NCT03921593 44 46 O
give NCT03921593 47 51 O
informed NCT03921593 52 60 O
consent NCT03921593 61 68 O
for NCT03921593 69 72 O
participation NCT03921593 73 86 O
in NCT03921593 87 89 O
the NCT03921593 90 93 O
study NCT03921593 94 99 O

- NCT03921593 102 103 O
Insulin NCT03921593 105 112 B-Modifier
Dependent NCT03921593 113 122 I-Modifier
Diabetic NCT03921593 123 131 B-Condition
Patients NCT03921593 132 140 O

- NCT03921593 143 144 O
Active NCT03921593 146 152 B-Eq-Comparison
on NCT03921593 153 155 O
Pancreas NCT03921593 156 164 B-Observation
Transplant NCT03921593 165 175 I-Observation
Wait NCT03921593 176 180 I-Observation
List NCT03921593 181 185 I-Observation

Exclusion NCT03921593 186 195 O
Criteria NCT03921593 196 204 O
: NCT03921593 205 206 O

- NCT03921593 210 211 O
Not NCT03921593 213 216 B-Negation
fluent NCT03921593 217 223 O
in NCT03921593 224 226 O
English NCT03921593 227 234 O

Inclusion NCT03927690 0 9 O
Criteria NCT03927690 10 18 O

1 NCT03927690 21 22 O
. NCT03927690 22 23 O
Written NCT03927690 25 32 O
informed NCT03927690 33 41 O
consent NCT03927690 42 49 O
must NCT03927690 50 54 O
be NCT03927690 55 57 O
obtained NCT03927690 58 66 O
before NCT03927690 67 73 O
any NCT03927690 74 77 O
assessment NCT03927690 78 88 O
is NCT03927690 89 91 O
performed NCT03927690 92 101 O
. NCT03927690 101 102 O

2 NCT03927690 106 107 O
. NCT03927690 107 108 O
Male NCT03927690 110 114 O
and NCT03927690 115 118 B-Or
female NCT03927690 119 125 O
patients NCT03927690 126 134 O
age NCT03927690 135 138 B-Age
18 NCT03927690 139 141 B-Eq-Comparison
to NCT03927690 142 144 I-Eq-Comparison
85 NCT03927690 145 147 I-Eq-Comparison
years NCT03927690 148 153 I-Eq-Comparison
of NCT03927690 154 156 O
age NCT03927690 157 160 O
inclusive NCT03927690 161 170 O
at NCT03927690 171 173 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03927690 174 183 B-Study

3 NCT03927690 186 187 O
. NCT03927690 187 188 O
Presence NCT03927690 190 198 O
of NCT03927690 199 201 O
type NCT03927690 202 206 B-Modifier
I NCT03927690 207 208 I-Modifier
or NCT03927690 209 211 B-Or
type NCT03927690 212 216 B-Modifier
II NCT03927690 217 219 I-Modifier
diabetes NCT03927690 220 228 B-Condition
mellitus NCT03927690 229 237 I-Condition

4 NCT03927690 240 241 O
. NCT03927690 241 242 O
The NCT03927690 244 247 O
ETDRS NCT03927690 248 253 B-Observation
letter NCT03927690 254 260 I-Observation
score NCT03927690 261 266 I-Observation
in NCT03927690 267 269 O
the NCT03927690 270 273 O
study NCT03927690 274 279 O
eye NCT03927690 280 283 B-Modifier
must NCT03927690 284 288 O
be NCT03927690 289 291 B-Eq-Comparison
between NCT03927690 292 299 O
24 NCT03927690 300 302 I-Eq-Comparison
and NCT03927690 303 306 I-Eq-Comparison
70 NCT03927690 307 309 I-Eq-Comparison
letters NCT03927690 310 317 I-Eq-Comparison
( NCT03927690 318 319 O
approximate NCT03927690 320 331 O
Snellen NCT03927690 332 339 B-Observation
equivalent NCT03927690 340 350 O
of NCT03927690 351 353 O
20 NCT03927690 354 356 I-Eq-Comparison
/ NCT03927690 357 358 O
40 NCT03927690 359 361 O
- NCT03927690 362 363 B-Eq-Comparison
20 NCT03927690 364 366 O
/ NCT03927690 367 368 O
320 NCT03927690 369 372 O
) NCT03927690 373 374 O
. NCT03927690 375 376 O
The NCT03927690 378 381 O
non NCT03927690 382 385 O
- NCT03927690 386 387 O
study NCT03927690 388 393 O
eye NCT03927690 394 397 O
( NCT03927690 398 399 O
fellow NCT03927690 400 406 O
eye NCT03927690 407 410 O
) NCT03927690 411 412 O
should NCT03927690 413 419 O
be NCT03927690 420 422 I-Eq-Comparison
≥ NCT03927690 423 424 B-Eq-Comparison
34 NCT03927690 425 427 I-Eq-Comparison
letters NCT03927690 428 435 I-Eq-Comparison
or NCT03927690 436 438 I-Eq-Comparison
better NCT03927690 439 445 O
( NCT03927690 446 447 O
approximate NCT03927690 448 459 O
Snellen NCT03927690 460 467 B-Observation
equivalent NCT03927690 468 478 O
of NCT03927690 479 481 O
20 NCT03927690 482 484 B-Eq-Comparison
/ NCT03927690 485 486 I-Eq-Comparison
200 NCT03927690 487 490 O
) NCT03927690 491 492 O
at NCT03927690 493 495 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03927690 496 505 B-Study

5 NCT03927690 508 509 O
. NCT03927690 509 510 O
Presence NCT03927690 512 520 O
of NCT03927690 521 523 O
DME NCT03927690 524 527 B-Condition
in NCT03927690 528 530 O
the NCT03927690 531 534 O
study NCT03927690 535 540 O
eye NCT03927690 541 544 B-Modifier
, NCT03927690 545 546 O
with NCT03927690 547 551 B-And
decrease NCT03927690 552 560 O
in NCT03927690 561 563 O
vision NCT03927690 564 570 B-Condition
due NCT03927690 571 574 O
to NCT03927690 575 577 O
foveal NCT03927690 578 584 B-Condition
thickening NCT03927690 585 595 I-Condition
of NCT03927690 596 598 O
central NCT03927690 599 606 B-Observation
macular NCT03927690 607 614 I-Observation
thickness NCT03927690 615 624 I-Observation
≥ NCT03927690 625 626 B-Eq-Comparison
320 NCT03927690 627 630 I-Eq-Comparison
µm NCT03927690 631 633 I-Eq-Comparison
in NCT03927690 634 636 O
the NCT03927690 637 640 O
central NCT03927690 641 648 B-Modifier
subfield NCT03927690 649 657 I-Modifier
, NCT03927690 658 659 O
as NCT03927690 660 662 O
assessed NCT03927690 663 671 O
on NCT03927690 672 674 O
SD NCT03927690 675 677 B-Procedure
- NCT03927690 678 679 I-Procedure
OCT NCT03927690 680 683 I-Procedure
and NCT03927690 684 687 O
confirmed NCT03927690 688 697 O
by NCT03927690 698 700 O
the NCT03927690 701 704 O
central NCT03927690 705 712 O
reading NCT03927690 713 720 O
center NCT03927690 721 727 O
at NCT03927690 728 730 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03927690 731 740 B-Study

Other NCT03927690 741 746 O
protocol NCT03927690 747 755 O
specified NCT03927690 756 765 O
inclusion NCT03927690 766 775 O
/ NCT03927690 776 777 O
exclusion NCT03927690 778 787 O
criteria NCT03927690 788 796 O
apply NCT03927690 797 802 O
. NCT03927690 802 803 O

Inclusion NCT03926559 0 9 O
Criteria NCT03926559 10 18 O
: NCT03926559 19 20 O

- NCT03926559 24 25 O
Patients NCT03926559 27 35 O
with NCT03926559 36 40 O
a NCT03926559 41 42 O
second NCT03926559 43 49 B-Modifier
degree NCT03926559 50 56 I-Modifier
, NCT03926559 57 58 O
third NCT03926559 59 64 B-Modifier
degree NCT03926559 65 71 I-Modifier
, NCT03926559 72 73 O
or NCT03926559 74 76 B-Or
fourth NCT03926559 77 83 B-Modifier
degree NCT03926559 84 90 I-Modifier
perineal NCT03926559 91 99 B-Condition
tear NCT03926559 100 104 I-Condition
identified NCT03926559 105 115 O
in NCT03926559 116 118 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926559 119 122 O
immediate NCT03926559 123 132 O
postpartum NCT03926559 133 143 B-Condition
period NCT03926559 144 150 O
. NCT03926559 150 151 O

- NCT03926559 155 156 O
Pregnant NCT03926559 158 166 B-Condition
patients NCT03926559 167 175 O
who NCT03926559 176 179 B-And
received NCT03926559 180 188 B-Eq-Comparison
neuraxial NCT03926559 189 198 B-Procedure
anesthesia NCT03926559 199 209 I-Procedure
during NCT03926559 210 216 B-Temporal-Connection___Temporal-Connection-Type-Value:during
their NCT03926559 217 222 O
labor NCT03926559 223 228 B-Condition
course NCT03926559 229 235 O

- NCT03926559 238 239 O
Women NCT03926559 241 246 O
> NCT03926559 247 248 B-Eq-Comparison
18 NCT03926559 249 251 I-Eq-Comparison
yo NCT03926559 252 254 B-Age

Exclusion NCT03926559 255 264 O
Criteria NCT03926559 265 273 O
: NCT03926559 274 275 O

- NCT03926559 279 280 O
Unwillingness NCT03926559 282 295 O
to NCT03926559 296 298 O
participate NCT03926559 299 310 O
in NCT03926559 311 313 O
the NCT03926559 314 317 O
study NCT03926559 318 323 B-Study

- NCT03926559 326 327 O
Allergy NCT03926559 329 336 B-Allergy
to NCT03926559 337 339 O
morphine NCT03926559 340 348 B-Drug

- NCT03926559 351 352 O
Women NCT03926559 354 359 O
with NCT03926559 360 364 B-And
history NCT03926559 365 372 B-Eq-Comparison
of NCT03926559 373 375 O
polysubstance NCT03926559 376 389 B-Condition
abuse NCT03926559 390 395 I-Condition
/ NCT03926559 396 397 B-Or
narcotic NCT03926559 398 406 B-Condition
abuse NCT03926559 407 412 I-Condition

- NCT03926559 415 416 O
Women NCT03926559 418 423 O
< NCT03926559 424 425 B-Eq-Comparison
18 NCT03926559 426 428 I-Eq-Comparison
yo NCT03926559 429 431 B-Age

Inclusion NCT03924414 0 9 O
Criteria NCT03924414 10 18 O
: NCT03924414 19 20 O

- NCT03924414 24 25 O
Men NCT03924414 27 30 O
and NCT03924414 31 34 B-Or
women NCT03924414 35 40 O
age NCT03924414 41 44 B-Age
65 NCT03924414 45 47 B-Eq-Comparison
years NCT03924414 48 53 I-Eq-Comparison
or NCT03924414 54 56 I-Eq-Comparison
older NCT03924414 57 62 I-Eq-Comparison

- NCT03924414 65 66 O
Current NCT03924414 68 75 B-Eq-Comparison
PD NCT03924414 76 78 B-Condition
diagnosis NCT03924414 79 88 O
with NCT03924414 89 93 B-And
symptoms NCT03924414 94 102 O
severity NCT03924414 103 111 O
at NCT03924414 112 114 O
Hoehn NCT03924414 115 120 B-Condition
& NCT03924414 121 122 I-Condition
Yahr NCT03924414 123 127 I-Condition
( NCT03924414 128 129 O
H&Y NCT03924414 130 133 B-Condition
) NCT03924414 134 135 O
stage NCT03924414 136 141 B-Eq-Comparison
1 NCT03924414 142 143 I-Eq-Comparison
- NCT03924414 144 145 I-Eq-Comparison
4 NCT03924414 146 147 I-Eq-Comparison
based NCT03924414 148 153 O
on NCT03924414 154 156 O
an NCT03924414 157 159 O
expert NCT03924414 160 166 O
assessment NCT03924414 167 177 O
( NCT03924414 178 179 O
movement NCT03924414 180 188 B-Condition
disorders NCT03924414 189 198 I-Condition
neurologist NCT03924414 199 210 B-Provider
report NCT03924414 211 217 O
or NCT03924414 218 220 B-Or
telemedicine NCT03924414 221 233 B-Procedure
evaluation NCT03924414 234 244 I-Procedure
) NCT03924414 245 246 O

- NCT03924414 250 251 O
Willing NCT03924414 253 260 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03924414 261 264 B-And
able NCT03924414 265 269 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924414 270 272 O
continue NCT03924414 273 281 O
in NCT03924414 282 284 O
follow NCT03924414 285 291 B-Encounter
- NCT03924414 292 293 I-Encounter
up NCT03924414 294 296 I-Encounter
for NCT03924414 297 300 O
at NCT03924414 301 303 B-Eq-Comparison
least NCT03924414 304 309 I-Eq-Comparison
2 NCT03924414 310 311 I-Eq-Comparison
years NCT03924414 312 317 I-Eq-Comparison

- NCT03924414 320 321 O
Willing NCT03924414 323 330 O
and NCT03924414 331 334 O
able NCT03924414 335 339 O
to NCT03924414 340 342 O
provide NCT03924414 343 350 O
informed NCT03924414 351 359 O
consent NCT03924414 360 367 O

Exclusion NCT03924414 368 377 O
Criteria NCT03924414 378 386 O
: NCT03924414 387 388 O

- NCT03924414 392 393 O
History NCT03924414 395 402 B-Eq-Comparison
of NCT03924414 403 405 O
hip NCT03924414 406 409 B-Modifier
fracture NCT03924414 410 418 B-Condition

- NCT03924414 421 422 O
Any NCT03924414 424 427 O
use NCT03924414 428 431 O
of NCT03924414 432 434 O
a NCT03924414 435 436 O
bisphosphonate NCT03924414 437 451 B-Drug
drug NCT03924414 452 456 I-Drug
within NCT03924414 457 463 B-Eq-Comparison
the NCT03924414 464 467 I-Eq-Comparison
last NCT03924414 468 472 I-Eq-Comparison
12 NCT03924414 473 475 I-Eq-Comparison
months NCT03924414 476 482 I-Eq-Comparison

- NCT03924414 485 486 O
Use NCT03924414 488 491 O
of NCT03924414 492 494 O
any NCT03924414 495 498 O
other NCT03924414 499 504 B-Other
osteoporosis NCT03924414 505 517 B-Procedure
treatment NCT03924414 518 527 I-Procedure
( NCT03924414 528 529 O
such NCT03924414 530 534 O
as NCT03924414 535 537 O
SERMs NCT03924414 538 543 B-Drug
and NCT03924414 544 547 B-Or
denosumab NCT03924414 548 557 B-Drug
) NCT03924414 558 559 O
within NCT03924414 560 566 B-Eq-Comparison
the NCT03924414 567 570 I-Eq-Comparison
last NCT03924414 571 575 I-Eq-Comparison
6 NCT03924414 576 577 I-Eq-Comparison
months NCT03924414 578 584 I-Eq-Comparison

- NCT03924414 592 593 O
Tooth NCT03924414 595 600 B-Procedure
extraction NCT03924414 601 611 I-Procedure
or NCT03924414 612 614 B-Or
invasive NCT03924414 615 623 B-Modifier
dental NCT03924414 624 630 B-Procedure
procedures NCT03924414 631 641 I-Procedure
within NCT03924414 642 648 B-Eq-Comparison
the NCT03924414 649 652 I-Eq-Comparison
past NCT03924414 653 657 I-Eq-Comparison
30 NCT03924414 658 660 I-Eq-Comparison
days NCT03924414 661 665 I-Eq-Comparison
or NCT03924414 666 668 O
planned NCT03924414 669 676 B-Eq-Comparison
/ NCT03924414 677 678 B-Or
scheduled NCT03924414 679 688 B-Eq-Comparison
extraction NCT03924414 689 699 B-Procedure
/ NCT03924414 700 701 B-Or
procedure NCT03924414 702 711 B-Procedure
in NCT03924414 712 714 O
the NCT03924414 715 718 O
next NCT03924414 719 723 B-Eq-Comparison
12 NCT03924414 724 726 I-Eq-Comparison
months NCT03924414 727 733 I-Eq-Comparison

- NCT03924414 736 737 I-Condition
Non NCT03924414 739 742 B-Condition
- NCT03924414 743 744 O
ambulatory NCT03924414 745 755 I-Condition
, NCT03924414 756 757 O
i. NCT03924414 758 760 O
e. NCT03924414 761 763 O
, NCT03924414 764 765 O
unable NCT03924414 766 772 B-Condition
to NCT03924414 773 775 I-Condition
walk NCT03924414 776 780 I-Condition
without NCT03924414 781 788 O
assistance NCT03924414 789 799 O
of NCT03924414 800 802 O
another NCT03924414 803 810 O
person NCT03924414 811 817 O
. NCT03924414 817 818 O

- NCT03924414 822 823 O
Undergoing NCT03924414 825 835 B-Eq-Comparison
kidney NCT03924414 836 842 B-Procedure
dialysis NCT03924414 843 851 I-Procedure

- NCT03924414 854 855 O
A NCT03924414 857 858 O
diagnosis NCT03924414 859 868 O
of NCT03924414 869 871 O
multiple NCT03924414 872 880 B-Condition
myeloma NCT03924414 881 888 I-Condition
or NCT03924414 889 891 B-Or
Paget NCT03924414 892 897 B-Condition
's NCT03924414 897 899 O
disease NCT03924414 900 907 I-Condition

- NCT03924414 910 911 O
Unable NCT03924414 913 919 B-Negation
to NCT03924414 920 922 O
speak NCT03924414 923 928 O
or NCT03924414 929 931 O
read NCT03924414 932 936 O
English NCT03924414 937 944 O
sufficiently NCT03924414 945 957 O
to NCT03924414 958 960 O
complete NCT03924414 961 969 O
informed NCT03924414 970 978 O
consent NCT03924414 979 986 O

- NCT03924414 989 990 O
Any NCT03924414 992 995 O
other NCT03924414 996 1001 B-Other
criteria NCT03924414 1002 1010 B-Condition
, NCT03924414 1011 1012 O
which NCT03924414 1013 1018 O
would NCT03924414 1019 1024 O
make NCT03924414 1025 1029 O
the NCT03924414 1030 1033 O
patient NCT03924414 1034 1041 O
unsuitable NCT03924414 1042 1052 O
to NCT03924414 1053 1055 O
participate NCT03924414 1056 1067 O
in NCT03924414 1068 1070 O
this NCT03924414 1071 1075 O
study NCT03924414 1076 1081 O
as NCT03924414 1082 1084 O
determined NCT03924414 1085 1095 O
by NCT03924414 1096 1098 O
the NCT03924414 1099 1102 O
study NCT03924414 1103 1108 O
staff NCT03924414 1109 1114 O
( NCT03924414 1115 1116 O
e. NCT03924414 1117 1119 O
g. NCT03924414 1120 1122 O
, NCT03924414 1123 1124 O
an NCT03924414 1125 1127 B-Or
uncontrolled NCT03924414 1128 1140 O
drug NCT03924414 1141 1145 B-Modifier
and NCT03924414 1146 1149 O
/ NCT03924414 1150 1151 I-Or
or NCT03924414 1152 1154 I-Or
alcohol NCT03924414 1155 1162 B-Modifier
addiction NCT03924414 1163 1172 B-Condition
) NCT03924414 1173 1174 O


Inclusion NCT03928548 0 9 O
Criteria NCT03928548 10 18 O
: NCT03928548 19 20 O

- NCT03928548 24 25 O
Adult NCT03928548 27 32 O
and NCT03928548 33 36 B-Or
pediatric NCT03928548 37 46 O
acute NCT03928548 47 52 B-Encounter
care NCT03928548 53 57 I-Encounter
patients NCT03928548 58 66 O
at NCT03928548 67 69 O
participating NCT03928548 70 83 O
facility NCT03928548 84 92 O

- NCT03928548 95 96 O
Newly NCT03928548 98 103 B-Eq-Comparison
identified NCT03928548 104 114 I-Eq-Comparison
as NCT03928548 115 117 O
needing NCT03928548 118 125 B-Assertion___Assertion-Type-Value:hypothetical
in NCT03928548 126 128 B-Encounter
- NCT03928548 129 130 I-Encounter
patient NCT03928548 131 138 I-Encounter
nutrition NCT03928548 139 148 B-Procedure
care NCT03928548 149 153 I-Procedure
through NCT03928548 154 161 O
current NCT03928548 162 169 O
facility NCT03928548 170 178 O
policy NCT03928548 179 185 O

- NCT03928548 188 189 O
Receive NCT03928548 191 198 O
initial NCT03928548 199 206 B-Eq-Comparison
nutrition NCT03928548 207 216 B-Procedure
care NCT03928548 217 221 I-Procedure
one NCT03928548 222 225 B-Eq-Comparison
day NCT03928548 226 229 I-Eq-Comparison
before NCT03928548 230 236 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928548 237 242 B-Study
enrollment NCT03928548 243 253 O
day NCT03928548 254 257 O

- NCT03928548 260 261 O
Patient NCT03928548 263 270 O
is NCT03928548 271 273 O
over NCT03928548 274 278 B-Eq-Comparison
one NCT03928548 279 282 I-Eq-Comparison
month NCT03928548 283 288 I-Eq-Comparison
of NCT03928548 289 291 O
age NCT03928548 292 295 B-Age
, NCT03928548 296 297 O
including NCT03928548 298 307 O
infants NCT03928548 308 315 O
, NCT03928548 316 317 O
children NCT03928548 318 326 O
, NCT03928548 327 328 O
teenagers NCT03928548 329 338 O
and NCT03928548 339 342 B-Or
adult NCT03928548 343 348 O
patients NCT03928548 349 357 O
who NCT03928548 358 361 B-And
are NCT03928548 362 365 B-Eq-Comparison
intubated NCT03928548 366 375 B-Procedure
and NCT03928548 376 379 B-Or
/ NCT03928548 380 381 I-Or
or NCT03928548 382 384 I-Or
sedated NCT03928548 385 392 B-Procedure

- NCT03928548 395 396 O
Patient NCT03928548 398 405 O
, NCT03928548 406 407 O
parent NCT03928548 408 414 B-Family-Member___Family-Member-Type:parent
, NCT03928548 415 416 O
legal NCT03928548 417 422 O
guardian NCT03928548 423 431 O
or NCT03928548 432 434 O
legally NCT03928548 435 442 O
authorized NCT03928548 443 453 O
representative NCT03928548 454 468 O
provide NCT03928548 469 476 O
informed NCT03928548 477 485 O
consent NCT03928548 486 493 O
; NCT03928548 493 494 O
children NCT03928548 495 503 O
7 NCT03928548 504 505 B-Eq-Comparison
and NCT03928548 506 509 I-Eq-Comparison
older NCT03928548 510 515 I-Age|Eq-Comparison
provide NCT03928548 516 523 O
assent NCT03928548 524 530 O

- NCT03928548 533 534 O
Patient NCT03928548 536 543 O
and NCT03928548 544 547 O
/ NCT03928548 548 549 O
or NCT03928548 550 552 O
parent NCT03928548 553 559 O
, NCT03928548 560 561 O
legal NCT03928548 562 567 O
guardian NCT03928548 568 576 O
or NCT03928548 577 579 O
legally NCT03928548 580 587 O
authorized NCT03928548 588 598 O
representative NCT03928548 599 613 O
are NCT03928548 614 617 O
fluent NCT03928548 618 624 O
in NCT03928548 625 627 O
English NCT03928548 628 635 O
or NCT03928548 636 638 B-Or
Spanish NCT03928548 639 646 O

Exclusion NCT03928548 647 656 O
Criteria NCT03928548 657 665 O
: NCT03928548 666 667 O

- NCT03928548 671 672 O
Received NCT03928548 674 682 B-Eq-Comparison
nutrition NCT03928548 683 692 B-Procedure
care NCT03928548 693 697 I-Procedure
previously NCT03928548 698 708 B-Eq-Comparison
during NCT03928548 709 715 B-Temporal-Connection___Temporal-Connection-Type-Value:during
current NCT03928548 716 723 B-Eq-Comparison
admission NCT03928548 724 733 B-Encounter

- NCT03928548 736 737 O
Pregnant NCT03928548 739 747 B-Condition
women NCT03928548 748 753 O

- NCT03928548 756 757 O
Prisoners NCT03928548 759 768 B-Observation

- NCT03928548 771 772 O
Infants NCT03928548 774 781 O
currently NCT03928548 782 791 B-Eq-Comparison
in NCT03928548 792 794 B-Encounter
the NCT03928548 795 798 O
neonatal NCT03928548 799 807 O
intensive NCT03928548 808 817 O
care NCT03928548 818 822 O
unit NCT03928548 823 827 O
( NCT03928548 828 829 O
NICU NCT03928548 830 834 O
) NCT03928548 835 836 O
with NCT03928548 837 841 B-And
a NCT03928548 842 843 O
diagnosis NCT03928548 844 853 O
of NCT03928548 854 856 O
prematurity NCT03928548 857 868 B-Condition

- NCT03928548 871 872 O
Neonates NCT03928548 874 882 O
of NCT03928548 883 885 O
uncertain NCT03928548 886 895 B-Condition
viability NCT03928548 896 905 I-Condition
or NCT03928548 906 908 B-Or
non NCT03928548 909 912 B-Condition
- NCT03928548 913 914 I-Condition
viable NCT03928548 915 921 I-Condition
neonates NCT03928548 922 930 O

- NCT03928548 933 934 O
Patients NCT03928548 936 944 O
receiving NCT03928548 945 954 B-Eq-Comparison
palliative NCT03928548 955 965 O
/ NCT03928548 966 967 B-Or
hospice NCT03928548 968 975 O
care NCT03928548 976 980 B-Encounter

- NCT03928548 983 984 O
Patient NCT03928548 986 993 O
admitted NCT03928548 994 1002 B-Encounter
for NCT03928548 1003 1006 O
long NCT03928548 1007 1011 B-Procedure
- NCT03928548 1012 1013 I-Procedure
term NCT03928548 1014 1018 I-Procedure
acute NCT03928548 1019 1024 I-Procedure
care NCT03928548 1025 1029 I-Procedure
( NCT03928548 1030 1031 O
LTAC NCT03928548 1032 1036 B-Procedure
) NCT03928548 1037 1038 O

Subject NCT03927781 0 7 O
Population NCT03927781 8 18 O
Undergoing NCT03927781 19 29 B-Eq-Comparison
elective NCT03927781 30 38 B-Modifier
ureteroscopy NCT03927781 39 51 B-Procedure
with NCT03927781 52 56 O
stent NCT03927781 57 62 B-Procedure
placement NCT03927781 63 72 I-Procedure
by NCT03927781 73 75 O
Dr. NCT03927781 76 79 B-Provider
Murray NCT03927781 81 87 I-Provider
at NCT03927781 88 90 O
University NCT03927781 91 101 O
of NCT03927781 102 104 O
Missouri NCT03927781 105 113 O
Hospital NCT03927781 114 122 O
and NCT03927781 123 126 O
affiliated NCT03927781 127 137 O
facilities NCT03927781 138 148 O

Subject NCT03927781 149 156 O
Inclusion NCT03927781 157 166 O

Age NCT03927781 167 170 B-Age
> NCT03927781 171 172 B-Eq-Comparison
= NCT03927781 174 175 I-Eq-Comparison
18 NCT03927781 176 178 I-Eq-Comparison
years NCT03927781 179 184 I-Eq-Comparison

Subject NCT03927781 185 192 O
Exclusion NCT03927781 193 202 O

- NCT03927781 205 206 O
Renal NCT03927781 208 213 B-Condition
insufficiency NCT03927781 214 227 I-Condition
( NCT03927781 228 229 O
eGFR NCT03927781 230 234 B-Observation
< NCT03927781 235 236 B-Eq-Comparison
30 NCT03927781 237 239 I-Eq-Comparison
mL NCT03927781 240 242 I-Eq-Comparison
/ NCT03927781 243 244 I-Eq-Comparison
minute NCT03927781 245 251 I-Eq-Comparison
/ NCT03927781 252 253 O
1.73 NCT03927781 254 258 I-Eq-Comparison
m2 NCT03927781 259 261 I-Eq-Comparison
) NCT03927781 262 263 O

- NCT03927781 267 268 O
Chronic NCT03927781 270 277 B-Modifier
indwelling NCT03927781 278 288 I-Modifier
ureteral NCT03927781 289 297 B-Procedure
stent NCT03927781 298 303 I-Procedure

- NCT03927781 306 307 O
Chronic NCT03927781 309 316 B-Modifier
opioid NCT03927781 317 323 B-Condition
use NCT03927781 324 327 I-Condition

- NCT03927781 330 331 O
History NCT03927781 333 340 B-Eq-Comparison
of NCT03927781 341 343 O
opioid NCT03927781 344 350 B-Condition
abuse NCT03927781 351 356 I-Condition

- NCT03927781 359 360 O
Chronic NCT03927781 362 369 B-Modifier
gabapentinoid NCT03927781 370 383 B-Drug
use NCT03927781 384 387 O

- NCT03927781 390 391 O
Plan NCT03927781 393 397 B-Eq-Comparison
for NCT03927781 398 401 O
inpatient NCT03927781 402 411 B-Encounter
hospitalization NCT03927781 412 427 I-Encounter

- NCT03927781 430 431 O
Pregnancy NCT03927781 433 442 B-Condition

- NCT03927781 445 446 O
Inability NCT03927781 448 457 B-Negation
of NCT03927781 458 460 O
the NCT03927781 461 464 O
patient NCT03927781 465 472 O
to NCT03927781 473 475 O
consent NCT03927781 476 483 O
for NCT03927781 484 487 O
themselves NCT03927781 488 498 O
in NCT03927781 499 501 O
English NCT03927781 502 509 O

- NCT03927781 512 513 O
Allergy NCT03927781 515 522 B-Allergy
to NCT03927781 523 525 O
gabapentinoid NCT03927781 526 539 B-Drug

- NCT03927781 542 543 O
Liver NCT03927781 545 550 B-Condition
failure NCT03927781 551 558 I-Condition
or NCT03927781 559 561 B-Or
hepatic NCT03927781 562 569 B-Condition
dysfunction NCT03927781 570 581 I-Condition


Inclusion NCT03924908 0 9 O
Criteria NCT03924908 10 18 O
: NCT03924908 19 20 O

- NCT03924908 24 25 O
Burn NCT03924908 27 31 B-Condition
patient NCT03924908 32 39 O
treated NCT03924908 40 47 B-Procedure
as NCT03924908 48 50 B-Temporal-Connection___Temporal-Connection-Type-Value:during
outpatient NCT03924908 51 61 B-Encounter

- NCT03924908 64 65 O
Burn NCT03924908 67 71 B-Observation
surface NCT03924908 72 79 I-Observation
area NCT03924908 80 84 I-Observation
> NCT03924908 85 86 B-Eq-Comparison
or NCT03924908 87 89 I-Eq-Comparison
= NCT03924908 90 91 I-Eq-Comparison
5 NCT03924908 92 93 I-Eq-Comparison
% NCT03924908 94 95 O
of NCT03924908 96 98 O
the NCT03924908 99 102 O
total NCT03924908 103 108 O
body NCT03924908 109 113 O
surface NCT03924908 114 121 O
area NCT03924908 122 126 O

- NCT03924908 129 130 O
mainly NCT03924908 132 138 O
2 NCT03924908 139 140 B-Condition
nd NCT03924908 141 143 O
degree NCT03924908 144 150 I-Condition
burn NCT03924908 151 155 I-Condition

Exclusion NCT03924908 156 165 O
Criteria NCT03924908 166 174 O
: NCT03924908 175 176 O

- NCT03924908 180 181 O
Psychiatric NCT03924908 183 194 B-Condition
antecedents NCT03924908 195 206 I-Condition

- NCT03924908 209 210 O
Claustrophobia NCT03924908 212 226 B-Condition

- NCT03924908 229 230 O
Heavy NCT03924908 232 237 B-Condition
hearing NCT03924908 238 245 I-Condition

- NCT03924908 248 249 O
Visual NCT03924908 251 257 B-Condition
impairment NCT03924908 258 268 I-Condition

- NCT03924908 271 272 O
Face NCT03924908 274 278 B-Modifier
burn NCT03924908 279 283 B-Condition

- NCT03924908 286 287 O
Conjunctivitis NCT03924908 289 303 B-Condition

- NCT03924908 306 307 O
Consent NCT03924908 309 316 O
not NCT03924908 317 320 O
obtained NCT03924908 321 329 O

Inclusion NCT03924934 0 9 O
Criteria NCT03924934 10 18 O
: NCT03924934 19 20 O

Category NCT03924934 22 30 O
1 NCT03924934 31 32 O
: NCT03924934 33 34 O
Patients NCT03924934 35 43 O
who NCT03924934 44 47 O
live NCT03924934 48 52 O
at NCT03924934 53 55 O
home NCT03924934 56 60 O
and NCT03924934 61 64 O
meet NCT03924934 65 69 O
the NCT03924934 70 73 O
following NCT03924934 74 83 O
criteria NCT03924934 84 92 O
: NCT03924934 93 94 O

- NCT03924934 98 99 O
CDC NCT03924934 101 104 O
- NCT03924934 105 106 O
defined NCT03924934 107 114 O
CRE NCT03924934 115 118 B-Organism
isolated NCT03924934 119 127 I-Organism
during NCT03924934 128 134 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03924934 135 150 B-Encounter
or NCT03924934 151 153 B-Or
outpatient NCT03924934 154 164 B-Encounter
visit NCT03924934 165 170 I-Encounter

- NCT03924934 173 174 O
Home NCT03924934 176 180 O
origin NCT03924934 181 187 O

- NCT03924934 190 191 O
First NCT03924934 193 198 B-Eq-Comparison
positive NCT03924934 199 207 O
CRE NCT03924934 208 211 B-Organism
culture NCT03924934 212 219 I-Organism
within NCT03924934 220 226 B-Eq-Comparison
48 NCT03924934 227 229 I-Eq-Comparison
hours NCT03924934 230 235 I-Eq-Comparison
of NCT03924934 236 238 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03924934 239 248 B-Encounter
( NCT03924934 249 250 O
in NCT03924934 251 253 O
case NCT03924934 254 258 O
of NCT03924934 259 261 O
hospitalization NCT03924934 262 277 B-Encounter
) NCT03924934 278 279 O

Category NCT03924934 281 289 O
2 NCT03924934 290 291 O
: NCT03924934 292 293 O
Hospitalized NCT03924934 294 306 B-Encounter
patients NCT03924934 307 315 O
with NCT03924934 316 320 B-And
CDC NCT03924934 321 324 O
- NCT03924934 325 326 O
defined NCT03924934 327 334 O
CRE NCT03924934 335 338 B-Organism
isolated NCT03924934 339 347 I-Organism
during NCT03924934 348 354 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03924934 355 370 B-Encounter
who NCT03924934 371 374 B-And
are NCT03924934 375 378 O
not NCT03924934 379 382 B-Negation
discharged NCT03924934 383 393 B-Encounter
home NCT03924934 394 398 O
and NCT03924934 399 402 O
who NCT03924934 403 406 O
meet NCT03924934 407 411 O
any NCT03924934 412 415 O
of NCT03924934 416 418 O
the NCT03924934 419 422 B-Criteria-Count
following NCT03924934 423 432 I-Criteria-Count
criteria NCT03924934 433 441 I-Criteria-Count
: NCT03924934 442 443 O

- NCT03924934 447 448 O
Admitted NCT03924934 450 458 B-Encounter
from NCT03924934 459 463 O
other NCT03924934 464 469 B-Other
care NCT03924934 470 474 O
facility NCT03924934 475 483 O
( NCT03924934 484 485 O
not NCT03924934 486 489 O
home NCT03924934 490 494 O
origin NCT03924934 495 501 O
) NCT03924934 502 503 O

- NCT03924934 507 508 O
Do NCT03924934 510 512 O
not NCT03924934 513 516 B-Negation
have NCT03924934 517 521 O
first NCT03924934 522 527 B-Eq-Comparison
positive NCT03924934 528 536 O
CRE NCT03924934 537 540 B-Organism
culture NCT03924934 541 548 I-Organism
within NCT03924934 549 555 B-Eq-Comparison
48 NCT03924934 556 558 I-Eq-Comparison
hours NCT03924934 559 564 I-Eq-Comparison
of NCT03924934 565 567 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03924934 568 577 B-Encounter

Category NCT03924934 578 586 O
3 NCT03924934 587 588 O
: NCT03924934 589 590 O
Patients NCT03924934 591 599 O
with NCT03924934 600 604 O
CDC NCT03924934 605 608 O
- NCT03924934 609 610 O
defined NCT03924934 611 618 O
CRE NCT03924934 619 622 B-Organism
isolated NCT03924934 623 631 I-Organism
during NCT03924934 632 638 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03924934 639 654 B-Encounter
or NCT03924934 655 657 B-Or
outpatient NCT03924934 658 668 B-Encounter
visit NCT03924934 669 674 I-Encounter
who NCT03924934 675 678 B-And
are NCT03924934 679 682 O
discharged NCT03924934 683 693 B-Encounter
home NCT03924934 694 698 O
and NCT03924934 699 702 O
who NCT03924934 703 706 O
meet NCT03924934 707 711 O
any NCT03924934 712 715 O
of NCT03924934 716 718 O
the NCT03924934 719 722 O
following NCT03924934 723 732 O
criteria NCT03924934 733 741 O
: NCT03924934 742 743 O

- NCT03924934 747 748 O
Admitted NCT03924934 750 758 B-Encounter
from NCT03924934 759 763 O
other NCT03924934 764 769 B-Other
care NCT03924934 770 774 O
facility NCT03924934 775 783 O
( NCT03924934 784 785 O
not NCT03924934 786 789 O
home NCT03924934 790 794 O
origin NCT03924934 795 801 O
) NCT03924934 802 803 O

- NCT03924934 807 808 O
Do NCT03924934 810 812 O
not NCT03924934 813 816 B-Negation
have NCT03924934 817 821 O
first NCT03924934 822 827 B-Eq-Comparison
positive NCT03924934 828 836 O
CRE NCT03924934 837 840 B-Organism
culture NCT03924934 841 848 I-Organism
within NCT03924934 849 855 B-Eq-Comparison
48 NCT03924934 856 858 I-Eq-Comparison
hours NCT03924934 859 864 I-Eq-Comparison
of NCT03924934 865 867 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03924934 868 877 B-Encounter
( NCT03924934 878 879 O
in NCT03924934 880 882 O
case NCT03924934 883 887 O
of NCT03924934 888 890 O
hospitalization NCT03924934 891 906 B-Encounter
) NCT03924934 907 908 O

Category NCT03924934 910 918 O
4 NCT03924934 919 920 O
: NCT03924934 921 922 O
Participants NCT03924934 923 935 O
who NCT03924934 936 939 O
meet NCT03924934 940 944 O
the NCT03924934 945 948 O
following NCT03924934 949 958 O
criteria NCT03924934 959 967 O
: NCT03924934 968 969 O

• NCT03924934 971 972 O
Community NCT03924934 973 982 O
contact NCT03924934 983 990 O
of NCT03924934 991 993 O
a NCT03924934 994 995 O
participant NCT03924934 996 1007 O
in NCT03924934 1008 1010 O
Category NCT03924934 1011 1019 O
1 NCT03924934 1020 1021 O
and NCT03924934 1022 1025 O
/ NCT03924934 1026 1027 O
or NCT03924934 1028 1030 O
3 NCT03924934 1031 1032 O
. NCT03924934 1032 1033 O

Exclusion NCT03924934 1035 1044 O
Criteria NCT03924934 1045 1053 O
: NCT03924934 1054 1055 O

In NCT03924934 1057 1059 O
all NCT03924934 1060 1063 O
categories NCT03924934 1064 1074 O
, NCT03924934 1075 1076 O
participants NCT03924934 1077 1089 O
who NCT03924934 1090 1093 O
meet NCT03924934 1094 1098 O
the NCT03924934 1099 1102 O
following NCT03924934 1103 1112 O
criteria NCT03924934 1113 1121 O
will NCT03924934 1122 1126 O
be NCT03924934 1127 1129 O
excluded NCT03924934 1130 1138 O
: NCT03924934 1139 1140 O

• NCT03924934 1142 1143 O
Age NCT03924934 1144 1147 B-Age
< NCT03924934 1148 1149 B-Eq-Comparison
18 NCT03924934 1150 1152 I-Eq-Comparison
years NCT03924934 1153 1158 I-Eq-Comparison

In NCT03924934 1159 1161 O
category NCT03924934 1162 1170 O
1 NCT03924934 1171 1172 O
, NCT03924934 1173 1174 O
the NCT03924934 1175 1178 O
following NCT03924934 1179 1188 O
are NCT03924934 1189 1192 O
exclusionary NCT03924934 1193 1205 O
: NCT03924934 1206 1207 O

- NCT03924934 1211 1212 I-Eq-Comparison|Eq-Comparison
pre NCT03924934 1214 1217 B-Eq-Comparison|Eq-Comparison
- NCT03924934 1218 1219 O
existing NCT03924934 1220 1228 I-Eq-Comparison|Eq-Comparison
renal NCT03924934 1229 1234 B-Condition
failure NCT03924934 1235 1242 I-Condition

- NCT03924934 1245 1246 O
pre NCT03924934 1248 1251 O
- NCT03924934 1252 1253 O
existing NCT03924934 1254 1262 O
liver NCT03924934 1263 1268 B-Condition
disease NCT03924934 1269 1276 I-Condition

- NCT03924934 1279 1280 O
immunocompromised NCT03924934 1282 1299 B-Condition

- NCT03924934 1302 1303 O
history NCT03924934 1305 1312 B-Eq-Comparison
of NCT03924934 1313 1315 O
malignancy NCT03924934 1316 1326 B-Condition

- NCT03924934 1329 1330 O
pregnancy NCT03924934 1332 1341 B-Condition

In NCT03924934 1342 1344 O
addition NCT03924934 1345 1353 O
, NCT03924934 1354 1355 O
in NCT03924934 1356 1358 O
category NCT03924934 1359 1367 O
1 NCT03924934 1368 1369 O
, NCT03924934 1370 1371 O
3 NCT03924934 1372 1373 O
and NCT03924934 1374 1377 O
4 NCT03924934 1378 1379 O
, NCT03924934 1380 1381 O
who NCT03924934 1382 1385 O
meet NCT03924934 1386 1390 O
the NCT03924934 1391 1394 O
following NCT03924934 1395 1404 O
criteria NCT03924934 1405 1413 O
will NCT03924934 1414 1418 O
be NCT03924934 1419 1421 O
excluded NCT03924934 1422 1430 O
: NCT03924934 1431 1432 O

• NCT03924934 1434 1435 O
Unable NCT03924934 1436 1442 O
to NCT03924934 1443 1445 O
provide NCT03924934 1446 1453 O
informed NCT03924934 1454 1462 O
consent NCT03924934 1463 1470 O


Inclusion NCT03924713 0 9 O
Criteria NCT03924713 10 18 O
: NCT03924713 19 20 O

- NCT03924713 24 25 O
Either NCT03924713 27 33 O
have NCT03924713 34 38 O
had NCT03924713 39 42 O
more NCT03924713 43 47 B-Eq-Comparison
than NCT03924713 48 52 I-Eq-Comparison
3 NCT03924713 53 54 I-Eq-Comparison
ED NCT03924713 55 57 B-Encounter
visits NCT03924713 58 64 I-Encounter
in NCT03924713 65 67 O
the NCT03924713 68 71 O
prior NCT03924713 72 77 B-Eq-Comparison
12 NCT03924713 78 80 I-Eq-Comparison
months NCT03924713 81 87 I-Eq-Comparison
, NCT03924713 88 89 O
or NCT03924713 90 92 B-Or
at NCT03924713 93 95 B-Eq-Comparison
least NCT03924713 96 101 I-Eq-Comparison
1 NCT03924713 102 103 I-Eq-Comparison
ambulatory NCT03924713 104 114 B-Modifier
care NCT03924713 115 119 I-Modifier
- NCT03924713 120 121 I-Modifier
sensitive NCT03924713 122 131 I-Modifier
hospitalization NCT03924713 132 147 B-Encounter
in NCT03924713 148 150 O
the NCT03924713 151 154 O
prior NCT03924713 155 160 B-Eq-Comparison
12 NCT03924713 161 163 I-Eq-Comparison
months NCT03924713 164 170 I-Eq-Comparison

Exclusion NCT03924713 171 180 O
Criteria NCT03924713 181 189 O
: NCT03924713 190 191 O

- NCT03924713 195 196 O
None NCT03924713 198 202 O
if NCT03924713 203 205 O
they NCT03924713 206 210 O
meet NCT03924713 211 215 O
above NCT03924713 216 221 O
criteria NCT03924713 222 230 O
. NCT03924713 230 231 O

Inclusion NCT03929237 0 9 O
Criteria NCT03929237 10 18 O
: NCT03929237 19 20 O

- NCT03929237 24 25 O
ACL NCT03929237 27 30 B-Procedure
reconstruction NCT03929237 31 45 I-Procedure
surgery NCT03929237 46 53 I-Procedure

- NCT03929237 56 57 O
currently NCT03929237 59 68 B-Eq-Comparison
enrolled NCT03929237 69 77 O
in NCT03929237 78 80 O
middle NCT03929237 81 87 O
or NCT03929237 88 90 O
high NCT03929237 91 95 O
school NCT03929237 96 102 O
( NCT03929237 103 104 O
grades NCT03929237 105 111 O
6 NCT03929237 112 113 O
- NCT03929237 114 115 O
12 NCT03929237 116 118 O
) NCT03929237 119 120 O

- NCT03929237 124 125 O
Surgery NCT03929237 127 134 B-Procedure
occurs NCT03929237 135 141 O
during NCT03929237 142 148 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03929237 149 152 O
school NCT03929237 153 159 B-Observation
year NCT03929237 160 164 I-Observation

- NCT03929237 167 168 O
No NCT03929237 170 172 B-Negation
concomitant NCT03929237 173 184 B-Modifier
additional NCT03929237 185 195 I-Modifier
ligament NCT03929237 196 204 B-Procedure
surgery NCT03929237 205 212 I-Procedure
( NCT03929237 213 214 O
ie NCT03929237 215 217 O
. NCT03929237 217 218 O
PCL NCT03929237 220 223 B-Procedure
, NCT03929237 224 225 O
MCL NCT03929237 226 229 B-Procedure
, NCT03929237 230 231 O
LCL NCT03929237 232 235 B-Procedure
or NCT03929237 236 238 B-Or
MPFL NCT03929237 239 243 B-Procedure
) NCT03929237 244 245 O

Exclusion NCT03929237 247 256 O
Criteria NCT03929237 257 265 O
: NCT03929237 266 267 O

- NCT03929237 271 272 O
patient NCT03929237 274 281 O
is NCT03929237 282 284 O
home NCT03929237 285 289 B-Observation
schooled NCT03929237 290 298 I-Observation
or NCT03929237 299 301 B-Or
in NCT03929237 302 304 O
non NCT03929237 305 308 B-Observation
- NCT03929237 309 310 I-Observation
traditional NCT03929237 311 322 I-Observation
school NCT03929237 323 329 I-Observation
setting NCT03929237 330 337 I-Observation
( NCT03929237 338 339 O
ie NCT03929237 340 342 O
. NCT03929237 342 343 O
school NCT03929237 345 351 B-Observation
for NCT03929237 352 355 I-Observation
special NCT03929237 356 363 I-Observation
needs NCT03929237 364 369 I-Observation
) NCT03929237 370 371 O

- NCT03929237 375 376 O
concomitant NCT03929237 378 389 B-Modifier
additional NCT03929237 390 400 I-Modifier
ligament NCT03929237 401 409 B-Procedure
surgery NCT03929237 410 417 I-Procedure|Procedure

- NCT03929237 420 421 O
surgery NCT03929237 423 430 O
occurs NCT03929237 431 437 B-Temporal-Connection___Temporal-Connection-Type-Value:during
outside NCT03929237 438 445 B-Negation
of NCT03929237 446 448 O
the NCT03929237 449 452 O
school NCT03929237 453 459 B-Observation
year NCT03929237 460 464 I-Observation
or NCT03929237 465 467 O
on NCT03929237 468 470 O
a NCT03929237 471 472 O
scheduled NCT03929237 473 482 O
break NCT03929237 483 488 O
from NCT03929237 489 493 O
school NCT03929237 494 500 O

Inclusion NCT03926104 0 9 O
Criteria NCT03926104 10 18 O
: NCT03926104 19 20 O

- NCT03926104 24 25 O
Ability NCT03926104 27 34 O
to NCT03926104 35 37 O
provide NCT03926104 38 45 O
an NCT03926104 46 48 O
informed NCT03926104 49 57 O
consent NCT03926104 58 65 O

- NCT03926104 68 69 O
Age NCT03926104 71 74 B-Age
> NCT03926104 75 76 B-Eq-Comparison
18 NCT03926104 77 79 I-Eq-Comparison
years NCT03926104 80 85 I-Eq-Comparison
old NCT03926104 86 89 O

- NCT03926104 92 93 O
Elective NCT03926104 95 103 O
abdominal NCT03926104 104 113 B-Condition
aortic NCT03926104 114 120 I-Condition
aneurysm NCT03926104 121 129 I-Condition
surgery NCT03926104 130 137 B-Procedure

Exclusion NCT03926104 138 147 O
Criteria NCT03926104 148 156 O
: NCT03926104 157 158 O

- NCT03926104 162 163 O
Emergency NCT03926104 165 174 B-Modifier
surgery NCT03926104 175 182 B-Procedure

- NCT03926104 185 186 O
Age NCT03926104 188 191 B-Age
˂ NCT03926104 192 193 B-Eq-Comparison
18 NCT03926104 194 196 I-Eq-Comparison
years NCT03926104 197 202 I-Eq-Comparison
old NCT03926104 203 206 O

- NCT03926104 209 210 O
Creatinine NCT03926104 212 222 B-Observation
> NCT03926104 223 224 B-Eq-Comparison
2 NCT03926104 225 226 I-Eq-Comparison
mg NCT03926104 227 229 O
/ NCT03926104 230 231 I-Eq-Comparison
dl NCT03926104 232 234 I-Eq-Comparison

- NCT03926104 237 238 O
Diseases NCT03926104 240 248 B-Condition
of NCT03926104 249 251 O
ascending NCT03926104 252 261 B-Modifier
aorta NCT03926104 262 267 I-Modifier
, NCT03926104 268 269 O
aortic NCT03926104 270 276 B-Modifier
arch NCT03926104 277 281 I-Modifier
or NCT03926104 282 284 B-Or
thoracic NCT03926104 285 293 B-Modifier
aorta NCT03926104 294 299 I-Modifier

- NCT03926104 302 303 O
Chronic NCT03926104 305 312 B-Modifier
atrial NCT03926104 313 319 B-Condition
fibrillation NCT03926104 320 332 I-Condition

- NCT03926104 335 336 O
Patient NCT03926104 338 345 O
refusal NCT03926104 346 353 O
to NCT03926104 354 356 O
provide NCT03926104 357 364 O
informed NCT03926104 365 373 O
consent NCT03926104 374 381 O

Inclusion NCT03926676 0 9 O
Criteria NCT03926676 10 18 O
: NCT03926676 19 20 O

- NCT03926676 24 25 O
patients NCT03926676 27 35 O
with NCT03926676 36 40 O
badly NCT03926676 41 46 B-Modifier
broken NCT03926676 47 53 B-Condition
vital NCT03926676 54 59 I-Condition
teeth NCT03926676 60 65 I-Condition

good NCT03926676 66 70 B-Modifier
oral NCT03926676 71 75 B-Condition
hygiene NCT03926676 76 83 I-Condition
measures NCT03926676 84 92 O

young NCT03926676 93 98 O
adults NCT03926676 99 105 O
males NCT03926676 106 111 O
or NCT03926676 112 114 B-Or
females NCT03926676 115 122 O

cooperative NCT03926676 123 134 O
patients NCT03926676 135 143 O
approving NCT03926676 144 153 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926676 154 156 O
participate NCT03926676 157 168 O
in NCT03926676 169 171 O
the NCT03926676 172 175 O
study NCT03926676 176 181 B-Study

Exclusion NCT03926676 182 191 O
Criteria NCT03926676 192 200 O
: NCT03926676 201 202 O

- NCT03926676 206 207 O
patients NCT03926676 209 217 O
with NCT03926676 218 222 O
compromised NCT03926676 223 234 B-Modifier
medical NCT03926676 235 242 B-Condition
history NCT03926676 243 250 I-Condition

lack NCT03926676 251 255 O
of NCT03926676 256 258 O
compliance NCT03926676 259 269 O

severe NCT03926676 270 276 O
medical NCT03926676 277 284 B-Condition
condition NCT03926676 285 294 I-Condition

severe NCT03926676 295 301 O
or NCT03926676 302 304 B-Or
active NCT03926676 305 311 B-Eq-Comparison
periodontal NCT03926676 312 323 B-Condition
disease NCT03926676 324 331 I-Condition

Inclusion NCT03922438 0 9 O
Criteria NCT03922438 10 18 O
: NCT03922438 19 20 O

- NCT03922438 24 25 O
Non NCT03922438 27 30 B-Negation
syndromic NCT03922438 31 40 B-Condition
patients NCT03922438 41 49 O

- NCT03922438 52 53 O
Medically NCT03922438 55 64 O
fit NCT03922438 65 68 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03922438 69 72 I-Assertion___Assertion-Type-Value:hypothetical
Surgery NCT03922438 73 80 B-Procedure

- NCT03922438 83 84 O
Patient NCT03922438 86 93 O
with NCT03922438 94 98 O
Primary NCT03922438 99 106 B-Modifier
, NCT03922438 107 108 O
complete NCT03922438 109 117 B-Modifier
cleft NCT03922438 118 123 B-Condition
lip NCT03922438 124 127 I-Condition

- NCT03922438 130 131 O
Patient NCT03922438 133 140 O
's NCT03922438 140 142 O
age NCT03922438 143 146 B-Age
younger NCT03922438 147 154 B-Eq-Comparison
than NCT03922438 155 159 I-Eq-Comparison
six NCT03922438 160 163 I-Eq-Comparison
months NCT03922438 164 170 I-Eq-Comparison

Exclusion NCT03922438 171 180 O
Criteria NCT03922438 181 189 O
: NCT03922438 190 191 O

- NCT03922438 195 196 O
Patient NCT03922438 198 205 O
with NCT03922438 206 210 O
syndromic NCT03922438 211 220 B-Modifier
cleft NCT03922438 221 226 B-Condition
lip NCT03922438 227 230 I-Condition

- NCT03922438 233 234 O
Previous NCT03922438 236 244 B-Eq-Comparison
operated NCT03922438 245 253 B-Procedure
cases NCT03922438 254 259 O

- NCT03922438 262 263 O
Incomplete NCT03922438 265 275 B-Modifier
cleft NCT03922438 276 281 B-Condition
lip NCT03922438 282 285 I-Condition

- NCT03922438 288 289 O
Patient NCT03922438 291 298 O
older NCT03922438 299 304 I-Eq-Comparison
than NCT03922438 305 309 I-Eq-Comparison
six NCT03922438 310 313 I-Eq-Comparison
months NCT03922438 314 320 I-Eq-Comparison

- NCT03922438 323 324 O
Patients NCT03922438 326 334 O
with NCT03922438 335 339 O
any NCT03922438 340 343 O
systemic NCT03922438 344 352 B-Modifier
condition NCT03922438 353 362 B-Condition

Inclusion NCT03921125 0 9 O
Criteria NCT03921125 10 18 O
: NCT03921125 19 20 O

- NCT03921125 24 25 O
Sample NCT03921125 27 33 O
of NCT03921125 34 36 O
40 NCT03921125 37 39 O
healthy NCT03921125 40 47 O
ASA NCT03921125 48 51 B-Condition
I NCT03921125 52 53 B-Eq-Comparison
or NCT03921125 54 56 I-Eq-Comparison
II NCT03921125 57 59 I-Eq-Comparison
donors NCT03921125 60 66 O
' NCT03921125 66 67 O
candidate NCT03921125 68 77 O
for NCT03921125 78 81 O
right NCT03921125 82 87 B-Modifier
lobe NCT03921125 88 92 I-Modifier
hepatectomy NCT03921125 93 104 B-Procedure
for NCT03921125 105 108 O
living NCT03921125 109 115 B-Modifier
donor NCT03921125 116 121 I-Modifier
liver NCT03921125 122 127 B-Procedure
transplantation NCT03921125 128 143 I-Procedure

Exclusion NCT03921125 144 153 O
Criteria NCT03921125 154 162 O
: NCT03921125 163 164 O

- NCT03921125 168 169 O
Lack NCT03921125 171 175 O
of NCT03921125 176 178 O
consent NCT03921125 179 186 O

Inclusion NCT03928561 0 9 O
Criteria NCT03928561 10 18 O
: NCT03928561 19 20 O

- NCT03928561 24 25 O
Controlled NCT03928561 27 37 B-Modifier
intermittent NCT03928561 38 50 I-Modifier
asthma NCT03928561 51 57 B-Condition
( NCT03928561 58 59 O
step NCT03928561 60 64 O
1 NCT03928561 65 66 O
treatment NCT03928561 67 76 O
, NCT03928561 77 78 O
according NCT03928561 79 88 O
to NCT03928561 89 91 O
GINA NCT03928561 92 96 O
Guideline NCT03928561 97 106 O
2016 NCT03928561 107 111 O
) NCT03928561 112 113 O
with NCT03928561 114 118 B-And
or NCT03928561 119 121 O
without NCT03928561 122 129 O
association NCT03928561 130 141 O
with NCT03928561 142 146 O
cat NCT03928561 147 150 O
allergy NCT03928561 151 158 B-Allergy
related NCT03928561 159 166 O
rhino NCT03928561 167 172 B-Modifier
- NCT03928561 173 174 O
conjunctivitis NCT03928561 175 189 B-Condition
; NCT03928561 189 190 O

- NCT03928561 193 194 O
Sensitization NCT03928561 196 209 B-Allergy
to NCT03928561 210 212 O
cat NCT03928561 213 216 O
allergen NCT03928561 217 225 O
extract NCT03928561 226 233 O
as NCT03928561 234 236 O
defined NCT03928561 237 244 O
by NCT03928561 245 247 O
skin NCT03928561 248 252 B-Observation
prick NCT03928561 253 258 I-Observation
test NCT03928561 259 263 I-Observation
for NCT03928561 264 267 O
cat NCT03928561 268 271 B-Modifier
extract NCT03928561 272 279 I-Modifier
with NCT03928561 280 284 O
a NCT03928561 285 286 O
wheal NCT03928561 287 292 O
diameter NCT03928561 293 301 O
of NCT03928561 302 304 O
≥ NCT03928561 305 306 B-Eq-Comparison
3 NCT03928561 307 308 I-Eq-Comparison
mm NCT03928561 309 311 I-Eq-Comparison
greater NCT03928561 312 319 I-Eq-Comparison
than NCT03928561 320 324 I-Eq-Comparison
negative NCT03928561 325 333 I-Eq-Comparison
control NCT03928561 334 341 I-Eq-Comparison
( NCT03928561 342 343 O
ALK NCT03928561 344 347 O
, NCT03928561 348 349 O
HØrsholm NCT03928561 350 358 O
, NCT03928561 359 360 O
Denmark NCT03928561 361 368 O
) NCT03928561 369 370 O
and NCT03928561 371 374 O
specific NCT03928561 375 383 O
IgE NCT03928561 384 387 B-Observation
anti NCT03928561 388 392 I-Observation
Fel NCT03928561 393 396 I-Observation
d NCT03928561 397 398 I-Observation
1 NCT03928561 399 400 B-Eq-Comparison
≥ NCT03928561 401 402 I-Eq-Comparison
0.7 NCT03928561 403 406 I-Eq-Comparison
kU NCT03928561 407 409 I-Eq-Comparison
/ NCT03928561 410 411 I-Eq-Comparison
L NCT03928561 412 413 I-Eq-Comparison
( NCT03928561 414 415 O
ImmunoCAP NCT03928561 416 425 O
, NCT03928561 426 427 O
Thermofisher NCT03928561 428 440 O
, NCT03928561 441 442 O
Uppsala NCT03928561 443 450 O
, NCT03928561 451 452 O
Sweden NCT03928561 453 459 O
) NCT03928561 460 461 O
; NCT03928561 462 463 O

- NCT03928561 466 467 O
FEV1 NCT03928561 469 473 B-Observation
≥ NCT03928561 474 475 B-Eq-Comparison
70 NCT03928561 476 478 I-Eq-Comparison
% NCT03928561 479 480 O
of NCT03928561 481 483 O
the NCT03928561 484 487 O
predicted NCT03928561 488 497 O
value NCT03928561 498 503 O
; NCT03928561 503 504 O

- NCT03928561 507 508 O
No NCT03928561 510 512 B-Negation
cat NCT03928561 513 516 B-Condition
exposure NCT03928561 517 525 I-Condition
at NCT03928561 526 528 O
home NCT03928561 529 533 O
or NCT03928561 534 536 B-Or
outside NCT03928561 537 544 B-Negation
of NCT03928561 545 547 O
the NCT03928561 548 551 O
home NCT03928561 552 556 O
during NCT03928561 557 563 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928561 564 567 O
study NCT03928561 568 573 B-Study
; NCT03928561 573 574 O

- NCT03928561 577 578 O
Positive NCT03928561 580 588 O
methacholine NCT03928561 589 601 B-Observation
challenge NCT03928561 602 611 I-Observation
test NCT03928561 612 616 I-Observation
performed NCT03928561 617 626 B-Eq-Comparison
using NCT03928561 627 632 O
an NCT03928561 633 635 O
AeroDoseur NCT03928561 636 646 B-Modifier
DTF NCT03928561 647 650 I-Modifier
- NCT03928561 651 652 I-Modifier
Atomisor NCT03928561 653 661 I-Modifier
ATO NCT03928561 662 665 I-Modifier
- NCT03928561 666 667 O
AD NCT03928561 668 670 I-Modifier
12 NCT03928561 671 673 O
( NCT03928561 674 675 O
Saint NCT03928561 676 681 O
- NCT03928561 682 683 O
Etienne NCT03928561 684 691 O
, NCT03928561 692 693 O
France NCT03928561 694 700 O
) NCT03928561 701 702 O
; NCT03928561 703 704 O

- NCT03928561 712 713 O
Early NCT03928561 715 720 B-Modifier
asthmatic NCT03928561 721 730 B-Condition
response NCT03928561 731 739 O
during NCT03928561 740 746 O
baseline NCT03928561 747 755 O
cat NCT03928561 756 759 B-Condition
allergen NCT03928561 760 768 I-Condition
exposure NCT03928561 769 777 I-Condition
. NCT03928561 777 778 O

Exclusion NCT03928561 780 789 O
Criteria NCT03928561 790 798 O
: NCT03928561 799 800 O

- NCT03928561 804 805 O
Uncontrolled NCT03928561 807 819 B-Modifier
asthma NCT03928561 820 826 B-Condition|Observation
, NCT03928561 827 828 O
asthma NCT03928561 829 835 O
control NCT03928561 836 843 I-Observation
test NCT03928561 844 848 I-Observation
inferior NCT03928561 849 857 B-Eq-Comparison
to NCT03928561 858 860 I-Eq-Comparison
20 NCT03928561 861 863 I-Eq-Comparison
within NCT03928561 864 870 B-Eq-Comparison
the NCT03928561 871 874 I-Eq-Comparison
4 NCT03928561 875 876 I-Eq-Comparison
weeks NCT03928561 877 882 I-Eq-Comparison
preceding NCT03928561 883 892 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03928561 893 896 O
study NCT03928561 897 902 B-Study
. NCT03928561 902 903 O

- NCT03928561 907 908 O
Uncontrolled NCT03928561 910 922 B-Modifier
asthma NCT03928561 923 929 B-Condition
2 NCT03928561 930 931 B-Eq-Comparison
weeks NCT03928561 932 937 I-Eq-Comparison
after NCT03928561 938 943 B-Temporal-Connection___Temporal-Connection-Type-Value:after
stopping NCT03928561 944 952 O
LABA NCT03928561 953 957 B-Drug|Drug
treatment NCT03928561 958 967 B-Procedure|Procedure
. NCT03928561 967 968 O

- NCT03928561 972 973 O
LABA NCT03928561 975 979 O
treatment NCT03928561 980 989 O
within NCT03928561 990 996 B-Eq-Comparison
the NCT03928561 997 1000 I-Eq-Comparison
2 NCT03928561 1001 1002 I-Eq-Comparison
weeks NCT03928561 1003 1008 I-Eq-Comparison
preceding NCT03928561 1009 1018 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03928561 1019 1022 O
study NCT03928561 1023 1028 B-Study
. NCT03928561 1028 1029 O

- NCT03928561 1033 1034 O
Severe NCT03928561 1036 1042 O
asthma NCT03928561 1043 1049 B-Condition
( NCT03928561 1050 1051 O
> NCT03928561 1053 1054 B-Eq-Comparison
GINA NCT03928561 1055 1059 B-Observation
2 NCT03928561 1060 1061 O
) NCT03928561 1062 1063 O

- NCT03928561 1067 1068 O
Subject NCT03928561 1070 1077 O
lives NCT03928561 1078 1083 O
with NCT03928561 1084 1088 B-Eq-Comparison
a NCT03928561 1089 1090 O
cat NCT03928561 1091 1094 O

- NCT03928561 1097 1098 O
Cat NCT03928561 1100 1103 B-Condition
desensibilisation NCT03928561 1104 1121 I-Condition
within NCT03928561 1122 1128 O
the NCT03928561 1129 1132 I-Eq-Comparison
6 NCT03928561 1133 1134 I-Eq-Comparison
previous NCT03928561 1135 1143 I-Eq-Comparison
months NCT03928561 1144 1150 I-Eq-Comparison
. NCT03928561 1150 1151 O

- NCT03928561 1155 1156 O
Active NCT03928561 1158 1164 B-Eq-Comparison
smoker NCT03928561 1165 1171 B-Condition


Inclusion NCT03922919 0 9 O
Criteria NCT03922919 10 18 O
: NCT03922919 19 20 O

- NCT03922919 24 25 O
Age NCT03922919 27 30 B-Age
≥ NCT03922919 31 32 B-Eq-Comparison
18 NCT03922919 33 35 I-Eq-Comparison
years NCT03922919 36 41 I-Eq-Comparison
old NCT03922919 42 45 O

- NCT03922919 48 49 O
Indication NCT03922919 51 61 B-Indication
for NCT03922919 62 65 O
antibiotic NCT03922919 66 76 B-Drug
treatment NCT03922919 77 86 B-Procedure
with NCT03922919 87 91 O
a NCT03922919 92 93 O
3 NCT03922919 94 95 B-Modifier
rd NCT03922919 96 98 O
generation NCT03922919 99 109 I-Modifier
injectable NCT03922919 110 120 I-Modifier
cephalosporin NCT03922919 121 134 B-Drug
( NCT03922919 135 136 O
cefotaxime NCT03922919 137 147 B-Drug
or NCT03922919 148 150 B-Or
ceftriaxone NCT03922919 151 162 B-Drug
) NCT03922919 163 164 O

- NCT03922919 168 169 O
Signed NCT03922919 171 177 O
Informed NCT03922919 178 186 O
Consent NCT03922919 187 194 O

Exclusion NCT03922919 195 204 O
Criteria NCT03922919 205 213 O
: NCT03922919 214 215 O

- NCT03922919 219 220 O
Hypersensitivity NCT03922919 222 238 B-Condition
to NCT03922919 239 241 O
ceftriaxone NCT03922919 242 253 B-Drug
or NCT03922919 254 256 B-Or
cefotaxime NCT03922919 257 267 B-Drug
, NCT03922919 268 269 O
to NCT03922919 270 272 O
another NCT03922919 273 280 B-Other
cephalosporin NCT03922919 281 294 B-Drug
or NCT03922919 295 297 O
to NCT03922919 298 300 O
any NCT03922919 301 304 O
of NCT03922919 305 307 O
the NCT03922919 308 311 O
excipients NCT03922919 312 322 O
of NCT03922919 323 325 O
the NCT03922919 326 329 O
specialities NCT03922919 330 342 O
concerned NCT03922919 343 352 O
. NCT03922919 352 353 O

- NCT03922919 357 358 O
History NCT03922919 360 367 B-Eq-Comparison
of NCT03922919 368 370 O
severe NCT03922919 371 377 O
hypersensitivity NCT03922919 378 394 B-Condition
( NCT03922919 395 396 O
e. NCT03922919 397 399 O
g. NCT03922919 400 402 O
, NCT03922919 403 404 O
anaphylactic NCT03922919 405 417 B-Condition
reaction NCT03922919 418 426 I-Condition
) NCT03922919 427 428 O
to NCT03922919 429 431 O
another NCT03922919 432 439 B-Other
class NCT03922919 440 445 O
of NCT03922919 446 448 O
antibacterial NCT03922919 449 462 B-Drug
agent NCT03922919 463 468 I-Drug
of NCT03922919 469 471 O
the NCT03922919 472 475 O
beta NCT03922919 476 480 B-Modifier
- NCT03922919 481 482 I-Modifier
lactam NCT03922919 483 489 I-Modifier
family NCT03922919 490 496 O
( NCT03922919 497 498 O
penicillins NCT03922919 499 510 B-Drug
, NCT03922919 511 512 O
monobactams NCT03922919 513 524 B-Drug
and NCT03922919 525 528 B-Or
carbapenes NCT03922919 529 539 B-Drug
) NCT03922919 540 541 O

- NCT03922919 545 546 O
Subcutaneous NCT03922919 548 560 B-Modifier
administration NCT03922919 561 575 O
of NCT03922919 576 578 O
ceftriaxone NCT03922919 579 590 B-Drug

- NCT03922919 593 594 O
Pregnant NCT03922919 596 604 B-Condition
and NCT03922919 605 608 B-Or
breastfeeding NCT03922919 609 622 B-Condition
woman NCT03922919 623 628 O

- NCT03922919 631 632 O
Suspicion NCT03922919 634 643 B-Assertion___Assertion-Type-Value:possible
of NCT03922919 644 646 O
Pseudomonas NCT03922919 647 658 B-Condition
infection NCT03922919 659 668 I-Condition
or NCT03922919 669 671 B-Or
documented NCT03922919 672 682 O
Pseudomonas NCT03922919 683 694 B-Condition
infection NCT03922919 695 704 I-Condition
requiring NCT03922919 705 714 B-Assertion___Assertion-Type-Value:hypothetical
ceftazidime NCT03922919 715 726 B-Drug
treatment NCT03922919 727 736 B-Procedure

- NCT03922919 739 740 O
Suspicion NCT03922919 742 751 B-Assertion___Assertion-Type-Value:possible
of NCT03922919 752 754 O
group NCT03922919 755 760 B-Eq-Comparison
III NCT03922919 761 764 I-Eq-Comparison
enterobacteriaceae NCT03922919 765 783 B-Condition
infection NCT03922919 784 793 I-Condition
or NCT03922919 794 796 B-Or
group NCT03922919 797 802 B-Eq-Comparison
III NCT03922919 803 806 I-Eq-Comparison
enterobacteriaceae NCT03922919 807 825 B-Condition
infection NCT03922919 826 835 I-Condition
requiring NCT03922919 836 845 O
cefepime NCT03922919 846 854 B-Drug
treatment NCT03922919 855 864 B-Procedure

Inclusion NCT03926000 0 9 O
Criteria NCT03926000 10 18 O
: NCT03926000 19 20 O

- NCT03926000 24 25 O
Patients NCT03926000 27 35 O
scheduled NCT03926000 36 45 B-Eq-Comparison
for NCT03926000 46 49 O
elective NCT03926000 50 58 B-Modifier
knee NCT03926000 59 63 I-Modifier
arthroscopy NCT03926000 64 75 B-Procedure
. NCT03926000 75 76 O

- NCT03926000 80 81 O
Patients NCT03926000 83 91 O
aged NCT03926000 92 96 B-Age
between NCT03926000 97 104 B-Eq-Comparison
21 NCT03926000 105 107 I-Eq-Comparison
and NCT03926000 108 111 I-Eq-Comparison
50 NCT03926000 112 114 I-Eq-Comparison
years NCT03926000 115 120 I-Eq-Comparison
old NCT03926000 121 124 O
. NCT03926000 124 125 O

- NCT03926000 129 130 O
Patients NCT03926000 132 140 O
with NCT03926000 141 145 O
American NCT03926000 146 154 B-Condition
Society NCT03926000 155 162 I-Condition
of NCT03926000 163 165 I-Condition
Anaesthesiologists NCT03926000 166 184 I-Condition
physical NCT03926000 185 193 O
status NCT03926000 194 200 O
I NCT03926000 201 202 B-Eq-Comparison
or NCT03926000 203 205 I-Eq-Comparison
II NCT03926000 206 208 I-Eq-Comparison
. NCT03926000 208 209 O

Exclusion NCT03926000 211 220 O
Criteria NCT03926000 221 229 O
: NCT03926000 230 231 O

- NCT03926000 235 236 O
Patients NCT03926000 238 246 O
with NCT03926000 247 251 O
known NCT03926000 252 257 O
allergy NCT03926000 258 265 B-Allergy
to NCT03926000 266 268 O
any NCT03926000 269 272 O
drug NCT03926000 273 277 B-Drug
used NCT03926000 278 282 O
in NCT03926000 283 285 O
the NCT03926000 286 289 O
study NCT03926000 290 295 B-Study
. NCT03926000 295 296 O

- NCT03926000 300 301 O
Patients NCT03926000 303 311 O
with NCT03926000 312 316 O
chronic NCT03926000 317 324 B-Modifier
use NCT03926000 325 328 O
of NCT03926000 329 331 O
analgesics NCT03926000 332 342 B-Drug
and NCT03926000 343 346 B-Or
/ NCT03926000 347 348 I-Or
or NCT03926000 349 351 I-Or
sedatives NCT03926000 352 361 B-Drug
. NCT03926000 361 362 O

- NCT03926000 366 367 O
Patients NCT03926000 369 377 O
with NCT03926000 378 382 O
sleep NCT03926000 383 388 B-Condition
apnea NCT03926000 389 394 I-Condition
syndrome NCT03926000 395 403 I-Condition
. NCT03926000 403 404 O

- NCT03926000 408 409 O
Patients NCT03926000 411 419 O
with NCT03926000 420 424 O
renal NCT03926000 425 430 B-Modifier
or NCT03926000 431 433 B-Or
hepatic NCT03926000 434 441 B-Modifier
dysfunction NCT03926000 442 453 B-Condition
. NCT03926000 453 454 O

- NCT03926000 458 459 O
Patients NCT03926000 461 469 O
with NCT03926000 470 474 O
psychiatric NCT03926000 475 486 B-Condition
disorders NCT03926000 487 496 I-Condition
. NCT03926000 496 497 O

Inclusion NCT03924830 0 9 O
Criteria NCT03924830 10 18 O
: NCT03924830 19 20 O

- NCT03924830 24 25 O
All NCT03924830 27 30 O
patients NCT03924830 31 39 O
must NCT03924830 40 44 O
have NCT03924830 45 49 O
at NCT03924830 50 52 O
only NCT03924830 53 57 B-Eq-Comparison
20 NCT03924830 58 60 I-Eq-Comparison
teeth NCT03924830 61 66 B-Condition
in NCT03924830 67 69 I-Condition
function NCT03924830 70 78 I-Condition
, NCT03924830 79 80 O
must NCT03924830 81 85 O
have NCT03924830 86 90 O
at NCT03924830 91 93 O
only NCT03924830 94 98 B-Eq-Comparison
3 NCT03924830 99 100 I-Eq-Comparison
carious NCT03924830 101 108 B-Modifier
occlusal NCT03924830 109 117 I-Modifier
or NCT03924830 118 120 B-Or
proximo NCT03924830 121 128 B-Modifier
- NCT03924830 129 130 I-Modifier
occlusal NCT03924830 131 139 I-Modifier
lesions NCT03924830 140 147 B-Condition
, NCT03924830 148 149 O
or NCT03924830 150 152 B-Or
old NCT03924830 153 156 B-Modifier
restorations NCT03924830 157 169 B-Condition
that NCT03924830 170 174 O
need NCT03924830 175 179 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924830 180 182 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03924830 183 185 I-Assertion___Assertion-Type-Value:hypothetical
changed NCT03924830 186 193 O
, NCT03924830 194 195 O
in NCT03924830 196 198 O
different NCT03924830 199 208 B-Modifier
teeth NCT03924830 209 214 I-Modifier
. NCT03924830 214 215 O
Those NCT03924830 217 222 B-Coreference
lesions NCT03924830 223 230 B-Condition
must NCT03924830 231 235 O
be NCT03924830 236 238 O
more NCT03924830 239 243 B-Eq-Comparison
than NCT03924830 244 248 I-Eq-Comparison
2 NCT03924830 249 250 I-Eq-Comparison
mm NCT03924830 251 253 I-Eq-Comparison
deep NCT03924830 254 258 B-Observation
, NCT03924830 259 260 O
should NCT03924830 261 267 O
have NCT03924830 268 272 O
exposed NCT03924830 273 280 B-Condition
dentin NCT03924830 281 287 I-Condition
, NCT03924830 288 289 O
and NCT03924830 290 293 B-And
must NCT03924830 294 298 O
have NCT03924830 299 303 O
at NCT03924830 304 306 O
only NCT03924830 307 311 B-Eq-Comparison
50 NCT03924830 312 314 I-Eq-Comparison
% NCT03924830 315 316 O
of NCT03924830 317 319 O
margins NCT03924830 320 327 B-Observation
in NCT03924830 328 330 I-Observation
enamel NCT03924830 331 337 I-Observation
. NCT03924830 337 338 O
Teeth NCT03924830 340 345 B-Modifier
should NCT03924830 346 352 O
not NCT03924830 353 356 B-Negation
present NCT03924830 357 364 O
periodontal NCT03924830 365 376 B-Condition
mobility NCT03924830 377 385 I-Condition
. NCT03924830 385 386 O

Exclusion NCT03924830 388 397 O
Criteria NCT03924830 398 406 O
: NCT03924830 407 408 O

- NCT03924830 412 413 O
Volunteers NCT03924830 415 425 O
with NCT03924830 426 430 O
periodontal NCT03924830 431 442 B-Condition
disease NCT03924830 443 450 I-Condition
; NCT03924830 450 451 O
with NCT03924830 452 456 B-Or
gingival NCT03924830 457 465 B-Condition
bleeding NCT03924830 466 474 I-Condition
; NCT03924830 474 475 O
use NCT03924830 476 479 O
of NCT03924830 480 482 O
anti NCT03924830 483 487 B-Drug
- NCT03924830 488 489 I-Drug
inflammatory NCT03924830 490 502 I-Drug
drugs NCT03924830 503 508 I-Drug
in NCT03924830 509 511 O
the NCT03924830 512 515 O
last NCT03924830 516 520 B-Eq-Comparison
30 NCT03924830 521 523 I-Eq-Comparison
days NCT03924830 524 528 I-Eq-Comparison
. NCT03924830 528 529 O

Inclusion NCT03924011 0 9 O
Criteria NCT03924011 10 18 O
: NCT03924011 19 20 O

- NCT03924011 24 25 O
Informed NCT03924011 27 35 O
Consent NCT03924011 36 43 O
as NCT03924011 44 46 O
documented NCT03924011 47 57 O
by NCT03924011 58 60 O
signature NCT03924011 61 70 O

- NCT03924011 73 74 O
Diagnosis NCT03924011 76 85 O
of NCT03924011 86 88 O
non NCT03924011 89 92 B-Modifier
- NCT03924011 93 94 I-Modifier
invasive NCT03924011 95 103 I-Modifier
( NCT03924011 104 105 O
stage NCT03924011 106 111 B-Eq-Comparison
0 NCT03924011 112 113 I-Eq-Comparison
) NCT03924011 114 115 O
or NCT03924011 116 118 B-Or
invasive NCT03924011 119 127 B-Modifier
( NCT03924011 128 129 O
stage NCT03924011 130 135 B-Eq-Comparison
1 NCT03924011 136 137 I-Eq-Comparison
, NCT03924011 138 139 O
2 NCT03924011 140 141 I-Eq-Comparison
and NCT03924011 142 145 I-Eq-Comparison
3 NCT03924011 146 147 I-Eq-Comparison
A NCT03924011 148 149 O
) NCT03924011 150 151 O
breast NCT03924011 152 158 B-Condition
adenocarcinoma NCT03924011 159 173 I-Condition

- NCT03924011 176 177 O
Treatment NCT03924011 179 188 B-Procedure
with NCT03924011 189 193 O
primary NCT03924011 194 201 B-Modifier
breast NCT03924011 202 208 B-Procedure
- NCT03924011 209 210 I-Procedure
sparing NCT03924011 211 218 I-Procedure
surgery NCT03924011 219 226 I-Procedure
( NCT03924011 227 228 O
lumpectomy NCT03924011 229 239 B-Procedure
) NCT03924011 240 241 O
and NCT03924011 242 245 B-Or
/ NCT03924011 246 247 I-Or
or NCT03924011 248 250 I-Or
neoadjuvant NCT03924011 251 262 B-Modifier
( NCT03924011 263 264 O
pre NCT03924011 265 268 B-Modifier
- NCT03924011 269 270 O
- NCT03924011 272 273 O
operative NCT03924011 274 283 O
) NCT03924011 284 285 O
or NCT03924011 286 288 O
adjuvant NCT03924011 289 297 B-Modifier
( NCT03924011 298 299 O
post NCT03924011 300 304 B-Modifier
- NCT03924011 305 306 O
- NCT03924011 308 309 O
operative NCT03924011 310 319 O
) NCT03924011 320 321 O
chemotherapy NCT03924011 322 334 B-Procedure
or NCT03924011 335 337 B-Or
hormonal NCT03924011 338 346 B-Procedure
therapy NCT03924011 347 354 I-Procedure

- NCT03924011 357 358 O
Scheduled NCT03924011 360 369 B-Eq-Comparison
for NCT03924011 370 373 O
post NCT03924011 374 378 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03924011 379 380 O
- NCT03924011 382 383 O
operative NCT03924011 384 393 B-Procedure
radiotherapy NCT03924011 394 406 B-Procedure
at NCT03924011 407 409 O
Ziekenhuis NCT03924011 410 420 O
Oost NCT03924011 421 425 O
- NCT03924011 426 427 O
Limburg NCT03924011 428 435 O
, NCT03924011 436 437 O
Genk NCT03924011 438 442 O
: NCT03924011 443 444 O

- NCT03924011 448 449 O
Hypofractionated NCT03924011 451 467 B-Procedure
radiotherapy NCT03924011 468 480 I-Procedure
regimen NCT03924011 481 488 O
( NCT03924011 489 490 O
i. NCT03924011 491 493 O
e. NCT03924011 494 496 O
16 NCT03924011 498 500 B-Eq-Comparison
daily NCT03924011 501 506 I-Eq-Comparison
fractions NCT03924011 507 516 O
of NCT03924011 517 519 O
2.66 NCT03924011 520 524 B-Procedure
Gray NCT03924011 525 529 I-Procedure
to NCT03924011 530 532 O
the NCT03924011 533 536 O
whole NCT03924011 537 542 B-Modifier
breast NCT03924011 543 549 I-Modifier
followed NCT03924011 550 558 B-Temporal-Connection___Temporal-Connection-Type-Value:before
by NCT03924011 559 561 I-Temporal-Connection___Temporal-Connection-Type-Value:before
a NCT03924011 562 563 O
boost NCT03924011 564 569 O
of NCT03924011 570 572 O
5 NCT03924011 573 574 B-Eq-Comparison|Eq-Comparison
fractions NCT03924011 575 584 O
of NCT03924011 585 587 O
2.66 NCT03924011 588 592 B-Procedure
Gray NCT03924011 593 597 I-Procedure
to NCT03924011 598 600 O
the NCT03924011 601 604 O
tumor NCT03924011 605 610 B-Modifier
bed NCT03924011 611 614 I-Modifier
, NCT03924011 615 616 O
5 NCT03924011 617 618 O
x NCT03924011 619 620 O
/ NCT03924011 621 622 I-Eq-Comparison
week NCT03924011 623 627 I-Eq-Comparison
) NCT03924011 628 629 O

Exclusion NCT03924011 635 644 O
Criteria NCT03924011 645 653 O
: NCT03924011 654 655 O

- NCT03924011 659 660 O
Scheduled NCT03924011 662 671 B-Eq-Comparison
for NCT03924011 672 675 O
post NCT03924011 676 680 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03924011 681 682 O
- NCT03924011 684 685 O
operative NCT03924011 686 695 B-Procedure
radiotherapy NCT03924011 696 708 B-Procedure
at NCT03924011 709 711 O
Jessa NCT03924011 712 717 O
Hospital NCT03924011 718 726 O
, NCT03924011 727 728 O
Hasselt NCT03924011 729 736 O
, NCT03924011 737 738 O
Belgium NCT03924011 739 746 O

- NCT03924011 749 750 O
Previous NCT03924011 752 760 B-Eq-Comparison
irradiation NCT03924011 761 772 B-Procedure
to NCT03924011 773 775 O
the NCT03924011 776 779 O
same NCT03924011 780 784 B-Modifier
breast NCT03924011 785 791 I-Modifier

- NCT03924011 794 795 O
Metastatic NCT03924011 797 807 O
disease NCT03924011 808 815 O

- NCT03924011 818 819 O
Concurrent NCT03924011 821 831 O
chemotherapy NCT03924011 832 844 B-Procedure

- NCT03924011 847 848 O
Required NCT03924011 850 858 B-Assertion___Assertion-Type-Value:hypothetical
use NCT03924011 859 862 O
of NCT03924011 863 865 O
bolus NCT03924011 866 871 B-Procedure
material NCT03924011 872 880 O
to NCT03924011 881 883 O
deliver NCT03924011 884 891 O
radiotherapy NCT03924011 892 904 B-Procedure
( NCT03924011 905 906 O
i. NCT03924011 907 909 O
e NCT03924011 910 911 O
material NCT03924011 912 920 O
placed NCT03924011 921 927 O
on NCT03924011 928 930 O
the NCT03924011 931 934 O
to NCT03924011 935 937 O
- NCT03924011 938 939 O
be NCT03924011 940 942 O
- NCT03924011 943 944 O
irradiated NCT03924011 945 955 O
zone NCT03924011 956 960 O
to NCT03924011 961 963 O
modulate NCT03924011 964 972 O
the NCT03924011 973 976 O
delivered NCT03924011 977 986 O
dose NCT03924011 987 991 O
in NCT03924011 992 994 O
order NCT03924011 995 1000 O
to NCT03924011 1001 1003 O
ensure NCT03924011 1004 1010 O
an NCT03924011 1011 1013 O
optimal NCT03924011 1014 1021 O
distribution NCT03924011 1022 1034 O
of NCT03924011 1035 1037 O
the NCT03924011 1038 1041 O
radiation NCT03924011 1042 1051 O
dose NCT03924011 1052 1056 O
; NCT03924011 1056 1057 O
mostly NCT03924011 1058 1064 O
used NCT03924011 1065 1069 O
for NCT03924011 1070 1073 O
treatment NCT03924011 1074 1083 O
of NCT03924011 1084 1086 O
superficial NCT03924011 1087 1098 O
tumors NCT03924011 1099 1105 O
) NCT03924011 1106 1107 O

- NCT03924011 1111 1112 I-Condition
Known NCT03924011 1114 1119 O
or NCT03924011 1120 1122 B-Or
suspected NCT03924011 1123 1132 B-Assertion___Assertion-Type-Value:possible
non NCT03924011 1133 1136 B-Condition
- NCT03924011 1137 1138 O
compliance NCT03924011 1139 1149 I-Condition
, NCT03924011 1150 1151 O
drug NCT03924011 1152 1156 B-Modifier
or NCT03924011 1157 1159 O
alcohol NCT03924011 1160 1167 B-Modifier
abuse NCT03924011 1168 1173 B-Condition

- NCT03924011 1176 1177 O
Inability NCT03924011 1179 1188 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03924011 1189 1191 O
follow NCT03924011 1192 1198 O
the NCT03924011 1199 1202 O
procedures NCT03924011 1203 1213 B-Procedure
of NCT03924011 1214 1216 O
the NCT03924011 1217 1220 O
study NCT03924011 1221 1226 B-Study
, NCT03924011 1227 1228 O
e. NCT03924011 1229 1231 O
g. NCT03924011 1232 1234 O
due NCT03924011 1236 1239 O
to NCT03924011 1240 1242 O
language NCT03924011 1243 1251 B-Condition
problems NCT03924011 1252 1260 I-Condition
, NCT03924011 1261 1262 O
psyschological NCT03924011 1263 1277 B-Condition
disorders NCT03924011 1278 1287 I-Condition
, NCT03924011 1288 1289 O
dementia NCT03924011 1290 1298 B-Condition
, NCT03924011 1299 1300 O
etc NCT03924011 1301 1304 O
. NCT03924011 1304 1305 O
of NCT03924011 1307 1309 O
the NCT03924011 1310 1313 O
participant NCT03924011 1314 1325 O

- NCT03924011 1328 1329 O
Seizure NCT03924011 1331 1338 B-Condition

- NCT03924011 1341 1342 O
Disorders NCT03924011 1344 1353 B-Condition
triggered NCT03924011 1354 1363 O
by NCT03924011 1364 1366 O
lighttake NCT03924011 1367 1376 O
anticoagulants NCT03924011 1377 1391 B-Drug

- NCT03924011 1394 1395 O
Hemorrhagic NCT03924011 1397 1408 B-Condition
diatheses NCT03924011 1409 1418 I-Condition

- NCT03924011 1421 1422 O
Pregnancy NCT03924011 1424 1433 B-Condition

- NCT03924011 1436 1437 O
Suspected NCT03924011 1439 1448 B-Assertion___Assertion-Type-Value:possible
of NCT03924011 1449 1451 O
carrying NCT03924011 1452 1460 O
serious NCT03924011 1461 1468 O
infectious NCT03924011 1469 1479 B-Condition
disease NCT03924011 1480 1487 I-Condition

- NCT03924011 1490 1491 O
HIV NCT03924011 1493 1496 B-Condition
positive NCT03924011 1497 1505 O
history NCT03924011 1506 1513 B-Eq-Comparison


Inclusion NCT03928171 0 9 O
Criteria NCT03928171 10 18 O
: NCT03928171 19 20 O

- NCT03928171 24 25 O
Adults NCT03928171 27 33 O
( NCT03928171 34 35 O
≥ NCT03928171 37 38 B-Eq-Comparison
18 NCT03928171 39 41 I-Eq-Comparison
years NCT03928171 42 47 I-Eq-Comparison
old NCT03928171 48 51 B-Age
) NCT03928171 52 53 O

- NCT03928171 57 58 O
Scheduled NCT03928171 60 69 B-Eq-Comparison
for NCT03928171 70 73 O
robot NCT03928171 74 79 B-Modifier
- NCT03928171 80 81 I-Modifier
assisted NCT03928171 82 90 I-Modifier
colorectal NCT03928171 91 101 I-Modifier
laparoscopic NCT03928171 102 114 B-Procedure
surgery NCT03928171 115 122 I-Procedure

Exclusion NCT03928171 123 132 O
Criteria NCT03928171 133 141 O
: NCT03928171 142 143 O

- NCT03928171 147 148 O
Severe NCT03928171 150 156 O
liver NCT03928171 157 162 B-Modifier
- NCT03928171 163 164 O
or NCT03928171 165 167 B-Or
renal NCT03928171 168 173 B-Modifier
disease NCT03928171 174 181 B-Condition

- NCT03928171 184 185 O
Pregnancy NCT03928171 187 196 B-Condition
or NCT03928171 197 199 B-Or
lactation NCT03928171 200 209 B-Condition

- NCT03928171 212 213 O
Planned NCT03928171 215 222 B-Eq-Comparison
diagnostics NCT03928171 223 234 B-Procedure
or NCT03928171 235 237 B-Or
treatment NCT03928171 238 247 B-Procedure
with NCT03928171 248 252 O
radioactive NCT03928171 253 264 B-Procedure
iodine NCT03928171 265 271 I-Procedure
< NCT03928171 272 273 B-Eq-Comparison
1 NCT03928171 274 275 I-Eq-Comparison
week NCT03928171 276 280 I-Eq-Comparison
after NCT03928171 281 286 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03928171 287 294 B-Procedure

- NCT03928171 297 298 O
BMI NCT03928171 300 303 B-Observation
> NCT03928171 304 305 B-Eq-Comparison
35 NCT03928171 306 308 I-Eq-Comparison
kg NCT03928171 309 311 I-Eq-Comparison
/ NCT03928171 312 313 I-Eq-Comparison
m2 NCT03928171 314 316 I-Eq-Comparison

- NCT03928171 319 320 O
Known NCT03928171 322 327 O
or NCT03928171 328 330 O
suspected NCT03928171 331 340 B-Assertion___Assertion-Type-Value:possible
hypersensitivity NCT03928171 341 357 B-Condition
to NCT03928171 358 360 O
indocyanine NCT03928171 361 372 B-Modifier
green NCT03928171 373 378 I-Modifier
, NCT03928171 379 380 O
sodium NCT03928171 381 387 B-Modifier
iodide NCT03928171 388 394 I-Modifier
or NCT03928171 395 397 O
iodine NCT03928171 398 404 B-Modifier

- NCT03928171 407 408 O
Hyperthyroidism NCT03928171 410 425 B-Condition
or NCT03928171 426 428 B-Or
thyroid NCT03928171 429 436 B-Condition
adenomas NCT03928171 437 445 I-Condition

- NCT03928171 448 449 O
Use NCT03928171 451 454 B-Eq-Comparison
of NCT03928171 455 457 O
medication NCT03928171 458 468 B-Drug
interfering NCT03928171 469 480 O
with NCT03928171 481 485 O
ICG NCT03928171 486 489 B-Condition
absorption NCT03928171 490 500 I-Condition
as NCT03928171 501 503 O
listed NCT03928171 504 510 O
in NCT03928171 511 513 O
the NCT03928171 514 517 O
summary NCT03928171 518 525 O
of NCT03928171 526 528 O
product NCT03928171 529 536 O
characteristics NCT03928171 537 552 O
. NCT03928171 552 553 O

Inclusion NCT03925441 0 9 O
Criteria NCT03925441 10 18 O
: NCT03925441 19 20 O

- NCT03925441 24 25 O
Children NCT03925441 27 35 O
and NCT03925441 36 39 B-Or
adolescents NCT03925441 40 51 O
who NCT03925441 52 55 B-And
are NCT03925441 56 59 O
diagnosed NCT03925441 60 69 O
with NCT03925441 70 74 O
pediatric NCT03925441 75 84 B-Modifier
chronic NCT03925441 85 92 I-Modifier
severe NCT03925441 93 99 O
plaque NCT03925441 100 106 B-Condition
psoriasis NCT03925441 107 116 I-Condition
. NCT03925441 116 117 O

- NCT03925441 121 122 O
Prior NCT03925441 124 129 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03925441 130 132 O
participating NCT03925441 133 146 O
in NCT03925441 147 149 O
the NCT03925441 150 153 O
study NCT03925441 154 159 B-Study
, NCT03925441 160 161 O
adalimumab NCT03925441 162 172 B-Drug
treatment NCT03925441 173 182 B-Procedure
was NCT03925441 183 186 O
determined NCT03925441 187 197 O
according NCT03925441 198 207 O
to NCT03925441 208 210 O
clinical NCT03925441 211 219 O
judgement NCT03925441 220 229 O
of NCT03925441 230 232 O
the NCT03925441 233 236 O
physician NCT03925441 237 246 O
. NCT03925441 246 247 O

- NCT03925441 251 252 O
Participants NCT03925441 254 266 O
( NCT03925441 267 268 O
or NCT03925441 269 271 O
legal NCT03925441 272 277 O
representative NCT03925441 278 292 O
) NCT03925441 293 294 O
who NCT03925441 295 298 O
voluntarily NCT03925441 299 310 O
agreed NCT03925441 311 317 O
to NCT03925441 318 320 O
participate NCT03925441 321 332 O
in NCT03925441 333 335 O
this NCT03925441 336 340 O
study NCT03925441 341 346 O
and NCT03925441 347 350 O
signed NCT03925441 351 357 O
informed NCT03925441 358 366 O
consent NCT03925441 367 374 O
. NCT03925441 374 375 O

Exclusion NCT03925441 377 386 O
Criteria NCT03925441 387 395 O
: NCT03925441 396 397 O

- NCT03925441 401 402 O
Participants NCT03925441 404 416 O
with NCT03925441 417 421 O
contraindication NCT03925441 422 438 B-Contraindication
to NCT03925441 439 441 O
adalimumab NCT03925441 442 452 B-Drug
as NCT03925441 453 455 O
listed NCT03925441 456 462 O
in NCT03925441 463 465 O
the NCT03925441 466 469 O
approved NCT03925441 470 478 O
Korean NCT03925441 479 485 O
label NCT03925441 486 491 O
. NCT03925441 491 492 O

- NCT03925441 496 497 O
Participants NCT03925441 499 511 O
with NCT03925441 512 516 O
prior NCT03925441 517 522 B-Eq-Comparison
treatment NCT03925441 523 532 B-Procedure
with NCT03925441 533 537 O
adalimumab NCT03925441 538 548 B-Drug
. NCT03925441 548 549 O

Inclusion NCT03923959 0 9 O
Criteria NCT03923959 10 18 O
: NCT03923959 19 20 O

1 NCT03923959 24 25 O
. NCT03923959 25 26 O
Provision NCT03923959 28 37 O
of NCT03923959 38 40 O
written NCT03923959 41 48 O
informed NCT03923959 49 57 O
consent NCT03923959 58 65 O

2 NCT03923959 68 69 O
. NCT03923959 69 70 O
Age NCT03923959 72 75 B-Age
> NCT03923959 76 77 B-Eq-Comparison
or NCT03923959 78 80 I-Eq-Comparison
= NCT03923959 81 82 I-Eq-Comparison
to NCT03923959 83 85 I-Eq-Comparison
65 NCT03923959 86 88 I-Eq-Comparison
years NCT03923959 89 94 I-Eq-Comparison

3 NCT03923959 97 98 O
. NCT03923959 98 99 O
Hip NCT03923959 101 104 B-Modifier
fracture NCT03923959 105 113 B-Condition
location NCT03923959 114 122 O
within NCT03923959 123 129 O
the NCT03923959 130 133 O
femoral NCT03923959 134 141 B-Modifier
neck NCT03923959 142 146 I-Modifier
, NCT03923959 147 148 O
intertrochanteric NCT03923959 149 166 B-Modifier
, NCT03923959 167 168 O
and NCT03923959 169 172 O
subtrochanteric NCT03923959 173 188 B-Modifier
regions NCT03923959 189 196 O

4 NCT03923959 199 200 O
. NCT03923959 200 201 O
Indication NCT03923959 203 213 B-Indication
for NCT03923959 214 217 O
one NCT03923959 218 221 B-Eq-Comparison
of NCT03923959 222 224 O
the NCT03923959 225 228 B-Criteria-Count
following NCT03923959 229 238 I-Criteria-Count
surgical NCT03923959 239 247 B-Procedure
interventions NCT03923959 248 261 I-Procedure
: NCT03923959 262 263 O
hemiarthroplasty NCT03923959 264 280 B-Procedure
, NCT03923959 281 282 O
total NCT03923959 283 288 B-Procedure
hip NCT03923959 289 292 I-Procedure
replacement NCT03923959 293 304 I-Procedure
, NCT03923959 305 306 O
sliding NCT03923959 307 314 B-Modifier
plate NCT03923959 315 320 I-Modifier
and NCT03923959 321 324 B-Or
screw NCT03923959 325 330 B-Modifier
fixation NCT03923959 331 339 B-Procedure
, NCT03923959 340 341 O
or NCT03923959 342 344 B-Or
intramedullary NCT03923959 345 359 B-Modifier
fixation NCT03923959 360 368 B-Procedure

Exclusion NCT03923959 369 378 O
Criteria NCT03923959 379 387 O
: NCT03923959 388 389 O

1 NCT03923959 393 394 O
. NCT03923959 394 395 O
Indication NCT03923959 397 407 B-Indication
for NCT03923959 408 411 O
closed NCT03923959 412 418 B-Procedure
reduction NCT03923959 419 428 I-Procedure
or NCT03923959 429 431 B-Or
percutaneous NCT03923959 432 444 B-Procedure
screw NCT03923959 445 450 I-Procedure

2 NCT03923959 453 454 O
. NCT03923959 454 455 O
Allergy NCT03923959 457 464 B-Allergy
to NCT03923959 465 467 O
TXA NCT03923959 468 471 B-Drug

3 NCT03923959 474 475 O
. NCT03923959 475 476 O
Cerebrovascular NCT03923959 478 493 B-Condition
accident NCT03923959 494 502 I-Condition
/ NCT03923959 503 504 B-Or
stroke NCT03923959 505 511 B-Condition
, NCT03923959 512 513 O
active NCT03923959 514 520 B-Eq-Comparison
coronary NCT03923959 521 529 B-Condition
disease NCT03923959 530 537 I-Condition
/ NCT03923959 538 539 B-Or
myocardial NCT03923959 540 550 B-Condition
infarction NCT03923959 551 561 I-Condition
, NCT03923959 562 563 O
or NCT03923959 564 566 B-Or
deep NCT03923959 567 571 B-Condition
vein NCT03923959 572 576 I-Condition
thrombosis NCT03923959 577 587 I-Condition
/ NCT03923959 588 589 B-Or
pulmonary NCT03923959 590 599 B-Condition
emboli NCT03923959 600 606 I-Condition
within NCT03923959 607 613 B-Eq-Comparison
one NCT03923959 614 617 I-Eq-Comparison
( NCT03923959 618 619 I-Eq-Comparison
1 NCT03923959 620 621 O
) NCT03923959 622 623 O
month NCT03923959 624 629 I-Eq-Comparison
of NCT03923959 630 632 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923959 633 636 O
fracture NCT03923959 637 645 B-Condition

4 NCT03923959 648 649 O
. NCT03923959 649 650 O
Presence NCT03923959 652 660 O
of NCT03923959 661 663 O
hypercoaguable NCT03923959 664 678 B-Condition
disorder NCT03923959 679 687 I-Condition

Inclusion NCT03923192 0 9 O
Criteria NCT03923192 10 18 O
: NCT03923192 19 20 O

- NCT03923192 24 25 O
Patients NCT03923192 27 35 O
aged NCT03923192 36 40 B-Age
from NCT03923192 41 45 O
15 NCT03923192 46 48 B-Eq-Comparison
to NCT03923192 49 51 I-Eq-Comparison
50 NCT03923192 52 54 I-Eq-Comparison
years NCT03923192 55 60 I-Eq-Comparison
. NCT03923192 60 61 O

- NCT03923192 65 66 O
No NCT03923192 68 70 O
gender NCT03923192 71 77 O
restriction NCT03923192 78 89 O
. NCT03923192 89 90 O

- NCT03923192 94 95 O
Patients NCT03923192 97 105 O
should NCT03923192 106 112 O
have NCT03923192 113 117 O
an NCT03923192 118 120 O
acceptable NCT03923192 121 131 O
oral NCT03923192 132 136 O
hygiene NCT03923192 137 144 O
level NCT03923192 145 150 O
. NCT03923192 150 151 O

- NCT03923192 155 156 O
Patients NCT03923192 158 166 O
must NCT03923192 167 171 O
have NCT03923192 172 176 O
at NCT03923192 177 179 B-Eq-Comparison
least NCT03923192 180 185 I-Eq-Comparison
one NCT03923192 186 189 I-Eq-Comparison
posterior NCT03923192 190 199 B-Modifier
proximal NCT03923192 200 208 I-Modifier
caries NCT03923192 209 215 B-Condition

Exclusion NCT03923192 216 225 O
Criteria NCT03923192 226 234 O
: NCT03923192 235 236 O

- NCT03923192 240 241 O
Patients NCT03923192 243 251 O
with NCT03923192 252 256 O
a NCT03923192 257 258 O
compromised NCT03923192 259 270 B-Condition
medical NCT03923192 271 278 O
history NCT03923192 279 286 B-Eq-Comparison
. NCT03923192 286 287 O

- NCT03923192 291 292 O
Severe NCT03923192 294 300 O
or NCT03923192 301 303 B-Or
active NCT03923192 304 310 B-Eq-Comparison
periodontal NCT03923192 311 322 B-Condition
disease NCT03923192 323 330 I-Condition
. NCT03923192 330 331 O

- NCT03923192 335 336 O
Heavy NCT03923192 338 343 B-Modifier
bruxism NCT03923192 344 351 B-Condition
or NCT03923192 352 354 B-Or
a NCT03923192 355 356 O
traumatic NCT03923192 357 366 B-Modifier
occlusion NCT03923192 367 376 B-Condition
. NCT03923192 376 377 O

- NCT03923192 381 382 O
Acute NCT03923192 384 389 O
or NCT03923192 390 392 B-Or
chronic NCT03923192 393 400 B-Modifier
dental NCT03923192 401 407 I-Modifier
infection NCT03923192 408 417 B-Condition
. NCT03923192 417 418 O

- NCT03923192 422 423 O
Pregnant NCT03923192 425 433 B-Condition
or NCT03923192 434 436 B-Or
breastfeeding NCT03923192 437 450 B-Condition
women NCT03923192 451 456 O
. NCT03923192 456 457 O

- NCT03923192 461 462 O
Patients NCT03923192 464 472 O
with NCT03923192 473 477 O
posterior NCT03923192 478 487 B-Modifier
restorations NCT03923192 488 500 B-Procedure
on NCT03923192 501 503 O
molars NCT03923192 504 510 B-Modifier
or NCT03923192 511 513 B-Or
premolars NCT03923192 514 523 B-Modifier

Inclusion NCT03925285 0 9 O
Criteria NCT03925285 10 18 O
: NCT03925285 19 20 O

- NCT03925285 24 25 O
Biopsy NCT03925285 27 33 B-Procedure
confirmed NCT03925285 34 43 O
diagnosis NCT03925285 44 53 O
of NCT03925285 54 56 O
SNIP NCT03925285 57 61 B-Condition
and NCT03925285 62 65 B-And
scheduled NCT03925285 66 75 B-Eq-Comparison
to NCT03925285 76 78 O
undergo NCT03925285 79 86 O
surgical NCT03925285 87 95 B-Procedure
resection NCT03925285 96 105 I-Procedure
; NCT03925285 105 106 O

- NCT03925285 109 110 O
Age NCT03925285 112 115 B-Age
≥ NCT03925285 116 117 B-Eq-Comparison
18 NCT03925285 118 120 I-Eq-Comparison
years NCT03925285 121 126 I-Eq-Comparison
; NCT03925285 126 127 O

- NCT03925285 130 131 O
Written NCT03925285 133 140 O
informed NCT03925285 141 149 O
consent NCT03925285 150 157 O
; NCT03925285 157 158 O

- NCT03925285 161 162 O
Mentally NCT03925285 164 172 B-Condition
competent NCT03925285 173 182 I-Condition
person NCT03925285 183 189 O
that NCT03925285 190 194 O
is NCT03925285 195 197 O
able NCT03925285 198 202 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03925285 203 206 I-Assertion___Assertion-Type-Value:hypothetical
willing NCT03925285 207 214 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03925285 215 217 O
comply NCT03925285 218 224 O
with NCT03925285 225 229 O
study NCT03925285 230 235 B-Study
procedures NCT03925285 236 246 B-Procedure
. NCT03925285 246 247 O

Exclusion NCT03925285 249 258 O
Criteria NCT03925285 259 267 O
: NCT03925285 268 269 O

- NCT03925285 273 274 O
Medical NCT03925285 276 283 B-Modifier
or NCT03925285 284 286 B-Or
psychiatric NCT03925285 287 298 B-Modifier
conditions NCT03925285 299 309 B-Condition
that NCT03925285 310 314 O
compromise NCT03925285 315 325 O
the NCT03925285 326 329 O
patient NCT03925285 330 337 O
's NCT03925285 337 339 O
ability NCT03925285 340 347 O
to NCT03925285 348 350 O
give NCT03925285 351 355 O
informed NCT03925285 356 364 O
consent NCT03925285 365 372 O
; NCT03925285 372 373 O

- NCT03925285 376 377 O
Concurrent NCT03925285 379 389 B-Modifier
uncontrolled NCT03925285 390 402 I-Modifier
medical NCT03925285 403 410 B-Condition
conditions NCT03925285 411 421 I-Condition
; NCT03925285 421 422 O

- NCT03925285 425 426 O
Received NCT03925285 428 436 B-Eq-Comparison
an NCT03925285 437 439 O
investigational NCT03925285 440 455 B-Study
drug NCT03925285 456 460 B-Drug
within NCT03925285 461 467 B-Eq-Comparison
30 NCT03925285 468 470 I-Eq-Comparison
days NCT03925285 471 475 I-Eq-Comparison
prior NCT03925285 476 481 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03925285 482 484 O
the NCT03925285 485 488 O
dose NCT03925285 489 493 O
of NCT03925285 494 496 O
bevacizumab NCT03925285 497 508 B-Drug
- NCT03925285 509 510 I-Drug
IRDye800 NCT03925285 511 519 I-Drug
CW NCT03925285 520 522 O
; NCT03925285 522 523 O

- NCT03925285 526 527 O
Tumors NCT03925285 529 535 B-Condition
at NCT03925285 536 538 O
sites NCT03925285 539 544 B-Modifier
of NCT03925285 545 547 O
which NCT03925285 548 553 O
the NCT03925285 554 557 O
surgeon NCT03925285 558 565 O
would NCT03925285 566 571 O
assess NCT03925285 572 578 O
that NCT03925285 579 583 O
in NCT03925285 584 586 B-Procedure
vivo NCT03925285 587 591 I-Procedure
imaging NCT03925285 592 599 I-Procedure
would NCT03925285 600 605 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03925285 606 609 B-Negation
be NCT03925285 610 612 O
feasible NCT03925285 613 621 O
; NCT03925285 621 622 O

- NCT03925285 625 626 O
History NCT03925285 628 635 B-Eq-Comparison
of NCT03925285 636 638 O
myocardial NCT03925285 639 649 B-Condition
infarction NCT03925285 650 660 I-Condition
, NCT03925285 661 662 O
cerebrovascular NCT03925285 663 678 B-Condition
accident NCT03925285 679 687 I-Condition
, NCT03925285 688 689 O
uncontrolled NCT03925285 690 702 B-Modifier
cardiac NCT03925285 703 710 I-Modifier
heart NCT03925285 711 716 B-Condition
failure NCT03925285 717 724 I-Condition
, NCT03925285 725 726 O
significant NCT03925285 727 738 O
liver NCT03925285 739 744 B-Condition
disease NCT03925285 745 752 I-Condition
or NCT03925285 753 755 B-Or
unstable NCT03925285 756 764 B-Condition
angina NCT03925285 765 771 I-Condition
within NCT03925285 772 778 B-Eq-Comparison
6 NCT03925285 779 780 I-Eq-Comparison
months NCT03925285 781 787 I-Eq-Comparison
prior NCT03925285 788 793 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03925285 794 796 O
enrollment NCT03925285 797 807 B-Study
; NCT03925285 807 808 O

- NCT03925285 811 812 O
Inadequately NCT03925285 814 826 B-Modifier
controlled NCT03925285 827 837 I-Modifier
hypertension NCT03925285 838 850 B-Condition
with NCT03925285 851 855 O
or NCT03925285 856 858 O
without NCT03925285 859 866 O
current NCT03925285 867 874 B-Eq-Comparison
antihypertensive NCT03925285 875 891 B-Drug
medications NCT03925285 892 903 I-Drug
; NCT03925285 903 904 O

- NCT03925285 907 908 O
History NCT03925285 910 917 B-Eq-Comparison
of NCT03925285 918 920 O
infusion NCT03925285 921 929 B-Modifier
reactions NCT03925285 930 939 B-Condition
to NCT03925285 940 942 O
bevacizumab NCT03925285 943 954 B-Drug
or NCT03925285 955 957 B-Or
other NCT03925285 958 963 B-Other
monoclonal NCT03925285 964 974 B-Procedure
antibody NCT03925285 975 983 I-Procedure
therapies NCT03925285 984 993 I-Procedure
; NCT03925285 993 994 O

- NCT03925285 997 998 O
Pregnant NCT03925285 1000 1008 B-Condition
or NCT03925285 1009 1011 B-Or
lactating NCT03925285 1012 1021 B-Condition
women NCT03925285 1022 1027 O
. NCT03925285 1027 1028 O
Documentation NCT03925285 1030 1043 O
of NCT03925285 1044 1046 O
a NCT03925285 1047 1048 O
negative NCT03925285 1049 1057 O
pregnancy NCT03925285 1058 1067 B-Observation
test NCT03925285 1068 1072 I-Observation
must NCT03925285 1073 1077 O
be NCT03925285 1078 1080 O
available NCT03925285 1081 1090 O
for NCT03925285 1091 1094 O
women NCT03925285 1095 1100 O
of NCT03925285 1101 1103 O
childbearing NCT03925285 1104 1116 B-Condition
potential NCT03925285 1117 1126 I-Condition
. NCT03925285 1126 1127 O
Woman NCT03925285 1129 1134 O
of NCT03925285 1135 1137 O
childbearing NCT03925285 1138 1150 B-Condition
potential NCT03925285 1151 1160 I-Condition
are NCT03925285 1161 1164 B-And
premenopausal NCT03925285 1165 1178 B-Condition
women NCT03925285 1179 1184 O
with NCT03925285 1185 1189 B-And
intact NCT03925285 1190 1196 B-Condition
reproductive NCT03925285 1197 1209 I-Condition
organs NCT03925285 1210 1216 I-Condition
and NCT03925285 1217 1220 B-And
women NCT03925285 1221 1226 O
less NCT03925285 1227 1231 B-Eq-Comparison
than NCT03925285 1232 1236 I-Eq-Comparison
two NCT03925285 1237 1240 I-Eq-Comparison
years NCT03925285 1241 1246 I-Eq-Comparison
after NCT03925285 1247 1252 B-Temporal-Connection___Temporal-Connection-Type-Value:after
menopause NCT03925285 1253 1262 B-Condition
; NCT03925285 1262 1263 O

- NCT03925285 1266 1267 O
Lab NCT03925285 1269 1272 B-Observation
values NCT03925285 1273 1279 I-Observation
that NCT03925285 1280 1284 O
in NCT03925285 1285 1287 O
the NCT03925285 1288 1291 O
opinion NCT03925285 1292 1299 O
of NCT03925285 1300 1302 O
the NCT03925285 1303 1306 O
primary NCT03925285 1307 1314 O
surgeon NCT03925285 1315 1322 O
would NCT03925285 1323 1328 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03925285 1329 1336 B-Negation
surgical NCT03925285 1337 1345 B-Procedure
resection NCT03925285 1346 1355 I-Procedure
; NCT03925285 1355 1356 O

- NCT03925285 1359 1360 O
Life NCT03925285 1362 1366 B-Observation
expectancy NCT03925285 1367 1377 I-Observation
< NCT03925285 1378 1379 B-Eq-Comparison
12 NCT03925285 1380 1382 I-Eq-Comparison
weeks NCT03925285 1383 1388 I-Eq-Comparison
; NCT03925285 1388 1389 O

Inclusion NCT03928951 0 9 O
Criteria NCT03928951 10 18 O
: NCT03928951 19 20 O

- NCT03928951 24 25 O
Every NCT03928951 27 32 O
patient NCT03928951 33 40 O
more NCT03928951 41 45 B-Eq-Comparison
than NCT03928951 46 50 I-Eq-Comparison
18 NCT03928951 51 53 I-Eq-Comparison
years NCT03928951 54 59 I-Age|Eq-Comparison
who NCT03928951 60 63 B-And
was NCT03928951 64 67 O
administered NCT03928951 68 80 B-Eq-Comparison
antibiotherapy NCT03928951 81 95 B-Procedure
for NCT03928951 96 99 O
urinary NCT03928951 100 107 B-Modifier
infection NCT03928951 108 117 B-Condition
in NCT03928951 118 120 O
emergency NCT03928951 121 130 O
department NCT03928951 131 141 O
or NCT03928951 142 144 B-Or
for NCT03928951 145 148 O
whom NCT03928951 149 153 O
urinary NCT03928951 154 161 B-Modifier
infection NCT03928951 162 171 B-Condition
was NCT03928951 172 175 O
diagnosed NCT03928951 176 185 O
in NCT03928951 186 188 O
emergency NCT03928951 189 198 O
department NCT03928951 199 209 O
( NCT03928951 210 211 O
cystitis NCT03928951 212 220 B-Condition
, NCT03928951 221 222 O
acute NCT03928951 223 228 O
pyelonephritis NCT03928951 229 243 B-Condition
, NCT03928951 244 245 O
prostatitis NCT03928951 246 257 B-Condition
) NCT03928951 258 259 O

Exclusion NCT03928951 261 270 O
Criteria NCT03928951 271 279 O
: NCT03928951 280 281 O

- NCT03928951 285 286 O
Patients NCT03928951 288 296 O
less NCT03928951 297 301 B-Eq-Comparison
than NCT03928951 302 306 I-Eq-Comparison
18 NCT03928951 307 309 I-Eq-Comparison
years NCT03928951 310 315 I-Eq-Comparison
old NCT03928951 316 319 B-Age

- NCT03928951 322 323 O
Patients NCT03928951 325 333 O
opposed NCT03928951 334 341 O
to NCT03928951 342 344 O
their NCT03928951 345 350 O
data NCT03928951 351 355 O
use NCT03928951 356 359 O

- NCT03928951 362 363 O
Patients NCT03928951 365 373 O
hospitalized NCT03928951 374 386 B-Encounter
more NCT03928951 387 391 B-Eq-Comparison
than NCT03928951 392 396 I-Eq-Comparison
24 NCT03928951 397 399 I-Eq-Comparison
hours NCT03928951 400 405 I-Eq-Comparison

- NCT03928951 408 409 O
Patients NCT03928951 411 419 O
taking NCT03928951 420 426 B-Eq-Comparison
antibiotherapy NCT03928951 427 441 B-Procedure
already NCT03928951 442 449 O
before NCT03928951 450 456 B-Temporal-Connection___Temporal-Connection-Type-Value:before
their NCT03928951 457 462 O
arrival NCT03928951 463 470 B-Encounter
in NCT03928951 471 473 O
emergency NCT03928951 474 483 O
department NCT03928951 484 494 O

- NCT03928951 497 498 O
Patients NCT03928951 500 508 O
without NCT03928951 509 516 B-Negation
sufficient NCT03928951 517 527 O
reading NCT03928951 528 535 O
capacities NCT03928951 536 546 O
or NCT03928951 547 549 O
understanding NCT03928951 550 563 O
of NCT03928951 564 566 O
french NCT03928951 567 573 O
language NCT03928951 574 582 O
to NCT03928951 583 585 O
express NCT03928951 586 593 O
opposition NCT03928951 594 604 O
to NCT03928951 605 607 O
their NCT03928951 608 613 O
research NCT03928951 614 622 O
participation NCT03928951 623 636 O

- NCT03928951 639 640 O
Any NCT03928951 642 645 O
other NCT03928951 646 651 O
reason NCT03928951 652 658 O
which NCT03928951 659 664 O
, NCT03928951 665 666 O
according NCT03928951 667 676 O
to NCT03928951 677 679 O
investigator NCT03928951 680 692 O
, NCT03928951 693 694 O
might NCT03928951 695 700 O
interfere NCT03928951 701 710 O
with NCT03928951 711 715 O
research NCT03928951 716 724 O
objective NCT03928951 725 734 O
evaluation NCT03928951 735 745 O

Inclusion NCT03921034 0 9 O
Criteria NCT03921034 10 18 O
: NCT03921034 19 20 O

- NCT03921034 24 25 O
Unilateral NCT03921034 27 37 B-Modifier
, NCT03921034 38 39 O
primary NCT03921034 40 47 B-Modifier
tricompartment NCT03921034 48 62 I-Modifier
total NCT03921034 63 68 I-Modifier
knee NCT03921034 69 73 I-Modifier
arthroplasty NCT03921034 74 86 B-Procedure

- NCT03921034 89 90 O
Age NCT03921034 92 95 B-Age
18 NCT03921034 96 98 B-Eq-Comparison
years NCT03921034 99 104 I-Eq-Comparison
or NCT03921034 105 107 I-Eq-Comparison
older NCT03921034 108 113 I-Eq-Comparison

- NCT03921034 116 117 O
ASA NCT03921034 119 122 B-Condition
I NCT03921034 123 124 B-Eq-Comparison
- NCT03921034 125 126 I-Eq-Comparison
III NCT03921034 127 130 I-Eq-Comparison

- NCT03921034 133 134 O
Eligible NCT03921034 136 144 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03921034 145 148 I-Assertion___Assertion-Type-Value:hypothetical
spinal NCT03921034 149 155 B-Modifier
or NCT03921034 156 158 B-Or
combined NCT03921034 159 167 B-Modifier
spinal NCT03921034 168 174 I-Modifier
epidural NCT03921034 175 183 B-Procedure
anesthetic NCT03921034 184 194 I-Procedure

- NCT03921034 197 198 O
Able NCT03921034 200 204 O
to NCT03921034 205 207 O
speak NCT03921034 208 213 O
, NCT03921034 214 215 O
read NCT03921034 216 220 O
, NCT03921034 221 222 O
and NCT03921034 223 226 O
understand NCT03921034 227 237 O
English NCT03921034 238 245 O

- NCT03921034 248 249 O
Willing NCT03921034 251 258 O
to NCT03921034 259 261 O
participate NCT03921034 262 273 O
in NCT03921034 274 276 O
the NCT03921034 277 280 O
trial NCT03921034 281 286 B-Study

Exclusion NCT03921034 287 296 O
Criteria NCT03921034 297 305 O
: NCT03921034 306 307 O

- NCT03921034 311 312 O
Contraindication NCT03921034 314 330 B-Contraindication
to NCT03921034 331 333 O
regional NCT03921034 334 342 B-Procedure
anesthesia NCT03921034 343 353 I-Procedure
or NCT03921034 354 356 B-Or
peripheral NCT03921034 357 367 B-Modifier
nerve NCT03921034 368 373 B-Procedure
blocks NCT03921034 374 380 I-Procedure

- NCT03921034 383 384 O
Allergy NCT03921034 386 393 B-Allergy
to NCT03921034 394 396 O
local NCT03921034 397 402 B-Procedure
anesthetics NCT03921034 403 414 I-Procedure

- NCT03921034 417 418 O
Allergy NCT03921034 420 427 B-Allergy
to NCT03921034 428 430 O
NSAIDs NCT03921034 431 437 B-Drug

- NCT03921034 440 441 O
Chronic NCT03921034 443 450 B-Modifier
renal NCT03921034 451 456 B-Condition
insufficiency NCT03921034 457 470 I-Condition
with NCT03921034 471 475 B-And
Cr NCT03921034 476 478 B-Observation
> NCT03921034 479 480 B-Eq-Comparison
1.4 NCT03921034 481 484 I-Eq-Comparison
or NCT03921034 485 487 B-Or
GFR NCT03921034 488 491 B-Observation
< NCT03921034 492 493 B-Eq-Comparison
60 NCT03921034 494 496 I-Eq-Comparison

- NCT03921034 500 501 O
Have NCT03921034 503 507 O
chronic NCT03921034 508 515 B-Modifier
pain NCT03921034 516 520 B-Condition
that NCT03921034 521 525 O
is NCT03921034 526 528 O
not NCT03921034 529 532 B-Negation
related NCT03921034 533 540 O
to NCT03921034 541 543 O
their NCT03921034 544 549 O
knee NCT03921034 550 554 B-Modifier
joint NCT03921034 555 560 I-Modifier

- NCT03921034 563 564 O
Have NCT03921034 566 570 O
been NCT03921034 571 575 O
using NCT03921034 576 581 B-Eq-Comparison
opioids NCT03921034 582 589 B-Drug
on NCT03921034 590 592 O
a NCT03921034 593 594 O
chronic NCT03921034 595 602 B-Modifier
basis NCT03921034 603 608 O
( NCT03921034 609 610 O
daily NCT03921034 611 616 B-Eq-Comparison
or NCT03921034 617 619 B-Or
almost NCT03921034 620 626 O
daily NCT03921034 627 632 B-Eq-Comparison
opioid NCT03921034 633 639 B-Drug
use NCT03921034 640 643 O
for NCT03921034 644 647 O
3 NCT03921034 648 649 B-Eq-Comparison
months NCT03921034 650 656 I-Eq-Comparison
or NCT03921034 657 659 I-Eq-Comparison
longer NCT03921034 660 666 I-Eq-Comparison
) NCT03921034 667 668 O

- NCT03921034 672 673 I-Eq-Comparison
Have NCT03921034 675 679 O
a NCT03921034 680 681 O
pre NCT03921034 682 685 B-Eq-Comparison
- NCT03921034 686 687 O
existing NCT03921034 688 696 I-Eq-Comparison
peripheral NCT03921034 697 707 B-Condition
neuropathy NCT03921034 708 718 I-Condition
involving NCT03921034 719 728 O
the NCT03921034 729 732 O
operative NCT03921034 733 742 B-Modifier
site NCT03921034 743 747 I-Modifier

- NCT03921034 750 751 O
Body NCT03921034 753 757 B-Observation
mass NCT03921034 758 762 I-Observation
index NCT03921034 763 768 I-Observation
greater NCT03921034 769 776 B-Eq-Comparison
than NCT03921034 777 781 I-Eq-Comparison
or NCT03921034 782 784 I-Eq-Comparison
equal NCT03921034 785 790 I-Eq-Comparison
to NCT03921034 791 793 I-Eq-Comparison
40 NCT03921034 794 796 I-Eq-Comparison

Inclusion NCT03922529 0 9 O
Criteria NCT03922529 10 18 O
: NCT03922529 19 20 O

- NCT03922529 24 25 O
Age NCT03922529 27 30 B-Age
≥ NCT03922529 31 32 B-Eq-Comparison
70 NCT03922529 33 35 I-Eq-Comparison
year NCT03922529 36 40 I-Eq-Comparison

- NCT03922529 43 44 O
Eligible NCT03922529 46 54 O
cardiovascular NCT03922529 55 69 B-Condition
disease NCT03922529 70 77 I-Condition
( NCT03922529 78 79 O
CVD NCT03922529 80 83 B-Condition
) NCT03922529 84 85 O
diagnosis NCT03922529 86 95 O
( NCT03922529 96 97 O
hospitalization NCT03922529 98 113 B-Encounter
for NCT03922529 114 117 O
Acute NCT03922529 118 123 B-Condition
myocardial NCT03922529 124 134 I-Condition
infarction NCT03922529 135 145 I-Condition
( NCT03922529 146 147 O
AMI NCT03922529 148 151 B-Condition
) NCT03922529 152 153 O
/ NCT03922529 155 156 B-Or
Acute NCT03922529 157 162 B-Condition
coronary NCT03922529 163 171 I-Condition
syndrome NCT03922529 172 180 I-Condition
( NCT03922529 181 182 O
ACS NCT03922529 183 186 B-Condition
) NCT03922529 187 188 O
, NCT03922529 190 191 O
stable NCT03922529 192 198 O
Ischemic NCT03922529 199 207 B-Condition
Heart NCT03922529 208 213 I-Condition
Disease NCT03922529 214 221 I-Condition
, NCT03922529 222 223 O
revascularization NCT03922529 224 241 B-Modifier
Coronary NCT03922529 242 250 B-Procedure
artery NCT03922529 251 257 I-Procedure
bypass NCT03922529 258 264 I-Procedure
graft NCT03922529 265 270 I-Procedure
surgery NCT03922529 271 278 I-Procedure
and NCT03922529 279 282 B-Or
Percutaneous NCT03922529 283 295 B-Procedure
Coronary NCT03922529 296 304 I-Procedure
Intervention NCT03922529 305 317 I-Procedure
[ NCT03922529 318 319 O
CABG NCT03922529 320 324 B-Procedure
, NCT03922529 325 326 O
PCI NCT03922529 327 330 B-Procedure
] NCT03922529 331 332 O
, NCT03922529 334 335 O
valvular NCT03922529 336 344 B-Condition
heart NCT03922529 345 350 I-Condition
disease NCT03922529 351 358 I-Condition
[ NCT03922529 359 360 O
specifically NCT03922529 361 373 O
, NCT03922529 374 375 O
surgical NCT03922529 376 384 B-Modifier
or NCT03922529 385 387 B-Or
percutaneous NCT03922529 388 400 B-Modifier
intervention NCT03922529 401 413 B-Procedure
for NCT03922529 414 417 O
mitral NCT03922529 418 424 B-Condition
regurgitation NCT03922529 425 438 I-Condition
or NCT03922529 439 441 B-Or|Or
aortic NCT03922529 442 448 B-Condition
stenosis NCT03922529 449 457 I-Condition
] NCT03922529 458 459 O
, NCT03922529 461 462 O
or NCT03922529 463 465 O
heart NCT03922529 466 471 B-Condition
failure NCT03922529 472 479 I-Condition
( NCT03922529 480 481 O
HF NCT03922529 482 484 B-Condition
) NCT03922529 485 486 O
) NCT03922529 488 489 O

- NCT03922529 493 494 O
English NCT03922529 496 503 O
speaking NCT03922529 504 512 O

- NCT03922529 515 516 O
able NCT03922529 518 522 O
to NCT03922529 523 525 O
provide NCT03922529 526 533 O
written NCT03922529 534 541 O
informed NCT03922529 542 550 O
consent NCT03922529 551 558 O

- NCT03922529 561 562 O
able NCT03922529 564 568 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922529 569 571 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03922529 572 574 O
assessed NCT03922529 575 583 O
and NCT03922529 584 587 O
undergo NCT03922529 588 595 O
study NCT03922529 596 601 B-Study
interventions NCT03922529 602 615 O
. NCT03922529 615 616 O

Exclusion NCT03922529 618 627 O
Criteria NCT03922529 628 636 O
: NCT03922529 637 638 O

- NCT03922529 642 643 O
Unstable NCT03922529 645 653 O
medical NCT03922529 654 661 B-Condition
condition NCT03922529 662 671 I-Condition
as NCT03922529 672 674 O
indicated NCT03922529 675 684 O
by NCT03922529 685 687 O
history NCT03922529 688 695 O
, NCT03922529 696 697 O
physical NCT03922529 698 706 B-Procedure
exam NCT03922529 707 711 I-Procedure
, NCT03922529 712 713 O
and NCT03922529 714 717 B-Or
/ NCT03922529 718 719 I-Or
or NCT03922529 720 722 I-Or
laboratory NCT03922529 723 733 B-Observation
findings NCT03922529 734 742 I-Observation

- NCT03922529 745 746 O
Presence NCT03922529 748 756 O
of NCT03922529 757 759 O
non NCT03922529 760 763 B-Exception
- NCT03922529 764 765 O
CVD NCT03922529 766 769 B-Condition
conditions NCT03922529 770 780 B-Condition
likely NCT03922529 781 787 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922529 788 790 B-Eq-Comparison
be NCT03922529 791 793 I-Eq-Comparison
fatal NCT03922529 794 799 B-Death
within NCT03922529 800 806 B-Eq-Comparison
12 NCT03922529 807 809 I-Eq-Comparison
months NCT03922529 810 816 I-Eq-Comparison
( NCT03922529 817 818 O
e. NCT03922529 819 821 O
g. NCT03922529 822 824 O
, NCT03922529 825 826 O
metastatic NCT03922529 827 837 B-Modifier
cancer NCT03922529 838 844 B-Condition
) NCT03922529 845 846 O

- NCT03922529 850 851 O
Severe NCT03922529 853 859 O
cognitive NCT03922529 860 869 B-Condition
impairment NCT03922529 870 880 I-Condition
: NCT03922529 881 882 O
Short NCT03922529 883 888 B-Observation
Blessed NCT03922529 889 896 I-Observation
screening NCT03922529 897 906 I-Observation
with NCT03922529 907 911 O
a NCT03922529 912 913 O
score NCT03922529 914 919 O
of NCT03922529 920 922 O
13 NCT03922529 923 925 B-Eq-Comparison
or NCT03922529 926 928 I-Eq-Comparison|Or
greater NCT03922529 929 936 I-Eq-Comparison
or NCT03922529 937 939 O
can NCT03922529 940 943 O
not NCT03922529 943 946 O
consent NCT03922529 947 954 O
( NCT03922529 955 956 O
as NCT03922529 957 959 O
indicated NCT03922529 960 969 O
by NCT03922529 970 972 O
medical NCT03922529 973 980 O
record NCT03922529 981 987 O
) NCT03922529 988 989 O

- NCT03922529 993 994 I-Procedure
Long NCT03922529 996 1000 B-Procedure
- NCT03922529 1001 1002 O
term NCT03922529 1003 1007 I-Procedure
care NCT03922529 1008 1012 I-Procedure
resident NCT03922529 1013 1021 O
at NCT03922529 1022 1024 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03922529 1025 1034 B-Encounter
with NCT03922529 1035 1039 B-And
no NCT03922529 1040 1042 B-Negation
plans NCT03922529 1043 1048 B-Assertion___Assertion-Type-Value:intention
to NCT03922529 1049 1051 O
return NCT03922529 1052 1058 O
to NCT03922529 1059 1061 O
independent NCT03922529 1062 1073 B-Observation
living NCT03922529 1074 1080 I-Observation

- NCT03922529 1083 1084 O
anticipates NCT03922529 1086 1097 B-Assertion___Assertion-Type-Value:hypothetical
inability NCT03922529 1098 1107 B-Negation
to NCT03922529 1108 1110 O
return NCT03922529 1111 1117 O
for NCT03922529 1118 1121 O
required NCT03922529 1122 1130 O
reassessments NCT03922529 1131 1144 B-Procedure
at NCT03922529 1145 1147 O
3 NCT03922529 1148 1149 B-Eq-Comparison
, NCT03922529 1150 1151 O
6 NCT03922529 1152 1153 I-Eq-Comparison
and NCT03922529 1154 1157 I-Eq-Comparison
12 NCT03922529 1158 1160 I-Eq-Comparison
months NCT03922529 1161 1167 I-Eq-Comparison

- NCT03922529 1170 1171 I-Procedure
long NCT03922529 1173 1177 B-Procedure
- NCT03922529 1178 1179 O
term NCT03922529 1180 1184 I-Procedure
care NCT03922529 1185 1189 I-Procedure
residents NCT03922529 1190 1199 O
at NCT03922529 1200 1202 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03922529 1203 1212 B-Encounter
with NCT03922529 1213 1217 B-And
no NCT03922529 1218 1220 B-Negation
plans NCT03922529 1221 1226 B-Assertion___Assertion-Type-Value:intention
to NCT03922529 1227 1229 O
return NCT03922529 1230 1236 O
to NCT03922529 1237 1239 O
independent NCT03922529 1240 1251 B-Observation
living NCT03922529 1252 1258 I-Observation
. NCT03922529 1258 1259 O

Inclusion NCT03926767 0 9 O
Criteria NCT03926767 10 18 O
: NCT03926767 19 20 O

- NCT03926767 24 25 O
A NCT03926767 27 28 O
diagnosis NCT03926767 29 38 O
of NCT03926767 39 41 O
painful NCT03926767 42 49 B-Modifier
TMD NCT03926767 50 53 B-Condition
Research NCT03926767 54 62 O
Diagnostic NCT03926767 63 73 O
Criteria NCT03926767 74 82 O
for NCT03926767 83 86 O
TMD NCT03926767 87 90 O
( NCT03926767 91 92 O
RDC NCT03926767 93 96 O
/ NCT03926767 97 98 O
TMD NCT03926767 99 102 O
) NCT03926767 103 104 O

- NCT03926767 108 109 O
A NCT03926767 111 112 O
history NCT03926767 113 120 B-Eq-Comparison
of NCT03926767 121 123 O
orofacial NCT03926767 124 133 B-Modifier
pain NCT03926767 134 138 B-Condition
at NCT03926767 139 141 B-Eq-Comparison
least NCT03926767 142 147 I-Eq-Comparison
three NCT03926767 148 153 I-Eq-Comparison
months NCT03926767 154 160 I-Eq-Comparison
prior NCT03926767 161 166 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926767 167 169 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03926767 170 173 O
study NCT03926767 174 179 B-Study
( NCT03926767 180 181 O
TREEDE NCT03926767 182 188 O
et NCT03926767 189 191 O
al NCT03926767 192 194 O
, NCT03926767 195 196 O
2015 NCT03926767 197 201 O
) NCT03926767 202 203 O

- NCT03926767 211 212 O
age NCT03926767 214 217 B-Age
ranging NCT03926767 218 225 O
between NCT03926767 226 233 O
18 NCT03926767 234 236 B-Eq-Comparison
to NCT03926767 237 239 I-Eq-Comparison
55 NCT03926767 240 242 I-Eq-Comparison
years NCT03926767 243 248 I-Eq-Comparison
, NCT03926767 249 250 O
considering NCT03926767 251 262 O
the NCT03926767 263 266 O
greater NCT03926767 267 274 O
prevalence NCT03926767 275 285 O
of NCT03926767 286 288 O
TMD NCT03926767 289 292 O
associated NCT03926767 293 303 O
with NCT03926767 304 308 O
this NCT03926767 309 313 O
age NCT03926767 314 317 O
period NCT03926767 318 324 O
. NCT03926767 324 325 O

Exclusion NCT03926767 327 336 O
Criteria NCT03926767 337 345 O
: NCT03926767 346 347 O

- NCT03926767 351 352 O
Patients NCT03926767 354 362 O
with NCT03926767 363 367 O
illiteracy NCT03926767 368 378 B-Condition
, NCT03926767 379 380 O
severe NCT03926767 381 387 O
depression NCT03926767 388 398 B-Condition
( NCT03926767 399 400 O
medical NCT03926767 401 408 O
diagnoses NCT03926767 409 418 O
) NCT03926767 419 420 O
, NCT03926767 422 423 O
clinical NCT03926767 424 432 O
history NCT03926767 433 440 B-Eq-Comparison
of NCT03926767 441 443 O
tumors NCT03926767 444 450 B-Condition
in NCT03926767 451 453 O
the NCT03926767 454 457 O
craniofacial NCT03926767 458 470 B-Modifier
region NCT03926767 471 477 I-Modifier
, NCT03926767 478 479 O
patients NCT03926767 480 488 O
in NCT03926767 489 491 O
the NCT03926767 492 495 O
post NCT03926767 496 500 B-Temporal-Connection___Temporal-Connection-Type-Value:after
dental NCT03926767 501 507 B-Procedure
surgery NCT03926767 508 515 I-Procedure
period NCT03926767 516 522 O
or NCT03926767 523 525 B-Or
submitted NCT03926767 526 535 O
to NCT03926767 536 538 O
previous NCT03926767 539 547 B-Eq-Comparison
physical NCT03926767 548 556 B-Procedure
therapy NCT03926767 557 564 I-Procedure
in NCT03926767 565 567 O
the NCT03926767 568 571 O
past NCT03926767 572 576 B-Eq-Comparison
year NCT03926767 577 581 I-Eq-Comparison
or NCT03926767 582 584 B-Or
to NCT03926767 585 587 O
any NCT03926767 588 591 O
health NCT03926767 592 598 B-Modifier
/ NCT03926767 599 600 B-Or
pain NCT03926767 601 605 B-Modifier
education NCT03926767 606 615 B-Procedure
strategy NCT03926767 616 624 I-Procedure
, NCT03926767 625 626 O
pregnant NCT03926767 627 635 B-Condition
women NCT03926767 636 641 O
, NCT03926767 642 643 O
infections NCT03926767 644 654 B-Condition
, NCT03926767 655 656 O
whiplash NCT03926767 657 665 B-Condition
- NCT03926767 666 667 O
associated NCT03926767 668 678 O
disorders NCT03926767 679 688 B-Condition
and NCT03926767 689 692 B-Or
with NCT03926767 693 697 O
chronic NCT03926767 698 705 B-Modifier
degenerative NCT03926767 706 718 I-Modifier
inflammatory NCT03926767 719 731 I-Modifier
or NCT03926767 732 734 B-Or
neurologic NCT03926767 735 745 B-Modifier
disorders NCT03926767 746 755 B-Condition
were NCT03926767 756 760 O
excluded NCT03926767 761 769 B-Negation
from NCT03926767 770 774 O
this NCT03926767 775 779 O
study NCT03926767 780 785 B-Study
. NCT03926767 785 786 O
Patients NCT03926767 788 796 O
will NCT03926767 797 801 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03926767 802 804 I-Assertion___Assertion-Type-Value:hypothetical
instructed NCT03926767 805 815 O
to NCT03926767 816 818 O
not NCT03926767 819 822 B-Negation
use NCT03926767 823 826 O
pain NCT03926767 827 831 B-Condition
relief NCT03926767 832 838 O
medications NCT03926767 839 850 B-Drug
during NCT03926767 851 857 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926767 858 861 O
intervention NCT03926767 862 874 B-Study
period NCT03926767 875 881 O
of NCT03926767 882 884 O
this NCT03926767 885 889 O
trial NCT03926767 890 895 O
and NCT03926767 896 899 O
if NCT03926767 900 902 O
any NCT03926767 903 906 O
medication NCT03926767 907 917 O
be NCT03926767 918 920 O
used NCT03926767 921 925 O
, NCT03926767 926 927 O
participants NCT03926767 928 940 O
will NCT03926767 941 945 O
be NCT03926767 946 948 O
encouraged NCT03926767 949 959 O
to NCT03926767 960 962 O
report NCT03926767 963 969 O
. NCT03926767 969 970 O


Inclusion NCT03920670 0 9 O
Criteria NCT03920670 10 18 O

- NCT03920670 21 22 O
Age NCT03920670 24 27 B-Age
> NCT03920670 28 29 B-Eq-Comparison
or NCT03920670 30 32 I-Eq-Comparison
= NCT03920670 33 34 I-Eq-Comparison
18 NCT03920670 35 37 I-Eq-Comparison
years NCT03920670 38 43 I-Eq-Comparison
old NCT03920670 44 47 O

- NCT03920670 50 51 O
Patients NCT03920670 53 61 O
willing NCT03920670 62 69 O
to NCT03920670 70 72 O
participate NCT03920670 73 84 O
and NCT03920670 85 88 O
provide NCT03920670 89 96 O
an NCT03920670 97 99 O
informed NCT03920670 100 108 O
consent NCT03920670 109 116 O

- NCT03920670 119 120 O
Patients NCT03920670 122 130 O
undergoing NCT03920670 131 141 B-Eq-Comparison
an NCT03920670 142 144 O
elective NCT03920670 145 153 B-Modifier
surgical NCT03920670 154 162 B-Procedure
procedure NCT03920670 163 172 I-Procedure
that NCT03920670 173 177 O
requires NCT03920670 178 186 B-Assertion___Assertion-Type-Value:hypothetical
use NCT03920670 187 190 O
of NCT03920670 191 193 O
non NCT03920670 194 197 B-Drug
- NCT03920670 198 199 I-Drug
depolarizing NCT03920670 200 212 I-Drug
NMBA NCT03920670 213 217 I-Drug
agents NCT03920670 218 224 I-Drug
administered NCT03920670 225 237 O
intraoperatively NCT03920670 238 254 B-Modifier
. NCT03920670 254 255 O

Exclusion NCT03920670 257 266 O
Criteria NCT03920670 267 275 O

- NCT03920670 278 279 O
Patients NCT03920670 281 289 O
with NCT03920670 290 294 O
unilateral NCT03920670 295 305 B-Condition
disorders NCT03920670 306 315 I-Condition
, NCT03920670 316 317 O
such NCT03920670 318 322 O
as NCT03920670 323 325 O
stroke NCT03920670 326 332 B-Condition
, NCT03920670 333 334 O
carpal NCT03920670 335 341 B-Condition
tunnel NCT03920670 342 348 I-Condition
syndrome NCT03920670 349 357 I-Condition
, NCT03920670 358 359 O
broken NCT03920670 360 366 B-Condition
wrist NCT03920670 367 372 B-Modifier
with NCT03920670 373 377 B-And
nerve NCT03920670 378 383 B-Modifier
damage NCT03920670 384 390 I-Modifier
, NCT03920670 391 392 O
Dupuytren NCT03920670 393 402 B-Condition
contracture NCT03920670 403 414 I-Condition
, NCT03920670 415 416 O
or NCT03920670 417 419 B-Or
any NCT03920670 420 423 O
similar NCT03920670 424 431 O
wrist NCT03920670 432 437 B-Modifier
injury NCT03920670 438 444 B-Condition
. NCT03920670 444 445 O

- NCT03920670 449 450 O
Patients NCT03920670 452 460 O
with NCT03920670 461 465 O
systemic NCT03920670 466 474 B-Modifier
neuromuscular NCT03920670 475 488 B-Condition
diseases NCT03920670 489 497 I-Condition
such NCT03920670 498 502 O
as NCT03920670 503 505 O
myasthenia NCT03920670 506 516 B-Condition
gravis NCT03920670 517 523 I-Condition

- NCT03920670 526 527 O
Patients NCT03920670 529 537 O
with NCT03920670 538 542 O
significant NCT03920670 543 554 O
organ NCT03920670 555 560 B-Condition
dysfunction NCT03920670 561 572 I-Condition
that NCT03920670 573 577 O
can NCT03920670 578 581 B-Assertion___Assertion-Type-Value:hypothetical
significantly NCT03920670 582 595 O
affect NCT03920670 596 602 O
pharmacokinetics NCT03920670 603 619 O
of NCT03920670 620 622 O
neuromuscular NCT03920670 623 636 B-Modifier
blocking NCT03920670 637 645 I-Modifier
and NCT03920670 646 649 B-Or
reversal NCT03920670 650 658 B-Modifier
agents NCT03920670 659 665 B-Drug
, NCT03920670 666 667 O
i. NCT03920670 668 670 O
e. NCT03920670 671 673 O
, NCT03920670 674 675 O
severe NCT03920670 676 682 O
renal NCT03920670 683 688 B-Condition
impairment NCT03920670 689 699 I-Condition
or NCT03920670 700 702 B-Or
end NCT03920670 703 706 B-Modifier
- NCT03920670 707 708 I-Modifier
stage NCT03920670 709 714 I-Modifier
liver NCT03920670 715 720 B-Condition
disease NCT03920670 721 728 I-Condition
. NCT03920670 728 729 O

Inclusion NCT03929640 0 9 O
Criteria NCT03929640 10 18 O
: NCT03929640 19 20 O

- NCT03929640 24 25 O
Pregnant NCT03929640 27 35 B-Condition
women NCT03929640 36 41 O
at NCT03929640 42 44 B-Eq-Comparison
least NCT03929640 45 50 I-Eq-Comparison
18 NCT03929640 51 53 I-Eq-Comparison
years NCT03929640 54 59 I-Eq-Comparison
of NCT03929640 60 62 O
age NCT03929640 63 66 B-Age

- NCT03929640 69 70 O
Planned NCT03929640 72 79 B-Eq-Comparison
delivery NCT03929640 80 88 B-Procedure
via NCT03929640 89 92 O
C NCT03929640 93 94 B-Procedure
- NCT03929640 95 96 I-Procedure
section NCT03929640 97 104 I-Procedure

- NCT03929640 107 108 O
Pfannenstiel NCT03929640 110 122 B-Modifier
skin NCT03929640 123 127 B-Procedure
incision NCT03929640 128 136 I-Procedure

- NCT03929640 139 140 O
Lower NCT03929640 142 147 B-Modifier
uterine NCT03929640 148 155 I-Modifier
segment NCT03929640 156 163 I-Modifier
transverse NCT03929640 164 174 I-Modifier
hysterotomy NCT03929640 175 186 B-Procedure

- NCT03929640 189 190 O
English NCT03929640 192 199 O
speaking NCT03929640 200 208 O

Exclusion NCT03929640 209 218 O
Criteria NCT03929640 219 227 O
: NCT03929640 228 229 O

- NCT03929640 233 234 O
Major NCT03929640 236 241 O
intra NCT03929640 242 247 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03929640 248 249 O
operative NCT03929640 250 259 B-Procedure
or NCT03929640 260 262 B-Or
post NCT03929640 263 267 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03929640 268 269 O
- NCT03929640 271 272 O
operative NCT03929640 273 282 B-Procedure
complication NCT03929640 283 295 B-Condition
such NCT03929640 296 300 O
that NCT03929640 301 305 O
clinician NCT03929640 306 315 O
recommends NCT03929640 316 326 B-Assertion___Assertion-Type-Value:hypothetical
patient NCT03929640 327 334 O
should NCT03929640 335 341 O
not NCT03929640 342 345 B-Negation
receive NCT03929640 346 353 O
non NCT03929640 354 357 B-Drug
- NCT03929640 358 359 I-Drug
steroidal NCT03929640 360 369 I-Drug
anti NCT03929640 370 374 I-Drug
- NCT03929640 375 376 O
inflammatory NCT03929640 377 389 I-Drug
drugs NCT03929640 390 395 I-Drug
or NCT03929640 396 398 B-Or
that NCT03929640 399 403 O
patient NCT03929640 404 411 O
requires NCT03929640 412 420 B-Assertion___Assertion-Type-Value:hypothetical
acetaminophen NCT03929640 421 434 B-Drug
to NCT03929640 435 437 O
treat NCT03929640 438 443 O
fever NCT03929640 444 449 B-Condition
( NCT03929640 450 451 O
ie NCT03929640 452 454 O
suspected NCT03929640 455 464 B-Assertion___Assertion-Type-Value:possible
endometritis NCT03929640 465 477 B-Condition
) NCT03929640 478 479 O

- NCT03929640 483 484 O
Unplanned NCT03929640 486 495 B-Modifier
surgery NCT03929640 496 503 B-Procedure
( NCT03929640 504 505 O
hysterectomy NCT03929640 506 518 B-Procedure
, NCT03929640 519 520 O
bowel NCT03929640 521 526 B-Modifier
/ NCT03929640 527 528 B-Or
bladder NCT03929640 529 536 B-Modifier
repair NCT03929640 537 543 B-Procedure
) NCT03929640 544 545 O

- NCT03929640 549 550 O
Allergy NCT03929640 552 559 B-Allergy
or NCT03929640 560 562 B-Or
contraindication NCT03929640 563 579 B-Contraindication
to NCT03929640 580 582 O
study NCT03929640 583 588 B-Study
medication NCT03929640 589 599 B-Drug

- NCT03929640 602 603 O
Non NCT03929640 605 608 B-Negation
- NCT03929640 609 610 O
English NCT03929640 611 618 O
speaking NCT03929640 619 627 O

- NCT03929640 630 631 O
Inability NCT03929640 633 642 O
to NCT03929640 643 645 O
provide NCT03929640 646 653 O
informed NCT03929640 654 662 O
consent NCT03929640 663 670 O

- NCT03929640 673 674 O
History NCT03929640 676 683 B-Eq-Comparison
of NCT03929640 684 686 O
opioid NCT03929640 687 693 B-Modifier
, NCT03929640 694 695 O
other NCT03929640 696 701 B-Other
illicit NCT03929640 702 709 B-Modifier
substance NCT03929640 710 719 B-Condition
, NCT03929640 720 721 O
or NCT03929640 722 724 B-Or
alcohol NCT03929640 725 732 B-Condition
use NCT03929640 733 736 I-Condition
disorder NCT03929640 737 745 I-Condition
either NCT03929640 746 752 O
before NCT03929640 753 759 B-Temporal-Connection___Temporal-Connection-Type-Value:before
or NCT03929640 760 762 B-Or
during NCT03929640 763 769 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pregnancy NCT03929640 770 779 B-Condition

- NCT03929640 782 783 O
Severe NCT03929640 785 791 O
renal NCT03929640 792 797 B-Modifier
or NCT03929640 798 800 B-Or
hepatic NCT03929640 801 808 B-Modifier
impairment NCT03929640 809 819 B-Condition

Inclusion NCT03927651 0 9 O
Criteria NCT03927651 10 18 O
: NCT03927651 19 20 O

- NCT03927651 24 25 O
Patients NCT03927651 27 35 O
attending NCT03927651 36 45 O
a NCT03927651 46 47 O
pre NCT03927651 48 51 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03927651 52 53 O
- NCT03927651 55 56 O
operative NCT03927651 57 66 B-Procedure
visit NCT03927651 67 72 B-Encounter
at NCT03927651 73 75 O
the NCT03927651 76 79 O
Center NCT03927651 80 86 O
for NCT03927651 87 90 O
Comprehensive NCT03927651 91 104 O
Gynecology NCT03927651 105 115 O
who NCT03927651 116 119 B-And
will NCT03927651 120 124 B-Eq-Comparison
undergo NCT03927651 125 132 O
surgery NCT03927651 133 140 B-Procedure
. NCT03927651 140 141 O

Exclusion NCT03927651 143 152 O
Criteria NCT03927651 153 161 O
: NCT03927651 162 163 O

- NCT03927651 167 168 O
Not NCT03927651 170 173 O
able NCT03927651 174 178 O
to NCT03927651 179 181 O
comprehend NCT03927651 182 192 O
and NCT03927651 193 196 O
sign NCT03927651 197 201 O
a NCT03927651 202 203 O
written NCT03927651 204 211 O
consent NCT03927651 212 219 O

- NCT03927651 222 223 O
Patients NCT03927651 225 233 O
with NCT03927651 234 238 O
a NCT03927651 239 240 O
history NCT03927651 241 248 B-Eq-Comparison
of NCT03927651 249 251 O
allergy NCT03927651 252 259 B-Allergy
to NCT03927651 260 262 O
iodides NCT03927651 263 270 O

- NCT03927651 273 274 O
Patients NCT03927651 276 284 O
history NCT03927651 285 292 B-Eq-Comparison
of NCT03927651 293 295 O
renal NCT03927651 296 301 B-Condition
failure NCT03927651 302 309 I-Condition
or NCT03927651 310 312 B-Or
uremia NCT03927651 313 319 B-Condition
, NCT03927651 320 321 O
and NCT03927651 322 325 B-And
those NCT03927651 326 331 O
on NCT03927651 332 334 B-Eq-Comparison
dialysis NCT03927651 335 343 B-Procedure

Inclusion NCT03926598 0 9 O
Criteria NCT03926598 10 18 O
: NCT03926598 19 20 O

- NCT03926598 24 25 O
Existing NCT03926598 27 35 O
patients NCT03926598 36 44 O
of NCT03926598 45 47 O
Children NCT03926598 48 56 O
's NCT03926598 56 58 O
Healthcare NCT03926598 59 69 O
of NCT03926598 70 72 O
Atlanta NCT03926598 73 80 O
( NCT03926598 81 82 O
CHOA NCT03926598 83 87 O
) NCT03926598 88 89 O
with NCT03926598 90 94 B-And
Type NCT03926598 95 99 B-Condition
2 NCT03926598 100 101 I-Condition
Diabetes NCT03926598 102 110 I-Condition
that NCT03926598 111 115 O
are NCT03926598 116 119 B-And
12 NCT03926598 120 122 B-Eq-Comparison
or NCT03926598 123 125 I-Eq-Comparison
older NCT03926598 126 131 I-Age|Eq-Comparison
at NCT03926598 132 134 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926598 135 138 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03926598 139 143 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03926598 144 146 O
participation NCT03926598 147 160 B-Study
or NCT03926598 161 163 O
caretakers NCT03926598 164 174 O
of NCT03926598 175 177 O
existing NCT03926598 178 186 O
patients NCT03926598 187 195 O
of NCT03926598 196 198 O
CHOA NCT03926598 199 203 O
with NCT03926598 204 208 O
Type NCT03926598 209 213 B-Condition
2 NCT03926598 214 215 I-Condition
Diabetes NCT03926598 216 224 I-Condition

- NCT03926598 227 228 O
Front NCT03926598 230 235 O
desk NCT03926598 236 240 O
staff NCT03926598 241 246 O

- NCT03926598 249 250 O
Nurses NCT03926598 252 258 B-Provider
at NCT03926598 259 261 O
CHOA NCT03926598 262 266 O

- NCT03926598 269 270 O
Certified NCT03926598 272 281 O
Diabetes NCT03926598 282 290 O
Educators NCT03926598 291 300 O
at NCT03926598 301 303 O
CHOA NCT03926598 304 308 O

- NCT03926598 311 312 O
Physicians NCT03926598 314 324 B-Provider
working NCT03926598 325 332 O
at NCT03926598 333 335 O
CHOA NCT03926598 336 340 O

- NCT03926598 343 344 O
Participants NCT03926598 346 358 O
must NCT03926598 359 363 O
also NCT03926598 364 368 O
be NCT03926598 369 371 O
fluent NCT03926598 372 378 O
in NCT03926598 379 381 O
English NCT03926598 382 389 O
, NCT03926598 390 391 O
either NCT03926598 392 398 O
as NCT03926598 399 401 O
a NCT03926598 402 403 O
first NCT03926598 404 409 O
or NCT03926598 410 412 O
secondary NCT03926598 413 422 O
language NCT03926598 423 431 O
, NCT03926598 432 433 O
as NCT03926598 434 436 O
the NCT03926598 437 440 O
Guide NCT03926598 441 446 O
- NCT03926598 447 448 O
To NCT03926598 449 451 O
- NCT03926598 452 453 O
Goals NCT03926598 454 459 O
app NCT03926598 460 463 O
is NCT03926598 464 466 O
in NCT03926598 467 469 O
English NCT03926598 470 477 O
. NCT03926598 477 478 O

Exclusion NCT03926598 480 489 O
Criteria NCT03926598 490 498 O
: NCT03926598 499 500 O

- NCT03926598 504 505 O
Individuals NCT03926598 507 518 O
that NCT03926598 519 523 O
are NCT03926598 524 527 O
using NCT03926598 528 533 B-Eq-Comparison
a NCT03926598 534 535 O
care NCT03926598 536 540 B-Procedure
coordination NCT03926598 541 553 I-Procedure
tool NCT03926598 554 558 I-Procedure
other NCT03926598 559 564 B-Exception
than NCT03926598 565 569 I-Exception
GTG NCT03926598 570 573 B-Procedure
to NCT03926598 574 576 O
translate NCT03926598 577 586 O
ADA NCT03926598 587 590 O
clinical NCT03926598 591 599 O
standards NCT03926598 600 609 O
of NCT03926598 610 612 O
care NCT03926598 613 617 O
for NCT03926598 618 621 O
children NCT03926598 622 630 O
with NCT03926598 631 635 O
T2D NCT03926598 636 639 B-Condition
during NCT03926598 640 646 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926598 647 650 O
study NCT03926598 651 656 B-Study
period NCT03926598 657 663 O
will NCT03926598 664 668 O
be NCT03926598 669 671 O
excluded NCT03926598 672 680 B-Negation
from NCT03926598 681 685 O
this NCT03926598 686 690 O
study NCT03926598 691 696 O
in NCT03926598 697 699 B-Assertion___Assertion-Type-Value:hypothetical
order NCT03926598 700 705 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03926598 706 708 I-Assertion___Assertion-Type-Value:hypothetical
avoid NCT03926598 709 714 O
confounding NCT03926598 715 726 O
factors NCT03926598 727 734 O
. NCT03926598 734 735 O
Examples NCT03926598 737 745 O
of NCT03926598 746 748 O
care NCT03926598 749 753 O
coordination NCT03926598 754 766 O
tools NCT03926598 767 772 O
include NCT03926598 773 780 O
products NCT03926598 781 789 O
that NCT03926598 790 794 O
have NCT03926598 795 799 O
the NCT03926598 800 803 O
capabilities NCT03926598 804 816 O
to NCT03926598 817 819 O
send NCT03926598 820 824 O
and NCT03926598 825 828 O
receive NCT03926598 829 836 O
electronic NCT03926598 837 847 O
messages NCT03926598 848 856 O
to NCT03926598 857 859 O
the NCT03926598 860 863 O
care NCT03926598 864 868 O
team NCT03926598 869 873 O
, NCT03926598 874 875 O
receive NCT03926598 876 883 O
and NCT03926598 884 887 O
discuss NCT03926598 888 895 O
care NCT03926598 896 900 O
plans NCT03926598 901 906 O
, NCT03926598 907 908 O
and NCT03926598 909 912 O
create NCT03926598 913 919 O
and NCT03926598 920 923 O
share NCT03926598 924 929 O
health NCT03926598 930 936 O
logs NCT03926598 937 941 O
. NCT03926598 941 942 O

Participant NCT03922932 0 11 O
- NCT03922932 12 13 O
Related NCT03922932 14 21 O
Inclusion NCT03922932 22 31 O
Criteria NCT03922932 32 40 O
: NCT03922932 41 42 O

I. NCT03922932 44 46 O
All NCT03922932 48 51 O
Diabetics NCT03922932 52 61 B-Condition
( NCT03922932 62 63 O
Groups NCT03922932 64 70 O
A NCT03922932 71 72 O
, NCT03922932 73 74 O
B NCT03922932 75 76 O
, NCT03922932 77 78 O
C NCT03922932 79 80 O
) NCT03922932 81 82 O

- NCT03922932 86 87 O
Type NCT03922932 89 93 B-Condition
1 NCT03922932 94 95 I-Condition
diabetes NCT03922932 96 104 I-Condition
of NCT03922932 105 107 O
at NCT03922932 108 110 B-Eq-Comparison
least NCT03922932 111 116 I-Eq-Comparison
5 NCT03922932 117 118 I-Eq-Comparison
years NCT03922932 119 124 I-Eq-Comparison
duration NCT03922932 125 133 O
or NCT03922932 134 136 B-Or

- NCT03922932 139 140 O
Type NCT03922932 142 146 B-Condition
2 NCT03922932 147 148 I-Condition
diabetes NCT03922932 149 157 I-Condition
of NCT03922932 158 160 O
any NCT03922932 161 164 O
duration NCT03922932 165 173 O
II NCT03922932 174 176 O
. NCT03922932 176 177 O
Group NCT03922932 179 184 O
B NCT03922932 185 186 O

- NCT03922932 189 190 O
Able NCT03922932 192 196 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922932 197 199 I-Assertion___Assertion-Type-Value:hypothetical
return NCT03922932 200 206 O
for NCT03922932 207 210 O
follow NCT03922932 211 217 B-Encounter
- NCT03922932 218 219 I-Encounter
up NCT03922932 220 222 I-Encounter
over NCT03922932 223 227 B-Eq-Comparison
3 NCT03922932 228 229 I-Eq-Comparison
years NCT03922932 230 235 I-Eq-Comparison

Participant NCT03922932 236 247 O
- NCT03922932 248 249 O
Related NCT03922932 250 257 O
Exclusion NCT03922932 258 267 O
Criteria NCT03922932 268 276 O
: NCT03922932 277 278 O

I. NCT03922932 280 282 O
Group NCT03922932 284 289 O
B NCT03922932 290 291 O

- NCT03922932 294 295 O
Significant NCT03922932 297 308 O
medical NCT03922932 309 316 B-Condition
condition NCT03922932 317 326 I-Condition
that NCT03922932 327 331 O
would NCT03922932 332 337 B-Assertion___Assertion-Type-Value:hypothetical
make NCT03922932 338 342 O
long NCT03922932 343 347 O
- NCT03922932 348 349 I-Encounter
term NCT03922932 350 354 O
follow NCT03922932 355 361 B-Encounter
- NCT03922932 362 363 O
up NCT03922932 364 366 I-Encounter
difficult NCT03922932 367 376 B-Negation
II NCT03922932 377 379 O
. NCT03922932 379 380 O
Controls NCT03922932 382 390 O
( NCT03922932 391 392 O
Group NCT03922932 393 398 O
D NCT03922932 399 400 O
) NCT03922932 401 402 O

- NCT03922932 406 407 O
Any NCT03922932 409 412 O
medical NCT03922932 413 420 B-Condition
problems NCT03922932 421 429 I-Condition
associated NCT03922932 430 440 O
with NCT03922932 441 445 O
retinal NCT03922932 446 453 B-Condition
vascular NCT03922932 454 462 I-Condition
abnormalities NCT03922932 463 476 I-Condition
( NCT03922932 477 478 O
i. NCT03922932 479 481 O
e. NCT03922932 482 484 O
, NCT03922932 485 486 O
hypertension NCT03922932 487 499 B-Condition
, NCT03922932 500 501 O
systemic NCT03922932 502 510 B-Condition
vasculitis NCT03922932 511 521 I-Condition
, NCT03922932 522 523 O
carotid NCT03922932 524 531 B-Condition
insufficiency NCT03922932 532 545 I-Condition
, NCT03922932 546 547 O
etc NCT03922932 548 551 O
. NCT03922932 551 552 O
) NCT03922932 553 554 O

Eye NCT03922932 556 559 O
- NCT03922932 560 561 O
Related NCT03922932 562 569 O
Inclusion NCT03922932 570 579 O
Criteria NCT03922932 580 588 O
: NCT03922932 589 590 O

I. NCT03922932 592 594 O
Group NCT03922932 596 601 O
A NCT03922932 602 603 O
: NCT03922932 604 605 O

- NCT03922932 609 610 O
Presence NCT03922932 612 620 O
of NCT03922932 621 623 O
active NCT03922932 624 630 B-Eq-Comparison
neovascularization NCT03922932 631 649 B-Condition
, NCT03922932 650 651 O
with NCT03922932 652 656 B-Assertion___Assertion-Type-Value:hypothetical
or NCT03922932 657 659 I-Assertion___Assertion-Type-Value:hypothetical
without NCT03922932 660 667 O
prior NCT03922932 668 673 B-Eq-Comparison
treatment NCT03922932 674 683 B-Procedure

- NCT03922932 686 687 O
Presence NCT03922932 689 697 O
of NCT03922932 698 700 O
involuted NCT03922932 701 710 B-Modifier
fibrovascular NCT03922932 711 724 B-Condition
proliferans NCT03922932 725 736 I-Condition

II NCT03922932 737 739 O
. NCT03922932 739 740 O
Group NCT03922932 742 747 O
B NCT03922932 748 749 O
: NCT03922932 750 751 O

- NCT03922932 755 756 O
NPDR NCT03922932 758 762 B-Condition
of NCT03922932 763 765 O
any NCT03922932 766 769 O
severity NCT03922932 770 778 O
as NCT03922932 779 781 O
defined NCT03922932 782 789 O
by NCT03922932 790 792 O
the NCT03922932 793 796 O
International NCT03922932 797 810 B-Observation
Clinical NCT03922932 811 819 I-Observation
Diabetic NCT03922932 820 828 I-Observation
Retinopathy NCT03922932 829 840 I-Observation
Severity NCT03922932 841 849 I-Observation
Scale NCT03922932 850 855 I-Observation

III NCT03922932 856 859 O
. NCT03922932 859 860 O
Groups NCT03922932 862 868 O
C NCT03922932 869 870 O
& NCT03922932 871 872 O
D NCT03922932 873 874 O
: NCT03922932 875 876 O

- NCT03922932 880 881 O
No NCT03922932 883 885 B-Negation
evidence NCT03922932 886 894 O
of NCT03922932 895 897 O
diabetic NCT03922932 898 906 B-Condition
retinopathy NCT03922932 907 918 I-Condition

IV NCT03922932 919 921 O
. NCT03922932 921 922 O
Group NCT03922932 924 929 O
ME NCT03922932 930 932 O
: NCT03922932 933 934 O

- NCT03922932 938 939 I-Modifier
Presence NCT03922932 941 949 O
of NCT03922932 950 952 O
center NCT03922932 953 959 B-Modifier
- NCT03922932 960 961 O
involving NCT03922932 962 971 I-Modifier
macular NCT03922932 972 979 B-Condition
edema NCT03922932 980 985 I-Condition
requiring NCT03922932 986 995 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03922932 996 1005 B-Procedure

Eye NCT03922932 1006 1009 O
- NCT03922932 1010 1011 O
Related NCT03922932 1012 1019 O
Exclusion NCT03922932 1020 1029 O
Criteria NCT03922932 1030 1038 O
: NCT03922932 1039 1040 O
( NCT03922932 1041 1042 O
Applies NCT03922932 1043 1050 O
to NCT03922932 1051 1053 O
study NCT03922932 1054 1059 O
eye NCT03922932 1060 1063 O
only NCT03922932 1064 1068 O
. NCT03922932 1068 1069 O
May NCT03922932 1071 1074 O
be NCT03922932 1075 1077 O
present NCT03922932 1078 1085 O
in NCT03922932 1086 1088 O
non NCT03922932 1089 1092 O
- NCT03922932 1093 1094 O
study NCT03922932 1095 1100 O
eye NCT03922932 1101 1104 O
. NCT03922932 1104 1105 O
) NCT03922932 1106 1107 O

- NCT03922932 1111 1112 O
Visual NCT03922932 1114 1120 B-Observation
acuity NCT03922932 1121 1127 I-Observation
worse NCT03922932 1128 1133 B-Eq-Comparison
than NCT03922932 1134 1138 I-Eq-Comparison
20 NCT03922932 1139 1141 I-Eq-Comparison
/ NCT03922932 1142 1143 I-Eq-Comparison
200 NCT03922932 1144 1147 O

- NCT03922932 1151 1152 O
Inability NCT03922932 1154 1163 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03922932 1164 1166 O
maintain NCT03922932 1167 1175 O
stable NCT03922932 1176 1182 O
fixation NCT03922932 1183 1191 O
for NCT03922932 1192 1195 O
OCT NCT03922932 1196 1199 B-Procedure
imaging NCT03922932 1200 1207 I-Procedure

- NCT03922932 1210 1211 O
History NCT03922932 1213 1220 B-Eq-Comparison
of NCT03922932 1221 1223 O
major NCT03922932 1224 1229 O
eye NCT03922932 1230 1233 B-Procedure
surgery NCT03922932 1234 1241 I-Procedure|Procedure
( NCT03922932 1242 1243 O
vitrectomy NCT03922932 1244 1254 B-Procedure
, NCT03922932 1255 1256 O
cataract NCT03922932 1257 1265 B-Procedure
surgery NCT03922932 1266 1273 I-Procedure
, NCT03922932 1274 1275 O
scleral NCT03922932 1276 1283 B-Procedure
buckle NCT03922932 1284 1290 I-Procedure
, NCT03922932 1291 1292 O
other NCT03922932 1293 1298 B-Other
intraocular NCT03922932 1299 1310 B-Procedure
surgery NCT03922932 1311 1318 O
, NCT03922932 1319 1320 O
etc NCT03922932 1321 1324 O
. NCT03922932 1324 1325 O
) NCT03922932 1326 1327 O
within NCT03922932 1328 1334 B-Eq-Comparison
90 NCT03922932 1335 1337 I-Eq-Comparison
days NCT03922932 1338 1342 I-Eq-Comparison
of NCT03922932 1343 1345 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03922932 1346 1356 B-Study

- NCT03922932 1359 1360 O
History NCT03922932 1362 1369 B-Eq-Comparison
of NCT03922932 1370 1372 O
another NCT03922932 1373 1380 B-Other
eye NCT03922932 1381 1384 B-Condition
disease NCT03922932 1385 1392 I-Condition
or NCT03922932 1393 1395 B-Or|Or
condition NCT03922932 1396 1405 B-Condition
that NCT03922932 1406 1410 O
may NCT03922932 1411 1414 B-Assertion___Assertion-Type-Value:hypothetical
alter NCT03922932 1415 1420 O
retinal NCT03922932 1421 1428 B-Condition|Modifier
perfusion NCT03922932 1429 1438 B-Modifier
, NCT03922932 1439 1440 O
permeability NCT03922932 1441 1453 B-Modifier
, NCT03922932 1454 1455 O
or NCT03922932 1456 1458 O
retinal NCT03922932 1459 1466 O
anatomy NCT03922932 1467 1474 I-Modifier

- NCT03922932 1477 1478 O
Substantial NCT03922932 1480 1491 O
media NCT03922932 1492 1497 B-Condition
opacity NCT03922932 1498 1505 I-Condition
( NCT03922932 1506 1507 O
cataract NCT03922932 1508 1516 B-Condition
, NCT03922932 1517 1518 O
corneal NCT03922932 1519 1526 B-Condition
scar NCT03922932 1527 1531 I-Condition
, NCT03922932 1532 1533 O
vitreous NCT03922932 1534 1542 B-Condition
hemorrhage NCT03922932 1543 1553 I-Condition
) NCT03922932 1554 1555 O
that NCT03922932 1556 1560 O
may NCT03922932 1561 1564 O
interfere NCT03922932 1565 1574 O
with NCT03922932 1575 1579 O
study NCT03922932 1580 1585 B-Study
imaging NCT03922932 1586 1593 B-Procedure


Inclusion NCT03922503 0 9 O
Criteria NCT03922503 10 18 O
: NCT03922503 19 20 O

- NCT03922503 24 25 O
Stage NCT03922503 27 32 B-Eq-Comparison
III NCT03922503 33 36 I-Eq-Comparison
periodontitis NCT03922503 37 50 B-Condition
patient NCT03922503 51 58 O
having NCT03922503 59 65 B-And
at NCT03922503 66 68 B-Eq-Comparison
least NCT03922503 69 74 I-Eq-Comparison
one NCT03922503 75 78 I-Eq-Comparison
tooth NCT03922503 79 84 B-Observation
with NCT03922503 85 89 B-And
one NCT03922503 90 93 B-Modifier
wall NCT03922503 94 98 I-Modifier
or NCT03922503 99 101 B-Or
combined1 NCT03922503 102 111 B-Modifier
- NCT03922503 112 113 I-Modifier
to NCT03922503 114 116 I-Modifier
2 NCT03922503 117 118 I-Modifier
- NCT03922503 119 120 I-Modifier
wall NCT03922503 121 125 I-Modifier
intraosseous NCT03922503 126 138 B-Observation
defect NCT03922503 139 145 I-Observation
≥ NCT03922503 146 147 B-Eq-Comparison
3 NCT03922503 148 149 I-Eq-Comparison
mm NCT03922503 150 152 I-Eq-Comparison
deep NCT03922503 153 157 O
( NCT03922503 158 159 O
assessed NCT03922503 160 168 O
by NCT03922503 169 171 O
trans NCT03922503 172 177 B-Procedure
- NCT03922503 178 179 I-Procedure
gingival NCT03922503 180 188 I-Procedure
probing NCT03922503 189 196 I-Procedure
, NCT03922503 197 198 O
radiographic NCT03922503 199 211 B-Procedure
examination NCT03922503 212 223 I-Procedure
) NCT03922503 224 225 O
with NCT03922503 226 230 O
clinical NCT03922503 231 239 B-Observation
attachment NCT03922503 240 250 I-Observation
level NCT03922503 251 256 I-Observation
( NCT03922503 257 258 O
CAL NCT03922503 259 262 B-Observation
) NCT03922503 263 264 O
≥ NCT03922503 265 266 B-Eq-Comparison
5 NCT03922503 267 268 I-Eq-Comparison
mm NCT03922503 269 271 O
and NCT03922503 272 275 O
pocket NCT03922503 276 282 B-Observation
depth NCT03922503 283 288 I-Observation
( NCT03922503 289 290 O
PD NCT03922503 291 293 B-Observation
) NCT03922503 294 295 O
≥ NCT03922503 296 297 B-Eq-Comparison
6 NCT03922503 298 299 I-Eq-Comparison
mm NCT03922503 300 302 I-Eq-Comparison
. NCT03922503 302 303 O

- NCT03922503 307 308 O
Defect NCT03922503 310 316 B-Condition
not NCT03922503 317 320 B-Negation
extending NCT03922503 321 330 O
to NCT03922503 331 333 O
a NCT03922503 334 335 O
root NCT03922503 336 340 B-Modifier
furcation NCT03922503 341 350 I-Modifier
area NCT03922503 351 355 I-Modifier

- NCT03922503 358 359 O
Vital NCT03922503 361 366 B-Condition
teeth NCT03922503 367 372 I-Condition

- NCT03922503 375 376 O
Non NCT03922503 378 381 B-Negation
- NCT03922503 382 383 O
smokers NCT03922503 384 391 B-Condition
. NCT03922503 391 392 O

- NCT03922503 396 397 O
No NCT03922503 399 401 B-Negation
history NCT03922503 402 409 B-Eq-Comparison
of NCT03922503 410 412 O
intake NCT03922503 413 419 O
of NCT03922503 420 422 O
antibiotics NCT03922503 423 434 B-Drug
or NCT03922503 435 437 B-Or
other NCT03922503 438 443 B-Other
medications NCT03922503 444 455 B-Drug
affecting NCT03922503 456 465 O
the NCT03922503 466 469 O
periodontium NCT03922503 470 482 B-Condition
in NCT03922503 483 485 O
the NCT03922503 486 489 O
previous NCT03922503 490 498 B-Eq-Comparison
6 NCT03922503 499 500 I-Eq-Comparison
months NCT03922503 501 507 I-Eq-Comparison
. NCT03922503 507 508 O

- NCT03922503 512 513 O
No NCT03922503 515 517 B-Negation
periodontal NCT03922503 518 529 B-Procedure
therapy NCT03922503 530 537 I-Procedure
carried NCT03922503 538 545 O
out NCT03922503 546 549 O
in NCT03922503 550 552 O
the NCT03922503 553 556 O
past NCT03922503 557 561 B-Eq-Comparison
6 NCT03922503 562 563 I-Eq-Comparison
months NCT03922503 564 570 I-Eq-Comparison
. NCT03922503 570 571 O

- NCT03922503 575 576 O
Able NCT03922503 578 582 O
to NCT03922503 583 585 O
sign NCT03922503 586 590 O
an NCT03922503 591 593 O
informed NCT03922503 594 602 O
consent NCT03922503 603 610 O
form NCT03922503 611 615 O
. NCT03922503 615 616 O

- NCT03922503 620 621 O
Patients NCT03922503 623 631 O
age NCT03922503 632 635 B-Age
between NCT03922503 636 643 B-Eq-Comparison
25 NCT03922503 644 646 I-Eq-Comparison
and NCT03922503 647 650 I-Eq-Comparison
50 NCT03922503 651 653 I-Eq-Comparison
years NCT03922503 654 659 I-Eq-Comparison
old NCT03922503 660 663 O
. NCT03922503 663 664 O

- NCT03922503 668 669 O
Patients NCT03922503 671 679 O
who NCT03922503 680 683 O
are NCT03922503 684 687 O
cooperative NCT03922503 688 699 O
, NCT03922503 700 701 O
motivated NCT03922503 702 711 O
, NCT03922503 712 713 O
and NCT03922503 714 717 O
hygiene NCT03922503 718 725 O
conscious NCT03922503 726 735 O
. NCT03922503 735 736 O

- NCT03922503 740 741 O
Systemically NCT03922503 743 755 B-Condition
free NCT03922503 756 760 I-Condition
according NCT03922503 761 770 O
to NCT03922503 771 773 O
Cornell NCT03922503 774 781 O
Medical NCT03922503 782 789 O
Index NCT03922503 790 795 O

Exclusion NCT03922503 796 805 O
Criteria NCT03922503 806 814 O
: NCT03922503 815 816 O

- NCT03922503 820 821 O
Pregnancy NCT03922503 823 832 B-Condition
or NCT03922503 833 835 B-Or
breast NCT03922503 836 842 B-Condition
feeding NCT03922503 843 850 I-Condition

- NCT03922503 853 854 O
The NCT03922503 856 859 O
presence NCT03922503 860 868 O
of NCT03922503 869 871 O
an NCT03922503 872 874 O
orthodontic NCT03922503 875 886 B-Procedure
appliance NCT03922503 887 896 I-Procedure

- NCT03922503 899 900 O
Teeth NCT03922503 902 907 B-Observation
mobility NCT03922503 908 916 I-Observation
greater NCT03922503 917 924 B-Eq-Comparison
than NCT03922503 925 929 I-Eq-Comparison
grade NCT03922503 930 935 I-Eq-Comparison
I NCT03922503 936 937 I-Eq-Comparison

Inclusion NCT03928990 0 9 O
Criteria NCT03928990 10 18 O
: NCT03928990 19 20 O

- NCT03928990 24 25 O
Patients NCT03928990 27 35 O
aged NCT03928990 36 40 B-Age
18 NCT03928990 41 43 B-Eq-Comparison
to NCT03928990 44 46 I-Eq-Comparison
80 NCT03928990 47 49 I-Eq-Comparison
years NCT03928990 50 55 I-Eq-Comparison
old NCT03928990 56 59 O

- NCT03928990 62 63 O
Multiple NCT03928990 65 73 B-Condition
sclerosis NCT03928990 74 83 I-Condition
according NCT03928990 84 93 O
to NCT03928990 94 96 O
McDonald NCT03928990 97 105 O
criteria NCT03928990 106 114 O
; NCT03928990 115 116 O

- NCT03928990 119 120 O
Expanded NCT03928990 122 130 B-Observation
Disability NCT03928990 131 141 I-Observation
Status NCT03928990 142 148 I-Observation
Scale NCT03928990 149 154 I-Observation
( NCT03928990 155 156 O
EDSS NCT03928990 157 161 B-Observation
) NCT03928990 162 163 O
between NCT03928990 164 171 B-Eq-Comparison
0 NCT03928990 172 173 I-Eq-Comparison
and NCT03928990 174 177 I-Eq-Comparison
6.5 NCT03928990 178 181 I-Eq-Comparison
; NCT03928990 182 183 O

- NCT03928990 186 187 O
Patient NCT03928990 189 196 O
able NCT03928990 197 201 B-Condition
to NCT03928990 202 204 I-Condition
move NCT03928990 205 209 I-Condition
with NCT03928990 210 214 O
or NCT03928990 215 217 O
without NCT03928990 218 225 O
mechanical NCT03928990 226 236 B-Procedure
assistance NCT03928990 237 247 I-Procedure
. NCT03928990 247 248 O

Exclusion NCT03928990 250 259 O
Criteria NCT03928990 260 268 O
: NCT03928990 269 270 O

- NCT03928990 274 275 O
Deterioration NCT03928990 277 290 O
of NCT03928990 291 293 O
neurological NCT03928990 294 306 B-Condition
symptomatology NCT03928990 307 321 I-Condition
within NCT03928990 322 328 B-Eq-Comparison
60 NCT03928990 329 331 I-Eq-Comparison
day NCT03928990 332 335 I-Eq-Comparison
before NCT03928990 336 342 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03928990 343 353 B-Study
; NCT03928990 354 355 O

- NCT03928990 358 359 O
Changes NCT03928990 361 368 O
brought NCT03928990 369 376 O
to NCT03928990 377 379 O
the NCT03928990 380 383 O
multiple NCT03928990 384 392 B-Condition
sclerosis NCT03928990 393 402 I-Condition
treatment NCT03928990 403 412 B-Procedure
within NCT03928990 413 419 B-Eq-Comparison
6 NCT03928990 420 421 I-Eq-Comparison
months NCT03928990 422 428 I-Eq-Comparison
before NCT03928990 429 435 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03928990 436 446 B-Study
; NCT03928990 447 448 O

- NCT03928990 451 452 O
Introduction NCT03928990 454 466 B-Eq-Comparison
of NCT03928990 467 469 O
a NCT03928990 470 471 O
treatment NCT03928990 472 481 B-Procedure
acting NCT03928990 482 488 O
on NCT03928990 489 491 O
spasticity NCT03928990 492 502 B-Condition
or NCT03928990 503 505 B-Or
fatigue NCT03928990 506 513 B-Condition
within NCT03928990 514 520 B-Eq-Comparison
30 NCT03928990 521 523 I-Eq-Comparison
day NCT03928990 524 527 I-Eq-Comparison
before NCT03928990 528 534 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03928990 535 545 B-Study

- NCT03928990 548 549 O
Changes NCT03928990 551 558 O
brought NCT03928990 559 566 O
to NCT03928990 567 569 O
reeducation NCT03928990 570 581 B-Procedure
protocol NCT03928990 582 590 I-Procedure
throughout NCT03928990 591 601 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928990 602 605 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03928990 606 614 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03928990 615 617 O
the NCT03928990 618 621 O
study NCT03928990 622 627 B-Study

- NCT03928990 630 631 O
Patient NCT03928990 633 640 O
unable NCT03928990 641 647 B-Negation
to NCT03928990 648 650 O
provide NCT03928990 651 658 O
an NCT03928990 659 661 O
effort NCT03928990 662 668 O
equivalent NCT03928990 669 679 O
to NCT03928990 680 682 O
3 NCT03928990 683 684 B-Eq-Comparison
times NCT03928990 685 690 I-Eq-Comparison
the NCT03928990 691 694 O
resting NCT03928990 695 702 B-Observation
metabolic NCT03928990 703 712 I-Observation
value NCT03928990 713 718 I-Observation
= NCT03928990 719 720 O
3 NCT03928990 721 722 B-Eq-Comparison
Metabolic NCT03928990 723 732 B-Observation
Equivalent NCT03928990 733 743 I-Observation
of NCT03928990 744 746 I-Observation
Task NCT03928990 747 751 I-Observation
( NCT03928990 752 753 O
METs NCT03928990 754 758 B-Observation
) NCT03928990 759 760 O
. NCT03928990 761 762 O

Inclusion NCT03923621 0 9 O
Criteria NCT03923621 10 18 O
: NCT03923621 19 20 O

- NCT03923621 24 25 O
ASA NCT03923621 27 30 B-Condition
I NCT03923621 31 32 B-Eq-Comparison
or NCT03923621 33 35 I-Eq-Comparison
II NCT03923621 36 38 I-Eq-Comparison

- NCT03923621 41 42 O
Pilonidal NCT03923621 44 53 B-Condition
disease NCT03923621 54 61 I-Condition
< NCT03923621 62 63 B-Eq-Comparison
3 NCT03923621 64 65 I-Eq-Comparison
previous NCT03923621 66 74 B-Eq-Comparison
treatments NCT03923621 75 85 B-Procedure

- NCT03923621 88 89 O
Previous NCT03923621 91 99 B-Eq-Comparison
incision NCT03923621 100 108 B-Procedure
and NCT03923621 109 112 B-Or
drainage NCT03923621 113 121 B-Procedure
allowed NCT03923621 122 129 O

- NCT03923621 132 133 O
Over NCT03923621 135 139 B-Eq-Comparison
16 NCT03923621 140 142 I-Eq-Comparison
years NCT03923621 143 148 I-Age|Eq-Comparison

Exclusion NCT03923621 149 158 O
Criteria NCT03923621 159 167 O
: NCT03923621 168 169 O

- NCT03923621 173 174 I-Condition
Co NCT03923621 176 178 B-Condition
- NCT03923621 179 180 O
morbidity NCT03923621 181 190 I-Condition
> NCT03923621 191 192 O
ASA NCT03923621 193 196 B-Condition
II NCT03923621 197 199 B-Eq-Comparison

- NCT03923621 202 203 O
Unable NCT03923621 205 211 O
to NCT03923621 212 214 O
consent NCT03923621 215 222 O
themselves NCT03923621 223 233 O

- NCT03923621 236 237 O
Under NCT03923621 239 244 B-Eq-Comparison
16 NCT03923621 245 247 I-Eq-Comparison
years NCT03923621 248 253 I-Age|Eq-Comparison

- NCT03923621 256 257 O
Vulnerable NCT03923621 259 269 B-Condition
adults NCT03923621 270 276 O

Inclusion NCT03923153 0 9 O
Criteria NCT03923153 10 18 O
: NCT03923153 19 20 O

- NCT03923153 24 25 O
No NCT03923153 27 29 B-Negation
contraindication NCT03923153 30 46 B-Contraindication
for NCT03923153 47 50 O
pulmonary NCT03923153 51 60 B-Procedure
physiotherapy NCT03923153 61 74 I-Procedure

- NCT03923153 77 78 O
Anjina NCT03923153 80 86 B-Condition
patients NCT03923153 87 95 O
who NCT03923153 96 99 O
are NCT03923153 100 103 O
clinically NCT03923153 104 114 O
stable NCT03923153 115 121 O

- NCT03923153 124 125 O
have NCT03923153 127 131 O
no NCT03923153 132 134 B-Negation
other NCT03923153 135 140 B-Other
disease NCT03923153 141 148 B-Condition
that NCT03923153 149 153 O
may NCT03923153 154 157 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03923153 158 164 O
respiratory NCT03923153 165 176 B-Condition
function NCT03923153 177 185 I-Condition

- NCT03923153 188 189 O
Individuals NCT03923153 191 202 O
who NCT03923153 203 206 O
have NCT03923153 207 211 O
the NCT03923153 212 215 O
good NCT03923153 216 220 O
cooperation NCT03923153 221 232 O

Exclusion NCT03923153 233 242 O
Criteria NCT03923153 243 251 O
: NCT03923153 252 253 O

- NCT03923153 257 258 O
Patients NCT03923153 260 268 O
under NCT03923153 269 274 B-Eq-Comparison
the NCT03923153 275 278 I-Eq-Comparison
age NCT03923153 279 282 I-Eq-Comparison
of NCT03923153 283 285 I-Eq-Comparison
18 NCT03923153 286 288 I-Eq-Comparison

- NCT03923153 292 293 O
Pregnancy NCT03923153 295 304 B-Condition

- NCT03923153 307 308 O
Active NCT03923153 310 316 B-Eq-Comparison
infection NCT03923153 317 326 B-Condition

- NCT03923153 329 330 O
Patients NCT03923153 332 340 O
with NCT03923153 341 345 O
known NCT03923153 346 351 O
malignancies NCT03923153 352 364 B-Condition

- NCT03923153 367 368 O
patients NCT03923153 370 378 O
without NCT03923153 379 386 O
consent NCT03923153 387 394 O

- NCT03923153 397 398 O
known NCT03923153 400 405 O
arrhythmia NCT03923153 406 416 B-Condition
, NCT03923153 417 418 O
dilated NCT03923153 419 426 B-Modifier
or NCT03923153 427 429 B-Or
hypertrophic NCT03923153 430 442 B-Modifier
cardiomyopathy NCT03923153 443 457 B-Condition
, NCT03923153 458 459 O
heart NCT03923153 460 465 B-Condition
failure NCT03923153 466 473 I-Condition
( NCT03923153 474 475 O
EF NCT03923153 476 478 B-Observation
< NCT03923153 479 480 B-Eq-Comparison
40 NCT03923153 481 483 I-Eq-Comparison
% NCT03923153 484 485 O
) NCT03923153 486 487 O

Inclusion NCT03926611 0 9 O
Criteria NCT03926611 10 18 O
: NCT03926611 19 20 O

- NCT03926611 24 25 O
Male NCT03926611 27 31 O
and NCT03926611 32 35 B-Or
female NCT03926611 36 42 O
subjects NCT03926611 43 51 O
aged NCT03926611 52 56 B-Age
≥ NCT03926611 57 58 B-Eq-Comparison
18 NCT03926611 59 61 I-Eq-Comparison
years NCT03926611 62 67 I-Eq-Comparison
of NCT03926611 68 70 O
age NCT03926611 71 74 O

- NCT03926611 77 78 O
CSU NCT03926611 80 83 B-Condition
diagnosis NCT03926611 84 93 O
for NCT03926611 94 97 O
≥ NCT03926611 98 99 B-Eq-Comparison
6 NCT03926611 100 101 I-Eq-Comparison
months NCT03926611 102 108 I-Eq-Comparison
prior NCT03926611 109 114 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926611 115 117 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03926611 118 127 B-Study

- NCT03926611 130 131 O
Presence NCT03926611 133 141 O
of NCT03926611 142 144 O
itch NCT03926611 145 149 B-Condition
and NCT03926611 150 153 B-And
hives NCT03926611 154 159 B-Condition
for NCT03926611 160 163 O
≥ NCT03926611 164 165 B-Eq-Comparison
6 NCT03926611 166 167 I-Eq-Comparison
consecutive NCT03926611 168 179 I-Eq-Comparison
weeks NCT03926611 180 185 I-Eq-Comparison
prior NCT03926611 186 191 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926611 192 194 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03926611 195 204 B-Study
in NCT03926611 205 207 B-And
spite NCT03926611 208 213 I-And
of NCT03926611 214 216 I-And
use NCT03926611 217 220 O
of NCT03926611 221 223 O
non NCT03926611 224 227 B-Modifier
- NCT03926611 228 229 I-Modifier
sedating NCT03926611 230 238 I-Modifier
H1 NCT03926611 239 241 B-Drug
- NCT03926611 242 243 I-Drug
antihistamines NCT03926611 244 258 I-Drug
according NCT03926611 259 268 O
to NCT03926611 269 271 O
local NCT03926611 272 277 O
Treatment NCT03926611 278 287 O
guidelines NCT03926611 288 298 O
during NCT03926611 299 305 O
this NCT03926611 306 310 O
time NCT03926611 311 315 O
period NCT03926611 316 322 O

- NCT03926611 325 326 O
UAS7 NCT03926611 328 332 B-Observation
score NCT03926611 333 338 I-Observation
( NCT03926611 339 340 O
range NCT03926611 341 346 O
0 NCT03926611 347 348 B-Eq-Comparison
- NCT03926611 349 350 I-Eq-Comparison
42 NCT03926611 351 353 O
) NCT03926611 354 355 O
≥ NCT03926611 356 357 B-Eq-Comparison
16 NCT03926611 358 360 I-Eq-Comparison
and NCT03926611 361 364 B-And
HSS7 NCT03926611 365 369 B-Observation
score NCT03926611 370 375 I-Observation
( NCT03926611 376 377 O
range NCT03926611 378 383 O
0 NCT03926611 384 385 B-Eq-Comparison
- NCT03926611 386 387 I-Eq-Comparison
21 NCT03926611 388 390 O
) NCT03926611 391 392 O
≥ NCT03926611 393 394 B-Eq-Comparison
8 NCT03926611 395 396 I-Eq-Comparison
during NCT03926611 397 403 B-Temporal-Connection___Temporal-Connection-Type-Value:during
7 NCT03926611 404 405 B-Eq-Comparison
days NCT03926611 406 410 I-Eq-Comparison
prior NCT03926611 411 416 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926611 417 419 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03926611 420 433 B-Study
( NCT03926611 434 435 O
Day NCT03926611 436 439 O
1 NCT03926611 440 441 O
) NCT03926611 442 443 O

- NCT03926611 447 448 O
Willing NCT03926611 450 457 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03926611 458 461 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03926611 462 466 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03926611 467 469 O
complete NCT03926611 470 478 O
an NCT03926611 479 481 O
Urticaria NCT03926611 482 491 B-Procedure
Participant NCT03926611 492 503 I-Procedure
Daily NCT03926611 504 509 I-Procedure
eDiary NCT03926611 510 516 I-Procedure
( NCT03926611 517 518 O
UPDD NCT03926611 519 523 B-Procedure
) NCT03926611 524 525 O
for NCT03926611 526 529 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926611 530 533 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03926611 534 542 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03926611 543 545 O
the NCT03926611 546 549 O
study NCT03926611 550 555 B-Study

Exclusion NCT03926611 556 565 O
Criteria NCT03926611 566 574 O
: NCT03926611 575 576 O

- NCT03926611 580 581 O
Hypersensitivity NCT03926611 583 599 B-Condition
to NCT03926611 600 602 O
any NCT03926611 603 606 O
of NCT03926611 607 609 O
the NCT03926611 610 613 O
study NCT03926611 614 619 B-Study
treatments NCT03926611 620 630 B-Procedure

- NCT03926611 633 634 O
Clearly NCT03926611 636 643 O
defined NCT03926611 644 651 O
predominant NCT03926611 652 663 B-Modifier
or NCT03926611 664 666 B-Or
sole NCT03926611 667 671 B-Modifier
trigger NCT03926611 672 679 I-Modifier
of NCT03926611 680 682 O
their NCT03926611 683 688 O
chronic NCT03926611 689 696 B-Condition|Modifier
urticaria NCT03926611 697 706 I-Condition
( NCT03926611 707 708 O
chronic NCT03926611 709 716 O
inducible NCT03926611 717 726 B-Condition
urticaria NCT03926611 727 736 I-Condition
) NCT03926611 737 738 O

- NCT03926611 742 743 O
Other NCT03926611 745 750 B-Other
diseases NCT03926611 751 759 B-Condition
with NCT03926611 760 764 O
symptoms NCT03926611 765 773 B-Assertion___Assertion-Type-Value:possible
of NCT03926611 774 776 O
urticaria NCT03926611 777 786 B-Condition
or NCT03926611 787 789 B-Or
angioedema NCT03926611 790 800 B-Condition

- NCT03926611 803 804 O
Other NCT03926611 806 811 B-Other
skin NCT03926611 812 816 B-Condition
disease NCT03926611 817 824 I-Condition
associated NCT03926611 825 835 O
with NCT03926611 836 840 O
chronic NCT03926611 841 848 B-Modifier
itching NCT03926611 849 856 B-Condition
that NCT03926611 857 861 O
might NCT03926611 862 867 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03926611 868 877 O
in NCT03926611 878 880 O
the NCT03926611 881 884 O
investigators NCT03926611 885 898 O
opinion NCT03926611 899 906 O
the NCT03926611 907 910 O
study NCT03926611 911 916 B-Study
evaluations NCT03926611 917 928 O
and NCT03926611 929 932 O
results NCT03926611 933 940 O
, NCT03926611 941 942 O

- NCT03926611 946 947 O
Known NCT03926611 949 954 O
or NCT03926611 955 957 O
suspected NCT03926611 958 967 B-Assertion___Assertion-Type-Value:possible
history NCT03926611 968 975 B-Eq-Comparison
of NCT03926611 976 978 O
an NCT03926611 979 981 O
ongoing NCT03926611 982 989 B-Eq-Comparison
, NCT03926611 990 991 O
chronic NCT03926611 992 999 B-Modifier
or NCT03926611 1000 1002 B-Or
recurrent NCT03926611 1003 1012 B-Modifier
infectious NCT03926611 1013 1023 B-Condition
disease NCT03926611 1024 1031 I-Condition
including NCT03926611 1032 1041 O
but NCT03926611 1042 1045 O
not NCT03926611 1046 1049 O
limited NCT03926611 1050 1057 O
to NCT03926611 1058 1060 O
opportunistic NCT03926611 1061 1074 B-Condition
infections NCT03926611 1075 1085 I-Condition
( NCT03926611 1086 1087 O
eg NCT03926611 1088 1090 O
tuberculosis NCT03926611 1091 1103 B-Condition
, NCT03926611 1104 1105 O
atypical NCT03926611 1106 1114 B-Modifier
mycobacterioses NCT03926611 1115 1130 B-Condition
, NCT03926611 1131 1132 O
listeriosis NCT03926611 1133 1144 B-Condition
or NCT03926611 1145 1147 B-Or
aspergillosis NCT03926611 1148 1161 B-Condition
) NCT03926611 1162 1163 O
, NCT03926611 1165 1166 O
HIV NCT03926611 1167 1170 B-Condition
, NCT03926611 1171 1172 O
Hepatitis NCT03926611 1173 1182 B-Condition
B NCT03926611 1183 1184 B-Modifier
/ NCT03926611 1185 1186 B-Or
C. NCT03926611 1187 1189 B-Modifier

- NCT03926611 1193 1194 O
Pregnant NCT03926611 1196 1204 B-Condition
or NCT03926611 1205 1207 B-Or
nursing NCT03926611 1208 1215 B-Condition
( NCT03926611 1216 1217 O
lactating NCT03926611 1218 1227 B-Condition
) NCT03926611 1228 1229 O
women NCT03926611 1230 1235 O

- NCT03926611 1238 1239 I-Condition
Women NCT03926611 1241 1246 O
of NCT03926611 1247 1249 B-And
child NCT03926611 1250 1255 B-Condition
- NCT03926611 1256 1257 O
bearing NCT03926611 1258 1265 I-Condition
potential NCT03926611 1266 1275 I-Condition
not NCT03926611 1276 1279 B-Negation
using NCT03926611 1280 1285 B-Eq-Comparison
highly NCT03926611 1286 1292 B-Modifier
effective NCT03926611 1293 1302 I-Modifier
methods NCT03926611 1303 1310 I-Modifier
of NCT03926611 1311 1313 O
contraception NCT03926611 1314 1327 B-Procedure

Other NCT03926611 1328 1333 O
protocol NCT03926611 1334 1342 O
- NCT03926611 1343 1344 O
defined NCT03926611 1345 1352 O
inclusion NCT03926611 1353 1362 O
/ NCT03926611 1363 1364 O
exclusion NCT03926611 1365 1374 O
criteria NCT03926611 1375 1383 O
may NCT03926611 1384 1387 O
apply NCT03926611 1388 1393 O
. NCT03926611 1393 1394 O

Inclusion NCT03929536 0 9 O
Criteria NCT03929536 10 18 O
: NCT03929536 19 20 O

- NCT03929536 24 25 O
surgical NCT03929536 27 35 B-Procedure
treatment NCT03929536 36 45 I-Procedure
of NCT03929536 46 48 O
acetabular NCT03929536 49 59 B-Modifier
fracture NCT03929536 60 68 B-Condition
between NCT03929536 69 76 B-Eq-Comparison
2009 NCT03929536 77 81 I-Eq-Comparison
and NCT03929536 82 85 I-Eq-Comparison
2018 NCT03929536 86 90 I-Eq-Comparison

Exclusion NCT03929536 92 101 O
Criteria NCT03929536 102 110 O
: NCT03929536 111 112 O

- NCT03929536 116 117 O
pathological NCT03929536 119 131 B-Modifier
fractures NCT03929536 132 141 B-Condition
due NCT03929536 142 145 O
to NCT03929536 146 148 O
neoplasm NCT03929536 149 157 B-Condition
or NCT03929536 158 160 B-Or
metastasis NCT03929536 161 171 B-Condition

- NCT03929536 174 175 O
status NCT03929536 177 183 O
after NCT03929536 184 189 B-Temporal-Connection___Temporal-Connection-Type-Value:after
implantation NCT03929536 190 202 B-Procedure
of NCT03929536 203 205 I-Procedure
an NCT03929536 206 208 I-Procedure
endoprosthesis NCT03929536 209 223 I-Procedure

Inclusion NCT03928600 0 9 O
Criteria NCT03928600 10 18 O
: NCT03928600 19 20 O

- NCT03928600 24 25 O
full NCT03928600 27 31 B-Condition
- NCT03928600 32 33 I-Condition
term NCT03928600 34 38 I-Condition
( NCT03928600 39 40 O
≥ NCT03928600 42 43 B-Eq-Comparison
37 NCT03928600 44 46 I-Eq-Comparison
weeks NCT03928600 47 52 I-Eq-Comparison
of NCT03928600 53 55 O
gestation NCT03928600 56 65 B-Observation
) NCT03928600 66 67 O

- NCT03928600 71 72 O
singleton NCT03928600 74 83 B-Condition

- NCT03928600 86 87 O
vertex NCT03928600 89 95 B-Condition
- NCT03928600 96 97 I-Condition
presenting NCT03928600 98 108 I-Condition
gestations NCT03928600 109 119 I-Condition

- NCT03928600 122 123 O
with NCT03928600 125 129 O
no NCT03928600 130 132 B-Negation
contraindication NCT03928600 133 149 B-Contraindication
to NCT03928600 150 152 O
vaginal NCT03928600 153 160 B-Procedure
delivery NCT03928600 161 169 I-Procedure

- NCT03928600 172 173 O
intact NCT03928600 175 181 B-Condition
membranes NCT03928600 182 191 I-Condition

- NCT03928600 194 195 O
Bishop NCT03928600 197 203 B-Observation
score NCT03928600 204 209 I-Observation
< NCT03928600 210 211 B-Eq-Comparison
7 NCT03928600 212 213 I-Eq-Comparison
and NCT03928600 214 217 B-And
cervical NCT03928600 218 226 B-Observation
dilation NCT03928600 227 235 I-Observation
≤ NCT03928600 236 237 B-Eq-Comparison
2 NCT03928600 238 239 I-Eq-Comparison
cm NCT03928600 240 242 I-Eq-Comparison

Exclusion NCT03928600 243 252 O
Criteria NCT03928600 253 261 O
: NCT03928600 262 263 O

- NCT03928600 267 268 O
contraindication NCT03928600 270 286 B-Contraindication
for NCT03928600 287 290 O
misoprostol NCT03928600 291 302 B-Drug

- NCT03928600 305 306 O
history NCT03928600 308 315 B-Eq-Comparison
of NCT03928600 316 318 I-Eq-Comparison
previous NCT03928600 319 327 I-Eq-Comparison
caesarean NCT03928600 328 337 B-Procedure

- NCT03928600 340 341 O
rupture NCT03928600 343 350 B-Condition
of NCT03928600 351 353 I-Condition
membranes NCT03928600 354 363 I-Condition
, NCT03928600 364 365 O

- NCT03928600 369 370 O
fetal NCT03928600 372 377 B-Modifier
or NCT03928600 378 380 B-Or
maternal NCT03928600 381 389 B-Modifier
morbidities NCT03928600 390 401 B-Condition
( NCT03928600 402 403 O
fetal NCT03928600 404 409 B-Condition
major NCT03928600 410 415 I-Condition
abnormalities NCT03928600 416 429 I-Condition
, NCT03928600 430 431 O
FIGO NCT03928600 432 436 O
definition NCT03928600 437 447 O
of NCT03928600 448 450 O
pathological NCT03928600 451 463 B-Modifier
CTG NCT03928600 464 467 B-Condition
, NCT03928600 468 469 O
HELLP NCT03928600 470 475 B-Condition
syndrome NCT03928600 476 484 I-Condition
, NCT03928600 485 486 O
preeclampsia NCT03928600 487 499 B-Condition
or NCT03928600 500 502 B-Or
hypertension NCT03928600 503 515 B-Condition
with NCT03928600 516 520 O
severe NCT03928600 521 527 O
features NCT03928600 528 536 O
, NCT03928600 537 538 O
fetal NCT03928600 539 544 B-Condition
growth NCT03928600 545 551 I-Condition
restriction NCT03928600 552 563 I-Condition
) NCT03928600 564 565 O

Inclusion NCT03923972 0 9 O
Criteria NCT03923972 10 18 O
: NCT03923972 19 20 O

- NCT03923972 24 25 O
all NCT03923972 27 30 O
adult NCT03923972 31 36 O
patients NCT03923972 37 45 O
with NCT03923972 46 50 O
non NCT03923972 51 54 B-Modifier
- NCT03923972 55 56 I-Modifier
dialysis NCT03923972 57 65 I-Modifier
dependent NCT03923972 66 75 I-Modifier
chronic NCT03923972 76 83 B-Condition
kidney NCT03923972 84 90 I-Condition
disease NCT03923972 91 98 I-Condition
, NCT03923972 99 100 O
peritoneal NCT03923972 101 111 B-Procedure
dialysis NCT03923972 112 120 I-Procedure
, NCT03923972 121 122 O
hemodialysis NCT03923972 123 135 B-Procedure
, NCT03923972 136 137 O
renal NCT03923972 138 143 B-Procedure
transplantation NCT03923972 144 159 I-Procedure

- NCT03923972 162 163 O
all NCT03923972 165 168 O
active NCT03923972 169 175 B-Eq-Comparison
physicians NCT03923972 176 186 O
in NCT03923972 187 189 O
the NCT03923972 190 193 O
department NCT03923972 194 204 O
of NCT03923972 205 207 O
nephrology NCT03923972 208 218 B-Provider
involved NCT03923972 219 227 O
in NCT03923972 228 230 O
patient NCT03923972 231 238 O
care NCT03923972 239 243 O

- NCT03923972 246 247 O
all NCT03923972 249 252 O
active NCT03923972 253 259 B-Eq-Comparison
nurses NCT03923972 260 266 O
in NCT03923972 267 269 O
the NCT03923972 270 273 O
department NCT03923972 274 284 O
of NCT03923972 285 287 O
nephrology NCT03923972 288 298 B-Provider
involved NCT03923972 299 307 O
in NCT03923972 308 310 O
patient NCT03923972 311 318 O
care NCT03923972 319 323 O

- NCT03923972 326 327 O
all NCT03923972 329 332 O
heads NCT03923972 333 338 O
of NCT03923972 339 341 O
nephrology NCT03923972 342 352 B-Provider
departments NCT03923972 353 364 O

Exclusion NCT03923972 365 374 O
Criteria NCT03923972 375 383 O
: NCT03923972 384 385 O

- NCT03923972 389 390 O
children NCT03923972 392 400 O

- NCT03923972 403 404 O
no NCT03923972 406 408 B-Negation
physical NCT03923972 409 417 B-Condition
disability NCT03923972 418 428 I-Condition
making NCT03923972 429 435 O
it NCT03923972 436 438 O
impossible NCT03923972 439 449 B-Negation
to NCT03923972 450 452 B-Assertion___Assertion-Type-Value:hypothetical
conduct NCT03923972 453 460 I-Assertion___Assertion-Type-Value:hypothetical
exercise NCT03923972 461 469 B-Procedure
training NCT03923972 470 478 I-Procedure

- NCT03923972 481 482 O
no NCT03923972 484 486 B-Negation
mental NCT03923972 487 493 B-Condition
disability NCT03923972 494 504 I-Condition
or NCT03923972 505 507 B-Or
language NCT03923972 508 516 B-Condition
problem NCT03923972 517 524 I-Condition
making NCT03923972 525 531 O
it NCT03923972 532 534 O
impossible NCT03923972 535 545 B-Negation
to NCT03923972 546 548 O
understand NCT03923972 549 559 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03923972 560 563 I-Assertion___Assertion-Type-Value:hypothetical
fill NCT03923972 564 568 I-Assertion___Assertion-Type-Value:hypothetical
in NCT03923972 569 571 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03923972 572 573 O
questionnaire NCT03923972 574 587 B-Observation

Inclusion NCT03922113 0 9 O
Criteria NCT03922113 10 18 O
: NCT03922113 19 20 O

- NCT03922113 24 25 O
Collaborative NCT03922113 27 40 O
ICU NCT03922113 41 44 B-Encounter
patients NCT03922113 45 53 O
with NCT03922113 54 58 O
length NCT03922113 59 65 O
of NCT03922113 66 68 O
stay NCT03922113 69 73 O
> NCT03922113 74 75 B-Eq-Comparison
48 NCT03922113 76 78 I-Eq-Comparison
h NCT03922113 79 80 O

- NCT03922113 83 84 O
Surgical NCT03922113 86 94 O
patients NCT03922113 95 103 O
scheduled NCT03922113 104 113 B-Eq-Comparison
for NCT03922113 114 117 O
colorectal NCT03922113 118 128 B-Procedure
surgery NCT03922113 129 136 I-Procedure

- NCT03922113 139 140 O
Healthy NCT03922113 142 149 B-Condition
subjects NCT03922113 150 158 O

Exclusion NCT03922113 159 168 O
Criteria NCT03922113 169 177 O
: NCT03922113 178 179 O

- NCT03922113 183 184 O
a NCT03922113 186 187 O
score NCT03922113 188 193 O
> NCT03922113 194 195 B-Eq-Comparison
1 NCT03922113 196 197 I-Eq-Comparison
or NCT03922113 198 200 B-Or
< NCT03922113 201 202 B-Eq-Comparison
- NCT03922113 203 204 I-Eq-Comparison
1 NCT03922113 205 206 I-Eq-Comparison
on NCT03922113 207 209 O
the NCT03922113 210 213 O
Richmond NCT03922113 214 222 B-Observation
Agitation NCT03922113 223 232 I-Observation
and NCT03922113 233 236 I-Observation
Sedation NCT03922113 237 245 I-Observation
Scale NCT03922113 246 251 I-Observation
( NCT03922113 252 253 O
RASS NCT03922113 254 258 B-Observation
) NCT03922113 259 260 O

- NCT03922113 264 265 O
coma NCT03922113 267 271 B-Condition

- NCT03922113 274 275 O
total NCT03922113 277 282 B-Modifier
hip NCT03922113 283 286 I-Modifier
or NCT03922113 287 289 B-Or
knee NCT03922113 290 294 B-Modifier
arthroplasty NCT03922113 295 307 B-Procedure
in NCT03922113 308 310 O
the NCT03922113 311 314 O
dominant NCT03922113 315 323 B-Modifier
limb NCT03922113 324 328 I-Modifier

- NCT03922113 331 332 O
unauthorized NCT03922113 334 346 B-Condition
support NCT03922113 347 354 I-Condition
on NCT03922113 355 357 O
the NCT03922113 358 361 O
dominant NCT03922113 362 370 B-Modifier
leg NCT03922113 371 374 I-Modifier

- NCT03922113 377 378 O
open NCT03922113 380 384 B-Condition
wound NCT03922113 385 390 I-Condition
located NCT03922113 391 398 O
at NCT03922113 399 401 O
the NCT03922113 402 405 O
ankle NCT03922113 406 411 B-Modifier
's NCT03922113 411 413 O
anterior NCT03922113 414 422 I-Modifier
face NCT03922113 423 427 I-Modifier
of NCT03922113 428 430 I-Modifier
the NCT03922113 431 434 I-Modifier
dominant NCT03922113 435 443 I-Modifier
leg NCT03922113 444 447 I-Modifier

- NCT03922113 450 451 I-Eq-Comparison
pre NCT03922113 453 456 B-Eq-Comparison
- NCT03922113 457 458 O
existing NCT03922113 459 467 I-Eq-Comparison
myopathy NCT03922113 468 476 B-Condition
or NCT03922113 477 479 B-Or
polyneuropathy NCT03922113 480 494 B-Condition

- NCT03922113 497 498 O
para NCT03922113 500 504 B-Modifier
- NCT03922113 505 506 O
or NCT03922113 507 509 B-Or
tetraparesis NCT03922113 510 522 B-Condition
, NCT03922113 523 524 O
para NCT03922113 525 529 B-Modifier
- NCT03922113 530 531 O
or NCT03922113 532 534 B-Or
tetraplegia NCT03922113 535 546 B-Condition

- NCT03922113 549 550 O
refusal NCT03922113 552 559 O
. NCT03922113 559 560 O

Inclusion NCT03923231 0 9 O
Criteria NCT03923231 10 18 O
: NCT03923231 19 20 O

1 NCT03923231 24 25 O
. NCT03923231 25 26 O
Evidence NCT03923231 28 36 O
of NCT03923231 37 39 O
a NCT03923231 40 41 O
personally NCT03923231 42 52 O
signed NCT03923231 53 59 O
and NCT03923231 60 63 O
dated NCT03923231 64 69 O
informed NCT03923231 70 78 O
consent NCT03923231 79 86 O
document NCT03923231 87 95 O
indicating NCT03923231 96 106 O
that NCT03923231 107 111 O
the NCT03923231 112 115 O
participant NCT03923231 116 127 O
( NCT03923231 128 129 O
or NCT03923231 130 132 O
a NCT03923231 133 134 O
legal NCT03923231 135 140 O
representative NCT03923231 141 155 O
) NCT03923231 156 157 O
has NCT03923231 158 161 O
been NCT03923231 162 166 O
informed NCT03923231 167 175 O
of NCT03923231 176 178 O
all NCT03923231 179 182 O
pertinent NCT03923231 183 192 O
aspects NCT03923231 193 200 O
of NCT03923231 201 203 O
the NCT03923231 204 207 O
study NCT03923231 208 213 O
. NCT03923231 213 214 O

2 NCT03923231 218 219 O
. NCT03923231 219 220 O
In NCT03923231 222 224 O
a NCT03923231 225 226 O
child NCT03923231 227 232 O
aged NCT03923231 233 237 B-Age
≥ NCT03923231 238 239 B-Eq-Comparison
7 NCT03923231 240 241 I-Eq-Comparison
years NCT03923231 242 247 I-Eq-Comparison
( NCT03923231 248 249 O
South NCT03923231 250 255 O
Africa NCT03923231 256 262 O
) NCT03923231 263 264 O
or NCT03923231 265 267 B-Or
aged NCT03923231 268 272 B-Age
≥ NCT03923231 273 274 B-Eq-Comparison
8 NCT03923231 275 276 I-Eq-Comparison
years NCT03923231 277 282 I-Eq-Comparison
( NCT03923231 283 284 O
Uganda NCT03923231 285 291 O
) NCT03923231 292 293 O
, NCT03923231 295 296 O
evidence NCT03923231 297 305 O
of NCT03923231 306 308 O
assent NCT03923231 309 315 O
to NCT03923231 316 318 O
participate NCT03923231 319 330 O

3 NCT03923231 333 334 O
. NCT03923231 334 335 O
Participants NCT03923231 337 349 O
who NCT03923231 350 353 O
are NCT03923231 354 357 O
willing NCT03923231 358 365 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03923231 366 369 B-And
able NCT03923231 370 374 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03923231 375 377 O
comply NCT03923231 378 384 O
with NCT03923231 385 389 O
scheduled NCT03923231 390 399 B-Eq-Comparison
visits NCT03923231 400 406 B-Encounter
, NCT03923231 407 408 O
laboratory NCT03923231 409 419 B-Observation
tests NCT03923231 420 425 I-Observation
, NCT03923231 426 427 O
and NCT03923231 428 431 B-And
other NCT03923231 432 437 O
study NCT03923231 438 443 B-Study
procedures NCT03923231 444 454 O
. NCT03923231 454 455 O

4 NCT03923231 459 460 O
. NCT03923231 460 461 O
HIV NCT03923231 463 466 B-Condition
- NCT03923231 467 468 I-Condition
infected NCT03923231 469 477 I-Condition
, NCT03923231 478 479 O
receiving NCT03923231 480 489 B-Eq-Comparison
ATV NCT03923231 490 493 B-Drug
- NCT03923231 494 495 O
based NCT03923231 496 501 O
ART NCT03923231 502 505 B-Procedure
treatment NCT03923231 506 515 I-Procedure
OR NCT03923231 516 518 B-Or
HIV NCT03923231 519 522 B-Condition
- NCT03923231 523 524 I-Condition|Modifier
infected NCT03923231 525 533 I-Condition
receiving NCT03923231 534 543 B-Eq-Comparison
second NCT03923231 544 550 B-Modifier
- NCT03923231 551 552 O
line NCT03923231 553 557 I-Modifier
ART NCT03923231 558 561 B-Procedure
with NCT03923231 562 566 B-And
concurrent NCT03923231 567 577 B-Eq-Comparison
rifamycin NCT03923231 578 587 B-Drug
- NCT03923231 588 589 O
based NCT03923231 590 595 O
TB NCT03923231 596 598 B-Procedure
treatment NCT03923231 599 608 I-Procedure

5 NCT03923231 611 612 O
. NCT03923231 612 613 O
Participant NCT03923231 615 626 O
is NCT03923231 627 629 O
within NCT03923231 630 636 O
one NCT03923231 637 640 O
of NCT03923231 641 643 O
the NCT03923231 644 647 O
target NCT03923231 648 654 O
populations NCT03923231 655 666 O
: NCT03923231 667 668 O

1 NCT03923231 677 678 O
. NCT03923231 678 679 O
Pregnant NCT03923231 681 689 B-Condition
( NCT03923231 690 691 O
> NCT03923231 693 694 B-Eq-Comparison|Eq-Comparison
20 NCT03923231 695 697 I-Eq-Comparison
weeks NCT03923231 698 703 I-Eq-Comparison
) NCT03923231 704 705 O

2 NCT03923231 714 715 O
. NCT03923231 715 716 O
Body NCT03923231 718 722 B-Observation
mass NCT03923231 723 727 I-Observation
index NCT03923231 728 733 I-Observation
> NCT03923231 734 735 O
30 NCT03923231 736 738 I-Eq-Comparison
or NCT03923231 739 741 B-Or|Or
< NCT03923231 742 743 B-Eq-Comparison
18.5 NCT03923231 744 748 I-Eq-Comparison
Kg NCT03923231 749 751 I-Eq-Comparison
/ NCT03923231 752 753 I-Eq-Comparison
m2 NCT03923231 754 756 I-Eq-Comparison

3 NCT03923231 764 765 O
. NCT03923231 765 766 O
Child NCT03923231 768 773 O
or NCT03923231 774 776 O
adolescent NCT03923231 777 787 O
aged NCT03923231 788 792 B-Age
< NCT03923231 793 794 B-Eq-Comparison
18 NCT03923231 795 797 I-Eq-Comparison
years NCT03923231 798 803 I-Eq-Comparison

Exclusion NCT03923231 804 813 O
Criteria NCT03923231 814 822 O
: NCT03923231 823 824 O

1 NCT03923231 828 829 O
. NCT03923231 829 830 O
Medical NCT03923231 832 839 B-Modifier
, NCT03923231 840 841 O
psychiatric NCT03923231 842 853 B-Modifier
or NCT03923231 854 856 B-Or
obstetric NCT03923231 857 866 B-Modifier
condition NCT03923231 867 876 B-Condition
that NCT03923231 877 881 O
might NCT03923231 882 887 O
affect NCT03923231 888 894 O
participation NCT03923231 895 908 O
in NCT03923231 909 911 O
the NCT03923231 912 915 O
stuy NCT03923231 916 920 B-Study
based NCT03923231 921 926 O
on NCT03923231 927 929 O
investigator NCT03923231 930 942 O
judgement NCT03923231 943 952 O

2 NCT03923231 955 956 O
. NCT03923231 956 957 O
Dissent NCT03923231 959 966 O
from NCT03923231 967 971 O
a NCT03923231 972 973 O
minor NCT03923231 974 979 O

3 NCT03923231 982 983 O
. NCT03923231 983 984 O
For NCT03923231 986 989 O
pregnant NCT03923231 990 998 B-Condition
women NCT03923231 999 1004 O
in NCT03923231 1005 1007 B-And
Uganda NCT03923231 1008 1014 O
, NCT03923231 1015 1016 O
where NCT03923231 1017 1022 B-And
the NCT03923231 1023 1026 O
husband NCT03923231 1027 1034 B-Family-Member___Family-Member-Type:spouse
is NCT03923231 1035 1037 O
reasonably NCT03923231 1038 1048 O
involved NCT03923231 1049 1057 O
, NCT03923231 1058 1059 O
paternal NCT03923231 1060 1068 O
objection NCT03923231 1069 1078 O

Inclusion NCT03923543 0 9 O
Criteria NCT03923543 10 18 O
: NCT03923543 19 20 O

- NCT03923543 24 25 O
newborn NCT03923543 27 34 O
to NCT03923543 35 37 B-Eq-Comparison
be NCT03923543 38 40 I-Eq-Comparison
operated NCT03923543 41 49 B-Procedure
with NCT03923543 50 54 B-And
the NCT03923543 55 58 O
diagnosis NCT03923543 59 68 O
of NCT03923543 69 71 O
congenital NCT03923543 72 82 B-Condition
heart NCT03923543 83 88 I-Condition
disease NCT03923543 89 96 I-Condition

Exclusion NCT03923543 97 106 O
Criteria NCT03923543 107 115 O
: NCT03923543 116 117 O

- NCT03923543 121 122 O
age NCT03923543 124 127 B-Age
older NCT03923543 128 133 B-Eq-Comparison
than NCT03923543 134 138 I-Eq-Comparison
1 NCT03923543 139 140 I-Eq-Comparison
month NCT03923543 141 146 I-Eq-Comparison
not NCT03923543 147 150 B-Negation
to NCT03923543 151 153 B-Eq-Comparison
be NCT03923543 154 156 I-Eq-Comparison
operated NCT03923543 157 165 B-Procedure

Inclusion NCT03923595 0 9 O
Criteria NCT03923595 10 18 O
: NCT03923595 19 20 O

- NCT03923595 24 25 O
all NCT03923595 27 30 O
consecutive NCT03923595 31 42 O
patients NCT03923595 43 51 O
from NCT03923595 52 56 O
SERD NCT03923595 57 61 O
of NCT03923595 62 64 O
18 NCT03923595 65 67 B-Eq-Comparison
yrs NCT03923595 68 71 I-Eq-Comparison
or NCT03923595 72 74 I-Eq-Comparison
older NCT03923595 75 80 I-Age|Eq-Comparison
either NCT03923595 81 87 O
naive NCT03923595 88 93 B-Condition
or NCT03923595 94 96 B-Or
previously NCT03923595 97 107 B-Eq-Comparison
treated NCT03923595 108 115 B-Procedure
including NCT03923595 116 125 O
HBsAg NCT03923595 126 131 B-Condition
positive NCT03923595 132 140 O
and NCT03923595 141 144 B-Or
HIV NCT03923595 145 148 B-Condition
positive NCT03923595 149 157 O
. NCT03923595 157 158 O

Exclusion NCT03923595 160 169 O
Criteria NCT03923595 170 178 O
: NCT03923595 179 180 O

- NCT03923595 184 185 O
GFR NCT03923595 187 190 B-Observation
< NCT03923595 191 192 B-Eq-Comparison
50 NCT03923595 193 195 I-Eq-Comparison
ml NCT03923595 196 198 I-Eq-Comparison
/ NCT03923595 199 200 I-Eq-Comparison
min NCT03923595 201 204 I-Eq-Comparison
, NCT03923595 205 206 O
pregnancy NCT03923595 207 216 B-Condition
, NCT03923595 217 218 O
breast NCT03923595 219 225 B-Condition
- NCT03923595 226 227 I-Condition
feeding NCT03923595 228 235 I-Condition
, NCT03923595 236 237 O
cirrhosis NCT03923595 238 247 B-Condition
of NCT03923595 248 250 B-And
CHILD NCT03923595 251 256 B-Condition
- NCT03923595 257 258 I-Condition
PUGH NCT03923595 259 263 I-Condition
- NCT03923595 264 265 O
TURCOTTE NCT03923595 266 274 I-Condition
B7 NCT03923595 275 277 B-Eq-Comparison
o NCT03923595 278 279 I-Eq-Comparison
> NCT03923595 280 281 I-Eq-Comparison
. NCT03923595 282 283 O

Inclusion NCT03923556 0 9 O
Criteria NCT03923556 10 18 O
: NCT03923556 19 20 O

- NCT03923556 24 25 O
At NCT03923556 27 29 B-Eq-Comparison
least NCT03923556 30 35 I-Eq-Comparison
18 NCT03923556 36 38 I-Eq-Comparison
years NCT03923556 39 44 I-Eq-Comparison
or NCT03923556 45 47 I-Eq-Comparison
older NCT03923556 48 53 I-Age|Eq-Comparison

- NCT03923556 56 57 O
Diagnosed NCT03923556 59 68 O
with NCT03923556 69 73 O
severe NCT03923556 74 80 O
kidney NCT03923556 81 87 B-Condition
dysfunction NCT03923556 88 99 I-Condition
( NCT03923556 100 101 O
defined NCT03923556 102 109 O
by NCT03923556 110 112 O
plasma NCT03923556 113 119 B-Observation
creatinine NCT03923556 120 130 I-Observation
clearance NCT03923556 131 140 I-Observation
< NCT03923556 141 142 B-Eq-Comparison
30 NCT03923556 143 145 I-Eq-Comparison
mL NCT03923556 146 148 I-Eq-Comparison
/ NCT03923556 149 150 I-Eq-Comparison
min NCT03923556 151 154 I-Eq-Comparison
) NCT03923556 155 156 O

- NCT03923556 160 161 O
Planning NCT03923556 163 171 B-Assertion___Assertion-Type-Value:intention
on NCT03923556 172 174 O
kidney NCT03923556 175 181 B-Procedure
transplantation NCT03923556 182 197 I-Procedure
surgery NCT03923556 198 205 I-Procedure
at NCT03923556 206 208 O
the NCT03923556 209 212 O
University NCT03923556 213 223 O
of NCT03923556 224 226 O
Colorado NCT03923556 227 235 O
Hospital NCT03923556 236 244 O
. NCT03923556 244 245 O

Exclusion NCT03923556 247 256 O
Criteria NCT03923556 257 265 O
: NCT03923556 266 267 O

- NCT03923556 271 272 O
Patients NCT03923556 274 282 O
unable NCT03923556 283 289 O
to NCT03923556 290 292 O
sign NCT03923556 293 297 O
the NCT03923556 298 301 O
informed NCT03923556 302 310 O
consent NCT03923556 311 318 O

- NCT03923556 321 322 O
Pregnant NCT03923556 324 332 B-Condition
women NCT03923556 333 338 O

- NCT03923556 341 342 O
Body NCT03923556 344 348 B-Observation
Mass NCT03923556 349 353 I-Observation
Index NCT03923556 354 359 I-Observation
( NCT03923556 360 361 O
BMI NCT03923556 362 365 B-Observation
) NCT03923556 366 367 O
> NCT03923556 368 369 B-Eq-Comparison
40 NCT03923556 370 372 I-Eq-Comparison
kg NCT03923556 373 375 I-Eq-Comparison
/ NCT03923556 376 377 I-Eq-Comparison
m2 NCT03923556 378 380 I-Eq-Comparison

- NCT03923556 383 384 I-Eq-Comparison
Pre NCT03923556 386 389 B-Eq-Comparison
- NCT03923556 390 391 O
existing NCT03923556 392 400 I-Eq-Comparison
oxygen NCT03923556 401 407 B-Modifier
or NCT03923556 408 410 B-Or
ventilatory NCT03923556 411 422 B-Modifier
dependency NCT03923556 423 433 B-Condition
( NCT03923556 434 435 O
24 NCT03923556 436 438 B-Eq-Comparison
h NCT03923556 439 440 O
use NCT03923556 441 444 O
of NCT03923556 445 447 O
oxygen NCT03923556 448 454 B-Procedure
or NCT03923556 455 457 B-Or
other NCT03923556 458 463 B-Other
noninvasive NCT03923556 464 475 B-Modifier
or NCT03923556 476 478 B-Or
invasive NCT03923556 479 487 B-Modifier
ventilatory NCT03923556 488 499 B-Procedure
support NCT03923556 500 507 I-Procedure
) NCT03923556 508 509 O

- NCT03923556 513 514 O
Patients NCT03923556 516 524 O
with NCT03923556 525 529 O
any NCT03923556 530 533 O
pulmonary NCT03923556 534 543 B-Modifier
, NCT03923556 544 545 O
neuromuscular NCT03923556 546 559 B-Modifier
or NCT03923556 560 562 B-Or
other NCT03923556 563 568 B-Other
disease NCT03923556 569 576 B-Condition
that NCT03923556 577 581 O
severely NCT03923556 582 590 O
limits NCT03923556 591 597 O
their NCT03923556 598 603 O
respiratory NCT03923556 604 615 B-Condition
functional NCT03923556 616 626 I-Condition
status NCT03923556 627 633 O
( NCT03923556 634 635 O
e. NCT03923556 636 638 O
g. NCT03923556 639 641 O
unable NCT03923556 643 649 B-Negation
to NCT03923556 650 652 O
achieve NCT03923556 653 660 O
4 NCT03923556 661 662 B-Eq-Comparison
Metabolic NCT03923556 663 672 B-Observation
Equivalent NCT03923556 673 683 I-Observation
of NCT03923556 684 686 I-Observation
Tasks NCT03923556 687 692 I-Observation
, NCT03923556 693 694 O
METs NCT03923556 695 699 B-Observation
, NCT03923556 700 701 O
such NCT03923556 702 706 O
as NCT03923556 707 709 O
climbing NCT03923556 710 718 B-Observation
up NCT03923556 719 721 I-Observation
1 NCT03923556 722 723 I-Observation
flight NCT03923556 724 730 I-Observation
of NCT03923556 731 733 I-Observation
stairs NCT03923556 734 740 I-Observation
) NCT03923556 741 742 O

- NCT03923556 746 747 O
Presence NCT03923556 749 757 O
of NCT03923556 758 760 O
any NCT03923556 761 764 O
contraindication NCT03923556 765 781 B-Contraindication
for NCT03923556 782 785 O
any NCT03923556 786 789 O
of NCT03923556 790 792 O
the NCT03923556 793 796 O
study NCT03923556 797 802 B-Study
- NCT03923556 803 804 O
related NCT03923556 805 812 O
medications NCT03923556 813 824 B-Drug
or NCT03923556 825 827 B-Or
interventions NCT03923556 828 841 B-Procedure
. NCT03923556 841 842 O

Inclusion NCT03923218 0 9 O
Criteria NCT03923218 10 18 O
for NCT03923218 19 22 O
chronic NCT03923218 23 30 B-Condition
periodontitis NCT03923218 31 44 I-Condition
groups NCT03923218 45 51 O
: NCT03923218 52 53 O

- NCT03923218 57 58 O
Clinical NCT03923218 60 68 B-Observation
attachment NCT03923218 69 79 I-Observation
loss NCT03923218 80 84 I-Observation
≥ NCT03923218 85 86 B-Eq-Comparison
5 NCT03923218 87 88 I-Eq-Comparison
mm NCT03923218 89 91 O

- NCT03923218 94 95 O
Probing NCT03923218 97 104 B-Observation
depth NCT03923218 105 110 I-Observation
≥ NCT03923218 111 112 B-Eq-Comparison
5 NCT03923218 113 114 I-Eq-Comparison
mm NCT03923218 115 117 O

- NCT03923218 120 121 O
Bone NCT03923218 123 127 B-Observation
loss NCT03923218 128 132 I-Observation
affecting NCT03923218 133 142 O
> NCT03923218 143 144 B-Eq-Comparison
30 NCT03923218 145 147 I-Eq-Comparison
% NCT03923218 148 149 O
of NCT03923218 150 152 O
the NCT03923218 153 156 O
existing NCT03923218 157 165 O
teeth NCT03923218 166 171 B-Modifier
on NCT03923218 172 174 O
clinical NCT03923218 175 183 B-Modifier
and NCT03923218 184 187 B-Or
radiographic NCT03923218 188 200 B-Modifier
examination NCT03923218 201 212 B-Procedure

- NCT03923218 215 216 O
gingival NCT03923218 218 226 B-Observation
index NCT03923218 227 232 I-Observation
( NCT03923218 233 234 O
GI NCT03923218 235 237 B-Observation
) NCT03923218 238 239 O
score NCT03923218 240 245 O
> NCT03923218 246 247 B-Eq-Comparison
1 NCT03923218 248 249 I-Eq-Comparison

Inclusion NCT03923218 251 260 O
criteria NCT03923218 261 269 O
for NCT03923218 270 273 O
control NCT03923218 274 281 O
group NCT03923218 282 287 O
: NCT03923218 288 289 O

- NCT03923218 293 294 I-Modifier
full NCT03923218 296 300 B-Modifier
- NCT03923218 301 302 O
mouth NCT03923218 303 308 I-Modifier
PD NCT03923218 309 311 B-Observation
was NCT03923218 312 315 O
≤ NCT03923218 316 317 B-Eq-Comparison
3 NCT03923218 318 319 I-Eq-Comparison
mm NCT03923218 320 322 O
, NCT03923218 323 324 O

- NCT03923218 328 329 O
Gingival NCT03923218 331 339 B-Observation
index NCT03923218 340 345 I-Observation
< NCT03923218 346 347 B-Eq-Comparison
1 NCT03923218 348 349 I-Eq-Comparison

- NCT03923218 353 354 O
there NCT03923218 356 361 O
was NCT03923218 362 365 O
no NCT03923218 366 368 B-Negation
indication NCT03923218 369 379 O
of NCT03923218 380 382 O
Attachment NCT03923218 383 393 B-Condition
Loss NCT03923218 394 398 I-Condition
or NCT03923218 399 401 B-Or
no NCT03923218 402 404 B-Negation
radiographic NCT03923218 405 417 B-Procedure
evidence NCT03923218 418 426 I-Procedure
of NCT03923218 427 429 O
alveolar NCT03923218 430 438 B-Condition
bone NCT03923218 439 443 I-Condition
loss NCT03923218 444 448 I-Condition
in NCT03923218 449 451 O
control NCT03923218 452 459 O
group NCT03923218 460 465 O
. NCT03923218 465 466 O

- NCT03923218 470 471 O
Non NCT03923218 473 476 B-Negation
- NCT03923218 477 478 O
smokers NCT03923218 479 486 B-Condition
. NCT03923218 486 487 O

Smoking NCT03923218 489 496 B-Condition
criteria NCT03923218 497 505 O
for NCT03923218 506 509 O
groups NCT03923218 510 516 O
: NCT03923218 517 518 O

- NCT03923218 522 523 O
patients NCT03923218 525 533 O
smoked NCT03923218 534 540 B-Observation
more NCT03923218 541 545 B-Eq-Comparison
than NCT03923218 546 550 I-Eq-Comparison
10 NCT03923218 551 553 I-Eq-Comparison
cigarettes NCT03923218 554 564 I-Eq-Comparison
in NCT03923218 565 567 I-Eq-Comparison
a NCT03923218 568 569 I-Eq-Comparison
day NCT03923218 570 573 I-Eq-Comparison

- NCT03923218 576 577 O
smoking NCT03923218 579 586 B-Condition
for NCT03923218 587 590 O
3 NCT03923218 591 592 B-Eq-Comparison
or NCT03923218 593 595 I-Eq-Comparison
more NCT03923218 596 600 I-Eq-Comparison
years NCT03923218 601 606 I-Eq-Comparison
, NCT03923218 607 608 O

Exclusion NCT03923218 610 619 O
Criteria NCT03923218 620 628 O
: NCT03923218 629 630 O

- NCT03923218 634 635 O
systemic NCT03923218 637 645 B-Modifier
condition NCT03923218 646 655 B-Condition
( NCT03923218 656 657 O
diabetes NCT03923218 658 666 B-Condition
, NCT03923218 667 668 O
cardiovascular NCT03923218 669 683 B-Condition
disease NCT03923218 684 691 I-Condition
, NCT03923218 692 693 O
immunologic NCT03923218 694 705 B-Condition
disorders NCT03923218 706 715 I-Condition
, NCT03923218 716 717 O
hepatitis NCT03923218 718 727 B-Condition
, NCT03923218 728 729 O
e. NCT03923218 730 732 O
g. NCT03923218 733 735 O
) NCT03923218 736 737 O

- NCT03923218 741 742 O
pregnancy NCT03923218 744 753 B-Condition
, NCT03923218 754 755 O
lactation NCT03923218 756 765 B-Condition
or NCT03923218 766 768 B-Or
menopause NCT03923218 769 778 B-Condition
term NCT03923218 779 783 O
, NCT03923218 784 785 O

- NCT03923218 789 790 I-Drug
antibiotic NCT03923218 792 802 B-Drug|Drug
treatment NCT03923218 803 812 B-Procedure
or NCT03923218 813 815 B-Or
non NCT03923218 816 819 B-Drug
- NCT03923218 820 821 I-Drug
steroidal NCT03923218 822 831 I-Drug
anti NCT03923218 832 836 O
- NCT03923218 837 838 O
inflammatory NCT03923218 839 851 I-Drug
medications NCT03923218 852 863 I-Drug
within NCT03923218 864 870 B-Eq-Comparison
the NCT03923218 871 874 I-Eq-Comparison
last NCT03923218 875 879 I-Eq-Comparison
3 NCT03923218 880 881 I-Eq-Comparison
months NCT03923218 882 888 I-Eq-Comparison
before NCT03923218 889 895 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923218 896 899 O
study NCT03923218 900 905 B-Study
, NCT03923218 906 907 O

- NCT03923218 911 912 I-Modifier
non NCT03923218 914 917 B-Modifier
- NCT03923218 918 919 O
surgical NCT03923218 920 928 I-Modifier
periodontal NCT03923218 929 940 B-Procedure
treatment NCT03923218 941 950 I-Procedure
during NCT03923218 951 957 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923218 958 961 O
last NCT03923218 962 966 B-Eq-Comparison
6 NCT03923218 967 968 I-Eq-Comparison
months NCT03923218 969 975 I-Eq-Comparison
before NCT03923218 976 982 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923218 983 986 O
study NCT03923218 987 992 B-Study
, NCT03923218 993 994 O

- NCT03923218 998 999 O
treatment NCT03923218 1001 1010 B-Procedure
with NCT03923218 1011 1015 O
Vitamin NCT03923218 1016 1023 B-Drug
D NCT03923218 1024 1025 I-Drug
supplementation NCT03923218 1026 1041 I-Drug
before NCT03923218 1042 1048 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923218 1049 1052 O
study NCT03923218 1053 1058 B-Study

Inclusion NCT03923998 0 9 O
Criteria NCT03923998 10 18 O
: NCT03923998 19 20 O

1 NCT03923998 24 25 O
. NCT03923998 25 26 O
Histologically NCT03923998 28 42 B-Procedure
confirmed NCT03923998 43 52 O
stage NCT03923998 53 58 B-Eq-Comparison
IVa NCT03923998 59 62 I-Eq-Comparison
squamous NCT03923998 63 71 B-Condition
cell NCT03923998 72 76 I-Condition
carcinoma NCT03923998 77 86 I-Condition
of NCT03923998 87 89 O
the NCT03923998 90 93 O
oral NCT03923998 94 98 B-Modifier
cavity NCT03923998 99 105 I-Modifier
. NCT03923998 105 106 O

2 NCT03923998 110 111 O
. NCT03923998 111 112 O
Surgically NCT03923998 114 124 B-Modifier
resectable NCT03923998 125 135 I-Modifier
oral NCT03923998 136 140 I-Modifier
squamous NCT03923998 141 149 B-Condition
carcinoma NCT03923998 150 159 I-Condition
with NCT03923998 160 164 O
invasion NCT03923998 165 173 B-Modifier
of NCT03923998 174 176 I-Modifier
mandible NCT03923998 177 185 I-Modifier
or NCT03923998 186 188 B-Or
maxilla NCT03923998 189 196 B-Modifier
. NCT03923998 196 197 O

3 NCT03923998 201 202 O
. NCT03923998 202 203 O
Newly NCT03923998 205 210 B-Eq-Comparison
diagnosed NCT03923998 211 220 O
or NCT03923998 221 223 B-Or
previously NCT03923998 224 234 B-Eq-Comparison
untreated NCT03923998 235 244 B-Modifier
squamous NCT03923998 245 253 B-Condition
cell NCT03923998 254 258 I-Condition
carcinoma NCT03923998 259 268 I-Condition
of NCT03923998 269 271 O
the NCT03923998 272 275 O
oral NCT03923998 276 280 B-Modifier
cavity NCT03923998 281 287 I-Modifier
. NCT03923998 287 288 O

Exclusion NCT03923998 290 299 O
Criteria NCT03923998 300 308 O
: NCT03923998 309 310 O

1 NCT03923998 314 315 O
. NCT03923998 315 316 O
Patients NCT03923998 318 326 O
with NCT03923998 327 331 O
distant NCT03923998 332 339 B-Condition
metastases NCT03923998 340 350 I-Condition
. NCT03923998 350 351 O

2 NCT03923998 355 356 O
. NCT03923998 356 357 O
Patients NCT03923998 359 367 O
with NCT03923998 368 372 O
contraindication NCT03923998 373 389 B-Contraindication
to NCT03923998 390 392 O
radiotherapy NCT03923998 393 405 B-Procedure
. NCT03923998 405 406 O

3 NCT03923998 410 411 O
. NCT03923998 411 412 O
Patients NCT03923998 414 422 O
with NCT03923998 423 427 O
vascular NCT03923998 428 436 B-Condition
disorders NCT03923998 437 446 I-Condition
or NCT03923998 447 449 B-Or
ischemic NCT03923998 450 458 B-Condition
heart NCT03923998 459 464 I-Condition
disease NCT03923998 465 472 I-Condition
. NCT03923998 472 473 O
- NCT03923998 475 476 O

Inclusion NCT03921619 0 9 O
Criteria NCT03921619 10 18 O
: NCT03921619 19 20 O

- NCT03921619 24 25 O
Greater NCT03921619 27 34 B-Eq-Comparison
than NCT03921619 35 39 I-Eq-Comparison
or NCT03921619 40 42 I-Eq-Comparison
equal NCT03921619 43 48 I-Eq-Comparison
to NCT03921619 49 51 I-Eq-Comparison
65 NCT03921619 52 54 I-Eq-Comparison
years NCT03921619 55 60 I-Eq-Comparison
of NCT03921619 61 63 O
age NCT03921619 64 67 B-Age

Exclusion NCT03921619 68 77 O
Criteria NCT03921619 78 86 O
: NCT03921619 87 88 O

- NCT03921619 92 93 O
Younger NCT03921619 95 102 B-Eq-Comparison
than NCT03921619 103 107 I-Eq-Comparison
65 NCT03921619 108 110 I-Eq-Comparison
years NCT03921619 111 116 I-Eq-Comparison
of NCT03921619 117 119 O
age NCT03921619 120 123 B-Age

- NCT03921619 126 127 O
Pre NCT03921619 129 132 B-Eq-Comparison
- NCT03921619 133 134 I-Eq-Comparison
existing NCT03921619 135 143 I-Eq-Comparison
cognitive NCT03921619 144 153 B-Condition
impairment NCT03921619 154 164 I-Condition

- NCT03921619 167 168 I-Eq-Comparison
Pre NCT03921619 170 173 B-Eq-Comparison
- NCT03921619 174 175 O
existing NCT03921619 176 184 I-Eq-Comparison
mobility NCT03921619 185 193 B-Condition
impairment NCT03921619 194 204 I-Condition

- NCT03921619 207 208 I-Eq-Comparison
Pre NCT03921619 210 213 B-Eq-Comparison
- NCT03921619 214 215 O
existing NCT03921619 216 224 I-Eq-Comparison
symptomatic NCT03921619 225 236 B-Assertion___Assertion-Type-Value:possible
upper NCT03921619 237 242 B-Modifier
or NCT03921619 243 245 B-Or
lower NCT03921619 246 251 B-Modifier
extremity NCT03921619 252 261 I-Modifier
disease NCT03921619 262 269 B-Condition

Inclusion NCT03929523 0 9 O
Criteria NCT03929523 10 18 O
: NCT03929523 19 20 O

- NCT03929523 24 25 O
Provide NCT03929523 27 34 O
written NCT03929523 35 42 O
informed NCT03929523 43 51 O
consent NCT03929523 52 59 O
prior NCT03929523 60 65 O
to NCT03929523 66 68 O
the NCT03929523 69 72 O
performance NCT03929523 73 84 O
of NCT03929523 85 87 O
any NCT03929523 88 91 O
study NCT03929523 92 97 B-Study
specific NCT03929523 98 106 O
procedure NCT03929523 107 116 B-Procedure

- NCT03929523 119 120 O
Affiliated NCT03929523 122 132 O
to NCT03929523 133 135 O
the NCT03929523 136 139 O
French NCT03929523 140 146 O
social NCT03929523 147 153 O
security NCT03929523 154 162 O
system NCT03929523 163 169 O

- NCT03929523 172 173 O
Recipient NCT03929523 175 184 O
age NCT03929523 185 188 B-Age
≥ NCT03929523 189 190 B-Eq-Comparison
18 NCT03929523 191 193 I-Eq-Comparison
years NCT03929523 194 199 I-Eq-Comparison

- NCT03929523 202 203 O
Patients NCT03929523 205 213 O
undergoing NCT03929523 214 224 B-Eq-Comparison
primary NCT03929523 225 232 B-Modifier
liver NCT03929523 233 238 B-Procedure
transplantation NCT03929523 239 254 I-Procedure
. NCT03929523 254 255 O

- NCT03929523 259 260 O
Candidate NCT03929523 262 271 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929523 272 275 O
a NCT03929523 276 277 O
first NCT03929523 278 283 B-Eq-Comparison
elective NCT03929523 284 292 B-Modifier
liver NCT03929523 293 298 B-Procedure
transplantation NCT03929523 299 314 I-Procedure
, NCT03929523 315 316 O
whatever NCT03929523 317 325 O
the NCT03929523 326 329 O
indication NCT03929523 330 340 O
, NCT03929523 341 342 O
with NCT03929523 343 347 B-And
a NCT03929523 348 349 O
liver NCT03929523 350 355 B-Procedure
graft NCT03929523 356 361 I-Procedure
harvested NCT03929523 362 371 O
from NCT03929523 372 376 O
a NCT03929523 377 378 O
brain NCT03929523 379 384 B-Procedure
- NCT03929523 385 386 I-Procedure
dead NCT03929523 387 391 I-Procedure
ECD NCT03929523 392 395 I-Procedure
defined NCT03929523 396 403 O
by NCT03929523 404 406 O
the NCT03929523 407 410 O
presence NCT03929523 411 419 O
of NCT03929523 420 422 O
at NCT03929523 423 425 B-Eq-Comparison
least NCT03929523 426 431 I-Eq-Comparison
one NCT03929523 432 435 I-Eq-Comparison
of NCT03929523 436 438 O
the NCT03929523 439 442 B-Criteria-Count
following NCT03929523 443 452 I-Criteria-Count
criteria NCT03929523 453 461 I-Criteria-Count
: NCT03929523 462 463 O

- NCT03929523 472 473 O
Donor NCT03929523 475 480 B-Modifier
age NCT03929523 481 484 B-Age
> NCT03929523 485 486 B-Eq-Comparison
65 NCT03929523 487 489 I-Eq-Comparison
years NCT03929523 490 495 I-Eq-Comparison

- NCT03929523 503 504 O
Intensive NCT03929523 506 515 B-Encounter
care NCT03929523 516 520 I-Encounter
unit NCT03929523 521 525 I-Encounter
stay NCT03929523 526 530 O
> NCT03929523 531 532 B-Eq-Comparison
7 NCT03929523 533 534 I-Eq-Comparison
days NCT03929523 535 539 I-Eq-Comparison

- NCT03929523 547 548 O
BMI NCT03929523 550 553 B-Observation
> NCT03929523 554 555 B-Eq-Comparison
30 NCT03929523 556 558 I-Eq-Comparison

- NCT03929523 567 568 O
Proven NCT03929523 570 576 O
macro NCT03929523 577 582 B-Observation
- NCT03929523 583 584 I-Observation
steatosis NCT03929523 585 594 I-Observation
biopsy NCT03929523 595 601 B-Procedure
≥ NCT03929523 602 603 B-Eq-Comparison
30 NCT03929523 604 606 I-Eq-Comparison
% NCT03929523 607 608 O

- NCT03929523 616 617 O
Natremia NCT03929523 619 627 B-Observation
> NCT03929523 628 629 B-Eq-Comparison
155 NCT03929523 630 633 I-Eq-Comparison
mmol NCT03929523 634 638 I-Eq-Comparison
/ NCT03929523 639 640 I-Eq-Comparison
L NCT03929523 641 642 I-Eq-Comparison
at NCT03929523 643 645 B-Eq-Comparison
any NCT03929523 646 649 I-Eq-Comparison
time NCT03929523 650 654 I-Eq-Comparison

- NCT03929523 662 663 O
AST NCT03929523 665 668 B-Observation
> NCT03929523 669 670 B-Eq-Comparison
150 NCT03929523 671 674 I-Eq-Comparison
IU NCT03929523 675 677 I-Eq-Comparison
/ NCT03929523 678 679 I-Eq-Comparison
mL NCT03929523 680 682 I-Eq-Comparison
at NCT03929523 683 685 B-Eq-Comparison
any NCT03929523 686 689 I-Eq-Comparison
time NCT03929523 690 694 I-Eq-Comparison

- NCT03929523 702 703 O
ALT NCT03929523 705 708 B-Observation
> NCT03929523 709 710 B-Eq-Comparison
170 NCT03929523 711 714 I-Eq-Comparison
IU NCT03929523 715 717 I-Eq-Comparison
/ NCT03929523 718 719 I-Eq-Comparison
mL NCT03929523 720 722 I-Eq-Comparison
at NCT03929523 723 725 B-Eq-Comparison
any NCT03929523 726 729 I-Eq-Comparison
time NCT03929523 730 734 I-Eq-Comparison
. NCT03929523 734 735 O

Exclusion NCT03929523 737 746 O
Criteria NCT03929523 747 755 O
: NCT03929523 756 757 O

- NCT03929523 761 762 O
Fulminant NCT03929523 764 773 B-Condition
hepatic NCT03929523 774 781 I-Condition
failure NCT03929523 782 789 I-Condition

- NCT03929523 792 793 O
Retransplantation NCT03929523 795 812 B-Procedure

- NCT03929523 815 816 O
Split NCT03929523 818 823 B-Modifier
liver NCT03929523 824 829 B-Procedure
transplantation NCT03929523 830 845 I-Procedure

- NCT03929523 848 849 O
Living NCT03929523 851 857 B-Modifier
donor NCT03929523 858 863 I-Modifier
liver NCT03929523 864 869 B-Procedure
transplantation NCT03929523 870 885 I-Procedure

- NCT03929523 888 889 O
Grafts NCT03929523 891 897 B-Observation
donated NCT03929523 898 905 I-Observation
after NCT03929523 906 911 B-Temporal-Connection___Temporal-Connection-Type-Value:after
cardiac NCT03929523 912 919 B-Condition
arrest NCT03929523 920 926 I-Condition
( NCT03929523 927 928 O
DCD NCT03929523 929 932 B-Observation
grafts NCT03929523 933 939 I-Observation
) NCT03929523 940 941 O

- NCT03929523 945 946 O
Domino NCT03929523 948 954 B-Modifier
transplantation NCT03929523 955 970 B-Procedure

- NCT03929523 973 974 O
Combined NCT03929523 976 984 B-Modifier
liver NCT03929523 985 990 B-Procedure
transplant NCT03929523 991 1001 I-Procedure

- NCT03929523 1004 1005 O
Unexpected NCT03929523 1007 1017 O
medical NCT03929523 1018 1025 O
contraindication NCT03929523 1026 1042 B-Contraindication
to NCT03929523 1043 1045 O
liver NCT03929523 1046 1051 B-Procedure
transplantation NCT03929523 1052 1067 I-Procedure

- NCT03929523 1070 1071 O
Patient NCT03929523 1073 1080 O
participating NCT03929523 1081 1094 B-Eq-Comparison
in NCT03929523 1095 1097 B-Study
other NCT03929523 1098 1103 B-Other
interventional NCT03929523 1104 1118 O
research NCT03929523 1119 1127 I-Study
, NCT03929523 1128 1129 O
excluding NCT03929523 1130 1139 B-Exception
routine NCT03929523 1140 1147 B-Modifier
care NCT03929523 1148 1152 I-Modifier
research NCT03929523 1153 1161 B-Study
( NCT03929523 1162 1163 O
old NCT03929523 1164 1167 B-Modifier
regulation NCT03929523 1168 1178 I-Modifier
) NCT03929523 1179 1180 O
and NCT03929523 1181 1184 B-Or
category NCT03929523 1185 1193 B-Modifier
2 NCT03929523 1194 1195 I-Modifier
research NCT03929523 1196 1204 B-Study
not NCT03929523 1205 1208 B-Negation
interfering NCT03929523 1209 1220 O
with NCT03929523 1221 1225 O
primary NCT03929523 1226 1233 O
endpoint NCT03929523 1234 1242 O
analysis NCT03929523 1243 1251 B-Study

- NCT03929523 1254 1255 O
Patient NCT03929523 1257 1264 O
under NCT03929523 1265 1270 O
legal NCT03929523 1271 1276 B-Observation
protection NCT03929523 1277 1287 I-Observation

- NCT03929523 1290 1291 O
Patient NCT03929523 1293 1300 O
deprived NCT03929523 1301 1309 B-Observation
of NCT03929523 1310 1312 I-Observation
liberty NCT03929523 1313 1320 I-Observation
by NCT03929523 1321 1323 O
a NCT03929523 1324 1325 O
judicial NCT03929523 1326 1334 O
or NCT03929523 1335 1337 O
administrative NCT03929523 1338 1352 O
decision NCT03929523 1353 1361 O

- NCT03929523 1364 1365 O
Patient NCT03929523 1367 1374 O
refusing NCT03929523 1375 1383 O
to NCT03929523 1384 1386 O
participate NCT03929523 1387 1398 O
in NCT03929523 1399 1401 O
the NCT03929523 1402 1405 O
study NCT03929523 1406 1411 O

- NCT03929523 1414 1415 O
Pregnant NCT03929523 1417 1425 B-Condition
or NCT03929523 1426 1428 B-Or
lactating NCT03929523 1429 1438 B-Condition
women NCT03929523 1439 1444 O

- NCT03929523 1447 1448 O
Inability NCT03929523 1450 1459 B-Condition
to NCT03929523 1460 1462 I-Condition
understand NCT03929523 1463 1473 I-Condition
information NCT03929523 1474 1485 O
concerning NCT03929523 1486 1496 O
the NCT03929523 1497 1500 O
protocol NCT03929523 1501 1509 O

Inclusion NCT03922516 0 9 O
Criteria NCT03922516 10 18 O
: NCT03922516 19 20 O

- NCT03922516 24 25 O
all NCT03922516 27 30 O
patients NCT03922516 31 39 O
who NCT03922516 40 43 O
are NCT03922516 44 47 O
assigned NCT03922516 48 56 O
to NCT03922516 57 59 O
a NCT03922516 60 61 O
clinically NCT03922516 62 72 O
indicated NCT03922516 73 82 B-Indication
chest NCT03922516 83 88 B-Modifier
X NCT03922516 89 90 B-Procedure
- NCT03922516 91 92 I-Procedure
ray NCT03922516 93 96 I-Procedure
by NCT03922516 97 99 O
the NCT03922516 100 103 O
emergency NCT03922516 104 113 O
department NCT03922516 114 124 O
of NCT03922516 125 127 O
Vienna NCT03922516 128 134 O
General NCT03922516 135 142 O
Hospital NCT03922516 143 151 O

- NCT03922516 154 155 O
ability NCT03922516 157 164 O
to NCT03922516 165 167 O
provide NCT03922516 168 175 O
informed NCT03922516 176 184 O
consent NCT03922516 185 192 O

- NCT03922516 195 196 O
informed NCT03922516 198 206 O
consent NCT03922516 207 214 O
after NCT03922516 215 220 O
detailed NCT03922516 221 229 O
patient NCT03922516 230 237 O
briefing NCT03922516 238 246 O

Exclusion NCT03922516 247 256 O
Criteria NCT03922516 257 265 O
: NCT03922516 266 267 O

- NCT03922516 271 272 O
the NCT03922516 274 277 O
emergency NCT03922516 278 287 O
departments NCT03922516 288 299 O
assessment NCT03922516 300 310 B-Procedure
of NCT03922516 311 313 O
a NCT03922516 314 315 O
critical NCT03922516 316 324 O
clinical NCT03922516 325 333 B-Condition
condition NCT03922516 334 343 I-Condition
oppose NCT03922516 344 350 B-Assertion___Assertion-Type-Value:hypothetical
an NCT03922516 351 353 O
examination NCT03922516 354 365 B-Procedure
with NCT03922516 366 370 O
both NCT03922516 371 375 B-Modifier
modalities NCT03922516 376 386 I-Modifier
( NCT03922516 387 388 O
ULDCT NCT03922516 389 394 B-Procedure
of NCT03922516 395 397 O
the NCT03922516 398 401 O
chest NCT03922516 402 407 B-Modifier|Modifier
, NCT03922516 408 409 O
chest NCT03922516 410 415 O
X NCT03922516 416 417 B-Procedure
- NCT03922516 418 419 I-Procedure
ray NCT03922516 420 423 I-Procedure
) NCT03922516 424 425 O

- NCT03922516 429 430 O
assigned NCT03922516 432 440 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922516 441 443 O
chest NCT03922516 444 449 B-Modifier
X NCT03922516 450 451 B-Procedure
- NCT03922516 452 453 I-Procedure
ray NCT03922516 454 457 I-Procedure
as NCT03922516 458 460 O
follow NCT03922516 461 467 O
- NCT03922516 468 469 O
up NCT03922516 470 472 O

- NCT03922516 475 476 O
women NCT03922516 478 483 O
with NCT03922516 484 488 B-And
positive NCT03922516 489 497 O
ß NCT03922516 498 499 B-Observation
- NCT03922516 500 501 I-Observation
HCG NCT03922516 502 505 I-Observation
- NCT03922516 506 507 O
test NCT03922516 508 512 I-Observation

Inclusion NCT03923608 0 9 O
Criteria NCT03923608 10 18 O
: NCT03923608 19 20 O
should NCT03923608 21 27 O
report NCT03923608 28 34 O
the NCT03923608 35 38 O
absence NCT03923608 39 46 B-Negation
of NCT03923608 47 49 O
: NCT03923608 50 51 O

- NCT03923608 55 56 O
anemia NCT03923608 58 64 B-Condition
, NCT03923608 65 66 O

- NCT03923608 70 71 O
diabetes NCT03923608 73 81 B-Condition
, NCT03923608 82 83 O

- NCT03923608 87 88 O
cardiovascular NCT03923608 90 104 B-Condition
disease NCT03923608 105 112 I-Condition
, NCT03923608 113 114 O

- NCT03923608 118 119 O
and NCT03923608 121 124 O
upper NCT03923608 125 130 B-Modifier
limb NCT03923608 131 135 I-Modifier
and NCT03923608 136 139 B-Or
spinal NCT03923608 140 146 B-Modifier
muscular NCT03923608 147 155 I-Modifier
injuries NCT03923608 156 164 B-Condition
in NCT03923608 165 167 O
the NCT03923608 168 171 O
last NCT03923608 172 176 B-Eq-Comparison
six NCT03923608 177 180 I-Eq-Comparison
months NCT03923608 181 187 I-Eq-Comparison

Exclusion NCT03923608 188 197 O
Criteria NCT03923608 198 206 O
: NCT03923608 207 208 O

- NCT03923608 212 213 O
absence NCT03923608 215 222 B-Negation
at NCT03923608 223 225 O
any NCT03923608 226 229 O
study NCT03923608 230 235 B-Study
session NCT03923608 236 243 O
and NCT03923608 244 247 O

- NCT03923608 250 251 O
episode NCT03923608 253 260 O
of NCT03923608 261 263 O
muscle NCT03923608 264 270 B-Modifier
- NCT03923608 271 272 I-Modifier
tendon NCT03923608 273 279 I-Modifier
or NCT03923608 280 282 B-Or
osteoarticular NCT03923608 283 297 B-Modifier
injury NCT03923608 298 304 B-Condition
in NCT03923608 305 307 O
the NCT03923608 308 311 O
upper NCT03923608 312 317 B-Modifier
limbs NCT03923608 318 323 I-Modifier
during NCT03923608 324 330 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923608 331 334 O
study NCT03923608 335 340 B-Study
. NCT03923608 340 341 O

Inclusion NCT03924167 0 9 O
Criteria NCT03924167 10 18 O
: NCT03924167 19 20 O

Inclusion NCT03924167 22 31 O
Criteria NCT03924167 32 40 O
for NCT03924167 41 44 O
community NCT03924167 45 54 O
health NCT03924167 55 61 O
representatives NCT03924167 62 77 O
( NCT03924167 78 79 O
CHR NCT03924167 80 83 B-Condition
) NCT03924167 84 85 O
s. NCT03924167 86 88 O
> NCT03924167 90 91 B-Eq-Comparison
> NCT03924167 93 94 O
18 NCT03924167 95 97 I-Eq-Comparison
years NCT03924167 98 103 I-Eq-Comparison
of NCT03924167 104 106 O
age NCT03924167 107 110 B-Age
or NCT03924167 111 113 O
older NCT03924167 114 119 O

- NCT03924167 122 123 O
have NCT03924167 125 129 O
at NCT03924167 130 132 B-Eq-Comparison
least NCT03924167 133 138 I-Eq-Comparison
a NCT03924167 139 140 O
high NCT03924167 141 145 B-Observation
school NCT03924167 146 152 I-Observation
degree NCT03924167 153 159 I-Observation

- NCT03924167 162 163 O
have NCT03924167 165 169 O
experience NCT03924167 170 180 O
and NCT03924167 181 184 O
/ NCT03924167 185 186 O
or NCT03924167 187 189 O
interest NCT03924167 190 198 O
in NCT03924167 199 201 O
working NCT03924167 202 209 O
with NCT03924167 210 214 O
tribal NCT03924167 215 221 O
children NCT03924167 222 230 O
and NCT03924167 231 234 O
families NCT03924167 235 243 O
. NCT03924167 243 244 O

Exclusion NCT03924167 246 255 O
criteria NCT03924167 256 264 O
: NCT03924167 265 266 O

- NCT03924167 270 271 O
having NCT03924167 273 279 O
less NCT03924167 280 284 B-Eq-Comparison
than NCT03924167 285 289 I-Eq-Comparison
a NCT03924167 290 291 O
high NCT03924167 292 296 B-Observation
school NCT03924167 297 303 I-Observation
degree NCT03924167 304 310 I-Observation

- NCT03924167 313 314 O
not NCT03924167 316 319 O
having NCT03924167 320 326 O
experience NCT03924167 327 337 O
with NCT03924167 338 342 O
tribal NCT03924167 343 349 O
families NCT03924167 350 358 O

Inclusion NCT03924167 359 368 O
criteria NCT03924167 369 377 O
for NCT03924167 378 381 O
families NCT03924167 382 390 O

- NCT03924167 393 394 O
includes NCT03924167 396 404 O
written NCT03924167 405 412 O
consent NCT03924167 413 420 O
for NCT03924167 421 424 O
adults NCT03924167 425 431 O
and NCT03924167 432 435 O
assent NCT03924167 436 442 O
for NCT03924167 443 446 O
children NCT03924167 447 455 O
ages NCT03924167 456 460 B-Age
12 NCT03924167 461 463 B-Eq-Comparison
- NCT03924167 464 465 I-Eq-Comparison
17 NCT03924167 466 468 O
. NCT03924167 468 469 O

- NCT03924167 473 474 O
at NCT03924167 476 478 O
least NCT03924167 479 484 O
one NCT03924167 485 488 O
parent NCT03924167 489 495 O
/ NCT03924167 496 497 O
caregiver NCT03924167 498 507 O
who NCT03924167 508 511 O
is NCT03924167 512 514 O
a NCT03924167 515 516 O
member NCT03924167 517 523 O
of NCT03924167 524 526 O
the NCT03924167 527 530 O
focal NCT03924167 531 536 O
tribe NCT03924167 537 542 O
and NCT03924167 543 546 O
at NCT03924167 547 549 O
least NCT03924167 550 555 O
one NCT03924167 556 559 O
child NCT03924167 560 565 O
, NCT03924167 566 567 O
aged NCT03924167 568 572 B-Age
12 NCT03924167 573 575 B-Eq-Comparison
- NCT03924167 576 577 I-Eq-Comparison
18 NCT03924167 578 580 O
living NCT03924167 581 587 O
in NCT03924167 588 590 O
the NCT03924167 591 594 O
household NCT03924167 595 604 O

Exclusion NCT03924167 605 614 O
Criteria NCT03924167 615 623 O
: NCT03924167 624 625 O

- NCT03924167 629 630 O
current NCT03924167 632 639 B-Eq-Comparison
protective NCT03924167 640 650 B-Observation
order NCT03924167 651 656 I-Observation

- NCT03924167 659 660 O
current NCT03924167 662 669 B-Eq-Comparison
intimate NCT03924167 670 678 B-Condition
partner NCT03924167 679 686 I-Condition
violence NCT03924167 687 695 I-Condition
( NCT03924167 696 697 O
IPV NCT03924167 698 701 B-Condition
) NCT03924167 702 703 O
record NCT03924167 704 710 O
will NCT03924167 711 715 O
be NCT03924167 716 718 O
excluded NCT03924167 719 727 B-Negation
. NCT03924167 727 728 O

Inclusion NCT03926572 0 9 O
Criteria NCT03926572 10 18 O
: NCT03926572 19 20 O

- NCT03926572 24 25 O
Adult NCT03926572 27 32 O
patients NCT03926572 33 41 O
over NCT03926572 42 46 B-Eq-Comparison
18 NCT03926572 47 49 I-Eq-Comparison
years NCT03926572 50 55 I-Age|Eq-Comparison

- NCT03926572 58 59 O
Diagnosis NCT03926572 61 70 O
of NCT03926572 71 73 O
Pulmonary NCT03926572 74 83 B-Condition
arterial NCT03926572 84 92 I-Condition
hypertension NCT03926572 93 105 I-Condition
or NCT03926572 106 108 B-Or
non NCT03926572 109 112 B-Modifier
- NCT03926572 113 114 I-Modifier
operable NCT03926572 115 123 I-Modifier
chronic NCT03926572 124 131 I-Modifier
thromboembolic NCT03926572 132 146 B-Condition
pulmonary NCT03926572 147 156 I-Condition
hypertension NCT03926572 157 169 I-Condition
established NCT03926572 170 181 O
by NCT03926572 182 184 O
right NCT03926572 185 190 B-Procedure
cardiac NCT03926572 191 198 I-Procedure
catheterization NCT03926572 199 214 I-Procedure
prior NCT03926572 215 220 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926572 221 223 O
inclusion NCT03926572 224 233 O
in NCT03926572 234 236 O
the NCT03926572 237 240 O
study NCT03926572 241 246 B-Study

- NCT03926572 249 250 O
Patients NCT03926572 252 260 O
admitted NCT03926572 261 269 B-Encounter
in NCT03926572 270 272 I-Encounter
intensive NCT03926572 273 282 O
care NCT03926572 283 287 I-Encounter
unit NCT03926572 288 292 I-Encounter
for NCT03926572 293 296 O
acute NCT03926572 297 302 O
decompensation NCT03926572 303 317 B-Modifier
of NCT03926572 318 320 O
pulmonary NCT03926572 321 330 B-Condition
hypertension NCT03926572 331 343 I-Condition
requiring NCT03926572 344 353 O
intravenous NCT03926572 354 365 B-Modifier
diuretic NCT03926572 366 374 B-Procedure
therapy NCT03926572 375 382 I-Procedure
± NCT03926572 383 384 B-Or
use NCT03926572 385 388 O
of NCT03926572 389 391 O
inotropes NCT03926572 392 401 B-Drug
or NCT03926572 402 404 B-Or
vasopressors NCT03926572 405 417 B-Drug
. NCT03926572 417 418 O

- NCT03926572 422 423 O
Patients NCT03926572 425 433 O
must NCT03926572 434 438 O
have NCT03926572 439 443 O
given NCT03926572 444 449 O
their NCT03926572 450 455 O
written NCT03926572 456 463 O
informed NCT03926572 464 472 O
consent NCT03926572 473 480 O
to NCT03926572 481 483 O
participate NCT03926572 484 495 O
in NCT03926572 496 498 O
the NCT03926572 499 502 O
study NCT03926572 503 508 B-Study
after NCT03926572 509 514 O
having NCT03926572 515 521 O
received NCT03926572 522 530 O
adequate NCT03926572 531 539 O
previous NCT03926572 540 548 O
information NCT03926572 549 560 O
and NCT03926572 561 564 O
prior NCT03926572 565 570 O
to NCT03926572 571 573 O
any NCT03926572 574 577 O
study NCT03926572 578 583 B-Study
- NCT03926572 584 585 O
specific NCT03926572 586 594 O
procedures NCT03926572 595 605 B-Procedure

Exclusion NCT03926572 606 615 O
Criteria NCT03926572 616 624 O
: NCT03926572 625 626 O

- NCT03926572 630 631 O
Patients NCT03926572 633 641 O
with NCT03926572 642 646 O
post NCT03926572 647 651 B-Modifier
- NCT03926572 652 653 I-Modifier
capillary NCT03926572 654 663 I-Modifier
pulmonary NCT03926572 664 673 B-Condition
hypertension NCT03926572 674 686 I-Condition

- NCT03926572 689 690 O
Patients NCT03926572 692 700 O
with NCT03926572 701 705 O
pulmonary NCT03926572 706 715 B-Condition
hypertension NCT03926572 716 728 I-Condition
associated NCT03926572 729 739 O
with NCT03926572 740 744 O
chronic NCT03926572 745 752 B-Modifier
respiratory NCT03926572 753 764 B-Condition
disease NCT03926572 765 772 I-Condition

- NCT03926572 775 776 O
Patients NCT03926572 778 786 O
with NCT03926572 787 791 O
pulmonary NCT03926572 792 801 B-Condition
hypertension NCT03926572 802 814 I-Condition
with NCT03926572 815 819 O
unclear NCT03926572 820 827 B-Modifier
/ NCT03926572 828 829 O
or NCT03926572 830 832 B-Or
multifactorial NCT03926572 833 847 B-Modifier
mechanisms NCT03926572 848 858 I-Modifier

- NCT03926572 861 862 O
Patients NCT03926572 864 872 O
with NCT03926572 873 877 O
operable NCT03926572 878 886 B-Modifier
chronic NCT03926572 887 894 I-Modifier
thromboembolic NCT03926572 895 909 I-Modifier
pulmonary NCT03926572 910 919 B-Condition
hypertension NCT03926572 920 932 I-Condition

- NCT03926572 935 936 O
Shock NCT03926572 938 943 B-Condition
due NCT03926572 944 947 O
to NCT03926572 948 950 O
another NCT03926572 951 958 B-Other
cause NCT03926572 959 964 B-Condition
than NCT03926572 965 969 B-Exception
acute NCT03926572 970 975 O
decompensation NCT03926572 976 990 B-Modifier
of NCT03926572 991 993 O
pulmonary NCT03926572 994 1003 B-Condition
hypertension NCT03926572 1004 1016 I-Condition

- NCT03926572 1019 1020 O
Pregnant NCT03926572 1022 1030 B-Condition
women NCT03926572 1031 1036 O
, NCT03926572 1037 1038 O
or NCT03926572 1039 1041 B-Or
breast NCT03926572 1042 1048 B-Condition
feeding NCT03926572 1049 1056 I-Condition
women NCT03926572 1057 1062 O

- NCT03926572 1065 1066 O
Adult NCT03926572 1068 1073 O
protected NCT03926572 1074 1083 B-Observation
person NCT03926572 1084 1090 I-Observation

- NCT03926572 1093 1094 O
Person NCT03926572 1096 1102 O
deprived NCT03926572 1103 1111 B-Observation
of NCT03926572 1112 1114 I-Observation
liberty NCT03926572 1115 1122 I-Observation

- NCT03926572 1125 1126 O
Person NCT03926572 1128 1134 O
admitted NCT03926572 1135 1143 O
without NCT03926572 1144 1151 O
consent NCT03926572 1152 1159 O

- NCT03926572 1162 1163 O
Pregnant NCT03926572 1165 1173 B-Condition
or NCT03926572 1174 1176 B-Or
breastfeeding NCT03926572 1177 1190 B-Condition
women NCT03926572 1191 1196 O

Inclusion NCT03926273 0 9 O
Criteria NCT03926273 10 18 O
: NCT03926273 19 20 O

- NCT03926273 24 25 O
All NCT03926273 27 30 O
participants NCT03926273 31 43 O
were NCT03926273 44 48 O
included NCT03926273 49 57 O
if NCT03926273 58 60 O
their NCT03926273 61 66 O
age NCT03926273 67 70 B-Age
more NCT03926273 71 75 B-Eq-Comparison
than NCT03926273 76 80 I-Eq-Comparison
or NCT03926273 81 83 I-Eq-Comparison
equal NCT03926273 84 89 I-Eq-Comparison
to NCT03926273 90 92 I-Eq-Comparison
18 NCT03926273 93 95 I-Eq-Comparison
years NCT03926273 96 101 I-Eq-Comparison
. NCT03926273 101 102 O
Body NCT03926273 104 108 B-Observation
mass NCT03926273 109 113 I-Observation
index NCT03926273 114 119 I-Observation
< NCT03926273 120 121 B-Eq-Comparison
30 NCT03926273 122 124 I-Eq-Comparison
kg NCT03926273 125 127 I-Eq-Comparison
/ NCT03926273 128 129 I-Eq-Comparison
m2 NCT03926273 130 132 I-Eq-Comparison
, NCT03926273 133 134 O
total NCT03926273 135 140 B-Observation
cholesterol NCT03926273 141 152 I-Observation
< NCT03926273 153 154 B-Eq-Comparison
200 NCT03926273 155 158 I-Eq-Comparison
mg NCT03926273 159 161 O
/ NCT03926273 162 163 I-Eq-Comparison
dl NCT03926273 164 166 I-Eq-Comparison
, NCT03926273 167 168 O
serum NCT03926273 169 174 B-Observation
triglycerides NCT03926273 175 188 I-Observation
< NCT03926273 189 190 B-Eq-Comparison
200 NCT03926273 191 194 I-Eq-Comparison
mg NCT03926273 195 197 I-Eq-Comparison
/ NCT03926273 198 199 I-Eq-Comparison
dl NCT03926273 200 202 I-Eq-Comparison
and NCT03926273 203 206 B-And
random NCT03926273 207 213 B-Modifier
blood NCT03926273 214 219 B-Observation
glucose NCT03926273 220 227 I-Observation
level NCT03926273 228 233 I-Observation
< NCT03926273 234 235 B-Eq-Comparison
126 NCT03926273 236 239 I-Eq-Comparison
mg NCT03926273 240 242 I-Eq-Comparison
/ NCT03926273 243 244 I-Eq-Comparison
dl NCT03926273 245 247 I-Eq-Comparison
. NCT03926273 247 248 O

Exclusion NCT03926273 250 259 O
Criteria NCT03926273 260 268 O
: NCT03926273 269 270 O

- NCT03926273 274 275 O
Participants NCT03926273 277 289 O
had NCT03926273 290 293 O
acute NCT03926273 294 299 O
or NCT03926273 300 302 B-Or
chronic NCT03926273 303 310 B-Modifier
metabolic NCT03926273 311 320 B-Condition
disorders NCT03926273 321 330 I-Condition
( NCT03926273 331 332 O
liver NCT03926273 333 338 B-Modifier
, NCT03926273 339 340 O
kidney NCT03926273 341 347 B-Modifier
, NCT03926273 348 349 O
thyroid NCT03926273 350 357 B-Modifier
, NCT03926273 358 359 O
endocrine NCT03926273 360 369 B-Modifier
or NCT03926273 370 372 B-Or
gastrointestinal NCT03926273 373 389 B-Modifier
disorders NCT03926273 390 399 B-Condition
) NCT03926273 400 401 O
. NCT03926273 402 403 O

- NCT03926273 407 408 O
Females NCT03926273 410 417 O
with NCT03926273 418 422 B-And
irregular NCT03926273 423 432 B-Condition
menstrual NCT03926273 433 442 I-Condition
cycle NCT03926273 443 448 I-Condition
or NCT03926273 449 451 B-Or
on NCT03926273 452 454 B-Eq-Comparison
estrogen NCT03926273 455 463 B-Procedure
therapy NCT03926273 464 471 I-Procedure
( NCT03926273 472 473 O
7 NCT03926273 474 475 O
) NCT03926273 476 477 O
. NCT03926273 478 479 O

- NCT03926273 483 484 O
Participants NCT03926273 486 498 O
with NCT03926273 499 503 O
organic NCT03926273 504 511 B-Modifier
cerebral NCT03926273 512 520 B-Condition
lesion NCT03926273 521 527 I-Condition
that NCT03926273 528 532 O
was NCT03926273 533 536 O
detected NCT03926273 537 545 O
on NCT03926273 546 548 O
cranial NCT03926273 549 556 B-Modifier
computed NCT03926273 557 565 B-Procedure
tomography NCT03926273 566 576 I-Procedure
( NCT03926273 577 578 O
CT NCT03926273 579 581 B-Procedure
) NCT03926273 582 583 O
or NCT03926273 584 586 B-Or
cranial NCT03926273 587 594 B-Modifier
magnetic NCT03926273 595 603 B-Procedure
resonance NCT03926273 604 613 I-Procedure
imaging NCT03926273 614 621 I-Procedure
( NCT03926273 622 623 O
MRI NCT03926273 624 627 B-Procedure
) NCT03926273 628 629 O
. NCT03926273 630 631 O

Inclusion NCT03925961 0 9 O
Criteria NCT03925961 10 18 O
: NCT03925961 19 20 O

- NCT03925961 24 25 O
General NCT03925961 27 34 O
surgical NCT03925961 35 43 O
patients NCT03925961 44 52 O
who NCT03925961 53 56 O
will NCT03925961 57 61 B-Eq-Comparison
undergo NCT03925961 62 69 I-Eq-Comparison
same NCT03925961 70 74 B-Modifier
- NCT03925961 75 76 I-Modifier
day NCT03925961 77 80 I-Modifier
laparoscopic NCT03925961 81 93 B-Procedure
ventral NCT03925961 94 101 I-Procedure
hernia NCT03925961 102 108 I-Procedure
, NCT03925961 109 110 O
inguinal NCT03925961 111 119 B-Procedure
hernia NCT03925961 120 126 I-Procedure
, NCT03925961 127 128 O
and NCT03925961 129 132 B-Or
gallbladder NCT03925961 133 144 B-Procedure
surgery NCT03925961 145 152 I-Procedure
at NCT03925961 153 155 O
Howard NCT03925961 156 162 O
County NCT03925961 163 169 O
General NCT03925961 170 177 O
Hospital NCT03925961 178 186 O
with NCT03925961 187 191 O
the NCT03925961 192 195 O
general NCT03925961 196 203 B-Provider
surgery NCT03925961 204 211 I-Provider
practice NCT03925961 212 220 I-Provider
at NCT03925961 221 223 O
Johns NCT03925961 224 229 O
Hopkins NCT03925961 230 237 O
Community NCT03925961 238 247 O
Physicians NCT03925961 248 258 O
. NCT03925961 258 259 O

Exclusion NCT03925961 261 270 O
Criteria NCT03925961 271 279 O
: NCT03925961 280 281 O

- NCT03925961 285 286 O
Patients NCT03925961 288 296 O
less NCT03925961 297 301 B-Eq-Comparison
than NCT03925961 302 306 I-Eq-Comparison
18 NCT03925961 307 309 I-Eq-Comparison
years NCT03925961 310 315 I-Eq-Comparison
of NCT03925961 316 318 O
age NCT03925961 319 322 B-Age

- NCT03925961 325 326 O
Adults NCT03925961 328 334 O
who NCT03925961 335 338 O
lack NCT03925961 339 343 O
the NCT03925961 344 347 O
capacity NCT03925961 348 356 O
to NCT03925961 357 359 O
consent NCT03925961 360 367 O

- NCT03925961 370 371 O
Pregnant NCT03925961 373 381 B-Condition
women NCT03925961 382 387 O

- NCT03925961 390 391 O
Prisoners NCT03925961 393 402 B-Observation

- NCT03925961 405 406 O
Non NCT03925961 408 411 B-Negation
- NCT03925961 412 413 O
English NCT03925961 414 421 O
speakers NCT03925961 422 430 O
. NCT03925961 430 431 O

Inclusion NCT03921736 0 9 O
Criteria NCT03921736 10 18 O
: NCT03921736 19 20 O

- NCT03921736 24 25 O
Treatment NCT03921736 27 36 B-Procedure
- NCT03921736 37 38 O
naive NCT03921736 39 44 B-Negation
postmenopausal NCT03921736 45 59 B-Condition
women NCT03921736 60 65 O

- NCT03921736 68 69 O
Diagnosed NCT03921736 71 80 O
hypertension NCT03921736 81 93 B-Condition
( NCT03921736 94 95 O
grade NCT03921736 96 101 B-Eq-Comparison
1 NCT03921736 102 103 I-Eq-Comparison
or NCT03921736 104 106 I-Eq-Comparison
2 NCT03921736 107 108 I-Eq-Comparison
according NCT03921736 109 118 O
to NCT03921736 119 121 O
ESH NCT03921736 122 125 O
/ NCT03921736 126 127 O
ESC NCT03921736 128 131 O
2013 NCT03921736 132 136 O
guidelines NCT03921736 137 147 O
) NCT03921736 148 149 O

Exclusion NCT03921736 151 160 O
Criteria NCT03921736 161 169 O
: NCT03921736 170 171 O

- NCT03921736 175 176 O
breast NCT03921736 178 184 B-Modifier
cancer NCT03921736 185 191 B-Condition
in NCT03921736 192 194 O
a NCT03921736 195 196 O
first NCT03921736 197 202 B-Family-Member
- NCT03921736 203 204 I-Family-Member
degree NCT03921736 205 211 I-Family-Member
relative NCT03921736 212 220 I-Family-Member

- NCT03921736 223 224 O
hyperplasia NCT03921736 226 237 B-Condition
diagnosed NCT03921736 238 247 O
by NCT03921736 248 250 O
endometrial NCT03921736 251 262 B-Procedure
biopsy NCT03921736 263 269 I-Procedure
, NCT03921736 270 271 O

- NCT03921736 275 276 O
history NCT03921736 278 285 B-Eq-Comparison
of NCT03921736 286 288 O
thromboembolic NCT03921736 289 303 B-Condition
diseases NCT03921736 304 312 I-Condition
, NCT03921736 313 314 O

- NCT03921736 318 319 O
current NCT03921736 321 328 B-Eq-Comparison
or NCT03921736 329 331 B-Or
history NCT03921736 332 339 B-Eq-Comparison
of NCT03921736 340 342 O
use NCT03921736 343 346 O
of NCT03921736 347 349 O
estrogen NCT03921736 350 358 B-Procedure
- NCT03921736 359 360 I-Procedure
progestin NCT03921736 361 370 I-Procedure
therapy NCT03921736 371 378 I-Procedure
or NCT03921736 379 381 B-Or
contraceptives NCT03921736 382 396 B-Procedure

- NCT03921736 399 400 O
diabetes NCT03921736 402 410 B-Condition
, NCT03921736 411 412 O

- NCT03921736 416 417 O
kidney NCT03921736 419 425 B-Condition
failure NCT03921736 426 433 I-Condition
, NCT03921736 434 435 O

- NCT03921736 439 440 O
thyroid NCT03921736 442 449 B-Condition
disease NCT03921736 450 457 I-Condition
, NCT03921736 458 459 O

- NCT03921736 463 464 O
heart NCT03921736 466 471 B-Modifier
and NCT03921736 472 475 B-Or
other NCT03921736 476 481 B-Other
chronic NCT03921736 482 489 B-Modifier
diseases NCT03921736 490 498 B-Condition
( NCT03921736 499 500 O
secondary NCT03921736 501 510 B-Condition
hypertension NCT03921736 511 523 I-Condition
, NCT03921736 524 525 O
atrial NCT03921736 526 532 B-Condition
fibrillation NCT03921736 533 545 I-Condition
) NCT03921736 546 547 O

Inclusion NCT03923647 0 9 O
Criteria NCT03923647 10 18 O
: NCT03923647 19 20 O

- NCT03923647 24 25 O
stable NCT03923647 27 33 O
patients NCT03923647 34 42 O
with NCT03923647 43 47 O
definite NCT03923647 48 56 O
occurrence NCT03923647 57 67 O
of NCT03923647 68 70 O
intra NCT03923647 71 76 B-Modifier
- NCT03923647 77 78 I-Modifier
abdominal NCT03923647 79 88 I-Modifier
injury NCT03923647 89 95 B-Condition

- NCT03923647 98 99 O
patients NCT03923647 101 109 O
with NCT03923647 110 114 O
equivocal NCT03923647 115 124 O
result NCT03923647 125 131 O
by NCT03923647 132 134 O
clinical NCT03923647 135 143 O
and NCT03923647 144 147 O
radiological NCT03923647 148 160 B-Procedure
evaluation NCT03923647 161 171 I-Procedure

Exclusion NCT03923647 172 181 O
Criteria NCT03923647 182 190 O
: NCT03923647 191 192 O

- NCT03923647 196 197 O
patients NCT03923647 199 207 O
with NCT03923647 208 212 O
penetrating NCT03923647 213 224 B-Modifier
abdominal NCT03923647 225 234 I-Modifier
trauma NCT03923647 235 241 B-Condition

- NCT03923647 244 245 O
stable NCT03923647 247 253 O
patients NCT03923647 254 262 O
not NCT03923647 263 266 B-Negation
in NCT03923647 267 269 O
need NCT03923647 270 274 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03923647 275 278 I-Assertion___Assertion-Type-Value:hypothetical
any NCT03923647 279 282 O
intervention NCT03923647 283 295 B-Procedure
for NCT03923647 296 299 O
conservative NCT03923647 300 312 B-Procedure
management NCT03923647 313 323 I-Procedure

- NCT03923647 326 327 O
patients NCT03923647 329 337 O
with NCT03923647 338 342 O
marked NCT03923647 343 349 O
haemodynamic NCT03923647 350 362 B-Condition
instability NCT03923647 363 374 I-Condition

- NCT03923647 377 378 O
polyt NCT03923647 380 385 B-Condition
- NCT03923647 386 387 I-Condition
traumatized NCT03923647 388 399 I-Condition
Patients NCT03923647 400 408 O

Inclusion NCT03924128 0 9 O
Criteria NCT03924128 10 18 O
: NCT03924128 19 20 O

- NCT03924128 24 25 O
Selected NCT03924128 27 35 O
will NCT03924128 36 40 O
be NCT03924128 41 43 O
subjects NCT03924128 44 52 O
to NCT03924128 53 55 O
meeting NCT03924128 56 63 O
the NCT03924128 64 67 O
following NCT03924128 68 77 O
criteria NCT03924128 78 86 O
: NCT03924128 87 88 O
male NCT03924128 89 93 O
and NCT03924128 94 97 B-Or
female NCT03924128 98 104 O
subjects NCT03924128 105 113 O
age NCT03924128 114 117 B-Age
≥ NCT03924128 118 119 B-Eq-Comparison
20 NCT03924128 120 122 I-Eq-Comparison
years NCT03924128 123 128 I-Eq-Comparison
old NCT03924128 129 132 O
, NCT03924128 133 134 O
diagnosed NCT03924128 135 144 O
with NCT03924128 145 149 O
Osteoarthritis NCT03924128 150 164 B-Condition
stages NCT03924128 165 171 B-Eq-Comparison
III NCT03924128 172 175 I-Eq-Comparison
and NCT03924128 176 179 I-Eq-Comparison
IV NCT03924128 180 182 I-Eq-Comparison
according NCT03924128 183 192 O
to NCT03924128 193 195 O
the NCT03924128 196 199 O
American NCT03924128 200 208 O
College NCT03924128 209 216 O
of NCT03924128 217 219 O
Rheumatology NCT03924128 220 232 O
, NCT03924128 233 234 O
manifesting NCT03924128 235 246 O
pain NCT03924128 247 251 B-Condition
, NCT03924128 252 253 O
functional NCT03924128 254 264 B-Condition
impairment NCT03924128 265 275 I-Condition
for NCT03924128 276 279 O
more NCT03924128 280 284 B-Eq-Comparison
than NCT03924128 285 289 I-Eq-Comparison
3 NCT03924128 290 291 I-Eq-Comparison
months NCT03924128 292 298 I-Eq-Comparison
, NCT03924128 299 300 O
able NCT03924128 301 305 B-Condition
to NCT03924128 306 308 I-Condition
wander NCT03924128 309 315 I-Condition
with NCT03924128 316 320 B-Modifier
or NCT03924128 321 323 I-Modifier
without NCT03924128 324 331 O
canes NCT03924128 332 337 I-Modifier
. NCT03924128 337 338 O

Exclusion NCT03924128 340 349 O
Criteria NCT03924128 350 358 O
: NCT03924128 359 360 O

- NCT03924128 364 365 O
Will NCT03924128 367 371 O
be NCT03924128 372 374 O
excluded NCT03924128 375 383 B-Negation
from NCT03924128 384 388 O
study NCT03924128 389 394 B-Study
subjects NCT03924128 395 403 O
with NCT03924128 404 408 O
history NCT03924128 409 416 B-Eq-Comparison
of NCT03924128 417 419 O
cancer NCT03924128 420 426 B-Condition
, NCT03924128 427 428 O
unstable NCT03924128 429 437 O
cardiovascular NCT03924128 438 452 B-Condition
disease NCT03924128 453 460 I-Condition
, NCT03924128 461 462 O
uncontrolled NCT03924128 463 475 B-Modifier
hypertension NCT03924128 476 488 B-Condition
, NCT03924128 489 490 O
morbid NCT03924128 491 497 B-Condition
obesity NCT03924128 498 505 I-Condition
, NCT03924128 506 507 O
that NCT03924128 508 512 O
is NCT03924128 513 515 O
, NCT03924128 516 517 O
BMI NCT03924128 518 521 B-Observation
≥ NCT03924128 522 523 B-Eq-Comparison
40 NCT03924128 524 526 I-Eq-Comparison
, NCT03924128 527 528 O
terminal NCT03924128 529 537 B-Condition
illness NCT03924128 538 545 I-Condition
, NCT03924128 546 547 O
cerebrovascular NCT03924128 548 563 B-Condition
disease NCT03924128 564 571 I-Condition
, NCT03924128 572 573 O
dementia NCT03924128 574 582 B-Condition
, NCT03924128 583 584 O
heart NCT03924128 585 590 B-Procedure
pacemaker NCT03924128 591 600 I-Procedure
, NCT03924128 601 602 O
superior NCT03924128 603 611 B-Modifier
or NCT03924128 612 614 B-Or
inferior NCT03924128 615 623 B-Modifier
limb NCT03924128 624 628 I-Modifier
fractures NCT03924128 629 638 B-Condition
. NCT03924128 638 639 O

Inclusion NCT03924882 0 9 O
Criteria NCT03924882 10 18 O
: NCT03924882 19 20 O

1 NCT03924882 24 25 O
. NCT03924882 25 26 O
Female NCT03924882 28 34 O
, NCT03924882 35 36 O
age NCT03924882 37 40 B-Age
≥ NCT03924882 41 42 B-Eq-Comparison
18 NCT03924882 43 45 I-Eq-Comparison
years NCT03924882 46 51 I-Eq-Comparison
and NCT03924882 52 55 B-And
≤ NCT03924882 56 57 B-Eq-Comparison
70 NCT03924882 58 60 I-Eq-Comparison
years NCT03924882 61 66 I-Eq-Comparison
, NCT03924882 67 68 O
signed NCT03924882 69 75 O
informed NCT03924882 76 84 O
consent NCT03924882 85 92 O
. NCT03924882 92 93 O

2 NCT03924882 97 98 O
. NCT03924882 98 99 O
Histologically NCT03924882 101 115 B-Procedure
or NCT03924882 116 118 B-Or
pathologically NCT03924882 119 133 B-Procedure
confirmed NCT03924882 134 143 O
diagnosis NCT03924882 144 153 O
of NCT03924882 154 156 O
epithelial NCT03924882 157 167 B-Condition
carcinoma NCT03924882 168 177 I-Condition
of NCT03924882 178 180 O
the NCT03924882 181 184 O
ovary NCT03924882 185 190 B-Modifier
. NCT03924882 190 191 O

3 NCT03924882 195 196 O
. NCT03924882 196 197 O
Platinum NCT03924882 199 207 B-Modifier
resistant NCT03924882 208 217 I-Modifier
ovarian NCT03924882 218 225 I-Modifier
cancer NCT03924882 226 232 B-Condition
( NCT03924882 233 234 O
defined NCT03924882 235 242 O
as NCT03924882 243 245 O
relapsing NCT03924882 246 255 B-Coreference
within NCT03924882 256 262 B-Eq-Comparison
6 NCT03924882 263 264 I-Eq-Comparison
months NCT03924882 265 271 I-Eq-Comparison
after NCT03924882 272 277 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03924882 278 281 O
last NCT03924882 282 286 B-Eq-Comparison
administration NCT03924882 287 301 O
of NCT03924882 302 304 O
platinum NCT03924882 305 313 B-Modifier
- NCT03924882 314 315 I-Modifier
based NCT03924882 316 321 I-Modifier
chemotherapy NCT03924882 322 334 B-Procedure
) NCT03924882 335 336 O
OR NCT03924882 337 339 B-Or
platinum NCT03924882 340 348 B-Modifier
refractory NCT03924882 349 359 I-Modifier
ovarian NCT03924882 360 367 I-Modifier
cancer NCT03924882 368 374 B-Condition
( NCT03924882 375 376 O
defined NCT03924882 377 384 O
as NCT03924882 385 387 O
progressing NCT03924882 388 399 B-Coreference
while NCT03924882 400 405 B-Temporal-Connection___Temporal-Connection-Type-Value:during
on NCT03924882 406 408 I-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03924882 409 410 O
platinum NCT03924882 411 419 B-Modifier
- NCT03924882 420 421 I-Modifier
based NCT03924882 422 427 I-Modifier
chemotherapy NCT03924882 428 440 B-Procedure
) NCT03924882 441 442 O

4 NCT03924882 446 447 O
. NCT03924882 447 448 O
At NCT03924882 450 452 B-Eq-Comparison
least NCT03924882 453 458 I-Eq-Comparison
treated NCT03924882 459 466 I-Eq-Comparison
with NCT03924882 467 471 I-Eq-Comparison
one NCT03924882 472 475 I-Eq-Comparison
line NCT03924882 476 480 O
of NCT03924882 481 483 O
platinum NCT03924882 484 492 B-Modifier
- NCT03924882 493 494 I-Modifier
based NCT03924882 495 500 I-Modifier
chemotherapy NCT03924882 501 513 B-Procedure

5 NCT03924882 516 517 O
. NCT03924882 517 518 O
Eastern NCT03924882 520 527 B-Observation
Cooperative NCT03924882 528 539 I-Observation
Oncology NCT03924882 540 548 I-Observation
Group NCT03924882 549 554 I-Observation
( NCT03924882 555 556 O
ECOG NCT03924882 557 561 B-Observation
) NCT03924882 562 563 O
performance NCT03924882 564 575 O
status NCT03924882 576 582 O
0 NCT03924882 583 584 B-Eq-Comparison
- NCT03924882 585 586 I-Eq-Comparison
2 NCT03924882 587 588 O

6 NCT03924882 592 593 O
. NCT03924882 593 594 O
Measurable NCT03924882 596 606 B-Observation
disease NCT03924882 607 614 I-Observation
according NCT03924882 615 624 O
to NCT03924882 625 627 O
Response NCT03924882 628 636 O
Evaluation NCT03924882 637 647 O
Criteria NCT03924882 648 656 O
in NCT03924882 657 659 O
Solid NCT03924882 660 665 O
Tumors NCT03924882 666 672 O
( NCT03924882 673 674 O
RECIST NCT03924882 675 681 O
) NCT03924882 682 683 O
1.1 NCT03924882 684 687 O
version NCT03924882 688 695 O
or NCT03924882 696 698 O
CA125 NCT03924882 699 704 B-Observation

7 NCT03924882 712 713 O
. NCT03924882 713 714 O
Patients NCT03924882 716 724 O
must NCT03924882 725 729 O
have NCT03924882 730 734 O
a NCT03924882 735 736 O
life NCT03924882 737 741 B-Observation
expectancy NCT03924882 742 752 I-Observation
of NCT03924882 753 755 O
at NCT03924882 756 758 B-Eq-Comparison
least NCT03924882 759 764 I-Eq-Comparison
3 NCT03924882 765 766 I-Eq-Comparison
months NCT03924882 767 773 I-Eq-Comparison
. NCT03924882 773 774 O

8 NCT03924882 778 779 O
. NCT03924882 779 780 O
Patients NCT03924882 782 790 O
must NCT03924882 791 795 O
have NCT03924882 796 800 O
adequate NCT03924882 801 809 O
organ NCT03924882 810 815 B-Condition
function NCT03924882 816 824 I-Condition
. NCT03924882 824 825 O

Exclusion NCT03924882 827 836 O
Criteria NCT03924882 837 845 O
: NCT03924882 846 847 O

1 NCT03924882 851 852 O
. NCT03924882 852 853 O
Had NCT03924882 855 858 O
prior NCT03924882 859 864 B-Eq-Comparison
exposure NCT03924882 865 873 O
to NCT03924882 874 876 O
anlotinib NCT03924882 877 886 B-Drug
or NCT03924882 887 889 B-Or
has NCT03924882 890 893 O
known NCT03924882 894 899 O
allegies NCT03924882 900 908 B-Allergy
to NCT03924882 909 911 O
any NCT03924882 912 915 O
of NCT03924882 916 918 O
the NCT03924882 919 922 O
excipients NCT03924882 923 933 O
, NCT03924882 934 935 O
Inadequately NCT03924882 936 948 B-Modifier
controlled NCT03924882 949 959 I-Modifier
hypertension NCT03924882 960 972 B-Condition

2 NCT03924882 975 976 O
. NCT03924882 976 977 O
History NCT03924882 979 986 B-Eq-Comparison
of NCT03924882 987 989 O
myocardial NCT03924882 990 1000 B-Condition
infarction NCT03924882 1001 1011 I-Condition
, NCT03924882 1012 1013 O
or NCT03924882 1014 1016 B-Or|Or
unstable NCT03924882 1017 1025 B-Condition
angina NCT03924882 1026 1032 I-Condition
, NCT03924882 1033 1034 O
or NCT03924882 1035 1037 O
New NCT03924882 1038 1041 B-Condition
York NCT03924882 1042 1046 I-Condition
Heart NCT03924882 1047 1052 I-Condition
Association NCT03924882 1053 1064 I-Condition
( NCT03924882 1065 1066 O
NYHA NCT03924882 1067 1071 B-Condition
) NCT03924882 1072 1073 O
Grade NCT03924882 1074 1079 B-Eq-Comparison
III NCT03924882 1080 1083 I-Eq-Comparison
- NCT03924882 1084 1085 I-Eq-Comparison
IV NCT03924882 1086 1088 I-Eq-Comparison
within NCT03924882 1089 1095 B-Eq-Comparison
6 NCT03924882 1096 1097 I-Eq-Comparison
months NCT03924882 1098 1104 I-Eq-Comparison
prior NCT03924882 1105 1110 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924882 1111 1113 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03924882 1114 1117 B-Study
1 NCT03924882 1118 1119 O
. NCT03924882 1119 1120 O

3 NCT03924882 1124 1125 O
. NCT03924882 1125 1126 O
History NCT03924882 1128 1135 B-Eq-Comparison
of NCT03924882 1136 1138 O
abdominal NCT03924882 1139 1148 B-Condition
fistula NCT03924882 1149 1156 I-Condition
or NCT03924882 1157 1159 B-Or
gastrointestinal NCT03924882 1160 1176 B-Condition
perforation NCT03924882 1177 1188 I-Condition
within NCT03924882 1189 1195 B-Eq-Comparison
28 NCT03924882 1196 1198 I-Eq-Comparison
days NCT03924882 1199 1203 I-Eq-Comparison
prior NCT03924882 1204 1209 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924882 1210 1212 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03924882 1213 1216 B-Study
1 NCT03924882 1217 1218 O

4 NCT03924882 1222 1223 O
. NCT03924882 1223 1224 O
Major NCT03924882 1226 1231 O
surgical NCT03924882 1232 1240 B-Procedure
procedure NCT03924882 1241 1250 I-Procedure
within NCT03924882 1251 1257 B-Eq-Comparison
28 NCT03924882 1258 1260 I-Eq-Comparison
days NCT03924882 1261 1265 I-Eq-Comparison
prior NCT03924882 1266 1271 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924882 1272 1274 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03924882 1275 1278 B-Study
1 NCT03924882 1279 1280 O
, NCT03924882 1281 1282 O
Serious NCT03924882 1283 1290 O
, NCT03924882 1291 1292 O
non NCT03924882 1293 1296 B-Modifier
- NCT03924882 1297 1298 I-Modifier
healing NCT03924882 1299 1306 I-Modifier
wound NCT03924882 1307 1312 B-Condition
, NCT03924882 1313 1314 O
active NCT03924882 1315 1321 B-Eq-Comparison
ulcer NCT03924882 1322 1327 B-Condition
, NCT03924882 1328 1329 O
bowel NCT03924882 1330 1335 B-Condition
obstruction NCT03924882 1336 1347 I-Condition
within NCT03924882 1348 1354 B-Eq-Comparison
28 NCT03924882 1355 1357 I-Eq-Comparison
days NCT03924882 1358 1362 I-Eq-Comparison
prior NCT03924882 1363 1368 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924882 1369 1371 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03924882 1372 1375 B-Study
1 NCT03924882 1376 1377 O

5 NCT03924882 1381 1382 O
. NCT03924882 1382 1383 O
Symptomatic NCT03924882 1385 1396 B-Assertion___Assertion-Type-Value:possible
central NCT03924882 1397 1404 B-Modifier
nervous NCT03924882 1405 1412 I-Modifier
system NCT03924882 1413 1419 I-Modifier
( NCT03924882 1420 1421 O
CNS NCT03924882 1422 1425 B-Modifier
) NCT03924882 1426 1427 O
metastasis NCT03924882 1428 1438 B-Condition


Inclusion NCT03921905 0 9 O
Criteria NCT03921905 10 18 O
: NCT03921905 19 20 O

- NCT03921905 24 25 O
Patients NCT03921905 27 35 O
of NCT03921905 36 38 O
both NCT03921905 39 43 O
sexes NCT03921905 44 49 O
with NCT03921905 50 54 O
a NCT03921905 55 56 O
diagnosis NCT03921905 57 66 O
of NCT03921905 67 69 O
stable NCT03921905 70 76 O
CAD NCT03921905 77 80 B-Condition
as NCT03921905 81 83 O
follows NCT03921905 84 91 O
: NCT03921905 92 93 O
acute NCT03921905 94 99 B-Condition
myocardial NCT03921905 100 110 I-Condition
infarction NCT03921905 111 121 I-Condition
or NCT03921905 122 124 B-Or
percutaneous NCT03921905 125 137 B-Procedure
coronary NCT03921905 138 146 I-Procedure
revascularization NCT03921905 147 164 I-Procedure
or NCT03921905 165 167 B-Or
coronary NCT03921905 168 176 B-Procedure
artery NCT03921905 177 183 I-Procedure
bypass NCT03921905 184 190 I-Procedure
graft NCT03921905 191 196 I-Procedure
surgery NCT03921905 197 204 I-Procedure
occured NCT03921905 205 212 O
at NCT03921905 213 215 B-Eq-Comparison
least NCT03921905 216 221 I-Eq-Comparison
12 NCT03921905 222 224 I-Eq-Comparison
months NCT03921905 225 231 I-Eq-Comparison
before NCT03921905 232 238 B-Temporal-Connection___Temporal-Connection-Type-Value:before
entering NCT03921905 239 247 O
the NCT03921905 248 251 O
study NCT03921905 252 257 B-Study
or NCT03921905 258 260 B-Or
chronic NCT03921905 261 268 B-Modifier
stable NCT03921905 269 275 O
angina NCT03921905 276 282 B-Condition
. NCT03921905 282 283 O

Exclusion NCT03921905 285 294 O
Criteria NCT03921905 295 303 O
: NCT03921905 304 305 O

- NCT03921905 309 310 O
Mental NCT03921905 312 318 B-Condition
illness NCT03921905 319 326 I-Condition
limiting NCT03921905 327 335 O
the NCT03921905 336 339 O
capacity NCT03921905 340 348 O
of NCT03921905 349 351 O
self NCT03921905 352 356 B-Procedure
- NCT03921905 357 358 I-Procedure
care NCT03921905 359 363 I-Procedure
or NCT03921905 364 366 B-Or
any NCT03921905 367 370 O
condition NCT03921905 371 380 B-Condition
limiting NCT03921905 381 389 O
seriously NCT03921905 390 399 O
the NCT03921905 400 403 O
life NCT03921905 404 408 B-Observation
expectancy NCT03921905 409 419 I-Observation
less NCT03921905 420 424 B-Eq-Comparison
than NCT03921905 425 429 I-Eq-Comparison
12 NCT03921905 430 432 I-Eq-Comparison
months NCT03921905 433 439 I-Eq-Comparison
. NCT03921905 439 440 O

Inclusion NCT03926663 0 9 O
Criteria NCT03926663 10 18 O
: NCT03926663 19 20 O

- NCT03926663 24 25 O
Patients NCT03926663 27 35 O
aged NCT03926663 36 40 B-Age
from NCT03926663 41 45 O
18 NCT03926663 46 48 B-Eq-Comparison
- NCT03926663 49 50 I-Eq-Comparison
60 NCT03926663 51 53 I-Eq-Comparison
years NCT03926663 54 59 I-Eq-Comparison

- NCT03926663 62 63 O
ASA NCT03926663 65 68 B-Condition
physical NCT03926663 69 77 O
status NCT03926663 78 84 O
I NCT03926663 85 86 B-Eq-Comparison

- NCT03926663 89 90 O
Undergoing NCT03926663 92 102 B-Eq-Comparison
septoplasty NCT03926663 103 114 B-Procedure

Exclusion NCT03926663 115 124 O
Criteria NCT03926663 125 133 O
: NCT03926663 134 135 O

- NCT03926663 139 140 O
Patients NCT03926663 142 150 O
with NCT03926663 151 155 O
cardiovascular NCT03926663 156 170 B-Condition
disease NCT03926663 171 178 I-Condition
( NCT03926663 179 180 O
congestive NCT03926663 181 191 B-Condition
heart NCT03926663 192 197 I-Condition
failure NCT03926663 198 205 I-Condition
, NCT03926663 206 207 O
coronary NCT03926663 208 216 B-Condition
artery NCT03926663 217 223 I-Condition
disease NCT03926663 224 231 I-Condition
, NCT03926663 232 233 O
hypertension NCT03926663 234 246 B-Condition
. NCT03926663 246 247 O

- NCT03926663 251 252 O
History NCT03926663 254 261 B-Eq-Comparison
of NCT03926663 262 264 O
renal NCT03926663 265 270 B-Modifier
or NCT03926663 271 273 B-Or
hepatic NCT03926663 274 281 B-Modifier
insufficiency NCT03926663 282 295 B-Condition

- NCT03926663 298 299 O
Endocrinal NCT03926663 301 311 B-Condition
Diseases NCT03926663 312 320 I-Condition

Inclusion NCT03924921 0 9 O
Criteria NCT03924921 10 18 O
: NCT03924921 19 20 O

- NCT03924921 24 25 O
Being NCT03924921 27 32 O
older NCT03924921 33 38 I-Eq-Comparison
than NCT03924921 39 43 I-Eq-Comparison
18 NCT03924921 44 46 I-Eq-Comparison
; NCT03924921 47 48 O

- NCT03924921 51 52 O
have NCT03924921 54 58 O
a NCT03924921 59 60 O
diagnosis NCT03924921 61 70 O
of NCT03924921 71 73 O
HIV NCT03924921 74 77 B-Condition
; NCT03924921 77 78 O

- NCT03924921 81 82 O
present NCT03924921 84 91 O
at NCT03924921 92 94 B-Eq-Comparison
least NCT03924921 95 100 I-Eq-Comparison
one NCT03924921 101 104 I-Eq-Comparison
of NCT03924921 105 107 O
the NCT03924921 108 111 B-Criteria-Count
following NCT03924921 112 121 I-Criteria-Count
symptoms NCT03924921 122 130 I-Criteria-Count
during NCT03924921 131 137 O
the NCT03924921 138 141 O
preceding NCT03924921 142 151 B-Eq-Comparison
two NCT03924921 152 155 I-Eq-Comparison
weeks NCT03924921 156 161 I-Eq-Comparison
: NCT03924921 162 163 O
sleep NCT03924921 164 169 B-Condition
problems NCT03924921 170 178 I-Condition
, NCT03924921 179 180 O
fatigue NCT03924921 181 188 B-Condition
, NCT03924921 189 190 O
pain NCT03924921 191 195 B-Condition
, NCT03924921 196 197 O
anxiety NCT03924921 198 205 B-Condition
or NCT03924921 206 208 B-Or
symptoms NCT03924921 209 217 B-Assertion___Assertion-Type-Value:possible
of NCT03924921 218 220 O
depression NCT03924921 221 231 B-Condition
; NCT03924921 231 232 O

- NCT03924921 235 236 O
understand NCT03924921 238 248 O
and NCT03924921 249 252 O
speak NCT03924921 253 258 O
French NCT03924921 259 265 O
and NCT03924921 266 269 O
; NCT03924921 269 270 O

- NCT03924921 273 274 O
be NCT03924921 276 278 O
able NCT03924921 279 283 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924921 284 286 I-Assertion___Assertion-Type-Value:hypothetical
follow NCT03924921 287 293 O
the NCT03924921 294 297 O
instructions NCT03924921 298 310 O
to NCT03924921 311 313 O
learn NCT03924921 314 319 O
the NCT03924921 320 323 O
relaxation NCT03924921 324 334 B-Procedure
technique NCT03924921 335 344 I-Procedure
. NCT03924921 344 345 O

Exclusion NCT03924921 347 356 O
Criteria NCT03924921 357 365 O
: NCT03924921 366 367 O

- NCT03924921 370 371 O

Inclusion NCT03928470 0 9 O
Criteria NCT03928470 10 18 O
: NCT03928470 19 20 O

1 NCT03928470 24 25 O
. NCT03928470 25 26 O
Male NCT03928470 28 32 O
or NCT03928470 33 35 B-Or
Female NCT03928470 36 42 O
aged NCT03928470 43 47 B-Age
≥ NCT03928470 48 49 B-Eq-Comparison
19 NCT03928470 50 52 I-Eq-Comparison
years NCT03928470 53 58 I-Eq-Comparison

2 NCT03928470 61 62 O
. NCT03928470 62 63 O
Episode NCT03928470 65 72 O
of NCT03928470 73 75 O
heartburn NCT03928470 76 85 B-Condition
for NCT03928470 86 89 O
3 NCT03928470 90 91 B-Eq-Comparison
months NCT03928470 92 98 I-Eq-Comparison
or NCT03928470 99 101 I-Eq-Comparison
more NCT03928470 102 106 I-Eq-Comparison
during NCT03928470 107 113 B-Temporal-Connection___Temporal-Connection-Type-Value:during
prior NCT03928470 114 119 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928470 120 122 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03928470 123 136 B-Study
visit NCT03928470 137 142 O
. NCT03928470 142 143 O

3 NCT03928470 147 148 O
. NCT03928470 148 149 O
Episode NCT03928470 151 158 O
of NCT03928470 159 161 O
heartburn NCT03928470 162 171 B-Condition
for NCT03928470 172 175 O
2 NCT03928470 176 177 B-Eq-Comparison
days NCT03928470 178 182 I-Eq-Comparison
or NCT03928470 183 185 I-Eq-Comparison
more NCT03928470 186 190 I-Eq-Comparison
during NCT03928470 191 197 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928470 198 201 O
last NCT03928470 202 206 B-Eq-Comparison
7 NCT03928470 207 208 I-Eq-Comparison
days NCT03928470 209 213 I-Eq-Comparison
prior NCT03928470 214 219 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928470 220 222 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03928470 223 236 B-Study
visit NCT03928470 237 242 O
. NCT03928470 242 243 O

4 NCT03928470 247 248 O
. NCT03928470 248 249 O
Grade NCT03928470 251 256 B-Eq-Comparison
N NCT03928470 257 258 I-Eq-Comparison
, NCT03928470 259 260 O
M NCT03928470 261 262 I-Eq-Comparison
by NCT03928470 263 265 O
EGD NCT03928470 266 269 B-Procedure
test NCT03928470 270 274 I-Procedure
. NCT03928470 274 275 O

Exclusion NCT03928470 277 286 O
Criteria NCT03928470 287 295 O
: NCT03928470 296 297 O

1 NCT03928470 301 302 O
. NCT03928470 302 303 O
Surgery NCT03928470 305 312 B-Procedure
history NCT03928470 313 320 B-Eq-Comparison
on NCT03928470 321 323 O
stomach NCT03928470 324 331 B-Modifier
or NCT03928470 332 334 B-Or
esophagus NCT03928470 335 344 B-Modifier

2 NCT03928470 347 348 O
. NCT03928470 348 349 O
Active NCT03928470 351 357 B-Eq-Comparison
medical NCT03928470 358 365 O
history NCT03928470 366 373 O
of NCT03928470 374 376 O
stomach NCT03928470 377 384 B-Modifier
, NCT03928470 385 386 O
esophagus NCT03928470 387 396 B-Modifier
area NCT03928470 397 401 O

3 NCT03928470 404 405 O
. NCT03928470 405 406 O
Other NCT03928470 408 413 B-Other
system NCT03928470 414 420 B-Modifier
disorder NCT03928470 421 429 B-Condition
which NCT03928470 430 435 O
can NCT03928470 436 439 B-Assertion___Assertion-Type-Value:hypothetical
disturb NCT03928470 440 447 O
this NCT03928470 448 452 O
trial NCT03928470 453 458 B-Study

4 NCT03928470 461 462 O
. NCT03928470 462 463 O
Patients NCT03928470 465 473 O
taking NCT03928470 474 480 B-Eq-Comparison
the NCT03928470 481 484 O
contraindication NCT03928470 485 501 B-Contraindication
of NCT03928470 502 504 O
concomitant NCT03928470 505 516 B-Modifier
medications NCT03928470 517 528 B-Drug

5 NCT03928470 531 532 O
. NCT03928470 532 533 O
Clinically NCT03928470 535 545 O
significant NCT03928470 546 557 O
Abnormal NCT03928470 558 566 O
Lab NCT03928470 567 570 B-Observation
test NCT03928470 571 575 I-Observation

6 NCT03928470 578 579 O
. NCT03928470 579 580 O
Pregnant NCT03928470 582 590 B-Condition
woman NCT03928470 591 596 O
, NCT03928470 597 598 O
Breastfeeding NCT03928470 599 612 B-Condition
woman NCT03928470 613 618 O
. NCT03928470 618 619 O

Inclusion NCT03925168 0 9 O
Criteria NCT03925168 10 18 O
: NCT03925168 19 20 O

- NCT03925168 24 25 O
English NCT03925168 27 34 O
- NCT03925168 35 36 O
speaking NCT03925168 37 45 O
, NCT03925168 46 47 O
adult NCT03925168 48 53 O
( NCT03925168 54 55 O
21 NCT03925168 56 58 B-Eq-Comparison
+ NCT03925168 59 60 O
) NCT03925168 62 63 O
hemodialysis NCT03925168 64 76 B-Procedure
patients NCT03925168 77 85 O
who NCT03925168 86 89 B-And
receive NCT03925168 90 97 B-Eq-Comparison
dialysis NCT03925168 98 106 B-Procedure
at NCT03925168 107 109 O
the NCT03925168 110 113 O
one NCT03925168 114 117 O
of NCT03925168 118 120 O
the NCT03925168 121 124 O
two NCT03925168 125 128 O
outpatient NCT03925168 129 139 O
dialysis NCT03925168 140 148 O
centers NCT03925168 149 156 O

Exclusion NCT03925168 157 166 O
Criteria NCT03925168 167 175 O
: NCT03925168 176 177 O

- NCT03925168 181 182 O
do NCT03925168 184 186 O
not NCT03925168 187 190 B-Negation
speak NCT03925168 191 196 O
English NCT03925168 197 204 O
, NCT03925168 205 206 O
deafness NCT03925168 207 215 B-Condition

Inclusion NCT03922607 0 9 O
Criteria NCT03922607 10 18 O
: NCT03922607 19 20 O

- NCT03922607 24 25 O
Volunteer NCT03922607 27 36 O
should NCT03922607 37 43 O
be NCT03922607 44 46 O
between NCT03922607 47 54 B-Eq-Comparison
18 NCT03922607 55 57 I-Eq-Comparison
and NCT03922607 58 61 I-Eq-Comparison
55 NCT03922607 62 64 I-Eq-Comparison
years NCT03922607 65 70 I-Eq-Comparison
of NCT03922607 71 73 O
age NCT03922607 74 77 B-Age
and NCT03922607 78 81 B-And
in NCT03922607 82 84 O
general NCT03922607 85 92 B-Condition
good NCT03922607 93 97 I-Condition
health NCT03922607 98 104 I-Condition
for NCT03922607 105 108 O
Substudy NCT03922607 109 117 O
1 NCT03922607 118 119 O
and NCT03922607 120 123 B-And
participant NCT03922607 124 135 O
with NCT03922607 136 140 O
moderate NCT03922607 141 149 B-Eq-Comparison
to NCT03922607 150 152 I-Eq-Comparison
severe NCT03922607 153 159 I-Eq-Comparison
chronic NCT03922607 160 167 B-Modifier
plaque NCT03922607 168 174 B-Condition
psoriasis NCT03922607 175 184 I-Condition
between NCT03922607 185 192 B-Eq-Comparison
18 NCT03922607 193 195 I-Eq-Comparison
and NCT03922607 196 199 I-Eq-Comparison
75 NCT03922607 200 202 I-Eq-Comparison
years NCT03922607 203 208 I-Eq-Comparison
of NCT03922607 209 211 O
age NCT03922607 212 215 B-Age
for NCT03922607 216 219 O
Substudy NCT03922607 220 228 O
2 NCT03922607 229 230 O
at NCT03922607 231 233 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03922607 234 237 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03922607 238 242 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03922607 243 245 O
enrollment NCT03922607 246 256 B-Study
. NCT03922607 256 257 O

- NCT03922607 261 262 O
Participant NCT03922607 264 275 O
should NCT03922607 276 282 O
meet NCT03922607 283 287 O
the NCT03922607 288 291 O
laboratory NCT03922607 292 302 O
assessments NCT03922607 303 314 O
as NCT03922607 315 317 O
mentioned NCT03922607 318 327 O
in NCT03922607 328 330 O
the NCT03922607 331 334 O
protocol NCT03922607 335 343 O
. NCT03922607 343 344 O

Exclusion NCT03922607 346 355 O
Criteria NCT03922607 356 364 O
: NCT03922607 365 366 O

- NCT03922607 370 371 O
Participant NCT03922607 373 384 O
has NCT03922607 385 388 O
a NCT03922607 389 390 O
history NCT03922607 391 398 B-Eq-Comparison
of NCT03922607 399 401 O
epilepsy NCT03922607 402 410 B-Condition
, NCT03922607 411 412 O
any NCT03922607 413 416 O
significant NCT03922607 417 428 O
cardiac NCT03922607 429 436 B-Modifier
, NCT03922607 437 438 O
respiratory NCT03922607 439 450 B-Modifier
, NCT03922607 451 452 O
renal NCT03922607 453 458 B-Modifier
, NCT03922607 459 460 O
hepatic NCT03922607 461 468 B-Modifier
, NCT03922607 469 470 O
gastrointestinal NCT03922607 471 487 B-Modifier
, NCT03922607 488 489 O
opthalmologic NCT03922607 490 503 B-Modifier
, NCT03922607 504 505 O
hematologic NCT03922607 506 517 B-Modifier
, NCT03922607 518 519 O
or NCT03922607 520 522 B-Or
psychiatric NCT03922607 523 534 B-Modifier
disease NCT03922607 535 542 B-Condition
or NCT03922607 543 545 B-Or|Or
disorder NCT03922607 546 554 B-Condition
, NCT03922607 555 556 O
or NCT03922607 557 559 O
any NCT03922607 560 563 O
uncontrolled NCT03922607 564 576 B-Modifier
medical NCT03922607 577 584 B-Condition
illness NCT03922607 585 592 I-Condition
. NCT03922607 592 593 O

Inclusion NCT03927794 0 9 O
Criteria NCT03927794 10 18 O
: NCT03927794 19 20 O

- NCT03927794 24 25 O
≥ NCT03927794 27 28 B-Eq-Comparison
1 NCT03927794 29 30 I-Eq-Comparison
Primary NCT03927794 31 38 B-Modifier
Anterior NCT03927794 39 47 I-Modifier
Teeth NCT03927794 48 53 I-Modifier
with NCT03927794 54 58 O
early NCT03927794 59 64 B-Modifier
carious NCT03927794 65 72 B-Condition
lesion NCT03927794 73 79 I-Condition
( NCT03927794 80 81 O
Class NCT03927794 82 87 B-Eq-Comparison
V NCT03927794 88 89 I-Eq-Comparison
) NCT03927794 90 91 O
of NCT03927794 92 94 B-And
ICDAS NCT03927794 95 100 B-Observation
scores NCT03927794 101 107 I-Observation
1 NCT03927794 108 109 B-Eq-Comparison
- NCT03927794 110 111 I-Eq-Comparison
2 NCT03927794 112 113 O
. NCT03927794 113 114 O

- NCT03927794 118 119 O
Subjects NCT03927794 121 129 O
whose NCT03927794 130 135 O
parents NCT03927794 136 143 O
are NCT03927794 144 147 O
willing NCT03927794 148 155 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03927794 156 159 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03927794 160 164 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03927794 165 167 O
maintain NCT03927794 168 176 O
good NCT03927794 177 181 O
oral NCT03927794 182 186 B-Condition
hygiene NCT03927794 187 194 I-Condition
for NCT03927794 195 198 O
their NCT03927794 199 204 O
children NCT03927794 205 213 B-Family-Member___Family-Member-Type:child
and NCT03927794 214 217 B-And
attend NCT03927794 218 224 O
study NCT03927794 225 230 B-Study
visits NCT03927794 231 237 O
. NCT03927794 237 238 O

- NCT03927794 242 243 O
Subjects NCT03927794 245 253 O
with NCT03927794 254 258 O
Saliva NCT03927794 259 265 B-Observation
of NCT03927794 266 268 O
normal NCT03927794 269 275 O
flow NCT03927794 276 280 B-Modifier
rates NCT03927794 281 286 I-Modifier
( NCT03927794 287 288 O
30 NCT03927794 289 291 B-Eq-Comparison
- NCT03927794 292 293 I-Eq-Comparison
60 NCT03927794 294 296 I-Eq-Comparison
sec NCT03927794 297 300 O
) NCT03927794 301 302 O
and NCT03927794 303 306 B-And
with NCT03927794 307 311 O
healthy NCT03927794 312 319 O
saliva NCT03927794 320 326 B-Observation
pH NCT03927794 327 329 I-Observation
6.75 NCT03927794 330 334 B-Eq-Comparison
- NCT03927794 335 336 I-Eq-Comparison
7.25 NCT03927794 337 341 I-Eq-Comparison
. NCT03927794 341 342 O

- NCT03927794 351 352 O
Patients NCT03927794 354 362 O
aged NCT03927794 363 367 B-Age
between NCT03927794 368 375 B-Eq-Comparison
3 NCT03927794 376 377 I-Eq-Comparison
- NCT03927794 378 379 I-Eq-Comparison
5 NCT03927794 380 381 I-Eq-Comparison
years NCT03927794 382 387 I-Eq-Comparison
. NCT03927794 387 388 O

- NCT03927794 392 393 O
Subjects NCT03927794 395 403 O
with NCT03927794 404 408 O
a NCT03927794 409 410 O
minimum NCT03927794 411 418 B-Eq-Comparison
of NCT03927794 419 421 I-Eq-Comparison|Eq-Comparison
1 NCT03927794 422 423 I-Eq-Comparison
and NCT03927794 424 427 O
a NCT03927794 428 429 O
maximum NCT03927794 430 437 B-Eq-Comparison
of NCT03927794 438 440 O
12 NCT03927794 441 443 I-Eq-Comparison
primary NCT03927794 444 451 B-Modifier
anterior NCT03927794 452 460 I-Modifier
teeth NCT03927794 461 466 I-Modifier
with NCT03927794 467 471 O
early NCT03927794 472 477 B-Modifier
carious NCT03927794 478 485 B-Condition
lesions NCT03927794 486 493 I-Condition
Class NCT03927794 494 499 B-Eq-Comparison
V NCT03927794 500 501 I-Eq-Comparison
of NCT03927794 502 504 B-And
ICDAS NCT03927794 505 510 B-Observation
score NCT03927794 511 516 I-Observation
1 NCT03927794 517 518 B-Eq-Comparison
- NCT03927794 519 520 I-Eq-Comparison
2 NCT03927794 521 522 O
. NCT03927794 522 523 O

Exclusion NCT03927794 525 534 O
Criteria NCT03927794 535 543 O
: NCT03927794 544 545 O

- NCT03927794 549 550 O
Primary NCT03927794 552 559 B-Modifier
anterior NCT03927794 560 568 I-Modifier
teeth NCT03927794 569 574 I-Modifier
in NCT03927794 575 577 O
which NCT03927794 578 583 O
carious NCT03927794 584 591 B-Condition
lesions NCT03927794 592 599 I-Condition
are NCT03927794 600 603 O
scored NCT03927794 604 610 O
with NCT03927794 611 615 B-And
ICDAS NCT03927794 616 621 B-Observation
≥ NCT03927794 622 623 B-Eq-Comparison
3 NCT03927794 624 625 I-Eq-Comparison
. NCT03927794 625 626 O

- NCT03927794 630 631 O
Subjects NCT03927794 633 641 O
on NCT03927794 642 644 B-Eq-Comparison
medication NCT03927794 645 655 B-Drug
that NCT03927794 656 660 O
affects NCT03927794 661 668 O
the NCT03927794 669 672 O
salivary NCT03927794 673 681 B-Observation
flow NCT03927794 682 686 I-Observation
rate NCT03927794 687 691 I-Observation
. NCT03927794 691 692 O

- NCT03927794 696 697 O
Subjects NCT03927794 699 707 O
with NCT03927794 708 712 O
evidence NCT03927794 713 721 O
of NCT03927794 722 724 O
reduced NCT03927794 725 732 O
salivary NCT03927794 733 741 B-Observation
flow NCT03927794 742 746 I-Observation
( NCT03927794 747 748 O
> NCT03927794 750 751 B-Eq-Comparison
60 NCT03927794 752 754 I-Eq-Comparison
sec NCT03927794 755 758 I-Eq-Comparison
) NCT03927794 759 760 O
or NCT03927794 761 763 B-Or
with NCT03927794 764 768 O
acidic NCT03927794 769 775 B-Modifier
saliva NCT03927794 776 782 B-Observation
pH NCT03927794 783 785 I-Observation
˂ NCT03927794 786 787 B-Eq-Comparison
5.8 NCT03927794 788 791 O
. NCT03927794 791 792 O


Inclusion NCT03924505 0 9 O
Criteria NCT03924505 10 18 O
: NCT03924505 19 20 O

- NCT03924505 24 25 O
SSPs NCT03924505 27 31 B-Condition
that NCT03924505 32 36 O
participate NCT03924505 37 48 O
in NCT03924505 49 51 O
the NCT03924505 52 55 O
on NCT03924505 56 58 O
- NCT03924505 59 60 O
line NCT03924505 61 65 O
screening NCT03924505 66 75 B-Study
survey NCT03924505 76 82 O
and NCT03924505 83 86 B-And
fall NCT03924505 87 91 O
into NCT03924505 92 96 O
the NCT03924505 97 100 O
implementation NCT03924505 101 115 B-Modifier
phase NCT03924505 116 121 I-Modifier
of NCT03924505 122 124 O
the NCT03924505 125 128 O
EPIS NCT03924505 129 133 B-Condition
continuum NCT03924505 134 143 I-Condition
will NCT03924505 144 148 O
be NCT03924505 149 151 O
recruited NCT03924505 152 161 O
into NCT03924505 162 166 O
the NCT03924505 167 170 O
study NCT03924505 171 176 O
. NCT03924505 176 177 O

Exclusion NCT03924505 179 188 O
Criteria NCT03924505 189 197 O
: NCT03924505 198 199 O

- NCT03924505 202 203 O

Inclusion NCT03926312 0 9 O
Criteria NCT03926312 10 18 O
: NCT03926312 19 20 O

1 NCT03926312 24 25 O
. NCT03926312 25 26 O
Signed NCT03926312 28 34 O
informed NCT03926312 35 43 O
consent NCT03926312 44 51 O
with NCT03926312 52 56 O
the NCT03926312 57 60 O
study NCT03926312 61 66 O

2 NCT03926312 69 70 O
. NCT03926312 70 71 O
Men NCT03926312 73 76 O
and NCT03926312 77 80 B-Or
women NCT03926312 81 86 O
> NCT03926312 87 88 B-Eq-Comparison
18 NCT03926312 89 91 I-Eq-Comparison
years NCT03926312 92 97 I-Eq-Comparison
of NCT03926312 98 100 O
age NCT03926312 101 104 B-Age

3 NCT03926312 107 108 O
. NCT03926312 108 109 O
Patients NCT03926312 111 119 O
≥ NCT03926312 120 121 B-Eq-Comparison
1 NCT03926312 122 123 I-Eq-Comparison
and NCT03926312 124 127 B-And
≤ NCT03926312 128 129 B-Eq-Comparison
6 NCT03926312 130 131 I-Eq-Comparison
months NCT03926312 132 138 I-Eq-Comparison
after NCT03926312 139 144 B-Temporal-Connection___Temporal-Connection-Type-Value:after
type NCT03926312 145 149 B-Eq-Comparison
I NCT03926312 150 151 I-Eq-Comparison
myocardial NCT03926312 152 162 B-Condition
infarction NCT03926312 163 173 I-Condition

4 NCT03926312 176 177 O
. NCT03926312 177 178 O
Physical NCT03926312 180 188 B-Condition
inactivity NCT03926312 189 199 I-Condition
before NCT03926312 200 206 B-Temporal-Connection___Temporal-Connection-Type-Value:before
MI NCT03926312 207 209 B-Condition
defined NCT03926312 210 217 O
as NCT03926312 218 220 O
the NCT03926312 221 224 O
absence NCT03926312 225 232 B-Negation
of NCT03926312 233 235 O
moderate NCT03926312 236 244 B-Eq-Comparison
to NCT03926312 245 247 I-Eq-Comparison
vigorous NCT03926312 248 256 I-Eq-Comparison
exercise NCT03926312 257 265 B-Observation
for NCT03926312 266 269 O
at NCT03926312 270 272 B-Eq-Comparison
least NCT03926312 273 278 I-Eq-Comparison
30 NCT03926312 279 281 I-Eq-Comparison
minutes NCT03926312 282 289 I-Eq-Comparison
5 NCT03926312 290 291 B-Eq-Comparison
or NCT03926312 292 294 I-Eq-Comparison
more NCT03926312 295 299 I-Eq-Comparison
days NCT03926312 300 304 I-Eq-Comparison
a NCT03926312 305 306 I-Eq-Comparison
week NCT03926312 307 311 I-Eq-Comparison

Exclusion NCT03926312 312 321 O
Criteria NCT03926312 322 330 O
: NCT03926312 331 332 O

1 NCT03926312 336 337 O
. NCT03926312 337 338 O
Heart NCT03926312 340 345 B-Condition
failure NCT03926312 346 353 I-Condition
NYHA NCT03926312 354 358 B-Condition
IIIB NCT03926312 359 363 B-Eq-Comparison
- NCT03926312 364 365 I-Eq-Comparison
IV NCT03926312 366 368 I-Eq-Comparison

2 NCT03926312 371 372 O
. NCT03926312 372 373 O
Planned NCT03926312 375 382 B-Eq-Comparison
coronary NCT03926312 383 391 B-Procedure
revascularization NCT03926312 392 409 I-Procedure

3 NCT03926312 412 413 O
. NCT03926312 413 414 O
Planned NCT03926312 416 423 B-Eq-Comparison
major NCT03926312 424 429 O
surgery NCT03926312 430 437 B-Procedure
within NCT03926312 438 444 B-Eq-Comparison
the NCT03926312 445 448 I-Eq-Comparison
next NCT03926312 449 453 I-Eq-Comparison
12 NCT03926312 454 456 I-Eq-Comparison
months NCT03926312 457 463 I-Eq-Comparison

4 NCT03926312 466 467 O
. NCT03926312 467 468 O
Inability NCT03926312 470 479 B-Condition
to NCT03926312 480 482 I-Condition
walk NCT03926312 483 487 I-Condition
for NCT03926312 488 491 O
any NCT03926312 492 495 O
reason NCT03926312 496 502 O

5 NCT03926312 505 506 O
. NCT03926312 506 507 O
Comorbidities NCT03926312 509 522 B-Condition
that NCT03926312 523 527 O
would NCT03926312 528 533 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03926312 534 542 O
adherence NCT03926312 543 552 O
to NCT03926312 553 555 O
the NCT03926312 556 559 O
rehabilitation NCT03926312 560 574 B-Procedure
program NCT03926312 575 582 I-Procedure
( NCT03926312 583 584 O
e. NCT03926312 585 587 O
g. NCT03926312 588 590 O
arthrosis NCT03926312 592 601 B-Condition
, NCT03926312 602 603 O
active NCT03926312 604 610 B-Eq-Comparison
malignancy NCT03926312 611 621 B-Condition
, NCT03926312 622 623 O
major NCT03926312 624 629 B-Condition
depression NCT03926312 630 640 I-Condition
or NCT03926312 641 643 O
other NCT03926312 644 649 B-Other
significant NCT03926312 650 661 O
psychiatric NCT03926312 662 673 B-Condition
disorder NCT03926312 674 682 I-Condition
, NCT03926312 683 684 O
cognitive NCT03926312 685 694 B-Condition
impairment NCT03926312 695 705 I-Condition
) NCT03926312 706 707 O
- NCT03926312 708 709 O
at NCT03926312 710 712 O
the NCT03926312 713 716 O
discretion NCT03926312 717 727 O
of NCT03926312 728 730 O
the NCT03926312 731 734 O
physician NCT03926312 735 744 O

6 NCT03926312 747 748 O
. NCT03926312 748 749 O
Life NCT03926312 751 755 B-Observation
expectancy NCT03926312 756 766 I-Observation
less NCT03926312 767 771 B-Eq-Comparison
than NCT03926312 772 776 I-Eq-Comparison
12 NCT03926312 777 779 I-Eq-Comparison
months NCT03926312 780 786 I-Eq-Comparison

7 NCT03926312 789 790 O
. NCT03926312 790 791 O
Pregnancy NCT03926312 793 802 B-Condition

8 NCT03926312 805 806 O
. NCT03926312 806 807 O
Inability NCT03926312 809 818 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03926312 819 821 O
operate NCT03926312 822 829 B-Observation
the NCT03926312 830 833 I-Observation
smart NCT03926312 834 839 I-Observation
- NCT03926312 840 841 I-Observation
watch NCT03926312 842 847 I-Observation

Inclusion NCT03927742 0 9 O
Criteria NCT03927742 10 18 O
: NCT03927742 19 20 O

- NCT03927742 24 25 O
18 NCT03927742 27 29 B-Eq-Comparison
- NCT03927742 30 31 I-Eq-Comparison
75 NCT03927742 32 34 I-Eq-Comparison
years NCT03927742 35 40 I-Eq-Comparison
old NCT03927742 41 44 B-Age

- NCT03927742 47 48 O
Diagnosed NCT03927742 50 59 O
with NCT03927742 60 64 O
cutaneous NCT03927742 65 74 B-Condition
invasive NCT03927742 75 83 I-Condition
melanoma NCT03927742 84 92 I-Condition
within NCT03927742 93 99 O
HealthPartners NCT03927742 100 114 O
system NCT03927742 115 121 O
since NCT03927742 122 127 B-Eq-Comparison
2010 NCT03927742 128 132 I-Eq-Comparison

- NCT03927742 136 137 O
Able NCT03927742 139 143 O
to NCT03927742 144 146 O
read NCT03927742 147 151 O
/ NCT03927742 152 153 O
write NCT03927742 154 159 O
in NCT03927742 160 162 O
English NCT03927742 163 170 O

- NCT03927742 173 174 O
Own NCT03927742 176 179 O
a NCT03927742 180 181 O
smartphone NCT03927742 182 192 O

- NCT03927742 195 196 O
Able NCT03927742 198 202 O
to NCT03927742 203 205 O
provide NCT03927742 206 213 O
voluntary NCT03927742 214 223 O
informed NCT03927742 224 232 O
consent NCT03927742 233 240 O

Exclusion NCT03927742 241 250 O
Criteria NCT03927742 251 259 O
: NCT03927742 260 261 O

- NCT03927742 265 266 O
Inability NCT03927742 268 277 O
to NCT03927742 278 280 O
provide NCT03927742 281 288 O
informed NCT03927742 289 297 O
written NCT03927742 298 305 O
consent NCT03927742 306 313 O

- NCT03927742 316 317 O
Pregnancy NCT03927742 319 328 B-Condition

Inclusion NCT03925155 0 9 O
Criteria NCT03925155 10 18 O
: NCT03925155 19 20 O

- NCT03925155 24 25 O
Females NCT03925155 27 34 O
aged NCT03925155 35 39 B-Age
18 NCT03925155 40 42 B-Eq-Comparison
- NCT03925155 43 44 I-Eq-Comparison
50 NCT03925155 45 47 I-Eq-Comparison
years NCT03925155 48 53 I-Eq-Comparison

- NCT03925155 56 57 O
The NCT03925155 59 62 O
study NCT03925155 63 68 O
will NCT03925155 69 73 O
be NCT03925155 74 76 O
offered NCT03925155 77 84 O
to NCT03925155 85 87 O
women NCT03925155 88 93 O
at NCT03925155 94 96 B-And
> NCT03925155 97 98 B-Eq-Comparison
24 NCT03925155 99 101 I-Eq-Comparison
weeks NCT03925155 102 107 I-Eq-Comparison
gestation NCT03925155 108 117 B-Observation
who NCT03925155 118 121 B-And
are NCT03925155 122 125 O
undergoing NCT03925155 126 136 B-Eq-Comparison
nonemergent NCT03925155 137 148 B-Modifier
cesarean NCT03925155 149 157 B-Procedure
delivery NCT03925155 158 166 I-Procedure
with NCT03925155 167 171 B-And
ruptured NCT03925155 172 180 B-Condition
amniotic NCT03925155 181 189 I-Condition
membranes NCT03925155 190 199 I-Condition
. NCT03925155 199 200 O

- NCT03925155 204 205 O
All NCT03925155 207 210 O
patients NCT03925155 211 219 O
undergoing NCT03925155 220 230 B-Eq-Comparison
cesarean NCT03925155 231 239 B-Procedure
delivery NCT03925155 240 248 I-Procedure
with NCT03925155 249 253 B-And
ruptured NCT03925155 254 262 B-Condition
amniotic NCT03925155 263 271 I-Condition
membranes NCT03925155 272 281 I-Condition
. NCT03925155 281 282 O

Exclusion NCT03925155 284 293 O
Criteria NCT03925155 294 302 O
: NCT03925155 303 304 O

- NCT03925155 308 309 O
Minors NCT03925155 311 317 O

- NCT03925155 320 321 O
Emergent NCT03925155 323 331 B-Modifier
cesarean NCT03925155 332 340 B-Procedure
delivery NCT03925155 341 349 I-Procedure
. NCT03925155 349 350 O

- NCT03925155 354 355 O
No NCT03925155 357 359 B-Negation
ruptured NCT03925155 360 368 B-Condition
membranes NCT03925155 369 378 I-Condition
. NCT03925155 378 379 O

- NCT03925155 383 384 O
Allergy NCT03925155 386 393 B-Allergy
to NCT03925155 394 396 O
chlorhexidine NCT03925155 397 410 B-Drug
or NCT03925155 411 413 B-Or
povidone NCT03925155 414 422 B-Drug
- NCT03925155 423 424 I-Drug
iodine NCT03925155 425 431 I-Drug
. NCT03925155 431 432 O

Inclusion NCT03929380 0 9 O
Criteria NCT03929380 10 18 O
: NCT03929380 19 20 O

- NCT03929380 24 25 O
Males NCT03929380 27 32 O
, NCT03929380 33 34 O
with NCT03929380 35 39 B-And
at NCT03929380 40 42 B-Eq-Comparison
least NCT03929380 43 48 I-Eq-Comparison
a NCT03929380 49 50 I-Eq-Comparison
year NCT03929380 51 55 I-Eq-Comparison
of NCT03929380 56 58 O
experience NCT03929380 59 69 O
in NCT03929380 70 72 O
heavylift NCT03929380 73 82 B-Modifier
exercises NCT03929380 83 92 B-Observation
, NCT03929380 93 94 O
age NCT03929380 95 98 B-Age
between NCT03929380 99 106 B-Eq-Comparison
20 NCT03929380 107 109 I-Eq-Comparison
and NCT03929380 110 113 I-Eq-Comparison
35 NCT03929380 114 116 I-Eq-Comparison
years NCT03929380 117 122 I-Eq-Comparison
. NCT03929380 122 123 O

Exclusion NCT03929380 125 134 O
Criteria NCT03929380 135 143 O
: NCT03929380 144 145 O

- NCT03929380 149 150 O


Inclusion NCT03921086 0 9 O
Criteria NCT03921086 10 18 O
: NCT03921086 19 20 O

- NCT03921086 24 25 O
Adult NCT03921086 27 32 O
( NCT03921086 33 34 O
older NCT03921086 35 40 I-Eq-Comparison
than NCT03921086 41 45 I-Eq-Comparison
18 NCT03921086 46 48 I-Eq-Comparison
years NCT03921086 49 54 I-Eq-Comparison
) NCT03921086 55 56 O

- NCT03921086 60 61 O
Elective NCT03921086 63 71 B-Modifier
surgery NCT03921086 72 79 B-Procedure
at NCT03921086 80 82 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pre NCT03921086 83 86 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03921086 87 88 O
- NCT03921086 90 91 O
operative NCT03921086 92 101 B-Procedure
in NCT03921086 102 104 B-Encounter
- NCT03921086 105 106 I-Encounter
hospital NCT03921086 107 115 I-Encounter
visit NCT03921086 116 121 I-Encounter

- NCT03921086 124 125 O
All NCT03921086 127 130 O
stage NCT03921086 131 136 I-Eq-Comparison
1 NCT03921086 137 138 B-Eq-Comparison
and NCT03921086 139 142 I-Eq-Comparison
stage NCT03921086 143 148 O
2 NCT03921086 149 150 I-Eq-Comparison
hypertensive NCT03921086 151 163 B-Condition
patients NCT03921086 164 172 O
as NCT03921086 173 175 O
defined NCT03921086 176 183 O
by NCT03921086 184 186 O
the NCT03921086 187 190 O
South NCT03921086 191 196 O
African NCT03921086 197 204 O
Hypertension NCT03921086 205 217 O
Practice NCT03921086 218 226 O
Guideline NCT03921086 227 236 O
2014 NCT03921086 237 241 O

Exclusion NCT03921086 243 252 O
Criteria NCT03921086 253 261 O
: NCT03921086 262 263 O

- NCT03921086 267 268 O
Patient NCT03921086 270 277 O
refusal NCT03921086 278 285 O

- NCT03921086 288 289 O
Day NCT03921086 291 294 B-Modifier
case NCT03921086 295 299 I-Modifier
surgery NCT03921086 300 307 B-Procedure

- NCT03921086 310 311 O
Obstetric NCT03921086 313 322 B-Modifier
and NCT03921086 323 326 B-Or
cardiac NCT03921086 327 334 B-Modifier
surgery NCT03921086 335 342 B-Procedure

- NCT03921086 345 346 O
Patients NCT03921086 348 356 O
with NCT03921086 357 361 O
severe NCT03921086 362 368 O
hypertension NCT03921086 369 381 B-Condition|Observation
( NCT03921086 382 383 O
> NCT03921086 385 386 B-Eq-Comparison
180 NCT03921086 387 390 I-Eq-Comparison
/ NCT03921086 391 392 I-Eq-Comparison
110 NCT03921086 393 396 I-Eq-Comparison
mmHg NCT03921086 397 401 I-Eq-Comparison
) NCT03921086 402 403 O
as NCT03921086 404 406 O
defined NCT03921086 407 414 O
by NCT03921086 415 417 O
the NCT03921086 418 421 O
South NCT03921086 422 427 O
African NCT03921086 428 435 O
Hypertension NCT03921086 436 448 O
Practice NCT03921086 449 457 O
Guideline NCT03921086 458 467 O
2014 NCT03921086 468 472 O

Inclusion NCT03927391 0 9 O
Criteria NCT03927391 10 18 O
: NCT03927391 19 20 O

- NCT03927391 24 25 O
Frailᵃ NCT03927391 27 33 B-Condition
male NCT03927391 34 38 O
patients NCT03927391 39 47 O
with NCT03927391 48 52 B-And
prostate NCT03927391 53 61 B-Modifier
cancer NCT03927391 62 68 B-Condition
who NCT03927391 69 72 B-And
will NCT03927391 73 77 B-Eq-Comparison
start NCT03927391 78 83 B-Eq-Comparison
treatment NCT03927391 84 93 B-Procedure
with NCT03927391 94 98 O
enzalutamide NCT03927391 99 111 B-Drug
within NCT03927391 112 118 B-Modifier
label NCT03927391 119 124 I-Modifier

- NCT03927391 127 128 O
Age NCT03927391 130 133 B-Age
at NCT03927391 134 136 B-Eq-Comparison
least NCT03927391 137 142 I-Eq-Comparison
18 NCT03927391 143 145 I-Eq-Comparison
years NCT03927391 146 151 I-Eq-Comparison

- NCT03927391 154 155 O
Patient NCT03927391 157 164 O
who NCT03927391 165 168 O
are NCT03927391 169 172 O
able NCT03927391 173 177 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03927391 178 181 I-Assertion___Assertion-Type-Value:hypothetical
willing NCT03927391 182 189 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03927391 190 192 O
give NCT03927391 193 197 O
written NCT03927391 198 205 O
informed NCT03927391 206 214 O
consent NCT03927391 215 222 O
prior NCT03927391 223 228 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03927391 229 231 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03927391 232 241 B-Study

- NCT03927391 244 245 O
Patients NCT03927391 247 255 O
from NCT03927391 256 260 O
whom NCT03927391 261 265 O
it NCT03927391 266 268 O
is NCT03927391 269 271 O
possible NCT03927391 272 280 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03927391 281 283 I-Assertion___Assertion-Type-Value:hypothetical
collect NCT03927391 284 291 I-Assertion___Assertion-Type-Value:hypothetical
blood NCT03927391 292 297 B-Observation
samples NCT03927391 298 305 I-Observation

- NCT03927391 308 309 O
Patients NCT03927391 311 319 O
who NCT03927391 320 323 O
are NCT03927391 324 327 O
willing NCT03927391 328 335 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03927391 336 338 I-Assertion___Assertion-Type-Value:hypothetical
answer NCT03927391 339 345 O
the NCT03927391 346 349 O
questionnaires NCT03927391 350 364 B-Observation
and NCT03927391 365 368 B-And
test NCT03927391 369 373 B-Observation

- NCT03927391 376 377 O
Life NCT03927391 379 383 B-Observation
expectancy NCT03927391 384 394 I-Observation
of NCT03927391 395 397 O
> NCT03927391 398 399 B-Eq-Comparison
6 NCT03927391 400 401 I-Eq-Comparison
months NCT03927391 402 408 I-Eq-Comparison

- NCT03927391 411 412 O
Capable NCT03927391 414 421 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03927391 422 424 I-Assertion___Assertion-Type-Value:hypothetical
understanding NCT03927391 425 438 O
and NCT03927391 439 442 O
answering NCT03927391 443 452 O
Dutch NCT03927391 453 458 O
tests NCT03927391 459 464 B-Observation
and NCT03927391 465 468 B-And
questionnaires NCT03927391 469 483 B-Observation
, NCT03927391 484 485 O
as NCT03927391 486 488 O
determined NCT03927391 489 499 O
by NCT03927391 500 502 O
the NCT03927391 503 506 O
investigator NCT03927391 507 519 O

ᵃ NCT03927391 520 521 O
Frail NCT03927391 522 527 B-Condition
is NCT03927391 528 530 O
defined NCT03927391 531 538 O
as NCT03927391 539 541 O
: NCT03927391 542 543 O

- NCT03927391 547 548 O
a NCT03927391 550 551 O
score NCT03927391 552 557 O
on NCT03927391 558 560 O
the NCT03927391 561 564 O
comprehensive NCT03927391 565 578 O
G8 NCT03927391 579 581 B-Observation
assessment NCT03927391 582 592 I-Observation
with NCT03927391 593 597 O
cut NCT03927391 598 601 O
- NCT03927391 602 603 O
off NCT03927391 604 607 O
≤ NCT03927391 608 609 B-Eq-Comparison
14 NCT03927391 610 612 I-Eq-Comparison
points NCT03927391 613 619 O
and NCT03927391 620 623 O

- NCT03927391 626 627 O
score NCT03927391 629 634 O
≥ NCT03927391 635 636 B-Eq-Comparison
grade NCT03927391 637 642 I-Eq-Comparison
1 NCT03927391 643 644 I-Eq-Comparison
for NCT03927391 645 648 O
Central NCT03927391 649 656 B-Condition
Nervous NCT03927391 657 664 I-Condition
Disorders NCT03927391 665 674 I-Condition
according NCT03927391 675 684 O
to NCT03927391 685 687 O
the NCT03927391 688 691 O
Common NCT03927391 692 698 O
Toxicity NCT03927391 699 707 O
Criteria NCT03927391 708 716 O
Adverse NCT03927391 717 724 O
Event NCT03927391 725 730 O
( NCT03927391 731 732 O
CTCAE NCT03927391 733 738 O
) NCT03927391 739 740 O
criteria NCT03927391 741 749 O
, NCT03927391 750 751 O
of NCT03927391 752 754 O
one NCT03927391 755 758 B-Eq-Comparison
of NCT03927391 759 761 O
the NCT03927391 762 765 B-Criteria-Count
following NCT03927391 766 775 I-Criteria-Count
: NCT03927391 776 777 O
Fatigue NCT03927391 778 785 B-Condition
, NCT03927391 786 787 O
Concentration NCT03927391 788 801 B-Condition
impairment NCT03927391 802 812 I-Condition
, NCT03927391 813 814 O
cognitive NCT03927391 815 824 B-Condition
disturbance NCT03927391 825 836 I-Condition
, NCT03927391 837 838 O
amnesia NCT03927391 839 846 B-Condition
, NCT03927391 847 848 O
depressed NCT03927391 849 858 B-Condition
level NCT03927391 859 864 I-Condition
of NCT03927391 865 867 I-Condition
consciousness NCT03927391 868 881 I-Condition
, NCT03927391 882 883 O
memory NCT03927391 884 890 B-Condition
impairment NCT03927391 891 901 I-Condition
, NCT03927391 902 903 O
hypersomnia NCT03927391 904 915 B-Condition
. NCT03927391 915 916 O

Exclusion NCT03927391 918 927 O
Criteria NCT03927391 928 936 O
: NCT03927391 937 938 O

- NCT03927391 942 943 O
change NCT03927391 945 951 O
in NCT03927391 952 954 O
dose NCT03927391 955 959 O
of NCT03927391 960 962 O
opioids NCT03927391 963 970 B-Drug
/ NCT03927391 971 972 B-Or|Or
sedatives NCT03927391 973 982 B-Drug
/ NCT03927391 983 984 O
benzodiazepines NCT03927391 985 1000 B-Drug
during NCT03927391 1001 1007 B-Temporal-Connection___Temporal-Connection-Type-Value:during
last NCT03927391 1008 1012 B-Eq-Comparison
2 NCT03927391 1013 1014 I-Eq-Comparison
weeks NCT03927391 1015 1020 I-Eq-Comparison
before NCT03927391 1021 1027 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03927391 1028 1033 B-Study
) NCT03927391 1034 1035 O

- NCT03927391 1039 1040 O
Use NCT03927391 1042 1045 O
of NCT03927391 1046 1048 O
psychostimulants NCT03927391 1049 1065 B-Drug
such NCT03927391 1066 1070 O
as NCT03927391 1071 1073 O
methylphenidate NCT03927391 1074 1089 B-Drug
within NCT03927391 1090 1096 B-Eq-Comparison
1 NCT03927391 1097 1098 I-Eq-Comparison
week NCT03927391 1099 1103 I-Eq-Comparison
of NCT03927391 1104 1106 B-Temporal-Connection___Temporal-Connection-Type-Value:before
start NCT03927391 1107 1112 B-Eq-Comparison
of NCT03927391 1113 1115 O
study NCT03927391 1116 1121 B-Study

- NCT03927391 1124 1125 O
Diagnosed NCT03927391 1127 1136 O
with NCT03927391 1137 1141 O
medical NCT03927391 1142 1149 B-Condition
conditions NCT03927391 1150 1160 I-Condition
that NCT03927391 1161 1165 O
affect NCT03927391 1166 1172 O
cognition NCT03927391 1173 1182 B-Condition
: NCT03927391 1183 1184 O
Dementia NCT03927391 1185 1193 B-Condition
, NCT03927391 1194 1195 O
Alzheimer NCT03927391 1196 1205 B-Condition
disease NCT03927391 1206 1213 I-Condition|Condition
, NCT03927391 1214 1215 O
Parkinson NCT03927391 1216 1225 B-Condition
's NCT03927391 1225 1227 O
disease NCT03927391 1228 1235 O
, NCT03927391 1236 1237 O
psychiatric NCT03927391 1238 1249 B-Condition
disorders NCT03927391 1250 1259 I-Condition
that NCT03927391 1260 1264 O
affect NCT03927391 1265 1271 O
cognition NCT03927391 1272 1281 B-Condition
other NCT03927391 1282 1287 B-Exception
than NCT03927391 1288 1292 I-Exception
depression NCT03927391 1293 1303 B-Condition
or NCT03927391 1304 1306 B-Or
anxiety NCT03927391 1307 1314 B-Condition
complaints NCT03927391 1315 1325 O
related NCT03927391 1326 1333 O
to NCT03927391 1334 1336 O
the NCT03927391 1337 1340 B-Coreference
disease NCT03927391 1341 1348 I-Coreference

- NCT03927391 1351 1352 O
Active NCT03927391 1354 1360 B-Eq-Comparison
infection NCT03927391 1361 1370 B-Condition
or NCT03927391 1371 1373 B-Or
other NCT03927391 1374 1379 B-Other
comorbidities NCT03927391 1380 1393 B-Condition
that NCT03927391 1394 1398 O
may NCT03927391 1399 1402 O
contribute NCT03927391 1403 1413 O
to NCT03927391 1414 1416 O
REDOSE NCT03927391 1417 1423 O
, NCT03927391 1424 1425 O
February NCT03927391 1426 1434 O
2019 NCT03927391 1435 1439 O
Page NCT03927391 1440 1444 O
7 NCT03927391 1445 1446 O
of NCT03927391 1447 1449 O
53 NCT03927391 1450 1452 O
fatigue NCT03927391 1453 1460 B-Condition
or NCT03927391 1461 1463 B-Or
cognition NCT03927391 1464 1473 B-Condition
change NCT03927391 1474 1480 O
within NCT03927391 1481 1487 B-Eq-Comparison
4 NCT03927391 1488 1489 I-Eq-Comparison
weeks NCT03927391 1490 1495 I-Eq-Comparison
of NCT03927391 1496 1498 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03927391 1499 1504 B-Study
entry NCT03927391 1505 1510 O

- NCT03927391 1513 1514 O
Clinical NCT03927391 1516 1524 O
relevant NCT03927391 1525 1533 O
anaemia NCT03927391 1534 1541 B-Condition

- NCT03927391 1544 1545 O
MoCa NCT03927391 1547 1551 B-Observation
score NCT03927391 1552 1557 I-Observation
< NCT03927391 1558 1559 B-Eq-Comparison
20 NCT03927391 1560 1562 I-Eq-Comparison

- NCT03927391 1566 1567 O
Hypersensitivity NCT03927391 1569 1585 B-Condition
to NCT03927391 1586 1588 O
the NCT03927391 1589 1592 I-Modifier
active NCT03927391 1593 1599 B-Drug
substance NCT03927391 1600 1609 I-Drug
or NCT03927391 1610 1612 B-Or
to NCT03927391 1613 1615 O
any NCT03927391 1616 1619 B-Modifier
of NCT03927391 1620 1622 I-Modifier
the NCT03927391 1623 1626 O
excipients NCT03927391 1627 1637 I-Modifier
. NCT03927391 1637 1638 O

Inclusion NCT03924115 0 9 O
Criteria NCT03924115 10 18 O
: NCT03924115 19 20 O

- NCT03924115 24 25 O
People NCT03924115 27 33 O
under NCT03924115 34 39 B-Eq-Comparison
treatment NCT03924115 40 49 B-Procedure
for NCT03924115 50 53 O
hypertension NCT03924115 54 66 B-Condition

- NCT03924115 69 70 O
Both NCT03924115 72 76 O
sexes NCT03924115 77 82 O

- NCT03924115 85 86 O
Older NCT03924115 88 93 I-Eq-Comparison
than NCT03924115 94 98 I-Eq-Comparison
60 NCT03924115 99 101 I-Eq-Comparison
years NCT03924115 102 107 I-Eq-Comparison

- NCT03924115 110 111 O
Autovalent NCT03924115 113 123 B-Condition

- NCT03924115 126 127 O
read NCT03924115 129 133 O
and NCT03924115 134 137 O
write NCT03924115 138 143 O

Exclusion NCT03924115 144 153 O
Criteria NCT03924115 154 162 O
: NCT03924115 163 164 O

- NCT03924115 168 169 O
Under NCT03924115 171 176 B-Eq-Comparison
treatment NCT03924115 177 186 B-Procedure
for NCT03924115 187 190 O
severe NCT03924115 191 197 O
psychiatric NCT03924115 198 209 B-Condition
pathology NCT03924115 210 219 I-Condition

- NCT03924115 222 223 O
Mental NCT03924115 225 231 B-Condition
retardation NCT03924115 232 243 I-Condition
. NCT03924115 243 244 O

Inclusion NCT03926702 0 9 O
Criteria NCT03926702 10 18 O
: NCT03926702 19 20 O

- NCT03926702 24 25 O
Healthy NCT03926702 27 34 O
Volunteers NCT03926702 35 45 O
: NCT03926702 46 47 O
Subjects NCT03926702 48 56 O
must NCT03926702 57 61 O
be NCT03926702 62 64 O
aged NCT03926702 65 69 B-Age
50 NCT03926702 70 72 B-Eq-Comparison
and NCT03926702 73 76 I-Eq-Comparison
over NCT03926702 77 81 I-Eq-Comparison
. NCT03926702 81 82 O
These NCT03926702 84 89 O
individuals NCT03926702 90 101 O
will NCT03926702 102 106 O
all NCT03926702 107 110 O
be NCT03926702 111 113 O
of NCT03926702 114 116 O
good NCT03926702 117 121 O
general NCT03926702 122 129 B-Condition
medical NCT03926702 130 137 I-Condition
health NCT03926702 138 144 I-Condition
with NCT03926702 145 149 B-And
no NCT03926702 150 152 B-Negation
neurological NCT03926702 153 165 B-Condition
diseases NCT03926702 166 174 I-Condition
and NCT03926702 175 178 O
capable NCT03926702 179 186 O
of NCT03926702 187 189 O
providing NCT03926702 190 199 O
informed NCT03926702 200 208 O
consent NCT03926702 209 216 O
. NCT03926702 216 217 O

- NCT03926702 221 222 O
Patients NCT03926702 224 232 O
: NCT03926702 233 234 O
Subjects NCT03926702 235 243 O
must NCT03926702 244 248 O
be NCT03926702 249 251 O
aged NCT03926702 252 256 B-Age
50 NCT03926702 257 259 B-Eq-Comparison
and NCT03926702 260 263 I-Eq-Comparison
over NCT03926702 264 268 I-Eq-Comparison
. NCT03926702 268 269 O
Patients NCT03926702 271 279 O
will NCT03926702 280 284 O
meet NCT03926702 285 289 O
diagnostic NCT03926702 290 300 O
criteria NCT03926702 301 309 O
at NCT03926702 310 312 O
UCSF NCT03926702 313 317 O
for NCT03926702 318 321 O
Alzheimer NCT03926702 322 331 B-Condition
's NCT03926702 331 333 O
disease NCT03926702 334 341 I-Condition
( NCT03926702 342 343 O
AD NCT03926702 344 346 B-Condition
) NCT03926702 347 348 O
, NCT03926702 350 351 O
mild NCT03926702 352 356 O
cognitive NCT03926702 357 366 B-Condition
impairment NCT03926702 367 377 I-Condition
( NCT03926702 378 379 O
MCI NCT03926702 380 383 B-Condition
) NCT03926702 384 385 O
, NCT03926702 387 388 O
or NCT03926702 389 391 B-Or
progressive NCT03926702 392 403 B-Condition
supranuclear NCT03926702 404 416 I-Condition
palsy NCT03926702 417 422 I-Condition
( NCT03926702 423 424 O
PSP NCT03926702 425 428 B-Condition
) NCT03926702 429 430 O
. NCT03926702 431 432 O

Exclusion NCT03926702 434 443 O
Criteria NCT03926702 444 452 O
: NCT03926702 453 454 O

- NCT03926702 458 459 O
Any NCT03926702 461 464 O
medical NCT03926702 465 472 O
contraindications NCT03926702 473 490 B-Contraindication
to NCT03926702 491 493 O
an NCT03926702 494 496 O
MRI NCT03926702 497 500 B-Procedure
scan NCT03926702 501 505 I-Procedure

- NCT03926702 508 509 O
A NCT03926702 511 512 O
pacemaker NCT03926702 513 522 B-Procedure

- NCT03926702 525 526 O
Metal NCT03926702 528 533 B-Condition
clips NCT03926702 534 539 I-Condition
in NCT03926702 540 542 O
brain NCT03926702 543 548 B-Modifier
or NCT03926702 549 551 B-Or
tattoos NCT03926702 552 559 B-Observation
above NCT03926702 560 565 B-Modifier
neck NCT03926702 566 570 I-Modifier

- NCT03926702 573 574 O
Metallic NCT03926702 576 584 B-Condition
implants NCT03926702 585 593 I-Condition
or NCT03926702 594 596 B-Or
shrapnel NCT03926702 597 605 B-Condition
in NCT03926702 606 608 O
body NCT03926702 609 613 B-Modifier|Modifier

- NCT03926702 616 617 O
Any NCT03926702 619 622 O
body NCT03926702 623 627 O
jewelry NCT03926702 628 635 B-Observation
or NCT03926702 636 638 B-Or
piercings NCT03926702 639 648 B-Observation
that NCT03926702 649 653 O
are NCT03926702 654 657 O
not NCT03926702 658 661 B-Modifier
removable NCT03926702 662 671 I-Modifier

- NCT03926702 674 675 O
A NCT03926702 677 678 O
history NCT03926702 679 686 B-Eq-Comparison
of NCT03926702 687 689 O
claustrophobia NCT03926702 690 704 B-Condition

- NCT03926702 707 708 O
A NCT03926702 710 711 O
known NCT03926702 712 717 O
major NCT03926702 718 723 O
systemic NCT03926702 724 732 B-Condition
disease NCT03926702 733 740 I-Condition

- NCT03926702 743 744 O
A NCT03926702 746 747 O
history NCT03926702 748 755 B-Eq-Comparison
of NCT03926702 756 758 O
a NCT03926702 759 760 O
psychiatric NCT03926702 761 772 B-Condition
disorder NCT03926702 773 781 I-Condition

- NCT03926702 784 785 O
A NCT03926702 787 788 O
history NCT03926702 789 796 B-Eq-Comparison
of NCT03926702 797 799 O
substance NCT03926702 800 809 B-Condition
abuse NCT03926702 810 815 I-Condition
( NCT03926702 816 817 O
prescription NCT03926702 818 830 B-Modifier|Modifier
or NCT03926702 831 833 B-Or
non NCT03926702 834 837 B-Modifier
- NCT03926702 838 839 I-Modifier
prescription NCT03926702 840 852 O
) NCT03926702 853 854 O
within NCT03926702 855 861 B-Eq-Comparison
the NCT03926702 862 865 I-Eq-Comparison
past NCT03926702 866 870 I-Eq-Comparison
5 NCT03926702 871 872 I-Eq-Comparison
years NCT03926702 873 878 I-Eq-Comparison

- NCT03926702 881 882 O
A NCT03926702 884 885 O
current NCT03926702 886 893 B-Eq-Comparison
weight NCT03926702 894 900 B-Observation
of NCT03926702 901 903 O
less NCT03926702 904 908 B-Eq-Comparison
than NCT03926702 909 913 I-Eq-Comparison
45 NCT03926702 914 916 I-Eq-Comparison
kilograms NCT03926702 917 926 I-Eq-Comparison
( NCT03926702 927 928 O
100 NCT03926702 929 932 B-Eq-Comparison
pounds NCT03926702 933 939 I-Eq-Comparison
) NCT03926702 940 941 O

- NCT03926702 945 946 O
Difficulty NCT03926702 948 958 B-Condition
in NCT03926702 959 961 I-Condition
urinating NCT03926702 962 971 I-Condition
or NCT03926702 972 974 B-Or
emptying NCT03926702 975 983 B-Condition
the NCT03926702 984 987 I-Condition
bladder NCT03926702 988 995 I-Condition

- NCT03926702 998 999 O
Under NCT03926702 1001 1006 B-Eq-Comparison
age NCT03926702 1007 1010 I-Eq-Comparison
50 NCT03926702 1011 1013 I-Eq-Comparison

- NCT03926702 1017 1018 O
Participating NCT03926702 1020 1033 B-Eq-Comparison
in NCT03926702 1034 1036 O
an NCT03926702 1037 1039 O
experimental NCT03926702 1040 1052 B-Modifier
radiotracer NCT03926702 1053 1064 B-Procedure
study NCT03926702 1065 1070 B-Study

- NCT03926702 1073 1074 O
Subjects NCT03926702 1076 1084 O
must NCT03926702 1085 1089 O
be NCT03926702 1090 1092 O
fluent NCT03926702 1093 1099 O
English NCT03926702 1100 1107 O
speakers NCT03926702 1108 1116 O

Inclusion NCT03929419 0 9 O
Criteria NCT03929419 10 18 O
: NCT03929419 19 20 O

- NCT03929419 24 25 O
female NCT03929419 27 33 O
volunteer NCT03929419 34 43 O
adults NCT03929419 44 50 O

- NCT03929419 53 54 O
HbA1c NCT03929419 56 61 B-Observation
< NCT03929419 62 63 B-Eq-Comparison
6.0 NCT03929419 64 67 I-Eq-Comparison
% NCT03929419 68 69 O

- NCT03929419 72 73 O
Age NCT03929419 75 78 B-Age
between NCT03929419 79 86 B-Eq-Comparison
18 NCT03929419 87 89 I-Eq-Comparison
and NCT03929419 90 93 I-Eq-Comparison
30 NCT03929419 94 96 I-Eq-Comparison
years NCT03929419 97 102 I-Eq-Comparison

- NCT03929419 105 106 O
Standard NCT03929419 108 116 O
routine NCT03929419 117 124 B-Modifier
laboratory NCT03929419 125 135 B-Observation

- NCT03929419 138 139 O
No NCT03929419 141 143 B-Negation
underlying NCT03929419 144 154 O
diseases NCT03929419 155 163 B-Condition

- NCT03929419 166 167 O
No NCT03929419 169 171 B-Negation
medication NCT03929419 172 182 B-Drug

- NCT03929419 185 186 O
No NCT03929419 188 190 B-Negation
hormonal NCT03929419 191 199 B-Procedure
contraception NCT03929419 200 213 I-Procedure

- NCT03929419 216 217 O
Understanding NCT03929419 219 232 O
of NCT03929419 233 235 O
the NCT03929419 236 239 O
explanations NCT03929419 240 252 O
of NCT03929419 253 255 O
the NCT03929419 256 259 O
study NCT03929419 260 265 O
and NCT03929419 266 269 O
the NCT03929419 270 273 O
instructions NCT03929419 274 286 O

Exclusion NCT03929419 287 296 O
Criteria NCT03929419 297 305 O
: NCT03929419 306 307 O

- NCT03929419 311 312 O
Persons NCT03929419 314 321 O
with NCT03929419 322 326 O
limited NCT03929419 327 334 O
temperature NCT03929419 335 346 B-Condition
perception NCT03929419 347 357 I-Condition
and NCT03929419 358 361 B-Or
/ NCT03929419 362 363 I-Or
or NCT03929419 364 366 I-Or
increased NCT03929419 367 376 O
temperature NCT03929419 377 388 B-Condition
Sensitivity NCT03929419 389 400 I-Condition
to NCT03929419 401 403 O
warming NCT03929419 404 411 B-Modifier
of NCT03929419 412 414 I-Modifier
the NCT03929419 415 418 I-Modifier
body NCT03929419 419 423 I-Modifier

- NCT03929419 426 427 O
Cardiovascular NCT03929419 429 443 B-Condition
disease NCT03929419 444 451 I-Condition
, NCT03929419 452 453 O
such NCT03929419 454 458 O
as NCT03929419 459 461 O
manifest NCT03929419 462 470 O
coronary NCT03929419 471 479 B-Condition
Heart NCT03929419 480 485 I-Condition
disease NCT03929419 486 493 I-Condition
, NCT03929419 494 495 O
heart NCT03929419 496 501 B-Condition
failure NCT03929419 502 509 I-Condition
greater NCT03929419 510 517 B-Eq-Comparison
than NCT03929419 518 522 I-Eq-Comparison
NYHA NCT03929419 523 527 I-Condition|Eq-Comparison
2 NCT03929419 528 529 I-Eq-Comparison
, NCT03929419 530 531 O
recent NCT03929419 532 538 B-Eq-Comparison
myocardial NCT03929419 539 549 B-Condition
infarction NCT03929419 550 560 I-Condition

- NCT03929419 563 564 O
People NCT03929419 566 572 O
with NCT03929419 573 577 O
a NCT03929419 578 579 O
hearing NCT03929419 580 587 B-Condition
disorder NCT03929419 588 596 I-Condition
or NCT03929419 597 599 B-Or
increased NCT03929419 600 609 O
sensitivity NCT03929419 610 621 B-Condition
to NCT03929419 622 624 I-Condition
loud NCT03929419 625 629 I-Condition
Sounds NCT03929419 630 636 I-Condition

- NCT03929419 639 640 O
persons NCT03929419 642 649 O
with NCT03929419 650 654 O
claustrophobia NCT03929419 655 669 B-Condition

- NCT03929419 672 673 O
Minors NCT03929419 675 681 O
or NCT03929419 682 684 O
non NCT03929419 685 688 O
- NCT03929419 689 690 O
consenting NCT03929419 691 701 O
subjects NCT03929419 702 710 O
are NCT03929419 711 714 O
also NCT03929419 715 719 O
excluded NCT03929419 720 728 B-Negation

- NCT03929419 731 732 O
Pregnancy NCT03929419 734 743 B-Condition
or NCT03929419 744 746 B-Or
breastfeeding NCT03929419 747 760 B-Condition
women NCT03929419 761 766 O

- NCT03929419 769 770 O
Surgery NCT03929419 772 779 B-Procedure
less NCT03929419 780 784 B-Eq-Comparison
than NCT03929419 785 789 I-Eq-Comparison
3 NCT03929419 790 791 I-Eq-Comparison
months NCT03929419 792 798 I-Eq-Comparison
ago NCT03929419 799 802 I-Eq-Comparison

- NCT03929419 805 806 O
Simultaneous NCT03929419 808 820 O
participation NCT03929419 821 834 O
in NCT03929419 835 837 O
other NCT03929419 838 843 B-Other
interventional NCT03929419 844 858 O
studies NCT03929419 859 866 B-Study

- NCT03929419 869 870 O
Acute NCT03929419 872 877 O
illness NCT03929419 878 885 B-Condition
or NCT03929419 886 888 B-Or
infection NCT03929419 889 898 B-Condition
within NCT03929419 899 905 B-Eq-Comparison
the NCT03929419 906 909 I-Eq-Comparison
last NCT03929419 910 914 I-Eq-Comparison
4 NCT03929419 915 916 I-Eq-Comparison
weeks NCT03929419 917 922 I-Eq-Comparison

- NCT03929419 925 926 O
Neurological NCT03929419 928 940 B-Modifier
and NCT03929419 941 944 B-Or
psychiatric NCT03929419 945 956 B-Modifier
disorders NCT03929419 957 966 B-Condition

- NCT03929419 969 970 O
Subjects NCT03929419 972 980 O
with NCT03929419 981 985 O
hemoglobin NCT03929419 986 996 B-Observation
Hb NCT03929419 997 999 I-Observation
< NCT03929419 1000 1001 B-Eq-Comparison
12 NCT03929419 1002 1004 I-Eq-Comparison
g NCT03929419 1005 1006 O
/ NCT03929419 1007 1008 I-Eq-Comparison
dl NCT03929419 1009 1011 I-Eq-Comparison
( NCT03929419 1012 1013 O
at NCT03929419 1014 1016 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03929419 1017 1026 B-Study
) NCT03929419 1027 1028 O

- NCT03929419 1032 1033 O
Allergic NCT03929419 1035 1043 B-Allergy
diseases NCT03929419 1044 1052 B-Condition

- NCT03929419 1055 1056 O
Individuals NCT03929419 1058 1069 O
with NCT03929419 1070 1074 O
a NCT03929419 1075 1076 O
history NCT03929419 1077 1084 B-Eq-Comparison
of NCT03929419 1085 1087 O
heparin NCT03929419 1088 1095 B-Drug
- NCT03929419 1096 1097 O
induced NCT03929419 1098 1105 B-Modifier
thrombocytopenia NCT03929419 1106 1122 B-Condition
( NCT03929419 1123 1124 O
HIT NCT03929419 1125 1128 B-Condition
) NCT03929419 1129 1130 O

Inclusion NCT03928288 0 9 O
Criteria NCT03928288 10 18 O
: NCT03928288 19 20 O

- NCT03928288 24 25 O
Female NCT03928288 27 33 O
with NCT03928288 34 38 O
surgically NCT03928288 39 49 B-Procedure
- NCT03928288 50 51 O
confirmed NCT03928288 52 61 O
endometriosis NCT03928288 62 75 B-Condition
, NCT03928288 76 77 O
determined NCT03928288 78 88 O
at NCT03928288 89 91 O
laparoscopy NCT03928288 92 103 B-Procedure
performed NCT03928288 104 113 O
within NCT03928288 114 120 B-Eq-Comparison
3 NCT03928288 121 122 I-Eq-Comparison
y NCT03928288 123 124 O
prior NCT03928288 125 130 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928288 131 133 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928288 134 139 B-Study
baseline NCT03928288 140 148 O

- NCT03928288 151 152 O
Age NCT03928288 154 157 B-Age
15 NCT03928288 158 160 B-Eq-Comparison
years NCT03928288 161 166 I-Eq-Comparison
to NCT03928288 167 169 I-Eq-Comparison
40 NCT03928288 170 172 I-Eq-Comparison
years NCT03928288 173 178 I-Eq-Comparison

- NCT03928288 181 182 O
Current NCT03928288 184 191 B-Eq-Comparison
use NCT03928288 192 195 O
≥ NCT03928288 196 197 B-Eq-Comparison
2 NCT03928288 198 199 I-Eq-Comparison
months NCT03928288 200 206 I-Eq-Comparison
duration NCT03928288 207 215 O
of NCT03928288 216 218 O
hormonal NCT03928288 219 227 B-Procedure
therapy NCT03928288 228 235 I-Procedure
such NCT03928288 236 240 O
as NCT03928288 241 243 O
combined NCT03928288 244 252 B-Modifier
oral NCT03928288 253 257 B-Procedure
contraceptives NCT03928288 258 272 I-Procedure
, NCT03928288 273 274 O
norethindrone NCT03928288 275 288 B-Drug
acetate NCT03928288 289 296 I-Drug
, NCT03928288 297 298 O
or NCT03928288 299 301 B-Or
levonorgestrel NCT03928288 302 316 B-Procedure
intrauterine NCT03928288 317 329 I-Procedure
device NCT03928288 330 336 I-Procedure

- NCT03928288 339 340 O
Current NCT03928288 342 349 B-Eq-Comparison
pelvic NCT03928288 350 356 B-Modifier
pain NCT03928288 357 361 B-Condition|Observation
( NCT03928288 362 363 O
score NCT03928288 364 369 O
≥ NCT03928288 370 371 B-Eq-Comparison
3 NCT03928288 372 373 I-Eq-Comparison
on NCT03928288 374 376 O
Visual NCT03928288 377 383 O
Analog NCT03928288 384 390 O
Scale NCT03928288 391 396 O
, NCT03928288 397 398 O
where NCT03928288 399 404 O
0 NCT03928288 405 406 O
represents NCT03928288 407 417 O
absence NCT03928288 418 425 O
of NCT03928288 426 428 O
pain NCT03928288 429 433 O
and NCT03928288 434 437 O
10 NCT03928288 438 440 O
indicates NCT03928288 441 450 O
unbearable NCT03928288 451 461 O
pain NCT03928288 462 466 O
) NCT03928288 467 468 O
present NCT03928288 469 476 O
for NCT03928288 477 480 O
≥ NCT03928288 481 482 B-Eq-Comparison
14 NCT03928288 483 485 I-Eq-Comparison
days NCT03928288 486 490 I-Eq-Comparison
/ NCT03928288 491 492 I-Eq-Comparison
month NCT03928288 493 498 I-Eq-Comparison
over NCT03928288 499 503 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928288 504 507 O
2 NCT03928288 508 509 B-Eq-Comparison
months NCT03928288 510 516 I-Eq-Comparison
prior NCT03928288 517 522 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928288 523 525 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928288 526 531 B-Study
enrollment NCT03928288 532 542 O

- NCT03928288 545 546 O
Willingness NCT03928288 548 559 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928288 560 562 O
comply NCT03928288 563 569 O
with NCT03928288 570 574 O
visit NCT03928288 575 580 B-Encounter
schedule NCT03928288 581 589 O
and NCT03928288 590 593 O
protocol NCT03928288 594 602 O

Exclusion NCT03928288 603 612 O
Criteria NCT03928288 613 621 O
: NCT03928288 622 623 O

- NCT03928288 627 628 O
Pre NCT03928288 630 633 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03928288 634 635 O
menarche NCT03928288 636 644 B-Condition
or NCT03928288 645 647 B-Or
post NCT03928288 648 652 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03928288 653 654 O
menopause NCT03928288 655 664 B-Condition

- NCT03928288 667 668 O
Contraindications NCT03928288 670 687 B-Contraindication
to NCT03928288 688 690 O
cabergoline NCT03928288 691 702 B-Drug
( NCT03928288 703 704 O
e. NCT03928288 705 707 O
g. NCT03928288 708 710 O
, NCT03928288 711 712 O
cardiac NCT03928288 713 720 B-Condition
valve NCT03928288 721 726 I-Condition
disorder NCT03928288 727 735 I-Condition
; NCT03928288 735 736 O
pulmonary NCT03928288 737 746 B-Modifier
, NCT03928288 747 748 O
pericardial NCT03928288 749 760 B-Modifier
, NCT03928288 761 762 O
retroperitoneal NCT03928288 763 778 B-Modifier
fibrotic NCT03928288 779 787 I-Modifier
disorder NCT03928288 788 796 B-Condition
; NCT03928288 796 797 O
hypersensitivity NCT03928288 798 814 B-Condition
to NCT03928288 815 817 O
ergot NCT03928288 818 823 B-Modifier
derivatives NCT03928288 824 835 I-Modifier
; NCT03928288 835 836 O
uncontrolled NCT03928288 837 849 B-Modifier
hypertension NCT03928288 850 862 B-Condition
) NCT03928288 863 864 O

- NCT03928288 868 869 O
Significant NCT03928288 871 882 O
mental NCT03928288 883 889 B-Modifier
or NCT03928288 890 892 B-Or
chronic NCT03928288 893 900 B-Modifier
systemic NCT03928288 901 909 I-Modifier
illness NCT03928288 910 917 B-Condition
that NCT03928288 918 922 O
might NCT03928288 923 928 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03928288 929 937 O
pain NCT03928288 938 942 B-Procedure
assessment NCT03928288 943 953 I-Procedure
or NCT03928288 954 956 B-Or
the NCT03928288 957 960 O
ability NCT03928288 961 968 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928288 969 971 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03928288 972 980 O
the NCT03928288 981 984 O
study NCT03928288 985 990 B-Study

- NCT03928288 993 994 O
Pregnant NCT03928288 996 1004 B-Condition
, NCT03928288 1005 1006 O
breastfeeding NCT03928288 1007 1020 B-Condition
, NCT03928288 1021 1022 O
or NCT03928288 1023 1025 B-Or
planning NCT03928288 1026 1034 B-Assertion___Assertion-Type-Value:intention
to NCT03928288 1035 1037 I-Assertion___Assertion-Type-Value:intention
become NCT03928288 1038 1044 I-Assertion___Assertion-Type-Value:intention
pregnant NCT03928288 1045 1053 B-Condition
in NCT03928288 1054 1056 O
the NCT03928288 1057 1060 O
next NCT03928288 1061 1065 B-Eq-Comparison
6 NCT03928288 1066 1067 I-Eq-Comparison
months NCT03928288 1068 1074 I-Eq-Comparison

- NCT03928288 1077 1078 O
Impaired NCT03928288 1080 1088 O
liver NCT03928288 1089 1094 O
function NCT03928288 1095 1103 O
( NCT03928288 1104 1105 O
ALT NCT03928288 1106 1109 O
> NCT03928288 1110 1111 O
2 NCT03928288 1112 1113 O
x NCT03928288 1114 1115 O
normal NCT03928288 1116 1122 O
) NCT03928288 1123 1124 O
or NCT03928288 1125 1127 O
liver NCT03928288 1128 1133 O
disease NCT03928288 1134 1141 O

- NCT03928288 1144 1145 O
Breast NCT03928288 1147 1153 B-Modifier
cancer NCT03928288 1154 1160 B-Condition
, NCT03928288 1161 1162 O
current NCT03928288 1163 1170 B-Eq-Comparison
or NCT03928288 1171 1173 B-Or
previous NCT03928288 1174 1182 B-Eq-Comparison

- NCT03928288 1185 1186 O
Thromboembolic NCT03928288 1188 1202 B-Condition
disease NCT03928288 1203 1210 I-Condition
, NCT03928288 1211 1212 O
current NCT03928288 1213 1220 B-Eq-Comparison
or NCT03928288 1221 1223 B-Or
previous NCT03928288 1224 1232 B-Eq-Comparison

- NCT03928288 1235 1236 O
Use NCT03928288 1238 1241 O
of NCT03928288 1242 1244 O
other NCT03928288 1245 1250 B-Other
drugs NCT03928288 1251 1256 B-Drug
that NCT03928288 1257 1261 O
affect NCT03928288 1262 1268 O
dopamine NCT03928288 1269 1277 B-Drug
( NCT03928288 1278 1279 O
e. NCT03928288 1280 1282 O
g. NCT03928288 1283 1285 O
, NCT03928288 1286 1287 O
phenothiazines NCT03928288 1288 1302 B-Drug
, NCT03928288 1303 1304 O
metoclopramide NCT03928288 1305 1319 B-Drug
, NCT03928288 1320 1321 O
butyrophenones NCT03928288 1322 1336 B-Drug
) NCT03928288 1337 1338 O

Inclusion NCT03925948 0 9 O
Criteria NCT03925948 10 18 O
: NCT03925948 19 20 O

- NCT03925948 24 25 O
African NCT03925948 27 34 O
Americans NCT03925948 35 44 O
residing NCT03925948 45 53 O
in NCT03925948 54 56 O
Baltimore NCT03925948 57 66 O
, NCT03925948 67 68 O
Maryland NCT03925948 69 77 O

- NCT03925948 80 81 O
had NCT03925948 83 86 O
uncontrolled NCT03925948 87 99 B-Modifier
diabetes NCT03925948 100 108 B-Condition
( NCT03925948 109 110 O
defined NCT03925948 111 118 O
as NCT03925948 119 121 O
HbA1C NCT03925948 122 127 B-Observation
> NCT03925948 128 129 B-Eq-Comparison
7 NCT03925948 130 131 I-Eq-Comparison
% NCT03925948 132 133 O
) NCT03925948 134 135 O

Exclusion NCT03925948 137 146 O
Criteria NCT03925948 147 155 O
: NCT03925948 156 157 O

- NCT03925948 161 162 O
Unable NCT03925948 164 170 O
to NCT03925948 171 173 O
give NCT03925948 174 178 O
informed NCT03925948 179 187 O
consent NCT03925948 188 195 O

- NCT03925948 198 199 O
Physical NCT03925948 201 209 B-Modifier
or NCT03925948 210 212 B-Or
mental NCT03925948 213 219 B-Modifier
health NCT03925948 220 226 B-Condition
conditions NCT03925948 227 237 I-Condition
that NCT03925948 238 242 O
could NCT03925948 243 248 B-Assertion___Assertion-Type-Value:hypothetical
limit NCT03925948 249 254 O
active NCT03925948 255 261 O
participation NCT03925948 262 275 O
in NCT03925948 276 278 O
the NCT03925948 279 282 O
study NCT03925948 283 288 B-Study
( NCT03925948 289 290 O
e. NCT03925948 291 293 O
g. NCT03925948 294 296 O
, NCT03925948 297 298 O
blindness NCT03925948 299 308 B-Condition
in NCT03925948 309 311 O
both NCT03925948 312 316 B-Modifier
eyes NCT03925948 317 321 I-Modifier
, NCT03925948 322 323 O
severe NCT03925948 324 330 O
immobility NCT03925948 331 341 B-Condition
, NCT03925948 342 343 O
psychiatric NCT03925948 344 355 B-Condition
diseases NCT03925948 356 364 I-Condition
) NCT03925948 365 366 O

- NCT03925948 370 371 O
Hematological NCT03925948 373 386 B-Condition
condition NCT03925948 387 396 I-Condition
that NCT03925948 397 401 O
would NCT03925948 402 407 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03925948 408 414 O
HbA1C NCT03925948 415 420 B-Observation
assay NCT03925948 421 426 I-Observation
, NCT03925948 427 428 O
e. NCT03925948 429 431 O
g. NCT03925948 432 434 O
, NCT03925948 435 436 O
hemolytic NCT03925948 437 446 B-Condition
anemia NCT03925948 447 453 I-Condition|Condition
, NCT03925948 454 455 O
sickle NCT03925948 456 462 B-Condition
cell NCT03925948 463 467 I-Condition
anemia NCT03925948 468 474 O

Inclusion NCT03926299 0 9 O
criteria NCT03926299 10 18 O
: NCT03926299 19 20 O

- NCT03926299 24 25 O
Diagnosis NCT03926299 27 36 O
of NCT03926299 37 39 O
vulvar NCT03926299 40 46 B-Condition
lichen NCT03926299 47 53 I-Condition
sclerosus NCT03926299 54 63 I-Condition

- NCT03926299 66 67 O
Clinical NCT03926299 69 77 O
LS NCT03926299 78 80 B-Observation
score NCT03926299 81 86 I-Observation
≥ NCT03926299 87 88 B-Eq-Comparison
4 NCT03926299 89 90 I-Eq-Comparison

Exclusion NCT03926299 92 101 O
criteria NCT03926299 102 110 O
: NCT03926299 111 112 O

- NCT03926299 116 117 O
Concomitant NCT03926299 119 130 B-Modifier
steroid NCT03926299 131 138 B-Drug
, NCT03926299 139 140 O
calcineurin NCT03926299 141 152 B-Drug
inhibitor NCT03926299 153 162 I-Drug
or NCT03926299 163 165 B-Or
any NCT03926299 166 169 O
other NCT03926299 170 175 B-Other
topical NCT03926299 176 183 B-Modifier
or NCT03926299 184 186 B-Or
systemic NCT03926299 187 195 B-Modifier
treatment NCT03926299 196 205 B-Procedure
for NCT03926299 206 209 O
LS NCT03926299 210 212 B-Condition

- NCT03926299 215 216 O
< NCT03926299 218 219 B-Eq-Comparison
3 NCT03926299 220 221 I-Eq-Comparison
months NCT03926299 222 228 I-Eq-Comparison
since NCT03926299 229 234 B-Temporal-Connection___Temporal-Connection-Type-Value:after
start NCT03926299 235 240 B-Eq-Comparison
of NCT03926299 241 243 O
vaginal NCT03926299 244 251 B-Modifier
estrogen NCT03926299 252 260 B-Procedure
treatment NCT03926299 261 270 I-Procedure

- NCT03926299 273 274 O
Malignant NCT03926299 276 285 B-Condition
disease NCT03926299 286 293 I-Condition
as NCT03926299 294 296 O
the NCT03926299 297 300 O
cause NCT03926299 301 306 O
of NCT03926299 307 309 O
the NCT03926299 310 313 O
vulval NCT03926299 314 320 B-Condition
symptoms NCT03926299 321 329 B-Assertion___Assertion-Type-Value:possible

- NCT03926299 332 333 O
BMI NCT03926299 335 338 B-Observation
> NCT03926299 339 340 B-Eq-Comparison
35 NCT03926299 341 343 I-Eq-Comparison
kg NCT03926299 344 346 I-Eq-Comparison
/ NCT03926299 347 348 I-Eq-Comparison
m² NCT03926299 349 351 I-Eq-Comparison

- NCT03926299 354 355 O
Acute NCT03926299 357 362 O
infection NCT03926299 363 372 B-Condition
( NCT03926299 373 374 O
fungal NCT03926299 375 381 B-Modifier
, NCT03926299 382 383 O
bacterial NCT03926299 384 393 B-Modifier
, NCT03926299 394 395 O
viral NCT03926299 396 401 B-Modifier
) NCT03926299 402 403 O
of NCT03926299 404 406 O
the NCT03926299 407 410 O
vulva NCT03926299 411 416 B-Modifier
, NCT03926299 417 418 O
vagina NCT03926299 419 425 B-Modifier
or NCT03926299 426 428 B-Or
bladder NCT03926299 429 436 B-Modifier

- NCT03926299 439 440 O
Presence NCT03926299 442 450 O
of NCT03926299 451 453 O
contraindications NCT03926299 454 471 B-Contraindication
for NCT03926299 472 475 O
the NCT03926299 476 479 O
laser NCT03926299 480 485 B-Procedure
treatment NCT03926299 486 495 I-Procedure
or NCT03926299 496 498 B-Or
topical NCT03926299 499 506 B-Drug
steroid NCT03926299 507 514 I-Drug
treatment NCT03926299 515 524 B-Procedure

Inclusion NCT03923478 0 9 O
Criteria NCT03923478 10 18 O
: NCT03923478 19 20 O

- NCT03923478 24 25 O
Established NCT03923478 27 38 O
diagnosis NCT03923478 39 48 O
of NCT03923478 49 51 O
UC NCT03923478 52 54 B-Condition
for NCT03923478 55 58 O
at NCT03923478 59 61 B-Eq-Comparison
least NCT03923478 62 67 I-Eq-Comparison
3 NCT03923478 68 69 I-Eq-Comparison
months NCT03923478 70 76 I-Eq-Comparison
prior NCT03923478 77 82 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923478 83 85 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03923478 86 95 B-Study
, NCT03923478 96 97 O
with NCT03923478 98 102 B-And
minimum NCT03923478 103 110 B-Observation
disease NCT03923478 111 118 I-Observation
extent NCT03923478 119 125 I-Observation
of NCT03923478 126 128 O
15 NCT03923478 129 131 B-Eq-Comparison
cm NCT03923478 132 134 I-Eq-Comparison
from NCT03923478 135 139 O
the NCT03923478 140 143 O
anal NCT03923478 144 148 B-Modifier
verge NCT03923478 149 154 I-Modifier

- NCT03923478 157 158 O
Mildly NCT03923478 160 166 B-Eq-Comparison
to NCT03923478 167 169 I-Eq-Comparison
moderately NCT03923478 170 180 I-Eq-Comparison
active NCT03923478 181 187 B-Eq-Comparison
UC NCT03923478 188 190 B-Condition

- NCT03923478 193 194 O
Inadequate NCT03923478 196 206 B-Modifier
response NCT03923478 207 215 I-Modifier
to NCT03923478 216 218 O
ongoing NCT03923478 219 226 B-Eq-Comparison
treatment NCT03923478 227 236 B-Procedure
with NCT03923478 237 241 O
oral NCT03923478 242 246 B-Drug
mesalamine NCT03923478 247 257 I-Drug
≥ NCT03923478 258 259 B-Eq-Comparison
2.4 NCT03923478 260 263 I-Eq-Comparison
g NCT03923478 264 265 I-Eq-Comparison
/ NCT03923478 266 267 I-Eq-Comparison
day NCT03923478 268 271 I-Eq-Comparison
for NCT03923478 272 275 O
≥ NCT03923478 276 277 B-Eq-Comparison
4 NCT03923478 278 279 I-Eq-Comparison
weeks NCT03923478 280 285 I-Eq-Comparison
from NCT03923478 286 290 B-Temporal-Connection___Temporal-Connection-Type-Value:after
screening NCT03923478 291 300 B-Study
visit NCT03923478 301 306 O

Exclusion NCT03923478 307 316 O
Criteria NCT03923478 317 325 O
: NCT03923478 326 327 O

- NCT03923478 331 332 O
Possible NCT03923478 334 342 B-Assertion___Assertion-Type-Value:possible
or NCT03923478 343 345 O
confirmed NCT03923478 346 355 O
diagnosis NCT03923478 356 365 O
of NCT03923478 366 368 O
Crohn NCT03923478 369 374 B-Condition
's NCT03923478 374 376 O
Disease NCT03923478 377 384 I-Condition
or NCT03923478 385 387 B-Or
other NCT03923478 388 393 B-Other
forms NCT03923478 394 399 O
of NCT03923478 400 402 O
inflammatory NCT03923478 403 415 B-Modifier
bowel NCT03923478 416 421 B-Condition
disorders NCT03923478 422 431 I-Condition

- NCT03923478 434 435 O
Ongoing NCT03923478 437 444 B-Eq-Comparison
or NCT03923478 445 447 B-Or
failed NCT03923478 448 454 B-Modifier
prior NCT03923478 455 460 B-Eq-Comparison
treatment NCT03923478 461 470 B-Procedure
for NCT03923478 471 474 O
UC NCT03923478 475 477 B-Condition
with NCT03923478 478 482 O
methotrexate NCT03923478 483 495 B-Drug
, NCT03923478 496 497 O
azathioprine NCT03923478 498 510 B-Drug
, NCT03923478 511 512 O

6 NCT03923478 519 520 B-Drug
- NCT03923478 521 522 I-Drug
mercaptopurine NCT03923478 523 537 I-Drug
, NCT03923478 538 539 O
cyclosporine NCT03923478 540 552 B-Drug
, NCT03923478 553 554 O
tofacitinib NCT03923478 555 566 B-Drug
, NCT03923478 567 568 O
mycophenolate NCT03923478 569 582 B-Drug
mofetil NCT03923478 583 590 I-Drug
, NCT03923478 591 592 O
sirolimus NCT03923478 593 602 B-Drug
( NCT03923478 603 604 O
rapamycin NCT03923478 605 614 B-Drug
) NCT03923478 615 616 O
, NCT03923478 618 619 O
thalidomide NCT03923478 620 631 B-Drug
, NCT03923478 632 633 O
tacrolimus NCT03923478 634 644 B-Drug
( NCT03923478 645 646 O
FK NCT03923478 647 649 B-Drug
- NCT03923478 650 651 I-Drug
506 NCT03923478 652 655 I-Drug
) NCT03923478 656 657 O
, NCT03923478 659 660 O
or NCT03923478 661 663 B-Or
biologics NCT03923478 664 673 B-Drug
( NCT03923478 674 675 O
e. NCT03923478 676 678 O
g. NCT03923478 679 681 O
, NCT03923478 682 683 O
TNF NCT03923478 684 687 B-Drug
- NCT03923478 688 689 I-Drug|Drug
alpha NCT03923478 690 695 I-Drug
- NCT03923478 696 697 O
antagonists NCT03923478 698 709 I-Drug
, NCT03923478 710 711 O
anti NCT03923478 712 716 B-Drug
- NCT03923478 717 718 O
integrin NCT03923478 719 727 I-Drug
therapies NCT03923478 728 737 I-Drug
, NCT03923478 738 739 O
or NCT03923478 740 742 B-Or|Or
agents NCT03923478 743 749 B-Drug
targeting NCT03923478 750 759 I-Drug
IL NCT03923478 760 762 B-Modifier|Modifier
- NCT03923478 763 764 I-Modifier|Modifier
12 NCT03923478 765 767 I-Modifier
or NCT03923478 768 770 O
IL NCT03923478 771 773 O
- NCT03923478 774 775 O
23 NCT03923478 776 778 I-Modifier
, NCT03923478 779 780 O
etc NCT03923478 781 784 O
. NCT03923478 784 785 O
) NCT03923478 786 787 O

- NCT03923478 791 792 O
Any NCT03923478 794 797 O
immunosuppressive NCT03923478 798 815 B-Condition|Drug
condition NCT03923478 816 825 I-Condition
or NCT03923478 826 828 B-Or
treatment NCT03923478 829 838 B-Procedure
with NCT03923478 839 843 O
immunosuppressive NCT03923478 844 861 O
medications NCT03923478 862 873 I-Drug

- NCT03923478 876 877 O
History NCT03923478 879 886 B-Eq-Comparison
of NCT03923478 887 889 I-Eq-Comparison
prior NCT03923478 890 895 I-Eq-Comparison
surgical NCT03923478 896 904 B-Procedure
intervention NCT03923478 905 917 I-Procedure
in NCT03923478 918 920 O
any NCT03923478 921 924 O
region NCT03923478 925 931 O
of NCT03923478 932 934 O
the NCT03923478 935 938 O
gastrointestinal NCT03923478 939 955 B-Modifier
tract NCT03923478 956 961 I-Modifier
( NCT03923478 962 963 O
excluding NCT03923478 964 973 B-Exception
minor NCT03923478 974 979 B-Procedure
surgery NCT03923478 980 987 I-Procedure
) NCT03923478 988 989 O

- NCT03923478 993 994 O
Prior NCT03923478 996 1001 B-Eq-Comparison
diagnosis NCT03923478 1002 1011 O
of NCT03923478 1012 1014 O
any NCT03923478 1015 1018 O
cardiovascular NCT03923478 1019 1033 B-Modifier
, NCT03923478 1034 1035 O
renal NCT03923478 1036 1041 B-Modifier
, NCT03923478 1042 1043 O
hepatic NCT03923478 1044 1051 B-Modifier
, NCT03923478 1052 1053 O
endocrine NCT03923478 1054 1063 B-Modifier
, NCT03923478 1064 1065 O
infectious NCT03923478 1066 1076 B-Modifier
, NCT03923478 1077 1078 O
hematological NCT03923478 1079 1092 B-Modifier
, NCT03923478 1093 1094 O
oncologic NCT03923478 1095 1104 B-Modifier
, NCT03923478 1105 1106 O
neuro NCT03923478 1107 1112 B-Modifier
- NCT03923478 1113 1114 I-Modifier|Modifier
psychiatric NCT03923478 1115 1126 I-Modifier
or NCT03923478 1127 1129 B-Or
immune NCT03923478 1130 1136 B-Modifier
- NCT03923478 1137 1138 O
mediated NCT03923478 1139 1147 I-Modifier
disorder NCT03923478 1148 1156 B-Condition
, NCT03923478 1157 1158 O
which NCT03923478 1159 1164 O
in NCT03923478 1165 1167 O
the NCT03923478 1168 1171 O
opinion NCT03923478 1172 1179 O
of NCT03923478 1180 1182 O
the NCT03923478 1183 1186 O
Principal NCT03923478 1187 1196 O
Investigator NCT03923478 1197 1209 O
might NCT03923478 1210 1215 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03923478 1216 1222 O
the NCT03923478 1223 1226 O
subject NCT03923478 1227 1234 O
's NCT03923478 1234 1236 O
safety NCT03923478 1237 1243 O
or NCT03923478 1244 1246 O
compliance NCT03923478 1247 1257 O
, NCT03923478 1258 1259 O
or NCT03923478 1260 1262 O
the NCT03923478 1263 1266 O
interpretation NCT03923478 1267 1281 O
of NCT03923478 1282 1284 O
results NCT03923478 1285 1292 B-Study

- NCT03923478 1295 1296 O
Treatment NCT03923478 1298 1307 B-Procedure
with NCT03923478 1308 1312 O
any NCT03923478 1313 1316 O
other NCT03923478 1317 1322 B-Other
investigational NCT03923478 1323 1338 B-Study
drugs NCT03923478 1339 1344 B-Drug
≤ NCT03923478 1345 1346 B-Eq-Comparison
12 NCT03923478 1347 1349 I-Eq-Comparison
weeks NCT03923478 1350 1355 I-Eq-Comparison
prior NCT03923478 1356 1361 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923478 1362 1364 I-Temporal-Connection___Temporal-Connection-Type-Value:before
baseline NCT03923478 1365 1373 B-Study
visit NCT03923478 1374 1379 O

- NCT03923478 1382 1383 O
The NCT03923478 1385 1388 O
participant NCT03923478 1389 1400 O
has NCT03923478 1401 1404 O
a NCT03923478 1405 1406 O
condition NCT03923478 1407 1416 B-Condition
or NCT03923478 1417 1419 O
is NCT03923478 1420 1422 O
in NCT03923478 1423 1425 O
a NCT03923478 1426 1427 O
situation NCT03923478 1428 1437 O
which NCT03923478 1438 1443 O
, NCT03923478 1444 1445 O
in NCT03923478 1446 1448 O
the NCT03923478 1449 1452 O
Principal NCT03923478 1453 1462 O
Investigator NCT03923478 1463 1475 O
's NCT03923478 1475 1477 O
opinion NCT03923478 1478 1485 O
, NCT03923478 1486 1487 O
may NCT03923478 1488 1491 B-Assertion___Assertion-Type-Value:hypothetical
put NCT03923478 1492 1495 O
the NCT03923478 1496 1499 O
participant NCT03923478 1500 1511 O
at NCT03923478 1512 1514 O
significant NCT03923478 1515 1526 O
risk NCT03923478 1527 1531 B-Risk
, NCT03923478 1532 1533 O
may NCT03923478 1534 1537 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03923478 1538 1546 O
the NCT03923478 1547 1550 O
study NCT03923478 1551 1556 B-Study
results NCT03923478 1557 1564 O
, NCT03923478 1565 1566 O
or NCT03923478 1567 1569 B-Or
may NCT03923478 1570 1573 O
interfere NCT03923478 1574 1583 O
significantly NCT03923478 1584 1597 O
with NCT03923478 1598 1602 O
the NCT03923478 1603 1606 O
participant NCT03923478 1607 1618 O
's NCT03923478 1618 1620 O
participation NCT03923478 1621 1634 O
in NCT03923478 1635 1637 O
the NCT03923478 1638 1641 O
study NCT03923478 1642 1647 B-Study

Inclusion NCT03925753 0 9 O
Criteria NCT03925753 10 18 O
: NCT03925753 19 20 O

- NCT03925753 24 25 O
Both NCT03925753 27 31 O
sexes NCT03925753 32 37 O
aged NCT03925753 38 42 B-Age
between NCT03925753 43 50 O
20 NCT03925753 51 53 B-Eq-Comparison
- NCT03925753 54 55 I-Eq-Comparison
90 NCT03925753 56 58 I-Eq-Comparison
years NCT03925753 59 64 I-Eq-Comparison
. NCT03925753 64 65 O

- NCT03925753 69 70 O
Received NCT03925753 72 80 B-Eq-Comparison
stable NCT03925753 81 87 O
hemodialysis NCT03925753 88 100 B-Procedure
at NCT03925753 101 103 B-Eq-Comparison
least NCT03925753 104 109 I-Eq-Comparison
3 NCT03925753 110 111 I-Eq-Comparison
months NCT03925753 112 118 I-Eq-Comparison
. NCT03925753 118 119 O

- NCT03925753 123 124 O
Written NCT03925753 126 133 O
informed NCT03925753 134 142 O
consent NCT03925753 143 150 O
. NCT03925753 150 151 O

Exclusion NCT03925753 153 162 O
Criteria NCT03925753 163 171 O
: NCT03925753 172 173 O

- NCT03925753 177 178 O
patients NCT03925753 180 188 O
with NCT03925753 189 193 O
severe NCT03925753 194 200 O
infections NCT03925753 201 211 B-Condition
, NCT03925753 212 213 O
severe NCT03925753 214 220 O
heart NCT03925753 221 226 B-Condition
disease NCT03925753 227 234 I-Condition
and NCT03925753 235 238 B-Or
liver NCT03925753 239 244 B-Condition
disease NCT03925753 245 252 I-Condition
, NCT03925753 253 254 O
malignancy NCT03925753 255 265 B-Condition
, NCT03925753 266 267 O
autoimmune NCT03925753 268 278 B-Condition
disorders NCT03925753 279 288 I-Condition
, NCT03925753 289 290 O
severe NCT03925753 291 297 O
malnutrition NCT03925753 298 310 B-Condition
, NCT03925753 311 312 O
or NCT03925753 313 315 B-Or
clinical NCT03925753 316 324 O
conditions NCT03925753 325 335 B-Condition
requiring NCT03925753 336 345 O
oral NCT03925753 346 350 B-Procedure
nutrition NCT03925753 351 360 I-Procedure
supplements NCT03925753 361 372 I-Procedure
; NCT03925753 372 373 O

- NCT03925753 376 377 O
Inability NCT03925753 379 388 O
to NCT03925753 389 391 O
follow NCT03925753 392 398 O
protocol NCT03925753 399 407 O
. NCT03925753 407 408 O

- NCT03925753 412 413 O
Pregnancy NCT03925753 415 424 B-Condition
or NCT03925753 425 427 B-Or
wishing NCT03925753 428 435 B-Assertion___Assertion-Type-Value:intention
/ NCT03925753 436 437 B-Or
trying NCT03925753 438 444 B-Assertion___Assertion-Type-Value:intention
to NCT03925753 445 447 O
get NCT03925753 448 451 O
pregnant NCT03925753 452 460 B-Condition

Inclusion NCT03925779 0 9 O
Criteria NCT03925779 10 18 O
: NCT03925779 19 20 O

- NCT03925779 24 25 O
ASA NCT03925779 27 30 B-Condition
I NCT03925779 31 32 B-Eq-Comparison
or NCT03925779 33 35 I-Eq-Comparison
II NCT03925779 36 38 I-Eq-Comparison
physical NCT03925779 39 47 O
status NCT03925779 48 54 O

- NCT03925779 57 58 O
18 NCT03925779 60 62 B-Eq-Comparison
- NCT03925779 63 64 I-Eq-Comparison
65 NCT03925779 65 67 I-Eq-Comparison
years NCT03925779 68 73 I-Age|Eq-Comparison

- NCT03925779 76 77 O
Scheduled NCT03925779 79 88 B-Eq-Comparison
for NCT03925779 89 92 O
elective NCT03925779 93 101 B-Modifier
colonoscopy NCT03925779 102 113 B-Procedure

Exclusion NCT03925779 114 123 O
Criteria NCT03925779 124 132 O
: NCT03925779 133 134 O

- NCT03925779 138 139 O
History NCT03925779 141 148 B-Eq-Comparison
of NCT03925779 149 151 O
allergy NCT03925779 152 159 B-Allergy
to NCT03925779 160 162 O
any NCT03925779 163 166 O
of NCT03925779 167 169 O
the NCT03925779 170 173 O
study NCT03925779 174 179 B-Study
drugs NCT03925779 180 185 B-Drug

- NCT03925779 188 189 O
Alcohol NCT03925779 191 198 B-Modifier
or NCT03925779 199 201 B-Or
drug NCT03925779 202 206 B-Modifier
abuse NCT03925779 207 212 B-Condition
. NCT03925779 212 213 O

- NCT03925779 217 218 O
Second NCT03925779 220 226 B-Eq-Comparison
and NCT03925779 227 230 I-Eq-Comparison
third NCT03925779 231 236 I-Eq-Comparison
- NCT03925779 237 238 I-Eq-Comparison
degree NCT03925779 239 245 I-Eq-Comparison
heart NCT03925779 246 251 B-Condition
block NCT03925779 252 257 I-Condition
. NCT03925779 257 258 O

- NCT03925779 262 263 O
Morbid NCT03925779 265 271 B-Condition
obesity NCT03925779 272 279 I-Condition
. NCT03925779 279 280 O

- NCT03925779 284 285 O
Pregnant NCT03925779 287 295 B-Condition
and NCT03925779 296 299 B-Or
lactating NCT03925779 300 309 B-Condition
women NCT03925779 310 315 O
. NCT03925779 315 316 O

- NCT03925779 320 321 O
Psychiatric NCT03925779 323 334 B-Condition
disorders NCT03925779 335 344 I-Condition
. NCT03925779 344 345 O

- NCT03925779 349 350 O
Severe NCT03925779 352 358 O
cardiac NCT03925779 359 366 B-Modifier
, NCT03925779 367 368 O
respiratory NCT03925779 369 380 B-Modifier
, NCT03925779 381 382 O
renal NCT03925779 383 388 B-Modifier
, NCT03925779 389 390 O
and NCT03925779 391 394 B-Or
liver NCT03925779 395 400 B-Modifier
diseases NCT03925779 401 409 B-Condition

Inclusion NCT03921047 0 9 O
Criteria NCT03921047 10 18 O
: NCT03921047 19 20 O

- NCT03921047 24 25 O
Diagnosis NCT03921047 27 36 O
of NCT03921047 37 39 O
AML NCT03921047 40 43 B-Condition
scheduled NCT03921047 44 53 B-Eq-Comparison
to NCT03921047 54 56 O
undergo NCT03921047 57 64 O
HSCT NCT03921047 65 69 B-Procedure
at NCT03921047 70 72 O
University NCT03921047 73 83 O
of NCT03921047 84 86 O
Southern NCT03921047 87 95 O
California NCT03921047 96 106 O
( NCT03921047 107 108 O
USC NCT03921047 109 112 O
) NCT03921047 113 114 O

Exclusion NCT03921047 116 125 O
Criteria NCT03921047 126 134 O
: NCT03921047 135 136 O

- NCT03921047 140 141 O
Inability NCT03921047 143 152 O
to NCT03921047 153 155 O
provide NCT03921047 156 163 O
consent NCT03921047 164 171 O
because NCT03921047 172 179 O
of NCT03921047 180 182 O
severe NCT03921047 183 189 B-Condition
mental NCT03921047 190 196 I-Condition
disorders NCT03921047 197 206 I-Condition

- NCT03921047 209 210 O
Donor NCT03921047 212 217 O
unwilling NCT03921047 218 227 O
to NCT03921047 228 230 O
provide NCT03921047 231 238 O
consent NCT03921047 239 246 O

Inclusion NCT03929341 0 9 O
Criteria NCT03929341 10 18 O
: NCT03929341 19 20 O

- NCT03929341 24 25 O
Men NCT03929341 27 30 O
and NCT03929341 31 34 B-Or
women NCT03929341 35 40 O
age NCT03929341 41 44 B-Age
≥ NCT03929341 45 46 B-Eq-Comparison
40 NCT03929341 47 49 I-Eq-Comparison
years NCT03929341 50 55 I-Eq-Comparison
of NCT03929341 56 58 O
age NCT03929341 59 62 O

- NCT03929341 65 66 O
Stable NCT03929341 68 74 O
chest NCT03929341 75 80 B-Modifier
pain NCT03929341 81 85 B-Condition
or NCT03929341 86 88 B-Or
equivalent NCT03929341 89 99 B-Modifier
symptoms NCT03929341 100 108 B-Assertion___Assertion-Type-Value:possible

- NCT03929341 111 112 O
Planned NCT03929341 114 121 B-Eq-Comparison
non NCT03929341 122 125 B-Negation
- NCT03929341 126 127 O
urgent NCT03929341 128 134 B-Modifier
, NCT03929341 135 136 O
non NCT03929341 137 140 B-Negation
- NCT03929341 141 142 O
invasive NCT03929341 143 151 B-Modifier
testing NCT03929341 152 159 B-Procedure
for NCT03929341 160 163 O
diagnosis NCT03929341 164 173 O
of NCT03929341 174 176 O
chest NCT03929341 177 182 B-Modifier
pain NCT03929341 183 187 B-Condition
or NCT03929341 188 190 B-Or
equivalent NCT03929341 191 201 B-Modifier
symptoms NCT03929341 202 210 B-Assertion___Assertion-Type-Value:possible

Exclusion NCT03929341 211 220 O
Criteria NCT03929341 221 229 O
: NCT03929341 230 231 O

- NCT03929341 235 236 O
Acute NCT03929341 238 243 O
coronary NCT03929341 244 252 B-Condition
syndrome NCT03929341 253 261 I-Condition
, NCT03929341 262 263 O
including NCT03929341 264 273 O
acute NCT03929341 274 279 O
myocardial NCT03929341 280 290 B-Condition
infarction NCT03929341 291 301 I-Condition
or NCT03929341 302 304 B-Or
unstable NCT03929341 305 313 O
angina NCT03929341 314 320 B-Condition
, NCT03929341 321 322 O
known NCT03929341 323 328 O
non NCT03929341 329 332 B-Negation
- NCT03929341 333 334 O
ischemic NCT03929341 335 343 B-Modifier
cardiomyopathy NCT03929341 344 358 B-Condition
or NCT03929341 359 361 B-Or
other NCT03929341 362 367 B-Other
cardiac NCT03929341 368 375 B-Condition
disease NCT03929341 376 383 I-Condition
( NCT03929341 384 385 O
e. NCT03929341 386 388 O
g. NCT03929341 389 391 O
mitral NCT03929341 393 399 B-Condition
valve NCT03929341 400 405 I-Condition
prolapse NCT03929341 406 414 I-Condition
, NCT03929341 415 416 O
etc NCT03929341 417 420 O
. NCT03929341 420 421 O
) NCT03929341 422 423 O
which NCT03929341 424 429 O
would NCT03929341 430 435 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03929341 436 443 O
urgent NCT03929341 444 450 B-Modifier
cardiac NCT03929341 451 458 B-Procedure
evaluation NCT03929341 459 469 I-Procedure

- NCT03929341 472 473 O
Known NCT03929341 475 480 O
CAD NCT03929341 481 484 B-Condition

- NCT03929341 487 488 O
Prior NCT03929341 490 495 B-Eq-Comparison
cardiac NCT03929341 496 503 B-Procedure
evaluation NCT03929341 504 514 I-Procedure
for NCT03929341 515 518 O
current NCT03929341 519 526 B-Eq-Comparison
episode NCT03929341 527 534 O
of NCT03929341 535 537 O
symptoms NCT03929341 538 546 B-Condition

- NCT03929341 549 550 O
Previously NCT03929341 552 562 B-Eq-Comparison
investigated NCT03929341 563 575 B-Procedure
for NCT03929341 576 579 O
CAD NCT03929341 580 583 B-Condition
in NCT03929341 584 586 O
the NCT03929341 587 590 O
last NCT03929341 591 595 B-Eq-Comparison
12 NCT03929341 596 598 I-Eq-Comparison
months NCT03929341 599 605 I-Eq-Comparison

- NCT03929341 608 609 O
Severe NCT03929341 611 617 O
allergic NCT03929341 618 626 B-Allergy
reaction NCT03929341 627 635 O
to NCT03929341 636 638 O
iodinated NCT03929341 639 648 O
contrast NCT03929341 649 657 O
( NCT03929341 658 659 O
mild NCT03929341 660 664 O
reactions NCT03929341 665 674 O
such NCT03929341 675 679 O
as NCT03929341 680 682 O
urticaria NCT03929341 683 692 B-Condition
that NCT03929341 693 697 O
can NCT03929341 698 701 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929341 702 704 O
controlled NCT03929341 705 715 O
by NCT03929341 716 718 O
premedication NCT03929341 719 732 B-Procedure
with NCT03929341 733 737 O
Benadryl NCT03929341 738 746 B-Drug
& NCT03929341 747 748 B-Or
Prednisone NCT03929341 749 759 B-Drug
may NCT03929341 760 763 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929341 764 766 O
included NCT03929341 767 775 O
in NCT03929341 776 778 O
the NCT03929341 779 782 O
study NCT03929341 783 788 B-Study
) NCT03929341 789 790 O

- NCT03929341 794 795 O
Renal NCT03929341 797 802 B-Condition
failure NCT03929341 803 810 I-Condition
or NCT03929341 811 813 B-Or
dysfunction NCT03929341 814 825 B-Condition
( NCT03929341 826 827 O
estimated NCT03929341 828 837 B-Observation
Glomerular NCT03929341 838 848 I-Observation
Filtration NCT03929341 849 859 I-Observation
Rate NCT03929341 860 864 I-Observation
< NCT03929341 865 866 B-Eq-Comparison
30 NCT03929341 867 869 I-Eq-Comparison
ml NCT03929341 870 872 O
/ NCT03929341 873 874 I-Eq-Comparison
min NCT03929341 875 878 I-Eq-Comparison
/ NCT03929341 879 880 O
m2 NCT03929341 881 883 I-Eq-Comparison
within NCT03929341 884 890 B-Eq-Comparison
the NCT03929341 891 894 I-Eq-Comparison
past NCT03929341 895 899 I-Eq-Comparison
3 NCT03929341 900 901 I-Eq-Comparison
months NCT03929341 902 908 I-Eq-Comparison
) NCT03929341 909 910 O

- NCT03929341 914 915 O
Pregnancy NCT03929341 917 926 B-Condition
( NCT03929341 927 928 O
status NCT03929341 929 935 O
will NCT03929341 936 940 O
be NCT03929341 941 943 O
confirmed NCT03929341 944 953 O
verbally NCT03929341 954 962 O
. NCT03929341 962 963 O
For NCT03929341 965 968 O
premenopausal NCT03929341 969 982 B-Condition
patients NCT03929341 983 991 O
who NCT03929341 992 995 O
are NCT03929341 996 999 O
unsure NCT03929341 1000 1006 O
, NCT03929341 1007 1008 O
status NCT03929341 1009 1015 O
will NCT03929341 1016 1020 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929341 1021 1023 I-Assertion___Assertion-Type-Value:hypothetical
confirmed NCT03929341 1024 1033 O
by NCT03929341 1034 1036 O
completing NCT03929341 1037 1047 O
a NCT03929341 1048 1049 O
pregnancy NCT03929341 1050 1059 B-Observation
strip NCT03929341 1060 1065 I-Observation
test NCT03929341 1066 1070 I-Observation
) NCT03929341 1071 1072 O
. NCT03929341 1073 1074 O

Inclusion NCT03927378 0 9 O
Criteria NCT03927378 10 18 O
: NCT03927378 19 20 O

- NCT03927378 24 25 O
Parturients NCT03927378 27 38 O
with NCT03927378 39 43 O
age NCT03927378 44 47 B-Age
≥ NCT03927378 48 49 B-Eq-Comparison
18 NCT03927378 50 52 I-Eq-Comparison
years NCT03927378 53 58 I-Eq-Comparison
; NCT03927378 58 59 O

- NCT03927378 62 63 O
Presence NCT03927378 65 73 O
of NCT03927378 74 76 O
prenatal NCT03927378 77 85 B-Modifier
depression NCT03927378 86 96 B-Condition
( NCT03927378 97 98 O
EPDS NCT03927378 99 103 B-Observation
score NCT03927378 104 109 I-Observation
≥ NCT03927378 110 111 B-Eq-Comparison
10 NCT03927378 112 114 I-Eq-Comparison
) NCT03927378 115 116 O
; NCT03927378 117 118 O

- NCT03927378 121 122 O
Provide NCT03927378 124 131 O
written NCT03927378 132 139 O
informed NCT03927378 140 148 O
consents NCT03927378 149 157 O
. NCT03927378 157 158 O

Exclusion NCT03927378 160 169 O
Criteria NCT03927378 170 178 O
: NCT03927378 179 180 O

- NCT03927378 184 185 O
History NCT03927378 187 194 B-Eq-Comparison
of NCT03927378 195 197 O
psychiatric NCT03927378 198 209 B-Condition
disease NCT03927378 210 217 I-Condition
( NCT03927378 218 219 O
schizophrenia NCT03927378 220 233 B-Condition
) NCT03927378 234 235 O
or NCT03927378 236 238 B-Or
communication NCT03927378 239 252 B-Condition
barriers NCT03927378 253 261 I-Condition
that NCT03927378 262 266 O
prevent NCT03927378 267 274 B-Negation
normal NCT03927378 275 281 O
communication NCT03927378 282 295 B-Observation
before NCT03927378 296 302 B-Temporal-Connection___Temporal-Connection-Type-Value:before
childbirth NCT03927378 303 313 B-Procedure
; NCT03927378 313 314 O

- NCT03927378 317 318 O
Severe NCT03927378 320 326 O
complications NCT03927378 327 340 B-Condition
during NCT03927378 341 347 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pregnancy NCT03927378 348 357 B-Condition
( NCT03927378 358 359 O
such NCT03927378 360 364 O
as NCT03927378 365 367 O
severe NCT03927378 368 374 O
preeclampsia NCT03927378 375 387 B-Condition
, NCT03927378 388 389 O
placenta NCT03927378 390 398 B-Condition
accreta NCT03927378 399 406 I-Condition
, NCT03927378 407 408 O
or NCT03927378 409 411 B-Or
HELLP NCT03927378 412 417 B-Condition
[ NCT03927378 418 419 O
Hemolysis NCT03927378 420 429 B-Condition
, NCT03927378 430 431 O
Elevated NCT03927378 432 440 I-Condition
Liver NCT03927378 441 446 I-Condition
enzymes NCT03927378 447 454 I-Condition
and NCT03927378 455 458 I-Condition
Low NCT03927378 459 462 I-Condition
Platelets NCT03927378 463 472 I-Condition
] NCT03927378 473 474 O
syndrome NCT03927378 475 483 B-Modifier
) NCT03927378 484 485 O
; NCT03927378 486 487 O

- NCT03927378 490 491 O
ASA NCT03927378 493 496 B-Condition
physical NCT03927378 497 505 O
status NCT03927378 506 512 O
classification NCT03927378 513 527 B-Eq-Comparison
≥ NCT03927378 528 529 I-Eq-Comparison
III NCT03927378 530 533 I-Eq-Comparison
; NCT03927378 533 534 O

- NCT03927378 537 538 O
Presence NCT03927378 540 548 O
of NCT03927378 549 551 O
contraindications NCT03927378 552 569 B-Contraindication
to NCT03927378 570 572 O
ketamine NCT03927378 573 581 B-Drug
, NCT03927378 582 583 O
including NCT03927378 584 593 O
refractory NCT03927378 594 604 B-Modifier
hypertension NCT03927378 605 617 B-Condition
, NCT03927378 618 619 O
severe NCT03927378 620 626 O
cardiovascular NCT03927378 627 641 B-Condition
disease NCT03927378 642 649 I-Condition
( NCT03927378 650 651 O
heart NCT03927378 652 657 B-Condition
function NCT03927378 658 666 I-Condition
classification NCT03927378 667 681 B-Eq-Comparison
≥ NCT03927378 682 683 I-Eq-Comparison
III NCT03927378 684 687 I-Eq-Comparison
) NCT03927378 688 689 O
, NCT03927378 691 692 O
or NCT03927378 693 695 B-Or
hyperthyroidism NCT03927378 696 711 B-Condition
; NCT03927378 711 712 O

- NCT03927378 715 716 O
Refuse NCT03927378 718 724 O
to NCT03927378 725 727 O
participate NCT03927378 728 739 O
. NCT03927378 739 740 O

Inclusion NCT03925584 0 9 O
Criteria NCT03925584 10 18 O
: NCT03925584 19 20 O

- NCT03925584 24 25 O
Greater NCT03925584 27 34 B-Eq-Comparison
than NCT03925584 35 39 I-Eq-Comparison
37 NCT03925584 40 42 I-Eq-Comparison
weeks NCT03925584 43 48 I-Eq-Comparison
gestation NCT03925584 49 58 B-Observation
, NCT03925584 59 60 O

- NCT03925584 64 65 O
Between NCT03925584 67 74 B-Eq-Comparison
0 NCT03925584 75 76 I-Eq-Comparison
to NCT03925584 77 79 I-Eq-Comparison
30 NCT03925584 80 82 I-Eq-Comparison
days NCT03925584 83 87 I-Eq-Comparison
of NCT03925584 88 90 O
age NCT03925584 91 94 B-Age

- NCT03925584 97 98 O
24 NCT03925584 100 102 B-Eq-Comparison
hours NCT03925584 103 108 I-Eq-Comparison
post NCT03925584 109 113 B-Temporal-Connection___Temporal-Connection-Type-Value:after
congenital NCT03925584 114 124 B-Modifier
heart NCT03925584 125 130 B-Procedure
surgery NCT03925584 131 138 I-Procedure

- NCT03925584 141 142 O
Receiving NCT03925584 144 153 B-Eq-Comparison
mechanical NCT03925584 154 164 B-Procedure
ventilation NCT03925584 165 176 I-Procedure

- NCT03925584 179 180 O
Background NCT03925584 182 192 B-Observation
noise NCT03925584 193 198 I-Observation
level NCT03925584 199 204 I-Observation
( NCT03925584 205 206 O
at NCT03925584 207 209 O
bedside NCT03925584 210 217 B-Modifier
) NCT03925584 218 219 O
at NCT03925584 220 222 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03925584 223 226 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03925584 227 231 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03925584 232 234 O
music NCT03925584 235 240 B-Procedure
therapy NCT03925584 241 248 I-Procedure
must NCT03925584 249 253 O
be NCT03925584 254 256 O
55 NCT03925584 257 259 B-Eq-Comparison
dB NCT03925584 260 262 O
or NCT03925584 263 265 I-Eq-Comparison
less NCT03925584 266 270 I-Eq-Comparison
. NCT03925584 270 271 O

Exclusion NCT03925584 273 282 O
Criteria NCT03925584 283 291 O
: NCT03925584 292 293 O

- NCT03925584 297 298 O
Hemodynamically NCT03925584 300 315 B-Condition
unstable NCT03925584 316 324 O
or NCT03925584 325 327 B-Or
end NCT03925584 328 331 B-Death|Risk
of NCT03925584 332 334 I-Death|Risk
life NCT03925584 335 339 I-Death|Risk

- NCT03925584 342 343 O
If NCT03925584 345 347 O
patient NCT03925584 348 355 O
is NCT03925584 356 358 O
in NCT03925584 359 361 O
a NCT03925584 362 363 O
closed NCT03925584 364 370 O
Giraffe NCT03925584 371 378 O
bed NCT03925584 379 382 O

- NCT03925584 385 386 O
Evidence NCT03925584 388 396 O
of NCT03925584 397 399 O
hearing NCT03925584 400 407 B-Condition
impairment NCT03925584 408 418 I-Condition

- NCT03925584 421 422 O
Patient NCT03925584 424 431 O
has NCT03925584 432 435 O
known NCT03925584 436 441 O
or NCT03925584 442 444 O
suspected NCT03925584 445 454 B-Assertion___Assertion-Type-Value:possible
active NCT03925584 455 461 B-Eq-Comparison
seizure NCT03925584 462 469 B-Condition
disorder NCT03925584 470 478 I-Condition

Inclusion NCT03925181 0 9 O
Criteria NCT03925181 10 18 O
for NCT03925181 19 22 O
Patients NCT03925181 23 31 O
: NCT03925181 32 33 O

- NCT03925181 37 38 O
Spent NCT03925181 40 45 O
more NCT03925181 46 50 B-Eq-Comparison
than NCT03925181 51 55 I-Eq-Comparison
4 NCT03925181 56 57 I-Eq-Comparison
days NCT03925181 58 62 I-Eq-Comparison
in NCT03925181 63 65 O
the NCT03925181 66 69 O
ICU NCT03925181 70 73 B-Encounter
, NCT03925181 74 75 O

- NCT03925181 79 80 O
Were NCT03925181 82 86 O
discharged NCT03925181 87 97 B-Encounter
into NCT03925181 98 102 O
the NCT03925181 103 106 O
community NCT03925181 107 116 O
within NCT03925181 117 123 B-Eq-Comparison
4 NCT03925181 124 125 I-Eq-Comparison
months NCT03925181 126 132 I-Eq-Comparison
of NCT03925181 133 135 B-Temporal-Connection___Temporal-Connection-Type-Value:after
transfer NCT03925181 136 144 B-Encounter
out NCT03925181 145 148 I-Encounter
of NCT03925181 149 151 I-Encounter
the NCT03925181 152 155 I-Encounter
ICU NCT03925181 156 159 I-Encounter
( NCT03925181 160 161 O
excluding NCT03925181 162 171 B-Exception
patients NCT03925181 172 180 O
who NCT03925181 181 184 O
were NCT03925181 185 189 O
in NCT03925181 190 192 O
hospital NCT03925181 193 201 B-Encounter
long NCT03925181 202 206 B-Eq-Comparison
- NCT03925181 207 208 I-Eq-Comparison
term NCT03925181 209 213 I-Eq-Comparison
) NCT03925181 214 215 O

- NCT03925181 219 220 O
Speaks NCT03925181 222 228 O
English NCT03925181 229 236 O

- NCT03925181 239 240 O
Has NCT03925181 242 245 O
a NCT03925181 246 247 O
fixed NCT03925181 248 253 O
address NCT03925181 254 261 O

- NCT03925181 264 265 O
Does NCT03925181 267 271 O
not NCT03925181 272 275 B-Negation
have NCT03925181 276 280 O
pre NCT03925181 281 284 B-Eq-Comparison
- NCT03925181 285 286 I-Eq-Comparison
existing NCT03925181 287 295 I-Eq-Comparison
psychiatric NCT03925181 296 307 B-Condition
diagnoses NCT03925181 308 317 O
documented NCT03925181 318 328 O
in NCT03925181 329 331 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03925181 332 335 O
ICU NCT03925181 336 339 B-Encounter
transfer NCT03925181 340 348 I-Encounter
summary NCT03925181 349 356 O

- NCT03925181 359 360 O
Lives NCT03925181 362 367 B-Observation
within NCT03925181 368 374 O
or NCT03925181 375 377 O
surrounding NCT03925181 378 389 O
Calgary NCT03925181 390 397 O
. NCT03925181 397 398 O

Inclusion NCT03925181 400 409 O
Criteria NCT03925181 410 418 O
for NCT03925181 419 422 O
Caregivers NCT03925181 423 433 O
: NCT03925181 434 435 O

- NCT03925181 439 440 O
Caregiver NCT03925181 442 451 O
of NCT03925181 452 454 O
an NCT03925181 455 457 O
ICU NCT03925181 458 461 O
survivor NCT03925181 462 470 O
participant NCT03925181 471 482 O
meeting NCT03925181 483 490 O
criteria NCT03925181 491 499 O
above NCT03925181 500 505 O

- NCT03925181 508 509 O
Speaks NCT03925181 511 517 O
English NCT03925181 518 525 O

- NCT03925181 528 529 O
Has NCT03925181 531 534 O
a NCT03925181 535 536 O
fixed NCT03925181 537 542 O
address NCT03925181 543 550 O

- NCT03925181 553 554 O
Lives NCT03925181 556 561 B-Observation
within NCT03925181 562 568 O
or NCT03925181 569 571 O
surrounding NCT03925181 572 583 O
Calgary NCT03925181 584 591 O
. NCT03925181 591 592 O

Exclusion NCT03925181 594 603 O
Criteria NCT03925181 604 612 O
for NCT03925181 613 616 O
Patients NCT03925181 617 625 O
: NCT03925181 626 627 O

- NCT03925181 630 631 I-Eq-Comparison
Long NCT03925181 632 636 B-Eq-Comparison
- NCT03925181 637 638 O
term NCT03925181 639 643 I-Eq-Comparison
hospital NCT03925181 644 652 B-Encounter
stay NCT03925181 653 657 O

Excluding NCT03925181 658 667 O
Criteria NCT03925181 668 676 O
for NCT03925181 677 680 O
Caregivers NCT03925181 681 691 O
: NCT03925181 692 693 O

- NCT03925181 696 697 O
None NCT03925181 698 702 O

Inclusion NCT03929744 0 9 O
Criteria NCT03929744 10 18 O
: NCT03929744 19 20 O

- NCT03929744 24 25 O
Healthy NCT03929744 27 34 B-Condition
male NCT03929744 35 39 O
or NCT03929744 40 42 B-Or
females NCT03929744 43 50 O
, NCT03929744 51 52 O
as NCT03929744 53 55 O
determined NCT03929744 56 66 O
by NCT03929744 67 69 O
medical NCT03929744 70 77 O
history NCT03929744 78 85 O

- NCT03929744 88 89 O
Have NCT03929744 91 95 O
safety NCT03929744 96 102 B-Modifier
laboratory NCT03929744 103 113 B-Observation
results NCT03929744 114 121 I-Observation
within NCT03929744 122 128 B-Eq-Comparison
normal NCT03929744 129 135 I-Eq-Comparison
reference NCT03929744 136 145 I-Eq-Comparison
ranges NCT03929744 146 152 I-Eq-Comparison

Exclusion NCT03929744 153 162 O
Criteria NCT03929744 163 171 O
: NCT03929744 172 173 O

- NCT03929744 177 178 O
Have NCT03929744 180 184 O
known NCT03929744 185 190 O
allergies NCT03929744 191 200 B-Allergy
to NCT03929744 201 203 O
LY3502970 NCT03929744 204 213 B-Drug
, NCT03929744 214 215 O
glucagon NCT03929744 216 224 B-Drug
- NCT03929744 225 226 I-Drug
like NCT03929744 227 231 I-Drug
peptide NCT03929744 232 239 I-Drug
- NCT03929744 240 241 I-Drug|Drug
1 NCT03929744 242 243 I-Drug|Drug
( NCT03929744 244 245 O
GLP NCT03929744 246 249 B-Drug
- NCT03929744 250 251 O
1 NCT03929744 252 253 O
) NCT03929744 254 255 O
analogs NCT03929744 256 263 B-Modifier
, NCT03929744 264 265 O
related NCT03929744 266 273 O
compounds NCT03929744 274 283 O

- NCT03929744 286 287 O
Abnormal NCT03929744 289 297 O
electrocardiogram NCT03929744 298 315 B-Procedure
( NCT03929744 316 317 O
ECG NCT03929744 318 321 B-Procedure
) NCT03929744 322 323 O
at NCT03929744 324 326 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03929744 327 336 B-Study

- NCT03929744 339 340 O
Significant NCT03929744 342 353 O
history NCT03929744 354 361 B-Eq-Comparison
of NCT03929744 362 364 O
or NCT03929744 365 367 B-Or
current NCT03929744 368 375 B-Eq-Comparison
cardiovascular NCT03929744 376 390 B-Modifier
, NCT03929744 391 392 O
respiratory NCT03929744 393 404 B-Modifier
, NCT03929744 405 406 O
hepatic NCT03929744 407 414 B-Modifier
, NCT03929744 415 416 O
renal NCT03929744 417 422 B-Modifier
, NCT03929744 423 424 O
gastrointestinal NCT03929744 425 441 B-Modifier
, NCT03929744 442 443 O
endocrine NCT03929744 444 453 B-Modifier
, NCT03929744 454 455 O
hematological NCT03929744 456 469 B-Modifier
or NCT03929744 470 472 B-Or
neurological NCT03929744 473 485 B-Modifier
disorders NCT03929744 486 495 B-Condition
. NCT03929744 495 496 O

Inclusion NCT03920774 0 9 O
Criteria NCT03920774 10 18 O
: NCT03920774 19 20 O

- NCT03920774 24 25 O
Patients NCT03920774 27 35 O
of NCT03920774 36 38 O
any NCT03920774 39 42 O
age NCT03920774 43 46 O
with NCT03920774 47 51 O
a NCT03920774 52 53 O
diagnosis NCT03920774 54 63 O
of NCT03920774 64 66 O
familial NCT03920774 67 75 B-Condition
dysautonomia NCT03920774 76 88 I-Condition
( NCT03920774 89 90 O
FD NCT03920774 91 93 B-Condition
) NCT03920774 94 95 O
with NCT03920774 96 100 B-And
molecular NCT03920774 101 110 O
confirmation NCT03920774 111 123 O
of NCT03920774 124 126 O
the NCT03920774 127 130 O
IKBKAP NCT03920774 131 137 B-Condition
mutation NCT03920774 138 146 I-Condition
. NCT03920774 146 147 O

- NCT03920774 151 152 O
Ability NCT03920774 154 161 O
to NCT03920774 162 164 O
provide NCT03920774 165 172 O
informed NCT03920774 173 181 O
consent NCT03920774 182 189 O
( NCT03920774 190 191 O
or NCT03920774 192 194 O
assent NCT03920774 195 201 O
) NCT03920774 202 203 O
and NCT03920774 204 207 O
comply NCT03920774 208 214 O
with NCT03920774 215 219 O
the NCT03920774 220 223 O
study NCT03920774 224 229 O
protocol NCT03920774 230 238 O

Exclusion NCT03920774 239 248 O
Criteria NCT03920774 249 257 O
: NCT03920774 258 259 O

- NCT03920774 263 264 O
Subjects NCT03920774 266 274 O
that NCT03920774 275 279 O
do NCT03920774 280 282 O
not NCT03920774 283 286 O
wish NCT03920774 287 291 O
to NCT03920774 292 294 O
be NCT03920774 295 297 O
a NCT03920774 298 299 O
part NCT03920774 300 304 O
of NCT03920774 305 307 O
the NCT03920774 308 311 O
study NCT03920774 312 317 O
. NCT03920774 317 318 O

Inclusion NCT03925142 0 9 O
Criteria NCT03925142 10 18 O
: NCT03925142 19 20 O

- NCT03925142 24 25 O
Male NCT03925142 27 31 O
or NCT03925142 32 34 B-Or
female NCT03925142 35 41 O

- NCT03925142 44 45 O
30 NCT03925142 47 49 B-Eq-Comparison
- NCT03925142 50 51 I-Eq-Comparison
69 NCT03925142 52 54 I-Eq-Comparison
years NCT03925142 55 60 I-Eq-Comparison
old NCT03925142 61 64 B-Age

- NCT03925142 67 68 O
BMI NCT03925142 70 73 B-Observation
25 NCT03925142 74 76 B-Eq-Comparison
- NCT03925142 77 78 I-Eq-Comparison
37 NCT03925142 79 81 I-Eq-Comparison
kg NCT03925142 82 84 I-Eq-Comparison
/ NCT03925142 85 86 I-Eq-Comparison
m2 NCT03925142 87 89 I-Eq-Comparison

- NCT03925142 92 93 O
Total NCT03925142 95 100 B-Observation
cholesterol NCT03925142 101 112 I-Observation
< NCT03925142 113 114 B-Eq-Comparison
260 NCT03925142 115 118 I-Eq-Comparison
mg NCT03925142 119 121 I-Eq-Comparison
/ NCT03925142 122 123 I-Eq-Comparison
dL NCT03925142 124 126 I-Eq-Comparison

- NCT03925142 129 130 I-Observation
Low NCT03925142 132 135 B-Observation
- NCT03925142 136 137 O
density NCT03925142 138 145 I-Observation
lipoprotein NCT03925142 146 157 I-Observation
cholesterol NCT03925142 158 169 I-Observation
< NCT03925142 170 171 B-Eq-Comparison
190 NCT03925142 172 175 I-Eq-Comparison
mg NCT03925142 176 178 I-Eq-Comparison
/ NCT03925142 179 180 I-Eq-Comparison
dL NCT03925142 181 183 I-Eq-Comparison

- NCT03925142 186 187 O
Glucose NCT03925142 189 196 B-Observation
< NCT03925142 197 198 B-Eq-Comparison
110 NCT03925142 199 202 I-Eq-Comparison
mg NCT03925142 203 205 I-Eq-Comparison
/ NCT03925142 206 207 I-Eq-Comparison|Or
dL NCT03925142 208 210 I-Eq-Comparison

- NCT03925142 213 214 O
Systolic NCT03925142 216 224 B-Modifier
/ NCT03925142 225 226 O
diastolic NCT03925142 227 236 B-Modifier
blood NCT03925142 237 242 B-Observation
pressure NCT03925142 243 251 I-Observation
< NCT03925142 252 253 B-Eq-Comparison
140 NCT03925142 254 257 I-Eq-Comparison
/ NCT03925142 258 259 I-Eq-Comparison
90 NCT03925142 260 262 I-Eq-Comparison

- NCT03925142 266 267 O
Body NCT03925142 269 273 B-Observation
weight NCT03925142 274 280 I-Observation
stable NCT03925142 281 287 O
for NCT03925142 288 291 O
3 NCT03925142 292 293 B-Eq-Comparison
months NCT03925142 294 300 I-Eq-Comparison
prior NCT03925142 301 306 I-Eq-Comparison
( NCT03925142 307 308 O
± NCT03925142 310 311 B-Eq-Comparison
3 NCT03925142 312 313 O
kg NCT03925142 314 316 I-Eq-Comparison
) NCT03925142 317 318 O

- NCT03925142 322 323 O
Stable NCT03925142 325 331 O
physical NCT03925142 332 340 B-Observation
activity NCT03925142 341 349 I-Observation
regimen NCT03925142 350 357 O
3 NCT03925142 358 359 B-Eq-Comparison
months NCT03925142 360 366 I-Eq-Comparison
prior NCT03925142 367 372 I-Eq-Comparison

- NCT03925142 375 376 O
Medication NCT03925142 378 388 B-Drug
use NCT03925142 389 392 O
stable NCT03925142 393 399 O
for NCT03925142 400 403 O
6 NCT03925142 404 405 B-Eq-Comparison
months NCT03925142 406 412 I-Eq-Comparison
prior NCT03925142 413 418 I-Eq-Comparison

- NCT03925142 421 422 O
Non NCT03925142 424 427 B-Negation
- NCT03925142 428 429 O
smoking NCT03925142 430 437 B-Condition

- NCT03925142 440 441 O
Not NCT03925142 443 446 B-Negation
drinking NCT03925142 447 455 B-Condition|Observation
more NCT03925142 456 460 B-Eq-Comparison
than NCT03925142 461 465 I-Eq-Comparison
2 NCT03925142 466 467 I-Eq-Comparison
alcoholic NCT03925142 468 477 I-Eq-Comparison
drinks NCT03925142 478 484 I-Eq-Comparison
per NCT03925142 485 488 I-Eq-Comparison
day NCT03925142 489 492 I-Eq-Comparison

- NCT03925142 495 496 O
Non NCT03925142 498 501 B-Negation
- NCT03925142 502 503 I-Condition
diabetic NCT03925142 504 512 B-Condition

- NCT03925142 515 516 O
Not NCT03925142 518 521 B-Negation|Negation
lactose NCT03925142 522 529 B-Condition
- NCT03925142 530 531 O
intolerant NCT03925142 532 542 I-Condition

- NCT03925142 545 546 O
Not NCT03925142 548 551 O
acutely NCT03925142 552 559 O
ill NCT03925142 560 563 B-Condition

- NCT03925142 566 567 O
Non NCT03925142 569 572 B-Negation
- NCT03925142 573 574 O
pregnant NCT03925142 575 583 B-Condition
and NCT03925142 584 587 B-And
not NCT03925142 588 591 B-Negation
lactating NCT03925142 592 601 B-Condition
. NCT03925142 601 602 O

- NCT03925142 606 607 O
Participants NCT03925142 609 621 O
must NCT03925142 622 626 O
be NCT03925142 627 629 O
willing NCT03925142 630 637 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03925142 638 641 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03925142 642 646 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03925142 647 649 O
consume NCT03925142 650 657 O
the NCT03925142 658 661 O
prescribed NCT03925142 662 672 O
diets NCT03925142 673 678 B-Procedure
( NCT03925142 679 680 O
lacto NCT03925142 681 686 B-Modifier
- NCT03925142 687 688 I-Modifier
ovo NCT03925142 689 692 I-Modifier
vegetarian NCT03925142 693 703 I-Modifier
and NCT03925142 704 707 B-Or
omnivorous NCT03925142 708 718 B-Modifier
) NCT03925142 719 720 O
. NCT03925142 721 722 O

Exclusion NCT03925142 724 733 O
Criteria NCT03925142 734 742 O
: NCT03925142 743 744 O

- NCT03925142 748 749 O
< NCT03925142 751 752 B-Eq-Comparison|Eq-Comparison
30 NCT03925142 753 755 I-Eq-Comparison
or NCT03925142 756 758 B-Or|Or
> NCT03925142 759 760 B-Eq-Comparison|Eq-Comparison
69 NCT03925142 761 763 I-Eq-Comparison
years NCT03925142 764 769 I-Eq-Comparison
old NCT03925142 770 773 B-Age

- NCT03925142 776 777 O
BMI NCT03925142 779 782 B-Observation
< NCT03925142 783 784 O
25.0 NCT03925142 785 789 I-Eq-Comparison
or NCT03925142 790 792 O
> NCT03925142 793 794 B-Eq-Comparison
37 NCT03925142 795 797 I-Eq-Comparison
kg NCT03925142 798 800 I-Eq-Comparison
/ NCT03925142 801 802 I-Eq-Comparison|Eq-Comparison
m2 NCT03925142 803 805 I-Eq-Comparison

- NCT03925142 808 809 O
Fasting NCT03925142 811 818 B-Modifier
serum NCT03925142 819 824 B-Observation
total NCT03925142 825 830 I-Observation
cholesterol NCT03925142 831 842 I-Observation|Observation
> NCT03925142 843 844 O
260 NCT03925142 845 848 I-Eq-Comparison
mg NCT03925142 849 851 I-Eq-Comparison|Eq-Comparison
/ NCT03925142 852 853 I-Eq-Comparison
dL NCT03925142 854 856 I-Eq-Comparison|Eq-Comparison

- NCT03925142 859 860 I-Observation
Low NCT03925142 862 865 B-Observation
- NCT03925142 866 867 O
density NCT03925142 868 875 I-Observation
lipoprotein NCT03925142 876 887 I-Observation
cholesterol NCT03925142 888 899 O
> NCT03925142 900 901 B-Eq-Comparison|Eq-Comparison
189 NCT03925142 902 905 I-Eq-Comparison
mg NCT03925142 906 908 I-Eq-Comparison
/ NCT03925142 909 910 I-Eq-Comparison|Or
dL NCT03925142 911 913 I-Eq-Comparison

- NCT03925142 916 917 O
Glucose NCT03925142 919 926 B-Observation
> NCT03925142 927 928 B-Eq-Comparison
110 NCT03925142 929 932 I-Eq-Comparison
mg NCT03925142 933 935 O
/ NCT03925142 936 937 I-Eq-Comparison
dL NCT03925142 938 940 O

- NCT03925142 943 944 O
Systolic NCT03925142 946 954 B-Modifier
/ NCT03925142 955 956 O
diastolic NCT03925142 957 966 B-Modifier
blood NCT03925142 967 972 B-Observation
pressure NCT03925142 973 981 I-Observation
> NCT03925142 982 983 O
140 NCT03925142 984 987 I-Eq-Comparison
/ NCT03925142 988 989 O
90 NCT03925142 990 992 I-Eq-Comparison

- NCT03925142 996 997 O
Body NCT03925142 999 1003 B-Observation
weight NCT03925142 1004 1010 I-Observation
stable NCT03925142 1011 1017 O
for NCT03925142 1018 1021 O
< NCT03925142 1022 1023 B-Eq-Comparison|Eq-Comparison
3 NCT03925142 1024 1025 I-Eq-Comparison|Eq-Comparison
months NCT03925142 1026 1032 I-Eq-Comparison|Eq-Comparison
prior NCT03925142 1033 1038 I-Eq-Comparison|Eq-Comparison
( NCT03925142 1039 1040 O
± NCT03925142 1042 1043 B-Eq-Comparison
3 NCT03925142 1044 1045 O
kg NCT03925142 1046 1048 I-Eq-Comparison
) NCT03925142 1049 1050 O

- NCT03925142 1054 1055 O
Stable NCT03925142 1057 1063 O
physical NCT03925142 1064 1072 B-Observation
activity NCT03925142 1073 1081 I-Observation
regimen NCT03925142 1082 1089 O
< NCT03925142 1090 1091 O
3 NCT03925142 1092 1093 O
months NCT03925142 1094 1100 I-Eq-Comparison
prior NCT03925142 1101 1106 I-Eq-Comparison

- NCT03925142 1109 1110 O
Medication NCT03925142 1112 1122 B-Drug
use NCT03925142 1123 1126 O
unstable NCT03925142 1127 1135 O
for NCT03925142 1136 1139 O
6 NCT03925142 1140 1141 B-Eq-Comparison
months NCT03925142 1142 1148 O
prior NCT03925142 1149 1154 O
and NCT03925142 1155 1158 B-And
using NCT03925142 1159 1164 B-Eq-Comparison
medications NCT03925142 1165 1176 B-Drug

- NCT03925142 1179 1180 O
Smoking NCT03925142 1182 1189 O

- NCT03925142 1192 1193 O
Drinking NCT03925142 1195 1203 B-Condition|Observation
more NCT03925142 1204 1208 B-Eq-Comparison
than NCT03925142 1209 1213 I-Eq-Comparison
2 NCT03925142 1214 1215 I-Eq-Comparison
alcoholic NCT03925142 1216 1225 I-Eq-Comparison
drinks NCT03925142 1226 1232 I-Eq-Comparison
per NCT03925142 1233 1236 I-Eq-Comparison
day NCT03925142 1237 1240 I-Eq-Comparison

- NCT03925142 1243 1244 O
Diabetic NCT03925142 1246 1254 B-Condition

- NCT03925142 1257 1258 O
Have NCT03925142 1260 1264 O
renal NCT03925142 1265 1270 B-Condition
failure NCT03925142 1271 1278 I-Condition|Condition

- NCT03925142 1281 1282 O
Have NCT03925142 1284 1288 O
liver NCT03925142 1289 1294 B-Condition
failure NCT03925142 1295 1302 O

- NCT03925142 1305 1306 O
Have NCT03925142 1308 1312 O
cardiovascular NCT03925142 1313 1327 B-Condition
events NCT03925142 1328 1334 I-Condition
( NCT03925142 1335 1336 O
myocardial NCT03925142 1337 1347 B-Condition
infarction NCT03925142 1348 1358 I-Condition
or NCT03925142 1359 1361 B-Or|Or
stroke NCT03925142 1362 1368 B-Condition
) NCT03925142 1369 1370 O
during NCT03925142 1371 1377 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03925142 1378 1381 O
6 NCT03925142 1382 1383 B-Eq-Comparison
months NCT03925142 1384 1390 I-Eq-Comparison
prior NCT03925142 1391 1396 I-Eq-Comparison
to NCT03925142 1397 1399 O
the NCT03925142 1400 1403 O
study NCT03925142 1404 1409 B-Study

- NCT03925142 1412 1413 O
Pregnant NCT03925142 1415 1423 B-Condition
or NCT03925142 1424 1426 O
lactating NCT03925142 1427 1436 B-Condition

Inclusion NCT03927755 0 9 O
Criteria NCT03927755 10 18 O
: NCT03927755 19 20 O

- NCT03927755 24 25 O
Physicians NCT03927755 27 37 B-Provider
with NCT03927755 38 42 O
experience NCT03927755 43 53 O
in NCT03927755 54 56 O
bedside NCT03927755 57 64 B-Modifier
cardiac NCT03927755 65 72 B-Procedure
ultrasound NCT03927755 73 83 I-Procedure

Exclusion NCT03927755 84 93 O
Criteria NCT03927755 94 102 O
: NCT03927755 103 104 O

- NCT03927755 108 109 O
Unwilling NCT03927755 111 120 O
to NCT03927755 121 123 O
consent NCT03927755 124 131 O
to NCT03927755 132 134 O
study NCT03927755 135 140 B-Study

- NCT03927755 143 144 O
Appropriate NCT03927755 146 157 O
ultrasound NCT03927755 158 168 B-Procedure
equipment NCT03927755 169 178 O
not NCT03927755 179 182 O
available NCT03927755 183 192 O

Inclusion NCT03920748 0 9 O
Criteria NCT03920748 10 18 O
: NCT03920748 19 20 O

- NCT03920748 24 25 O
Newborn NCT03920748 27 34 O
and NCT03920748 35 38 B-Or
infant NCT03920748 39 45 O
age NCT03920748 46 49 O
group NCT03920748 50 55 O

- NCT03920748 58 59 O
Undergoing NCT03920748 61 71 B-Eq-Comparison
elective NCT03920748 72 80 B-Modifier
surgery NCT03920748 81 88 B-Procedure
requiring NCT03920748 89 98 O
intubation NCT03920748 99 109 B-Procedure
under NCT03920748 110 115 O
general NCT03920748 116 123 B-Procedure
anesthesia NCT03920748 124 134 I-Procedure

Exclusion NCT03920748 135 144 O
Criteria NCT03920748 145 153 O
: NCT03920748 154 155 O

- NCT03920748 159 160 O
History NCT03920748 162 169 B-Eq-Comparison
of NCT03920748 170 172 O
congenital NCT03920748 173 183 B-Modifier
maxillofacial NCT03920748 184 197 B-Condition
defect NCT03920748 198 204 I-Condition
, NCT03920748 205 206 O

- NCT03920748 210 211 O
History NCT03920748 213 220 B-Eq-Comparison
of NCT03920748 221 223 O
upper NCT03920748 224 229 B-Condition
airway NCT03920748 230 236 I-Condition
pathology NCT03920748 237 246 I-Condition
( NCT03920748 247 248 O
tumor NCT03920748 249 254 B-Condition
, NCT03920748 255 256 O
cleft NCT03920748 257 262 B-Condition
palate NCT03920748 263 269 I-Condition
- NCT03920748 270 271 I-Condition
lips NCT03920748 272 276 I-Condition
, NCT03920748 277 278 O
etc NCT03920748 279 282 O
. NCT03920748 282 283 O
) NCT03920748 284 285 O

- NCT03920748 289 290 O
History NCT03920748 292 299 B-Eq-Comparison
of NCT03920748 300 302 O
head NCT03920748 303 307 B-Modifier
and NCT03920748 308 311 B-Or
neck NCT03920748 312 316 B-Modifier
trauma NCT03920748 317 323 B-Condition
( NCT03920748 324 325 O
fracture NCT03920748 326 334 B-Condition
, NCT03920748 335 336 O
swelling NCT03920748 337 345 B-Condition
, NCT03920748 346 347 O
scar NCT03920748 348 352 B-Condition
) NCT03920748 353 354 O

Inclusion NCT03921697 0 9 O
Criteria NCT03921697 10 18 O
: NCT03921697 19 20 O

- NCT03921697 24 25 O
Idiopathic NCT03921697 27 37 B-Modifier
Parkinson NCT03921697 38 47 B-Condition
's NCT03921697 47 49 O
disease NCT03921697 50 57 I-Condition
diagnosed NCT03921697 58 67 O
by NCT03921697 68 70 O
a NCT03921697 71 72 O
neurologist NCT03921697 73 84 B-Provider

- NCT03921697 87 88 O
Ability NCT03921697 90 97 O
to NCT03921697 98 100 O
sign NCT03921697 101 105 O
informed NCT03921697 106 114 O
consent NCT03921697 115 122 O

Exclusion NCT03921697 123 132 O
Criteria NCT03921697 133 141 O
: NCT03921697 142 143 O

- NCT03921697 147 148 O
Inability NCT03921697 150 159 O
to NCT03921697 160 162 O
sign NCT03921697 163 167 O
informed NCT03921697 168 176 O
consent NCT03921697 177 184 O

- NCT03921697 187 188 O
Inability NCT03921697 190 199 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03921697 200 202 O
fill NCT03921697 203 207 O
out NCT03921697 208 211 O
questionnaires NCT03921697 212 226 B-Observation
( NCT03921697 227 228 O
i. NCT03921697 229 231 O
e. NCT03921697 232 234 O
due NCT03921697 236 239 O
to NCT03921697 240 242 O
poor NCT03921697 243 247 B-Condition
vision NCT03921697 248 254 I-Condition
, NCT03921697 255 256 O
inability NCT03921697 257 266 B-Condition
to NCT03921697 267 269 I-Condition
read NCT03921697 270 274 I-Condition
, NCT03921697 275 276 O
etc NCT03921697 277 280 O
) NCT03921697 281 282 O

- NCT03921697 286 287 O
Presence NCT03921697 289 297 O
of NCT03921697 298 300 O
psychiatric NCT03921697 301 312 B-Condition
diseases NCT03921697 313 321 I-Condition
( NCT03921697 322 323 O
episode NCT03921697 324 331 O
or NCT03921697 332 334 O
any NCT03921697 335 338 O
form NCT03921697 339 343 O
of NCT03921697 344 346 O
psychosis NCT03921697 347 356 B-Condition
, NCT03921697 357 358 O
diagnosed NCT03921697 359 368 O
by NCT03921697 369 371 O
a NCT03921697 372 373 O
psychiatrist NCT03921697 374 386 B-Provider
in NCT03921697 387 389 O
the NCT03921697 390 393 O
last NCT03921697 394 398 B-Eq-Comparison
year NCT03921697 399 403 I-Eq-Comparison
) NCT03921697 404 405 O
. NCT03921697 406 407 O

- NCT03921697 411 412 O
Age NCT03921697 414 417 B-Age
under NCT03921697 418 423 B-Eq-Comparison
18 NCT03921697 424 426 I-Eq-Comparison
yrs NCT03921697 427 430 I-Eq-Comparison
old NCT03921697 431 434 I-Eq-Comparison

Inclusion NCT03924076 0 9 O
Criteria NCT03924076 10 18 O
: NCT03924076 19 20 O

- NCT03924076 24 25 O
children NCT03924076 27 35 O
at NCT03924076 36 38 B-And
age NCT03924076 39 42 B-Age
of NCT03924076 43 45 O
7 NCT03924076 46 47 B-Eq-Comparison
- NCT03924076 48 49 I-Eq-Comparison
9 NCT03924076 50 51 I-Eq-Comparison
years NCT03924076 52 57 I-Eq-Comparison

- NCT03924076 60 61 O
have NCT03924076 63 67 O
normal NCT03924076 68 74 O
body NCT03924076 75 79 B-Observation
mass NCT03924076 80 84 I-Observation
index NCT03924076 85 90 I-Observation
( NCT03924076 91 92 O
BMI NCT03924076 93 96 B-Observation
) NCT03924076 97 98 O
i. NCT03924076 99 101 O
e. NCT03924076 102 104 O
- NCT03924076 106 107 B-Eq-Comparison
2 NCT03924076 108 109 I-Eq-Comparison
≤ NCT03924076 110 111 I-Eq-Comparison
z NCT03924076 112 113 I-Eq-Comparison
- NCT03924076 114 115 O
score NCT03924076 116 121 I-Eq-Comparison
< NCT03924076 122 123 I-Eq-Comparison
+ NCT03924076 124 125 I-Eq-Comparison
1 NCT03924076 126 127 O
, NCT03924076 128 129 O
slightly NCT03924076 130 138 O
overweight NCT03924076 139 149 B-Observation
z NCT03924076 150 151 B-Eq-Comparison
- NCT03924076 152 153 I-Eq-Comparison
score NCT03924076 154 159 I-Eq-Comparison
< NCT03924076 160 161 I-Eq-Comparison
+ NCT03924076 162 163 I-Eq-Comparison
1.5 NCT03924076 164 167 O
, NCT03924076 168 169 O
and NCT03924076 170 173 B-Or
slightly NCT03924076 174 182 O
underweight NCT03924076 183 194 B-Observation
z NCT03924076 195 196 B-Eq-Comparison
- NCT03924076 197 198 I-Eq-Comparison
score NCT03924076 199 204 I-Eq-Comparison
> NCT03924076 205 206 I-Eq-Comparison
- NCT03924076 207 208 O
3 NCT03924076 209 210 I-Eq-Comparison
. NCT03924076 210 211 O

Exclusion NCT03924076 213 222 O
Criteria NCT03924076 223 231 O
: NCT03924076 232 233 O

- NCT03924076 237 238 O
allergic NCT03924076 240 248 B-Allergy
to NCT03924076 249 251 O
milk NCT03924076 252 256 O

- NCT03924076 259 260 O
consuming NCT03924076 262 271 B-Eq-Comparison
other NCT03924076 272 277 B-Other
probiotic NCT03924076 278 287 B-Drug
product NCT03924076 288 295 I-Drug

- NCT03924076 298 299 O
he NCT03924076 301 303 O
/ NCT03924076 304 305 O
she NCT03924076 306 309 O
do NCT03924076 310 312 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03924076 313 316 I-Assertion___Assertion-Type-Value:hypothetical
want NCT03924076 317 321 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03924076 322 324 O
stop NCT03924076 325 329 O
consumption NCT03924076 330 341 B-Coreference
& NCT03924076 342 343 B-And
doing NCT03924076 344 349 O
washout NCT03924076 350 357 B-Procedure
for NCT03924076 358 361 O
2 NCT03924076 362 363 B-Eq-Comparison
weeks NCT03924076 364 369 I-Eq-Comparison
. NCT03924076 369 370 O

Inclusion NCT03923686 0 9 O
Criteria NCT03923686 10 18 O
: NCT03923686 19 20 O

- NCT03923686 24 25 O
walled NCT03923686 27 33 B-Condition
- NCT03923686 34 35 I-Condition
off NCT03923686 36 39 I-Condition
pancreatic NCT03923686 40 50 I-Condition
necrosis NCT03923686 51 59 I-Condition
( NCT03923686 60 61 O
WON NCT03923686 62 65 B-Condition
) NCT03923686 66 67 O
indicated NCT03923686 68 77 B-Indication
for NCT03923686 78 81 O
endoscopical NCT03923686 82 94 B-Procedure
drainage NCT03923686 95 103 I-Procedure

- NCT03923686 106 107 O
signed NCT03923686 109 115 O
informed NCT03923686 116 124 O
consent NCT03923686 125 132 O
form NCT03923686 133 137 O

Exclusion NCT03923686 138 147 O
Criteria NCT03923686 148 156 O
: NCT03923686 157 158 O

- NCT03923686 162 163 O
patient NCT03923686 165 172 O
disagreement NCT03923686 173 185 O
with NCT03923686 186 190 O
the NCT03923686 191 194 O
study NCT03923686 195 200 O

- NCT03923686 203 204 O
types NCT03923686 206 211 O
of NCT03923686 212 214 O
collections NCT03923686 215 226 B-Condition
other NCT03923686 227 232 B-Exception
than NCT03923686 233 237 I-Exception
WON NCT03923686 238 241 B-Condition

- NCT03923686 244 245 O
drainage NCT03923686 247 255 B-Procedure
with NCT03923686 256 260 O
stents NCT03923686 261 267 B-Procedure
other NCT03923686 268 273 B-Exception
than NCT03923686 274 278 I-Exception
LAMS NCT03923686 279 283 B-Procedure

- NCT03923686 286 287 O
previous NCT03923686 289 297 B-Eq-Comparison
attempts NCT03923686 298 306 O
at NCT03923686 307 309 O
drainage NCT03923686 310 318 B-Procedure
of NCT03923686 319 321 O
WON NCT03923686 322 325 B-Condition

- NCT03923686 328 329 O
severe NCT03923686 331 337 O
coagulopathy NCT03923686 338 350 B-Condition
or NCT03923686 351 353 B-Or
thrombocytopenia NCT03923686 354 370 B-Condition

Inclusion NCT03924843 0 9 O
Criteria NCT03924843 10 18 O
: NCT03924843 19 20 O

- NCT03924843 24 25 O
Men NCT03924843 27 30 O
/ NCT03924843 31 32 B-Or
Women NCT03924843 33 38 O
age NCT03924843 39 42 B-Age
> NCT03924843 43 44 B-Eq-Comparison
40 NCT03924843 45 47 I-Eq-Comparison
years NCT03924843 48 53 I-Eq-Comparison
. NCT03924843 53 54 O

- NCT03924843 58 59 O
Diagnoses NCT03924843 61 70 O
of NCT03924843 71 73 O
COPD NCT03924843 74 78 B-Condition
according NCT03924843 79 88 O
to NCT03924843 89 91 O
criteria NCT03924843 92 100 O
of NCT03924843 101 103 O
the NCT03924843 104 107 O
American NCT03924843 108 116 O
Thoracic NCT03924843 117 125 O
Society NCT03924843 126 133 O
( NCT03924843 134 135 O
ATS NCT03924843 136 139 O
) NCT03924843 140 141 O
, NCT03924843 143 144 O
a NCT03924843 145 146 O
disease NCT03924843 147 154 O
state NCT03924843 155 160 O
characterized NCT03924843 161 174 O
by NCT03924843 175 177 O
the NCT03924843 178 181 O
presence NCT03924843 182 190 O
of NCT03924843 191 193 O
chronic NCT03924843 194 201 B-Condition
airway NCT03924843 202 208 I-Condition
obstruction NCT03924843 209 220 I-Condition
due NCT03924843 221 224 O
to NCT03924843 225 227 O
chronic NCT03924843 228 235 B-Condition
bronchitis NCT03924843 236 246 I-Condition
( NCT03924843 247 248 O
cough NCT03924843 249 254 B-Condition
/ NCT03924843 255 256 B-Or
sputum NCT03924843 257 263 B-Condition
on NCT03924843 264 266 O
most NCT03924843 267 271 O
days NCT03924843 272 276 B-Eq-Comparison
a NCT03924843 277 278 I-Eq-Comparison
week NCT03924843 279 283 I-Eq-Comparison
for NCT03924843 284 287 O
3 NCT03924843 288 289 B-Eq-Comparison
months NCT03924843 290 296 I-Eq-Comparison
in NCT03924843 297 299 I-Eq-Comparison
a NCT03924843 300 301 I-Eq-Comparison
year NCT03924843 302 306 I-Eq-Comparison
for NCT03924843 307 310 O
at NCT03924843 311 313 B-Eq-Comparison
least NCT03924843 314 319 I-Eq-Comparison
two NCT03924843 320 323 I-Eq-Comparison
successive NCT03924843 324 334 I-Eq-Comparison
years NCT03924843 335 340 I-Eq-Comparison
) NCT03924843 341 342 O
and NCT03924843 343 346 B-Or
/ NCT03924843 347 348 I-Or
or NCT03924843 349 351 I-Or
emphysema NCT03924843 352 361 B-Condition

- NCT03924843 364 365 O
Diagnosis NCT03924843 367 376 O
of NCT03924843 377 379 O
moderate NCT03924843 380 388 B-Eq-Comparison
or NCT03924843 389 391 I-Eq-Comparison
severe NCT03924843 392 398 I-Eq-Comparison
COPD NCT03924843 399 403 B-Condition
exacerbation NCT03924843 404 416 I-Condition
( NCT03924843 417 418 O
see NCT03924843 419 422 O
" NCT03924843 423 424 O
Definitions NCT03924843 424 435 O
" NCT03924843 435 436 O
) NCT03924843 437 438 O

- NCT03924843 442 443 O
FEV1 NCT03924843 445 449 B-Observation
> NCT03924843 450 451 B-Eq-Comparison
0.8 NCT03924843 452 455 I-Eq-Comparison
L NCT03924843 456 457 I-Eq-Comparison
and NCT03924843 458 461 B-And
ability NCT03924843 462 469 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924843 470 472 I-Assertion___Assertion-Type-Value:hypothetical
produce NCT03924843 473 480 B-Condition
sputum NCT03924843 481 487 I-Condition
after NCT03924843 488 493 B-Temporal-Connection___Temporal-Connection-Type-Value:after
hypertonic NCT03924843 494 504 B-Drug
saline NCT03924843 505 511 I-Drug
production NCT03924843 512 522 I-Drug

- NCT03924843 525 526 O
Post NCT03924843 528 532 B-Temporal-Connection___Temporal-Connection-Type-Value:after
bronchodilator NCT03924843 533 547 B-Procedure
FEV1 NCT03924843 548 552 B-Observation
/ NCT03924843 553 554 B-Or
Forced NCT03924843 555 561 B-Observation
Vital NCT03924843 562 567 I-Observation
Capacity NCT03924843 568 576 I-Observation
( NCT03924843 577 578 O
FVC NCT03924843 579 582 B-Observation
) NCT03924843 583 584 O
ratio NCT03924843 585 590 O
< NCT03924843 591 592 B-Eq-Comparison
70 NCT03924843 593 595 I-Eq-Comparison
% NCT03924843 596 597 I-Eq-Comparison
and NCT03924843 598 601 B-And
post NCT03924843 602 606 B-Temporal-Connection___Temporal-Connection-Type-Value:after
bronchodilator NCT03924843 607 621 B-Procedure
FEV1 NCT03924843 622 626 B-Observation
< NCT03924843 627 628 B-Eq-Comparison
80 NCT03924843 629 631 I-Eq-Comparison
% NCT03924843 632 633 O
pred NCT03924843 634 638 O
. NCT03924843 638 639 O

- NCT03924843 643 644 O
A NCT03924843 646 647 O
smoking NCT03924843 648 655 B-Condition|Observation
history NCT03924843 656 663 B-Eq-Comparison
of NCT03924843 664 666 O
> NCT03924843 667 668 B-Eq-Comparison
10 NCT03924843 669 671 I-Eq-Comparison
pack NCT03924843 672 676 I-Eq-Comparison
years NCT03924843 677 682 I-Eq-Comparison

Exclusion NCT03924843 683 692 O
Criteria NCT03924843 693 701 O
: NCT03924843 702 703 O

- NCT03924843 707 708 O
Pneumonia NCT03924843 710 719 B-Condition
as NCT03924843 720 722 O
determined NCT03924843 723 733 O
by NCT03924843 734 736 O
X NCT03924843 737 738 B-Procedure
- NCT03924843 739 740 I-Procedure
ray NCT03924843 741 744 I-Procedure

- NCT03924843 747 748 O
> NCT03924843 750 751 B-Eq-Comparison
48 NCT03924843 752 754 I-Eq-Comparison
h NCT03924843 755 756 I-Eq-Comparison
intake NCT03924843 757 763 O
of NCT03924843 764 766 O
prednisolon NCT03924843 767 778 B-Drug
/ NCT03924843 779 780 B-Or
antibiotics NCT03924843 781 792 B-Drug

- NCT03924843 795 796 O
Need NCT03924843 798 802 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924843 803 806 I-Assertion___Assertion-Type-Value:hypothetical
mechanical NCT03924843 807 817 B-Procedure
ventilation NCT03924843 818 829 I-Procedure
( NCT03924843 830 831 O
either NCT03924843 832 838 O
invasive NCT03924843 839 847 B-Modifier|Modifier
or NCT03924843 848 850 B-Or
non NCT03924843 851 854 B-Modifier
- NCT03924843 855 856 I-Modifier
invasive NCT03924843 857 865 O
) NCT03924843 866 867 O

- NCT03924843 871 872 I-Drug
Treatment NCT03924843 874 883 B-Procedure
with NCT03924843 884 888 O
immune NCT03924843 889 895 B-Drug
- NCT03924843 896 897 O
modulating NCT03924843 898 908 I-Drug
agents NCT03924843 909 915 I-Drug
for NCT03924843 916 919 O
any NCT03924843 920 923 O
disease NCT03924843 924 931 B-Condition

- NCT03924843 934 935 O
Experimental NCT03924843 937 949 O
interventions NCT03924843 950 963 B-Procedure
for NCT03924843 964 967 O
COPD NCT03924843 968 972 B-Condition
last NCT03924843 973 977 B-Eq-Comparison
half NCT03924843 978 982 I-Eq-Comparison
year NCT03924843 983 987 I-Eq-Comparison

- NCT03924843 990 991 O
Former NCT03924843 993 999 B-Eq-Comparison
/ NCT03924843 1000 1001 B-Or
concomitant NCT03924843 1002 1013 B-Modifier
diagnosis NCT03924843 1014 1023 O
of NCT03924843 1024 1026 O
asthma NCT03924843 1027 1033 B-Condition

- NCT03924843 1036 1037 O
Any NCT03924843 1039 1042 O
significant NCT03924843 1043 1054 O
other NCT03924843 1055 1060 B-Other
pulmonary NCT03924843 1061 1070 B-Modifier
disease NCT03924843 1071 1078 B-Condition|Condition
or NCT03924843 1079 1081 B-Or|Or
disorder NCT03924843 1082 1090 B-Condition|Condition

- NCT03924843 1093 1094 O
Other NCT03924843 1096 1101 O
significant NCT03924843 1102 1113 O
disease NCT03924843 1114 1121 O
or NCT03924843 1122 1124 O
disorder NCT03924843 1125 1133 O
( NCT03924843 1134 1135 O
like NCT03924843 1136 1140 O
alpha NCT03924843 1141 1146 B-Condition
- NCT03924843 1147 1148 I-Condition
1 NCT03924843 1149 1150 I-Condition
- NCT03924843 1151 1152 O
antitrypsine NCT03924843 1153 1165 I-Condition
deficiency NCT03924843 1166 1176 I-Condition
, NCT03924843 1177 1178 O
significant NCT03924843 1179 1190 O
bronchiectasis NCT03924843 1191 1205 B-Condition
, NCT03924843 1206 1207 O
cardiovascular NCT03924843 1208 1222 B-Modifier
, NCT03924843 1223 1224 O
gastrointestinal NCT03924843 1225 1241 B-Modifier
, NCT03924843 1242 1243 O
liver NCT03924843 1244 1249 B-Modifier
, NCT03924843 1250 1251 O
renal NCT03924843 1252 1257 B-Modifier
, NCT03924843 1258 1259 O
neurological NCT03924843 1260 1272 B-Modifier
, NCT03924843 1273 1274 O
musculoskeletal NCT03924843 1275 1290 B-Modifier
, NCT03924843 1291 1292 O
endocrine NCT03924843 1293 1302 B-Modifier
, NCT03924843 1303 1304 O
metabolic NCT03924843 1305 1314 B-Modifier
( NCT03924843 1315 1316 O
including NCT03924843 1317 1326 O
diagnosed NCT03924843 1327 1336 O
diabetes NCT03924843 1337 1345 B-Condition
) NCT03924843 1346 1347 O
, NCT03924843 1349 1350 O
malignant NCT03924843 1351 1360 B-Modifier
, NCT03924843 1361 1362 O
psychiatric NCT03924843 1363 1374 B-Modifier
, NCT03924843 1375 1376 O
major NCT03924843 1377 1382 B-Modifier
physical NCT03924843 1383 1391 I-Modifier
impairment NCT03924843 1392 1402 B-Condition
) NCT03924843 1403 1404 O
, NCT03924843 1406 1407 O
which NCT03924843 1408 1413 O
, NCT03924843 1414 1415 O
in NCT03924843 1416 1418 O
the NCT03924843 1419 1422 O
opinion NCT03924843 1423 1430 O
of NCT03924843 1431 1433 O
the NCT03924843 1434 1437 O
investigators NCT03924843 1438 1451 O
may NCT03924843 1452 1455 B-Assertion___Assertion-Type-Value:hypothetical
either NCT03924843 1456 1462 O
put NCT03924843 1463 1466 O
the NCT03924843 1467 1470 O
patient NCT03924843 1471 1478 O
at NCT03924843 1479 1481 O
risk NCT03924843 1482 1486 B-Risk
because NCT03924843 1487 1494 O
of NCT03924843 1495 1497 O
participation NCT03924843 1498 1511 O
in NCT03924843 1512 1514 O
the NCT03924843 1515 1518 O
study NCT03924843 1519 1524 B-Study
, NCT03924843 1525 1526 O
or NCT03924843 1527 1529 O
may NCT03924843 1530 1533 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03924843 1534 1543 O
the NCT03924843 1544 1547 O
results NCT03924843 1548 1555 O
of NCT03924843 1556 1558 O
the NCT03924843 1559 1562 O
study NCT03924843 1563 1568 O
, NCT03924843 1569 1570 O
or NCT03924843 1571 1573 O
the NCT03924843 1574 1577 O
patient NCT03924843 1578 1585 O
's NCT03924843 1585 1587 O
ability NCT03924843 1588 1595 O
to NCT03924843 1596 1598 O
participate NCT03924843 1599 1610 O
in NCT03924843 1611 1613 O
the NCT03924843 1614 1617 O
study NCT03924843 1618 1623 O
. NCT03924843 1623 1624 O

- NCT03924843 1628 1629 O
Existing NCT03924843 1631 1639 B-Eq-Comparison
pregnancy NCT03924843 1640 1649 B-Condition
/ NCT03924843 1650 1651 B-Or
current NCT03924843 1652 1659 B-Eq-Comparison
willingness NCT03924843 1660 1671 B-Assertion___Assertion-Type-Value:intention
for NCT03924843 1672 1675 I-Assertion___Assertion-Type-Value:intention
becoming NCT03924843 1676 1684 I-Assertion___Assertion-Type-Value:intention
pregnant NCT03924843 1685 1693 B-Condition

Inclusion NCT03929432 0 9 O
Criteria NCT03929432 10 18 O
: NCT03929432 19 20 O

- NCT03929432 24 25 O
Presence NCT03929432 27 35 O
of NCT03929432 36 38 O
post NCT03929432 39 43 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03929432 44 45 O
stroke NCT03929432 46 52 B-Condition
aphasia NCT03929432 53 60 B-Condition

- NCT03929432 63 64 O
Single NCT03929432 66 72 B-Eq-Comparison
left NCT03929432 73 77 B-Modifier
hemisphere NCT03929432 78 88 I-Modifier
stroke NCT03929432 89 95 B-Condition
etiology NCT03929432 96 104 B-Modifier

- NCT03929432 107 108 O
At NCT03929432 110 112 B-Eq-Comparison
least NCT03929432 113 118 I-Eq-Comparison
6 NCT03929432 119 120 I-Eq-Comparison
months NCT03929432 121 127 I-Eq-Comparison
post NCT03929432 128 132 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03929432 133 134 O
stroke NCT03929432 135 141 B-Condition

- NCT03929432 144 145 O
Age NCT03929432 147 150 B-Age
range NCT03929432 151 156 O
between NCT03929432 157 164 B-Eq-Comparison
18 NCT03929432 165 167 I-Eq-Comparison
and NCT03929432 168 171 I-Eq-Comparison
80 NCT03929432 172 174 I-Eq-Comparison
years NCT03929432 175 180 I-Eq-Comparison
old NCT03929432 181 184 O

- NCT03929432 187 188 O
Speak NCT03929432 190 195 O
English NCT03929432 196 203 O
as NCT03929432 204 206 O
a NCT03929432 207 208 O
native NCT03929432 209 215 O
language NCT03929432 216 224 O

- NCT03929432 227 228 O
Adequate NCT03929432 230 238 O
hearing NCT03929432 239 246 B-Condition
and NCT03929432 247 250 B-And
vision NCT03929432 251 257 B-Condition
to NCT03929432 258 260 B-Assertion___Assertion-Type-Value:hypothetical
complete NCT03929432 261 269 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03929432 270 273 O
tasks NCT03929432 274 279 B-Observation

Exclusion NCT03929432 280 289 O
Criteria NCT03929432 290 298 O
: NCT03929432 299 300 O

- NCT03929432 304 305 O
Severe NCT03929432 307 313 O
auditory NCT03929432 314 322 B-Condition
comprehension NCT03929432 323 336 I-Condition
deficits NCT03929432 337 345 I-Condition
( NCT03929432 346 347 O
determined NCT03929432 348 358 O
by NCT03929432 359 361 O
pretest NCT03929432 362 369 B-Procedure
) NCT03929432 370 371 O
( NCT03929432 372 373 O
i. NCT03929432 374 376 O
e. NCT03929432 377 379 O
, NCT03929432 380 381 O
global NCT03929432 382 388 B-Condition
aphasia NCT03929432 389 396 I-Condition
, NCT03929432 397 398 O
Wernicke NCT03929432 399 407 B-Condition
's NCT03929432 407 409 O
aphasia NCT03929432 410 417 I-Condition
, NCT03929432 418 419 O
transcortical NCT03929432 420 433 B-Condition
sensory NCT03929432 434 441 I-Condition
aphasia NCT03929432 442 449 I-Condition
) NCT03929432 450 451 O

- NCT03929432 455 456 O
Inability NCT03929432 458 467 O
to NCT03929432 468 470 O
provide NCT03929432 471 478 O
informed NCT03929432 479 487 O
consent NCT03929432 488 495 O

- NCT03929432 498 499 O
Co NCT03929432 501 503 O
- NCT03929432 504 505 O
occurring NCT03929432 506 515 O
history NCT03929432 516 523 B-Eq-Comparison
of NCT03929432 524 526 O
neurological NCT03929432 527 539 B-Modifier
disease NCT03929432 540 547 B-Condition
/ NCT03929432 548 549 B-Or|Or
disorder NCT03929432 550 558 B-Condition
/ NCT03929432 559 560 O
injury NCT03929432 561 567 B-Condition
( NCT03929432 568 569 O
e. NCT03929432 570 572 O
g. NCT03929432 573 575 O
, NCT03929432 576 577 O
traumatic NCT03929432 578 587 B-Condition
brain NCT03929432 588 593 I-Condition
injury NCT03929432 594 600 I-Condition
, NCT03929432 601 602 O
right NCT03929432 603 608 B-Modifier
hemisphere NCT03929432 609 619 I-Modifier
stroke NCT03929432 620 626 B-Condition
, NCT03929432 627 628 O
dementia NCT03929432 629 637 B-Condition
) NCT03929432 638 639 O

- NCT03929432 643 644 O
Co NCT03929432 646 648 O
- NCT03929432 649 650 O
occurring NCT03929432 651 660 O
history NCT03929432 661 668 B-Eq-Comparison
of NCT03929432 669 671 O
a NCT03929432 672 673 O
major NCT03929432 674 679 O
mental NCT03929432 680 686 B-Condition
illness NCT03929432 687 694 I-Condition
( NCT03929432 695 696 O
e. NCT03929432 697 699 O
g. NCT03929432 700 702 O
, NCT03929432 703 704 O
schizophrenia NCT03929432 705 718 B-Condition
, NCT03929432 719 720 O
drug NCT03929432 721 725 B-Condition
addiction NCT03929432 726 735 I-Condition
, NCT03929432 736 737 O
bipolar NCT03929432 738 745 B-Condition
) NCT03929432 746 747 O

- NCT03929432 751 752 O
Clinical NCT03929432 754 762 O
conditions NCT03929432 763 773 B-Condition
contraindicated NCT03929432 774 789 B-Contraindication
for NCT03929432 790 793 O
MRI NCT03929432 794 797 B-Procedure
or NCT03929432 798 800 B-Or
tDCS NCT03929432 801 805 B-Procedure
( NCT03929432 806 807 O
e. NCT03929432 808 810 O
g. NCT03929432 811 813 O
, NCT03929432 814 815 O
implanted NCT03929432 816 825 B-Procedure
electrical NCT03929432 826 836 I-Procedure
devices NCT03929432 837 844 I-Procedure
, NCT03929432 845 846 O
claustrophobia NCT03929432 847 861 B-Condition
, NCT03929432 862 863 O
seizure NCT03929432 864 871 B-Condition
disorder NCT03929432 872 880 I-Condition
) NCT03929432 881 882 O

- NCT03929432 886 887 O
Positive NCT03929432 889 897 O
pregnancy NCT03929432 898 907 B-Observation
test NCT03929432 908 912 I-Observation
( NCT03929432 913 914 O
for NCT03929432 915 918 O
females NCT03929432 919 926 O
) NCT03929432 927 928 O

Inclusion NCT03924102 0 9 O
Criteria NCT03924102 10 18 O
: NCT03924102 19 20 O

- NCT03924102 24 25 O
At NCT03924102 27 29 B-Eq-Comparison
least NCT03924102 30 35 I-Eq-Comparison
18 NCT03924102 36 38 I-Eq-Comparison
years NCT03924102 39 44 I-Eq-Comparison
of NCT03924102 45 47 O
age NCT03924102 48 51 B-Age
. NCT03924102 51 52 O

- NCT03924102 56 57 O
Enrollment NCT03924102 59 69 O
in NCT03924102 70 72 O
the NCT03924102 73 76 O
UAB NCT03924102 77 80 O
CMC NCT03924102 81 84 O
- NCT03924102 85 86 O
ADHF NCT03924102 87 91 O
study NCT03924102 92 97 O
under NCT03924102 98 103 O
the NCT03924102 104 107 O
separate NCT03924102 108 116 O
UAB NCT03924102 117 120 O
approved NCT03924102 121 129 O
research NCT03924102 130 138 O
protocol NCT03924102 139 147 O
( NCT03924102 148 149 O
IRB NCT03924102 150 153 O
- NCT03924102 154 155 O
300000114 NCT03924102 156 165 O
, NCT03924102 166 167 O
PI NCT03924102 168 170 O
Rajapreyar NCT03924102 171 181 O
) NCT03924102 182 183 O

- NCT03924102 187 188 O
Negative NCT03924102 190 198 O
urine NCT03924102 199 204 O
or NCT03924102 205 207 B-Or
serum NCT03924102 208 213 O
β NCT03924102 214 215 B-Observation
- NCT03924102 216 217 I-Observation
hCG NCT03924102 218 221 I-Observation
test NCT03924102 222 226 I-Observation
within NCT03924102 227 233 B-Eq-Comparison
48 NCT03924102 234 236 I-Eq-Comparison
hours NCT03924102 237 242 I-Eq-Comparison
of NCT03924102 243 245 B-Temporal-Connection___Temporal-Connection-Type-Value:after
[ NCT03924102 246 247 O
11 NCT03924102 248 250 B-Modifier
C NCT03924102 251 252 O
] NCT03924102 253 254 O
acetate NCT03924102 255 262 B-Drug
administration NCT03924102 263 277 I-Drug
in NCT03924102 278 280 B-And
women NCT03924102 281 286 O
of NCT03924102 287 289 B-And
child NCT03924102 290 295 B-Condition
bearing NCT03924102 296 303 I-Condition
potential NCT03924102 304 313 I-Condition
. NCT03924102 313 314 O
Women NCT03924102 316 321 O
who NCT03924102 322 325 B-And
are NCT03924102 326 329 O
post NCT03924102 330 334 B-Condition
- NCT03924102 335 336 I-Condition
menopausal NCT03924102 337 347 I-Condition
with NCT03924102 348 352 B-And
at NCT03924102 353 355 B-Eq-Comparison
least NCT03924102 356 361 I-Eq-Comparison
1 NCT03924102 362 363 I-Eq-Comparison
year NCT03924102 364 368 I-Eq-Comparison
since NCT03924102 369 374 B-Temporal-Connection___Temporal-Connection-Type-Value:after
last NCT03924102 375 379 B-Eq-Comparison
menses NCT03924102 380 386 B-Condition
or NCT03924102 387 389 B-Or
documented NCT03924102 390 400 O
surgical NCT03924102 401 409 B-Procedure
sterilization NCT03924102 410 423 I-Procedure
will NCT03924102 424 428 O
not NCT03924102 429 432 B-Negation
require NCT03924102 433 440 B-Assertion___Assertion-Type-Value:hypothetical
pregnancy NCT03924102 441 450 B-Observation
testing NCT03924102 451 458 I-Observation
. NCT03924102 458 459 O

Exclusion NCT03924102 461 470 O
Criteria NCT03924102 471 479 O
: NCT03924102 480 481 O

- NCT03924102 485 486 O
Inability NCT03924102 488 497 O
to NCT03924102 498 500 O
provide NCT03924102 501 508 O
informed NCT03924102 509 517 O
consent NCT03924102 518 525 O

- NCT03924102 528 529 O
Pregnancy NCT03924102 531 540 B-Condition

- NCT03924102 543 544 O
Inability NCT03924102 546 555 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03924102 556 558 O
lie NCT03924102 559 562 O
still NCT03924102 563 568 O
for NCT03924102 569 572 O
the NCT03924102 573 576 O
imaging NCT03924102 577 584 B-Procedure
study NCT03924102 585 590 I-Procedure

- NCT03924102 593 594 O
Weight NCT03924102 596 602 B-Observation
exceeding NCT03924102 603 612 O
the NCT03924102 613 616 O
weight NCT03924102 617 623 O
limit NCT03924102 624 629 O
of NCT03924102 630 632 O
the NCT03924102 633 636 O
PET NCT03924102 637 640 B-Procedure
imaging NCT03924102 641 648 I-Procedure
table NCT03924102 649 654 I-Procedure
( NCT03924102 655 656 O
500 NCT03924102 657 660 B-Eq-Comparison
pounds NCT03924102 661 667 I-Eq-Comparison
) NCT03924102 668 669 O
. NCT03924102 670 671 O

Inclusion NCT03924466 0 9 O
Criteria NCT03924466 10 18 O
: NCT03924466 19 20 O

Patients NCT03924466 22 30 O
will NCT03924466 31 35 O
only NCT03924466 36 40 O
be NCT03924466 41 43 O
included NCT03924466 44 52 O
in NCT03924466 53 55 O
the NCT03924466 56 59 O
study NCT03924466 60 65 O
if NCT03924466 66 68 O
they NCT03924466 69 73 O
meet NCT03924466 74 78 O
all NCT03924466 79 82 O
of NCT03924466 83 85 O
the NCT03924466 86 89 O
following NCT03924466 90 99 O
criteria NCT03924466 100 108 O
: NCT03924466 109 110 O

- NCT03924466 114 115 O
Patient NCT03924466 117 124 O
who NCT03924466 125 128 O
has NCT03924466 129 132 O
given NCT03924466 133 138 O
informed NCT03924466 139 147 O
consent NCT03924466 148 155 O

- NCT03924466 158 159 O
Patient NCT03924466 161 168 O
with NCT03924466 169 173 O
age NCT03924466 174 177 B-Age
18 NCT03924466 178 180 B-Eq-Comparison
years NCT03924466 181 186 I-Eq-Comparison
or NCT03924466 187 189 I-Eq-Comparison
older NCT03924466 190 195 I-Eq-Comparison

- NCT03924466 198 199 O
Patient NCT03924466 201 208 O
with NCT03924466 209 213 O
locally NCT03924466 214 221 B-Modifier
or NCT03924466 222 224 B-Or
distantly NCT03924466 225 234 B-Modifier
advanced NCT03924466 235 243 I-Modifier
breast NCT03924466 244 250 I-Modifier
carcinoma NCT03924466 251 260 B-Condition
, NCT03924466 261 262 O
with NCT03924466 263 267 B-And
at NCT03924466 268 270 B-Eq-Comparison
least NCT03924466 271 276 I-Eq-Comparison
1 NCT03924466 277 278 I-Eq-Comparison
lesion NCT03924466 279 285 B-Condition|Observation
of NCT03924466 286 288 O
at NCT03924466 289 291 B-Eq-Comparison
least NCT03924466 292 297 I-Eq-Comparison
12 NCT03924466 298 300 I-Eq-Comparison
mm NCT03924466 301 303 I-Eq-Comparison
maximal NCT03924466 304 311 B-Modifier
diameter NCT03924466 312 320 I-Modifier
. NCT03924466 320 321 O
For NCT03924466 323 326 O
lymph NCT03924466 327 332 B-Modifier
node NCT03924466 333 337 I-Modifier
metastases NCT03924466 338 348 B-Condition|Observation
, NCT03924466 349 350 O
the NCT03924466 351 354 O
largest NCT03924466 355 362 B-Modifier
diameter NCT03924466 363 371 I-Modifier
should NCT03924466 372 378 O
be NCT03924466 379 381 O
at NCT03924466 382 384 B-Eq-Comparison
least NCT03924466 385 390 I-Eq-Comparison
15 NCT03924466 391 393 I-Eq-Comparison
mm NCT03924466 394 396 I-Eq-Comparison
and NCT03924466 397 400 B-And
the NCT03924466 401 404 O
short NCT03924466 405 410 B-Observation
axis NCT03924466 411 415 I-Observation
at NCT03924466 416 418 B-Eq-Comparison
least NCT03924466 419 424 I-Eq-Comparison
12 NCT03924466 425 427 I-Eq-Comparison
mm NCT03924466 428 430 I-Eq-Comparison
. NCT03924466 430 431 O

Exclusion NCT03924466 433 442 O
Criteria NCT03924466 443 451 O
: NCT03924466 452 453 O

Patients NCT03924466 455 463 O
will NCT03924466 464 468 O
not NCT03924466 469 472 B-Negation
be NCT03924466 473 475 O
included NCT03924466 476 484 O
in NCT03924466 485 487 O
the NCT03924466 488 491 O
study NCT03924466 492 497 B-Study
if NCT03924466 498 500 O
one NCT03924466 501 504 O
or NCT03924466 505 507 O
more NCT03924466 508 512 O
of NCT03924466 513 515 O
the NCT03924466 516 519 O
following NCT03924466 520 529 O
criteria NCT03924466 530 538 O

applies NCT03924466 539 546 O
: NCT03924466 547 548 O

- NCT03924466 552 553 O
Patient NCT03924466 555 562 O
is NCT03924466 563 565 O
pregnant NCT03924466 566 574 B-Condition

- NCT03924466 577 578 O
Patient NCT03924466 580 587 O
is NCT03924466 588 590 O
breast NCT03924466 591 597 B-Condition
feeding NCT03924466 598 605 I-Condition

- NCT03924466 608 609 O
Patient NCT03924466 611 618 O
with NCT03924466 619 623 O
recent NCT03924466 624 630 B-Eq-Comparison
( NCT03924466 631 632 O
< NCT03924466 634 635 B-Eq-Comparison
1 NCT03924466 636 637 I-Eq-Comparison
week NCT03924466 638 642 I-Eq-Comparison
) NCT03924466 643 644 O
gastrointestinal NCT03924466 645 661 B-Condition
disorders NCT03924466 662 671 I-Condition
with NCT03924466 672 676 O
diarrhea NCT03924466 677 685 B-Condition
as NCT03924466 686 688 O
major NCT03924466 689 694 O
symptom NCT03924466 695 702 O

- NCT03924466 705 706 O
Patient NCT03924466 708 715 O
with NCT03924466 716 720 O
any NCT03924466 721 724 O
serious NCT03924466 725 732 O
active NCT03924466 733 739 B-Eq-Comparison
infection NCT03924466 740 749 B-Condition

- NCT03924466 752 753 O
Patient NCT03924466 755 762 O
who NCT03924466 763 766 O
has NCT03924466 767 770 O
any NCT03924466 771 774 O
other NCT03924466 775 780 B-Other
life NCT03924466 781 785 B-Death|Risk
- NCT03924466 786 787 I-Death|Risk
threatening NCT03924466 788 799 I-Death|Risk
illness NCT03924466 800 807 B-Condition
or NCT03924466 808 810 B-Modifier|Or
organ NCT03924466 811 816 O
system NCT03924466 817 823 I-Modifier
dysfunction NCT03924466 824 835 B-Condition
, NCT03924466 836 837 O
which NCT03924466 838 843 O
in NCT03924466 844 846 O
the NCT03924466 847 850 O
opinion NCT03924466 851 858 O
of NCT03924466 859 861 O
the NCT03924466 862 865 O
investigator NCT03924466 866 878 O
would NCT03924466 879 884 O
either NCT03924466 885 891 O
compromise NCT03924466 892 902 O
patient NCT03924466 903 910 O
safety NCT03924466 911 917 O
or NCT03924466 918 920 O
interfere NCT03924466 921 930 O
with NCT03924466 931 935 O
the NCT03924466 936 939 O
evaluation NCT03924466 940 950 O
of NCT03924466 951 953 O
the NCT03924466 954 957 O
test NCT03924466 958 962 B-Study
radiopharmaceutical NCT03924466 963 982 B-Procedure

- NCT03924466 985 986 O
Patient NCT03924466 988 995 O
who NCT03924466 996 999 O
can NCT03924466 1000 1003 B-Negation
not NCT03924466 1003 1006 O
communicate NCT03924466 1007 1018 B-Condition
reliably NCT03924466 1019 1027 O
with NCT03924466 1028 1032 O
the NCT03924466 1033 1036 O
investigator NCT03924466 1037 1049 O

- NCT03924466 1052 1053 O
Patient NCT03924466 1055 1062 O
who NCT03924466 1063 1066 O
is NCT03924466 1067 1069 O
unlikely NCT03924466 1070 1078 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924466 1079 1081 O
cooperate NCT03924466 1082 1091 O
with NCT03924466 1092 1096 O
the NCT03924466 1097 1100 O
requirements NCT03924466 1101 1113 O
of NCT03924466 1114 1116 O
the NCT03924466 1117 1120 O
study NCT03924466 1121 1126 B-Study

- NCT03924466 1129 1130 O
Patient NCT03924466 1132 1139 O
who NCT03924466 1140 1143 O
is NCT03924466 1144 1146 O
unwilling NCT03924466 1147 1156 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03924466 1157 1160 B-Or
/ NCT03924466 1161 1162 I-Or
or NCT03924466 1163 1165 I-Or
unable NCT03924466 1166 1172 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924466 1173 1175 O
give NCT03924466 1176 1180 O
informed NCT03924466 1181 1189 O
consent NCT03924466 1190 1197 O

- NCT03924466 1200 1201 O
Patient NCT03924466 1203 1210 O
at NCT03924466 1211 1213 O
increased NCT03924466 1214 1223 O
risk NCT03924466 1224 1228 B-Risk
of NCT03924466 1229 1231 O
death NCT03924466 1232 1237 B-Death
from NCT03924466 1238 1242 O
a NCT03924466 1243 1244 O
pre NCT03924466 1245 1248 B-Eq-Comparison
- NCT03924466 1249 1250 I-Eq-Comparison
existing NCT03924466 1251 1259 I-Eq-Comparison
concurrent NCT03924466 1260 1270 B-Modifier
illness NCT03924466 1271 1278 B-Condition

- NCT03924466 1281 1282 O
Patient NCT03924466 1284 1291 O
who NCT03924466 1292 1295 O
participated NCT03924466 1296 1308 O
already NCT03924466 1309 1316 O
in NCT03924466 1317 1319 O
this NCT03924466 1320 1324 O
study NCT03924466 1325 1330 O
. NCT03924466 1330 1331 O

Inclusion NCT03923309 0 9 O
Criteria NCT03923309 10 18 O
: NCT03923309 19 20 O

- NCT03923309 24 25 O
biopsy NCT03923309 27 33 B-Procedure
proven NCT03923309 34 40 O
rectal NCT03923309 41 47 B-Modifier
cancer NCT03923309 48 54 B-Condition
( NCT03923309 55 56 O
anal NCT03923309 57 61 B-Observation
verge NCT03923309 62 67 I-Observation
≤ NCT03923309 68 69 B-Eq-Comparison
10 NCT03923309 70 72 I-Eq-Comparison
cm NCT03923309 73 75 O
) NCT03923309 76 77 O

- NCT03923309 81 82 O
neoadjuvant NCT03923309 84 95 B-Modifier
radiotherapy NCT03923309 96 108 B-Procedure
or NCT03923309 109 111 B-Or
chemoradiotherapy NCT03923309 112 129 B-Procedure

- NCT03923309 132 133 O
no NCT03923309 135 137 B-Negation
radical NCT03923309 138 145 B-Modifier
surgery NCT03923309 146 153 B-Procedure
after NCT03923309 154 159 B-Temporal-Connection___Temporal-Connection-Type-Value:after
neoadjuvant NCT03923309 160 171 B-Procedure
therapy NCT03923309 172 179 I-Procedure

Exclusion NCT03923309 180 189 O
Criteria NCT03923309 190 198 O
: NCT03923309 199 200 O

- NCT03923309 204 205 O
other NCT03923309 207 212 B-Other
malignant NCT03923309 213 222 B-Condition
disease NCT03923309 223 230 I-Condition

- NCT03923309 233 234 O
other NCT03923309 236 241 B-Other
fatel NCT03923309 242 247 B-Condition
disease NCT03923309 248 255 I-Condition

- NCT03923309 258 259 O
incompletion NCT03923309 261 273 B-Negation
of NCT03923309 274 276 O
half NCT03923309 277 281 O
of NCT03923309 282 284 O
radiotherapy NCT03923309 285 297 B-Procedure
course NCT03923309 298 304 O

- NCT03923309 307 308 O
metastasis NCT03923309 310 320 B-Condition
on NCT03923309 321 323 B-Temporal-Connection___Temporal-Connection-Type-Value:during
initial NCT03923309 324 331 B-Eq-Comparison
presentation NCT03923309 332 344 B-Condition

Inclusion NCT03923335 0 9 O
Criteria NCT03923335 10 18 O
: NCT03923335 19 20 O

1 NCT03923335 24 25 O
. NCT03923335 25 26 O
TNM NCT03923335 28 31 O
stage NCT03923335 32 37 O
I NCT03923335 38 39 O
- NCT03923335 40 41 O
II NCT03923335 42 44 O
( NCT03923335 45 46 O
T1 NCT03923335 47 49 O
- NCT03923335 50 51 B-Eq-Comparison
4 NCT03923335 52 53 I-Eq-Comparison
N0M0 NCT03923335 54 58 O
) NCT03923335 59 60 O
colorectal NCT03923335 61 71 B-Modifier
cancer NCT03923335 72 78 B-Condition
cases NCT03923335 79 84 O

2 NCT03923335 87 88 O
. NCT03923335 88 89 O
receive NCT03923335 91 98 O
radical NCT03923335 99 106 B-Modifier
surgical NCT03923335 107 115 B-Procedure
resection NCT03923335 116 125 I-Procedure

3 NCT03923335 128 129 O
. NCT03923335 129 130 O
have NCT03923335 132 136 O
completed NCT03923335 137 146 O
data NCT03923335 147 151 O
of NCT03923335 152 154 O
tumor NCT03923335 155 160 B-Condition
location NCT03923335 161 169 B-Modifier
, NCT03923335 170 171 O
histological NCT03923335 172 184 B-Modifier
type NCT03923335 185 189 I-Modifier
, NCT03923335 190 191 O
behavioral NCT03923335 192 202 B-Modifier
characteristics NCT03923335 203 218 I-Modifier
or NCT03923335 219 221 B-Or
TNM NCT03923335 222 225 B-Modifier
staging NCT03923335 226 233 I-Modifier

4 NCT03923335 236 237 O
. NCT03923335 237 238 O
have NCT03923335 240 244 O
tumor NCT03923335 245 250 B-Observation
specimens NCT03923335 251 260 I-Observation
and NCT03923335 261 264 B-And
either NCT03923335 265 271 O
a NCT03923335 272 273 O
valid NCT03923335 274 279 O
microsatellite NCT03923335 280 294 B-Observation
instability NCT03923335 295 306 I-Observation
( NCT03923335 307 308 O
MSI NCT03923335 309 312 B-Observation
) NCT03923335 313 314 O
or NCT03923335 315 317 B-Or
immuno NCT03923335 318 324 B-Observation
- NCT03923335 325 326 I-Observation
histochemistry NCT03923335 327 341 I-Observation
( NCT03923335 342 343 O
IHC NCT03923335 344 347 B-Observation
) NCT03923335 348 349 O
data NCT03923335 350 354 O

5 NCT03923335 357 358 O
. NCT03923335 358 359 O
have NCT03923335 361 365 O
valid NCT03923335 366 371 O
V NCT03923335 372 373 B-Observation
- NCT03923335 374 375 I-Observation
raf NCT03923335 376 379 I-Observation
murine NCT03923335 380 386 I-Observation
sarcoma NCT03923335 387 394 I-Observation
viral NCT03923335 395 400 I-Observation
oncogene NCT03923335 401 409 I-Observation
homolog NCT03923335 410 417 I-Observation
B1 NCT03923335 418 420 I-Observation
( NCT03923335 421 422 O
BRAF NCT03923335 423 427 B-Observation
) NCT03923335 428 429 O
, NCT03923335 431 432 O
kirsten NCT03923335 433 440 B-Observation
rat NCT03923335 441 444 I-Observation
sarcoma NCT03923335 445 452 I-Observation
viral NCT03923335 453 458 I-Observation
oncogene NCT03923335 459 467 I-Observation
( NCT03923335 468 469 O
KRAS NCT03923335 470 474 B-Observation
) NCT03923335 475 476 O
, NCT03923335 478 479 O
CpG NCT03923335 480 483 B-Observation
island NCT03923335 484 490 I-Observation
methylator NCT03923335 491 501 I-Observation
phenotype NCT03923335 502 511 I-Observation
( NCT03923335 512 513 O
CIMP NCT03923335 514 518 B-Observation
) NCT03923335 519 520 O
results NCT03923335 521 528 O

6 NCT03923335 531 532 O
. NCT03923335 532 533 O
have NCT03923335 535 539 O
at NCT03923335 540 542 B-Eq-Comparison
least NCT03923335 543 548 I-Eq-Comparison
4 NCT03923335 549 550 I-Eq-Comparison
years NCT03923335 551 556 I-Eq-Comparison
of NCT03923335 557 559 O
follow NCT03923335 560 566 B-Encounter
- NCT03923335 567 568 I-Encounter
up NCT03923335 569 571 I-Encounter

7 NCT03923335 574 575 O
. NCT03923335 575 576 O
have NCT03923335 578 582 O
valid NCT03923335 583 588 O
time NCT03923335 589 593 B-Modifier
to NCT03923335 594 596 I-Modifier
local NCT03923335 597 602 I-Modifier
recurrence NCT03923335 603 613 B-Condition
/ NCT03923335 614 615 B-Or
metastasis NCT03923335 616 626 B-Condition
in NCT03923335 627 629 B-Temporal-Connection___Temporal-Connection-Type-Value:during
follow NCT03923335 630 636 B-Encounter
- NCT03923335 637 638 I-Encounter
up NCT03923335 639 641 I-Encounter

8 NCT03923335 644 645 O
. NCT03923335 645 646 O
have NCT03923335 648 652 O
clinical NCT03923335 653 661 O
/ NCT03923335 662 663 O
treatment NCT03923335 664 673 B-Procedure
record NCT03923335 674 680 O
data NCT03923335 681 685 O
and NCT03923335 686 689 B-And
valid NCT03923335 690 695 O
pre NCT03923335 696 699 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03923335 700 701 O
- NCT03923335 703 704 O
operative NCT03923335 705 714 B-Procedure
status NCT03923335 715 721 O
of NCT03923335 722 724 O
intestinal NCT03923335 725 735 B-Condition
obstruction NCT03923335 736 747 I-Condition
or NCT03923335 748 750 I-Condition
perforation NCT03923335 751 762 I-Condition
( NCT03923335 763 764 O
IOP NCT03923335 765 768 B-Condition
) NCT03923335 769 770 O
, NCT03923335 772 773 O
counts NCT03923335 774 780 B-Eq-Comparison
of NCT03923335 781 783 O
lymph NCT03923335 784 789 B-Procedure
node NCT03923335 790 794 I-Procedure
removed NCT03923335 795 802 I-Procedure
in NCT03923335 803 805 B-Temporal-Connection___Temporal-Connection-Type-Value:during
surgical NCT03923335 806 814 B-Procedure
resection NCT03923335 815 824 I-Procedure
. NCT03923335 824 825 O

Exclusion NCT03923335 827 836 O
Criteria NCT03923335 837 845 O
: NCT03923335 846 847 O

1 NCT03923335 851 852 O
. NCT03923335 852 853 O
have NCT03923335 855 859 O
had NCT03923335 860 863 O
a NCT03923335 864 865 O
previous NCT03923335 866 874 B-Eq-Comparison
diagnosis NCT03923335 875 884 O
of NCT03923335 885 887 O
any NCT03923335 888 891 O
cancer NCT03923335 892 898 B-Condition
or NCT03923335 899 901 B-Or
presence NCT03923335 902 910 O
of NCT03923335 911 913 O
any NCT03923335 914 917 O
tumor NCT03923335 918 923 B-Condition
other NCT03923335 924 929 B-Exception
than NCT03923335 930 934 I-Exception
the NCT03923335 935 938 O
CRC NCT03923335 939 942 B-Condition

2 NCT03923335 945 946 O
. NCT03923335 946 947 O
have NCT03923335 949 953 O
had NCT03923335 954 957 O
inflammatory NCT03923335 958 970 B-Condition
bowel NCT03923335 971 976 I-Condition
disease NCT03923335 977 984 I-Condition

3 NCT03923335 987 988 O
. NCT03923335 988 989 O
have NCT03923335 991 995 O
had NCT03923335 996 999 O
hereditary NCT03923335 1000 1010 B-Modifier
colorectal NCT03923335 1011 1021 I-Modifier
cancer NCT03923335 1022 1028 B-Condition
syndromes NCT03923335 1029 1038 I-Condition
, NCT03923335 1039 1040 O
including NCT03923335 1041 1050 O
Familial NCT03923335 1051 1059 B-Condition
adenomatous NCT03923335 1060 1071 I-Condition
polyposis NCT03923335 1072 1081 I-Condition|Condition
, NCT03923335 1082 1083 O
mutyh NCT03923335 1084 1089 B-Modifier
( NCT03923335 1090 1091 O
MYH NCT03923335 1092 1095 B-Modifier
) NCT03923335 1096 1097 O
- NCT03923335 1099 1100 I-Condition
associated NCT03923335 1101 1111 O
polyposis NCT03923335 1112 1121 I-Condition
, NCT03923335 1122 1123 O
Peutz NCT03923335 1124 1129 B-Condition
- NCT03923335 1130 1131 O
Jeghers NCT03923335 1132 1139 I-Condition
syndrome NCT03923335 1140 1148 I-Condition
, NCT03923335 1149 1150 O
Juvenile NCT03923335 1151 1159 B-Condition
polyposis NCT03923335 1160 1169 O
coli NCT03923335 1170 1174 I-Condition
, NCT03923335 1175 1176 O
phosphate NCT03923335 1177 1186 B-Condition
and NCT03923335 1187 1190 I-Condition
tension NCT03923335 1191 1198 I-Condition
homology NCT03923335 1199 1207 I-Condition
deleted NCT03923335 1208 1215 I-Condition
on NCT03923335 1216 1218 I-Condition
chromosome NCT03923335 1219 1229 I-Condition
ten NCT03923335 1230 1233 O
( NCT03923335 1234 1235 O
PTEN NCT03923335 1236 1240 B-Condition
) NCT03923335 1241 1242 O
tumor NCT03923335 1243 1248 B-Condition
- NCT03923335 1249 1250 I-Condition
hamartoma NCT03923335 1251 1260 I-Condition
syndromes NCT03923335 1261 1270 I-Condition
, NCT03923335 1271 1272 O
Lynch NCT03923335 1273 1278 B-Condition
Syndrome NCT03923335 1279 1287 I-Condition
, NCT03923335 1288 1289 O
and NCT03923335 1290 1293 B-Or
Familial NCT03923335 1294 1302 B-Modifier
Colorectal NCT03923335 1303 1313 I-Modifier
Cancer NCT03923335 1314 1320 B-Condition
Type NCT03923335 1321 1325 B-Modifier
X. NCT03923335 1326 1328 I-Modifier

